
<html lang="en"     class="pb-page"  data-request-id="9ef4f2e8-168e-4096-ad4e-4f28077fa90c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-19;article:article:10.1021/acs.jmedchem.6b00472"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules" /></meta><meta name="dc.Creator" content="Tanaji T.  Talele" /></meta><meta name="dc.Description" content="Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane r..." /></meta><meta name="Description" content="Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane r..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 30, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00472" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00472" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00472" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00472" /></link>
        
    
    

<title>The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00472" /></meta><meta property="og:title" content="The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0075.jpeg" /></meta><meta property="og:description" content="Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C–C bonds, (3) enhanced π-character of C–C bonds, and (4) C–H bonds are shorter and stronger than those in alkanes. The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs containing it. Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflux ratio." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00472"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00472">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00472&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00472&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00472&amp;href=/doi/10.1021/acs.jmedchem.6b00472" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8712-8756</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00463" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.6b01058" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tanaji+T.++Talele">Tanaji T. Talele</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, 8000 Utopia Parkway, Queens, New York 11439, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: (718)-990-5405. Fax: (718)-990-1877. E-mail: <a href="/cdn-cgi/l/email-protection#ccb8ada0a9a0a9b88cbfb8a6a3a4a2bfe2a9a8b9"><span class="__cf_email__" data-cfemail="7602171a131a13023605021c191e180558131203">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00472&amp;href=/doi/10.1021%2Facs.jmedchem.6b00472" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8712–8756</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 14, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 March 2016</li><li><span class="item_label"><b>Published</b> online</span>30 June 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00472" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00472</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8712%26pageCount%3D45%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTanaji%2BT.%2BTalele%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D19%26contentID%3Dacs.jmedchem.6b00472%26title%3DThe%2B%25E2%2580%259CCyclopropyl%2BFragment%25E2%2580%259D%2Bis%2Ba%2BVersatile%2BPlayer%2Bthat%2BFrequently%2BAppears%2Bin%2BPreclinical%252FClinical%2BDrug%2BMolecules%26numPages%3D45%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8756%26publicationDate%3DOctober%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00472"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">13974</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">297</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00472" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tanaji&quot;,&quot;last_name&quot;:&quot;T. Talele&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8712-8756&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00472&quot;},&quot;abstract&quot;:&quot;Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C–C bonds, (3) enhanced π-character of C–C bonds, and (4) C–H bonds are shorter and stronger than those in alkanes. The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs containing it. Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflu&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00472&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00472" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00472&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00472" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00472&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00472" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00472&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00472&amp;href=/doi/10.1021/acs.jmedchem.6b00472" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00472" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00472" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26pmid%3D27299736%26genre%3Darticle%26aulast%3DTalele%26date%3D2016%26atitle%3DThe%2B%25E2%2580%259CCyclopropyl%2BFragment%25E2%2580%259D%2Bis%2Ba%2BVersatile%2BPlayer%2Bthat%2BFrequently%2BAppears%2Bin%2BPreclinical%252FClinical%2BDrug%2BMolecules%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D19%26spage%3D8712%26epage%3D8756%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291456" title="Hydrocarbons">Hydrocarbons</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/jmcmar.2016.59.issue-19/20161013/jmcmar.2016.59.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0075.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C–C bonds, (3) enhanced π-character of C–C bonds, and (4) C–H bonds are shorter and stronger than those in alkanes. The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs containing it. Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug p<i>K</i><sub>a</sub> to reduce its P-glycoprotein efflux ratio.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Historical Synopsis of the Cyclopropane Ring</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cyclopropane ring was first synthesized in 1882.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is a colorless, flammable, sweet-smelling gas, with anesthetic properties.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The cyclopropyl skeleton, present in pyrethrins (e.g., compound <b>1</b>/<i>trans</i>-chrysanthemic acid) from pyrethrum flowers, contributes to the insecticidal properties of these compounds.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) 1-Aminocyclopropane carboxylic acid (compound <b>2</b>), of wide occurrence in green plants, serves as a precursor for the plant hormone ethylene.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>)</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of compounds <b>1</b> (<i>trans</i>-chrysanthemic acid) and <b>2</b> (1-aminocyclopropane carboxylic acid).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The introduction of the cyclopropyl ring into the structure of pharmacologically active compounds, dating back to the 1960s, is exemplified by two major classes of drugs: phenylcyclopropylamine-based, monoamine oxidase (MAO) inhibitors, and opioid antagonists such as naltrexone.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These two classes of drugs paved the way for the use of the cyclopropyl scaffold in drug research to achieve specific therapeutic goals. From the 1960s to the present, the cyclopropyl ring has appeared frequently in the U.S. FDA approved drugs and it is likely to continue to play a significant role in the development of new drugs to meet specific therapeutic goals.</div><div class="NLM_p last">The frequent appearance of the cyclopropyl ring system in drug molecules has led to advances in elegant synthetic methods<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> for the preparation of highly strained cyclopropane building blocks. As a result, the medicinal chemistry community has been able to incorporate this ring system into small, pharmacologically active drug molecules. Because synthetic methods for the preparation of cyclopropane building blocks have been extensively reviewed elsewhere,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> they will not be discussed in this review.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Physicochemical Properties of the Cyclopropane Ring</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The cyclopropane ring is exceptional among various carbocycles in both its properties and reactivity because of its uncommon bonding and characteristic ring strain (27.5 kcal/mol).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Its chemical reactivity is quite similar to that of an olefinic double bond. In essence, both groups interact with neighboring π–electron systems and π–electron centers.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The C–C single bond in cyclopropane resembles a C═C double bond.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The C–C bonds in the cyclopropane ring have more p character, whereas its C–H bonds have more s character.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The C–H bonds in the cyclopropane ring are shorter and stronger (106 kcal/mol) compared to the C–H bonds in ethane (101 kcal/mol).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> On the basis of this observation, one can expect to achieve a metabolically stable derivative upon replacement of the methyl group with a cyclopropane ring. This latter property occurs as proton abstraction from a cyclopropane ring would be more difficult than from a methyl group, which is required for oxidative metabolism to proceed. Because the three carbons of the cyclopropane ring are in the same plane, the C–H bonds are forced to remain eclipsed,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> making the less lipophilic cyclopropane ring an excellent surrogate for a hydrophobic phenyl ring. Moreover, existence of a bond angle of 60° between the sp<sup>3</sup> hybridized carbon atoms in the cyclopropane ring represents a significant shift from the 109° angle observed for sp<sup>3</sup> hybridized orbitals in aliphatic chains. This bond angle difference creates an enormous amount of angular strain in the cyclopropane ring.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Additional strain in the cyclopropane ring comes from the torsional strain, a consequence of the coplanar arrangement of the C atoms that forces the C–H bonds into an eclipsed conformation.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The cyclopropane ring serves as a π electron donor.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The cyclopropyl synthon, carrying a isocyanate group, can be conveniently transformed into cyclopropyl urea analogues that are kinase inhibitors. The cyclopropane scaffold may also contribute toward disruption of overall planarity due to increased sp<sup>3</sup> character and three-dimensionality favoring noncoplanarity, less crystal packing, low melting point, and higher aqueous solubility.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Influence of the Cyclopropane Ring on Pharmacological Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This perspective is focused on the frequently occurring cyclopropyl ring system in the form of a substituent, a fused cyclopropane ring, a spirocyclopropane ring, and a 1,2-disubstituted/1,2,3-trisubstituted cyclopropane chiral scaffold that contributed toward numerous drug properties, including increases in potency, receptor subtype selectivity, bioavailability, half-life, microsomal stability, brain permeability, adaptation to mutable binding site of target proteins, aqueous solubility, and entropically favorable binding, and decreases in lipophilicity, metabolic liability, off-target pharmacology, and entropic penalty upon binding factors that increases the likelihood of a drug molecule to be therapeutically useful. Some notable pharmaceutical properties that are influenced by the cyclopropane ring include intrinsic lipophilicity, metabolic stability, alteration of the p<i>K</i><sub>a</sub>, and binding to target proteins among others. The lipophilicity of a compound can be reduced by replacing the isopropyl (clogP ∼ 1.5) and phenyl (clogP ∼ 2.0) groups with the less lipophilic and isosteric cyclopropyl (clogP ∼ 1.2) group.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> Similarly, increased metabolic stability is achievable through (a) replacing the <i>N</i>-ethyl group, which is susceptible to CYP450-mediated oxidation, with the metabolically stable <i>N</i>-cyclopropyl moiety,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> (b) the spirocyclopropanation at the α-C of the glycine amide bond to prevent amide hydrolysis,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and (c) the replacement of the metabolically labile benzylic carbon atom with the spirocyclopropane.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Furthermore, locking the <i>E</i>/<i>Z</i>-isomerizable noncyclic alkene bond into a cyclopropane ring can lead to geometrically stable isomers for in vivo studies.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> The cyclopropane ring can be used to eliminate a reactive Michael acceptor (α,β-unsaturated carbonyl functionality) group in the form of a fused cyclopropyl carbonyl group.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The p<i>K</i><sub>a</sub> of the benzyl amine moiety in drug molecules can also be altered by the spirocyclopropyl substitution at the benzylic carbon to modulate central nervous system (CNS) permeability.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> A 1,2-disubstituted/1,2,3-trisubstituted cyclopropane ring could serve as a chiral scaffold to project pendant substituents into favorable binding sites of the target proteins.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> Geminal-dimethyl/geminal-difluoride and methylene groups have been replaced with a bioisosteric spirocyclopropyl ring in medicinal chemistry research.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Conformational restriction by inclusion of a cyclopropane ring can facilitate bioactive conformation.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">It is striking to find that eight of the 200 best selling drugs approved by the U.S. FDA contain a cyclopropyl ring.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Further analysis of the top 100 ring systems appearing in the 2012 FDA <i>Orange Book</i> drug database indicated the cyclopropane ring system had a frequency value of 28 and a rank order of 10.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> As of May 2016, there were at least 46 launched drugs containing the cyclopropane ring, which are rather close to that of fluorine-containing FDA approved drugs (DrugBank v4.5 database search).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> At present, there are about 65 unique cyclopropane-containing compounds that are in various stages of clinical trials and about 55 that are in preclinical stages (based on DrugBank v4.5 database search<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and examples described in this article). Some of the therapeutic areas where the cyclopropane ring has played a crucial role includes but not limited to cancer, AIDS, HCV infections, bacterial infections, hyperlipidemia, diabetes, CNS disorders, asthma, inflammation, cardiovascular diseases, bone disorders, and cystic fibrosis. Collectively, it is clearly evident that the cyclopropane ring system has a positive impact on the biological actions of drugs approved by the FDA for a wide range of human diseases. Consequently, the number of cyclopropyl-containing drugs will continue to rise. These facts point toward the firm establishment of the sp<sup>3</sup>-hybridized three-carbon ring system in modern drug discovery research. This perspective will discuss the role of the cyclopropane moiety as a determinant of the therapeutic activity of drugs already approved by the U.S. FDA or currently undergoing preclinical/clinical evaluation.</div><div class="NLM_p last">Though this perspective primarily highlights a direct/sole contribution of the cyclopropyl ring toward influencing target potency, target specificity, physicochemical, and pharmacokinetic (PK) properties, caution should be exercised as there are a few examples where the role of a cyclopropyl ring is amalgamated with additional molecular modifications. It is a daunting task to express, in detail, how the cyclopropane ring has contributed toward the evolution of clinical drug candidates; therefore, I have directed the reader to the original references for further information.</div></div><div id="sec1_3_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Preclinical/Clinical/Approved Drug Candidates for Cancer Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Kinase Inhibitors</h3><div id="sec1_3_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> MEK Kinase Inhibitor <b>4</b> (Trametinib/Mekinist)</h4><div class="NLM_p">Compound <b>4</b> (trametinib/GSK1120212), as a dimethyl sulfoxide solvate (JTP-74057),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> is a selective allosteric inhibitor of mitogen/extracellular signal-regulated kinases (MEK1 and MEK2) approved by the U.S. FDA to treat metastatic melanoma in adult patients carrying BRAF Val600Glu or Val600Lys mutations. MEK has been reported to be involved in the pathology of various malignant tumors.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Abe and co-workers<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> started their discovery chemistry with compound <b>3</b> that contained three aromatic rings on the pyridopyrimidine scaffold that presented an unattractive starting point for further optimization due to significant hydrophobicity. (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) Therefore, these investigators reduced the hydrophobicity of <b>3</b> by replacing the hydrophobic phenyl ring at <i>N</i>-3 with the bioisosteric, relatively polar cyclopropyl ring and by making other key modifications that involved replacement of <i>para</i>-chloroaniline with the frequently occurring MEK kinase inhibitory 2-fluoro-4-iodoaniline pharmacophore (<i>para</i>-iodine consistently forms electrostatic interactions with the backbone atoms of Val127)<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and a polarity-enhancing acetamide substitution on <i>N</i>1-phenyl ring. This work eventually yielded compound <b>4</b>, which exhibited significantly reduced hydrophobicity and improved cellular potency by ∼490- and ∼1700-fold, respectively, against the renal adenocarcinoma ACHN cell line and the colorectal adenocarcinoma HT-29 cell line as shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures and in vitro potency of compounds <b>3</b> and <b>4</b> (trametinib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7"> Tyrosine Kinase Inhibitor <b>5</b> (Lenvatinib/Lenvima)</h4><div class="NLM_p">Compound <b>5</b> (lenvatinib/E7080)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> is an orally active multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), platelet derived growth factor receptor α (PDGFRα), Kit, and rearranged during transfection (RET) kinases. It was approved by the U.S. FDA in 2015 to treat patients with differentiated thyroid cancer.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Chemically, compound <b>5</b> has a cyclopropyl urea moiety with a hinge-binding 4,6,7-trisubstituted quinoline ring (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Analysis of kinetic interactions of <b>5</b> with VEGFR2 indicated that <b>5</b> had a fast association rate constant and a slow dissociation rate constant, thereby increasing the amount of time it is bound to VEGFR2.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> X-ray cocrystal studies have shown that compound <b>5</b> binds to VEGFR2 in a DFG-in conformation, a situation that was facilitated by the presence of a small cyclopropane substituent. The cyclopropyl ring is usually occupied by the larger phenyl ring of other receptor tyrosine kinase inhibitors that bind in the DFG out conformations. Apart from the ATP-binding active site interactions, compound <b>5</b> interacts with the side chain of residue Phe1047 in the neighboring (allosteric site) region through a CH−π interaction with the cyclopropyl ring, eventually leading to a potentially long residence time in complex with VEGFR2.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of compound <b>5</b> (lenvatinib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Plk1 Inhibitor <b>6</b> (Volasertib)</h4><div class="NLM_p">Polo-like kinase 1 (Plk1), a serine/threonine protein kinase, plays an important role in multiple stages of mitosis and serves as a prime therapeutic target for the development of antineoplastic drugs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> An early compound <b>6</b> (BI 6727) (Plk1, IC<sub>50</sub> = 0.87 nM), discovered through the high-throughput screening of a small molecule library and subsequent lead optimization efforts, is an example of a dihydropteridinone compound, known to demonstrate a high potency and inhibitory selectivity toward Plk1<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). On the basis of the X-ray cocrystal structure of Plk1-compound <b>6</b>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> it is apparent that the benzamide substituent (cyclopropylmethyl-piperazinyl-cyclohexyl) is solvent-exposed and it has contributed toward improved PK properties of this compound. A structurally related analogue, compound <b>7</b> (BI 2536),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> lacked the cyclopropylmethyl-piperazinyl moiety and showed a poor PK profile compared to the PK profile of compound <b>6</b>, thereby substantiating the role of the cyclopropylmethyl-piperazinyl moiety in influencing the PK profile. It may be noted that the cyclopropylmethyl substituted piperazine ring serves as a solubilizing basic side chain that is solvent-exposed.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of compounds <b>6</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_1_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Polo-like Kinase 4 (Plk4) Inhibitor <b>10</b></h4><div class="NLM_p">This type of serine/threonine kinase is a conserved upstream regulator of centriole duplication that produces centrosome amplification, genome instability, and tumor development.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Work by Sampson and co-workers<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> on the lead compound <b>8</b><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> showed significant Plk4 potency and intraperitonial antitumor efficacy (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). However, this molecule had suboptimal PK properties (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). These investigators realized that the configurational instability of <b>8</b> was due to the presence of an alkene moiety, which permits the potential isomerization of pharmacologically active <i>E</i>-isomer into a mixture with a less active <i>Z</i>-isomer in vivo. By replacing the alkene bond with a bioisosteric cyclopropane ring, these authors not only achieved configurational stability in this series but also improved aqueous solubility due to the increased sp<sup>3</sup> character (three-dimensionality). These efforts led to the synthesis of <b>9</b>, a molecule with enzyme- and cell-based activity comparable to that of <b>8</b> but with an excellent PK profile (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Additional structure–activity relationship (SAR) studies on <b>9</b> resulted in the discovery of the orally bioavailable molecule, <b>10</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures, in vitro potency, and PK properties of Plk4 inhibitory compounds <b>8</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_1_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Multiple Tyrosine Kinase Inhibitors <b>12</b> (Cabozantinib/Cometriq), <b>13</b> (Foretinib), <b>14</b> (Altiratinib), and <b>15</b> (Golvatinib)</h4><div class="NLM_p">Compound <b>12</b> (cabozantinib) was approved by the U.S. FDA in 2012 for the treatment of medullary thyroid cancer. It is an inhibitor of multiple tyrosine kinase receptors as shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The replacement of a chemically unstable acyl thiourea linker in compound <b>11</b> with a novel cyclopropyl-1,1-dicarboxamide linker led to the discovery of many clinically important compounds, including compound <b>12</b>, with the ability to inhibit different types of kinases. For example, compound <b>13</b> (foretinib/XL-880), a structurally related analogue of cabozantinib, exhibiting a morpholinyl propoxy group in place of the 7-methoxy group, inhibited multiple kinases.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Similarly, compound <b>14</b> (altiratinib/DCC-2701) demonstrated balanced inhibition of c-Met/hepatocyte growth factor receptor (HGFR), VEGFR2, Tie 2 receptor tyrosine kinase (TIE2), and tropomycin receptor kinase (Trk) with promising oral antiangiogenic and antineoplastic efficacy.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Compound <b>14</b> is currently undergoing phase I clinical trials (NCT02228811). In contrast, compound <b>15</b> (golvatinib/E7050) inhibits only MET and VEGFR2, with nanomolar IC<sub>50</sub> values as shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The spirocyclopropyl substitution at the methylene unit of the malonamides in <b>12</b>–<b>15</b> primarily contributed toward PK properties.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and in vitro potency of tyrosine kinase inhibitors <b>11</b>–<b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_1_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Aurora Kinase Inhibitor <b>18</b></h4><div class="NLM_p">This compound has been found to inhibit not only Aurora A and Aurora B kinases but also other oncogenic kinases like Janus kinase 2 (JAK2) and Abelson tyrosine kinase (Abl) (Thr315Ile mutant). The discovery of compound <b>18</b> (AT9283) by Howard and co-workers<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> began with the ligand-efficient pyrazolyl benzimidazole fragment hit <b>16</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). This led to the identification of a cyclohexyl urea analogue <b>17</b>, which had acceptable affinity toward Aurora A and a 10-fold increased affinity for Aurora B compared to an early phenyl urea lead. However, analogue <b>17</b> was very lipophilic. To reduce the lipophilicity of <b>17</b>, the large lipophilic cyclohexyl urea moiety was replaced with a smaller and less lipophilic cyclopropyl urea moiety. This structural modification resulted in the discovery of a cyclopropyl urea-containing clinical candidate <b>18</b> that demonstrated significantly improved enzymatic- and cell-based potencies, clogP value, and aqueous solubility as shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Crystal structure studies (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2w1g">2w1g</a>) indicated that <b>18</b> has a folded bioactive conformation enforced by intramolecular hydrophobic interactions between the cyclopropyl group and the core benzimidazole ring.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Because <b>18</b> does not utilize the Thr315 gatekeeper residue for its binding, it can bind to the imatinib-resistant Thr315Ile mutant Abl kinase.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> On the basis of the above properties, <b>18</b> is currently undergoing clinical trials for the treatment of cancer (NCT00443976).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures, in vitro potency, and physicochemical properties of Aurora kinase inhibitors <b>16</b>–<b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional examples of clinically valuable cyclopropane-containing kinase inhibitory anticancer compounds including P21 activated kinase inhibitor, Pim kinase inhibitor, lucitanib, and XL228 are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Non-Kinase Inhibitory Drug Candidates</h3><div id="sec1_3_1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Poly(ADP-ribose)polymerase (PARP) Inhibitor <b>20</b> (Olaparib/Lynparza)</h4><div class="NLM_p">Compound <b>20</b> (olaparib/AZD2281/KU0059436),<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> a phthalazinone derivative with potent PARP-inhibitory activity, was introduced in 2014 as Lynparza for the treatment of germline breast cancer susceptibility gene (BRCA) mutated advanced ovarian cancers<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). The cyclopropyl moiety in <b>20</b> yielded the highest oral absorption (mouse plasma concentration 1 h after oral dosing of 0.59 vs 0.3 μg/mL for its precursor ethyl amide analogue, <b>19</b>).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Furthermore, a cyclopropyl amide analogue <b>20</b> showed a significantly higher oral exposure (100% bioavailability in rats) compared to an ethyl amide analogue (40% bioavailability in rats).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures, in vitro potency, and PK properties of PARP inhibitors <b>19</b> and <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Lysine Specific Demethylase 1 Inhibitor <b>21</b></h4><div class="NLM_p">Compound <b>21</b> (GSK2879552) is an orally active mechanism-based covalent inhibitor of the flavin-dependent lysine (K) specific demethylase 1 (LSD1), also referred to as KDM1A, with a potential application as an antineoplastic drug.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Because of the considerable similarity between the active sites of flavin-dependent LSD1 and MAO enzymes, Johnson and co-workers<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> began their mechanism-based LSD1 inhibitor discovery efforts with the clinically approved MAO inhibitor, tranylcypromine (compound <b>95</b>, see <a class="ref internalNav" href="#sec1_3_8" aria-label="CNS Active Drugs">CNS Active Drugs</a> section). Specifically, the 4-carboxybenzylpiperidinemethyl moiety was added onto the amine group of tranylcypromine to obtain a highly selective compound <b>21</b> as shown in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>. As stated for tranylcypromine (see <a class="ref internalNav" href="#sec1_3_8" aria-label="CNS Active Drugs">CNS Active Drugs</a> section), presence of a chiral cyclopropane linker moiety facilitated the projection of the phenyl and the amino groups in a desirable <i>trans</i>-geometry. Compound <b>21</b> is currently undergoing clinical trials for the treatment of refractory small cell lung carcinoma (NCT02034123) and acute myeloid leukemia (NCT02177812).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure and in vitro potency of LSD1 inhibitor <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_1_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> P-Glycoprotein (P-gp) Inhibitor <b>23</b> (Zosuquidar)</h4><div class="NLM_p">P-gp is a target for the treatment of certain types of multidrug resistance (MDR) cancer resulting from the overexpression of P-gp.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Compound <b>22</b> (MS-073), a dibenzosuberylpiperazine derivative, was developed by Sato and co-workers<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> to cope with cancers showing MDR (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). However, compound <b>22</b> had inadequate oral bioavailability owing to the unstable nature of the <i>N</i>-dibenzosuberyl moiety under acidic conditions (<i>t</i><sub>1/2</sub> at pH 2/37 °C ∼ 15 min). Subsequently, Pfister and co-workers<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> undertook the structural modification of compound <b>22</b> in an effort to improve the pharmacological activity of the parent compound. One of the modifications, a fusion of the cyclopropyl ring at the ethylene bridge of the dibenzosuberane, led to either similar or improved activity compared to compound <b>22</b>. A geminal difluoro substitution on the cyclopropane ring yielded the highly acid-stable, phase III clinical candidate, compound <b>23</b>/zosuquidar/RS 33295/LY-335979 (<i>t</i><sub>1/2</sub> at pH 2/37 °C > 72 h compared to hydrogen substituted counterpart, <i>t</i><sub>1/2</sub> ∼ 3 h) as shown in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, further development of <b>23</b> was discontinued due to toxicity and insufficient inhibition of P-gp.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of P-gp inhibitors <b>22</b> and <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Interested readers are directed to the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a> for additional examples of cyclopropane-containing nonkinase inhibitory anticancer compounds including histone deacetylase inhibitors, bromodomain inhibitors, heat shock protein 90 inhibitor, and LSD1 inhibitors.</div></div></div></div><div id="sec1_3_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Preclinical/Clinical/Approved Drug Candidates for Infectious Diseases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_2_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Anti-HCV Drug Candidates: Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors</h3><div id="sec1_3_2_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Compound <b>25</b> (Boceprevir/Victrelis)</h4><div class="NLM_p">Compound <b>25</b> (boceprevir/SCH 503034)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> is a direct-acting hepatitis C virus (HCV) NS3/4A protease inhibitor as shown in <a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>. HCV NS3/4A protease is critical to the replication of HCV. Therefore, it serves as a prime target for anti-HCV drug development. Venkatraman and co-workers<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> used an inhibitor design strategy that was entirely based on information gathered from substrate-HCV NS3/4A protease active site complex interactions. This strategy resulted in the synthesis of long peptidic compounds that spanned the entire substrate-binding site (P1–P6 and P1′–P5′). Early efforts were directed to designing small peptidomimetic/nonpeptidic compounds with enhanced potencies in both HCV NS3 protease enzymatic- and HCV replicon-based assays. To this end, the high molecular weight (1265 Da) undecapeptide ketoamide inhibitor (compound <b>24</b>), with a slow and tight two stage binding mechanism, served as a starting lead (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). Subsequently, this lead compound was subjected to a series of stepwise truncations at both ends. This was followed with optimization of enzymatic and replicon potencies and PK-enhancing P1 and P2 moieties, P3 capping, and a reversible warhead α-ketoamide Ser139-covalent trap, which resulted in the discovery of compound <b>25</b> as shown in <a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> One of the key synthetic modifications leading to this compound was the introduction of the <i>gem</i>-dimethylcyclopropylproline moiety at the P2 position as a surrogate of leucine, which was at that time proved to be the most optimal P2 moiety. Overall, the improved potency of compound <b>25</b> results from a favorable interaction of the <i>gem</i>-dimethylcyclopropylproline P2 moiety with the methyl side chain of Ala156 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LOX">3LOX</a>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of HCV NS3/4A protease inhibitors <b>24</b> and <b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_2_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Compound <b>29</b> (Telaprevir/Incivek)</h4><div class="NLM_p">Compound <b>29</b> received approval from the U.S. FDA in 2011 for the treatment of chronic genotype 1 HCV infected patients. Chemically, it is a tetrapeptide featuring a reversible α-ketoamide serving as a covalent trap for Ser139 at the active site of HCV protease. Initial work by Perni and co-workers<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> culminated in the design and synthesis of uncharged tetrapeptide with micromolar inhibitory action on the HCV protease. These efforts led to the sequential discovery of compounds <b>26</b> and <b>27</b>, with <b>27</b> providing a 4-fold increase in inhibition of HCV NS3/4A protease (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). Subsequently, Perni and co-workers<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> developed compound <b>28</b> by replacing the nondrug-like aldehyde functionality in <b>27</b> with drug-like α-ketoamide featuring an S1′-binding cyclopropane P1′ moiety, which had improved enzyme- and replicon-based potencies over <b>27</b>. Two papers<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56, 57)</a> described the synthesis of compound <b>29</b>, a bicycloproline P2 bearing compound as shown in <a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>. The increased enzyme- and cell-based potencies of <b>28</b> and <b>29</b> compared to <b>27</b> is a result of two molecular modifications: the P2/P2* moiety and the acyl cyclopropyl carboxamide P1′ moiety.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of HCV NS3/4A protease inhibitors <b>26</b>–<b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_2_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Compound <b>30</b> (Vaniprevir)</h4><div class="NLM_p">McCauley and co-workers<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> used a lead optimization program that was comprised of: (1) macrocyclization between the P2 and P4 moieties, (2) variations of the linker between P2 and P4, (3) addition of novel heterocycles at P2 moiety, and (4) a P1 side chain exploration. The aforementioned modifications resulted in the discovery of compound <b>30</b> (vaniprevir/MK-7009),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> a P2–P4 macrocyclic HCV genotype 1 and 2 NS3/4A protease inhibitor, which had an excellent liver exposure and desirable PK profile (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>). The rationale for the inclusion of the ethylcyclopropyl P1 moiety and the acylcyclopropylsulfonamide P1′ moiety in the structure of <b>30</b> was to increase enzymatic and HCV replicon-based potencies and to improve PK profile.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> A similar rationale was used for the synthesisis of other related HCV NS3/4A protease inhibitors.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structure and in vitro potency of HCV NS3/4A protease inhibitor <b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_2_1_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Compound <b>33</b> (Grazoprevir)</h4><div class="NLM_p">Compound <b>33</b> (grazoprevir/MK-5172) is a second-generation HCV NS3/4A protease inhibitor with substantial potency against HCV genotypes 1 and 3 and A156 mutant variants.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> To develop compounds with enhanced potency against broad genotypes and mutant variants of the HCV NS3/4A protease, as well as desirable cellular activity and liver exposure upon oral dosing, Harper and co-workers<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> used a P2–P4 linker and P2 moiety optimization approach. The potency of the lead compound <b>31</b> (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>) against A156 mutant variants and various genotypes, although difficult to achieve, was realized by the insertion of a fused cyclopropyl ring at C1 and C2 of the macrocyclic linker, leading to <b>32</b> as shown in <a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The excellent liver exposure of <b>32</b> was considered a favorable property due to the liver being the predominant organ where HCV replication occurs.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The rationale for the 4–10-fold increase in the potency of <b>32</b> against Ala156 mutant enzymes compared to <b>31</b> was based on molecular modeling studies. In general, if the compounds binding affinity is not dependent upon a highly mutable residue, then one can hypothesize the retention of the wild-type enzyme binding affinity against mutant variants, e.g., Ala156 of HCV NS3/4A protease in this case. The presence of a cyclopropyl steric constraint in <b>32</b> will move the macrocycle away from the Ala156 residue compared to compound <b>31</b> to create an additional space for the binding of <b>32</b> to drug-resistant A156 mutants such as Ala156Thr or Ala156Val. The increased potency of <b>32</b> was proposed to result from the entropically more favorable binding by a fused-cyclopropyl constrained analogue.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures and in vitro potency of HCV NS3/4A protease inhibitors <b>31</b>–<b>33</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an aqueous milieu, the solubility of the potassium salt of compound <b>32</b> is 9.7 mg/mL, but it quickly drops to <0.009 mg/mL when it disproportionates to the significantly less soluble crystalline zwitterionic form. The formation of this zwitterionic form is driven by the basic P2 quinoline ring nitrogen (calculated p<i>K</i><sub>a</sub> of 4.47) and acidic sulfonimide NH group (calculated p<i>K</i><sub>a</sub> of 3.67). This limitation to the aqueous solubility of compound <b>32</b> was addressed by insertion of an alternative P2 heterocycle (quinoxaline) that had a less basic characteristic (p<i>K</i><sub>a</sub> ∼ 1.2) and lower likelihood to generate the less soluble zwitterion. These efforts led to the discovery of clinical candidate compound <b>33</b>, with an optimal PK and pharmacodynamic profile as shown in <a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p last">The regularly featured cyclopropyl sulfonimide and the ethyl/vinyl cyclopropyl moieties at the P1′ and P1 positions, respectively, intended to bind to the shallow S1′ and S1 pockets, present in the core structures of many HCV NS3/4A protease inhibitors, has been rationalized in other examples, such as compound <b>36</b> (see below).</div></div><div id="sec1_3_2_1_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Compound <b>36</b></h4><div class="NLM_p">Compound <b>36</b> (BMS-605339) is a Boc-protected tripeptidic HCV NS3/4A protease inhibitor, whose structure is comprised of a novel isoquinoline ring on the P2 moiety and an acyl cyclopropylsulfonamide as P1′ group.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Scola and co-workers<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> began their search for potent HCV NS3/4A protease inhibitors based on early leads typified by the tripeptidic carboxylic acid <b>34</b> shown in <a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>. Guided by molecular modeling analysis, this group wanted to exploit the S1′ shallow pocket by introducing the bioisosteric replacement of the carboxyl group with an alkyl acylsulfonamide that fulfills the hydrogen bonding capacity of the original group while establishing new van der Waals interactions between the alkyl and the S1′ site residues. This concept resulted in the development of the next acyl cyclopropylsulfonamide, lead compound <b>35</b>, with significantly greater enzymatic and replicon potencies than compound <b>34</b>. (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>) Seeking improvement of the aqueous solubility and PK profile, these investigators focused on optimizing P2* heterocycles by replacing the 7-methoxy-2-phenylquinoline ring with a 6-methoxyisoquinoline ring, thus obtaining the orally bioavailable clinical candidate <b>36</b> (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>), with excellent in vivo efficacy in GT-1 infected patients. A cocrystal structure of <b>36</b> with HCV NS3/4A protease (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NWK">4NWK</a>) showed optimal van der Waals interactions between the cyclopropyl P1′ moiety and the hydrophobic residues of the shallow S1′ pocket.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure, in vitro potency, and PK properties of HCV NS3/4A protease inhibitor <b>34</b>–<b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_2_1_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Compound <b>38</b> (Simeprevir/Olysio)</h4><div class="NLM_p">Compound <b>38</b> (TMC435/simeprevir) was developed by Rosenquist and co-workers,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> starting from the P2 cyclopentanedicarbonyl, serving as a mimic of the P2 proline moiety in compound <b>37</b> as shown in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>. Compound <b>37</b> was developed into <b>38</b> through four structural modifications: (a) potency- and PK-enhancing replacement of the carboxylic acid with a bioisosteric S1′ binding acyl cyclopropylsulfonamide, (b) truncation of the peptide backbone, (c) macrocyclization of truncated peptides, and (d) optimization of the P2* quinoline moiety. As shown in <a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>, compound <b>38</b> has an optimal pharmacodynamic and PK profile.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The function of the vinylcyclopropyl P1 moiety and the cyclopropyl sulfonamide as the P1′ moiety is the same as previously explained.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures, in vitro potency, and PK properties of HCV NS3/4A protease inhibitors <b>37</b> and <b>38</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_2_1_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> HCV NS5A Inhibitor <b>40</b> (Ledipasvir/Harvoni in Combination with Sofosbuvir)</h4><div class="NLM_p">Link and co-workers<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> sought to identify inhibitory compounds targeted to the HCV nonstructural protein 5A (NS5A) with a high potency and an extended half-life to reduce the emergence of viral resistance. Such inhibitors could be combined with direct acting antiviral drugs with complementary mechanisms of actions to obtain a significant, sustained virologic response in HCV infected patients. These investigators initiated SAR studies on a series of symmetric bis-benzimidazole and unsymmetric imidazole/benzimidazole scaffolds that ultimately yielded several HCV NS5A inhibitors. Among these, an unsymmetric series was found to be advantageous with respect to potency and PK optimization. As shown in <a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>, the precursor compound <b>39</b> proved to be a very potent HCV NS5A inhibitor. The protein-adjusted EC<sub>50</sub> of <b>39</b> against HCV genotype 1a was 784 pM, reflecting a protein-binding shift of 14-fold (<a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>). The final optimization of <b>39</b> involved the insertion of a spiro-cyclopropylpyrrolidine ring in place of the pyrrolidine ring to produce the most potent HCV NS5A inhibitor, compound <b>40</b> (ledipasvir/GS-5885), as shown in <a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The protein adjusted EC<sub>50</sub> values of compound <b>40</b> for GT-1a and GT-1b were 210 and 27 pM, respectively, corresponding to a protein-binding shift of only 6.7-fold as opposed to 14-fold obtained with its precursor compound <b>39</b>.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Thus, the presence of a spiro-cyclopropyl substituent at the 4-position of the pyrrolidine ring has been found to contribute not only to enhancing potency and improving protein-adjusted EC<sub>50</sub> values but also to a notable PK profile in monkeys (<a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>) and in healthy volunteers.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures, in vitro potency, and PK properties of HCV NS5A inhibitors <b>39</b> and <b>40</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_2_1_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> HCV NS5B Non-Nucleoside Inhibitor <b>42</b></h4><div class="NLM_p">The HCV nonstructural protein 5B (NS5B), a 66 kDa RNA-dependent RNA polymerase (RdRp), serves as an attractive anti-HCV target because of its key role in the replication of HCV RNA genome and humans lack its functional equivalent.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> It is a cyclopropyl-fused indolobenzazepine class of HCV NS5B polymerase inhibitor targeted to the allosteric thumb domain I. To gain complementary mechanism of action, this compound has the potential to be used in combination with direct acting antiviral drugs. Gentles and co-workers<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> began their drug discovery efforts with a general lead structure represented by compound <b>41</b> as shown in <a class="ref internalNav" href="#fig18" aria-label="Figure 18">Figure 18</a>. The transition of the novel lead indolobenzazepine structure <b>41</b> into <b>42</b> (BMS-791325)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> started with introducing a cyclopropyl moiety at the olefinic double bond of the tetracyclic indolobenzazepine core structure. This strategy has led to meet the following anticipated goals: (a) introducing a conformational rigidity within the tetracyclic ring system, (b) establishing productive molecular interactions between the cyclopropyl group and the residues from the thumb domain I of HCV NS5B polymerase,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and (c) eliminating a potentially reactive Michael acceptor (α,β-unsaturated carbonyl) functionality.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In general, the potency of the cyclopropyl analogues was greater than that of the olefin counterparts, presumably because of the interaction of the cyclopropyl ring hydrogens with the carbonyl oxygen backbone of Leu492 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NLD">4NLD</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These investigations eventually led to discovery of the clinical candidate, compound <b>42</b>, as shown in <a class="ref internalNav" href="#fig18" aria-label="Figure 18">Figure 18</a>. It is currently in phase III clinical trials in combination with daclatasvir (HCV NS5A inhibitor) and asunaprevir (HCV NS3/4A protease inhibitor) (NCT02170727).</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures, in vitro potency, and PK properties of HCV NS5B inhibitors <b>41</b> and <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional examples of cyclopropane-containing HCV NS3/4A protease inhibitors (MK-1220, asunaprevir, danoprevir, narlaprevir, vedroprevir, neceprevir, paritaprevir, and sovaprevir) are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Anti-Respiratory Syncytial Virus Clinical Candidate</h3><div id="sec1_3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Respiratory Syncytial Virus (RSV) Fusion Inhibitor <b>45</b></h4><div class="NLM_p">Compound <b>45</b> (BMS-433771)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> is a RSV fusion inhibitor. Yu and co-workers<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> began optimization of compound <b>43</b> that had oral anti-RSV activity in RSV-infected mice. However, <b>43</b> undergoes significant <i>N</i>-demethylation at its dimethylamine and dimethylamide functionalities as shown in <a class="ref internalNav" href="#fig19" aria-label="Figure 19">Figure 19</a>.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> To address this metabolic liability of <b>43</b>, these investigators replaced the dimethylamino ethyl substituent at <i>N</i><sub>1</sub> of the benzimidazole ring with the butyronitrile moiety and the bulky substituent at benzimidazolone ring with a small substituent (e.g., isopropyl) to yield compound <b>44</b>, having excellent antiviral potency and Caco-2 permeability as shown in <a class="ref internalNav" href="#fig19" aria-label="Figure 19">Figure 19</a>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, compound <b>44</b> had a poor human liver microsome (HLM) stability. This drawback was remediated by replacing the isopropyl substituent with an isosteric cyclopropyl ring, which is less lipophilic (hydrophobic substituent constant π for cyclopropyl is 1.2)<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> than the isopropyl group (π = 1.53).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Through polarity-enhancing molecular modifications (i.e., isopropyl to cyclopropyl and butyronitrile to hydroxybutyl), it was possible to develop candidate <b>45</b> as shown in <a class="ref internalNav" href="#fig19" aria-label="Figure 19">Figure 19</a>. Compound <b>45</b> showed excellent plasma exposure in rats, mice, dogs, and monkeys, a dose-dependent reduction in RSV titers in the lungs of infected animal models, did not produce genotoxicity in the Ames mutation assay, and an IC<sub>50s</sub> > 26.5 μM against major drug metabolizing CYP450 isoforms.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures, in vitro potency, and physicochemical properties of RSV fusion inhibitors <b>43</b>–<b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec1_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Anti-HIV Clinical Candidate Drugs</h3><div id="sec1_3_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> HIV-1 RT Inhibitor <b>47</b> (Nevirapine/Viramune)</h4><div class="NLM_p">Compound <b>47</b> (nevirapine), approved as a drug in 1996, is a first-generation non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV infected patients.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> HIV-1 RT is a well established target for the development of inhibitors for the treatment of HIV infections. The precursor of compound <b>47</b>, the <i>N</i>-11 ethyl analogue <b>46</b>, demonstrated potential metabolic liability due to oxidative <i>N</i>-deethylation metabolism. To overcome this problem, the <i>N</i>-11 ethyl group on the tricyclic bispyridodiazepinone core was replaced with the cyclopropyl moiety to yield the metabolically more stable compound <b>47</b> as shown in <a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures of HIV-1 RT inhibitors <b>46</b> and <b>47</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> HIV-1 RT Inhibitor <b>48</b> (Efavirenz/Sustiva)</h4><div class="NLM_p">Compound <b>48</b> (DMP-266/efavirenz),<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> approved in 1998, is a second-generation NNRTI used for the treatment of HIV infected patients (<a class="ref internalNav" href="#fig21" aria-label="Figure 21">Figure 21</a>). The favorable contacts between the smaller, less polarizable cyclopropyl ethynyl moiety in <b>48</b>, in contrast to bulky methyl substituted aromatic pyridine ring in <b>47</b>, and the mutable HIV-1 RT allosteric binding site aromatic side chains of Tyr181 and Tyr188 are very limited.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70, 71)</a> As a result, these interaction patterns with the target enzyme allow compound <b>48</b> to adapt to Tyr181Cys and Tyr188Cys of the mutant HIV-1 RT much better than compound <b>47</b>.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70, 71)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structure of HIV-1 RT inhibitor <b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> HIV-1 RT Inhibitor <b>50</b> (Abacavir/Ziagen)</h4><div class="NLM_p">Abacavir (compound <b>50</b>), approved by the U.S. FDA in 1998, is a synthetic carbocyclic nucleobase prodrug of carbovir (compound <b>49</b>) that upon oral administration undergoes unique intracellular metabolic activation to a potent HIV-1 RT inhibitor, carbovir triphosphate.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Compound <b>49</b> has shown excellent in vitro anti-HIV activity; however, it had low oral bioavailability in rats and monkeys and a limited CNS penetration.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Among the various C-6 amino substituents that were investigated to increase the oral bioavailability and CNS penetration of <b>49</b>, the cyclopropyl amino derivative yielded compound <b>50</b>, with significant oral bioavailability, as well as CNS penetration as shown in <a class="ref internalNav" href="#fig22" aria-label="Figure 22">Figure 22</a>.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of HIV-1 RT inhibitors <b>49</b> and <b>50</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A cyclopropane-containing clinical HIV-1 RT inhibitor (MIV-150) is described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Antibacterial Clinical Drug Candidates</h3><div id="sec1_3_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Quinolone Antibacterials <b>51</b>–<b>54</b></h4><div class="NLM_p">The quinolone antibacterials have become an important class of chemotherapeutic drugs since the introduction of nalidixic acid as an antibacterial drug in the 1960s.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> However, nalidixic acid and structurally related analogues lack activity against Gram-positive bacteria, a feature that limits their therapeutic effectiveness.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Extensive SAR studies have led to the introduction of a fluoro group at position 6, a piperazine ring at position 7, and more importantly, a cyclopropyl substituent at position 1 of the quinolone core.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75, 76)</a> These modifications eventually resulted in more than a dozen 1-cyclopropyl-containing fluoroquinolone antibacterial drugs. Representative of these are compound <b>51</b>/ciprofloxacin (Ciloxan, Cipro), compound <b>52</b>/moxifloxacin (Vigamox, Avelox, Moxeza), compound <b>53</b>/besifloxacin (Besivance), and compound <b>54</b>/sitafloxacin (Gracevit) as shown in <a class="ref internalNav" href="#fig23" aria-label="Figure 23">Figure 23</a>. The cyclopropyl ring contributed toward increased antibacterial potency and a wider antibacterial spectrum including both Gram-negative and Gram-positive bacterial infections. Moreover, the cyclopropyl ring in these quinolone antibacterials may contribute to drug binding to the binary complex of bacterial DNA gyrase/topoisomerase enzyme–DNA complex and produced an optimized PK profile.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of quinolone antibacterial drugs <b>51</b>–<b>54</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> DHP-I Inhibitor <b>55</b> (Cilastatin)</h4><div class="NLM_p">This cysteine derivative (compound <b>55/</b>MK0791) is a high affinity reversible inhibitor of the renal enzyme dehydropeptidase-I (DHP-I) as shown in <a class="ref internalNav" href="#fig24" aria-label="Figure 24">Figure 24</a>.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> DHP-I is responsible for the hydrolytic degradation of the β-lactam ring present in the antibacterial drug <b>56</b> (imipenem).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Thus, compound <b>55</b>, when combined with <b>56</b> (marketed as Primaxin), increases compound <b>56</b>’s in vivo stability and prolongs antibacterial action by preventing the metabolism of <b>56</b> to inactive compounds.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures of compounds <b>55</b> and <b>56</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>56</b> is rapidly metabolized in the kidney by the enzyme DHP-I, which decreases the urinary levels of the drug below the minimum inhibitory concentration of certain bacteria that cause urinary tract infections.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Birnbaum and co-workers<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> addressed this problem by designing peptide compounds carrying a dehydro (olefinic) bond to mimic the double bond present in the five membered ring of <b>56</b>, with the aim of developing a competitive inhibitor of DHP-I that could be used in combination with <b>56</b> to decrease its metabolism and thus to prolong its antibacterial action. These efforts led to discovery of the cyclopropyl-containing compound <b>55</b>, which, except for the dehydro bond and the carboxyl and the amino groups both directly attached to the dehydro bond, is dissimilar from <b>56</b>. The coordination of the <i>N</i>-terminal amino group with Zn1 is important for the hydrolysis of peptide substrates. Similarly, the hydroxyl group of <b>56</b> coordinates with Zn1 and undergoes hydrolysis. Because compound <b>55</b> contains a cyclopropyl moiety instead of an amino of dipeptide substrates and a hydroxyl group as in <b>56</b>, it does not coordinate with Zn1 and, thus, can inhibit enzyme activity.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p last">On the basis of X-ray crystallographic data<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> and on computational modeling,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> it was concluded that repulsion exists between the cyclopropyl ring and Zn1 at the active site of DHP-I. Moreover, the cyclopropyl moiety entered into hydrophobic interaction with the side chain of Tyr68, thus preventing departure of the leaving group from the transition state.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> As stated earlier, repulsion causes the carbonyl group of <b>55</b> to move slightly away and, thus, to be shielded from nucleophilic attack. Overall, the above observations explain why compound <b>55</b> is a DHP-I inhibitor and not a substrate.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div></div></div></div><div id="sec1_3_6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Respiratory System Preclinical/Clinical Drug Candidates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Phosphodiesterase 4 (PDE4) Inhibitor <b>57</b> (Roflumilast/Daliresp)</h3><div class="NLM_p">Compound <b>57</b>, introduced in the U.S. market in 2011, and its pharmacologically active <i>N</i>-oxide metabolite, are potent and selective PDE4 inhibitors (PDE4B IC<sub>50</sub> = 0.84 nM) as shown in <a class="ref internalNav" href="#fig25" aria-label="Figure 25">Figure 25</a>.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Compound <b>57</b> is indicated for the treatment of chronic obstructive pulmonary disease (COPD).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The cyclopropylmethyl moiety of this drug forms hydrophobic interactions within the large hydrophobic Q2 pocket formed by Met411, Phe414, Met431, and Phe446 residues of PDE4B (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structure of phosphodiesterase 4 inhibitor <b>57</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Leukotriene D<sub>4</sub> (LTD<sub>4</sub>) Antagonist <b>59</b> (Montelukast/Singulair)</h3><div class="NLM_p">This drug (compound <b>59</b>/MK-476)<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> is approved by the U.S. FDA for the treatment of asthma and allergic rhinitis. The montelukast precursor compound <b>58</b> (MK-679/Venzair), a LTD<sub>4</sub> antagonist (LTD<sub>4</sub> IC<sub>50</sub> = 3.1 nM), produced severe liver abnormalities in patients due to induction of peroxisomal enzyme activity (mice 400 mg/kg per oral peroxisomal enzyme induction/PEI = 65%), an effect that prompted its withdrawal from the market as shown in <a class="ref internalNav" href="#fig26" aria-label="Figure 26">Figure 26</a>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> To attenuate liver toxicity, Labele and colleagues<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> first replaced one of the thioacetal groups in <b>58</b> with an arylalkyl group and this resulted in enhanced potency. However, most of the <b>58</b>-induced peroxisomal enzyme activity was eliminated by introducing geminal substituents, specifically a spirocyclopropyl fragment, on the β-carbon of the thiopropionic acid side chain. Taking cues from the observation that peroxisomes recognize and β-oxidize fatty acids, the unsubstituted β-position, as in <b>58</b>, was thought to be the cause for significant PEI activity. Consequently, the PEI activity of <b>58</b> was successfully eliminated by attaching the spirocyclopropyl ring to the β-carbon.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> These aforementioned changes led to the clinically validated thiomethyl cyclopropyl acetic acid side chain analogue <b>59</b> (LTD<sub>4</sub> IC<sub>50</sub> = 0.5 nM, PEI = 16%) as shown in <a class="ref internalNav" href="#fig26" aria-label="Figure 26">Figure 26</a>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures of LTD<sub>4</sub> antagonists <b>58</b> and <b>59</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Adenosine A<sub>2B</sub> Receptor Antagonist <b>62</b></h3><div class="NLM_p">The adenosine A<sub>2B</sub> receptor, a G-protein coupled receptor, has been shown to mediate the release of inflammatory mediators from mast cells and airways epithelial cells, which plays a role in the pathophysiology of asthma.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Eastwood and co-workers<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> have conducted SAR studies on a promising diaryl substituted pyrazine amide lead <b>60</b> as shown in <a class="ref internalNav" href="#fig27" aria-label="Figure 27">Figure 27</a>, with the intention of developing orally active compound for the treatment of asthma. Although <b>60</b> showed an excellent bioavailability as well as an acceptable plasma exposure, it had a very short intravenous half-life (<a class="ref internalNav" href="#fig27" aria-label="Figure 27">Figure 27</a>). The replacement of the methyl amide of <b>60</b> with a cyclopropyl amide yielded compound <b>61</b>, with significantly improved potency and PK profile (<a class="ref internalNav" href="#fig27" aria-label="Figure 27">Figure 27</a>). Because the cyclopropyl amide analogue <b>61</b> had a better overall therapeutic feature than other alkyl and aryl amides, this ring structure was kept constant and the two pendant aryl rings were modified. Implementation of these changes led to the discovery of a potent, selective, and orally efficacious clinical candidate, compound <b>62</b> (LAS101057),<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> which, in addition, was devoid of metabolically labile and potentially toxicophoric furan ring<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> as shown in <a class="ref internalNav" href="#fig27" aria-label="Figure 27">Figure 27</a>.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures, in vitro potency, and PK properties of adenosine A2B antagonists <b>60</b>–<b>62</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> IκB Kinase 2 (IKK2) Inhibitor <b>64</b></h3><div class="NLM_p">The IKK complex is comprised of two catalytic subunits, IKK1 and IKK2, and a regulatory subunit, nuclear factor-κB (NF-κB) essential modulator (NEMO).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> It is hypothesized that IKK2 catalyzes the phosphorylation of IκB in the cytoplasm, decreasing its association with NF-κB and allowing for the nuclear translocation of NF-κB to regulate gene transcription.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The dysfunction of the NF-κB signaling pathway has been proposed to be involved in the pathophysiology of rheumatoid arthritis, COPD, and asthma.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Because IKK1-deficient mice showed skeletal and skin abnormalities,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> selective IKK2 inhibitors could be used to treat rheumatoid arthritis, COPD, and asthma. Liddle and co-workers<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> sought to develop selective IKK2 inhibitors for the treatment of various inflammatory disorders. Their program began with the potent and selective IKK2 inhibitor <b>63</b> shown in <a class="ref internalNav" href="#fig28" aria-label="Figure 28">Figure 28</a>. The activity of compound <b>63</b> in a whole blood cellular assay (inhibition of lipopolysaccharide (LPS) stimulated TNFα in human whole blood) was decreased by ∼100-fold compared to IKK2 enzymatic inhibitory activity. Subsequently, compound <b>63</b> optimization was initiated to increase whole blood activity and enhance the PK profile in preclinical studies without compromising potency and selectivity toward IKK2. Among the various noncyclic and cyclic aliphatic substituents introduced at the 2-position of the 7-azaindole core structure, the cyclopropyl substituent (compound <b>64</b>) turned out to be superior in terms of potency, selectivity, activity in whole blood, and favorable in vivo clearance and oral bioavailability in the rat as shown in <a class="ref internalNav" href="#fig28" aria-label="Figure 28">Figure 28</a>.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures, in vitro potency, and PK properties of IKK inhibitors <b>63</b> and <b>64</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> p38α MAP Kinase Inhibitor <b>67</b> (Losmapimod)</h3><div class="NLM_p">Compound <b>67</b> is currently undergoing clinical trials for the treatment of COPD (NCT01218126) and acute coronary syndrome (NCT02145468). p38α MAP kinase, a serine/threonine kinase, has been implicated in the production of inflammatory cytokines such as TNFα and IL-1β, thus making this kinase an attractive target for developing effective antirheumatic drugs.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Angell et al.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> began p38α MAP kinase inhibitor discovery chemistry with a biphenylbenzamide scaffold. These SAR investigations led to the isopropyl analogue <b>65</b> (<a class="ref internalNav" href="#fig29" aria-label="Figure 29">Figure 29</a>). The replacement of the isopropyl group with a cyclopropyl moiety yielded compound <b>66</b> (<a class="ref internalNav" href="#fig29" aria-label="Figure 29">Figure 29</a>). X-ray cocrystal studies (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IPH">3IPH</a>) revealed a perfect fit of the cyclopropyl ring within the precise lipophilic pocket lined by Leu74 and Phe169. These findings also revealed the strict steric requirements of this pocket in the enzyme.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Because compound <b>66</b> is endowed with an excellent PK profile in rats, further investigations on it are warranted (<a class="ref internalNav" href="#fig29" aria-label="Figure 29">Figure 29</a>). It should be noted that compound <b>66</b> had a low brain to plasma ratio, thus decreasing the likelihood of <b>66</b> producing CNS toxicity.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> On the knowledge that the cyclopropylamine moiety fits perfectly within the lipophilic pocket of p38α kinase, Aston and co-workers<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> kept this moiety while performing structural modifications on the rest of the structure of <b>66</b>. The goal was to improve the inhibition of TNFα production in human whole blood and decrease the inhibition of drug metabolizing CYP450 2C9 enzyme. To reach this goal, these investigators modified the biphenyl scaffold and replaced the cyclopropylmethyl substituent with a <i>tert</i>-butylmethyl group, leading to the discovery of the clinical candidate <b>67</b> as shown in <a class="ref internalNav" href="#fig29" aria-label="Figure 29">Figure 29</a>.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The replacement of the phenyl and cyclopropyl rings in <b>66</b> with pyridine-3-yl and <i>tert</i>-butylmethyl groups, respectively, was necessary to improve human whole blood activity and decrease CYP2C9 inhibition. The replacement of the cyclopropylmethyl group on biaryl carboxamide moiety in <b>66</b> with a <i>tert</i>-butylmethyl group led to a final candidate <b>67</b>.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structures, in vitro potency, and PK properties of p38α MAP kinase inhibitors <b>65</b>–<b>67</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitor <b>70</b></h3><div class="NLM_p">The ITK has been shown to play a role in T-cell development, differentiation, and effector functions.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Many studies have demonstrated that ITK is essential for the control of T helper 2 (Th2) responses and pathological conditions such as lung inflammation, eosinophil infiltration, and mucous production.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Consequently, ITK is a therapeutic target for the development of drugs to treat allergic asthma and inflammatory disorders.</div><div class="NLM_p">Burch and co-workers<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> previously disclosed a tetrahydroindazole scaffold <b>68</b> (GNE-9822), with potent and selective inhibition of ITK activity (<a class="ref internalNav" href="#fig30" aria-label="Figure 30">Figure 30</a>). Further profiling of <b>68</b> revealed its off-target binding and cytotoxicity toward hepatocytes and Jurkat cells. Furthermore, <b>68</b> significantly inhibited the human ether-a-go-go-related gene (hERG) encoded potassium channel.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> These liabilities made this compound unsuitable for the treatment of asthma. Therefore, Burch and colleagues<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> decided to optimize <b>68</b> to minimize adverse effects. Their results indicated that reducing the basicity of tetrahydroindazole compounds (p<i>K</i><sub>a</sub> < 7.5) was associated with reduced cytotoxicity. Consequently, they replaced the basic dimethylaminoethyl side chain on benzylic carbon with the cyclic sulfone, yielding compound <b>69</b>, with an excellent inhibition of ITK enzyme activity, phospholipase C-γ (PLC-γ) phosphorylation in Jurkat cells, and a desirable reduction in cytotoxicity to Jurkat cells as shown in <a class="ref internalNav" href="#fig30" aria-label="Figure 30">Figure 30</a>. Subsequently, these investigators focused on increasing the ITK inhibitory potency. Ultimately, they optimized <b>69</b> to increase the interactions between <b>69</b> and the lipophilic pocket present in the vicinity of Phe435 of ITK active site. This was done by replacing the geminal dimethyl substituent with a difluorocyclopropyl methyl group, leading to the identification of compound <b>70</b> (GNE-4997), with drug-like properties as shown in <a class="ref internalNav" href="#fig30" aria-label="Figure 30">Figure 30</a>.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> The X-ray cocrystal structure of <b>70</b> with ITK (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4rfm">4rfm</a>) revealed efficient space filling of the lipophilic pocket present in close proximity to a gatekeeper residue Phe435 by a difluoromethylene moiety of cyclopropane ring. This may explain the enhanced potency of <b>70</b>.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures, in vitro potency, and physicochemical properties of ITK inhibitors <b>68</b>–<b>70</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Histamine H<sub>4</sub> Receptor (H<sub>4</sub>R) Antagonist <b>72</b></h3><div class="NLM_p">The H<sub>4</sub>R, an aminergic G-protein coupled receptor, is expressed on immune cells and has been shown to be a contributing factor for diseases whose pathophysiology is linked to inflammation such as asthma, allergic rhinitis, pain, irritable bowel disease, and cancer. Consequently, the H<sub>4</sub>R antagonist may be useful in treating the above-mentioned diseases.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Mowbray and co-workers<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> recently disclosed the discovery of compound <b>72</b> (ZPL-3893787/PF-3893787). One of the early lead structures was the trisubstituted pyrimidine compound <b>71</b> that showed selective H<sub>4</sub>R antagonist potency. In addition, this compound had drug-like physicochemical properties including aqueous solubility, permeability, and oral bioavailability as shown in <a class="ref internalNav" href="#fig31" aria-label="Figure 31">Figure 31</a>. However, it was predicted to exhibit a high clearance and extended half-life from rat and dog PK studies. Nonetheless, compound <b>71</b> served as an excellent tool compound for further optimization and detailed preclinical investigations. These efforts eventually resulted in discovery of a clinical compound, <b>72</b>, as shown in <a class="ref internalNav" href="#fig31" aria-label="Figure 31">Figure 31</a>. Compound <b>72</b> had a significantly lower rate of clearance compared to <b>71</b> in both rat and dog.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> This was reasoned based on a one log unit lower log <i>D</i> of <b>72</b> compared to that of <b>71</b>. However, compound <b>72</b> was still predicted to exhibit a long human half-life of 40 h. Compound <b>72</b> is currently undergoing phase II clinical trials for the treatment of atopic dermatitis (NCT02424253).</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures, in vitro potency, and PK properties of histamine H<sub>4</sub> receptor antagonists <b>71</b> and <b>72</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The replacement of the <i>tert</i>-butylmethyl group in <b>71</b> with a cyclopropylmethyl group gave <b>72</b>, with an improved PK profile. In contrast, replacement of the cyclopropylmethyl group in <b>66</b> with the <i>tert</i>-butylmethyl group yielded a final drug candidate <b>67</b>. Therefore, there are no firm rules and that the same exchange of groups in different molecules does not give the same results.</div><div class="NLM_p last">Cyclopropane-containing lumacaftor useful in the treatment of cystic fibrosis is described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">Anti-Inflammatory Preclinical/Clinical Drug Candidates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Lymphocyte-Specific Protein Tyrosine Kinase (Lck) Inhibitor <b>74</b></h3><div class="NLM_p">Lck belong to the Src family of tyrosine kinases.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> It is primarily expressed in T cells, where it facilitates T cell proliferation and production of interleukin 2.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Therefore, a compound that can potently and selectively inhibit Lck will also inhibit T cell activation and, as a result, be of potential use in the treatment of acute and chronic T cell-mediated autoimmune and inflammatory disorders.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Wityak and colleagues<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> began SAR optimization of 2-amino-5-carboxamidothiazoles as novel Lck inhibitors. These SAR studies led to the identification of the phenyl carboxamide analogue <b>73</b> (hLck IC<sub>50</sub> = 0.89 μM), which was further modified to obtain the cyclopropane carboxamide analogue <b>74</b> (hLck IC<sub>50</sub> = 0.035 μM) (<a class="ref internalNav" href="#fig32" aria-label="Figure 32">Figure 32</a>). These compounds are clear demonstration of the remarkable influence that a less lipophilic cyclopropyl moiety can have as a successful surrogate for the phenyl substituent. Compound <b>74</b> also showed excellent selectivity when subjected to in vitro screening against a panel of potential kinase targets.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Whether a cyclopropyl ring has contributed toward excellent selectivity profile remains to be evaluated.</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures of lck inhibitors <b>73</b> and <b>74</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Bruton’s Tyrosine Kinase (BTK) Inhibitor <b>78</b></h3><div class="NLM_p">Pharmacological inhibition of BTK, a downstream kinase of SYK kinase, is an excellent strategy to develop drugs to treat rheumatoid arthritis due to its key role in activating B cells.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Consequently, Lou and co-workers<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> began their small molecule BTK inhibitor discovery efforts with the initial lead <b>75</b> (BTK IC<sub>50</sub> = 10 nM). (<a class="ref internalNav" href="#fig33" aria-label="Figure 33">Figure 33</a>) Compound <b>75</b> showed suboptimal efficacy when tested in human whole blood (HWB) assays (HWB IC<sub>50</sub> for CD69 inhibition >1 μM) and had a high molecular weight and lipophilicity.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> To surmount these problems, these investigators conducted further SAR studies involving three molecular modifications: (a) truncation of the imidazopyrazine ring to a monocyclic pyridone, (b) constraining of the carboxamide into a dihydroisoquinoline ring, and (c) replacing the hydrophobic <i>tert</i>-butyl group with a dimethylamino group that yielded <b>76</b> (BTK IC<sub>50</sub> = 7 nM and HWB IC<sub>50</sub> = 100 nM).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> However, the poor aqueous solubility of <b>76</b> prompted these authors to replace the morpholine carbonyl functionality with a water-solubilizing <i>N</i>-methylpiperazine moiety to yield compound <b>77</b>, which not only exhibited improved aqueous solubility but also a greater potency in HWB assays. Subsequent structural alterations, such as substitution of the fluoro and cyclopropyl groups on the isoquinoline ring and introduction of unsaturation in isoquinoline ring, yielded compound <b>78</b>/RN486 (BTK <i>K</i><sub>d</sub> = 0.3 nM and HWB IC<sub>50</sub> = 17 nM) as shown in <a class="ref internalNav" href="#fig33" aria-label="Figure 33">Figure 33</a>.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Furthermore, unlike <b>77</b>, compound <b>78</b>, bearing a cyclopropyl moiety instead of <i>N</i>,<i>N</i>-dimethylamino group, is expected to obviate the formation of hepatotoxic primary aniline metabolites upon didemethylation by CYP450 oxidizing enzymes.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of BTK inhibitors <b>75</b>–<b>78</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Uric Acid Transporter 1 (URAT1) Inhibitor <b>80</b> (Lesinurad/Zurampic)</h3><div class="NLM_p">By selectively inhibiting URAT1, a transporter in kidney cells that mediates the renal reabsorption of urate, compound <b>80</b> (lesinurad/RDEA-594) is a uricosuric drug with potential to treat gout.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Compound <b>80</b> was serendipitously discovered that the major amide hydrolysis metabolite of a discontinued NNRTI, compound <b>79</b> (RDEA-806), unexpectedly lowered the uric acid levels in HIV patients as shown in <a class="ref internalNav" href="#fig34" aria-label="Figure 34">Figure 34</a>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structures of URAT1 inhibitors <b>79</b> and <b>80</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> p38α MAP Kinase Inhibitor <b>83</b></h3><div class="NLM_p">Liu and co-workers<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> sought to develop potent p38α MAP kinase inhibitors for the treatment of rheumatoid arthritis. They began SAR studies with a potent lead compound <b>81</b>, which had a high in vivo clearance and lower plasma exposures as shown in <a class="ref internalNav" href="#fig35" aria-label="Figure 35">Figure 35</a>. These aforementioned undesired properties resulted from the hydrolytic degradation of <i>N</i>-methoxybenzamide into a major, inactive acid metabolite. Subsequently, they replaced the <i>N</i>-methoxy group with various alkyl groups, leading to significantly less potent compounds. They hypothesized that replacing the methoxy group with an electron withdrawing group would render the benzamide NH a strong hydrogen bond donor and higher potency. This NH forms a key hydrogen bond with the Glu71 of p38α. Among the alkyl groups tried, the cyclopropyl substituent (e.g., compound <b>82</b>) demonstrated p38α MAP kinase inhibition that was comparable to that of lead compound <b>81</b>. This could be a result of the sp<sup>2</sup> character of the cyclopropyl carbons. They also anticipated an improved PK profile as a result of insertion of the cyclopropyl moiety at the benzamide. Furthermore, SAR exploration at the other carboxamide group ultimately yielded clinical candidate, <b>83</b>, which had excellent enzyme potency and significant activity against LPS-induced TNFα production in human peripheral blood mononuclear cells (hPBMC). Compound <b>83</b> inhibited LPS-induced TNFα production in vivo more efficaciously than <b>81</b>. Although <b>83</b> is four times less potent than <b>81</b> against p38α, it showed higher in vivo efficacy in both acute and chronic disease models.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> This was shown through the improved PK properties of <b>83</b> compared to <b>81</b> (<a class="ref internalNav" href="#fig35" aria-label="Figure 35">Figure 35</a>). Compound <b>83</b> has been investigated in phase II clinical trials for the treatment of severe plaque psoriasis (NCT00399906), atherosclerosis (NCT00570752), and rheumatoid arthritis (NCT00605735).</div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structures, in vitro potency, and PK properties of p38α MAP kinase inhibitors <b>81</b>–<b>84</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>83</b> had a pH-dependent solubility of 0.280 and 0.003 mg/mL at pH 1.2 and 6.5, respectively. Consequently, it was considered to be of limited use for the treatment of rheumatoid arthritis as rheumatoid arthritis patients are usually prescribed with the drugs that increase stomach pH.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> To address the above problem, Liu and co-workers<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> decided to develop a prodrug of compound <b>83</b> that is chemically stable between pH 1 and pH 7 and totally biotransformed into active metabolite <b>83</b> without releasing toxic byproducts. Ultimately, prodrug <b>84</b> (BMS-582949), as shown in <a class="ref internalNav" href="#fig35" aria-label="Figure 35">Figure 35</a>, was developed and upon oral dosing to rats as a suspension showed a superior PK profile compared to the corresponding suspension dose of <b>83</b>.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div></div><div id="sec1_3_7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Retinoic Acid Receptor-Related Orphan Receptor Gamma (RORγ) Inhibitor <b>87</b></h3><div class="NLM_p">RORγ is a nuclear receptor that regulates the production of IL-17 and the differentiation of pro-inflammatory T helper 17 cells that play an important role in the pathogenesis of autoimmune diseases such as psoriasis and rheumatoid arthritis.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Therefore, RORγ serves as a therapeutic target to develop treatments for immunological diseases. Toward this objective, Hirata and co-workers<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> began optimization of HTS-derived 1,2,5-trisubstituted 1,3,4-triazole hit compound that resulted in <b>85</b>. However, <b>85</b> suffered from poor metabolic stability as shown in <a class="ref internalNav" href="#fig36" aria-label="Figure 36">Figure 36</a>. The replacement of the ethyl group with a cyclopropyl moiety led to <b>86</b> with comparable RORγ inhibition but with significantly improved metabolic stability. Because cyclopropyl analogue <b>86</b> was more stable in human liver microsomal preparations, this moiety was kept in subsequent optimization schemes that ultimately resulted in the discovery of <b>87</b>, which had submicromolar RORγ inhibition and excellent stability in human liver microsomal preparations (<a class="ref internalNav" href="#fig36" aria-label="Figure 36">Figure 36</a>).</div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Structures, in vitro potency, and liver microsomal stability data of RORγ inhibitors <b>85</b>–<b>87</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec1_3_8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">CNS Active Preclinical/Clinical Drug Candidates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45034" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45034" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Compounds <b>88</b> (Milnacipran/Savella) and <b>89</b> (Levomilnacipran/Fetzima)</h3><div class="NLM_p">Compound <b>88</b> (<i>Z</i>-Milnacipran), previously known as midalcipran, was discovered in 1987 by Bonnaud and co-workers.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Compound <b>88</b>, approved by the FDA in 2009, is a mixture of enantiomers, (1<i>R</i>,2<i>S</i>) and (1<i>S</i>,2<i>R</i>), whereas compound <b>89</b> (levomilnacipran), approved by the FDA in 2013 to treat major depressive disorders, is a pure enantiomer (1<i>S</i>,2<i>R</i>-milnacipran) as shown in <a class="ref internalNav" href="#fig37" aria-label="Figure 37">Figure 37</a>. Compound <b>89</b> produced a 50- and 13-fold greater inhibition of norepinephrine and serotonin reuptake, respectively, than that of the racemic <b>88</b>.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> It is likely that compounds <b>88</b> and <b>89</b> produce their antidepressant action by competitively inhibiting serotonin and norepinephrine reuptake in the CNS. The cyclopropyl ring conformationally restricts the pendant tertiary carboxamide and primary γ-amine groups in a <i>Z</i>-geometry.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> These geometric constraints produced by the cyclopropane ring, as well as the presence of an unsubstituted phenyl ring at the α-position of the carboxamide group and <i>trans</i> to the γ-amine (mimic of a typical <i>trans</i>-like arrangement of an aryl/heteroaryl ethylamine neurotransmitters: norepinephrine and serotonin), collectively form a pharmacophore framework.</div><figure id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0037.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Structures of serotonin and norepinephrine reuptake inhibitors <b>88</b> and <b>89</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Compounds <b>91</b> (Naltrexone/Vivitrol) and <b>92</b> (Nalmefene/Revex)</h3><div class="NLM_p">Compound <b>91</b> (naltrexone) binds with high affinity to μ-opioid (<i>K</i><sub>i</sub> = 0.11 nM) and κ-opioid (<i>K</i><sub>i</sub> = 0.19 nM) receptors and with lower affinity to δ-opioid receptor (<i>K</i><sub>i</sub> = 60 nM).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Compound <b>92</b> (nalmefene) is an opioid receptor antagonist (μ-opioid receptor <i>K</i><sub>i</sub> = 0.24 nM, κ-opioid receptor <i>K</i><sub>i</sub> = 0.083 nM, and δ-opioid receptor <i>K</i><sub>i</sub> = 16 nM).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> The cyclopropylmethyl substituent at the <i>N</i>-17 of the pentacyclic scaffold in <b>91</b> and <b>92</b> mimics the allyl “message” group present in compound <b>90</b> (naloxone) and is thought to optimally fit in a narrow hydrophobic antagonist cleft in the μ-opioid receptor as shown in <a class="ref internalNav" href="#fig38" aria-label="Figure 38">Figure 38</a>.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The cyclopropylmethyl-substituted opioid receptor antagonists <b>91</b> and <b>92</b> have improved potency compared to the allyl substituted compound <b>90</b>. The enhanced potency of compounds <b>91</b> and <b>92</b>, both more lipophilic than compound <b>90</b>, could be a result of their extensive CNS distribution. Moreover, the relatively bulky antagonist-directing cyclopropylmethyl group<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> contributed to their antagonism of the opioid receptors. Not unexpectedly, the <i>N</i>-dealkylated metabolites usually act as an opioid receptor agonists.</div><figure id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0038.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures of opioid antagonists <b>90</b>–<b>92</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Compound <b>93</b> (Buprenorphine/Buprenex/Subuxone/Subutex)</h3><div class="NLM_p">Compound <b>93</b> is a highly lipophilic compound with a long duration of action (<a class="ref internalNav" href="#fig39" aria-label="Figure 39">Figure 39</a>). It is a partial μ-opioid receptor agonist (monkey brain μ-opioid receptor apparent <i>K</i><sub>i</sub> = 0.08 nM) and a weak κ- (monkey brain κ-opioid receptor apparent <i>K</i><sub>i</sub> = 0.44 nM) and δ-opioid receptor (monkey brain δ-opioid receptor apparent <i>K</i><sub>i</sub> = 0.82 nM)<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> antagonist approved by the U.S. FDA for the treatment of pain and opioid addiction. As previously explained, the antagonist profile of compound <b>93</b> is derived from the presence of the antagonist-directing cyclopropylmethyl group at <i>N</i>-17, apart from a hydrophobic and hydrogen bond-forming functionality at <i>C</i>-7.</div><figure id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0039.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structure of opioid receptor partial agonist <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Compound <b>94</b> (Samidorphan)</h3><div class="NLM_p">Compound <b>94</b> as shown in <a class="ref internalNav" href="#fig40" aria-label="Figure 40">Figure 40</a> was discovered in 2005 by Wentland and co-workers.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> It was designed based on naltrexone as a template. It acts as a μ-opioid receptor (<i>K</i><sub>i</sub> = 0.052 nM) antagonist. As previously stated, an antagonist-directing cyclopropylmethyl substituent at the <i>N</i>-17 confers μ-opioid receptor antagonist property to this drug. In combination with buprenorphine, it is currently undergoing FDA fast track clinical trial for the treatment of major depressive disorder.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><figure id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0040.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structure of opioid receptor antagonist <b>94</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Compound <b>95</b> (Tranylcypromine/(±)-<i>trans</i>-2-phenylcyclopropan-1-amine/Parnate)</h3><div class="NLM_p">This drug is a cyclopropyl analogue of amphetamine synthesized by Burger and co-workers in 1948.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Subsequently, Tedeschi et al.,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> have shown that it is a potent MAO inhibitor in vivo (<a class="ref internalNav" href="#fig41" aria-label="Figure 41">Figure 41</a>). The presence of the cyclopropyl moiety makes it a more stable compound than its ethylene analogue. The cyclopropyl moiety also offers a fixed stereochemistry that is resistant to spontaneous and bidirectional <i>cis</i>- to <i>trans</i>-isomer interconversions. Furthermore, it provides a rigid chiral backbone for achieving the desired three-dimensional placement of its pendant phenyl and amine groups to mimic the bioactive conformation of the endogenous phenylethylamine pharmacophore substrates of MAO. Compound <b>95</b> forms a covalent adduct at the <i>C</i>-4a position of the cofactor flavin-MAO-B enzyme complex through opening of the strained cyclopropyl ring and either simultaneous or subsequent release of ammonia<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> (<a class="ref internalNav" href="#fig41" aria-label="Figure 41">Figure 41</a>).</div><figure id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0041.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure and mechanism of action of MAO inhibitor <b>95</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Compound <b>97</b> (Tasimelteon/Hetlioz)</h3><div class="NLM_p">Because compound <b>96</b> (melatonin), an endogenous ligand, regulates sleep and the circadian rhythms by activating melatonin 1 and 2 receptors (MT<sub>1</sub> and MT<sub>2</sub>), MT-receptors are an attractive area of research for development of drugs to treat insomnia.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Compound <b>97</b> (tasimelteon/VEC-162), a potent MT<sub>1</sub>/MT<sub>2</sub> agonist, is approved by the U.S. FDA for the treatment of non-24-h sleep–wake disorder.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> When compared to <b>96</b>, the structure of <b>97</b> shows two differences, a 5-methoxy group constrained onto <i>C</i>-4 to form an indole isosteric dihydrobenzofuran nucleus and a conformationally constrained chiral <i>trans</i>-geometrical cyclopropyl linker located between the aromatic ring and the side chain carboxamide functional group as shown in <a class="ref internalNav" href="#fig42" aria-label="Figure 42">Figure 42</a>. On the basis of pharmacophore modeling and constrained analogue synthetic approaches,<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> it was hypothesized that the chiral <i>trans</i>-geometrical cyclopropane ring linker facilitates the specific orientation of the pendant pharmacophoric groups of <b>97</b> (the 5-methoxy and the carboxamide highlighted in blue; the six-atom distance between the ether oxygen and the carboxamide <i>N</i> is highlighted in red) for effective binding to the MT-receptors.</div><figure id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0042.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structures of melatonin receptor agonists <b>96</b> and <b>97</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Glycine Uptake Transporter 1 (GlyT1) Inhibitor <b>99</b></h3><div class="NLM_p">It has been postulated that the dysfunction of the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor may play a critical role in the pathophysiology of schizophrenia.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> It has been proposed that the levels of glycine, a coagonist whose presence is an absolute requirement for NMDA activation, are below saturation at synapses that are tonically maintained by GlyT1, a Na<sup>+</sup>/Cl<sup>–</sup>-dependent type 1 glycine uptake transporter.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Therefore, GlyT1 inhibitors would be predicted to control synaptic glycine concentrations and to potentiate NMDA receptor function in vivo to ameliorate the negative symptoms of schizophrenia.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Blackaby and co-workers<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> initiated their human GlyT1 inhibitor development efforts around the cyclohexane sulfone analogue <b>98</b> as shown in <a class="ref internalNav" href="#fig43" aria-label="Figure 43">Figure 43</a>. Subsequent replacement of the <i>n</i>-propyl sulfonyl moiety with a cyclopropylmethyl sulfonyl moiety yielded <b>99</b> (DCCCyB),<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> with a marginal increase in potency. However, this molecular modification significantly improved human and rat liver microsomal turnover compared to <b>98</b> as shown in <a class="ref internalNav" href="#fig43" aria-label="Figure 43">Figure 43</a>.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Compound <b>99</b> has a good PK profile in animal models. Furthermore, it is not a substrate of P-gp and thus achieves a high brain to plasma ratio of 2.3 and is efficacious in various rodent models.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><figure id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0043.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Structures, in vitro potency, and liver microsomal stability data of GlyT1 inhibitors <b>98</b> and <b>99</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Neurokinin-3 (NK-3) Antagonists <b>102</b> and <b>103</b></h3><div class="NLM_p">The NK-3 receptor, a G-protein coupled receptor, activated by neurokinin B (NKB), is expressed in the brain regions such as cortical regions and basal ganglia structures of the mammalian CNS. It has been hypothesized that the antagonism of NK-3 receptors may be useful in treating certain psychiatric diseases.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Smith and co-workers<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> began SAR studies with a previously disclosed NK-3 antagonist, <b>100</b> (SB-222200), that also showed CNS activity.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> However, in vivo data obtained with <b>100</b> revealed formation of significant levels of the circulating racemic ketone metabolite <b>101</b>, which had a low CNS permeability (<a class="ref internalNav" href="#fig44" aria-label="Figure 44">Figure 44</a>). These investigators wanted to develop a novel quinoline series of NK-3 antagonists with increased metabolic stability and CNS NK-3 receptor occupancy. Many analogues of <b>100</b> were prepared containing the ethyl group at the chiral center. However, similar to <b>100</b>, all of these analogues underwent oxidative metabolism at the ethyl group. Consequently, Smith and co-workers<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> replaced the ethyl group with a cyclopropyl ring, with simultaneous substitution of the fluoro group on C-2 phenyl ring, leading to the identification of <b>102</b> (GSK172981), as shown in <a class="ref internalNav" href="#fig44" aria-label="Figure 44">Figure 44</a>. It may be noted that it is the ethyl to cyclopropyl exchange that contributed toward enhanced metabolic stability and not the other two molecular modifications such as methyl to amino and <i>meta</i>-fluoro substitutions.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Many of the compounds reported by Smith and colleagues<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> had a clogP of >6, including <b>102</b>. It is well-known that such a high clogP can increase the risk of attrition in later stages of drug development and therefore these investigators aimed to reduce the lipophilicity. To achieve this goal, they introduced a novel <i>tert</i>-sulfonamide substituent at the 3-position of the quinoline ring, yielding <b>103</b> (GSK256471),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> as shown in <a class="ref internalNav" href="#fig44" aria-label="Figure 44">Figure 44</a>. Furthermore, <b>102</b> and <b>103</b> had a significantly higher cortical NK-3 receptor occupancy than the starting lead compounds. Both <b>102</b> and <b>103</b> were efficacious in various in vitro, ex vivo, and in vivo models, suggesting that they may have utility for the treatment of schizophrenia.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><figure id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0044.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Structures, in vitro potency, and PK profile of NK-3 inhibitors <b>100</b>–<b>103</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> BACE1 Inhibitor <b>105</b></h3><div class="NLM_p">β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1), a membrane-bound aspartyl protease, catalyzes the production of amyloid β (Aβ) neuropeptides.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Because the formation of Aβ aggregates is a pathophysiologic hallmark of Alzheimer’s disease, BACE1 may serve as a prime target for the development of disease-modifying treatments for Alzheimer’s disease. To identify BACE1 inhibitors with reduced lipophilicity and improved brain penetration, Lerchner and colleagues<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> began discovery chemistry work using a macrocyclic BACE1 inhibitory lead compounds. This work led to the identification of improved lead compound <b>104</b>, belonging to macrocyclic ethanolamine series, which demonstrated excellent selectivity and potency against BACE1 as shown in <a class="ref internalNav" href="#fig45" aria-label="Figure 45">Figure 45</a>. However, it had a poor permeability and a high efflux ratio (ER) in the MDR1-MDCK cell line. Furthermore, it was apparent that the increased basicity of the ethanolamine moiety was associated with an increased ER by P-gp and, hence, a low permeability. To circumvent these problems, Lerchner and co-workers<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> used a p<i>K</i><sub>a</sub> lowering strategy around the ethanolamine group of lead <b>104</b>. The introduction of the spirocyclopropane moiety at the benzylic carbon adjacent to the ethanolamine group yielded <b>105</b> (p<i>K</i><sub>a</sub> = 7.3), a compound with improved passive permeability, lower ER values, and retention of potency against BACE1 as shown in <a class="ref internalNav" href="#fig45" aria-label="Figure 45">Figure 45</a>. The reduced ER value for compound <b>105</b> increased the concentration in the brain (<i>C</i><sub>b</sub> = 0.32 μM), resulting in a 72% reduction in the brain levels of Aβ40 compared to the precursor benzylamine analogue <b>104</b> (<i>C</i><sub>b</sub> = 0.04 μM; Aβ40 = 7%). The loss of selectivity of the cyclopropyl analogue over closely related aspartyl proteases resulted in termination of further progress with this series.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> It is interesting to note that the cyclopropyl ring has played a role in achieving selectivity in many of the exmaples described previously; however, a spirocyclopropyl substitution at the benzylic position in <b>105</b> led to the loss of selectivity. The reason for the loss of selelctivity of <b>105</b> is not known at this time. Therefore, one design strategy does not work for all cases and is context dependent.</div><figure id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0045.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structures, in vitro potency, and permeability data of BACE1 inhibitors <b>104</b> and <b>105</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> BACE1 Inhibitor <b>109</b></h3><div class="NLM_p">Cumming and co-workers<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> began a discovery program for small molecule BACE1 inhibitors that would penetrate the CNS and reduce CNS-derived Aβ40 levels. They started with the low micromolar, 5,5-diphenyl-2-iminohydantoin BACE1 inhibitor <b>106</b> (<a class="ref internalNav" href="#fig46" aria-label="Figure 46">Figure 46</a>). Although <b>106</b> was less potent than early lead compounds, it was endowed with excellent ligand efficiency, PK properties, and selectivity toward BACE1 over related aspartyl proteases such as cathepsin D. Therefore, <b>106</b> served as an excellent lead compound, particularly because its X-ray cocrystal structure was known, allowing structure-based optimization. The replacement of one of the phenyl rings with a 3-substituted biaryl ring system consistently provided compounds that significantly inhibited BACE1, e.g., compound <b>107</b> (<a class="ref internalNav" href="#fig46" aria-label="Figure 46">Figure 46</a>). Next, the influence of the modification of the second phenyl ring was examined. Subsequently, a replacement of the phenyl ring with an isosteric cyclopropyl ring yielded compound <b>108</b>, with a high affinity for BACE1 (<a class="ref internalNav" href="#fig46" aria-label="Figure 46">Figure 46</a>). Finally, a biaryl ring system optimization was used with the intention of improving the BACE1 affinity while decreasing the gap between the BACE1 <i>K</i><sub>i</sub> and cell Aβ40 IC<sub>50s</sub>. Eventually, the replacement of the distal chlorophenyl ring with the 3-propynylpyridyl moiety resulted in the discovery of <b>109</b> as shown in <a class="ref internalNav" href="#fig46" aria-label="Figure 46">Figure 46</a>, demonstrating a high oral efficacy, selectivity, and brain penetration.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><figure id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0046.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Structures, in vitro potency, and PK properties of BACE1 inhibitors <b>106</b>–<b>109</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> γ-Secretase Inhibitor <b>111</b></h3><div class="NLM_p">γ-Secretase is an evolving therapeutic target for the development of drugs to treat Alzheimer’s disease because it catalyzes the formation of Aβ peptides that are involved in the pathophysiology of this disease.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Josien et al.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> began their medicinal chemistry efforts with the 3,5-disubstituted morpholine lead compound <b>110</b>. This compound showed a minimal shift between cell and membrane Aβ40 IC<sub>50</sub> values and, most importantly, an improved CYP3A4 profile compared to their early hit compounds containing a piperidine core (<a class="ref internalNav" href="#fig47" aria-label="Figure 47">Figure 47</a>). Among the three molecular modifications (i.e., cyclopropyl substituent at the 5-position, a spiro-cyclopropyl ring at the 3-position flanked methylene, and the bridged piperazine ring at a carbamate functionality), the cyclopropyl rings consistently provided compounds with excellent metabolic stability and in vivo oral activity.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> A representative of the optimized series is compound <b>111</b> (<a class="ref internalNav" href="#fig47" aria-label="Figure 47">Figure 47</a>) that dose-dependently decreased Aβ40 levels in plasma as well as brain and had a 13-fold greater IC<sub>50</sub> of 194 nM against Notch processing in whole cells compared to cell Aβ40 IC<sub>50</sub> value.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> The inhibition of Notch processing in whole cells had been linked to adverse effects.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><figure id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0047.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structures, in vitro potency, and PK properties of gamma secretase inhibitors <b>110</b> and <b>111</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> α4β2 Selective Nicotinic Acetyl Choline Receptor (nAChR) Partial Agonist <b>116</b></h3><div class="NLM_p">The α4β2 nAChR serves as a therapeutic target for drugs to treat depression, attention deficit hyperactivity disorder (ADHD), and neuropathic pain.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Because binding of ligands to the ganglionic α3β4*-nAChR is thought to be associated with adverse effects, such as nausea and emesis,<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Zhang and colleagues<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> developed highly selective, fast acting partial agonists for the α4β2-nAChR. They began their efforts with lead compound <b>112</b> (sazetidine-A) that showed very potent α4β2-nAChR partial agonist activity, with significant selectivity over α3β4*-nAChR,<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> and had in vivo antidepressant and anxiolytic efficacy in rodent models.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> However, <b>112</b> generated concerns about its metabolic liability due to its acetylene group. Therefore, Zhang and co-workers<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> replaced the acetylene group with a small and constrained cyclopropane ring. It was anticipated that the cyclopropane ring will not only act as a spacer to place the pendant side chain moiety in the right position to interact with the receptor but will also interact with the receptor residues. Subsequently, a highly selective compound <b>113</b>, with subtype selective (1<i>S</i>,2<i>R</i>)-stereochemistry at the cyclopropane ring, was identified as shown in <a class="ref internalNav" href="#fig48" aria-label="Figure 48">Figure 48</a>. In vivo mouse PK studies revealed a promising profile for compound <b>113</b> as shown in <a class="ref internalNav" href="#fig48" aria-label="Figure 48">Figure 48</a>. When subjected to CYP isoform inhibition profiling, compound <b>113</b> only caused a 25% inhibition of major drug metabolizing CYP enzymes (CYP1A, CYP2C9, CYP2C19, CYP2D6, and CYP3A) at 10 μM. Because compound <b>113</b> only produced a 13.7% inhibition of hERG potassium channel at 10 μM concentration, it is less likely to cause hERG-related cardiovascular toxicity.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Further optimization of <b>113</b> by Zhang and co-workers<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> using X-ray and homology structural information resulted in identification of fluorinated compound <b>114</b>, which showed improved metabolic stability compared to compound <b>113</b> (<a class="ref internalNav" href="#fig48" aria-label="Figure 48">Figure 48</a>). Further systematic SAR around the azetidine and cyclopropane substituted side chains in the core pyridine ring led to discovery of compound <b>115</b> that featured a stable <i>N</i>-methylpyrrolidine ring in place of azetidine. Compound <b>115</b> had: (1) excellent human/mouse liver microsomal stability, (2) no more than 30% inhibition of CYP1A, CYP2C9, CYP2C19, and CYP3A isoforms at 10 μM, (3) a 31% binding to human plasma, (4) an excellent Caco-2 cell permeability, (5) no efflux by P-gp, (6) a negative Ames genotoxicity test at 100 μM concentration, and (7) a hERG potassium channel inhibition by 23% at a concentration of 10 μM.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></div><figure id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0048.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Structures and in vitro potency of α4β2 nAChR partial agonists <b>112</b>–<b>116</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The (1<i>S</i>,2<i>R</i>)-cyclopropane side chain at the 5-position of the pyridine scaffold is critical for achieving exceptional α4β2-nAChR subtype selectivity. Consequently, Onajole and co-workers<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> inserted a (1<i>S</i>,2<i>R</i>)-configured cyclopropane side chain at the 5-position of their <i>N</i>-pyridyldiazabicyclo[3.3.0]octane motif, a move that eventually led to the discovery of compound <b>116</b>, showing a 1600-fold selectivity for α4β2 over α3β4-nAChR as shown in <a class="ref internalNav" href="#fig48" aria-label="Figure 48">Figure 48</a>. In vivo mouse PK studies revealed an acceptable brain to plasma ratio (0.24 at 30 min and 1.75 at 120 min) of compound <b>116</b>. The binding of compound <b>116</b> to mouse plasma and brain tissue amounted to 27% and 73%, respectively.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div></div><div id="sec1_3_8_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Bradykinin B1 Receptor Antagonist <b>120</b></h3><div class="NLM_p">Because the bradykinin B1 receptor has been shown to play a role in chronic inflammation and pain, there is a great interest in developing compounds that could antagonize this receptor.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Although earlier peptidic<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> and nonpeptidic<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> antagonistic compounds supported the bradykinin B1 receptor as a therapeutic target, these compounds lacked the physicochemical and PK profile to make them effective by the oral route. Feng et al.,<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> reported SAR studies on the diaminopyridine scaffold <b>117</b> as a bradykinin B1 receptor antagonist (<a class="ref internalNav" href="#fig49" aria-label="Figure 49">Figure 49</a>). However, further developments along these lines were hampered by the realization that this scaffold formed reactive metabolites.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> To overcome this metabolic liability, Wood and co-workers<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> discovered that the problematic diaminopyridine scaffold could be efficiently replaced with a cyclopropylamino acid moiety. This design concept yielded biphenyl cyclopropane carboxamide compound <b>118</b>, with an improved PK profile, although potency was decreased (<a class="ref internalNav" href="#fig49" aria-label="Figure 49">Figure 49</a>). It was reasoned that the favorable PK profile of compound <b>118</b> could be a combined effect of the stability of unnatural α-amino acids toward proteolytic enzymes, in concert with the absence of the metabolically reactive diaminopyridine scaffold.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Although compound <b>118</b> had reasonable affinity toward B1 receptor, it did not have optimal PK properties and had only moderate CNS receptor occupancy. Moreover, compound <b>118</b>-related structures were found to be substrates of P-gp, thereby compromising their CNS penetration.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Therefore, the same research group<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> conducted further SAR optimization around the biphenyl and trifluoropropionamide regions of <b>118</b> to improve the shortcomings associated with early compounds. These studies led to compound <b>119</b> as shown in <a class="ref internalNav" href="#fig49" aria-label="Figure 49">Figure 49</a>. Compound <b>119</b> had a promising PK profile in the dog and rhesus monkey, as shown in <a class="ref internalNav" href="#fig49" aria-label="Figure 49">Figure 49</a>. Because compound <b>119</b> demonstrated moderate CNS receptor occupancy in a transgenic mouse model, further SAR optimization efforts were undertaken.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> These SAR studies identified several promising leads, notably compound <b>120</b>, which showed excellent potency and promising PK profile in dog and rhesus monkey as shown in <a class="ref internalNav" href="#fig49" aria-label="Figure 49">Figure 49</a>.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><figure id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0049.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Structures, in vitro potency, and PK properties of bradykinin B1 receptor antagonist <b>117</b>–<b>120</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Orexin Receptor Antagonist <b>121</b></h3><div class="NLM_p">Pharmacological blockade of both orexin receptor 1 and 2 (OX1R/OX2R) has been intensely pursued for the development of drugs to treat insomnia.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Suvorexant,<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> a dual orexin receptor antagonist, was approved by the U.S. FDA in 2014 for the treatment of insomnia. Suvorexant adopts a horseshoe-shaped (U-shape) conformation in the binding pocket of the human OX2R.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Yoshida and colleagues,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> using extensive SAR studies, discovered a cyclopropane carboxamide derivative typified by the most advanced compound <b>121</b> (E2006) as a dual OX1R/OX2R receptor antagonist as shown in <a class="ref internalNav" href="#fig50" aria-label="Figure 50">Figure 50</a>. Similar to the U-shaped conformation of OX2R-bound suvorexant,<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> molecular simulation studies on isolated <b>121</b> showed a U-shaped, low energy state conformation. The cyclopropyl moiety provides a chiral spacer that produces the above-mentioned bioactive U-shaped (<i>cis</i>) conformation of the pendant 5-pyrimidine and 2-pyridine rings as shown in <a class="ref internalNav" href="#fig50" aria-label="Figure 50">Figure 50</a>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0050.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. 2D Structure (left panel) and 3D model (right panel) of orexin receptor antagonist <b>121</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Histamine H<sub>3</sub> Receptor (H<sub>3</sub>R) Antagonist <b>123</b> (Bavisant)</h3><div class="NLM_p">It is a potent antagonist of the H<sub>3</sub>R, which has been implicated in the promotion of wakefulness. As a result, antagonists of this type of receptor may be useful in the treatment of daytime sleepiness, narcolepsy, and ADHD.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Letavic et al.,<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> began medicinal chemistry work to synthesize H<sub>3</sub> receptor antagonists with piperazinecarbonyl benzylamine as a lead scaffold. Several analogues were prepared and tested by these authors in histamine H<sub>3</sub> receptor binding affinity assays, resulting in the identification of clinically relevant compound <b>122</b> as shown in <a class="ref internalNav" href="#fig51" aria-label="Figure 51">Figure 51</a>. However, <b>122</b> produced prolonged insomnia due to a longer half-life. To eliminate this problem, Letavic et al.,<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> replaced the isopropyl moiety present on the terminal piperazine nitrogen with the cyclopropyl moiety to yield compound <b>123</b> (bavisant/JNJ-31001074) as shown in <a class="ref internalNav" href="#fig51" aria-label="Figure 51">Figure 51</a>. These results support the concept that fine-tuning of the PK profile of a compound is possible by altering its physicochemical properties. Specifically, introduction of a cyclopropyl ring reduced the p<i>K</i><sub>a</sub> of the piperazine ring compared to the isopropyl substitution, thereby increasing plasma clearance and reducing half-life.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> It may be noted that, unlike other examples (compounds <b>40</b>, <b>61</b>, <b>72</b>, and <b>130</b>) where a cyclopropyl ring led to increased half-life, in the case of <b>123</b> the cyclopropyl ring produced decreased half-life. Therefore, PK properties can be modulated with a cyclopropyl group; however, it is context dependent and one strategy does not work in all cases.</div><figure id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0051.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. Structures, in vitro potency, and PK properties of histamine H<sub>3</sub> receptor antagonists <b>122</b> and <b>123</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> PDE4 Inhibitor <b>127</b></h3><div class="NLM_p">Among the 11 phosphodiesterases (PDEs) so far known, cAMP-specific PDE4 is of great interest due to its role in controlling the intracellular levels of cAMP.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Therefore, inhibitors of PDE4 will increase cAMP level, promoting the late phase, long-term potentiation cascade, thereby increasing the likelihood of enhancing cognition.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Gallant et al.,<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> sought to develop brain-penetrating PDE4 inhibitors endowed with a significantly high plasma protein shift (low human whole blood potency) and high oral bioavailability and rapid GI absorption. These properties are postulated to enhance the therapeutic index and decrease gastrointestinal-related adverse side effects. To meet this goal, these authors selected compound <b>124</b> as the starting point (<a class="ref internalNav" href="#fig52" aria-label="Figure 52">Figure 52</a>). In this compound, the <i>N</i>-cyclopropyl amide functionality at the 3-position of the naphthyridinone scaffold was found to be optimal based on preliminary SAR work.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> The first SAR task involved optimization of the aliphatic carboxylic acid chain at the biphenyl moiety. Among the several groups tested, the cyclopropane carboxylic acid moiety in <b>125</b> was the best as it had low potency in the HWB assay and an improved oral bioavailability compared to <b>124</b> as shown in <a class="ref internalNav" href="#fig52" aria-label="Figure 52">Figure 52</a>.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> While keeping the biphenyl functionality of <b>125</b> constant, these investigators revisited optimization of the cyclopropyl amide moiety and obtained <b>126</b>, a compound with a suboptimal profile (<a class="ref internalNav" href="#fig52" aria-label="Figure 52">Figure 52</a>). Overall, it can be concluded that the cyclopropyl groups at the naphthyridinone and the biphenyl scaffolds are critical for the pharmacological profile of these PDE4 inhibitors. Final optimization involved elucidation of the bioactive stereochemical configuration of the chiral cyclopropane carboxylic acid center and substitution of the fluorine at the biphenyl scaffold. These molecular modifications eventually led to the discovery of the clinical candidate <b>127</b>/(<i>R</i>,<i>R</i>)-MK-0952 as shown in <a class="ref internalNav" href="#fig52" aria-label="Figure 52">Figure 52</a>.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></div><figure id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0052.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. Structures, in vitro potency, and PK properties of PDE4 inhibitors <b>124</b>–<b>127</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_8_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Triple Reuptake Inhibitor <b>128</b></h3><div class="NLM_p">The simultaneous inhibition of the serotonin reuptake transporter (SERT), norepinephrine reuptake transporter (NET), and dopamine reuptake transporter (DAT) has potential for the treatment of depression.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Micheli and colleagues<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> conducted developmental work on antidepressants based on a triple reuptake inhibitor pharmacophore model typified by the presence of a positive charge center, three hydrophobic groups, one aromatic ring, and a hydrogen bond acceptor group. Their goal was to develop new compounds with a inhibitory rank of SERT ≥ NET > DAT. This led to discovery of a clinical compound <b>128</b> (GSK1360707F), with a (1<i>S</i>, 6<i>R</i>) configuration at the cyclopropane ring, which showed a balanced inhibition of the three transporters (hSERT p<i>K</i><sub>i</sub> = 9.2, hNET p<i>K</i><sub>i</sub> = 8.1, and hDAT p<i>K</i><sub>i</sub> = 8.0)<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> (<a class="ref internalNav" href="#fig53" aria-label="Figure 53">Figure 53</a>). A chiral fused cyclopropane ring across the C3–C4 bond in the piperidine ring allowed the projection of the 3,4-dichlorophenyl and the methoxymethyl substituents of <b>128</b> into respective hydrophobic regions of the triple reuptake pharmacophore model.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><figure id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0053.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. Structure of a triple reuptake inhibitor <b>128</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional examples of cyclopropane-containing CNS active compounds including corticotrophin releasing factor 1 antagonist, amitifadine, etomidate prodrug, and cipralisant are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">Cardiovascular Preclinical/Clinical Drug Candidates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> β<sub>1</sub>-Adrenoceptor Blocker <b>130</b> (Betaxolol)</h3><div class="NLM_p">Manoury and co-workers<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> sought to develop antihypertensive β-blockers that (a) would be more potent than available β-blockers, (b) showed increased β<sub>1</sub> adrenoceptor selectivity, and (c) possessed a desirable PK profile, including excellent oral absorption, low first pass metabolism, and a plasma half-life >12 h that will permit once-a-day dosing. Because compound <b>129</b> (metoprolol) was known to be a cardioselective β<sub>1</sub>-adrenoceptor blocker, it was considered to be a good starting point for SAR studies. It should be noted that compound <b>129</b> has a short duration of action and a significant first-pass inactivation (through <i>O</i>-demethylation of the methoxyethyl side chain followed by oxidation to an acid metabolite)<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> and, consequently, to poor oral bioavailability. Manoury and co-workers<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> hypothesized that the metabolically labile methoxyethyl substituent in <b>129</b> could be replaced with a metabolically stable bulky substituent such as the cyclopropylmethoxyethyl group (<a class="ref internalNav" href="#fig54" aria-label="Figure 54">Figure 54</a>). In fact, this modification of compound <b>129</b> [β<sub>1</sub> antagonist activity in rat atria model (p<i>A</i><sub>2</sub> β<sub>1</sub>) = 7.64] led to the discovery of compound <b>130</b>/betaxolol (p<i>A</i><sub>2</sub> β<sub>1</sub> = 8.53), which showed a significantly improved β<sub>1</sub>-antagonist activity. Furthermore, the metabolism of compound <b>130</b> was 6-fold lower than that of <b>129</b>. The half-life of compound <b>130</b> in humans has ranged from 16 to 22 h compared to 3 to 6 h for <b>129</b>.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></div><figure id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0054.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. Structures of β blockers <b>129</b> and <b>130</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> P2Y<sub>12</sub> Receptor Antagonist <b>133</b> (Ticagrelor/Brilinta)</h3><div class="NLM_p">Compound <b>133</b> (ticagrelor), approved by the U.S. FDA in 2011, is the first reversible P2Y<sub>12</sub> receptor antagonist with antiplatelet activity and it has a conformationally constrained chiral cyclopropane bridge.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Unlike the thienopyridine compounds <b>134</b> (clopidogrel) and <b>135</b> (prasugrel), it is not a prodrug and, therefore, it does not require preliminary metabolism to a pharmacologically active form.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Moreover, in comparison to the irreversible P2Y<sub>12</sub> receptor antagonists <b>134</b> and <b>135</b>, it acts in a reversible manner. Chemically, it is a cyclopentyl triazolopyrimidine isosteric analogue of adenosine that is known to allosterically bind to the P2Y<sub>12</sub> receptor in an area dissimilar to the ADP-binding site.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> This allosteric binding mechanism is thought to lock the P2Y<sub>12</sub> receptor in its inactive conformational state, consequently inhibiting ADP signaling and P2Y<sub>12</sub> receptor conformational flexibility.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> On the knowledge that ATP is an endogenous P2Y<sub>12</sub> receptor antagonist, Springthorpe and colleagues<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> sought to develop novel drug-like nonphosphate ATP analogues. To meet this goal, they synthesized and tested ∼6000 compounds that ultimately yielded the nonacidic lead compound <b>131</b> as shown in <a class="ref internalNav" href="#fig55" aria-label="Figure 55">Figure 55</a>. Furthermore, these investigators replaced the butylamine group at position 7 of the triazolopyrimidine core of <b>131</b> with the lipophilic <i>trans</i>-2-phenylcyclopropylamine, resulting in compound <b>132</b>, with a 100-fold increase in affinity toward the P2Y<sub>12</sub> receptor and a good metabolic stability (<a class="ref internalNav" href="#fig55" aria-label="Figure 55">Figure 55</a>). Eventually, compound <b>133</b> was obtained by exchanging the hydroxymethyl group for a hydroxyethoxy group and a 3,4-difluoro substitution at the phenyl ring as shown in <a class="ref internalNav" href="#fig55" aria-label="Figure 55">Figure 55</a>.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><figure id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0055.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Structures, in vitro potency, and PK properties of P2Y<sub>12</sub> receptor antagonists <b>131</b>–<b>133</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> P2Y<sub>12</sub> Receptor Antagonist <b>135</b> (Prasugrel/Effient)</h3><div class="NLM_p">This third-generation thienopyridine compound <b>135</b> (prasugrel) is an irreversible P2Y<sub>12</sub> receptor antagonist that was approved by the U.S. FDA in 2009 as an antiplatelet drug. It blocks P2Y<sub>12</sub>-mediated platelet activation and aggregation. In an effort to circumvent the inactivation of compound <b>134</b> (clopidogrel) through hydrolysis of methyl ester group to an inactive carboxylic acid metabolite,<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> structural modifications were initiated, the most prominent being the conversion of the hydrolytically unstable methyl ester group to a stable cyclopropyl carbonyl group to yield compound <b>135</b> as shown in <a class="ref internalNav" href="#fig56" aria-label="Figure 56">Figure 56</a>. Unlike compound <b>134</b>, compound <b>135</b> is metabolically transformed to a single active metabolite as shown in <a class="ref internalNav" href="#fig56" aria-label="Figure 56">Figure 56</a>.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0056.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Structures and metabolism of P2Y<sub>12</sub> receptor antagonists <b>134</b> and <b>135</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Factor Xa (FXa) Inhibitor <b>137</b></h3><div class="NLM_p">FXa is a key enzyme of the coagulation cascade, and its inhibition significantly decreases the incidence of arterial and venous thrombosis.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Qiao et al.,<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> sought to optimize the in vitro and in vivo potencies of their previously reported lead compound <b>136</b> (FXa <i>K</i><sub>i</sub> = 0.3 nM) that is typified by an <i>ortho</i>-dimethylaminomethyl substituted biphenyl P4 moiety as shown in <a class="ref internalNav" href="#fig57" aria-label="Figure 57">Figure 57</a>.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> On the basis of the X-ray crystal structure and molecular modeling studies with lead compound <b>136</b>, it became apparent that the two phenyl rings of the biphenyl ring system are noncoplanar with a perpendicular arrangement of the basic <i>ortho</i>-substituent, an optimal pharmacophore for binding to the S4 subsite of FXa.<a onclick="showRef(event, 'ref176 ref178'); return false;" href="javascript:void(0);" class="ref ref176 ref178">(176, 178)</a> Subsequently, Qiao et al.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> replaced the terminal phenyl ring with a cyclopropane ring and added a pyrrolidinylmethyl moiety, a cyclic mimic of the dimethylamino methyl moiety, to the α-position of the cyclopropane ring. They hypothesized that the perpendicular conformation of a basic α-substituent on the phenylcyclopropane would mimic the bioactive conformation of the <i>ortho</i>-substituted biphenyl P4 moiety. It should be noted that among two possible conformations of the phenylcyclopropane ring (i.e., the perpendicular conformation and the bisected conformation), it was envisioned that the phenylcyclopropane with the α-substituent would preferentially adopt a perpendicular conformation,<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> thereby mimicking the bioactive conformation of the P4 moiety. The choice of the cyclopropyl ring over other cycloalkyl rings was dictated by its smaller size and greater metabolic stability. These efforts eventually led to discovery of novel compound <b>137</b> as a potent inhibitor of FXa (<i>K</i><sub>i</sub> = 0.021 nM) (<a class="ref internalNav" href="#fig57" aria-label="Figure 57">Figure 57</a>). The X-ray crystal structure of the most potent FXa inhibitor bound to human FXa indicated the existence of a perpendicular conformation of the phenylcyclopropyl P4 moiety within the S4 subsite of enzyme. These structural studies also showed extensive hydrophobic contacts between the cyclopropyl ring and the S4 subsite residues Tyr99, Phe174, and Trp215. These investigators stated that the exceptional potency of compound <b>137</b> could have resulted from the combined influence of (a) a favorable hydrophobic and polar interactions of pyrrolidinyl moiety, respectively, with the edges of Phe174 and Tyr99 and backbone of Glu97 and Thr98, and (b) a preferred perpendicular conformation of the phenylcyclopropyl that direct the bulky α-substituent orthogonal to the plane of the phenyl ring.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div><figure id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0057.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Structures of FXa inhibitors <b>136</b> and <b>137</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Slowly Activating Cardiac Delayed Rectifier Potassium Current (Iks) Inhibitor <b>141</b></h3><div class="NLM_p">The selective and potent pharmacological inhibition of the Iks over its rapid counterpart, Ikr, is a potential therapeutic approach for treating ventricular arrhythmias.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> To develop class III antiarrhythmic drugs with significantly enhanced Iks inhibition, Butcher et al.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> began their quest from the 1,5-disubstituted-1,4-benzodiazepin-2-one analogue <b>138</b> (Iks IC<sub>50</sub> = 6 nM, and Ikr IC<sub>50</sub> = 6000 nM), a selective, potent, and orally active Iks inhibitor, as shown in <a class="ref internalNav" href="#fig58" aria-label="Figure 58">Figure 58</a>.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> These investigators observed that substitution of the phenyl ring at position 5 of <b>138</b> with an isopropyl group yielded compound <b>139</b> (Iks IC<sub>50</sub> = 6 nM and Ikr IC<sub>50</sub> > 1000 nM) without loss of Iks inhibitory potency. However, the isopropyl analogue <b>139</b> underwent rapid and extensive in vitro deactivating metabolism, yielding first a hydroxylated 5-isopropyl metabolite which, upon dehydration, turned into the 5-isopropenyl metabolite as shown in <a class="ref internalNav" href="#fig58" aria-label="Figure 58">Figure 58</a>.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> To circumvent the metabolic liability of <b>139</b>, the 5-isopropyl group was replaced with the metabolically stable 5-cyclopropyl moiety to obtain compound <b>140</b> (Iks IC<sub>50</sub> = 1.5 nM, and Ikr IC<sub>50</sub> > 1000 nM) (<a class="ref internalNav" href="#fig58" aria-label="Figure 58">Figure 58</a>). These changes introduced metabolic stability because incubation of the cyclopropyl and the isopropyl analogues with human microsomes for 60 min, resulted in respective metabolism of ∼15% and ∼70% and also raised the Iks inhibitory potency by 4-fold compared to compounds <b>138</b> and <b>139</b>.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Compound <b>141</b>, a class III antiarrhythmic and highly selective Iks inhibitor, was synthesized by keeping the cyclopropyl ring at the 5-position and replacing the trifluoroethyl substituent at position 1 with the chiral <i>sec</i>-butyl (<i>R</i>-stereochemistry) group (Iks IC<sub>50</sub> = 0.08 nM, and Ikr IC<sub>50</sub> > 1000 nM) as shown in <a class="ref internalNav" href="#fig58" aria-label="Figure 58">Figure 58</a>.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><figure id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0058.jpeg" id="gr58" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Structures (left panel) and metabolism (right panel) of the Iks inhibitors <b>138</b>–<b>141</b>. Stereochemistry at the C3-chiral center in <b>139</b>–<b>141</b> is not determined.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Soluble Epoxide Hydrolase (sEH) Inhibitor <b>144</b></h3><div class="NLM_p">sEH is a cytosolic enzyme that catalyzes the breakdown of physiologically important epoxy-eicosa-trienoic acids into inactive hydrophilic dihydro-eicosa-trienoic acids.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> The epoxy-eicosa-trienoic acids are physiologically important for functions such as vasodilation, antimigratory actions on vascular smooth muscle cells, and analgesic and anti-inflammatory action. Therefore, the development of sEH inhibitors has been an active field of research for the treatment of cardiovascular diseases, inflammation, and neuropathic pain.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></div><div class="NLM_p">Takai and co-workers<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> sought to optimize their previously disclosed sEH inhibitory lead <b>142</b>, for which X-ray cocrystal structure with sEH is known (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X6Y">4X6Y</a>) (<a class="ref internalNav" href="#fig59" aria-label="Figure 59">Figure 59</a>). This cocrystal structure indicated that the phenoxypiperidine and the cyclopropylphenyl moieties occupied A and B pockets within the active site of sEH, respectively. Interestingly, these investigators noted the vacant C pocket around the C3-position of the cyclopropane ring. This information prompted them to branch out the third position of the cyclopropane ring with a phenyl substituent, yielding compound <b>143</b> (<a class="ref internalNav" href="#fig59" aria-label="Figure 59">Figure 59</a>). The cocrystal structure of <b>143</b> and sEH (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X6X">4X6X</a>) showed binding interactions similar to the lead <b>142</b>, with an additional binding of the phenyl ring to the C pocket. To expand the molecular space, these investigators initiated further optimization around the phenoxypiperidine region, leading to the discovery of the most potent sEH inhibitor, <b>144</b>, known so far<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> (<a class="ref internalNav" href="#fig59" aria-label="Figure 59">Figure 59</a>).</div><figure id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0059.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. Structures of sEH inhibitors <b>142</b>–<b>144</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional examples of cyclopropane-containing cardiovascular drugs, including saprisartan (GR138950), remikiren (Ro 42-5892), ciprokiren (Ro 44-9375), zoniporide (CP-597396), and BMS-795311, are provided in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">Preclinical/Clinical Drug Candidates for Metabolic Disorders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> HMG-CoA Reductase Inhibitor <b>146</b> (Pitavastatin/Livalo)</h3><div class="NLM_p">Compound <b>146</b> (pitavastatin/NK-104)<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> is a highly potent 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor approved by the U.S. FDA in 2009 for treating patients with high serum cholesterol levels (<a class="ref internalNav" href="#fig60" aria-label="Figure 60">Figure 60</a>). It was discovered by Suzuki and colleagues,<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> who were searching for synthetic statins with a greater potency than currently used statins such as pravastatin, symvastatin, atorvastatin, and lovastatin. During the course of a SAR optimization program, they identified compound <b>145</b>, having heptenoate as the basic structure, a quinoline ring at its core, and 4-fluorophenyl and isopropyl moieties as pendant groups and showing an IC<sub>50</sub> of 19 nM for HMG-CoA reductase.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> The replacement of the isopropyl group in <b>145</b> with the metabolically stable cyclopropyl moiety led to the discovery of <b>146</b>, an approximately 5-fold more potent compound (IC<sub>50</sub> = 4.1 nM). An additional advantage of introducing the cyclopropyl group was to curtail CYP3A4-mediated metabolism, thus allowing for increased bioavailability and longer duration of action of pitavastatin relative to other statins and previous analogues.</div><figure id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0060.jpeg" id="gr60" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Structures of HMG-CoA inhibitors <b>145</b> and <b>146</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The cyclopropane-containing farnesoid X receptor agonist (LY2562175) is described in the <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">Preclinical/Clinical Drug Candidates for the Endocrine System</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Dipeptidylpeptidase-IV (DPP-IV) Inhibitor <b>147</b> (Saxagliptin/Onglyza)</h3><div class="NLM_p">Compound <b>147</b> (Saxagliptin/BMS-477118),<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> a highly selective and competitive inhibitor of DPP-IV, was approved by the U.S. FDA in 2009 for the management of type 2 diabetes. One of the problems with earlier DPP-IV inhibitory cyanopyrrolidine structural analogues was their short duration of action and chemical instability as shown in <a class="ref internalNav" href="#fig61" aria-label="Figure 61">Figure 61</a> (right panel).<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Notably, the conversion of the DPP-IV binding <i>trans</i>-rotamer to the <i>cis</i>-rotamer, where the proximal nucleophilic amino group attacks the cyano group, leading to the intramolecular cyclized imidate intermediate and formation of the piperazine-2,5-dione, which are inactive against DPP-IV<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> (<a class="ref internalNav" href="#fig61" aria-label="Figure 61">Figure 61</a>). It was proposed that the locking of the cyanopyrrolidine into a stable <i>trans</i>-rotameric conformation would enhance favorable, directed binding within the active site of DPP-IV and preclude the inactivating intramolecular cyclization reaction.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> To substantiate this hypothesis, Magnin and co-workers<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> introduced the <i>cis</i>-4,5-methano (fused cyclopropyl ring) across the C4 and C5 of the cyanopyrroldine P1 moiety, and in a separate communication,<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Augeri and co-workers introduced the sterically demanding adamantyl P2 moiety on the <i>N</i>-terminus, leading to the discovery of compound <b>147</b> (<a class="ref internalNav" href="#fig61" aria-label="Figure 61">Figure 61</a>, left panel). Both the steric bulk at P2 and the sterically constrained cyclopropane fused pyrrolidine P1 moiety cooperatively contributed toward enhancing the <i>trans</i>-rotameric conformational stability and in vitro potency of <b>147</b>. The X-ray cocrystal structure of <b>147</b> and DPP-IV revealed an efficient filling of the hydrophobic S1 pocket of DPP-IV by the cyclopropane-fused pyrroldine P1 moiety.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Furthermore, it was also speculated that the cyclopropyl moiety in <b>147</b> displaces active site water molecules required for hydrolysis, thereby preventing <b>147</b> from undergoing hydrolysis. Thus, compound <b>147</b> is an inhibitor, not a substrate of DPP-IV. Compound <b>147</b> has excellent PK/PD features, such as a novel slow tight-binding kinetic inhibition<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> of hDPP-IV <i>K</i><sub>i</sub> = 0.6 nM, 87% ex vivo inhibition of plasma DPP-IV, a slow rate of microsomal turnover, no CYP3A4 inhibition up to 100 μM, and rat oral bioavailability of 75%, and a <i>t</i><sub>1/2</sub> = 2.1 h.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div><figure id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0061.jpeg" id="gr61" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. Structure of DPP-IV inhibitor <b>147</b> (left panel) and mechanism of acid catalyzed inactivation of noncyclopropane analogues of compound <b>147</b> (right panel).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor <b>149</b></h3><div class="NLM_p">Compound <b>149</b> (PF-06424439) was the first orally bioavailable advanced preclinical candidate that inhibits DGAT2.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Because DGAT2 represents a therapeutic target for the treatment of metabolic disorders such as hyperlipidemia and hyperglycemia, Futatsugi and co-workers<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> sought to identify highly potent, selective, and orally bioavailable DGAT2 inhibitors. One of their early lead DGAT2 inhibitory compounds, <b>148</b>, had high potency, appreciable selectivity over other acyltransferases, and ligand lipophilic efficiency as shown in <a class="ref internalNav" href="#fig62" aria-label="Figure 62">Figure 62</a>. Unfortunately, compound <b>148</b> showed a high metabolic turnover in HLM, a high clearance through <i>N</i>-glucuronidation, and undesirable off-target activities against adenosine A<sub>2A</sub>, muscarinic M<sub>1</sub>, histamine H<sub>1</sub>, adrenergic α<sub>1a</sub>, and phsophodiesterase 1B, 5A, 6A, and 11 receptors. The higher HLM turnover of <b>148</b> could be a result of increased lipophilicity and the presence of a metabolically unstable pyrrolidine ring.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0062.jpeg" id="gr62" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. Structures, in vitro potency, and microsomal stability data of DGAT2 inhibitors <b>148</b> and <b>149</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Follow up studies on compound <b>148</b> indicated that it underwent phase II metabolism via <i>N</i>-glucuronidation of the imidazopyridine ring −NH group. To circumvent off-target pharmacology and the <i>N</i>-glucuronidation associated with compound <b>148</b>, Futatsugi et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> carried out two elegant molecular modifications. The first involved the introduction of an sp<sup>3</sup>-hybridized carbon spacer between the imidazopyridine ring and the eastern heteroaryl ring, with the intention of increasing the three-dimensionality of the core structure to mitigate off-target effects. The second molecular modification involved the addition of steric bulkiness at the sp<sup>3</sup>-hybridized carbon spacer in the form of a spiro-cyclopropyl moiety to decrease the likelihood of <i>N</i>-glucuronidation. The spiro-cyclopropyl moiety in <b>149</b> significantly improved HLM turnover, in addition to producing desirable properties such as a moderate increase in lipophilicity and a nonchiral spacer as shown in <a class="ref internalNav" href="#fig62" aria-label="Figure 62">Figure 62</a>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec1_3_11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Lysosomal Cysteine Protease (Cathepsin K) Inhibitor <b>151</b> (Odanacatib)</h3><div class="NLM_p">Compound <b>151</b> (odanacatib/MK-0822) is a potent and selective inhibitor of lysosomal cysteine protease (cathepsin K)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (<a class="ref internalNav" href="#fig63" aria-label="Figure 63">Figure 63</a>). Because cathepsin K serves as a molecular target for treating osteoporosis, Gauthier et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> began their discovery chemistry work with a highly potent and selective cathepsin K inhibitory lead compound <b>150</b> (L-873724). Although <b>150</b> had an excellent activity against cathepsin K, with >800-fold selectivity over other cathepsin isoforms, it was unsuitable for further development due to significant metabolic liability as shown in <a class="ref internalNav" href="#fig63" aria-label="Figure 63">Figure 63</a>.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> One of the two metabolites resulted from the hydrolysis of the amide bond. To increase the stability of an amide bond toward hydrolysis, the spiro-cyclopropyl moiety was inserted at the Cα-atom of the P1 aminonitrile group. This molecular modification, in conjunction with the introduction of the 4-fluoroleucine as a P2 moiety, yielded a metabolically stable compound <b>151</b> and preserved the inhibitory activity and selectivity toward cathepsin K as shown in <a class="ref internalNav" href="#fig63" aria-label="Figure 63">Figure 63</a>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0063.jpeg" id="gr63" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. Structures, in vitro potency, and PK properties of cathepsin K inhibitors <b>150</b> and <b>151</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_11_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Compound <b>154</b> (Drospirenone)</h3><div class="NLM_p">Compound <b>152</b> (spironolactone), a steroidal aldosterone antagonist, is used as an antidiuretic drug and for the treatment of heart failure. It produces adverse hormonal effects such as gynecomastia, impotence, and menstrual irregularity.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> To develop steroid derivatives devoid of these adverse effects, Weichert and co-workers<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> synthesized several hundred steroid-like compounds. These studies led to the cyclopropane fused derivative <b>153</b> (spirorenone), which was 5-fold more potent than <b>152</b> as an aldosterone antagonist and produced fewer hormonal side effects (<a class="ref internalNav" href="#fig64" aria-label="Figure 64">Figure 64</a>). Compound <b>154</b> (drospirenone), a 1,2-dihydrospirorenone, is an orally active metabolite of <b>153</b> formed by the Δ<sup>1</sup>-hydrase enzyme (<a class="ref internalNav" href="#fig64" aria-label="Figure 64">Figure 64</a>). Compound <b>154</b> has progestin activity, as well as antiandrogen and antimineralocorticoid actions.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> It has been developed as a contraceptive. The potent activity of <b>154</b> was thought to be a result of C-1 saturation of the A ring and two cyclopropane rings fused to rings B and D across the 6,7 and 15,16 bonds. An enhanced in vivo activity of <b>153</b> and <b>154</b> compared to <b>152</b> is possibly due to inhibition of metabolic inactivation at the cyclopropane ring fused positions of the steroid nucleus.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></div><figure id="fig64" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Figure 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0064.jpeg" id="gr64" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 64. Structures of steroids <b>152</b>–<b>154</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig64"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional examples of cyclopropane-containing endocrine drugs (TGR5 agonist and calcipotriol) are given in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec1_3_12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">Miscellaneous Preclinical/Clinical Drug Candidates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02788" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02788" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_12_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Human Ghrelin (GRLN) Receptor Agonist <b>157</b> (Ulimorelin)</h3><div class="NLM_p">Compound <b>157</b> (ulimorelin/TZP-101)<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> is a human GRLN receptor agonist that is currently undergoing phase III clinical trials for the treatment of postoperative ileus. Hoveyda and co-workers<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> transformed the high-throughput screening derived macrocyclic lead GRLN agonist <b>155</b> (nor-valine/<i>n</i>-propyl at AA1 position) into a clinical candidate <b>157</b> (<a class="ref internalNav" href="#fig65" aria-label="Figure 65">Figure 65</a>). In the SAR optimization study, these investigators<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> retained the cyclopropyl group at AA1 as it is smaller in size and provides conformational restriction compared to the <i>sec</i>-butyl-containing Ile analogue <b>156</b> (<a class="ref internalNav" href="#fig65" aria-label="Figure 65">Figure 65</a>). In addition, these aforementioned changes provided a greater metabolic stability compared to the noncyclic alkyl counterparts.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> The cyclopropyl AA1 side chain in <b>157</b> turned out to be an important structural element for an improved PK profile in the rat compared to Ile analogue <b>156</b> as shown in <a class="ref internalNav" href="#fig65" aria-label="Figure 65">Figure 65</a>.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> The cyclopropyl ring is less lipophilic and electron-donating based on Hansch π and Hammett σ values compared to other cyclic alkyl groups. It was also noted that the electron-donating effect of the cyclopropyl moiety increased the basicity of the secondary amine at the AA1 position (p<i>K</i><sub>a</sub> of 7.17 ± 0.04 for ulimorelin <b>157</b> versus p<i>K</i><sub>a</sub> of 6.45 ± 0.08 for analogous <i>n</i>-propyl side chain at AA1 position), producing stronger intramolecular hydrogen bonding between the positively charged amine at AA1 and the phenoxy oxygen at the tether group.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> The cyclopropyl AA1 side chain was also postulated to shield this hydrogen bond from surrounding water molecules. An intramolecular hydrogen bond, supported by the cyclopropyl side chain, augmented the conformational rigidity of <b>157</b>. Compound <b>157</b>, being less lipophilic, had improved aqueous solubility at ca. pH 5 (1–8 mg/mL range), as opposed to 0.1 to 0.5 mg/mL observed for related compounds, where the cyclopropyl group was replaced with norvaline or Ile.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></div><figure id="fig65" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Figure 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0065.jpeg" id="gr65" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 65. Structures, in vitro potency, and PK properties of ghrelin receptor agonists <b>155</b>–<b>157</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig65"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">The Role of Cyclopropane Ring in Conformationally Restricted Peptidomimetics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The concept of preorganizing or locking of flexible biologically active compounds into their bioactive conformation has been widely used in medicinal chemistry research, particularly for the design of aspartyl protease inhibitors. This concept was based on the hypothesis that bioactive conformational locking would increase affinity through a decreased loss of conformational entropy upon binding to the active site of the target protein. Two representative examples are given below to illustrate the concept of ligand preorganization by comparing a flexible and constrained ligand pairs. Martin and co-workers<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> demonstrated that the 1,2,3-trisubstituted cyclopropane scaffold-derived peptidomimetics can efficiently stabilize the extended bioactive conformation of a peptidic compound as shown in <a class="ref internalNav" href="#fig66" aria-label="Figure 66">Figure 66</a>. They reported a marginal increase in affinity of constrained peptidomimetic analogue <b>158</b> when compared to the affinity of flexible peptide compound <b>159</b> toward HIV-1 protease. Furthermore, computational alignment studies of cyclopropanyl (rigid) and vanilyl (flexible) analogues revealed near-identical localization of the methyl groups of rigid analogues and the Cγ-methyl groups of flexible analogues. This has supported the observed comparable HIV-1 protease inhibitory potency as shown in <a class="ref internalNav" href="#fig66" aria-label="Figure 66">Figure 66</a>.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></div><figure id="fig66" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Figure 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0066.jpeg" id="gr66" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 66. Structures and in vitro potency of peptidomimetic HIV protease inhibitors <b>158</b> and <b>159</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig66"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As explained above, preorganizing/locking a ligand into a bioactive conformation will lead to entropically favorable binding. Davidson and co-workers<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> designed, synthesized, and thermodynamically characterized a novel cyclopropanated phosphotyrosyl peptidomimetics as Src SH2 domain binding inhibitors as shown in <a class="ref internalNav" href="#fig67" aria-label="Figure 67">Figure 67</a>. As expected, compound <b>160</b> bound to Src SH2 domain with a significant entropic advantage compared to the flexible compound <b>161</b>. This has strengthened the concept of conformational restriction by 1,2,3-trisubstituted cyclopropane ring leads to entropically favorable binding. However, conformationally rigid analogue <b>160</b> exhibited less favorable binding enthalpy. Comparable binding affinities of <b>160</b> and <b>161</b> to the Src SH2 domain is a result of favorable entropy change which is being compensated for by an unfavorable enthalpy change. Therefore, it is important to consider the enthalpic component during conformational restriction of the peptidic ligands.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a></div><figure id="fig67" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Figure 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0067.jpeg" id="gr67" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 67. Structures, binding affinity, and thermodynamic properties of peptidomimetic Src SH2 domain inhibitors <b>160</b> and <b>161</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig67"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">The Role of a Cyclopropane Ring in Probing the Receptor Topology and Development of Receptor Antagonists</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04312" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04312" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Watanabe and colleagues<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> utilized a stereochemical diversity oriented conformational restriction approach to develop potent histamine H<sub>3</sub> and H<sub>4</sub> receptor antagonists. The pendant pharmacophore groups, the imidazole ring, and the hydrophobic 4-chlorobenzyl moiety are projected in various three-dimensional arrangements due to the chiral <i>cis</i>- and <i>trans</i>-cyclopropane central spacer scaffold. The (1<i>R</i>,2<i>S</i>)-<i>trans</i>-cyclopropane isomer <b>162</b> had comparable antagonism of H<sub>3</sub> and H<sub>4</sub> receptors, whereas the (1<i>S</i>,2<i>R</i>)-<i>trans</i>-cyclopropane isomer <b>163</b> was a highly selective antagonist for H<sub>3</sub> receptor as shown in <a class="ref internalNav" href="#fig68" aria-label="Figure 68">Figure 68</a>.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Therefore, one can achieve receptor subtype potency and selectivity by modifying the molecular configuration at the cyclopropane spacer scaffold. Similarly, the cyclopropane ring has been successfully utilized for the development of antagonists/molecular probes for the understanding of receptors, including excitatory amino acid receptors<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> and nicotinic/muscarinic acetylcholine receptors.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><figure id="fig68" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Figure 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0068.jpeg" id="gr68" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 68. Structures and in vitro potency of H<sub>3</sub>/H<sub>4</sub> receptor antagonists <b>162</b> and <b>163</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig68"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The centrally located cyclopropane ring can impose significant steric constraints on the conformation of an entire molecule (e.g., milnacipran, tranylcypromine, tasimelteon, ticagrelor, cabozantinib, and montelukast), whereas the terminally located cyclopropane ring is expected to impose only limited steric rigidity (e.g., betaxolol, telaprevir, olaparib, abacavir, and lenvatinib). The centrally located chiral cyclopropane ring, through its considerable rigidity, helps to position pendant pharmacophore groups in complementary binding pockets of the target protein. Furthermore, the molecular configuration provided by the centrally located cyclopropane ring can enhance noncoplanarity, target specificity, mitigate off target activity, reduce crystal packing, and increase aqueous solubility. The cyclopropane ring has also been widely used as a convenient biological probe to understand molecular mechanisms, receptor topology, and receptor subtype selectivity, which can promote the design of new chemical entities.</div><div class="NLM_p">This perspective highlights the role played by the versatile cyclopropyl ring as exemplified by FDA approved drugs and preclinical/clinical candidates and summarized in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. The author anticipates that this perspective will inspire scientists involved in drug discovery to exploit the cyclopropane ring either as a substituent, as a chiral bridge, and as a spiro or fused ring in solving multiple challenges that occur during the course of drug discovery program and including target specificity, therapeutic potency, ligand efficiency, ligand lipophilic efficiency, aqueous solubility, p<i>K</i><sub>a</sub>, log <i>P</i>, tuning of phase I oxidative/hydrolytic drug metabolism, sterically limiting the phase II glucuronide conjugation, cell permeability, oral bioavailability, plasma clearance, biological half-life, chemical stability, liver microsomal stability, eliminating isomerizable noncyclic C═C bond through cyclopropanation, removal of Michael acceptor through cyclopropanation, and in the case of CNS active drugs, tuning of brain penetration, P-gp efflux ratio, and CNS receptor occupancy (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of the Contributions of a Cyclopropyl Ring towards the PK/PD/Physicochemical Properties of Selected Compounds Described in This Article</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0069.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0070.gif" alt="" id="GRAPHIC-d2879e5145-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0071.gif" alt="" id="GRAPHIC-d2879e5146-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0072.gif" alt="" id="GRAPHIC-d2879e5147-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0073.gif" alt="" id="GRAPHIC-d2879e5148-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0074.gif" alt="" id="GRAPHIC-d2879e5149-autogenerated" /></img><div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00472">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00472" class="ext-link">10.1021/acs.jmedchem.6b00472</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional examples of clinically relevant cyclopropane-containing compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf">jm6b00472_si_001.pdf (664.67 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00472" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50621" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50621" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tanaji T. Talele</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences, College of Pharmacy and Health
Sciences, St. John’s University, 8000 Utopia Parkway, Queens, New York 11439, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6b1f0a070e070e1f2b181f0104030518450e0f1e"><span class="__cf_email__" data-cfemail="14607578717871605467607e7b7c7a673a717061">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Tanaji T. Talele</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=BIO-d2879e5170-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tanaji T. Talele</b> received his B.S. degree (1992) in pharmacy from the University of Pune, India. He completed his M.S. (1994) and Ph.D. (1998) in Medicinal Chemistry from the University of Mumbai, India. He conducted postdoctoral research at UMD–New Jersey Medical School, Louisiana State University, and Moffitt Cancer Center (1999–2005). He joined the SJU’s College of Pharmacy and Health Sciences in 2005, where he is currently a Full Professor. He has been appointed as an Assistant Chair of the Department of Pharmaceutical Sciences since 2014. He has authored/coauthored 83 peer-reviewed original research papers and one book chapter, “Pharmaceutical Biotechnology” in <i>Foye’s Principles of Medicinal Chemistry</i>, 7th ed., 2012. His current research interests include design, synthesis, and development of small-molecule inhibitors of poly(ADP-ribose)polymerase and P-glycoprotein.</p></figure></div><div class="ack" id="ACK-d2879e5178-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67015" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67015" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The author is thankful to Drs. Charles R. Ashby, Jr. and Cesar A. Lau-Cam (St. John’s University) for critical reading of the manuscript. He also thanks his graduate students Uday Kiran Velagapudi and Bhargav A. Patel for technical help.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i90" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i90"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i91" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i91"> Abbreviations Used</h2><tr><td class="NLM_term">A<sub>2A</sub> and A<sub>2B</sub></td><td class="NLM_def"><p class="first last">adenosine receptor types 2A and 2B</p></td></tr><tr><td class="NLM_term">Abl</td><td class="NLM_def"><p class="first last">abelson tyrosine kinase</p></td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid β peptide</p></td></tr><tr><td class="NLM_term">nAChR</td><td class="NLM_def"><p class="first last">nicotinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">ADHD</td><td class="NLM_def"><p class="first last">attention deficit hyperactivity disorder</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BACE-1</td><td class="NLM_def"><p class="first last">β-site amyloid precursor protein (APP)-cleaving enzyme-1</p></td></tr><tr><td class="NLM_term">BRCA</td><td class="NLM_def"><p class="first last">breast cancer susceptibility gene</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>b</sub></td><td class="NLM_def"><p class="first last">concentration in the brain</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">Clp</td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term">DAT</td><td class="NLM_def"><p class="first last">dopamine reuptake transporter</p></td></tr><tr><td class="NLM_term">DGAT</td><td class="NLM_def"><p class="first last">diacylglycerol acyltransferase</p></td></tr><tr><td class="NLM_term">DHP-I</td><td class="NLM_def"><p class="first last">dehydropeptidase-I</p></td></tr><tr><td class="NLM_term">DPP-IV</td><td class="NLM_def"><p class="first last">dipeptidylpeptidase-IV</p></td></tr><tr><td class="NLM_term">FGFR 1 and 2</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1 and 2</p></td></tr><tr><td class="NLM_term">FXa</td><td class="NLM_def"><p class="first last">factor Xa</p></td></tr><tr><td class="NLM_term">GlyT1</td><td class="NLM_def"><p class="first last">human glycine uptake transporter 1</p></td></tr><tr><td class="NLM_term">GRLN</td><td class="NLM_def"><p class="first last">ghrelin</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene encoded potassium channel</p></td></tr><tr><td class="NLM_term">HGFR</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HMG-CoA</td><td class="NLM_def"><p class="first last">3-hydroxy-3-methyl-glutaryl-CoA</p></td></tr><tr><td class="NLM_term">hPBMC</td><td class="NLM_def"><p class="first last">human peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">H<sub>4</sub>R</td><td class="NLM_def"><p class="first last">histamine H<sub>4</sub> receptor</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">IKK</td><td class="NLM_def"><p class="first last">IκB kinase</p></td></tr><tr><td class="NLM_term">ITK</td><td class="NLM_def"><p class="first last">interleukin-2 inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">janus kinase 2</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>a</sub></td><td class="NLM_def"><p class="first last">association constant</p></td></tr><tr><td class="NLM_term">KDM</td><td class="NLM_def"><p class="first last">lysine (K) demethylase</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LSD1</td><td class="NLM_def"><p class="first last">lysine-specific demethylase 1</p></td></tr><tr><td class="NLM_term">LTD<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene D<sub>4</sub></p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">mitogen activated protein</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">MEK 1 and 2</td><td class="NLM_def"><p class="first last">mitogen/extracellular signal-regulated kinase 1 and 2</p></td></tr><tr><td class="NLM_term">MGAT</td><td class="NLM_def"><p class="first last">monoacylglycerol acyltransferase</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">MT</td><td class="NLM_def"><p class="first last">melatonin receptor</p></td></tr><tr><td class="NLM_term">NEMO</td><td class="NLM_def"><p class="first last">nuclear factor-κB essential modulator</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine reuptake transporter</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor-κ light-chain-enhancer of B cells</p></td></tr><tr><td class="NLM_term">NK-3</td><td class="NLM_def"><p class="first last">neurokinin-3</p></td></tr><tr><td class="NLM_term">NKB</td><td class="NLM_def"><p class="first last">neurokinin B</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NNRTI</td><td class="NLM_def"><p class="first last">non-nucleoside reverse transcriptase inhibitor</p></td></tr><tr><td class="NLM_term">OX1R/OX2R</td><td class="NLM_def"><p class="first last">orexin receptor 1 and 2</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">passive permeability</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)polymerase</p></td></tr><tr><td class="NLM_term">PDE4</td><td class="NLM_def"><p class="first last">phosphodiesterase 4</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PEI</td><td class="NLM_def"><p class="first last">peroxisomal enzyme induction</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PLC-γ</td><td class="NLM_def"><p class="first last">phospholipase C-γ</p></td></tr><tr><td class="NLM_term">Plk1 and 4</td><td class="NLM_def"><p class="first last">polo-like kinase 1 and 4</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">RORγ</td><td class="NLM_def"><p class="first last">retinoic acid receptor-related orphan receptor gamma</p></td></tr><tr><td class="NLM_term">RSV</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">sEH</td><td class="NLM_def"><p class="first last">soluble epoxide hydrolase</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin reuptake transporter</p></td></tr><tr><td class="NLM_term">Th2</td><td class="NLM_def"><p class="first last">T helper 2</p></td></tr><tr><td class="NLM_term">TIE2</td><td class="NLM_def"><p class="first last">Tie 2 receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TNFα</td><td class="NLM_def"><p class="first last">tumor necrosis factor α</p></td></tr><tr><td class="NLM_term">Trk</td><td class="NLM_def"><p class="first last">tropomycin receptor kinase</p></td></tr><tr><td class="NLM_term">URAT1</td><td class="NLM_def"><p class="first last">uric acid transporter 1</p></td></tr><tr><td class="NLM_term">VEGFR 1, 2, and 3</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 1, 2, and 3</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 203 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Freund, A.</span><span> </span><span class="NLM_article-title">Ueber trimethylen</span> <span class="citation_source-journal">J. Prakt. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1882</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span><span class="refDoi"> DOI: 10.1002/prac.18820260125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fprac.18820260125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1882&pages=367-377&author=A.+Freund&title=Ueber+trimethylen&doi=10.1002%2Fprac.18820260125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fprac.18820260125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.18820260125%26sid%3Dliteratum%253Aachs%26aulast%3DFreund%26aufirst%3DA.%26atitle%3DUeber%2520trimethylen%26jtitle%3DJ.%2520Prakt.%2520Chem.%26date%3D1882%26volume%3D26%26spage%3D367%26epage%3D377%26doi%3D10.1002%2Fprac.18820260125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Henderson, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, G. H. W.</span><span> </span><span class="NLM_article-title">Cyclopropane: a new anesthetic</span> <span class="citation_source-journal">Anesth. Analg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1930</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1213/00000539-193001000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1213%2F00000539-193001000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaA3cXhtlWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1930&pages=1-6&author=V.+E.+Hendersonauthor=G.+H.+W.+Lucas&title=Cyclopropane%3A+a+new+anesthetic&doi=10.1213%2F00000539-193001000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropane: a new anesthetic</span></div><div class="casAuthors">Henderson, V. E.; Lucas, G. H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">1930</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    </div><div class="casAbstract">The gas was first prepd. by reducing an alc. soln. of trimethylene bromide, to which a few drops of water had been added, with Zn dust.  Anesthesia was maintained in the dog for 90 min. with a very slight fall in the blood pressure and good respiratory vol. over a wide range in gas %.  The gas has a sweetish odor much like that of a mixt. of ethylene and chloroform and is not unpleasant to breathe.  It is heavier than air and is explosive in 5% and upward in O; mixts. above 10% in air are not explosive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj8KUF51z7bVg90H21EOLACvtfcHk0lha2uevKV_uzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA3cXhtlWmsg%253D%253D&md5=b76804bafa90a159c914c9f93e3c317a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1213%2F00000539-193001000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252F00000539-193001000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DV.%2BE.%26aulast%3DLucas%26aufirst%3DG.%2BH.%2BW.%26atitle%3DCyclopropane%253A%2520a%2520new%2520anesthetic%26jtitle%3DAnesth.%2520Analg.%26date%3D1930%26volume%3D9%26spage%3D1%26epage%3D6%26doi%3D10.1213%2F00000539-193001000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Staudinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzicka, L.</span><span> </span><span class="NLM_article-title">Insect poisons. I. Isolation and constitution of the active portion of dalmatian insect powder</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1924</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1002/hlca.19240070124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fhlca.19240070124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1924&pages=177-201&author=H.+Staudingerauthor=L.+Ruzicka&title=Insect+poisons.+I.+Isolation+and+constitution+of+the+active+portion+of+dalmatian+insect+powder&doi=10.1002%2Fhlca.19240070124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19240070124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19240070124%26sid%3Dliteratum%253Aachs%26aulast%3DStaudinger%26aufirst%3DH.%26aulast%3DRuzicka%26aufirst%3DL.%26atitle%3DInsect%2520poisons.%2520I.%2520Isolation%2520and%2520constitution%2520of%2520the%2520active%2520portion%2520of%2520dalmatian%2520insect%2520powder%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1924%26volume%3D7%26spage%3D177%26epage%3D201%26doi%3D10.1002%2Fhlca.19240070124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Yang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, N. E.</span><span> </span><span class="NLM_article-title">Ethylene biosynthesis and its regulation in higher plants</span> <span class="citation_source-journal">Annu. Rev. Plant Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1146/annurev.pp.35.060184.001103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1146%2Fannurev.pp.35.060184.001103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2cXkvVOnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1984&pages=155-189&author=S.+F.+Yangauthor=N.+E.+Hoffman&title=Ethylene+biosynthesis+and+its+regulation+in+higher+plants&doi=10.1146%2Fannurev.pp.35.060184.001103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Ethylene biosynthesis and its regulation in higher plants</span></div><div class="casAuthors">Yang, Shang Fa; Hoffman, Neil E.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Plant Physiology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-89</span>CODEN:
                <span class="NLM_cas:coden">ARPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0066-4294</span>.
    </div><div class="casAbstract">A review with 192 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuCcCtFPglebVg90H21EOLACvtfcHk0lha2uevKV_uzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvVOnsrg%253D&md5=5d938a2255e8f4c9393ade15c81a3282</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pp.35.060184.001103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pp.35.060184.001103%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DHoffman%26aufirst%3DN.%2BE.%26atitle%3DEthylene%2520biosynthesis%2520and%2520its%2520regulation%2520in%2520higher%2520plants%26jtitle%3DAnnu.%2520Rev.%2520Plant%2520Physiol.%26date%3D1984%26volume%3D35%26spage%3D155%26epage%3D189%26doi%3D10.1146%2Fannurev.pp.35.060184.001103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Burger, A.</span><span> </span><span class="NLM_article-title">Cyclopropane compounds of biological interest</span> <span class="citation_source-journal">Prog. Drug Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1007/978-3-0348-7078-8_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2F978-3-0348-7078-8_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaE38XltV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1971&pages=227-270&author=A.+Burger&title=Cyclopropane+compounds+of+biological+interest&doi=10.1007%2F978-3-0348-7078-8_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropane compounds of biological interest</span></div><div class="casAuthors">Burger, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Drug Research</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-70</span>CODEN:
                <span class="NLM_cas:coden">FAZMAE</span>;
        ISSN:<span class="NLM_cas:issn">0071-786X</span>.
    </div><div class="casAbstract">An extensive discussion and review with 145 refs. of cyclopropane compds. possessing biol. activity, such as tranylcypromine [3721-28-6], 2-(4-imidazolyl)cyclopropylamine [24160-41-6], cyclazocine [3572-80-3], cyclorphan [4163-15-9], prazepam [2955-38-6], and cyprolidol [7433-09-2].  The biol. actions of cyclopropane contg. fatty acids, steroids, triterpenes, and amino acids are included as well as the structure-activity relations of arylcyclopropylamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquy4v0ynjnJbVg90H21EOLACvtfcHk0lha2uevKV_uzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XltV2iu7Y%253D&md5=45aea895d4edba8fed5e9701b2df3e12</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2F978-3-0348-7078-8_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-0348-7078-8_7%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%26atitle%3DCyclopropane%2520compounds%2520of%2520biological%2520interest%26jtitle%3DProg.%2520Drug%2520Res.%26date%3D1971%26volume%3D15%26spage%3D227%26epage%3D270%26doi%3D10.1007%2F978-3-0348-7078-8_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Lebel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinaro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charette, A. B.</span><span> </span><span class="NLM_article-title">Stereoselective cyclopropanation reactions</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">1050</span><span class="refDoi"> DOI: 10.1021/cr010007e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr010007e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislSjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2003&pages=977-1050&author=H.+Lebelauthor=J.+F.+Marcouxauthor=C.+Molinaroauthor=A.+B.+Charette&title=Stereoselective+cyclopropanation+reactions&doi=10.1021%2Fcr010007e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Cyclopropanation Reactions</span></div><div class="casAuthors">Lebel, Helene; Marcoux, Jean-Francois; Molinaro, Carmela; Charette, Andre B.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">977-1050</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAxS9Vy1tYLVg90H21EOLACvtfcHk0ljajY7aLNsWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislSjt7o%253D&md5=ddd27c744fcd09d7991420025aa613d2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fcr010007e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr010007e%26sid%3Dliteratum%253Aachs%26aulast%3DLebel%26aufirst%3DH.%26aulast%3DMarcoux%26aufirst%3DJ.%2BF.%26aulast%3DMolinaro%26aufirst%3DC.%26aulast%3DCharette%26aufirst%3DA.%2BB.%26atitle%3DStereoselective%2520cyclopropanation%2520reactions%26jtitle%3DChem.%2520Rev.%26date%3D2003%26volume%3D103%26spage%3D977%26epage%3D1050%26doi%3D10.1021%2Fcr010007e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Bartoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencivenni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalpozzo, R.</span><span> </span><span class="NLM_article-title">Asymmetric cyclopropanation reactions</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">–</span> <span class="NLM_lpage">1029</span><span class="refDoi"> DOI: 10.1055/s-0033-1340838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1055%2Fs-0033-1340838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFeqsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=979-1029&author=G.+Bartoliauthor=G.+Bencivenniauthor=R.+Dalpozzo&title=Asymmetric+cyclopropanation+reactions&doi=10.1055%2Fs-0033-1340838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric cyclopropanation reactions</span></div><div class="casAuthors">Bartoli, Giuseppe; Bencivenni, Giorgio; Dalpozzo, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">979-1029, 51 pp.</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Both phys. and org. chemists are interested in the cyclopropane ring, the former owing to the strain inherent to the small ring structure, the latter prompted by the importance of this ring in naturally occurring compds.  In recent years, the increasing interest in enantioselective org. synthesis has led to a large no. of papers on the prepn. of cyclopropane compds. in enantioenriched form.  The last review on asym. cyclopropanation reactions is dated 2008, thus an update is necessary with crit. comparison of prepns. using chiral auxiliaries, chiral metal complexes and organocatalysts.  The aim of this review is an overview of these topics from 2008 to mid-2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIuWaZ3RVc7bVg90H21EOLACvtfcHk0ljajY7aLNsWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFeqsb3K&md5=2fc8619f099d7d5fde1e175565b8f1fb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1340838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1340838%26sid%3Dliteratum%253Aachs%26aulast%3DBartoli%26aufirst%3DG.%26aulast%3DBencivenni%26aufirst%3DG.%26aulast%3DDalpozzo%26aufirst%3DR.%26atitle%3DAsymmetric%2520cyclopropanation%2520reactions%26jtitle%3DSynthesis%26date%3D2014%26volume%3D46%26spage%3D979%26epage%3D1029%26doi%3D10.1055%2Fs-0033-1340838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wiberg, K. B.</span><span> </span><span class="NLM_article-title">The concept of strain in organic chemistry</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1002/anie.198603121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fanie.198603121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1986&pages=312-322&author=K.+B.+Wiberg&title=The+concept+of+strain+in+organic+chemistry&doi=10.1002%2Fanie.198603121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.198603121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198603121%26sid%3Dliteratum%253Aachs%26aulast%3DWiberg%26aufirst%3DK.%2BB.%26atitle%3DThe%2520concept%2520of%2520strain%2520in%2520organic%2520chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1986%26volume%3D25%26spage%3D312%26epage%3D322%26doi%3D10.1002%2Fanie.198603121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gagnon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duplessis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fader, L.</span><span> </span><span class="NLM_article-title">Arylcyclopropanes: properties, synthesis and use in medicinal chemistry</span> <span class="citation_source-journal">Org. Prep. Proced. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1080/00304940903507788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1080%2F00304940903507788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFGis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=1-69&author=A.+Gagnonauthor=M.+Duplessisauthor=L.+Fader&title=Arylcyclopropanes%3A+properties%2C+synthesis+and+use+in+medicinal+chemistry&doi=10.1080%2F00304940903507788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Arylcyclopropanes: properties, synthesis and use in medicinal chemistry</span></div><div class="casAuthors">Gagnon, Alexandre; Duplessis, Martin; Fader, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Organic Preparations and Procedures International</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-69</span>CODEN:
                <span class="NLM_cas:coden">OPPIAK</span>;
        ISSN:<span class="NLM_cas:issn">0030-4948</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Topics thus discussed included conjugative, phys. and conformation properties, microsomal metab., (aryl)cyclopropanes in medicinal chem., cross-coupling reactions between (cyclopropyl)metal compds. and aryl halides and pseudohalides, Negishi cross-coupling reaction, Kumada-Corriu reaction, Suzuki reaction, Stille coupling reaction and reactions of other metals.  Other topics included cross-coupling reactions between (aryl)metals and halocyclopropanes, addn. to cyclopropene derivs., carbon-hydrogen bond activation, formal arom. nucleophilic substitution, migration reaction, rearrangement reaction, other methods, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1nOaFva4JrbVg90H21EOLACvtfcHk0ljajY7aLNsWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFGis7g%253D&md5=663f28aec3b48d165e099062b75217f4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F00304940903507788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00304940903507788%26sid%3Dliteratum%253Aachs%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DFader%26aufirst%3DL.%26atitle%3DArylcyclopropanes%253A%2520properties%252C%2520synthesis%2520and%2520use%2520in%2520medicinal%2520chemistry%26jtitle%3DOrg.%2520Prep.%2520Proced.%2520Int.%26date%3D2010%26volume%3D42%26spage%3D1%26epage%3D69%26doi%3D10.1080%2F00304940903507788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">de Meijere, A.</span><span> </span><span class="NLM_article-title">Bonding properties of cyclopropane and their chemical consequences</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.1002/anie.197908093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fanie.197908093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1979&pages=809-826&author=A.+de+Meijere&title=Bonding+properties+of+cyclopropane+and+their+chemical+consequences&doi=10.1002%2Fanie.197908093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.197908093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.197908093%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMeijere%26aufirst%3DA.%26atitle%3DBonding%2520properties%2520of%2520cyclopropane%2520and%2520their%2520chemical%2520consequences%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1979%26volume%3D18%26spage%3D809%26epage%3D826%26doi%3D10.1002%2Fanie.197908093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Barnes-Seeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatsis, P.</span><span> </span><span class="NLM_article-title">Metabolically stable tert-butyl replacement</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1021/ml400045j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400045j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ymt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=514-516&author=D.+Barnes-Seemanauthor=M.+Jainauthor=L.+Bellauthor=S.+Ferreiraauthor=S.+Cohenauthor=X.+H.+Chenauthor=J.+Aminauthor=B.+Snodgrassauthor=P.+Hatsis&title=Metabolically+stable+tert-butyl+replacement&doi=10.1021%2Fml400045j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolically Stable tert-Butyl Replacement</span></div><div class="casAuthors">Barnes-Seeman, David; Jain, Monish; Bell, Leslie; Ferreira, Suzie; Cohen, Scott; Chen, Xiao-Hui; Amin, Jakal; Snodgrass, Brad; Hatsis, Panos</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">514-516</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Susceptibility to metab. is a common issue with the tert-Bu group on compds. of medicinal interest.  The authors demonstrate an approach of removing all the fully Sp3 C-Hs from a tert-Bu group: replacing some C-Hs with C-Fs and increasing the s-character of the remaining C-Hs.  This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability.  Trifluoromethylcyclopropyl-contg. analogs had consistently higher metabolic stability in vitro and in vivo compared to their tert-butyl-contg. counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrao2I5ukFsTrVg90H21EOLACvtfcHk0ljZI_N_tQ2qWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ymt78%253D&md5=156572485ea3a48f5e1b6ea7409f1f61</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml400045j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400045j%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes-Seeman%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DL.%26aulast%3DFerreira%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DAmin%26aufirst%3DJ.%26aulast%3DSnodgrass%26aufirst%3DB.%26aulast%3DHatsis%26aufirst%3DP.%26atitle%3DMetabolically%2520stable%2520tert-butyl%2520replacement%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D514%26epage%3D516%26doi%3D10.1021%2Fml400045j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Blanksby, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellison, G. B.</span><span> </span><span class="NLM_article-title">Bond dissociation energies of organic molecules</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1021/ar020230d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar020230d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=255-263&author=S.+J.+Blanksbyauthor=G.+B.+Ellison&title=Bond+dissociation+energies+of+organic+molecules&doi=10.1021%2Far020230d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Bond Dissociation Energies of Organic Molecules</span></div><div class="casAuthors">Blanksby, Stephen J.; Ellison, G. Barney</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this Account the authors have compiled a list of reliable bond energies that are based on a set of critically evaluated expts.  A brief description of the three most important exptl. techniques for measuring bond energies is provided.  The authors demonstrate how these exptl. data can be applied to yield the heats of formation of org. radicals and the bond enthalpies of more than 100 representative org. mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Gd4XRKVyrbVg90H21EOLACvtfcHk0ljZI_N_tQ2qWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D&md5=e313bd3c3a7809b70baa32c83e70d135</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Far020230d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far020230d%26sid%3Dliteratum%253Aachs%26aulast%3DBlanksby%26aufirst%3DS.%2BJ.%26aulast%3DEllison%26aufirst%3DG.%2BB.%26atitle%3DBond%2520dissociation%2520energies%2520of%2520organic%2520molecules%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D255%26epage%3D263%26doi%3D10.1021%2Far020230d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljZI_N_tQ2qWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yu, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalterio, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dando, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2006.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17169560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=895-901&author=K.+L.+Yuauthor=N.+Sinauthor=R.+L.+Civielloauthor=X.+A.+Wangauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=B.+L.+Venablesauthor=J.+J.+Wrightauthor=R.+A.+Dalterioauthor=L.+Zadjuraauthor=A.+Marinoauthor=S.+Dandoauthor=C.+D%E2%80%99Arienzoauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=Z.+Liauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=R.+J.+Colonnoauthor=Z.+Yangauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+4%3A+optimization+for+oral+bioavailability&doi=10.1016%2Fj.bmcl.2006.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span></div><div class="casAuthors">Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes.  1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (I, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTTCqYL_6iLVg90H21EOLACvtfcHk0ljgj7Yr9_lKbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D&md5=1df6d784bda1cabee0b57b799f1f165e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DDalterio%26aufirst%3DR.%2BA.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DDando%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25204%253A%2520optimization%2520for%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D895%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2006.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Abe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakefuda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakegawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmartin, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span> </span><span class="NLM_article-title">Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1021/ml200004g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+G.+Laquerre&title=Discovery+of+a+highly+potent+and+selective+MEK+inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+solvate%29&doi=10.1021%2Fml200004g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span></div><div class="casAuthors">Abe, Hiroyuki; Kikuchi, Shinichi; Hayakawa, Kazuhide; Iida, Tetsuya; Nagahashi, Noboru; Maeda, Katsuya; Sakamoto, Johei; Matsumoto, Noriaki; Miura, Tomoya; Matsumura, Koji; Seki, Noriyoshi; Inaba, Takashi; Kawasaki, Hisashi; Yamaguchi, Takayuki; Kakefuda, Reina; Nanayama, Toyomichi; Kurachi, Hironori; Hori, Yoshikazu; Yoshida, Takayuki; Kakegawa, Junya; Watanabe, Yoshihiro; Gilmartin, Aidan G.; Richter, Mark C.; Moss, Katherine G.; Laquerre, Sylvie G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">320-324</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) represents a promising strategy for the discovery of a new generation of anticancer chemotherapeutics.  Our synthetic efforts, beginning from the lead compd. 2, were directed at improving antiproliferative activity against cancer cells as well as various drug properties.  These efforts led to the discovery of N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethylsulfoxide solvate (GSK1120212, JTP-74057 DMSO solvate; 1), a selective and highly potent MEK inhibitor with improved drug properties.  We further confirmed that the antiproliferative activity correlates with cellular MEK inhibition and obsd. significant antitumor activity with daily oral dosing of 1 in a tumor xenograft model.  These qualities led to the selection of 1 for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCuItdsb_1bVg90H21EOLACvtfcHk0ljgj7Yr9_lKbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D&md5=0cb3bfa4e142b8d5ecc591e6792cd692</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%2520and%2520selective%2520MEK%2520inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D320%26epage%3D324%26doi%3D10.1021%2Fml200004g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4007</span><span class="NLM_x">–</span> <span class="NLM_lpage">4010</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.08.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.08.054" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4007-4010&author=J.+Wityakauthor=J.+Dasauthor=R.+V.+Moquinauthor=Z.+Shenauthor=J.+Linauthor=P.+Chenauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=G.+L.+Schievenauthor=S.+B.+Kannerauthor=J.+C.+Barrish&title=Discovery+and+initial+SAR+of+2-amino-5-carboxamidothiazoles+as+inhibitors+of+the+Src-family+kinase+p56%28Lck%29&doi=10.1016%2Fj.bmcl.2003.08.054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.08.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.08.054%26sid%3Dliteratum%253Aachs%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%25202-amino-5-carboxamidothiazoles%2520as%2520inhibitors%2520of%2520the%2520Src-family%2520kinase%2520p56%2528Lck%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4007%26epage%3D4010%26doi%3D10.1016%2Fj.bmcl.2003.08.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Smith, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafinowska, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coggon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murkitt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. A.</span><span> </span><span class="NLM_article-title">New quinoline NK3 receptor antagonists with CNS activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19117759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2itrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=837-840&author=P.+W.+Smithauthor=P.+A.+Wymanauthor=P.+Lovellauthor=C.+Goodacreauthor=H.+T.+Serafinowskaauthor=A.+Vongauthor=F.+Harringtonauthor=S.+Flynnauthor=D.+M.+Bradleyauthor=R.+Porterauthor=S.+Coggonauthor=G.+Murkittauthor=K.+Searleauthor=D.+R.+Thomasauthor=J.+M.+Watsonauthor=W.+Martinauthor=Z.+Wuauthor=L.+A.+Dawson&title=New+quinoline+NK3+receptor+antagonists+with+CNS+activity&doi=10.1016%2Fj.bmcl.2008.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">New quinoline NK3 receptor antagonists with CNS activity</span></div><div class="casAuthors">Smith, Paul W.; Wyman, Paul A.; Lovell, Peter; Goodacre, Caroline; Serafinowska, Halina T.; Vong, Antonio; Harrington, Frank; Flynn, Sean; Bradley, Daniel M.; Porter, Rod; Coggon, Sara; Murkitt, Graham; Searle, Kirsten; Thomas, David R.; Watson, Jeannette M.; Martin, William; Wu, Zining; Dawson, Lee A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">837-840</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lead optimization starting from the previously reported selective quinoline NK3 receptor antagonists talnetant (SB-223412) and (SB-222200) led to the identification of 3-aminoquinoline NK3 antagonist GSK172981 with excellent CNS penetration.  Investigation of a structurally related series of sulfonamides with reduced lipophilicity led to the discovery of GSK256471.  Both GSK172981 and GSK256471 are high affinity, potent NK3 receptor antagonists which despite having different degrees of CNS penetration produced excellent NK3 receptor occupancy in an ex vivo binding study in gerbil cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHKvtoPGv4rbVg90H21EOLACvtfcHk0lhR8zTEZD00nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2itrg%253D&md5=58b576420e152c8a008fea4bae4009a5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BW.%26aulast%3DWyman%26aufirst%3DP.%2BA.%26aulast%3DLovell%26aufirst%3DP.%26aulast%3DGoodacre%26aufirst%3DC.%26aulast%3DSerafinowska%26aufirst%3DH.%2BT.%26aulast%3DVong%26aufirst%3DA.%26aulast%3DHarrington%26aufirst%3DF.%26aulast%3DFlynn%26aufirst%3DS.%26aulast%3DBradley%26aufirst%3DD.%2BM.%26aulast%3DPorter%26aufirst%3DR.%26aulast%3DCoggon%26aufirst%3DS.%26aulast%3DMurkitt%26aufirst%3DG.%26aulast%3DSearle%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DD.%2BR.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26atitle%3DNew%2520quinoline%2520NK3%2520receptor%2520antagonists%2520with%2520CNS%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D837%26epage%3D840%26doi%3D10.1016%2Fj.bmcl.2008.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span> </span><span class="NLM_article-title">Adams discovery of nevirapine: a NNI of HIV-1 RT</span>. In  <span class="citation_source-book">The Search for Antiviral Drugs: Case Histories from Concept to Clinic</span>; <span class="NLM_contrib-group">Adams, J.; Merluzzi, V.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1993</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2F978-1-4899-6718-3_3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=45-70&author=J.+Adams&author=V.+Merluzzi&title=The+Search+for+Antiviral+Drugs%3A+Case+Histories+from+Concept+to+Clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2F978-1-4899-6718-3_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4899-6718-3_3%26sid%3Dliteratum%253Aachs%26atitle%3DAdams%2520discovery%2520of%2520nevirapine%253A%2520a%2520NNI%2520of%2520HIV-1%2520RT%26btitle%3DThe%2520Search%2520for%2520Antiviral%2520Drugs%253A%2520Case%2520Histories%2520from%2520Concept%2520to%2520Clinic%26aulast%3DAdams%26aufirst%3DJ.%26pub%3DSpringer%26date%3D1993%26spage%3D45%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauret, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromlish, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmarais, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamontagne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRiche, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oballa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodan, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venuti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, W. C.</span><span> </span><span class="NLM_article-title">The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">928</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2007.12.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18226527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=923-928&author=J.+Y.+Gauthierauthor=N.+Chauretauthor=W.+Cromlishauthor=S.+Desmaraisauthor=L.+T.+Duongauthor=J.+P.+Falgueyretauthor=D.+B.+Kimmelauthor=S.+Lamontagneauthor=S.+Legerauthor=T.+LeRicheauthor=C.+S.+Liauthor=F.+Masseauthor=D.+J.+McKayauthor=D.+A.+Nicoll-Griffithauthor=R.+M.+Oballaauthor=J.+T.+Palmerauthor=M.+D.+Percivalauthor=D.+Riendeauauthor=J.+Robichaudauthor=G.+A.+Rodanauthor=S.+B.+Rodanauthor=C.+Setoauthor=M.+Therienauthor=V.+L.+Truongauthor=M.+C.+Venutiauthor=G.+Wesolowskiauthor=R.+N.+Youngauthor=R.+Zamboniauthor=W.+C.+Black&title=The+discovery+of+odanacatib+%28MK-0822%29%2C+a+selective+inhibitor+of+cathepsin+K&doi=10.1016%2Fj.bmcl.2007.12.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K</span></div><div class="casAuthors">Gauthier, Jacques Yves; Chauret, Nathalie; Cromlish, Wanda; Desmarais, Sylvie; Duong, Le T.; Falgueyret, Jean-Pierre; Kimmel, Donald B.; Lamontagne, Sonia; Leger, Serge; LeRiche, Tammy; Li, Chun Sing; Masse, Frederic; McKay, Daniel J.; Nicoll-Griffith, Deborah A.; Oballa, Renata M.; Palmer, James T.; Percival, M. David; Riendeau, Denis; Robichaud, Joel; Rodan, Gideon A.; Rodan, Sevgi B.; Seto, Carmai; Therien, Michel; Truong, Vouy-Linh; Venuti, Michael C.; Wesolowski, Gregg; Young, Robert N.; Zamboni, Robert; Black, W. Cameron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">923-928</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724.  Substituting P1 and modifying the P2 side chain led to a metabolically robust inhibitor with a long half-life in preclin. species.  Odanacatib was more selective in whole cell assays than the published Cat K inhibitors balicatib and relacatib.  Evaluation in dermal fibroblast culture showed minimal intracellular collagen accumulation relative to less selective Cat K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7ytNI-SBgarVg90H21EOLACvtfcHk0lhR8zTEZD00nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWktro%253D&md5=e432a420a3ec99c784117750b9bbeda8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.047%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DDesmarais%26aufirst%3DS.%26aulast%3DDuong%26aufirst%3DL.%2BT.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DKimmel%26aufirst%3DD.%2BB.%26aulast%3DLamontagne%26aufirst%3DS.%26aulast%3DLeger%26aufirst%3DS.%26aulast%3DLeRiche%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRobichaud%26aufirst%3DJ.%26aulast%3DRodan%26aufirst%3DG.%2BA.%26aulast%3DRodan%26aufirst%3DS.%2BB.%26aulast%3DSeto%26aufirst%3DC.%26aulast%3DTherien%26aufirst%3DM.%26aulast%3DTruong%26aufirst%3DV.%2BL.%26aulast%3DVenuti%26aufirst%3DM.%2BC.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DW.%2BC.%26atitle%3DThe%2520discovery%2520of%2520odanacatib%2520%2528MK-0822%2529%252C%2520a%2520selective%2520inhibitor%2520of%2520cathepsin%2520K%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D923%26epage%3D928%26doi%3D10.1016%2Fj.bmcl.2007.12.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Futatsugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspnes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erion, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pabst, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goosen, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosset, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niosi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettersen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfefferkorn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, B.</span><span> </span><span class="NLM_article-title">Discovery and optimization of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7173</span><span class="NLM_x">–</span> <span class="NLM_lpage">7185</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7173-7185&author=K.+Futatsugiauthor=D.+W.+Kungauthor=S.+T.+Orrauthor=S.+Cabralauthor=D.+Hepworthauthor=G.+Aspnesauthor=S.+Baderauthor=J.+Bianauthor=M.+Boehmauthor=P.+A.+Carpinoauthor=S.+B.+Coffeyauthor=M.+S.+Dowlingauthor=M.+Herrauthor=W.+Jiaoauthor=S.+Y.+Lavergneauthor=Q.+Liauthor=R.+W.+Clarkauthor=D.+M.+Erionauthor=K.+Kouauthor=K.+Leeauthor=B.+A.+Pabstauthor=S.+M.+Perezauthor=J.+Purkalauthor=C.+C.+Jorgensenauthor=T.+C.+Goosenauthor=J.+R.+Gossetauthor=M.+Niosiauthor=J.+C.+Pettersenauthor=J.+A.+Pfefferkornauthor=K.+Ahnauthor=B.+Goodwin&title=Discovery+and+optimization+of+imidazopyridine-based+inhibitors+of+diacylglycerol+acyltransferase+2+%28DGAT2%29&doi=10.1021%2Facs.jmedchem.5b01006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)</span></div><div class="casAuthors">Futatsugi, Kentaro; Kung, Daniel W.; Orr, Suvi T. M.; Cabral, Shawn; Hepworth, David; Aspnes, Gary; Bader, Scott; Bian, Jianwei; Boehm, Markus; Carpino, Philip A.; Coffey, Steven B.; Dowling, Matthew S.; Herr, Michael; Jiao, Wenhua; Lavergne, Sophie Y.; Li, Qifang; Clark, Ronald W.; Erion, Derek M.; Kou, Kou; Lee, Kyuha; Pabst, Brandon A.; Perez, Sylvie M.; Purkal, Julie; Jorgensen, Csilla C.; Goosen, Theunis C.; Gosset, James R.; Niosi, Mark; Pettersen, John C.; Pfefferkorn, Jeffrey A.; Ahn, Kay; Goodwin, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7173-7185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. and preclin. biol. of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2) is described.  A screening hit 1 with low lipophilic efficiency (LipE) was optimized through two key structural modifications: (1) identification of the pyrrolidine amide group for a significant LipE improvement, and (2) insertion of a sp3-hybridized carbon center in the core of the mol. for simultaneous improvement of N-glucuronidation metabolic liability and off-target pharmacol.  The preclin. candidate I (PF-06424439) demonstrated excellent ADMET properties and decreased circulating and hepatic lipids when orally administered to dyslipidemic rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvVkKqv3LxSbVg90H21EOLACvtfcHk0lgqsevC8BKhhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7jK&md5=272bf0a5d0251e3a3716f7b6c34b3eb4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01006%26sid%3Dliteratum%253Aachs%26aulast%3DFutatsugi%26aufirst%3DK.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DCabral%26aufirst%3DS.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DAspnes%26aufirst%3DG.%26aulast%3DBader%26aufirst%3DS.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DDowling%26aufirst%3DM.%2BS.%26aulast%3DHerr%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DLavergne%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DClark%26aufirst%3DR.%2BW.%26aulast%3DErion%26aufirst%3DD.%2BM.%26aulast%3DKou%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DPabst%26aufirst%3DB.%2BA.%26aulast%3DPerez%26aufirst%3DS.%2BM.%26aulast%3DPurkal%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DC.%2BC.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DNiosi%26aufirst%3DM.%26aulast%3DPettersen%26aufirst%3DJ.%2BC.%26aulast%3DPfefferkorn%26aufirst%3DJ.%2BA.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DGoodwin%26aufirst%3DB.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520imidazopyridine-based%2520inhibitors%2520of%2520diacylglycerol%2520acyltransferase%25202%2520%2528DGAT2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7173%26epage%3D7185%26doi%3D10.1021%2Facs.jmedchem.5b01006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Sampson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">The discovery of polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3′[3H]indol]-2′(1′H).ones as orally bioavailable antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1021/jm500537u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500537u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=130-146&author=P.+B.+Sampsonauthor=Y.+Liuauthor=N.+K.+Patelauthor=M.+Feherauthor=B.+Forrestauthor=S.+W.+Liauthor=L.+Edwardsauthor=R.+Lauferauthor=Y.+Langauthor=F.+Banauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=J.+M.+Masonauthor=X.+Weiauthor=R.+Kiarashauthor=E.+Greenauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+discovery+of+polo-like+kinase+4+inhibitors%3A+design+and+optimization+of+spiro%5Bcyclopropane-1%2C3%E2%80%B2%5B3H%5Dindol%5D-2%E2%80%B2%281%E2%80%B2H%29.ones+as+orally+bioavailable+antitumor+agents&doi=10.1021%2Fjm500537u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3'[3H]indol]-2'(1'H)-ones as Orally Bioavailable Antitumor Agents</span></div><div class="casAuthors">Sampson, Peter B.; Liu, Yong; Patel, Narendra Kumar; Feher, Miklos; Forrest, Bryan; Li, Sze-Wan; Edwards, Louise; Laufer, Radoslaw; Lang, Yunhui; Ban, Fuqiang; Awrey, Donald E.; Mao, Guodong; Plotnikova, Olga; Leung, Genie; Hodgson, Richard; Mason, Jacqueline; Wei, Xin; Kiarash, Reza; Green, Erin; Qiu, Wei; Chirgadze, Nickolay Y.; Mak, Tak W.; Pan, Guohua; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 4 (PLK4), a unique member of the polo-like kinase family of serine-threonine kinases, is a master regulator of centriole duplication that is important for maintaining genome integrity.  Overexpression of PLK4 is found in several human cancers and is linked with a predisposition to tumorigenesis.  Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones reported herein.  Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 x-ray structure and SAR attained from the analogous alkene-linked series.  The racemic cyclopropane-linked compds. showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved physicochem., ADME, and pharmacokinetic properties.  Pos. xenograft results from the MDA-MB-468 human breast cancer xenograft model for compd. I support the investigation of PLK4 inhibitors as anticancer therapeutics.  A PLK4 x-ray co-structure with compd. I revealed preferential binding of the 1R,2S enantiomer to the PLK4 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nQjbJy_sMLVg90H21EOLACvtfcHk0lgqsevC8BKhhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D&md5=90d60867ee5d6c27f597ebe32db64278</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm500537u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500537u%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520polo-like%2520kinase%25204%2520inhibitors%253A%2520design%2520and%2520optimization%2520of%2520spiro%255Bcyclopropane-1%252C3%25E2%2580%25B2%255B3H%255Dindol%255D-2%25E2%2580%25B2%25281%25E2%2580%25B2H%2529.ones%2520as%2520orally%2520bioavailable%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D130%26epage%3D146%26doi%3D10.1021%2Fjm500537u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Vuligonda, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandraratna, R. A. S.</span><span> </span><span class="NLM_article-title">Synthesis of highly potent RXR-specific retinoids: the use of a cyclopropyl group as a double bond isostere</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00588-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0960-894X%2895%2900588-K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=213-218&author=V.+Vuligondaauthor=Y.+Linauthor=R.+A.+S.+Chandraratna&title=Synthesis+of+highly+potent+RXR-specific+retinoids%3A+the+use+of+a+cyclopropyl+group+as+a+double+bond+isostere&doi=10.1016%2F0960-894X%2895%2900588-K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900588-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900588-K%26sid%3Dliteratum%253Aachs%26aulast%3DVuligonda%26aufirst%3DV.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DChandraratna%26aufirst%3DR.%2BA.%2BS.%26atitle%3DSynthesis%2520of%2520highly%2520potent%2520RXR-specific%2520retinoids%253A%2520the%2520use%2520of%2520a%2520cyclopropyl%2520group%2520as%2520a%2520double%2520bond%2520isostere%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D213%26epage%3D218%26doi%3D10.1016%2F0960-894X%2895%2900588-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant-Young, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro-Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanumegowda, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.1021/jm4016894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.+S.+Yeungauthor=X.+Zhengauthor=S.+Chaoauthor=J.+H.+Sunauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.+H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.+K.+Wangauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+preclinical+characterization+of+the+cyclopropylindolobenzazepine+BMS-791325%2C+a+potent+allosteric+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase&doi=10.1021%2Fjm4016894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span></div><div class="casAuthors">Gentles, Robert G.; Ding, Min; Bender, John A.; Bergstrom, Carl P.; Grant-Young, Katharine; Hewawasam, Piyasena; Hudyma, Thomas; Martin, Scott; Nickel, Andrew; Regueiro-Ren, Alicia; Tu, Yong; Yang, Zhong; Yeung, Kap-Sun; Zheng, Xiaofan; Beno, Brett R.; Camac, Daniel M.; Chang, Chong-Hwan; Gao, Mian; Morin, Paul E.; Sheriff, Steven; Tredup, Jeff; Wan, John; Witmer, Mark R.; Xie, Dianlin; Hanumegowda, Umesh; Knipe, Jay; Mosure, Kathy; Santone, Kenneth S.; Parker, Dawn D.; Zhuo, Xiaoliang; Lemm, Julie; Liu, Mengping; Pelosi, Lenore; Rigat, Karen; Voss, Stacey; Wang, Yi; Wang, Ying-Kai; Colonno, Richard C.; Gao, Min; Roberts, Susan B.; Gao, Qi; Ng, Alicia; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1855-1879</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors.  Subsequent iterations of analog design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochem. properties of lead compds.  Those analogs exhibiting improved soly. and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.  Addnl., a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compd. BMS-791325 (I) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4YKQoSYkS7Vg90H21EOLACvtfcHk0ljNEDBvIh9A6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D&md5=f13f5d86a1c17737784e905c7843ff72</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520cyclopropylindolobenzazepine%2520BMS-791325%252C%2520a%2520potent%2520allosteric%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879%26doi%3D10.1021%2Fjm4016894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lerchner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machauer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betschart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veenstra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueeger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tintelnot-Blomley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaton, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desrayaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staufenbiel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paganetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondeau, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, U.</span><span> </span><span class="NLM_article-title">Macrocyclic BACE-1 inhibitors acutely reduce amyloid beta in brain after po application</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2009.11.092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=603-607&author=A.+Lerchnerauthor=R.+Machauerauthor=C.+Betschartauthor=S.+Veenstraauthor=H.+Rueegerauthor=C.+McCarthyauthor=M.+Tintelnot-Blomleyauthor=A.+L.+Jatonauthor=S.+Rabeauthor=S.+Desrayaudauthor=A.+Enzauthor=M.+Staufenbielauthor=P.+Paganettiauthor=J.+M.+Rondeauauthor=U.+Neumann&title=Macrocyclic+BACE-1+inhibitors+acutely+reduce+amyloid+beta+in+brain+after+po+application&doi=10.1016%2Fj.bmcl.2009.11.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.092%26sid%3Dliteratum%253Aachs%26aulast%3DLerchner%26aufirst%3DA.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DBetschart%26aufirst%3DC.%26aulast%3DVeenstra%26aufirst%3DS.%26aulast%3DRueeger%26aufirst%3DH.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DJaton%26aufirst%3DA.%2BL.%26aulast%3DRabe%26aufirst%3DS.%26aulast%3DDesrayaud%26aufirst%3DS.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DPaganetti%26aufirst%3DP.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DNeumann%26aufirst%3DU.%26atitle%3DMacrocyclic%2520BACE-1%2520inhibitors%2520acutely%2520reduce%2520amyloid%2520beta%2520in%2520brain%2520after%2520po%2520application%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D603%26epage%3D607%26doi%3D10.1016%2Fj.bmcl.2009.11.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Yoshida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorimachi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonaga, M.</span><span> </span><span class="NLM_article-title">Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluor opyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4648</span><span class="NLM_x">–</span> <span class="NLM_lpage">4664</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00217</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00217" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4648-4664&author=Y.+Yoshidaauthor=Y.+Naoeauthor=T.+Terauchiauthor=F.+Ozakiauthor=T.+Dokoauthor=A.+Takemuraauthor=T.+Tanakaauthor=K.+Sorimachiauthor=C.+T.+Beuckmannauthor=M.+Suzukiauthor=T.+Uenoauthor=S.+Ozakiauthor=M.+Yonaga&title=Discovery+of+%281R%2C2S%29-2-%7B%5B%282%2C4-Dimethylpyrimidin-5-yl%29oxy%5Dmethyl%7D-2-%283-fluorophenyl%29-N-%285-fluor+opyridin-2-yl%29cyclopropanecarboxamide+%28E2006%29%3A+a+potent+and+efficacious+oral+orexin+receptor+antagonist&doi=10.1021%2Facs.jmedchem.5b00217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00217%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DNaoe%26aufirst%3DY.%26aulast%3DTerauchi%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DDoko%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSorimachi%26aufirst%3DK.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25281R%252C2S%2529-2-%257B%255B%25282%252C4-Dimethylpyrimidin-5-yl%2529oxy%255Dmethyl%257D-2-%25283-fluorophenyl%2529-N-%25285-fluor%2520opyridin-2-yl%2529cyclopropanecarboxamide%2520%2528E2006%2529%253A%2520a%2520potent%2520and%2520efficacious%2520oral%2520orexin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4648%26epage%3D4664%26doi%3D10.1021%2Facs.jmedchem.5b00217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Marson, C. M.</span><span> </span><span class="NLM_article-title">New and unusual scaffolds in medicinal chemistry</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">5514</span><span class="NLM_x">–</span> <span class="NLM_lpage">5533</span><span class="refDoi"> DOI: 10.1039/c1cs15119c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1039%2Fc1cs15119c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=21837344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaiu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=5514-5533&author=C.+M.+Marson&title=New+and+unusual+scaffolds+in+medicinal+chemistry&doi=10.1039%2Fc1cs15119c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">New and unusual scaffolds in medicinal chemistry</span></div><div class="casAuthors">Marson, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5514-5533</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Contemporary medicinal chem. faces diverse challenges from several directions, including the need for both potency and specificity of any therapeutic agent; the increasingly demanding requirements of low toxicity shown across all patients treated; and the need for novelty in intellectual property, given the extensive use of benzenoid and heteroarom. ring systems in numerous patents.  Increasingly, such challenges are being met by a shift to new and/or unusual ring systems (scaffolds) that lie outside the field of (hetero)arom. systems.  This crit. review surveys a necessarily limited selection of currently atypical scaffolds, chiefly drawn from the literature of the last three years, that have found application in medicinal chem., some being present in agents with therapeutic potential while others are found in agents already in clin. use (163 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkgg5kRzVt8rVg90H21EOLACvtfcHk0lgT1DscfiFydg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaiu7fM&md5=9c2e6b865432fee1aaee7cc8dbb92213</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15119c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15119c%26sid%3Dliteratum%253Aachs%26aulast%3DMarson%26aufirst%3DC.%2BM.%26atitle%3DNew%2520and%2520unusual%2520scaffolds%2520in%2520medicinal%2520chemistry%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D5514%26epage%3D5533%26doi%3D10.1039%2Fc1cs15119c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Foote, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blades, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichard, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacq, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewsbury, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissink, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thommes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadhurst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, C.</span><span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2125</span><span class="NLM_x">–</span> <span class="NLM_lpage">2138</span><span class="refDoi"> DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6-%5B1-%28methylsulfonyl%29cyclopropyl%5Dpyrimidin-2-y+l%7D-1H-indole+%28AZ20%29%3A+a+potent+and+selective+inhibitor+of+ATR+protein+kinase+with+monotherapy+in+vivo+antitumor+activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6-%255B1-%2528methylsulfonyl%2529cyclopropyl%255Dpyrimidin-2-y%2520l%257D-1H-indole%2520%2528AZ20%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520ATR%2520protein%2520kinase%2520with%2520monotherapy%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Hogberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahlberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelhardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noreen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kangasmetsa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahlberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovgren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridborg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backbro, K.</span><span> </span><span class="NLM_article-title">Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4150</span><span class="NLM_x">–</span> <span class="NLM_lpage">4160</span><span class="refDoi"> DOI: 10.1021/jm990095j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990095j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4150-4160&author=M.+Hogbergauthor=C.+Sahlbergauthor=P.+Engelhardtauthor=R.+Noreenauthor=J.+Kangasmetsaauthor=N.+G.+Johanssonauthor=B.+Obergauthor=L.+Vrangauthor=H.+Zhangauthor=B.+L.+Sahlbergauthor=T.+Ungeauthor=S.+Lovgrenauthor=K.+Fridborgauthor=K.+Backbro&title=Urea-PETT+compounds+as+a+new+class+of+HIV-1+reverse+transcriptase+inhibitors.+3.+Synthesis+and+further+structure-activity+relationship+studies+of+PETT+analogues&doi=10.1021%2Fjm990095j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm990095j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990095j%26sid%3Dliteratum%253Aachs%26aulast%3DHogberg%26aufirst%3DM.%26aulast%3DSahlberg%26aufirst%3DC.%26aulast%3DEngelhardt%26aufirst%3DP.%26aulast%3DNoreen%26aufirst%3DR.%26aulast%3DKangasmetsa%26aufirst%3DJ.%26aulast%3DJohansson%26aufirst%3DN.%2BG.%26aulast%3DOberg%26aufirst%3DB.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSahlberg%26aufirst%3DB.%2BL.%26aulast%3DUnge%26aufirst%3DT.%26aulast%3DLovgren%26aufirst%3DS.%26aulast%3DFridborg%26aufirst%3DK.%26aulast%3DBackbro%26aufirst%3DK.%26atitle%3DUrea-PETT%2520compounds%2520as%2520a%2520new%2520class%2520of%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors.%25203.%2520Synthesis%2520and%2520further%2520structure-activity%2520relationship%2520studies%2520of%2520PETT%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4150%26epage%3D4160%26doi%3D10.1021%2Fjm990095j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><a href="http://www.pharmacytimes.com" class="extLink">http://www.pharmacytimes.com</a> (accessed March 9, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.pharmacytimes.com+%28accessed+March+9%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Taylor, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacCoss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, A. D.</span><span> </span><span class="NLM_article-title">Rings in drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5845</span><span class="NLM_x">–</span> <span class="NLM_lpage">5859</span><span class="refDoi"> DOI: 10.1021/jm4017625</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5845-5859&author=R.+D.+Taylorauthor=M.+MacCossauthor=A.+D.+Lawson&title=Rings+in+drugs&doi=10.1021%2Fjm4017625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rings in Drugs</span></div><div class="casAuthors">Taylor, Richard D.; MacCoss, Malcolm; Lawson, Alastair D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5845-5859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We have analyzed the rings, ring systems, and frameworks in drugs listed in the FDA Orange Book to understand the frequency, time-lines, mol. property space, and the application of these rings in different therapeutic areas and target classes.  This anal. shows that there are only 351 ring systems and 1197 frameworks in drugs that came onto the market before 2013.  Furthermore, on av. six new ring systems enter drug space each year and approx. 28% of new drugs contain a new ring system.  Moreover, it is very unusual for a drug to contain more than one new ring system and the majority of the most frequently used ring systems (83%) were first used in drugs developed prior to 1983.  These observations give insight into the chem. novelty of drugs and potentially efficient ways to assess compd. libraries and develop compds. from hit identification to lead optimization and beyond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_e_L4z4XCrVg90H21EOLACvtfcHk0liyGD5Uwl4mdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D&md5=c84ce84b8698eb6fad38fa82b0ab4912</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm4017625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017625%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%2BD.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DLawson%26aufirst%3DA.%2BD.%26atitle%3DRings%2520in%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5845%26epage%3D5859%26doi%3D10.1021%2Fjm4017625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Wishart, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stothard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolsey, J.</span><span> </span><span class="NLM_article-title">DrugBank: a comprehensive resource for in silico drug discovery and exploration</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">D668</span><span class="NLM_x">–</span> <span class="NLM_lpage">D672</span><span class="refDoi"> DOI: 10.1093/nar/gkj067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1093%2Fnar%2Fgkj067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16381955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=D668-D672&author=D.+S.+Wishartauthor=C.+Knoxauthor=A.+C.+Guoauthor=S.+Shrivastavaauthor=M.+Hassanaliauthor=P.+Stothardauthor=Z.+Changauthor=J.+Woolsey&title=DrugBank%3A+a+comprehensive+resource+for+in+silico+drug+discovery+and+exploration&doi=10.1093%2Fnar%2Fgkj067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">DrugBank: a comprehensive resource for in silico drug discovery and exploration</span></div><div class="casAuthors">Wishart, David S.; Knox, Craig; Guo, An Chi; Shrivastava, Savita; Hassanali, Murtaza; Stothard, Paul; Chang, Zhan; Woolsey, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Database</span>),
    <span class="NLM_cas:pages">D668-D672</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DrugBank is a unique bioinformatics/cheminformatics resource that combines detailed drug (i.e. chem.) data with comprehensive drug target (i.e. protein) information.  The database contains >4100 drug entries including >800 FDA approved small mol. and biotech drugs as well as >3200 exptl. drugs.  Addnl., >14 000 protein or drug target sequences are linked to these drug entries.  Each DrugCard entry contains >80 data fields with half of the information being devoted to drug/chem. data and the other half devoted to drug target or protein data.  Many data fields are hyperlinked to other databases (KEGG, PubChem, ChEBI, PDB, Swiss-Prot and GenBank) and a variety of structure viewing applets.  The database is fully searchable supporting extensive text, sequence, chem. structure and relational query searches.  Potential applications of DrugBank include in silico drug target discovery, drug design, drug docking or screening, drug metab. prediction, drug interaction prediction and general pharmaceutical education.  DrugBank is available at http://redpoll.pharmacy.ualberta.ca/drugbank/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaNy9WiVtlu7Vg90H21EOLACvtfcHk0liyGD5Uwl4mdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOrsw%253D%253D&md5=c3f4ad2fc489440be5b16f91bc9cf7db</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkj067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkj067%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DD.%2BS.%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DShrivastava%26aufirst%3DS.%26aulast%3DHassanali%26aufirst%3DM.%26aulast%3DStothard%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DZ.%26aulast%3DWoolsey%26aufirst%3DJ.%26atitle%3DDrugBank%253A%2520a%2520comprehensive%2520resource%2520for%2520in%2520silico%2520drug%2520discovery%2520and%2520exploration%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2006%26volume%3D34%26spage%3DD668%26epage%3DD672%26doi%3D10.1093%2Fnar%2Fgkj067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">McCubrey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tafuri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martelli, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steelman, L. S.</span><span> </span><span class="NLM_article-title">Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=614-630&author=J.+A.+McCubreyauthor=M.+Milellaauthor=A.+Tafuriauthor=A.+M.+Martelliauthor=P.+Lunghiauthor=A.+Bonatiauthor=M.+Cervelloauthor=J.+T.+Leeauthor=L.+S.+Steelman&title=Targeting+the+Raf%2FMEK%2FERK+pathway+with+small-molecule+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DMilella%26aufirst%3DM.%26aulast%3DTafuri%26aufirst%3DA.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DLunghi%26aufirst%3DP.%26aulast%3DBonati%26aufirst%3DA.%26aulast%3DCervello%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26atitle%3DTargeting%2520the%2520Raf%252FMEK%252FERK%2520pathway%2520with%2520small-molecule%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D614%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">McDermott, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, C.</span><span> </span><span class="NLM_article-title">Allosteric MEK1/2 inhibitors for the treatment of cancer: an overview</span> <span class="citation_source-journal">J. Drug. Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="refDoi"> DOI: 10.16966/2470-1009.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.16966%2F2470-1009.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=101&author=L.+McDermottauthor=C.+Qin&title=Allosteric+MEK1%2F2+inhibitors+for+the+treatment+of+cancer%3A+an+overview&doi=10.16966%2F2470-1009.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.16966%2F2470-1009.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.16966%252F2470-1009.101%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DC.%26atitle%3DAllosteric%2520MEK1%252F2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520an%2520overview%26jtitle%3DJ.%2520Drug.%2520Res.%2520Dev.%26date%3D2015%26volume%3D1%26spage%3D101%26doi%3D10.16966%2F2470-1009.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugi, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span> </span><span class="NLM_article-title">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1016/j.canlet.2013.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.canlet.2013.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=23856031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=97-103&author=K.+Okamotoauthor=K.+Kodamaauthor=K.+Takaseauthor=N.+H.+Sugiauthor=Y.+Yamamotoauthor=M.+Iwataauthor=A.+Tsuruoka&title=Antitumor+activities+of+the+targeted+multi-tyrosine+kinase+inhibitor+lenvatinib+%28E7080%29+against+RET+gene+fusion-driven+tumor+models&doi=10.1016%2Fj.canlet.2013.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span></div><div class="casAuthors">Okamoto, Kiyoshi; Kodama, Kotaro; Takase, Kazuma; Sugi, Naoko Hata; Yamamoto, Yuji; Iwata, Masao; Tsuruoka, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-103</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas.  Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clin. trials.  Here we evaluated lenvatinib in RET gene fusion-driven preclin. models.  In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET.  Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells.  These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr151nVk6WXn7Vg90H21EOLACvtfcHk0liyGD5Uwl4mdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M&md5=e2399184aae74ae2c4b18997a6b7273b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKodama%26aufirst%3DK.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DSugi%26aufirst%3DN.%2BH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DTsuruoka%26aufirst%3DA.%26atitle%3DAntitumor%2520activities%2520of%2520the%2520targeted%2520multi-tyrosine%2520kinase%2520inhibitor%2520lenvatinib%2520%2528E7080%2529%2520against%2520RET%2520gene%2520fusion-driven%2520tumor%2520models%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D97%26epage%3D103%26doi%3D10.1016%2Fj.canlet.2013.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikemori-Kawada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jestel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Konig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, J.</span><span> </span><span class="NLM_article-title">Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1021/ml500394m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500394m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=89-94&author=K.+Okamotoauthor=M.+Ikemori-Kawadaauthor=A.+Jestelauthor=K.+von+Konigauthor=Y.+Funahashiauthor=T.+Matsushimaauthor=A.+Tsuruokaauthor=A.+Inoueauthor=J.+Matsui&title=Distinct+binding+mode+of+multikinase+inhibitor+lenvatinib+revealed+by+biochemical+characterization&doi=10.1021%2Fml500394m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization</span></div><div class="casAuthors">Okamoto, Kiyoshi; Ikemori-Kawada, Megumi; Jestel, Anja; von Konig, Konstanze; Funahashi, Yasuhiro; Matsushima, Tomohiro; Tsuruoka, Akihiko; Inoue, Atsushi; Matsui, Junji</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-94</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases.  To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction anal. of lenvatinib with VEGFR2 and x-ray anal. of the crystal structure of VEGFR2-lenvatinib complexes.  Kinetic anal. revealed that lenvatinib had a rapid assocn. rate const. and a relatively slow dissocn. rate const. in complex with VEGFR2.  Co-crystal structure anal. demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation.  These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUysiHRGw3P7Vg90H21EOLACvtfcHk0lijOXpypLk9Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E&md5=5461832fad0577f2ea93b47521b4bbdc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fml500394m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500394m%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DIkemori-Kawada%26aufirst%3DM.%26aulast%3DJestel%26aufirst%3DA.%26aulast%3Dvon%2BKonig%26aufirst%3DK.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DMatsui%26aufirst%3DJ.%26atitle%3DDistinct%2520binding%2520mode%2520of%2520multikinase%2520inhibitor%2520lenvatinib%2520revealed%2520by%2520biochemical%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D89%26epage%3D94%26doi%3D10.1021%2Fml500394m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Strebhardt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Targeting polo-like kinase 1 for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1038/nrc1841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrc1841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16557283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=321-330&author=K.+Strebhardtauthor=A.+Ullrich&title=Targeting+polo-like+kinase+1+for+cancer+therapy&doi=10.1038%2Fnrc1841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting polo-like kinase 1 for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-330</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Human polo-like kinase 1 (PLK1) is essential during mitosis and in the maintenance of genomic stability.  PLK1 is overexpressed in human tumors and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.  The use of different PLK1 inhibitors has increased our knowledge of mitotic regulation and allowed us to assess their ability to suppress tumor growth in vivo.  We address the structural features of the kinase domain and the unique polo-box domain of PLK1 that are most suited for drug development and discuss our current understanding of the therapeutic potential of PLK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdeCr1fiAaaLVg90H21EOLACvtfcHk0lijOXpypLk9Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D&md5=b43638c4eb123292a507734fb87e89ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrc1841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1841%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DTargeting%2520polo-like%2520kinase%25201%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D321%26epage%3D330%26doi%3D10.1038%2Fnrc1841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Rudolph, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3094</span><span class="NLM_x">–</span> <span class="NLM_lpage">3102</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F1078-0432.CCR-08-2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19383823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3094-3102&author=D.+Rudolphauthor=M.+Steegmaierauthor=M.+Hoffmannauthor=M.+Grauertauthor=A.+Baumauthor=J.+Quantauthor=C.+Haslingerauthor=P.+Garin-Chesaauthor=G.+R.+Adolf&title=BI+6727%2C+a+polo-like+kinase+inhibitor+with+improved+pharmacokinetic+profile+and+broad+antitumor+activity&doi=10.1158%2F1078-0432.CCR-08-2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span></div><div class="casAuthors">Rudolph, Dorothea; Steegmaier, Martin; Hoffmann, Matthias; Grauert, Matthias; Baum, Anke; Quant, Jens; Haslinger, Christian; Garin-Chesa, Pilar; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3094-3102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers.  To identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.  The first compd. in this series, suitable for i.v. administration, has entered clin. development.  To fully explore the potential of Polo-like kinase 1 inhibition in oncol., we have profiled addnl. compds. and now describe a novel clin. candidate.  BI 6727 is a highly potent (enzyme IC50 = 0.87 nmol/L, EC50 = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties.  First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high vol. of distribution and a long terminal half-life in mice (Vss = 7.6 L/kg, t1/2 = 46 h) and rats (Vss = 22 L/kg, t1/2 = 54 h).  Second, BI 6727 has physicochem. and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules.  Finally, BI 6727 shows marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.  With oral and i.v. routes of administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated dosing schedules.  These findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clin. studies have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YEX91EOHHLVg90H21EOLACvtfcHk0lijOXpypLk9Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D&md5=daed550be9d9b99ac6797c359039d295</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2445%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DBI%25206727%252C%2520a%2520polo-like%2520kinase%2520inhibitor%2520with%2520improved%2520pharmacokinetic%2520profile%2520and%2520broad%2520antitumor%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3094%26epage%3D3102%26doi%3D10.1158%2F1078-0432.CCR-08-2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenart, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronczki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurtler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+Lenartauthor=M.+Petronczkiauthor=M.+Krssakauthor=U.+Gurtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.+M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+potent+and+selective+inhibitor+of+polo-like+kinase+1%2C+inhibits+tumor+growth+in+vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0lgujo1_AH4Wbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DLenart%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DGurtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520polo-like%2520kinase%25201%252C%2520inhibits%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Bettencourt-Dias, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues-Martins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riparbelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatt, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balloux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glover, D. M.</span><span> </span><span class="NLM_article-title">SAK/PLK4 is required for centriole duplication and flagella development</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2199</span><span class="NLM_x">–</span> <span class="NLM_lpage">2207</span><span class="refDoi"> DOI: 10.1016/j.cub.2005.11.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.cub.2005.11.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16326102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlahu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2199-2207&author=M.+Bettencourt-Diasauthor=A.+Rodrigues-Martinsauthor=L.+Carpenterauthor=M.+Riparbelliauthor=L.+Lehmannauthor=M.+K.+Gattauthor=N.+Carmoauthor=F.+Ballouxauthor=G.+Callainiauthor=D.+M.+Glover&title=SAK%2FPLK4+is+required+for+centriole+duplication+and+flagella+development&doi=10.1016%2Fj.cub.2005.11.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">SAK/PLK4 Is Required for Centriole Duplication and Flagella Development</span></div><div class="casAuthors">Bettencourt-Dias, M.; Rodrigues-Martins, A.; Carpenter, L.; Riparbelli, M.; Lehmann, L.; Gatt, M. K.; Carmo, N.; Balloux, F.; Callaini, G.; Glover, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2199-2207</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SAK/PLK4 is a distinct member of the polo-like kinase family.  SAK-/- mice die during embryogenesis, whereas SAK+/- mice develop liver and lung tumors and SAK+/- MEFs show mitotic abnormalities.  However, the mechanism underlying these phenotypes is still not known.  Here, the authors show that downregulation of SAK in Drosophila cells, by mutation or RNAi, leads to loss of centrioles, the core structures of centrosomes.  Such cells are able to undergo repeated rounds of cell division, but display broad disorganized mitotic spindle poles.  The authors also show that SAK mutants lose their centrioles during the mitotic divisions preceding male meiosis but still produce cysts of 16 primary spermatocytes as in the wild-type.  Math. modeling of the stereotyped cell divisions of spermatogenesis can account for such loss by defective centriole duplication.  The majority of spermatids in SAK mutants lack centrioles and so are unable to make sperm axonemes.  Finally, the authors show that depletion of SAK in human cells also prevents centriole duplication and gives rise to mitotic abnormalities.  SAK/PLK4 is necessary for centriole duplication both in Drosophila and human cells.  Drosophila cells tolerate the lack of centrioles and undertake mitosis but cannot form basal bodies and hence flagella.  Human cells depleted of SAK show error-prone mitosis, likely to underlie its tumor-suppressor role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFoGUh8x0B_7Vg90H21EOLACvtfcHk0lgujo1_AH4Wbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlahu7fP&md5=31069d55e1b8e6ecdaaababd791b72a7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2005.11.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2005.11.042%26sid%3Dliteratum%253Aachs%26aulast%3DBettencourt-Dias%26aufirst%3DM.%26aulast%3DRodrigues-Martins%26aufirst%3DA.%26aulast%3DCarpenter%26aufirst%3DL.%26aulast%3DRiparbelli%26aufirst%3DM.%26aulast%3DLehmann%26aufirst%3DL.%26aulast%3DGatt%26aufirst%3DM.%2BK.%26aulast%3DCarmo%26aufirst%3DN.%26aulast%3DBalloux%26aufirst%3DF.%26aulast%3DCallaini%26aufirst%3DG.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26atitle%3DSAK%252FPLK4%2520is%2520required%2520for%2520centriole%2520duplication%2520and%2520flagella%2520development%26jtitle%3DCurr.%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D2199%26epage%3D2207%26doi%3D10.1016%2Fj.cub.2005.11.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6069</span><span class="NLM_x">–</span> <span class="NLM_lpage">6087</span><span class="refDoi"> DOI: 10.1021/jm400380m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400380m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6069-6087&author=R.+Lauferauthor=B.+Forrestauthor=S.+W.+Liauthor=Y.+Liuauthor=P.+Sampsonauthor=L.+Edwardsauthor=Y.+Langauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=I.+Beletskayaauthor=J.+M.+Masonauthor=X.+Luoauthor=X.+Weiauthor=Y.+Yaoauthor=M.+Feherauthor=F.+Banauthor=R.+Kiarashauthor=E.+Greenauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+discovery+of+PLK4+inhibitors%3A+%28E%29-3-%28%281H-Indazol-6-yl%29methylene%29indolin-2-ones+as+novel+antiproliferative+agents&doi=10.1021%2Fjm400380m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm400380m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400380m%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSampson%26aufirst%3DP.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520PLK4%2520inhibitors%253A%2520%2528E%2529-3-%2528%25281H-Indazol-6-yl%2529methylene%2529indolin-2-ones%2520as%2520novel%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6069%26epage%3D6087%26doi%3D10.1021%2Fjm400380m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span><span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+Mullerauthor=P.+Schoffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0li4Cxt__FO3rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DMuller%26aufirst%3DS.%2BP.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases&doi=10.1158%2F0008-5472.CAN-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0li4Cxt__FO3rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensinger, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkoski, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarakoon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telikepalli, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogeti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. L.</span><span> </span><span class="NLM_article-title">Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2023</span><span class="NLM_x">–</span> <span class="NLM_lpage">2034</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F1535-7163.MCT-14-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26285778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2023-2034&author=B.+D.+Smithauthor=M.+D.+Kaufmanauthor=C.+B.+Learyauthor=B.+A.+Turnerauthor=S.+C.+Wiseauthor=Y.+M.+Ahnauthor=R.+J.+Boothauthor=T.+M.+Caldwellauthor=C.+L.+Ensingerauthor=M.+M.+Hoodauthor=W.+P.+Luauthor=T.+W.+Pattauthor=W.+C.+Pattauthor=T.+J.+Rutkoskiauthor=T.+Samarakoonauthor=H.+Telikepalliauthor=L.+Vogetiauthor=S.+Vogetiauthor=K.+M.+Yatesauthor=L.+Chunauthor=L.+J.+Stewartauthor=M.+Clareauthor=D.+L.+Flynn&title=Altiratinib+inhibits+tumor+growth%2C+invasion%2C+angiogenesis%2C+and+microenvironment-mediated+drug+resistance+via+balanced+inhibition+of+MET%2C+TIE2%2C+and+VEGFR2&doi=10.1158%2F1535-7163.MCT-14-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2</span></div><div class="casAuthors">Smith, Bryan D.; Kaufman, Michael D.; Leary, Cynthia B.; Turner, Benjamin A.; Wise, Scott C.; Ahn, Yu Mi; Booth, R. John; Caldwell, Timothy M.; Ensinger, Carol L.; Hood, Molly M.; Lu, Wei-Ping; Patt, Tristan W.; Patt, William C.; Rutkoski, Thomas J.; Samarakoon, Thiwanka; Telikepalli, Hanumaiah; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen M.; Chun, Lawrence; Stewart, Lance J.; Clare, Michael; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2023-2034</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1).  Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases.  This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations.  Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo.  Through its balanced inhibitory potency vs. MET, TIE2, and VEGFR2, altiratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis.  Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9E33eWjRqBrVg90H21EOLACvtfcHk0li4Cxt__FO3rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE&md5=34170ba7d22a7fbcea68715fd6a2179b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1105%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLeary%26aufirst%3DC.%2BB.%26aulast%3DTurner%26aufirst%3DB.%2BA.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DEnsinger%26aufirst%3DC.%2BL.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DLu%26aufirst%3DW.%2BP.%26aulast%3DPatt%26aufirst%3DT.%2BW.%26aulast%3DPatt%26aufirst%3DW.%2BC.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSamarakoon%26aufirst%3DT.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DK.%2BM.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DClare%26aufirst%3DM.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DAltiratinib%2520inhibits%2520tumor%2520growth%252C%2520invasion%252C%2520angiogenesis%252C%2520and%2520microenvironment-mediated%2520drug%2520resistance%2520via%2520balanced%2520inhibition%2520of%2520MET%252C%2520TIE2%252C%2520and%2520VEGFR2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2023%26epage%3D2034%26doi%3D10.1158%2F1535-7163.MCT-14-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohyama, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funasaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirotori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obaishi, H.</span><span> </span><span class="NLM_article-title">E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2009.01343.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1111%2Fj.1349-7006.2009.01343.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19832844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2010&pages=210-215&author=T.+Nakagawaauthor=O.+Tohyamaauthor=A.+Yamaguchiauthor=T.+Matsushimaauthor=K.+Takahashiauthor=S.+Funasakaauthor=S.+Shirotoriauthor=M.+Asadaauthor=H.+Obaishi&title=E7050%3A+a+dual+c-Met+and+VEGFR-2+tyrosine+kinase+inhibitor+promotes+tumor+regression+and+prolongs+survival+in+mouse+xenograft+models&doi=10.1111%2Fj.1349-7006.2009.01343.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span></div><div class="casAuthors">Nakagawa, Takayuki; Tohyama, Osamu; Yamaguchi, Atsumi; Matsushima, Tomohiro; Takahashi, Keiko; Funasaka, Setsuo; Shirotori, Shuji; Asada, Makoto; Obaishi, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">C-Met is the cellular receptor for hepatocyte growth factor (HGF) and is known to be dysregulated in various types of human cancers.  Activation of the HGF/c-Met pathway causes tumor progression, invasion, and metastasis.  Vascular endothelial growth factor (VEGF) is also known as a key mol. in tumor progression through the induction of tumor angiogenesis.  Because of their key roles in tumor progression, these pathways provide attractive targets for therapeutic intervention.  We have generated a novel, orally active, small mol. compd., E7050, which inhibits both c-Met and vascular endothelial growth factor receptor (VEGFR)-2.  In vitro studies indicate that E7050 potently inhibits phosphorylation of both c-Met and VEGFR-2.  E7050 also potently represses the growth of both c-met amplified tumor cells and endothelial cells stimulated with either HGF or VEGF.  In vivo studies using E7050 showed inhibition of the phosphorylation of c-Met and VEGFR-2 in tumors, and strong inhibition of tumor growth and tumor angiogenesis in xenograft models.  Treatment of some tumor lines contg. c-met amplifications with high doses of E7050 (50-200 mg/kg) induced tumor regression and disappearance.  In a peritoneal dissemination model, E7050 showed an antitumor effect against peritoneal tumors as well as a significant prolongation of lifespan in treated mice.  Our results indicate that E7050 is a potent inhibitor of c-Met and VEGFR-2 and has therapeutic potential for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd7smhBTumtLVg90H21EOLACvtfcHk0lgrjvd20vwu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D&md5=e8ce73fa1262f767cea173f0561d8e35</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2009.01343.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2009.01343.x%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DTohyama%26aufirst%3DO.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DFunasaka%26aufirst%3DS.%26aulast%3DShirotori%26aufirst%3DS.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DObaishi%26aufirst%3DH.%26atitle%3DE7050%253A%2520a%2520dual%2520c-Met%2520and%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitor%2520promotes%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DCancer%2520Sci.%26date%3D2010%26volume%3D101%26spage%3D210%26epage%3D215%26doi%3D10.1111%2Fj.1349-7006.2009.01343.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Howard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span><span class="refDoi"> DOI: 10.1021/jm800984v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800984v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Wn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=379-388&author=S.+Howardauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=J.+Curryauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=L.+Fazalauthor=A.+L.+Gillauthor=M.+Heathcoteauthor=S.+Mamanauthor=J.+E.+Matthewsauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=M.+Reuleauthor=D.+Tisiauthor=G.+Williamsauthor=M.+Vinkovicauthor=P.+G.+Wyatt&title=Fragment-based+discovery+of+the+pyrazol-4-yl+urea+%28AT9283%29%2C+a+multitargeted+kinase+inhibitor+with+potent+aurora+kinase+activity&doi=10.1021%2Fjm800984v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity</span></div><div class="casAuthors">Howard, Steven; Berdini, Valerio; Boulstridge, John A.; Carr, Maria G.; Cross, David M.; Curry, Jayne; Devine, Lindsay A.; Early, Theresa R.; Fazal, Lynsey; Gill, Adrian L.; Heathcote, Michelle; Maman, Sarita; Matthews, Julia E.; McMenamin, Rachel L.; Navarro, Eva F.; O'Brien, Michael A.; O'Reilly, Marc; Rees, David C.; Reule, Matthias; Tisi, Dominic; Williams, Glyn; Vinkovic, Mladen; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we describe the identification of a clin. candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment.  Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment of cancer.  X-ray crystallog. structures were generated using a novel soakable form of Aurora A and were used to drive the optimization toward potent (IC50 ≈ 3 nM) dual Aurora A/Aurora B inhibitors.  These compds. inhibited growth and survival of HCT116 cells and produced the polyploid cellular phenotype typically assocd. with Aurora B kinase inhibition.  Optimization of cellular activity and physicochem. properties ultimately led to the identification of compd. 16 (AT9283, I).  In addn. to Aurora A and Aurora B, compd. 16 was also found to inhibit a no. of other kinases including JAK2 and Abl (T315I).  This compd. demonstrated in vivo efficacy in mouse xenograft models and is currently under evaluation in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVEuaBVqyIq7Vg90H21EOLACvtfcHk0lgrjvd20vwu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Wn&md5=c24b9958c590e28210085df291c2207f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm800984v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800984v%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DHeathcote%26aufirst%3DM.%26aulast%3DMaman%26aufirst%3DS.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520the%2520pyrazol-4-yl%2520urea%2520%2528AT9283%2529%252C%2520a%2520multitargeted%2520kinase%2520inhibitor%2520with%2520potent%2520aurora%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D379%26epage%3D388%26doi%3D10.1021%2Fjm800984v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-+1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0lgWlbIJpo5Fkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-%25201-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Kim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricks, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladouceur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfuma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venugopal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4257</span><span class="NLM_x">–</span> <span class="NLM_lpage">4261</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F1078-0432.CCR-15-0887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26187614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1antL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4257-4261&author=G.+Kimauthor=G.+Isonauthor=A.+E.+McKeeauthor=H.+Zhangauthor=S.+Tangauthor=T.+Gwiseauthor=R.+Sridharaauthor=E.+Leeauthor=A.+Tzouauthor=R.+Philipauthor=H.+J.+Chiuauthor=T.+K.+Ricksauthor=T.+Palmbyauthor=A.+M.+Russellauthor=G.+Ladouceurauthor=E.+Pfumaauthor=H.+Liauthor=L.+Zhaoauthor=Q.+Liuauthor=R.+Venugopalauthor=A.+Ibrahimauthor=R.+Pazdur&title=FDA+approval+summary%3A+olaparib+monotherapy+in+patients+with+deleterious+germline+BRCA-mutated+advanced+ovarian+cancer+treated+with+three+or+more+lines+of+chemotherapy&doi=10.1158%2F1078-0432.CCR-15-0887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy</span></div><div class="casAuthors">Kim, Geoffrey; Ison, Gwynn; McKee, Amy E.; Zhang, Hui; Tang, Shenghui; Gwise, Thomas; Sridhara, Rajeshwari; Lee, Eunice; Tzou, Abraham; Philip, Reena; Chiu, Haw-Jyh; Ricks, Tiffany K.; Palmby, Todd; Russell, Anne Marie; Ladouceur, Gaetan; Pfuma, Elimika; Li, Hongshan; Zhao, Liang; Liu, Qi; Venugopal, Rajesh; Ibrahim, Amna; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4257-4261</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Dec. 19, 2014, the FDA approved olaparib capsules (Lynparza; AstraZeneca) for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.  The BRACAnal. CDx (Myriad Genetic Labs., Inc.) was approved concurrently.  An international multicenter, single-arm trial enrolled 137 patients with measurable gBRCAm-assocd. ovarian cancer treated with three or more prior lines of chemotherapy.  Patients received olaparib at a dose of 400 mg by mouth twice daily until disease progression or unacceptable toxicity.  The objective response rate (ORR) was 34% with median response duration of 7.9 mo in this cohort.  The most common adverse reactions (≥20%) in patients treated with olaparib were anemia, nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngitis/upper respiratory infection, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash, and abdominal pain/discomfort.  Myelodysplatic syndrome and/or acute myeloid leukemia occurred in 2% of the patients enrolled on this trial.  Clin Cancer Res; 21(19); 4257-61. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUGE-lJX1VTrVg90H21EOLACvtfcHk0lhbGQYJPDr7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1antL3P&md5=ae7b27e347759be47e84ee8d555ff094</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0887%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%26aulast%3DIson%26aufirst%3DG.%26aulast%3DMcKee%26aufirst%3DA.%2BE.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DGwise%26aufirst%3DT.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DTzou%26aufirst%3DA.%26aulast%3DPhilip%26aufirst%3DR.%26aulast%3DChiu%26aufirst%3DH.%2BJ.%26aulast%3DRicks%26aufirst%3DT.%2BK.%26aulast%3DPalmby%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DA.%2BM.%26aulast%3DLadouceur%26aufirst%3DG.%26aulast%3DPfuma%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DVenugopal%26aufirst%3DR.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520olaparib%2520monotherapy%2520in%2520patients%2520with%2520deleterious%2520germline%2520BRCA-mutated%2520advanced%2520ovarian%2520cancer%2520treated%2520with%2520three%2520or%2520more%2520lines%2520of%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4257%26epage%3D4261%26doi%3D10.1158%2F1078-0432.CCR-15-0887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Mohammad, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federowicz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aller, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneck, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butticello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnette, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappalardi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasparec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crouthamel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, R. G.</span><span> </span><span class="NLM_article-title">A DNA Hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.ccell.2015.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26175415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Grt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=57-69&author=H.+P.+Mohammadauthor=K.+N.+Smithemanauthor=C.+D.+Kamatauthor=D.+Soongauthor=K.+E.+Federowiczauthor=G.+S.+Van+Allerauthor=J.+L.+Schneckauthor=J.+D.+Carsonauthor=Y.+Liuauthor=M.+Butticelloauthor=W.+G.+Bonnetteauthor=S.+A.+Gormanauthor=Y.+Degenhardtauthor=Y.+Baiauthor=M.+T.+McCabeauthor=M.+B.+Pappalardiauthor=J.+Kasparecauthor=X.+Tianauthor=K.+C.+McNultyauthor=M.+Rouseauthor=P.+McDevittauthor=T.+Hoauthor=M.+Crouthamelauthor=T.+K.+Hartauthor=N.+O.+Conchaauthor=C.+F.+McHughauthor=W.+H.+Millerauthor=D.+Dhanakauthor=P.+J.+Tumminoauthor=C.+L.+Carpenterauthor=N.+W.+Johnsonauthor=C.+L.+Hannauthor=R.+G.+Kruger&title=A+DNA+Hypomethylation+signature+predicts+antitumor+activity+of+LSD1+inhibitors+in+SCLC&doi=10.1016%2Fj.ccell.2015.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC</span></div><div class="casAuthors">Mohammad, Helai P.; Smitheman, Kimberly N.; Kamat, Chandrashekhar D.; Soong, David; Federowicz, Kelly E.; Van Aller, Glenn S.; Schneck, Jess L.; Carson, Jeffrey D.; Liu, Yan; Butticello, Michael; Bonnette, William G.; Gorman, Shelby A.; Degenhardt, Yan; Bai, Yuchen; McCabe, Michael T.; Pappalardi, Melissa B.; Kasparec, Jiri; Tian, Xinrong; McNulty, Kenneth C.; Rouse, Meagan; McDevitt, Patrick; Ho, Thau; Crouthamel, Michelle; Hart, Timothy K.; Concha, Nestor O.; McHugh, Charles F.; Miller, William H.; Dhanak, Dashyant; Tummino, Peter J.; Carpenter, Christopher L.; Johnson, Neil W.; Hann, Christine L.; Kruger, Ryan G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-69</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Epigenetic dysregulation has emerged as an important mechanism in cancer.  Alterations in epigenetic machinery have become a major focus for targeted therapies.  The current report describes the discovery and biol. activity of a cyclopropylamine contg. inhibitor of Lysine Demethylase 1 (LSD1), GSK2879552.  This small mol. is a potent, selective, orally bioavailable, mechanism-based irreversible inactivator of LSD1.  A proliferation screen of cell lines representing a no. of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 inhibition.  The subset of SCLC lines and primary samples that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes, suggesting this may be used as a predictive biomarker of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppluiM41UspbVg90H21EOLACvtfcHk0lhbGQYJPDr7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Grt7fJ&md5=863924e99fa3576dc1c67824b45462f8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DH.%2BP.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKamat%26aufirst%3DC.%2BD.%26aulast%3DSoong%26aufirst%3DD.%26aulast%3DFederowicz%26aufirst%3DK.%2BE.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DSchneck%26aufirst%3DJ.%2BL.%26aulast%3DCarson%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DButticello%26aufirst%3DM.%26aulast%3DBonnette%26aufirst%3DW.%2BG.%26aulast%3DGorman%26aufirst%3DS.%2BA.%26aulast%3DDegenhardt%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DPappalardi%26aufirst%3DM.%2BB.%26aulast%3DKasparec%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DMcNulty%26aufirst%3DK.%2BC.%26aulast%3DRouse%26aufirst%3DM.%26aulast%3DMcDevitt%26aufirst%3DP.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DCrouthamel%26aufirst%3DM.%26aulast%3DHart%26aufirst%3DT.%2BK.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCarpenter%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DN.%2BW.%26aulast%3DHann%26aufirst%3DC.%2BL.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26atitle%3DA%2520DNA%2520Hypomethylation%2520signature%2520predicts%2520antitumor%2520activity%2520of%2520LSD1%2520inhibitors%2520in%2520SCLC%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D57%26epage%3D69%26doi%3D10.1016%2Fj.ccell.2015.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Johnson, N. W.; Kasparec, J.; Miller, W. H.; Rouse, M. B.; Suarez, D.; Tian, X.</span><span> </span><span class="NLM_article-title">Preparation of cyclopropylamines as LSD1 inhibitors in the treatment of cancer</span>. WO2012135113A2,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+W.+Johnson&author=J.+Kasparec&author=W.+H.+Miller&author=M.+B.+Rouse&author=D.+Suarez&author=X.+Tian&title=Preparation+of+cyclopropylamines+as+LSD1+inhibitors+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DN.%2BW.%26atitle%3DPreparation%2520of%2520cyclopropylamines%2520as%2520LSD1%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Lu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokharel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebawy, M.</span><span> </span><span class="NLM_article-title">MRP1 and its role in anticancer drug resistance</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.3109/03602532.2015.1105253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.3109%2F03602532.2015.1105253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26541366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2mtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=406-419&author=J.+F.+Luauthor=D.+Pokharelauthor=M.+Bebawy&title=MRP1+and+its+role+in+anticancer+drug+resistance&doi=10.3109%2F03602532.2015.1105253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">MRP1 and its role in anticancer drug resistance</span></div><div class="casAuthors">Lu, Jamie F.; Pokharel, Deep; Bebawy, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">406-419</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The phenomenon of multidrug resistance (MDR) in cancer is assocd. with the overexpression of the ATP-binding cassette (ABC) transporter proteins, including multidrug resistance-assocd. protein 1 (MRP1) and P-glycoprotein.  MRP1 plays an active role in protecting cells by its ability to efflux a vast array of drugs to sub-lethal levels.  There has been much effort in elucidating the mechanisms of action, structure and substrates and substrate binding sites of MRP1 in the last decade.  In this review, we detail our current understanding of MRP1, its clin. relevance and highlight the current environment in the search for MRP1 inhibitors.  We also look at the capacity for the rapid intercellular transfer of MRP1 phenotype from spontaneously shed membrane vesicles known as microparticles and discuss the clin. and therapeutic significance of this in the context of cancer MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO5yPSgh6OvbVg90H21EOLACvtfcHk0lhbGQYJPDr7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2mtr3I&md5=deed6bc06e93cc0667efdb58d53116c7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3109%2F03602532.2015.1105253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2015.1105253%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%2BF.%26aulast%3DPokharel%26aufirst%3DD.%26aulast%3DBebawy%26aufirst%3DM.%26atitle%3DMRP1%2520and%2520its%2520role%2520in%2520anticancer%2520drug%2520resistance%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2015%26volume%3D47%26spage%3D406%26epage%3D419%26doi%3D10.3109%2F03602532.2015.1105253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Sato, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukazawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruo, T.</span><span> </span><span class="NLM_article-title">Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2420</span><span class="NLM_x">–</span> <span class="NLM_lpage">2424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=2420-2424&author=W.+Satoauthor=N.+Fukazawaauthor=T.+Suzukiauthor=K.+Yusaauthor=T.+Tsuruo&title=Circumvention+of+multidrug+resistance+by+a+newly+synthesized+quinoline+derivative%2C+MS-073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DW.%26aulast%3DFukazawa%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DYusa%26aufirst%3DK.%26aulast%3DTsuruo%26aufirst%3DT.%26atitle%3DCircumvention%2520of%2520multidrug%2520resistance%2520by%2520a%2520newly%2520synthesized%2520quinoline%2520derivative%252C%2520MS-073%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D2420%26epage%3D2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Pfister, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makra, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehldorf, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zutshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slate, D. L.</span><span> </span><span class="NLM_article-title">Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2473</span><span class="NLM_x">–</span> <span class="NLM_lpage">2476</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00426-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0960-894X%2895%2900426-T" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=2473-2476&author=J.+R.+Pfisterauthor=F.+Makraauthor=A.+V.+Muehldorfauthor=H.+Wuauthor=J.+T.+Nelsonauthor=P.+Cheungauthor=N.+A.+Brunoauthor=S.+M.+Caseyauthor=N.+Zutshiauthor=D.+L.+Slate&title=Methanodibenzosuberylpiperazines+as+potent+multidrug+resistance+reversal+agents&doi=10.1016%2F0960-894X%2895%2900426-T"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900426-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900426-T%26sid%3Dliteratum%253Aachs%26aulast%3DPfister%26aufirst%3DJ.%2BR.%26aulast%3DMakra%26aufirst%3DF.%26aulast%3DMuehldorf%26aufirst%3DA.%2BV.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DJ.%2BT.%26aulast%3DCheung%26aufirst%3DP.%26aulast%3DBruno%26aufirst%3DN.%2BA.%26aulast%3DCasey%26aufirst%3DS.%2BM.%26aulast%3DZutshi%26aufirst%3DN.%26aulast%3DSlate%26aufirst%3DD.%2BL.%26atitle%3DMethanodibenzosuberylpiperazines%2520as%2520potent%2520multidrug%2520resistance%2520reversal%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D2473%26epage%3D2476%26doi%3D10.1016%2F0960-894X%2895%2900426-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arasappan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhanam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broske, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfmacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogdanowich-Knipp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6074</span><span class="NLM_x">–</span> <span class="NLM_lpage">6086</span><span class="refDoi"> DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.+T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.+C.+Chengauthor=Y.+Hsiehauthor=J.+M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-amino-1-%28cyclobutylmethyl%29-2%2C3-dioxopropyl%5D-+3-%5B2%28S%29-%5B%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5Damino%5D-3%2C3-dimethyl-1-oxobutyl%5D-+6%2C6-dimethyl-3-azabicyclo%5B3.1.0%5Dhexan-2%28S%29-carboxamide+%28SCH+503034%29%2C+a+selective%2C+potent%2C+orally+bioavailable+hepatitis+C+virus+NS3+protease+inhibitor%3A+a+potential+therapeutic+agent+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0lhEf1Hk8bEh8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.%2BM.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-amino-1-%2528cyclobutylmethyl%2529-2%252C3-dioxopropyl%255D-%25203-%255B2%2528S%2529-%255B%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255Damino%255D-3%252C3-dimethyl-1-oxobutyl%255D-%25206%252C6-dimethyl-3-azabicyclo%255B3.1.0%255Dhexan-2%2528S%2529-carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520selective%252C%2520potent%252C%2520orally%2520bioavailable%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%253A%2520a%2520potential%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britt, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landro, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schairer, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Drie, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4059</span><span class="NLM_x">–</span> <span class="NLM_lpage">4063</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.08.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4059-4063&author=R.+B.+Perniauthor=S.+D.+Brittauthor=J.+C.+Courtauthor=L.+F.+Courtneyauthor=D.+D.+Deiningerauthor=L.+J.+Farmerauthor=C.+A.+Gatesauthor=S.+L.+Harbesonauthor=J.+L.+Kimauthor=J.+A.+Landroauthor=R.+B.+Levinauthor=Y.+P.+Luongauthor=E.+T.+O%E2%80%99Malleyauthor=J.+Pitlikauthor=B.+G.+Raoauthor=W.+C.+Schairerauthor=J.+A.+Thomsonauthor=R.+D.+Tungauthor=J.+H.+Van+Drieauthor=Y.+Wei&title=Inhibitors+of+hepatitis+C+virus+NS3.4A+protease+1.+Non-charged+tetrapeptide+variants&doi=10.1016%2Fj.bmcl.2003.08.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DBritt%26aufirst%3DS.%2BD.%26aulast%3DCourt%26aufirst%3DJ.%2BC.%26aulast%3DCourtney%26aufirst%3DL.%2BF.%26aulast%3DDeininger%26aufirst%3DD.%2BD.%26aulast%3DFarmer%26aufirst%3DL.%2BJ.%26aulast%3DGates%26aufirst%3DC.%2BA.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DLevin%26aufirst%3DR.%2BB.%26aulast%3DLuong%26aufirst%3DY.%2BP.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DPitlik%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DSchairer%26aufirst%3DW.%2BC.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DInhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS3.4A%2520protease%25201.%2520Non-charged%2520tetrapeptide%2520variants%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4059%26epage%3D4063%26doi%3D10.1016%2Fj.bmcl.2003.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britt, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Drie, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1446</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2004.01.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1441-1446&author=R.+B.+Perniauthor=J.+Pitlikauthor=S.+D.+Brittauthor=J.+J.+Courtauthor=L.+F.+Courtneyauthor=D.+D.+Deiningerauthor=L.+J.+Farmerauthor=C.+A.+Gatesauthor=S.+L.+Harbesonauthor=R.+B.+Levinauthor=C.+Linauthor=K.+Linauthor=Y.+C.+Moonauthor=Y.+P.+Luongauthor=E.+T.+O%E2%80%99Malleyauthor=B.+G.+Raoauthor=J.+A.+Thomsonauthor=R.+D.+Tungauthor=J.+H.+Van+Drieauthor=Y.+Wei&title=Inhibitors+of+hepatitis+C+virus+NS3.4A+protease+2.+Warhead+SAR+and+optimization&doi=10.1016%2Fj.bmcl.2004.01.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DPitlik%26aufirst%3DJ.%26aulast%3DBritt%26aufirst%3DS.%2BD.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DCourtney%26aufirst%3DL.%2BF.%26aulast%3DDeininger%26aufirst%3DD.%2BD.%26aulast%3DFarmer%26aufirst%3DL.%2BJ.%26aulast%3DGates%26aufirst%3DC.%2BA.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DLevin%26aufirst%3DR.%2BB.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DY.%2BC.%26aulast%3DLuong%26aufirst%3DY.%2BP.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DInhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS3.4A%2520protease%25202.%2520Warhead%2520SAR%2520and%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1441%26epage%3D1446%26doi%3D10.1016%2Fj.bmcl.2004.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Yip, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barket, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venable, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakulchik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villarreal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yumibe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebbe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munroe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. H.</span><span> </span><span class="NLM_article-title">Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.09.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=251-256&author=Y.+Yipauthor=F.+Victorauthor=J.+Lamarauthor=R.+Johnsonauthor=Q.+M.+Wangauthor=D.+Barketauthor=J.+Glassauthor=L.+Jinauthor=L.+Liuauthor=D.+Venableauthor=M.+Wakulchikauthor=C.+Xieauthor=B.+Heinzauthor=E.+Villarrealauthor=J.+Colacinoauthor=N.+Yumibeauthor=M.+Tebbeauthor=J.+Munroeauthor=S.+H.+Chen&title=Discovery+of+a+novel+bicycloproline+P2+bearing+peptidyl+alpha-ketoamide+LY514962+as+HCV+protease+inhibitor&doi=10.1016%2Fj.bmcl.2003.09.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DYip%26aufirst%3DY.%26aulast%3DVictor%26aufirst%3DF.%26aulast%3DLamar%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DBarket%26aufirst%3DD.%26aulast%3DGlass%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DVenable%26aufirst%3DD.%26aulast%3DWakulchik%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DHeinz%26aufirst%3DB.%26aulast%3DVillarreal%26aufirst%3DE.%26aulast%3DColacino%26aufirst%3DJ.%26aulast%3DYumibe%26aufirst%3DN.%26aulast%3DTebbe%26aufirst%3DM.%26aulast%3DMunroe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520bicycloproline%2520P2%2520bearing%2520peptidyl%2520alpha-ketoamide%2520LY514962%2520as%2520HCV%2520protease%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D251%26epage%3D256%26doi%3D10.1016%2Fj.bmcl.2003.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Victor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yumibe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. H.</span><span> </span><span class="NLM_article-title">P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.09.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.09.075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=257-261&author=F.+Victorauthor=J.+Lamarauthor=N.+Snyderauthor=Y.+Yipauthor=D.+Guoauthor=N.+Yumibeauthor=R.+B.+Johnsonauthor=Q.+M.+Wangauthor=J.+I.+Glassauthor=S.+H.+Chen&title=P1+and+P3+optimization+of+novel+bicycloproline+P2+bearing+tetrapeptidyl+alpha-ketoamide+based+HCV+protease+inhibitors&doi=10.1016%2Fj.bmcl.2003.09.075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.09.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.09.075%26sid%3Dliteratum%253Aachs%26aulast%3DVictor%26aufirst%3DF.%26aulast%3DLamar%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DN.%26aulast%3DYip%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DYumibe%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DR.%2BB.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DGlass%26aufirst%3DJ.%2BI.%26aulast%3DChen%26aufirst%3DS.%2BH.%26atitle%3DP1%2520and%2520P3%2520optimization%2520of%2520novel%2520bicycloproline%2520P2%2520bearing%2520tetrapeptidyl%2520alpha-ketoamide%2520based%2520HCV%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D257%26epage%3D261%26doi%3D10.1016%2Fj.bmcl.2003.09.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span><span class="refDoi"> DOI: 10.1021/jm9015526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.+L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.+S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm9015526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0ljIeT3t1AoikQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.%2BS.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463%26doi%3D10.1021%2Fjm9015526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0ljIeT3t1AoikQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Unravelling hepatitis C virus replication from genome to function</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span><span class="refDoi"> DOI: 10.1038/nature04077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnature04077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16107832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=933-938&author=B.+D.+Lindenbachauthor=C.+M.+Rice&title=Unravelling+hepatitis+C+virus+replication+from+genome+to+function&doi=10.1038%2Fnature04077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Unravelling hepatitis C virus replication from genome to function</span></div><div class="casAuthors">Lindenbach, Brett D.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">7053</span>),
    <span class="NLM_cas:pages">933-938</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the discovery of the hepatitis C virus over 15 years ago, scientists have raced to develop diagnostics, study the virus and find new therapies.  Yet virtually every attempt to dissect this pathogen has met with roadblocks that impeded progress.  Its replication was restricted to humans or exptl. infected chimpanzees, and efficient growth of the virus in cell culture failed until very recently.  Nevertheless hard-fought progress has been made and the first wave of antiviral drugs is entering clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI6vc6EOs8vLVg90H21EOLACvtfcHk0ljIeT3t1AoikQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFent7o%253D&md5=553517cac32b797ef7a2d07f496a7b5c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnature04077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04077%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DUnravelling%2520hepatitis%2520C%2520virus%2520replication%2520from%2520genome%2520to%2520function%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D933%26epage%3D938%26doi%3D10.1038%2Fnature04077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1708</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span><span class="refDoi"> DOI: 10.1021/jm401840s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401840s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1708-1729&author=P.+M.+Scolaauthor=A.+X.+Wangauthor=A.+C.+Goodauthor=L.+Q.+Sunauthor=K.+D.+Combrinkauthor=J.+A.+Campbellauthor=J.+Chenauthor=Y.+Tuauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.+Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=M.+Dingauthor=J.+Thuringauthor=J.+Liauthor=D.+Hernandezauthor=F.+Yuauthor=P.+Falkauthor=G.+Zhaiauthor=A.+K.+Sheafferauthor=C.+Chenauthor=M.+S.+Leeauthor=D.+Barryauthor=J.+O.+Knipeauthor=W.+Liauthor=Y.+H.+Hanauthor=S.+Jenkinsauthor=C.+Gesenbergauthor=Q.+Gaoauthor=M.+W.+Sinzauthor=K.+S.+Santoneauthor=T.+Zvyagaauthor=R.+Rajamaniauthor=H.+E.+Kleiauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=E.+Hughesauthor=C.+Chienauthor=S.+Adamsauthor=P.+C.+Levesqueauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=Discovery+and+early+clinical+evaluation+of+BMS-605339%2C+a+potent+and+orally+efficacious+tripeptidic+acylsulfonamide+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401840s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Wang, Alan Xiangdong; Good, Andrew C.; Sun, Li-Qiang; Combrink, Keith D.; Campbell, Jeffrey A.; Chen, Jie; Tu, Yong; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley; Zheng, Barbara; Hewawasam, Piyasena; Ding, Min; Thuring, Jan; Li, Jianqing; Hernandez, Dennis; Yu, Fei; Falk, Paul; Zhai, Guangzhi; Sheaffer, Amy K.; Chen, Chaoqun; Lee, Min S.; Barry, Diana; Knipe, Jay O.; Li, Wenying; Han, Yong-Hae; Jenkins, Susan; Gesenberg, Christoph; Gao, Qi; Sinz, Michael W.; Santone, Kenneth S.; Zvyaga, Tatyana; Rajamani, Ramkumar; Klei, Herbert E.; Colonno, Richard J.; Grasela, Dennis M.; Hughes, Eric; Chien, Caly; Adams, Stephen; Levesque, Paul C.; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1708-1729</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of BMS-605339 (35), a tripeptidic inhibitor of the NS3/4A enzyme, is described.  This compd. incorporates a cyclopropylacylsulfonamide moiety that was designed to improve the potency of carboxylic acid prototypes through the introduction of favorable nonbonding interactions within the S1' site of the protease.  The identification of 35 was enabled through the optimization and balance of crit. properties including potency and pharmacokinetics (PK).  This was achieved through modulation of the P2* subsite of the inhibitor which identified the isoquinoline ring system as a key template for improving PK properties with further optimization achieved through functionalization.  A methoxy moiety at the C6 position of this isoquinoline ring system proved to be optimal with respect to potency and PK, thus providing the clin. compd. 35 which demonstrated antiviral activity in HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJmlq7vS_NcLVg90H21EOLACvtfcHk0lh96VDN6QelUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D&md5=cac18d2020ecf9d3ac1a8e1237e0ea7c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm401840s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401840s%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DSun%26aufirst%3DL.%2BQ.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DThuring%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520evaluation%2520of%2520BMS-605339%252C%2520a%2520potent%2520and%2520orally%2520efficacious%2520tripeptidic%2520acylsulfonamide%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1708%26epage%3D1729%26doi%3D10.1021%2Fjm401840s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">–</span> <span class="NLM_lpage">1693</span><span class="refDoi"> DOI: 10.1021/jm401507s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401507s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1673-1693&author=A.+Rosenquistauthor=B.+Samuelssonauthor=P.+O.+Johanssonauthor=M.+D.+Cummingsauthor=O.+Lenzauthor=P.+Raboissonauthor=K.+Simmenauthor=S.+Vendevilleauthor=H.+de+Kockauthor=M.+Nilssonauthor=A.+Horvathauthor=R.+Kalmeijerauthor=G.+de+la+Rosaauthor=M.+Beumont-Mauviel&title=Discovery+and+development+of+simeprevir+%28TMC435%29%2C+a+HCV+NS3%2F4A+protease+inhibitor&doi=10.1021%2Fjm401507s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor</span></div><div class="casAuthors">Rosenquist, Aasa; Samuelsson, Bertil; Johansson, Per-Ola; Cummings, Maxwell D.; Lenz, Oliver; Raboisson, Pierre; Simmen, Kenny; Vendeville, Sandrine; de Kock, Herman; Nilsson, Magnus; Horvath, Andras; Kalmeijer, Ronald; de la Rosa, Guy; Beumont-Mauviel, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1673-1693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus is a blood-borne infection and the leading cause of chronic liver disease (including cirrhosis and cancer) and liver transplantation.  Since the identification of HCV in 1989, there has been an extensive effort to identify and improve treatment options.  An important milestone was reached in 2011 with the approval of the first-generation HCV NS3/4A protease inhibitors.  However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tolerability.  Here we summarize the extensive medicinal chem. effort to develop novel P2 cyclopentane macrocyclic inhibitors guided by HCV NS3 protease assays, the cellular replicon system, structure-based design, and a panel of DMPK assays.  The selection of compd. 29 (simeprevir, TMC435) as clin. candidate was based on its excellent biol., PK, and safety pharmacol. profile.  Compd. 29 has recently been approved for treatment of chronic HCV infection in combination with pegylated interferon-α and ribavirin in Japan, Canada, and USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryCRg3NRRjzrVg90H21EOLACvtfcHk0lh96VDN6QelUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D&md5=fd9c1df095e47a111d9680af4c40ccc6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm401507s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401507s%26sid%3Dliteratum%253Aachs%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DJohansson%26aufirst%3DP.%2BO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DHorvath%26aufirst%3DA.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DG.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520simeprevir%2520%2528TMC435%2529%252C%2520a%2520HCV%2520NS3%252F4A%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1673%26epage%3D1693%26doi%3D10.1021%2Fjm401507s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Link, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mogalian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornpropst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, M. C.</span><span> </span><span class="NLM_article-title">Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2046</span><span class="refDoi"> DOI: 10.1021/jm401499g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401499g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2033-2046&author=J.+O.+Linkauthor=J.+G.+Taylorauthor=L.+Xuauthor=M.+Mitchellauthor=H.+Guoauthor=H.+Liuauthor=D.+Katoauthor=T.+Kirschbergauthor=J.+Sunauthor=N.+Squiresauthor=J.+Parrishauthor=T.+Kellerauthor=Z.+Y.+Yangauthor=C.+Yangauthor=M.+Matlesauthor=Y.+Wangauthor=K.+Wangauthor=G.+Chengauthor=Y.+Tianauthor=E.+Mogalianauthor=E.+Mondouauthor=M.+Cornpropstauthor=J.+Perryauthor=M.+C.+Desai&title=Discovery+of+ledipasvir+%28GS-5885%29%3A+a+potent%2C+once-daily+oral+NS5A+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401499g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Link, John O.; Taylor, James G.; Xu, Lianhong; Mitchell, Michael; Guo, Hongyan; Liu, Hongtao; Kato, Darryl; Kirschberg, Thorsten; Sun, Jianyu; Squires, Neil; Parrish, Jay; Kellar, Terry; Yang, Zheng-Yu; Yang, Chris; Matles, Mike; Wang, Yujin; Wang, Kelly; Cheng, Guofeng; Tian, Yang; Mogalian, Erik; Mondou, Elsa; Cornpropst, Melanie; Perry, Jason; Desai, Manoj C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2033-2046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of highly potent NS5A inhibitors with an unsym. benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]-azabicyclic ring system was discovered.  Optimization of antiviral potency and pharmacokinetics led to the identification of ledipasvir (GS-5885).  Ledipasvir (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load redn. in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. ledipasvir has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLazFwyH5rrVg90H21EOLACvtfcHk0lhtuDeTAaYGvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I&md5=30cec1d10b7b7dd02faae4fba4b88bd8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm401499g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401499g%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DJ.%2BO.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DKirschberg%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DSquires%26aufirst%3DN.%26aulast%3DParrish%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%2BY.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DMatles%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DMogalian%26aufirst%3DE.%26aulast%3DMondou%26aufirst%3DE.%26aulast%3DCornpropst%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26atitle%3DDiscovery%2520of%2520ledipasvir%2520%2528GS-5885%2529%253A%2520a%2520potent%252C%2520once-daily%2520oral%2520NS5A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2033%26epage%3D2046%26doi%3D10.1021%2Fjm401499g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Patil, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samanta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masand, N.</span><span> </span><span class="NLM_article-title">Current perspective of HCV NS5B inhibitors: a review</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5564</span><span class="NLM_x">–</span> <span class="NLM_lpage">5597</span><span class="refDoi"> DOI: 10.2174/092986711798347234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F092986711798347234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22172066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=5564-5597&author=V.+M.+Patilauthor=S.+P.+Guptaauthor=S.+Samantaauthor=N.+Masand&title=Current+perspective+of+HCV+NS5B+inhibitors%3A+a+review&doi=10.2174%2F092986711798347234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspective of HCV NS5B inhibitors: a review</span></div><div class="casAuthors">Patil, V. M.; Gupta, S. P.; Samanta, S.; Masand, N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5564-5597</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection has emerged as one of the most significant disease to affect humans.  Despite its large medical and economical impact, there are no vaccines or efficient therapies without major side effects.  The HCV non-structural protein 5B (NS5B) is the RNA-dependent RNA polymerase responsible for the complete copy of the RNA viral genome and is a target of choice for the development of anti-HCV drugs.  Although many small mols. have been identified as allosteric inhibitors of NS5B, very few are active in clin. applications.  Developments in the field have prompted us to review the research work on HCV NS5B polymerase inhibitors, esp. their structure activity relationships and mol. modeling studies.  This review will focus on the journey of drug discovery of HCV NS5B inhibitors covering both nucleoside and non-nucleosides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7q2y0ZJu6vLVg90H21EOLACvtfcHk0lhtuDeTAaYGvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbF&md5=06e6f5def2c5dd67974c057ead364322</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2174%2F092986711798347234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711798347234%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DV.%2BM.%26aulast%3DGupta%26aufirst%3DS.%2BP.%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DMasand%26aufirst%3DN.%26atitle%3DCurrent%2520perspective%2520of%2520HCV%2520NS5B%2520inhibitors%253A%2520a%2520review%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D5564%26epage%3D5597%26doi%3D10.2174%2F092986711798347234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2925</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2011.03.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2925-2929&author=X.+Zhengauthor=T.+W.+Hudymaauthor=S.+W.+Martinauthor=C.+Bergstromauthor=M.+Dingauthor=F.+Heauthor=J.+Romineauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=C.+H.+Changauthor=J.+Wanauthor=M.+R.+Witmerauthor=P.+Morinauthor=D.+M.+Camacauthor=S.+Sheriffauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+Fridellauthor=J.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Syntheses+and+initial+evaluation+of+a+series+of+indolo-fused+heterocyclic+inhibitors+of+the+polymerase+enzyme+%28NS5B%29+of+the+hepatitis+C+virus&doi=10.1016%2Fj.bmcl.2011.03.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DBergstrom%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DRomine%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSyntheses%2520and%2520initial%2520evaluation%2520of%2520a%2520series%2520of%2520indolo-fused%2520heterocyclic%2520inhibitors%2520of%2520the%2520polymerase%2520enzyme%2520%2528NS5B%2529%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2925%26epage%3D2929%26doi%3D10.1016%2Fj.bmcl.2011.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Yu, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehan, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyde, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 3: water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">–</span> <span class="NLM_lpage">1122</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.11.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.11.109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1115-1122&author=K.+L.+Yuauthor=X.+A.+Wangauthor=R.+L.+Civielloauthor=A.+K.+Trehanauthor=B.+C.+Pearceauthor=Z.+Yinauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=Y.+Zhangauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=P.+R.+Wydeauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+3%3A+water-soluble+benzimidazol-2-one+derivatives+with+antiviral+activity+in+vivo&doi=10.1016%2Fj.bmcl.2005.11.109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.11.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.11.109%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DTrehan%26aufirst%3DA.%2BK.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DWyde%26aufirst%3DP.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25203%253A%2520water-soluble%2520benzimidazol-2-one%2520derivatives%2520with%2520antiviral%2520activity%2520in%2520vivo%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1115%26epage%3D1122%26doi%3D10.1016%2Fj.bmcl.2005.11.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Hansch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S. M.</span><span> </span><span class="NLM_article-title">The structure-activity relationship in barbiturates and its similarity to that in other narcotics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1021/jm00317a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00317a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=745-753&author=C.+Hanschauthor=S.+M.+Anderson&title=The+structure-activity+relationship+in+barbiturates+and+its+similarity+to+that+in+other+narcotics&doi=10.1021%2Fjm00317a001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm00317a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00317a001%26sid%3Dliteratum%253Aachs%26aulast%3DHansch%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DS.%2BM.%26atitle%3DThe%2520structure-activity%2520relationship%2520in%2520barbiturates%2520and%2520its%2520similarity%2520to%2520that%2520in%2520other%2520narcotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26spage%3D745%26epage%3D753%26doi%3D10.1021%2Fjm00317a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Hansch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikaitani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, E. J.</span><span> </span><span class="NLM_article-title">″Aromatic″ substituent constants for structure-activity correlations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1216</span><span class="refDoi"> DOI: 10.1021/jm00269a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00269a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaE3sXlt1Wkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1973&pages=1207-1216&author=C.+Hanschauthor=A.+Leoauthor=S.+H.+Ungerauthor=K.+H.+Kimauthor=D.+Nikaitaniauthor=E.+J.+Lien&title=%E2%80%B3Aromatic%E2%80%B3+substituent+constants+for+structure-activity+correlations&doi=10.1021%2Fjm00269a003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatic substituent constants for structure-activity correlations</span></div><div class="casAuthors">Hansch, Corwin; Leo, Albert; Unger, Stefan H.; Kim, Ki Hwai; Nikaitani, Donald; Lien, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1207-16</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The arom. substituent consts. π (lipophilic), σm and σp (electronic), and molar refractivity (steric) were collected from the literature for 236 substituents, including 128 π values and 191 values for which both σm and σp were found.  The field and resonance electronic properties of C. G. Swain and E. C. Lupton (1968) were calcd. for these 191 substituents by a corrected procedure and were essentially orthogonal.  The mutual correlation of σm and σp was high.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLTaEbCgQaX7Vg90H21EOLACvtfcHk0lj0gZvzE4uPtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXlt1Wkt7o%253D&md5=e0ee110086f19b9853838f47ba1c1d4d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm00269a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00269a003%26sid%3Dliteratum%253Aachs%26aulast%3DHansch%26aufirst%3DC.%26aulast%3DLeo%26aufirst%3DA.%26aulast%3DUnger%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DNikaitani%26aufirst%3DD.%26aulast%3DLien%26aufirst%3DE.%2BJ.%26atitle%3D%25E2%2580%25B3Aromatic%25E2%2580%25B3%2520substituent%2520constants%2520for%2520structure-activity%2520correlations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1973%26volume%3D16%26spage%3D1207%26epage%3D1216%26doi%3D10.1021%2Fjm00269a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Patel, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benfield, P.</span><span> </span><span class="NLM_article-title">New drug profile: nevirapine</span> <span class="citation_source-journal">Clin. Immunother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1007/BF03259093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2FBF03259093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=307-317&author=S.+S.+Patelauthor=P.+Benfield&title=New+drug+profile%3A+nevirapine&doi=10.1007%2FBF03259093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2FBF03259093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03259093%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%2BS.%26aulast%3DBenfield%26aufirst%3DP.%26atitle%3DNew%2520drug%2520profile%253A%2520nevirapine%26jtitle%3DClin.%2520Immunother.%26date%3D1996%26volume%3D6%26spage%3D307%26epage%3D317%26doi%3D10.1007%2FBF03259093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, D. K.</span><span> </span><span class="NLM_article-title">Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1094</span><span class="refDoi"> DOI: 10.1016/S0969-2126(00)00513-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0969-2126%2800%2900513-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=11080630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVOiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=1089-1094&author=J.+Renauthor=J.+Miltonauthor=K.+L.+Weaverauthor=S.+A.+Shortauthor=D.+I.+Stuartauthor=D.+K.+Stammers&title=Structural+basis+for+the+resilience+of+efavirenz+%28DMP-266%29+to+drug+resistance+mutations+in+HIV-1+reverse+transcriptase&doi=10.1016%2FS0969-2126%2800%2900513-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Resilience of Efavirenz (DMP-266) to Drug Resistance Mutations in HIV-1 Reverse Transcriptase</span></div><div class="casAuthors">Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1089-1094</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Background: Efavirenz is a second-generation non-nucleoside inhibitor of HIV-1 reverse transcriptase (RT) that has recently been approved for use against HIV-1 infection.  Compared with first-generation drugs such as nevirapine, efavirenz shows greater resilience to drug resistance mutations within HIV-1 RT.  In order to understand the basis for this resilience at the mol. level and to help the design of further-improved anti-AIDS drugs, the authors have detd. crystal structures of efavirenz and nevirapine with wild-type RT and the clin. important K103N mutant.  Results: The relatively compact efavirenz mol. binds, as expected, within the non-nucleoside inhibitor binding pocket of RT.  There are significant rearrangements of the drug binding site within the mutant RT compared with the wild-type enzyme.  These changes, which lead to the repositioning of the inhibitor, are not seen in the interaction with the first-generation drug nevirapine.  Conclusions: The repositioning of efavirenz within the drug binding pocket of the mutant RT, together with conformational rearrangements in the protein, could represent a general mechanism whereby certain second-generation non-nucleoside inhibitors are able to reduce the effect of drug-resistance mutations on binding potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW53vhU1qR4rVg90H21EOLACvtfcHk0lj0gZvzE4uPtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVOiur0%253D&md5=a3349e79d1037c74527b4ced74d33b5c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2800%2900513-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252800%252900513-X%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520resilience%2520of%2520efavirenz%2520%2528DMP-266%2529%2520to%2520drug%2520resistance%2520mutations%2520in%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DStructure%26date%3D2000%26volume%3D8%26spage%3D1089%26epage%3D1094%26doi%3D10.1016%2FS0969-2126%2800%2900513-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Rizzo, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span> </span><span class="NLM_article-title">Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">12898</span><span class="NLM_x">–</span> <span class="NLM_lpage">12900</span><span class="refDoi"> DOI: 10.1021/ja003113r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja003113r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=12898-12900&author=R.+C.+Rizzoauthor=D.+P.+Wangauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Validation+of+a+model+for+the+complex+of+HIV-1+reverse+transcriptase+with+sustiva+through+computation+of+resistance+profiles&doi=10.1021%2Fja003113r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fja003113r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja003113r%26sid%3Dliteratum%253Aachs%26aulast%3DRizzo%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DD.%2BP.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DValidation%2520of%2520a%2520model%2520for%2520the%2520complex%2520of%2520HIV-1%2520reverse%2520transcriptase%2520with%2520sustiva%2520through%2520computation%2520of%2520resistance%2520profiles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D12898%26epage%3D12900%26doi%3D10.1021%2Fja003113r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Daluge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faletto, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Clair, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boone, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisdale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dornsife, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averett, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krenitsky, T. A.</span><span> </span><span class="NLM_article-title">1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1093</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1082-1093&author=S.+M.+Dalugeauthor=S.+S.+Goodauthor=M.+B.+Falettoauthor=W.+H.+Millerauthor=M.+H.+St.+Clairauthor=L.+R.+Booneauthor=M.+Tisdaleauthor=N.+R.+Parryauthor=J.+E.+Reardonauthor=R.+E.+Dornsifeauthor=D.+R.+Averettauthor=T.+A.+Krenitsky&title=1592U89%2C+a+novel+carbocyclic+nucleoside+analog+with+potent%2C+selective+anti-human+immunodeficiency+virus+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaluge%26aufirst%3DS.%2BM.%26aulast%3DGood%26aufirst%3DS.%2BS.%26aulast%3DFaletto%26aufirst%3DM.%2BB.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DSt.%2BClair%26aufirst%3DM.%2BH.%26aulast%3DBoone%26aufirst%3DL.%2BR.%26aulast%3DTisdale%26aufirst%3DM.%26aulast%3DParry%26aufirst%3DN.%2BR.%26aulast%3DReardon%26aufirst%3DJ.%2BE.%26aulast%3DDornsife%26aufirst%3DR.%2BE.%26aulast%3DAverett%26aufirst%3DD.%2BR.%26aulast%3DKrenitsky%26aufirst%3DT.%2BA.%26atitle%3D1592U89%252C%2520a%2520novel%2520carbocyclic%2520nucleoside%2520analog%2520with%2520potent%252C%2520selective%2520anti-human%2520immunodeficiency%2520virus%2520activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D1082%26epage%3D1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Lesher, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froelich, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brundage, R. P.</span><span> </span><span class="NLM_article-title">1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents</span> <span class="citation_source-journal">J. Med. Pharm. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1962</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1063</span><span class="NLM_x">–</span> <span class="NLM_lpage">1065</span><span class="refDoi"> DOI: 10.1021/jm01240a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm01240a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaF3sXhs1Ohsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1962&pages=1063-1065&author=G.+Y.+Lesherauthor=E.+J.+Froelichauthor=M.+D.+Gruettauthor=J.+H.+Baileyauthor=R.+P.+Brundage&title=1%2C8-Naphthyridine+derivatives.+A+new+class+of+chemotherapeutic+agents&doi=10.1021%2Fjm01240a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents</span></div><div class="casAuthors">Lesher, George Y.; Froelich, Ernest J.; Gruett, Monte D.; Bailey, John H.; Brundage, R. Pauline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1063-5</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">Six 1-alkyl-1,8-naphthyridines were prepd. from the appropriate 6-substituted-2-aminopyridine for testing against 10 microorganisms.  The most active compd. was3-carboxy-l-ethyl-7-methyl-1,8-naphthyridin-4-one.  The in vivo activity of the compd. was most pronounced against gram-neg. bacteria.  Chemotherapeutic studies in mice showed maximal activity against systemic infections caused by Escherichia coli, Aerobacter aerogenes, Proteus mirabilis, Shigella flexneri, Pasteurella multocida, and Salmonella typhimurium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1T0jx8kJWeLVg90H21EOLACvtfcHk0lj5admWSqKNFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXhs1Ohsg%253D%253D&md5=4436d03992230c76d547e2d002b54956</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm01240a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm01240a021%26sid%3Dliteratum%253Aachs%26aulast%3DLesher%26aufirst%3DG.%2BY.%26aulast%3DFroelich%26aufirst%3DE.%2BJ.%26aulast%3DGruett%26aufirst%3DM.%2BD.%26aulast%3DBailey%26aufirst%3DJ.%2BH.%26aulast%3DBrundage%26aufirst%3DR.%2BP.%26atitle%3D1%252C8-Naphthyridine%2520derivatives.%2520A%2520new%2520class%2520of%2520chemotherapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1962%26volume%3D5%26spage%3D1063%26epage%3D1065%26doi%3D10.1021%2Fjm01240a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Cornett, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wentland, M. P.</span><span> </span><span class="NLM_article-title">Quinolone antibacterial agents</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/S0065-7743(08)61124-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0065-7743%2808%2961124-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1986&pages=139-148&author=J.+B.+Cornettauthor=M.+P.+Wentland&title=Quinolone+antibacterial+agents&doi=10.1016%2FS0065-7743%2808%2961124-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2961124-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252961124-0%26sid%3Dliteratum%253Aachs%26aulast%3DCornett%26aufirst%3DJ.%2BB.%26aulast%3DWentland%26aufirst%3DM.%2BP.%26atitle%3DQuinolone%2520antibacterial%2520agents%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D1986%26volume%3D21%26spage%3D139%26epage%3D148%26doi%3D10.1016%2FS0065-7743%2808%2961124-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Wise, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1128/AAC.23.4.559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1128%2FAAC.23.4.559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=559-564&author=R.+Wiseauthor=J.+M.+Andrewsauthor=L.+J.+Edwards&title=In+vitro+activity+of+Bay+09867%2C+a+new+quinoline+derivative%2C+compared+with+those+of+other+antimicrobial+agents&doi=10.1128%2FAAC.23.4.559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.23.4.559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.23.4.559%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DJ.%2BM.%26aulast%3DEdwards%26aufirst%3DL.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bay%252009867%252C%2520a%2520new%2520quinoline%2520derivative%252C%2520compared%2520with%2520those%2520of%2520other%2520antimicrobial%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1983%26volume%3D23%26spage%3D559%26epage%3D564%26doi%3D10.1128%2FAAC.23.4.559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Sanchez, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domagala, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heifetz, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutt, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehan, A. K.</span><span> </span><span class="NLM_article-title">Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">991</span><span class="refDoi"> DOI: 10.1021/jm00400a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00400a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=983-991&author=J.+P.+Sanchezauthor=J.+M.+Domagalaauthor=S.+E.+Hagenauthor=C.+L.+Heifetzauthor=M.+P.+Huttauthor=J.+B.+Nicholsauthor=A.+K.+Trehan&title=Quinolone+antibacterial+agents.+Synthesis+and+structure-activity+relationships+of+8-substituted+quinoline-3-carboxylic+acids+and+1%2C8-naphthyridine-3-carboxylic+acids&doi=10.1021%2Fjm00400a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm00400a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00400a016%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DJ.%2BP.%26aulast%3DDomagala%26aufirst%3DJ.%2BM.%26aulast%3DHagen%26aufirst%3DS.%2BE.%26aulast%3DHeifetz%26aufirst%3DC.%2BL.%26aulast%3DHutt%26aufirst%3DM.%2BP.%26aulast%3DNichols%26aufirst%3DJ.%2BB.%26aulast%3DTrehan%26aufirst%3DA.%2BK.%26atitle%3DQuinolone%2520antibacterial%2520agents.%2520Synthesis%2520and%2520structure-activity%2520relationships%2520of%25208-substituted%2520quinoline-3-carboxylic%2520acids%2520and%25201%252C8-naphthyridine-3-carboxylic%2520acids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D983%26epage%3D991%26doi%3D10.1021%2Fjm00400a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Birnbaum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, J. S.</span><span> </span><span class="NLM_article-title">Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/0002-9343(85)90097-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0002-9343%2885%2990097-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=3859213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2MXlvVyrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1985&pages=3-21&author=J.+Birnbaumauthor=F.+M.+Kahanauthor=H.+Kroppauthor=J.+S.+MacDonald&title=Carbapenems%2C+a+new+class+of+beta-lactam+antibiotics.+Discovery+and+development+of+imipenem%2Fcilastatin&doi=10.1016%2F0002-9343%2885%2990097-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Carbapenems, a new class of beta-lactam antibiotics.  Discovery and development of imipenem/cilastatin</span></div><div class="casAuthors">Birnbaum, Jerome; Kahan, Frederick M.; Kropp, Helmut; Macdonald, James S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6A</span>),
    <span class="NLM_cas:pages">3-21</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">A review with 48 refs.  Cilastatin  [82009-34-5], coadministered with imipenem  [64221-86-9] in a 1:1 ratio, provided prolonged, reversible blockade of imipenem metab. and improved urinary recoveries to therapeutically significant levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCNK07atRIa7Vg90H21EOLACvtfcHk0liGs2rrqysrRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvVyrtb8%253D&md5=592664766841f1479bae6f0d68b46a50</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2885%2990097-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252885%252990097-X%26sid%3Dliteratum%253Aachs%26aulast%3DBirnbaum%26aufirst%3DJ.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DMacDonald%26aufirst%3DJ.%2BS.%26atitle%3DCarbapenems%252C%2520a%2520new%2520class%2520of%2520beta-lactam%2520antibiotics.%2520Discovery%2520and%2520development%2520of%2520imipenem%252Fcilastatin%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1985%26volume%3D78%26spage%3D3%26epage%3D21%26doi%3D10.1016%2F0002-9343%2885%2990097-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundelof, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, F. M.</span><span> </span><span class="NLM_article-title">Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1128/AAC.22.1.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1128%2FAAC.22.1.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1982&pages=62-70&author=H.+Kroppauthor=J.+G.+Sundelofauthor=R.+Hajduauthor=F.+M.+Kahan&title=Metabolism+of+thienamycin+and+related+carbapenem+antibiotics+by+the+renal+dipeptidase%2C+dehydropeptidase&doi=10.1128%2FAAC.22.1.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FAAC.22.1.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.22.1.62%26sid%3Dliteratum%253Aachs%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DSundelof%26aufirst%3DJ.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26atitle%3DMetabolism%2520of%2520thienamycin%2520and%2520related%2520carbapenem%2520antibiotics%2520by%2520the%2520renal%2520dipeptidase%252C%2520dehydropeptidase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1982%26volume%3D22%26spage%3D62%26epage%3D70%26doi%3D10.1128%2FAAC.22.1.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundelof, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, J.</span><span> </span><span class="NLM_article-title">MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span><span class="refDoi"> DOI: 10.1128/AAC.17.6.993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1128%2FAAC.17.6.993" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1980&pages=993-1000&author=H.+Kroppauthor=J.+G.+Sundelofauthor=J.+S.+Kahanauthor=F.+M.+Kahanauthor=J.+Birnbaum&title=MK0787+%28N-formimidoyl+thienamycin%29%3A+evaluation+of+in+vitro+and+in+vivo+activities&doi=10.1128%2FAAC.17.6.993"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1128%2FAAC.17.6.993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.17.6.993%26sid%3Dliteratum%253Aachs%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DSundelof%26aufirst%3DJ.%2BG.%26aulast%3DKahan%26aufirst%3DJ.%2BS.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DBirnbaum%26aufirst%3DJ.%26atitle%3DMK0787%2520%2528N-formimidoyl%2520thienamycin%2529%253A%2520evaluation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520activities%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1980%26volume%3D17%26spage%3D993%26epage%3D1000%26doi%3D10.1128%2FAAC.17.6.993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Kahan, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundelof, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, J.</span><span> </span><span class="NLM_article-title">Thienamycin: development of imipenen-cilastatin</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl D</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1093/jac/12.suppl_D.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1093%2Fjac%2F12.suppl_D.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=6365872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2cXhtlWrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1983&pages=1-35&issue=Suppl+D&author=F.+M.+Kahanauthor=H.+Kroppauthor=J.+G.+Sundelofauthor=J.+Birnbaum&title=Thienamycin%3A+development+of+imipenen-cilastatin&doi=10.1093%2Fjac%2F12.suppl_D.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Thienamycin:  development of imipenem-cilastatin</span></div><div class="casAuthors">Kahan, Frederick M.; Kropp, Helmut; Sundelof, Jon G.; Birnbaum, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">Suppl. D</span>),
    <span class="NLM_cas:pages">1-35, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    </div><div class="casAbstract">A review with 100 refs. on a new antimicrobial combination imipenem (I)  [64221-86-9]-cilastatin (II)  [81129-83-1].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL61M0vyPeObVg90H21EOLACvtfcHk0liGs2rrqysrRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhtlWrtL4%253D&md5=d3fe2b99658740ff431bf483206dd554</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F12.suppl_D.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F12.suppl_D.1%26sid%3Dliteratum%253Aachs%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DSundelof%26aufirst%3DJ.%2BG.%26aulast%3DBirnbaum%26aufirst%3DJ.%26atitle%3DThienamycin%253A%2520development%2520of%2520imipenen-cilastatin%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1983%26volume%3D12%26issue%3DSuppl%2520D%26spage%3D1%26epage%3D35%26doi%3D10.1093%2Fjac%2F12.suppl_D.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Liao, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R. Z.</span><span> </span><span class="NLM_article-title">Dipeptide hydrolysis by the dinuclear zinc enzyme human renal dipeptidase: mechanistic insights from DFT calculations</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2009.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.jinorgbio.2009.09.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=37-46&author=R.+Z.+Liaoauthor=F.+Himoauthor=J.+G.+Yuauthor=R.+Z.+Liu&title=Dipeptide+hydrolysis+by+the+dinuclear+zinc+enzyme+human+renal+dipeptidase%3A+mechanistic+insights+from+DFT+calculations&doi=10.1016%2Fj.jinorgbio.2009.09.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2009.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2009.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DR.%2BZ.%26aulast%3DHimo%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DJ.%2BG.%26aulast%3DLiu%26aufirst%3DR.%2BZ.%26atitle%3DDipeptide%2520hydrolysis%2520by%2520the%2520dinuclear%2520zinc%2520enzyme%2520human%2520renal%2520dipeptidase%253A%2520mechanistic%2520insights%2520from%2520DFT%2520calculations%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2010%26volume%3D104%26spage%3D37%26epage%3D46%26doi%3D10.1016%2Fj.jinorgbio.2009.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Nitanai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satow, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujimoto, M.</span><span> </span><span class="NLM_article-title">Crystal structure of human renal dipeptidase involved in beta-lactam hydrolysis</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1016/S0022-2836(02)00632-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0022-2836%2802%2900632-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2002&pages=177-184&author=Y.+Nitanaiauthor=Y.+Satowauthor=H.+Adachiauthor=M.+Tsujimoto&title=Crystal+structure+of+human+renal+dipeptidase+involved+in+beta-lactam+hydrolysis&doi=10.1016%2FS0022-2836%2802%2900632-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2802%2900632-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252802%252900632-0%26sid%3Dliteratum%253Aachs%26aulast%3DNitanai%26aufirst%3DY.%26aulast%3DSatow%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DH.%26aulast%3DTsujimoto%26aufirst%3DM.%26atitle%3DCrystal%2520structure%2520of%2520human%2520renal%2520dipeptidase%2520involved%2520in%2520beta-lactam%2520hydrolysis%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2002%26volume%3D321%26spage%3D177%26epage%3D184%26doi%3D10.1016%2FS0022-2836%2802%2900632-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Smyth, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitanai, Y.</span><span> </span><span class="NLM_article-title">A substrate variant as a high-affinity, reversible inhibitor: insight from the x-ray structure of cilastatin bound to membrane dipeptidase</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">998</span><span class="refDoi"> DOI: 10.1016/S0968-0896(02)00519-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0968-0896%2802%2900519-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=991-998&author=T.+P.+Smythauthor=J.+G.+Wallauthor=Y.+Nitanai&title=A+substrate+variant+as+a+high-affinity%2C+reversible+inhibitor%3A+insight+from+the+x-ray+structure+of+cilastatin+bound+to+membrane+dipeptidase&doi=10.1016%2FS0968-0896%2802%2900519-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900519-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900519-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DT.%2BP.%26aulast%3DWall%26aufirst%3DJ.%2BG.%26aulast%3DNitanai%26aufirst%3DY.%26atitle%3DA%2520substrate%2520variant%2520as%2520a%2520high-affinity%252C%2520reversible%2520inhibitor%253A%2520insight%2520from%2520the%2520x-ray%2520structure%2520of%2520cilastatin%2520bound%2520to%2520membrane%2520dipeptidase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D991%26epage%3D998%26doi%3D10.1016%2FS0968-0896%2802%2900519-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizizad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2233</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0liANUTsJED9Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Hohlfeld, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavae-Mokhtari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredenbroeker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krug, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, R.</span><span> </span><span class="NLM_article-title">Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">623</span><span class="refDoi"> DOI: 10.1016/j.pupt.2008.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.pupt.2008.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18374614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslWntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=616-623&author=J.+M.+Hohlfeldauthor=K.+Schoenfeldauthor=M.+Lavae-Mokhtariauthor=F.+Schaumannauthor=M.+Muellerauthor=D.+Bredenbroekerauthor=N.+Krugauthor=R.+Hermann&title=Roflumilast+attenuates+pulmonary+inflammation+upon+segmental+endotoxin+challenge+in+healthy+subjects%3A+a+randomized+placebo-controlled+trial&doi=10.1016%2Fj.pupt.2008.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial</span></div><div class="casAuthors">Hohlfeld, Jens M.; Schoenfeld, Kerstin; Lavae-Mokhtari, Mehyar; Schaumann, Frank; Mueller, Meike; Bredenbroeker, Dirk; Krug, Norbert; Hermann, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">616-623</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Roflumilast, an investigational, targeted phosphodiesterase 4 inhibitor, reduces the in vitro and in vivo inflammatory activity of cells such as neutrophils, eosinophils, macrophages, and monocytes.  The aim of this study was to explore the anti-inflammatory properties of roflumilast in a human model of segmental bronchial endotoxin challenge.  In a randomized, placebo-controlled, double-blind, single-center parallel-group study, 37 healthy subjects of either sex were treated for 28 days with either oral roflumilast 500 μg once daily or placebo.  At day 29, a baseline bronchoalveolar lavage was performed, followed by segmental endotoxin challenge (4 ng/kg) and saline control challenge.  After 24 h, bronchoalveolar lavage fluid was sampled from the challenged segments and cells were counted and differentiated.  After endotoxin challenge, influx of total cells (difference from baseline) in bronchoalveolar lavage of roflumilast-treated subjects was 36% lower than with placebo (p=0.02).  Correspondingly, the influx of neutrophils and eosinophils of roflumilast-treated subjects was 39% (p=0.02) and 74% (p=0.01) lower than with placebo, resp.  In contrast, endotoxin-induced influx of monocytes was not different between roflumilast- and placebo-treated subjects.  No significant differences existed between the groups pertaining to endotoxin-induced influx of macrophages and lymphocytes.  Roflumilast was well tolerated.  No unexpected or serious treatment-emergent signs and symptoms were obsd.  Roflumilast attenuated the endotoxin-induced influx of neutrophils and eosinophils into the airways.  This study demonstrates the anti-inflammatory properties of roflumilast on bronchoalveolar granulocytes in endotoxin-induced airway inflammation in healthy subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6bLT7qqY5KbVg90H21EOLACvtfcHk0liANUTsJED9Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslWntbg%253D&md5=fdeef042b32e68e44cbed0b1d2b411bc</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2008.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2008.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DHohlfeld%26aufirst%3DJ.%2BM.%26aulast%3DSchoenfeld%26aufirst%3DK.%26aulast%3DLavae-Mokhtari%26aufirst%3DM.%26aulast%3DSchaumann%26aufirst%3DF.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DBredenbroeker%26aufirst%3DD.%26aulast%3DKrug%26aufirst%3DN.%26aulast%3DHermann%26aufirst%3DR.%26atitle%3DRoflumilast%2520attenuates%2520pulmonary%2520inflammation%2520upon%2520segmental%2520endotoxin%2520challenge%2520in%2520healthy%2520subjects%253A%2520a%2520randomized%2520placebo-controlled%2520trial%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D21%26spage%3D616%26epage%3D623%26doi%3D10.1016%2Fj.pupt.2008.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Labelle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gareau, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarlane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metters, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouimet, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piechuta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford-Hutchinson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span> </span><span class="NLM_article-title">Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonists devoid of peroxisomal enzyme induction</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00023-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0960-894X%2895%2900023-M" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=283-288&author=M.+Labelleauthor=M.+Belleyauthor=Y.+Gareauauthor=J.+Y.+Gauthierauthor=D.+Guayauthor=R.+Gordonauthor=S.+G.+Grossmanauthor=T.+R.+Jonesauthor=Y.+Leblancauthor=M.+McAuliffeauthor=C.+McFarlaneauthor=P.+Massonauthor=K.+M.+Mettersauthor=N.+Ouimetauthor=D.+H.+Patrickauthor=H.+Piechutaauthor=C.+Rochetteauthor=N.+Sawyerauthor=Y.+B.+Xiangauthor=C.+B.+Pickettauthor=A.+W.+Ford-Hutchinsonauthor=R.+J.+Zamboniauthor=R.+N.+Young&title=Discovery+of+MK-0476%2C+a+potent+and+orally+active+leukotriene+D4+receptor+antagonists+devoid+of+peroxisomal+enzyme+induction&doi=10.1016%2F0960-894X%2895%2900023-M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900023-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900023-M%26sid%3Dliteratum%253Aachs%26aulast%3DLabelle%26aufirst%3DM.%26aulast%3DBelley%26aufirst%3DM.%26aulast%3DGareau%26aufirst%3DY.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGrossman%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DT.%2BR.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DMcAuliffe%26aufirst%3DM.%26aulast%3DMcFarlane%26aufirst%3DC.%26aulast%3DMasson%26aufirst%3DP.%26aulast%3DMetters%26aufirst%3DK.%2BM.%26aulast%3DOuimet%26aufirst%3DN.%26aulast%3DPatrick%26aufirst%3DD.%2BH.%26aulast%3DPiechuta%26aufirst%3DH.%26aulast%3DRochette%26aufirst%3DC.%26aulast%3DSawyer%26aufirst%3DN.%26aulast%3DXiang%26aufirst%3DY.%2BB.%26aulast%3DPickett%26aufirst%3DC.%2BB.%26aulast%3DFord-Hutchinson%26aufirst%3DA.%2BW.%26aulast%3DZamboni%26aufirst%3DR.%2BJ.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26atitle%3DDiscovery%2520of%2520MK-0476%252C%2520a%2520potent%2520and%2520orally%2520active%2520leukotriene%2520D4%2520receptor%2520antagonists%2520devoid%2520of%2520peroxisomal%2520enzyme%2520induction%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D283%26epage%3D288%26doi%3D10.1016%2F0960-894X%2895%2900023-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Holgate, S. T.</span><span> </span><span class="NLM_article-title">The quintiles prize lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1015</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0706272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fsj.bjp.0706272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15980878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2005&pages=1009-1015&author=S.+T.+Holgate&title=The+quintiles+prize+lecture+2004.+The+identification+of+the+adenosine+A2B+receptor+as+a+novel+therapeutic+target+in+asthma&doi=10.1038%2Fsj.bjp.0706272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The Quintiles Prize Lecture 2004: The identification of the adenosine A2B receptor as a novel therapeutic target in asthma</span></div><div class="casAuthors">Holgate, Stephen T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1009-1015</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine is a powerful bronchoconstrictor of asthmatic, but not normal, airways.  In vitro studies on isolated human mast cells and basophils revealed that adenosine and selective analogs augmented inflammatory mediator release from mast cells by stimulating A2 receptors.  Pharmacol. blockade of mast cell mediator release in vivo also attenuated adenosine-induced bronchoconstriction, as did theophylline, by adenosine A2 receptor antagonism.  Further in vitro studies revealed that the asthmatic response to adenosine is likely to be mediated via the A2B subtype which is selectively antagonized by enprofylline.  Studies in animal models, esp. mice, have shown a close synergistic interaction between adenosine, Th2 and airway remodelling responses.  The recent description of A2B receptors on human airway smooth muscle cells that mediate cytokine and chemokine release and induce differentiation of fibroblasts into myofibroblasts strengthens the view that adenosine maybe more than an inflammatory mediator in asthma but also participates in airway wall remodelling in this disease.  These data have provided a firm basis for developing adenosine A2B receptor antagonists as a new therapeutic approach to this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGLJSncqFzDrVg90H21EOLACvtfcHk0lie-CXDbtCRbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbo%253D&md5=864c391c58206f15fe4f818d600385b7</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706272%26sid%3Dliteratum%253Aachs%26aulast%3DHolgate%26aufirst%3DS.%2BT.%26atitle%3DThe%2520quintiles%2520prize%2520lecture%25202004.%2520The%2520identification%2520of%2520the%2520adenosine%2520A2B%2520receptor%2520as%2520a%2520novel%2520therapeutic%2520target%2520in%2520asthma%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D145%26spage%3D1009%26epage%3D1015%26doi%3D10.1038%2Fsj.bjp.0706272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Eastwood, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonquerna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiguade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carranco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domenech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordoba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godessart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loza, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadavid, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nueda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, B.</span><span> </span><span class="NLM_article-title">Discovery of LAS101057: a potent, selective, and orally efficacious A2B adenosine receptor antagonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1021/ml100249e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100249e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=213-218&author=P.+Eastwoodauthor=C.+Esteveauthor=J.+Gonzalezauthor=S.+Fonquernaauthor=J.+Aiguadeauthor=I.+Carrancoauthor=T.+Domenechauthor=M.+Apariciauthor=M.+Miralpeixauthor=J.+Albertiauthor=M.+Cordobaauthor=R.+Fernandezauthor=M.+Pontauthor=N.+Godessartauthor=N.+Pratsauthor=M.+I.+Lozaauthor=M.+I.+Cadavidauthor=A.+Nuedaauthor=B.+Vidal&title=Discovery+of+LAS101057%3A+a+potent%2C+selective%2C+and+orally+efficacious+A2B+adenosine+receptor+antagonist&doi=10.1021%2Fml100249e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fml100249e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100249e%26sid%3Dliteratum%253Aachs%26aulast%3DEastwood%26aufirst%3DP.%26aulast%3DEsteve%26aufirst%3DC.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DFonquerna%26aufirst%3DS.%26aulast%3DAiguade%26aufirst%3DJ.%26aulast%3DCarranco%26aufirst%3DI.%26aulast%3DDomenech%26aufirst%3DT.%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DAlberti%26aufirst%3DJ.%26aulast%3DCordoba%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DPont%26aufirst%3DM.%26aulast%3DGodessart%26aufirst%3DN.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DCadavid%26aufirst%3DM.%2BI.%26aulast%3DNueda%26aufirst%3DA.%26aulast%3DVidal%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520LAS101057%253A%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520A2B%2520adenosine%2520receptor%2520antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D213%26epage%3D218%26doi%3D10.1021%2Fml100249e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lie-CXDbtCRbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaynor, R. B.</span><span> </span><span class="NLM_article-title">IkappaB kinases: key regulators of the NF-kappaB pathway</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.tibs.2003.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.tibs.2003.12.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=72-79&author=Y.+Yamamotoauthor=R.+B.+Gaynor&title=IkappaB+kinases%3A+key+regulators+of+the+NF-kappaB+pathway&doi=10.1016%2Fj.tibs.2003.12.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2003.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2003.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DGaynor%26aufirst%3DR.%2BB.%26atitle%3DIkappaB%2520kinases%253A%2520key%2520regulators%2520of%2520the%2520NF-kappaB%2520pathway%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2004%26volume%3D29%26spage%3D72%26epage%3D79%26doi%3D10.1016%2Fj.tibs.2003.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baud, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhase, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deerinck, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellisman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span> </span><span class="NLM_article-title">Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.1126/science.284.5412.316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1126%2Fscience.284.5412.316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1999&pages=316-320&author=Y.+Huauthor=V.+Baudauthor=M.+Delhaseauthor=P.+Zhangauthor=T.+Deerinckauthor=M.+Ellismanauthor=R.+Johnsonauthor=M.+Karin&title=Abnormal+morphogenesis+but+intact+IKK+activation+in+mice+lacking+the+IKKalpha+subunit+of+IkappaB+kinase&doi=10.1126%2Fscience.284.5412.316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscience.284.5412.316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.284.5412.316%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBaud%26aufirst%3DV.%26aulast%3DDelhase%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DDeerinck%26aufirst%3DT.%26aulast%3DEllisman%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DR.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DAbnormal%2520morphogenesis%2520but%2520intact%2520IKK%2520activation%2520in%2520mice%2520lacking%2520the%2520IKKalpha%2520subunit%2520of%2520IkappaB%2520kinase%26jtitle%3DScience%26date%3D1999%26volume%3D284%26spage%3D316%26epage%3D320%26doi%3D10.1126%2Fscience.284.5412.316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Strnad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span> </span><span class="NLM_article-title">IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.tips.2007.01.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=142-148&author=J.+Strnadauthor=J.+R.+Burke&title=IkappaB+kinase+inhibitors+for+treating+autoimmune+and+inflammatory+disorders%3A+potential+and+challenges&doi=10.1016%2Fj.tips.2007.01.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DIkappaB%2520kinase%2520inhibitors%2520for%2520treating%2520autoimmune%2520and%2520inflammatory%2520disorders%253A%2520potential%2520and%2520challenges%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D142%26epage%3D148%26doi%3D10.1016%2Fj.tips.2007.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Liddle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousins, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez-Molina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumsey, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tape, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicentini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitworth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, R. A.</span><span> </span><span class="NLM_article-title">4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5222</span><span class="NLM_x">–</span> <span class="NLM_lpage">5226</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2012.06.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22801646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCjsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5222-5226&author=J.+Liddleauthor=P.+Bamboroughauthor=M.+D.+Barkerauthor=S.+Camposauthor=C.+W.+Chungauthor=R.+P.+Cousinsauthor=P.+Faulderauthor=M.+L.+Heathcoteauthor=H.+Hobbsauthor=D.+S.+Holmesauthor=C.+Ioannouauthor=C.+Ramirez-Molinaauthor=M.+A.+Morseauthor=R.+Osbornauthor=J.+J.+Payneauthor=J.+M.+Pritchardauthor=W.+L.+Rumseyauthor=D.+T.+Tapeauthor=G.+Vicentiniauthor=C.+Whitworthauthor=R.+A.+Williamson&title=4-Phenyl-7-azaindoles+as+potent%2C+selective+and+bioavailable+IKK2+inhibitors+demonstrating+good+in+vivo+efficacy&doi=10.1016%2Fj.bmcl.2012.06.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy</span></div><div class="casAuthors">Liddle, John; Bamborough, Paul; Barker, Michael D.; Campos, Sebastien; Chung, Chun-Wa; Cousins, Rick P. C.; Faulder, Paul; Heathcote, Michelle L.; Hobbs, Heather; Holmes, Duncan S.; Ioannou, Chris; Ramirez-Molina, Cesar; Morse, Mary A.; Osborn, Ruth; Payne, Jeremy J.; Pritchard, John M.; Rumsey, William L.; Tape, Daniel T.; Vicentini, Giorgia; Whitworth, Caroline; Williamson, Rick A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5222-5226</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The lead optimization of a series of potent azaindole IKK2 inhibitors is described.  Optimization of the human whole blood activity and selectivity over IKK1 in parallel led to the discovery of 16, a potent and selective IKK2 inhibitor showing good efficacy in a rat model of neutrophil activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDgiw_Aw0Bc7Vg90H21EOLACvtfcHk0lhxYKU7C_3wPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCjsbvE&md5=0cf65e328cf53e8ba1f72b1f08ad22bf</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.065%26sid%3Dliteratum%253Aachs%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DCousins%26aufirst%3DR.%2BP.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DHeathcote%26aufirst%3DM.%2BL.%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DIoannou%26aufirst%3DC.%26aulast%3DRamirez-Molina%26aufirst%3DC.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26aulast%3DOsborn%26aufirst%3DR.%26aulast%3DPayne%26aufirst%3DJ.%2BJ.%26aulast%3DPritchard%26aufirst%3DJ.%2BM.%26aulast%3DRumsey%26aufirst%3DW.%2BL.%26aulast%3DTape%26aufirst%3DD.%2BT.%26aulast%3DVicentini%26aufirst%3DG.%26aulast%3DWhitworth%26aufirst%3DC.%26aulast%3DWilliamson%26aufirst%3DR.%2BA.%26atitle%3D4-Phenyl-7-azaindoles%2520as%2520potent%252C%2520selective%2520and%2520bioavailable%2520IKK2%2520inhibitors%2520demonstrating%2520good%2520in%2520vivo%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5222%26epage%3D5226%26doi%3D10.1016%2Fj.bmcl.2012.06.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Herlaar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, Z.</span><span> </span><span class="NLM_article-title">P38 MAPK signalling cascades in inflammatory disease</span> <span class="citation_source-journal">Mol. Med. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1016/S1357-4310(99)01544-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS1357-4310%2899%2901544-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10498912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=439-447&author=E.+Herlaarauthor=Z.+Brown&title=P38+MAPK+signalling+cascades+in+inflammatory+disease&doi=10.1016%2FS1357-4310%2899%2901544-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAPK signalling cascades in inflammatory disease</span></div><div class="casAuthors">Herlaar, E.; Brown, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Today</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">439-447</span>CODEN:
                <span class="NLM_cas:coden">MMTOFK</span>;
        ISSN:<span class="NLM_cas:issn">1357-4310</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 44 refs.  Inflammatory mediators released during acute and chronic diseases activate multiple intracellular signaling cascades including the mitogen-activated protein kinase (MAPK) signal transduction pathway, which plays a significant role in the recruitment of leukocytes to sites of inflammation.  Stimulation of leukocytes by pro-inflammatory cytokines is known to result in the activation of the MAPK isoform p38.  However, the functional consequences of p38 MAPK activation during leukocyte recruitment, including adhesion, migration and effector functions such as oxidative burst and degranulation, are only just beginning to be elucidated.  Specific p38 inhibitors aimed at reducing the prodn. of inflammatory mediators are now being developed, and might in the future provide more effective treatment for inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIhoJ67g0sRrVg90H21EOLACvtfcHk0lhxYKU7C_3wPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWiu7g%253D&md5=3bf8c8ba39b01b5a3188d75b06107709</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS1357-4310%2899%2901544-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-4310%252899%252901544-0%26sid%3Dliteratum%253Aachs%26aulast%3DHerlaar%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DZ.%26atitle%3DP38%2520MAPK%2520signalling%2520cascades%2520in%2520inflammatory%2520disease%26jtitle%3DMol.%2520Med.%2520Today%26date%3D1999%26volume%3D5%26spage%3D439%26epage%3D447%26doi%3D10.1016%2FS1357-4310%2899%2901544-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Angell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBoeck, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span> </span><span class="NLM_article-title">Biphenyl amide p38 kinase inhibitors 3: improvement of cellular and in vivo activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4432</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.06.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18614366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVequ7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4428-4432&author=R.+Angellauthor=N.+M.+Astonauthor=P.+Bamboroughauthor=J.+B.+Bucktonauthor=S.+Cockerillauthor=S.+J.+deBoeckauthor=C.+D.+Edwardsauthor=D.+S.+Holmesauthor=K.+L.+Jonesauthor=D.+I.+Laineauthor=S.+Patelauthor=P.+A.+Smeeauthor=K.+J.+Smithauthor=D.+O.+Somersauthor=A.+L.+Walker&title=Biphenyl+amide+p38+kinase+inhibitors+3%3A+improvement+of+cellular+and+in+vivo+activity&doi=10.1016%2Fj.bmcl.2008.06.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity</span></div><div class="casAuthors">Angell, Richard; Aston, Nicola M.; Bamborough, Paul; Buckton, Jacky B.; Cockerill, Stuart; de Boeck, Suzanne J.; Edwards, Chris D.; Holmes, Duncan S.; Jones, Katherine L.; Laine, Dramane I.; Patel, Shila; Smee, Penny A.; Smith, Kathryn J.; Somers, Don O.; Walker, Ann L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4428-4432</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The biphenyl amides (BPAs) are a novel series of p38α MAP kinase inhibitor.  The optimization of the series to give compds. that are potent in an in vivo disease model is discussed.  SAR is presented and rationalised with ref. to the crystallog. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXT0cyGCATNLVg90H21EOLACvtfcHk0lg3gyrBOgp-3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVequ7c%253D&md5=89ae52223f0cffd31df2b0d830d40ec5</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.048%26sid%3Dliteratum%253Aachs%26aulast%3DAngell%26aufirst%3DR.%26aulast%3DAston%26aufirst%3DN.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBuckton%26aufirst%3DJ.%2BB.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DdeBoeck%26aufirst%3DS.%2BJ.%26aulast%3DEdwards%26aufirst%3DC.%2BD.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DLaine%26aufirst%3DD.%2BI.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSmee%26aufirst%3DP.%2BA.%26aulast%3DSmith%26aufirst%3DK.%2BJ.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26atitle%3DBiphenyl%2520amide%2520p38%2520kinase%2520inhibitors%25203%253A%2520improvement%2520of%2520cellular%2520and%2520in%2520vivo%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4428%26epage%3D4432%26doi%3D10.1016%2Fj.bmcl.2008.06.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Aston, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitulli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span> </span><span class="NLM_article-title">P38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6257</span><span class="NLM_x">–</span> <span class="NLM_lpage">6269</span><span class="refDoi"> DOI: 10.1021/jm9004779</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004779" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6257-6269&author=N.+M.+Astonauthor=P.+Bamboroughauthor=J.+B.+Bucktonauthor=C.+D.+Edwardsauthor=D.+S.+Holmesauthor=K.+L.+Jonesauthor=V.+K.+Patelauthor=P.+A.+Smeeauthor=D.+O.+Somersauthor=G.+Vitulliauthor=A.+L.+Walker&title=P38alpha+mitogen-activated+protein+kinase+inhibitors%3A+optimization+of+a+series+of+biphenylamides+to+give+a+molecule+suitable+for+clinical+progression&doi=10.1021%2Fjm9004779"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm9004779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004779%26sid%3Dliteratum%253Aachs%26aulast%3DAston%26aufirst%3DN.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBuckton%26aufirst%3DJ.%2BB.%26aulast%3DEdwards%26aufirst%3DC.%2BD.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DPatel%26aufirst%3DV.%2BK.%26aulast%3DSmee%26aufirst%3DP.%2BA.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26atitle%3DP38alpha%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%253A%2520optimization%2520of%2520a%2520series%2520of%2520biphenylamides%2520to%2520give%2520a%2520molecule%2520suitable%2520for%2520clinical%2520progression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6257%26epage%3D6269%26doi%3D10.1021%2Fjm9004779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Felices, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, L. J.</span><span> </span><span class="NLM_article-title">Tec kinases in T cell and mast cell signaling</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1016/S0065-2776(06)93004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0065-2776%2806%2993004-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=145-184&author=M.+Felicesauthor=M.+Falkauthor=Y.+Kosakaauthor=L.+J.+Berg&title=Tec+kinases+in+T+cell+and+mast+cell+signaling&doi=10.1016%2FS0065-2776%2806%2993004-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2806%2993004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252806%252993004-1%26sid%3Dliteratum%253Aachs%26aulast%3DFelices%26aufirst%3DM.%26aulast%3DFalk%26aufirst%3DM.%26aulast%3DKosaka%26aufirst%3DY.%26aulast%3DBerg%26aufirst%3DL.%2BJ.%26atitle%3DTec%2520kinases%2520in%2520T%2520cell%2520and%2520mast%2520cell%2520signaling%26jtitle%3DAdv.%2520Immunol.%26date%3D2007%26volume%3D93%26spage%3D145%26epage%3D184%26doi%3D10.1016%2FS0065-2776%2806%2993004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Sahu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">August, A.</span><span> </span><span class="NLM_article-title">Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine-mediated migration</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">3833</span><span class="NLM_x">–</span> <span class="NLM_lpage">3838</span><span class="refDoi"> DOI: 10.4049/jimmunol.180.6.3833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.4049%2Fjimmunol.180.6.3833" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=3833-3838&author=N.+Sahuauthor=C.+Muellerauthor=A.+Fischerauthor=A.+August&title=Differential+sensitivity+to+Itk+kinase+signals+for+T+helper+2+cytokine+production+and+chemokine-mediated+migration&doi=10.4049%2Fjimmunol.180.6.3833"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.180.6.3833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.180.6.3833%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DAugust%26aufirst%3DA.%26atitle%3DDifferential%2520sensitivity%2520to%2520Itk%2520kinase%2520signals%2520for%2520T%2520helper%25202%2520cytokine%2520production%2520and%2520chemokine-mediated%2520migration%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D3833%26epage%3D3838%26doi%3D10.4049%2Fjimmunol.180.6.3833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Burch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brookfield, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellebrandt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismaili, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kordt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwan, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span> </span><span class="NLM_article-title">Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5714</span><span class="NLM_x">–</span> <span class="NLM_lpage">5727</span><span class="refDoi"> DOI: 10.1021/jm500550e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500550e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Srtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5714-5727&author=J.+D.+Burchauthor=K.+Lauauthor=J.+J.+Barkerauthor=F.+Brookfieldauthor=Y.+Chenauthor=Y.+Chenauthor=C.+Eigenbrotauthor=C.+Ellebrandtauthor=M.+H.+Ismailiauthor=A.+Johnsonauthor=D.+Kordtauthor=C.+H.+MacKinnonauthor=P.+A.+McEwanauthor=D.+F.+Ortwineauthor=D.+B.+Steinauthor=X.+Wangauthor=D.+Winklerauthor=P.+W.+Yuenauthor=Y.+Zhangauthor=A.+A.+Zarrinauthor=Z.+Pei&title=Property-+and+structure-guided+discovery+of+a+tetrahydroindazole+series+of+interleukin-2+inducible+T-cell+kinase+inhibitors&doi=10.1021%2Fjm500550e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors</span></div><div class="casAuthors">Burch, Jason D.; Lau, Kevin; Barker, John J.; Brookfield, Fred; Chen, Yong; Chen, Yuan; Eigenbrot, Charles; Ellebrandt, Claire; Ismaili, M. Hicham A.; Johnson, Adam; Kordt, Daniel; MacKinnon, Colin H.; McEwan, Paul A.; Ortwine, Daniel F.; Stein, Daniel B.; Wang, Xiaolu; Winkler, Dirk; Yuen, Po-Wai; Zhang, Yamin; Zarrin, Ali A.; Pei, Zhonghua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5714-5727</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interleukin-2 inducible T-cell kinase (ITK), a member of the Tec family of tyrosine kinases, plays a major role in T-cell signaling downstream of the T-cell receptor (TCR), and considerable efforts have been directed toward discovery of ITK-selective inhibitors as potential treatments of inflammatory disorders such as asthma.  Using a previously disclosed indazole series of inhibitors as a starting point, and using x-ray crystallog. and soly. forecast index (SFI) as guides, we evolved a series of tetrahydroindazole inhibitors with improved potency, selectivity, and pharmaceutical properties.  Highlights include identification of a selectivity pocket above the ligand plane, and identification of appropriate lipophilic substituents to occupy this space.  This effort culminated in identification of a potent and selective ITK inhibitor (GNE-9822) with good ADME properties in preclin. species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdD-rop1z7rVg90H21EOLACvtfcHk0ljZWMGJUfUs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Srtrs%253D&md5=636420d73f6ad55bf5391b6c6aeb3dbd</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm500550e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500550e%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DBarker%26aufirst%3DJ.%2BJ.%26aulast%3DBrookfield%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllebrandt%26aufirst%3DC.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKordt%26aufirst%3DD.%26aulast%3DMacKinnon%26aufirst%3DC.%2BH.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DStein%26aufirst%3DD.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWinkler%26aufirst%3DD.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DProperty-%2520and%2520structure-guided%2520discovery%2520of%2520a%2520tetrahydroindazole%2520series%2520of%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5714%26epage%3D5727%26doi%3D10.1021%2Fjm500550e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Burch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismaili, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwan, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellebrandt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kordt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span> </span><span class="NLM_article-title">Tetrahydroindazoles as interleukin-2 inducible T-cell kinase inhibitors. Part II. Second-generation analogues with enhanced potency, selectivity, and pharmacodynamic modulation in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3806</span><span class="NLM_x">–</span> <span class="NLM_lpage">3816</span><span class="refDoi"> DOI: 10.1021/jm501998m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501998m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3806-3816&author=J.+D.+Burchauthor=K.+Barrettauthor=Y.+Chenauthor=J.+DeVossauthor=C.+Eigenbrotauthor=R.+Goldsmithauthor=M.+H.+Ismailiauthor=K.+Lauauthor=Z.+Linauthor=D.+F.+Ortwineauthor=A.+A.+Zarrinauthor=P.+A.+McEwanauthor=J.+J.+Barkerauthor=C.+Ellebrandtauthor=D.+Kordtauthor=D.+B.+Steinauthor=X.+Wangauthor=Y.+Chenauthor=B.+Huauthor=X.+Xuauthor=P.+W.+Yuenauthor=Y.+Zhangauthor=Z.+Pei&title=Tetrahydroindazoles+as+interleukin-2+inducible+T-cell+kinase+inhibitors.+Part+II.+Second-generation+analogues+with+enhanced+potency%2C+selectivity%2C+and+pharmacodynamic+modulation+in+vivo&doi=10.1021%2Fjm501998m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo</span></div><div class="casAuthors">Burch, Jason D.; Barrett, Kathy; Chen, Yuan; DeVoss, Jason; Eigenbrot, Charles; Goldsmith, Richard; Ismaili, M. Hicham A.; Lau, Kevin; Lin, Zhonghua; Ortwine, Daniel F.; Zarrin, Ali A.; McEwan, Paul A.; Barker, John J.; Ellebrandt, Claire; Kordt, Daniel; Stein, Daniel B.; Wang, Xiaolu; Chen, Yong; Hu, Baihua; Xu, Xiaofeng; Yuen, Po-Wai; Zhang, Yamin; Pei, Zhonghua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3806-3816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.  The authors have previously disclosed a structure- and property-guided lead optimization effort which resulted in the discovery of a new series of tetrahydroindazole-contg. selective ITK inhibitors.  Herein the authors disclose further optimization of this series that resulted in further potency improvements, reduced off-target receptor binding liabilities, and reduced cytotoxicity.  Specifically, the authors have identified a correlation between the basicity of solubilizing elements in the ITK inhibitors and off-target antiproliferative effects, which was exploited to reduce cytotoxicity while maintaining kinase selectivity.  Optimized analogs, e.g. I, were shown to reduce IL-2 and IL-13 prodn. in vivo following oral or i.p. dosing in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9z-34VWYnsbVg90H21EOLACvtfcHk0ljZWMGJUfUs1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D&md5=59a2cd1c2c9d368f9b49344af9b75545</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm501998m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501998m%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DBarker%26aufirst%3DJ.%2BJ.%26aulast%3DEllebrandt%26aufirst%3DC.%26aulast%3DKordt%26aufirst%3DD.%26aulast%3DStein%26aufirst%3DD.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DTetrahydroindazoles%2520as%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520inhibitors.%2520Part%2520II.%2520Second-generation%2520analogues%2520with%2520enhanced%2520potency%252C%2520selectivity%252C%2520and%2520pharmacodynamic%2520modulation%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3806%26epage%3D3816%26doi%3D10.1021%2Fjm501998m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Engelhardt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J.</span><span> </span><span class="NLM_article-title">A new generation of anti-histamines: histamine H4 receptor antagonists on their way to the clinic</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Devel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=628-643&author=H.+Engelhardtauthor=R.+A.+Smitsauthor=R.+Leursauthor=E.+Haaksmaauthor=I.+J.+de+Esch&title=A+new+generation+of+anti-histamines%3A+histamine+H4+receptor+antagonists+on+their+way+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DSmits%26aufirst%3DR.%2BA.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%26atitle%3DA%2520new%2520generation%2520of%2520anti-histamines%253A%2520histamine%2520H4%2520receptor%2520antagonists%2520on%2520their%2520way%2520to%2520the%2520clinic%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2009%26volume%3D12%26spage%3D628%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Mowbray, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenck, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span> </span><span class="NLM_article-title">Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6596</span><span class="NLM_x">–</span> <span class="NLM_lpage">6602</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2011.07.125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6596-6602&author=C.+E.+Mowbrayauthor=A.+S.+Bellauthor=N.+P.+Clarkeauthor=M.+Collinsauthor=R.+M.+Jonesauthor=C.+A.+Laneauthor=W.+L.+Liuauthor=S.+D.+Newmanauthor=M.+Paradowskiauthor=E.+J.+Schenckauthor=M.+D.+Selbyauthor=N.+A.+Swainauthor=D.+H.+Williams&title=Challenges+of+drug+discovery+in+novel+target+space.+The+discovery+and+evaluation+of+PF-3893787%3A+a+novel+histamine+H4+receptor+antagonist&doi=10.1016%2Fj.bmcl.2011.07.125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.125%26sid%3Dliteratum%253Aachs%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DW.%2BL.%26aulast%3DNewman%26aufirst%3DS.%2BD.%26aulast%3DParadowski%26aufirst%3DM.%26aulast%3DSchenck%26aufirst%3DE.%2BJ.%26aulast%3DSelby%26aufirst%3DM.%2BD.%26aulast%3DSwain%26aufirst%3DN.%2BA.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26atitle%3DChallenges%2520of%2520drug%2520discovery%2520in%2520novel%2520target%2520space.%2520The%2520discovery%2520and%2520evaluation%2520of%2520PF-3893787%253A%2520a%2520novel%2520histamine%2520H4%2520receptor%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6596%26epage%3D6602%26doi%3D10.1016%2Fj.bmcl.2011.07.125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Veillette, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolen, J. B.</span><span> </span><span class="NLM_article-title">Post-translational alterations of the tyrosine kinase p56lck in response to activators of protein kinase C</span> <span class="citation_source-journal">Oncogene Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=3041347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A280%3ADyaL1c3ovFSgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1988&pages=385-401&author=A.+Veilletteauthor=I.+D.+Horakauthor=J.+B.+Bolen&title=Post-translational+alterations+of+the+tyrosine+kinase+p56lck+in+response+to+activators+of+protein+kinase+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Post-translational alterations of the tyrosine kinase p56lck in response to activators of protein kinase C</span></div><div class="casAuthors">Veillette A; Horak I D; Bolen J B</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene research</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-401</span>
        ISSN:<span class="NLM_cas:issn">0890-6467</span>.
    </div><div class="casAbstract">We have found in different human cells of lymphoid and non-lymphoid origin that the 56 kilodalton (kDa) lck protein is rapidly converted to a product migrating at approximately 60 kDa (designated p60lck) in response to the phorbol ester 4 alpha-phorbol 12 beta-myristate (PMA) as well as the diacylglycerol analogue 1,2-dioctanoyl-sn-glycerol (diC8).  This conversion is associated with an increase in serine phosphorylation within the amino-terminal 18 kDa portion of the lck protein.  The serine phosphorylation modification and diminished electrophoretic mobility of the lck protein appear to be completely reversible within 60 min following treatment with diC8.  The changes in p56lck phosphorylation and gel mobility in response to activators of protein kinase C are also associated with a small but reproducible decrease in the ability of the lck protein to be phosphorylated in immune complex kinase assays.  While these alterations of the lck gene product may play an important role in antigen-mediated activation of T-lymphocytes, we demonstrated that they can also be induced independently of T-cell activation suggesting that they are not necessarily implicative of this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBSGHrthZSxJWtyewyzkyLfW6udTcc2eayxE0_MGppTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3ovFSgsg%253D%253D&md5=f9954131de26f8296bbbc1eddb508a82</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVeillette%26aufirst%3DA.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26atitle%3DPost-translational%2520alterations%2520of%2520the%2520tyrosine%2520kinase%2520p56lck%2520in%2520response%2520to%2520activators%2520of%2520protein%2520kinase%2520C%26jtitle%3DOncogene%2520Res.%26date%3D1988%26volume%3D2%26spage%3D385%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Anderson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlmutter, R. M.</span><span> </span><span class="NLM_article-title">Involvement of the protein tyrosine kinase p56lck in T cell signaling and thymocyte development</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/S0065-2776(08)60451-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0065-2776%2808%2960451-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1994&pages=151-178&author=S.+J.+Andersonauthor=S.+D.+Levinauthor=R.+M.+Perlmutter&title=Involvement+of+the+protein+tyrosine+kinase+p56lck+in+T+cell+signaling+and+thymocyte+development&doi=10.1016%2FS0065-2776%2808%2960451-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2808%2960451-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252808%252960451-4%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DS.%2BJ.%26aulast%3DLevin%26aufirst%3DS.%2BD.%26aulast%3DPerlmutter%26aufirst%3DR.%2BM.%26atitle%3DInvolvement%2520of%2520the%2520protein%2520tyrosine%2520kinase%2520p56lck%2520in%2520T%2520cell%2520signaling%2520and%2520thymocyte%2520development%26jtitle%3DAdv.%2520Immunol.%26date%3D1994%26volume%3D56%26spage%3D151%26epage%3D178%26doi%3D10.1016%2FS0065-2776%2808%2960451-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Kamens, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratnofsky, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, G. C.</span><span> </span><span class="NLM_article-title">Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1213</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=1213-1219&author=J.+S.+Kamensauthor=S.+E.+Ratnofskyauthor=G.+C.+Hirst&title=Lck+inhibitors+as+a+therapeutic+approach+to+autoimmune+disease+and+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamens%26aufirst%3DJ.%2BS.%26aulast%3DRatnofsky%26aufirst%3DS.%2BE.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26atitle%3DLck%2520inhibitors%2520as%2520a%2520therapeutic%2520approach%2520to%2520autoimmune%2520disease%2520and%2520transplant%2520rejection%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D2%26spage%3D1213%26epage%3D1219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span><span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0ljCZGoJtVYHBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frauchiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewdney, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecic, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taygerly, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0lh4yiqmaECRKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polvent, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hingorani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quart, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manhard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, S.</span><span> </span><span class="NLM_article-title">RDEA594–111 study group pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia</span> <span class="citation_source-journal">Rheumatology (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2174</span><span class="refDoi"> DOI: 10.1093/rheumatology/ket487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1093%2Frheumatology%2Fket487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=24509406" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=2167-2174&author=R.+Fleischmannauthor=B.+Kerrauthor=L.+T.+Yehauthor=M.+Susterauthor=Z.+Shenauthor=E.+Polventauthor=V.+Hingoraniauthor=B.+Quartauthor=K.+Manhardauthor=J.+N.+Minerauthor=S.+Baumgartner&title=RDEA594%E2%80%93111+study+group+pharmacodynamic%2C+pharmacokinetic+and+tolerability+evaluation+of+concomitant+administration+of+lesinurad+and+febuxostat+in+gout+patients+with+hyperuricaemia&doi=10.1093%2Frheumatology%2Fket487"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fket487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fket487%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DKerr%26aufirst%3DB.%26aulast%3DYeh%26aufirst%3DL.%2BT.%26aulast%3DSuster%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DPolvent%26aufirst%3DE.%26aulast%3DHingorani%26aufirst%3DV.%26aulast%3DQuart%26aufirst%3DB.%26aulast%3DManhard%26aufirst%3DK.%26aulast%3DMiner%26aufirst%3DJ.%2BN.%26aulast%3DBaumgartner%26aufirst%3DS.%26atitle%3DRDEA594%25E2%2580%2593111%2520study%2520group%2520pharmacodynamic%252C%2520pharmacokinetic%2520and%2520tolerability%2520evaluation%2520of%2520concomitant%2520administration%2520of%2520lesinurad%2520and%2520febuxostat%2520in%2520gout%2520patients%2520with%2520hyperuricaemia%26jtitle%3DRheumatology%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D53%26spage%3D2167%26epage%3D2174%26doi%3D10.1093%2Frheumatology%2Fket487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Kotz, J.</span><span> </span><span class="NLM_article-title">The gout pipeline crystallizes</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1038/nrd3748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd3748" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=425-426&author=J.+Kotz&title=The+gout+pipeline+crystallizes&doi=10.1038%2Fnrd3748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnrd3748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3748%26sid%3Dliteratum%253Aachs%26aulast%3DKotz%26aufirst%3DJ.%26atitle%3DThe%2520gout%2520pipeline%2520crystallizes%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D425%26epage%3D426%26doi%3D10.1038%2Fnrd3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][ 1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6639</span><span class="refDoi"> DOI: 10.1021/jm100540x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100540x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6629-6639&author=C.+Liuauthor=J.+Linauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=J.+Hynesauthor=H.+Wuauthor=A.+J.+Dyckmanauthor=T.+Liauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=D.+J.+Shusterauthor=H.+Zhangauthor=P.+H.+Maratheauthor=A.+M.+Doweykoauthor=J.+S.+Sackauthor=S.+E.+Kieferauthor=K.+F.+Kishauthor=J.+A.+Newittauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Discovery+of+4-%285-%28cyclopropylcarbamoyl%29-2-methylphenylamino%29-5-methyl-N-propylpyrrolo%5B1%2C2-f%5D%5B+1%2C2%2C4%5Dtriazine-6-carboxamide+%28BMS-582949%29%2C+a+clinical+p38alpha+MAP+kinase+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Fjm100540x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm100540x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100540x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204-%25285-%2528cyclopropylcarbamoyl%2529-2-methylphenylamino%2529-5-methyl-N-propylpyrrolo%255B1%252C2-f%255D%255B%25201%252C2%252C4%255Dtriazine-6-carboxamide%2520%2528BMS-582949%2529%252C%2520a%2520clinical%2520p38alpha%2520MAP%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6629%26epage%3D6639%26doi%3D10.1021%2Fjm100540x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Schiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peura, D.</span><span> </span><span class="NLM_article-title">HZT-501 (DUEXIS((R)); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis</span> <span class="citation_source-journal">Expert Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1586/egh.11.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1586%2Fegh.11.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22149579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SgsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=25-35&author=M.+Schiffauthor=D.+Peura&title=HZT-501+%28DUEXIS%28%28R%29%29%3B+ibuprofen+800+mg%2Ffamotidine+26.6+mg%29+gastrointestinal+protection+in+the+treatment+of+the+signs+and+symptoms+of+rheumatoid+arthritis+and+osteoarthritis&doi=10.1586%2Fegh.11.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">HZT-501 (DUEXIS; ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis</span></div><div class="casAuthors">Schiff, Michael; Peura, David</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Arthritis affects nearly 50 million people in the USA and, with the aging of the population, the prevalence is expected to rise.  While NSAIDs are very effective in relieving pain assocd. with osteoarthritis (OA) and rheumatoid arthritis (RA), they are assocd. with side effects, including gastrointestinal (GI) toxicity, which may manifest as dyspepsia, ulcers and/or bleeding.  A no. of approaches have been employed in an effort to either completely avoid or reduce the risk of GI toxicities assocd. with NSAID use.  Two new products combining an NSAID with a gastroprotective agent have recently been approved and other agents are in the pipeline.  Patient adherence to prescribed gastroprotective therapy is known to be poor, often resulting in an increased risk of GI events in patients taking NSAIDs.  These newer combination products may fulfill an important need for many patients who need to receive NSAIDs for the pain of OA and RA, but who are also at risk of upper GI events.  This article reviews preclin. and clin. results for a new fixed-dose combination of ibuprofen and famotidine, DUEXIS (HZT-501), which has recently been approved in the USA for the relief of signs and symptoms of RA and OA and to decrease the risk of developing upper GI ulcers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9fBCfYQlWLVg90H21EOLACvtfcHk0lh4yiqmaECRKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SgsLfO&md5=7e50e6619ae281cfba3dbcb9e669185d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1586%2Fegh.11.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fegh.11.88%26sid%3Dliteratum%253Aachs%26aulast%3DSchiff%26aufirst%3DM.%26aulast%3DPeura%26aufirst%3DD.%26atitle%3DHZT-501%2520%2528DUEXIS%2528%2528R%2529%2529%253B%2520ibuprofen%2520800%2520mg%252Ffamotidine%252026.6%2520mg%2529%2520gastrointestinal%2520protection%2520in%2520the%2520treatment%2520of%2520the%2520signs%2520and%2520symptoms%2520of%2520rheumatoid%2520arthritis%2520and%2520osteoarthritis%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2012%26volume%3D6%26spage%3D25%26epage%3D35%26doi%3D10.1586%2Fegh.11.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everlof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galella, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3033</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2013.03.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3028-3033&author=C.+Liuauthor=J.+Linauthor=G.+Everlofauthor=C.+Gesenbergauthor=H.+Zhangauthor=P.+H.+Maratheauthor=M.+Malleyauthor=M.+A.+Galellaauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Synthesis+and+evaluation+of+carbamoylmethylene+linked+prodrugs+of+BMS-582949%2C+a+clinical+p38alpha+inhibitor&doi=10.1016%2Fj.bmcl.2013.03.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DEverlof%26aufirst%3DG.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DMalley%26aufirst%3DM.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520carbamoylmethylene%2520linked%2520prodrugs%2520of%2520BMS-582949%252C%2520a%2520clinical%2520p38alpha%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3028%26epage%3D3033%26doi%3D10.1016%2Fj.bmcl.2013.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Ivanov, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadokoro, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepelley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafaille, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cua, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, D. R.</span><span> </span><span class="NLM_article-title">The orphan nuclear receptor RORgamma directs the differentiation program of proinflammatory IL-17+ T helper cells</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1133</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.07.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.cell.2006.07.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=1121-1133&author=I.+I.+Ivanovauthor=B.+S.+McKenzieauthor=L.+Zhouauthor=C.+E.+Tadokoroauthor=A.+Lepelleyauthor=J.+J.+Lafailleauthor=D.+J.+Cuaauthor=D.+R.+Littman&title=The+orphan+nuclear+receptor+RORgamma+directs+the+differentiation+program+of+proinflammatory+IL-17%2B+T+helper+cells&doi=10.1016%2Fj.cell.2006.07.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DIvanov%26aufirst%3DI.%2BI.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DTadokoro%26aufirst%3DC.%2BE.%26aulast%3DLepelley%26aufirst%3DA.%26aulast%3DLafaille%26aufirst%3DJ.%2BJ.%26aulast%3DCua%26aufirst%3DD.%2BJ.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26atitle%3DThe%2520orphan%2520nuclear%2520receptor%2520RORgamma%2520directs%2520the%2520differentiation%2520program%2520of%2520proinflammatory%2520IL-17%252B%2520T%2520helper%2520cells%26jtitle%3DCell%26date%3D2006%26volume%3D126%26spage%3D1121%26epage%3D1133%26doi%3D10.1016%2Fj.cell.2006.07.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Hirata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotoku, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obika, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aratsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiozaki, M.</span><span> </span><span class="NLM_article-title">SAR exploration guided by LE and Fsp(3): discovery of a selective and orally efficacious RORgamma inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00253</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00253" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=23-27&author=K.+Hirataauthor=M.+Kotokuauthor=N.+Sekiauthor=T.+Maebaauthor=K.+Maedaauthor=S.+Hirashimaauthor=T.+Sakaiauthor=S.+Obikaauthor=A.+Horiauthor=Y.+Haseauthor=T.+Yamaguchiauthor=Y.+Katsudaauthor=T.+Hataauthor=N.+Miyagawaauthor=K.+Aritaauthor=Y.+Nomuraauthor=K.+Asahinaauthor=Y.+Aratsuauthor=M.+Kamadaauthor=T.+Adachiauthor=M.+Noguchiauthor=S.+Doiauthor=P.+Croweauthor=E.+Bradleyauthor=R.+Steensmaauthor=H.+Taoauthor=M.+Fennauthor=R.+Babineauthor=X.+Liauthor=S.+Thacherauthor=H.+Hashimotoauthor=M.+Shiozaki&title=SAR+exploration+guided+by+LE+and+Fsp%283%29%3A+discovery+of+a+selective+and+orally+efficacious+RORgamma+inhibitor&doi=10.1021%2Facsmedchemlett.5b00253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00253%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DKotoku%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DMaeba%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DHirashima%26aufirst%3DS.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DObika%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKatsuda%26aufirst%3DY.%26aulast%3DHata%26aufirst%3DT.%26aulast%3DMiyagawa%26aufirst%3DN.%26aulast%3DArita%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DY.%26aulast%3DAsahina%26aufirst%3DK.%26aulast%3DAratsu%26aufirst%3DY.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DP.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DFenn%26aufirst%3DM.%26aulast%3DBabine%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DThacher%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DShiozaki%26aufirst%3DM.%26atitle%3DSAR%2520exploration%2520guided%2520by%2520LE%2520and%2520Fsp%25283%2529%253A%2520discovery%2520of%2520a%2520selective%2520and%2520orally%2520efficacious%2520RORgamma%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D23%26epage%3D27%26doi%3D10.1021%2Facsmedchemlett.5b00253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Bonnaud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousse, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouzin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauran, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couzinier, J. P.</span><span> </span><span class="NLM_article-title">1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1021/jm00385a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00385a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=318-325&author=B.+Bonnaudauthor=H.+Cousseauthor=G.+Mouzinauthor=M.+Brileyauthor=A.+Stengerauthor=F.+Fauranauthor=J.+P.+Couzinier&title=1-Aryl-2-%28aminomethyl%29cyclopropanecarboxylic+acid+derivatives.+A+new+series+of+potential+antidepressants&doi=10.1021%2Fjm00385a013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm00385a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00385a013%26sid%3Dliteratum%253Aachs%26aulast%3DBonnaud%26aufirst%3DB.%26aulast%3DCousse%26aufirst%3DH.%26aulast%3DMouzin%26aufirst%3DG.%26aulast%3DBriley%26aufirst%3DM.%26aulast%3DStenger%26aufirst%3DA.%26aulast%3DFauran%26aufirst%3DF.%26aulast%3DCouzinier%26aufirst%3DJ.%2BP.%26atitle%3D1-Aryl-2-%2528aminomethyl%2529cyclopropanecarboxylic%2520acid%2520derivatives.%2520A%2520new%2520series%2520of%2520potential%2520antidepressants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D318%26epage%3D325%26doi%3D10.1021%2Fjm00385a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Auclair, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assie, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heusler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depoortere, R.</span><span> </span><span class="NLM_article-title">Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.neuropharm.2013.02.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=338-347&author=A.+L.+Auclairauthor=J.+C.+Martelauthor=M.+B.+Assieauthor=L.+Bardinauthor=P.+Heuslerauthor=D.+Cussacauthor=M.+Marienauthor=A.+Newman-Tancrediauthor=J.+A.+O%E2%80%99Connorauthor=R.+Depoortere&title=Levomilnacipran+%28F2695%29%2C+a+norepinephrine-preferring+SNRI%3A+profile+in+vitro+and+in+models+of+depression+and+anxiety&doi=10.1016%2Fj.neuropharm.2013.02.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DMartel%26aufirst%3DJ.%2BC.%26aulast%3DAssie%26aufirst%3DM.%2BB.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DHeusler%26aufirst%3DP.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DMarien%26aufirst%3DM.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DJ.%2BA.%26aulast%3DDepoortere%26aufirst%3DR.%26atitle%3DLevomilnacipran%2520%2528F2695%2529%252C%2520a%2520norepinephrine-preferring%2520SNRI%253A%2520profile%2520in%2520vitro%2520and%2520in%2520models%2520of%2520depression%2520and%2520anxiety%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D70%26spage%3D338%26epage%3D347%26doi%3D10.1016%2Fj.neuropharm.2013.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Wentland, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bidlack, J. M.</span><span> </span><span class="NLM_article-title">Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2107</span><span class="NLM_x">–</span> <span class="NLM_lpage">2110</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.02.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2107-2110&author=M.+P.+Wentlandauthor=Q.+Luauthor=R.+Louauthor=Y.+Buauthor=B.+I.+Knappauthor=J.+M.+Bidlack&title=Synthesis+and+opioid+receptor+binding+properties+of+a+highly+potent+4-hydroxy+analogue+of+naltrexone&doi=10.1016%2Fj.bmcl.2005.02.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DWentland%26aufirst%3DM.%2BP.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DLou%26aufirst%3DR.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DB.%2BI.%26aulast%3DBidlack%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%2520and%2520opioid%2520receptor%2520binding%2520properties%2520of%2520a%2520highly%2520potent%25204-hydroxy%2520analogue%2520of%2520naltrexone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2107%26epage%3D2110%26doi%3D10.1016%2Fj.bmcl.2005.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Bart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schluger, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bidlack, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreek, M. J.</span><span> </span><span class="NLM_article-title">Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2254</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span><span class="refDoi"> DOI: 10.1038/sj.npp.1300811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fsj.npp.1300811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15988468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=2254-2262&author=G.+Bartauthor=J.+H.+Schlugerauthor=L.+Borgauthor=A.+Hoauthor=J.+M.+Bidlackauthor=M.+J.+Kreek&title=Nalmefene+induced+elevation+in+serum+prolactin+in+normal+human+volunteers%3A+partial+kappa+opioid+agonist+activity%3F&doi=10.1038%2Fsj.npp.1300811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?</span></div><div class="casAuthors">Bart, Gavin; Schluger, James H.; Borg, Lisa; Ho, Ann; Bidlack, Jean M.; Kreek, Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2254-2262</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In humans, mu- and kappa-opioid receptor agonists lower tuberoinfundibular dopamine, which tonically inhibits prolactin release.  Serum prolactin is, therefore, a useful biomarker for tuberoinfundibular dopamine.  The current study evaluated the unexpected finding that the relative mu- and kappa-opioid receptor selective antagonist nalmefene increases serum prolactin, indicating possible kappa-opioid receptor agonist activity.  In all, 33 healthy human volunteers (14 female) with no history of psychiatric or substance use disorders received placebo, nalmefene 3 mg, and nalmefene 10 mg in a double-blind manner.  Drugs were administered between 0900 and 1000 on sep. days via 2-min i.v. infusion.  Serial blood specimens were analyzed for serum levels of prolactin.  Addnl. in vitro studies of nalmefene binding to cloned human kappa-opioid receptors transfected into Chinese hamster ovary cells were performed.  Compared to placebo, both doses of nalmefene caused significant elevations in serum prolactin (p<0.002 for nalmefene 3 mg and p<0.0005 for nalmefene 10 mg).  There was no difference in prolactin response between the 3 and 10 mg doses.  Binding assays confirmed nalmefene's affinity at kappa-opioid receptors and antagonism of mu-opioid receptors. [35S]GTPγS binding studies demonstrated that nalmefene is a full antagonist at mu-opioid receptors and has partial agonist properties at kappa-opioid receptors.  Elevations in serum prolactin following nalmefene are consistent with this partial agonist effect at kappa-opioid receptors.  As kappa-opioid receptor activation can lower dopamine in brain regions important to the persistence of alc. and cocaine dependence, the partial kappa agonist effect of nalmefene may enhance its therapeutic efficacy in selected addictive diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNyaQ97u9HsbVg90H21EOLACvtfcHk0liAeae7_s5MmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN&md5=791e1e9c10f9c18157662e02d0d0ce2c</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300811%26sid%3Dliteratum%253Aachs%26aulast%3DBart%26aufirst%3DG.%26aulast%3DSchluger%26aufirst%3DJ.%2BH.%26aulast%3DBorg%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DBidlack%26aufirst%3DJ.%2BM.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DNalmefene%2520induced%2520elevation%2520in%2520serum%2520prolactin%2520in%2520normal%2520human%2520volunteers%253A%2520partial%2520kappa%2520opioid%2520agonist%2520activity%253F%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D2254%26epage%3D2262%26doi%3D10.1038%2Fsj.npp.1300811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Pogozheva, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomize, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosberg, H. I.</span><span> </span><span class="NLM_article-title">Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints</span> <span class="citation_source-journal">Biophys. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">634</span><span class="refDoi"> DOI: 10.1016/S0006-3495(98)77552-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0006-3495%2898%2977552-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=9675164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1cXltFyitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1998&pages=612-634&author=I.+D.+Pogozhevaauthor=A.+L.+Lomizeauthor=H.+I.+Mosberg&title=Opioid+receptor+three-dimensional+structures+from+distance+geometry+calculations+with+hydrogen+bonding+constraints&doi=10.1016%2FS0006-3495%2898%2977552-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints</span></div><div class="casAuthors">Pogozheva, Irina D.; Lomize, Andrei L.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">612-634</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Biophysical Society</span>)
        </div><div class="casAbstract">Three-dimensional structures of the transmembrane, seven α-helical domains and extracellular loops of δ, μ, and κ opioid receptors, were calcd. using the distance geometry algorithm, with hydrogen bonding constraints based on the previously developed general model of the transmembrane α-bundle for rhodopsin-like G-protein coupled receptors (Biophys. J. 1997. 70:1963).  Each calcd. opioid receptor structure has an extensive network of interhelical hydrogen bonds and a ligand-binding crevice that is partially covered by a β-hairpin formed by the second extracellular loop.  The binding cavities consist of an inner "conserved region" composed of 18 residues that are identical in δ, μ, and κ opioid receptors, and a peripheral "variable region," composed of 19 residues that are different in δ, μ, and κ subtypes and are responsible for the subtype specificity of various ligands.  Sixteen δ-, μ-, or κ-selective, conformationally constrained peptide and nonpeptide opioid agonists and antagonists and affinity labels were fit into the binding pockets of the opioid receptors.  All ligands considered have a similar spatial arrangement in the receptors, with the tyramine moiety of alkaloids or Tyr1 of opioid peptides interacting with conserved residues in the bottom of the pocket and the tyramine N+ and OH groups forming ionic interactions or H-bonds with a conserved aspartate from helix III and a conserved histidine from helix VI, resp.  The central, conformationally constrained fragments of the opioids (the disulfide-bridged cycles of the peptides and various ring structures in the nonpeptide ligands) are oriented approx. perpendicular to the tyramine and directed toward the extracellular surface.  The results obtained are qual. consistent with ligand affinities, crosslinking studies, and mutagenesis data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomsqriUZlUkLVg90H21EOLACvtfcHk0liAeae7_s5MmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFyitr4%253D&md5=d676d455db7c5e99247284e4315c2a04</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0006-3495%2898%2977552-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3495%252898%252977552-6%26sid%3Dliteratum%253Aachs%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DLomize%26aufirst%3DA.%2BL.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DOpioid%2520receptor%2520three-dimensional%2520structures%2520from%2520distance%2520geometry%2520calculations%2520with%2520hydrogen%2520bonding%2520constraints%26jtitle%3DBiophys.%2520J.%26date%3D1998%26volume%3D75%26spage%3D612%26epage%3D634%26doi%3D10.1016%2FS0006-3495%2898%2977552-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Feinberg, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creese, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">4215</span><span class="NLM_x">–</span> <span class="NLM_lpage">4219</span><span class="refDoi"> DOI: 10.1073/pnas.73.11.4215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.73.11.4215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=186791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4215-4219&author=A.+P.+Feinbergauthor=I.+Creeseauthor=S.+H.+Snyder&title=The+opiate+receptor%3A+a+model+explaining+structure-activity+relationships+of+opiate+agonists+and+antagonists&doi=10.1073%2Fpnas.73.11.4215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The opiate receptor:  A model explaining structure-activity relations of opiate agonists and antagonists</span></div><div class="casAuthors">Feinberg, Andrew P.; Creese, Ian; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4215-19</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A model of the opiate receptor is proposed which explains structure-activity relationships of opiate drugs, including the unique potency of certain opiates such as etonitazene, fentanyl, phenazocine, and oripavines; the role of N-allyl substituents in conferring antagonist properties; and chem. features that afford pure antagonists.  The model indicates mol. mechanisms for interconversion of the opiate receptor between respective states that bind agonists or antagonists with high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcp-YfSxhKX7Vg90H21EOLACvtfcHk0ljtwQf7N8wuag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D&md5=13320bdc14257c1f4c0fe84ad05e1421</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.4215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.4215%26sid%3Dliteratum%253Aachs%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DThe%2520opiate%2520receptor%253A%2520a%2520model%2520explaining%2520structure-activity%2520relationships%2520of%2520opiate%2520agonists%2520and%2520antagonists%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1976%26volume%3D73%26spage%3D4215%26epage%3D4219%26doi%3D10.1073%2Fpnas.73.11.4215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Lutfy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, A.</span><span> </span><span class="NLM_article-title">Buprenorphine: a unique drug with complex pharmacology</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span><span class="refDoi"> DOI: 10.2174/1570159043359477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F1570159043359477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18997874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFejtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=395-402&author=K.+Lutfyauthor=A.+Cowan&title=Buprenorphine%3A+a+unique+drug+with+complex+pharmacology&doi=10.2174%2F1570159043359477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Buprenorphine: A unique drug with complex pharmacology</span></div><div class="casAuthors">Lutfy, Kabirullah; Cowan, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-402</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1570-159X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Buprenorphine, an opioid with mixed agonist-antagonist activity at classical opioid receptors, has been approved recently for the treatment of opioid dependency.  Buprenorphine is also used as an analgesic.  The buprenorphine dose-response curve is sometimes submaximal, or even bell-shaped, in nociceptive assays, depending upon the nature and intensity of the noxious stimulus.  Moreover, buprenorphine, when administered with full agonists, such as morphine, antagonizes the action of these drugs.  Partial agonism at the mu opioid receptor and, in some cases, antagonism at the kappa or delta opioid receptor have been considered as possible underlying mechanisms for the ceiling effect and bell-shaped dose-response curve of buprenorphine.  While ceiling effects can be explained by the partial agonist activity of buprenorphine, the bell-shaped dose-response curve cannot be a consequence of this property of the drug.  Recently, buprenorphine has been shown to activate the opioid receptor-like (ORL-1; also known as NOP) receptor.  Supraspinal activation of the ORL-1 receptor counteracts the antinociceptive and rewarding actions of morphine, raising the possibility that these actions of buprenorphine can also be altered by its ability to concomitantly activate the ORL-1 receptor.  The use of mol. biol. techniques has advanced the knowledge regarding the role of opioid receptors in modulation of pain and reward.  In particular, generation of opioid receptor knockout mice has proven useful in this regard.  Indeed, using knockout mice, the authors have recently shown that the antinociceptive effect of buprenorphine mediated primarily by the mu opioid receptor is attenuated by the ability of the drug to activate the ORL-1 receptor.  Thus, the goal of this review is to provide evidence demonstrating that the ORL-1 receptor plays a functional role not only in the antinociceptive effect of buprenorphine but also in other actions of the drug as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6_wNsmaXoM7Vg90H21EOLACvtfcHk0ljtwQf7N8wuag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFejtbg%253D&md5=1771d5a23a42e2ff5347fb7270a2853e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.2174%2F1570159043359477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159043359477%26sid%3Dliteratum%253Aachs%26aulast%3DLutfy%26aufirst%3DK.%26aulast%3DCowan%26aufirst%3DA.%26atitle%3DBuprenorphine%253A%2520a%2520unique%2520drug%2520with%2520complex%2520pharmacology%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2004%26volume%3D2%26spage%3D395%26epage%3D402%26doi%3D10.2174%2F1570159043359477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Harrison, C.</span><span> </span><span class="NLM_article-title">Trial watch: opioid receptor blocker shows promise in phase II depression trial</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="refDoi"> DOI: 10.1038/nrd4028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd4028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=415&author=C.+Harrison&title=Trial+watch%3A+opioid+receptor+blocker+shows+promise+in+phase+II+depression+trial&doi=10.1038%2Fnrd4028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrd4028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4028%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26atitle%3DTrial%2520watch%253A%2520opioid%2520receptor%2520blocker%2520shows%2520promise%2520in%2520phase%2520II%2520depression%2520trial%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D415%26doi%3D10.1038%2Fnrd4028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Burger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, W. L.</span><span> </span><span class="NLM_article-title">Arylcycloalkylamines. I. 2-Phneylcyclopropylamine</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1948</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2198</span><span class="NLM_x">–</span> <span class="NLM_lpage">2201</span><span class="refDoi"> DOI: 10.1021/ja01186a062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01186a062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1948&pages=2198-2201&author=A.+Burgerauthor=W.+L.+Yost&title=Arylcycloalkylamines.+I.+2-Phneylcyclopropylamine&doi=10.1021%2Fja01186a062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fja01186a062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01186a062%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%26aulast%3DYost%26aufirst%3DW.%2BL.%26atitle%3DArylcycloalkylamines.%2520I.%25202-Phneylcyclopropylamine%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1948%26volume%3D70%26spage%3D2198%26epage%3D2201%26doi%3D10.1021%2Fja01186a062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Tedeschi, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedeschi, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fellows, E. J.</span><span> </span><span class="NLM_article-title">Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span><span class="refDoi"> DOI: 10.3181/00379727-102-25256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.3181%2F00379727-102-25256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaF3cXhvVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1959&pages=380-381&author=R.+E.+Tedeschiauthor=D.+H.+Tedeschiauthor=P.+L.+Amesauthor=L.+Cookauthor=P.+A.+Mattisauthor=E.+J.+Fellows&title=Some+pharmacological+observations+on+tranylcypromine+%28SKF+trans-385%29%2C+a+potent+inhibitor+of+monoamine+oxidase&doi=10.3181%2F00379727-102-25256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase</span></div><div class="casAuthors">Tedeschi, Ralph E.; Tedeschi, David H.; Ames, Peter L.; Cook, Leonard; Mattis, Paul A.; Fellows, Edwin J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">380-1</span>CODEN:
                <span class="NLM_cas:coden">PSEBAA</span>;
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    </div><div class="casAbstract">Treatment of rabbits with tranylcypromine (2-phenylcyclopropylamine-HCl) (I) followed by injection of reserpine produces central nervous system stimulation and a marked rise in rectal temp.  The effects of I are assumed to reflect its activity as an inhibitor of monoamine oxidase.  The activity of I is compared with that of iproniazid and d-amphetamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphjbU0S_o0VLVg90H21EOLACvtfcHk0ljtwQf7N8wuag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXhvVCksA%253D%253D&md5=cbe7ce410fd2ab862333341c0ed8e161</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3181%2F00379727-102-25256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3181%252F00379727-102-25256%26sid%3Dliteratum%253Aachs%26aulast%3DTedeschi%26aufirst%3DR.%2BE.%26aulast%3DTedeschi%26aufirst%3DD.%2BH.%26aulast%3DAmes%26aufirst%3DP.%2BL.%26aulast%3DCook%26aufirst%3DL.%26aulast%3DMattis%26aufirst%3DP.%2BA.%26aulast%3DFellows%26aufirst%3DE.%2BJ.%26atitle%3DSome%2520pharmacological%2520observations%2520on%2520tranylcypromine%2520%2528SKF%2520trans-385%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520monoamine%2520oxidase%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D1959%26volume%3D102%26spage%3D380%26epage%3D381%26doi%3D10.3181%2F00379727-102-25256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Binda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubalek, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattevi, A.</span><span> </span><span class="NLM_article-title">Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">9750</span><span class="NLM_x">–</span> <span class="NLM_lpage">9755</span><span class="refDoi"> DOI: 10.1073/pnas.1633804100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.1633804100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=12913124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVejt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=9750-9755&author=C.+Bindaauthor=M.+Liauthor=F.+Hubalekauthor=N.+Restelliauthor=D.+E.+Edmondsonauthor=A.+Mattevi&title=Insights+into+the+mode+of+inhibition+of+human+mitochondrial+monoamine+oxidase+B+from+high-resolution+crystal+structures&doi=10.1073%2Fpnas.1633804100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures</span></div><div class="casAuthors">Binda, Claudia; Li, Min; Hubalek, Frantisek; Restelli, Nadia; Edmondson, Dale E.; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9750-9755</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO-B) is an outer mitochondrial membrane-bound enzyme that catalyzes the oxidative deamination of arylalkylamine neurotransmitters and has been a target for a no. of clin. used drug inhibitors.  The 1.7-Å structure of the reversible isatin-MAO-B complex has been detd.; it forms a basis for the interpretation of the enzyme's structure when bound to either reversible or irreversible inhibitors.  1,4-Diphenyl-2-butene is found to be a reversible MAO-B inhibitor, which occupies both the entrance and substrate cavity space in the enzyme.  Comparison of these two structures identifies Ile-199 as a "gate" between the two cavities.  Rotation of the side chain allows for either sepn. or fusion of the two cavities.  Inhibition of the enzyme with N-(2-aminoethyl)-p-chlorobenzamide results in the formation of a covalent N(5) flavin adduct with the Ph ring of the inhibitor occupying a position in the catalytic site overlapping that of isatin.  Inhibition of MAO-B with the clin. used trans-2-phenylcyclopropylamine results in the formation of a covalent C(4a) flavin adduct with an opened cyclopropyl ring and the Ph ring in a parallel orientation to the flavin.  The peptide bond between the flavin-substituted Cys-397 and Tyr-398 is in a cis conformation, which allows the proper orientation of the phenolic ring of Tyr-398 in the active site.  The flavin ring exists in a twisted nonplanar conformation, which is obsd. in the oxidized form as well as in both the N(5) and the C(4a) adducts.  An immobile water mol. is H-bonded to Lys-296 and to the N(5) of the flavin as obsd. in other flavin-dependent amine oxidases.  The active site cavities are highly apolar; however, hydrophilic areas exist near the flavin and direct the amine moiety of the substrate for binding and catalysis.  Small conformational changes are obsd. on comparison of the different inhibitor-enzyme complexes.  Future MAO-B drug design will need to consider "induced fit" contributions as an element in ligand-enzyme interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0K1SiYQtmN7Vg90H21EOLACvtfcHk0li1Fm05Aa3RNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVejt7c%253D&md5=41ecf51fec3d1c4c811dc716c43beda5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1633804100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1633804100%26sid%3Dliteratum%253Aachs%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DF.%26aulast%3DRestelli%26aufirst%3DN.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520mode%2520of%2520inhibition%2520of%2520human%2520mitochondrial%2520monoamine%2520oxidase%2520B%2520from%2520high-resolution%2520crystal%2520structures%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D9750%26epage%3D9755%26doi%3D10.1073%2Fpnas.1633804100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Wafford, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B.</span><span> </span><span class="NLM_article-title">Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span><span class="refDoi"> DOI: 10.1038/nrd2464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd2464" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=530-540&author=K.+A.+Waffordauthor=B.+Ebert&title=Emerging+anti-insomnia+drugs%3A+tackling+sleeplessness+and+the+quality+of+wake+time&doi=10.1038%2Fnrd2464"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnrd2464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2464%26sid%3Dliteratum%253Aachs%26aulast%3DWafford%26aufirst%3DK.%2BA.%26aulast%3DEbert%26aufirst%3DB.%26atitle%3DEmerging%2520anti-insomnia%2520drugs%253A%2520tackling%2520sleeplessness%2520and%2520the%2520quality%2520of%2520wake%2520time%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D530%26epage%3D540%26doi%3D10.1038%2Fnrd2464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Lavedan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentile, A. J.</span><span> </span><span class="NLM_article-title">Tasimelteon: a selective and unique receptor binding profile</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.neuropharm.2014.12.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2015&pages=142-147&author=C.+Lavedanauthor=M.+Forsbergauthor=A.+J.+Gentile&title=Tasimelteon%3A+a+selective+and+unique+receptor+binding+profile&doi=10.1016%2Fj.neuropharm.2014.12.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DLavedan%26aufirst%3DC.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DGentile%26aufirst%3DA.%2BJ.%26atitle%3DTasimelteon%253A%2520a%2520selective%2520and%2520unique%2520receptor%2520binding%2520profile%26jtitle%3DNeuropharmacology%26date%3D2015%26volume%3D91%26spage%3D142%26epage%3D147%26doi%3D10.1016%2Fj.neuropharm.2014.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamantini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Giacomo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamba, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannacci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spadoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span> </span><span class="NLM_article-title">Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3383</span><span class="NLM_x">–</span> <span class="NLM_lpage">3391</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.12.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmc.2005.12.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3383-3391&author=S.+Rivaraauthor=G.+Diamantiniauthor=B.+Di+Giacomoauthor=D.+Lambaauthor=G.+Gattiauthor=V.+Luciniauthor=M.+Pannacciauthor=M.+Morauthor=G.+Spadoniauthor=G.+Tarzia&title=Reassessing+the+melatonin+pharmacophore%2D%2Denantiomeric+resolution%2C+pharmacological+activity%2C+structure+analysis%2C+and+molecular+modeling+of+a+constrained+chiral+melatonin+analogue&doi=10.1016%2Fj.bmc.2005.12.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.12.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.12.053%26sid%3Dliteratum%253Aachs%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DDiamantini%26aufirst%3DG.%26aulast%3DDi%2BGiacomo%26aufirst%3DB.%26aulast%3DLamba%26aufirst%3DD.%26aulast%3DGatti%26aufirst%3DG.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DPannacci%26aufirst%3DM.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DSpadoni%26aufirst%3DG.%26aulast%3DTarzia%26aufirst%3DG.%26atitle%3DReassessing%2520the%2520melatonin%2520pharmacophore--enantiomeric%2520resolution%252C%2520pharmacological%2520activity%252C%2520structure%2520analysis%252C%2520and%2520molecular%2520modeling%2520of%2520a%2520constrained%2520chiral%2520melatonin%2520analogue%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3383%26epage%3D3391%26doi%3D10.1016%2Fj.bmc.2005.12.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title">N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span> <span class="citation_source-journal">Psychopharmacology (Berl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.1007/s00213-005-2199-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2Fs00213-005-2199-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15761697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2005&pages=30-53&author=M.+J.+Millan&title=N-Methyl-D-aspartate+receptors+as+a+target+for+improved+antipsychotic+agents%3A+novel+insights+and+clinical+perspectives&doi=10.1007%2Fs00213-005-2199-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-53</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Activation of "co-agonist" N-methyl-d-aspartate (NMDA) and GlycineB sites is mandatory for the operation of NMDA receptors, which play an important role in the control of mood, cognition, and motor function.  This article outlines the complex regulation of activity at GlycineB/NMDA receptors by multiple classes of endogenous ligand.  It also summarizes the evidence that a hypoactivity of GlycineB/NMDA receptors contributes to the pathogenesis of psychotic states, and that drugs which enhance activity at these sites may possess antipsychotic properties.  Polymorphisms in several genes known to interact with NMDA receptors are related to an altered risk for schizophrenia, and psychotic patients display changes in levels of mRNA encoding NMDA receptors, including the NR1 subunit on which GlycineB sites are located.  Schizophrenia is also assocd. with an overall decrease in activity of endogenous agonists at GlycineB/NMDA sites, whereas levels of endogenous antagonists are elevated.  NMDA receptor "open channel blockers," such as phencyclidine, are psychotomimetic in man and in rodents, and antipsychotic agents attenuate certain of their effects.  Moreover, mice with genetically invalidated GlycineB/NMDA receptors reveal similar changes in behavior.  Finally, in initial clin. studies, GlycineB agonists and inhibitors of Gly reuptake were found to potentiate the ability of "conventional" antipsychotics to improve neg. and, albeit modestly, cognitive and pos. symptoms.  In contrast, therapeutic effects of clozapine are not reinforced, likely since clozapine itself enhances activity at NMDA receptors.  Reduced activity at NMDA receptors is implicated in the etiol. of schizophrenia.  Correspondingly, drugs that (directly or indirectly) increase activity at GlycineB sites may be of use as adjuncts to other classes of antipsychotic agent.  However, there is an urgent need for broader clin. evaluation of this possibility, and, to date, there is no evidence that stimulation of GlycineB sites alone improves psychotic states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrik4YrYY-zS7Vg90H21EOLACvtfcHk0li1Fm05Aa3RNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D&md5=08bfcddb54b062d8ec9c0f1294984608</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-2199-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-2199-1%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DN-Methyl-D-aspartate%2520receptors%2520as%2520a%2520target%2520for%2520improved%2520antipsychotic%2520agents%253A%2520novel%2520insights%2520and%2520clinical%2520perspectives%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2005%26volume%3D179%26spage%3D30%26epage%3D53%26doi%3D10.1007%2Fs00213-005-2199-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Zafra, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomeza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aragon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimenez, C.</span><span> </span><span class="NLM_article-title">Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1342</span><span class="NLM_x">–</span> <span class="NLM_lpage">1352</span><span class="refDoi"> DOI: 10.1111/j.1460-9568.1995.tb01125.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1111%2Fj.1460-9568.1995.tb01125.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=7582108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A280%3ADyaK28%252FntlansQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1995&pages=1342-1352&author=F.+Zafraauthor=J.+Gomezaauthor=L.+Olivaresauthor=C.+Aragonauthor=C.+Gimenez&title=Regional+distribution+and+developmental+variation+of+the+glycine+transporters+GLYT1+and+GLYT2+in+the+rat+CNS&doi=10.1111%2Fj.1460-9568.1995.tb01125.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS</span></div><div class="casAuthors">Zafra F; Gomeza J; Olivares L; Aragon C; Gimenez C</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1342-52</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">The high-affinity glycine transporter in neurons and glial cells is the primary means of inactivating synaptic glycine.  Previous molecular cloning studies have indicated heterogeneity of glycine transporters in the CNS.  Here the distribution of glycine transporter GLYT1 and GLYT2 transcripts and proteins in different regions and developmental stages of the rat brain were analysed by Northern, Western and in situ hybridization techniques.  Sequence-specific riboprobes and two specific antibodies raised against fusion proteins were used, containing either 76 or 193 amino acids of the C or N terminus of the GLYT1 and GLYT2 transporters respectively.  High levels of GLYT1 transcripts were found in the spinal cord, brainstem and cerebellum, and moderate levels in forebrain regions such as the cortex or hippocampus.  GLYT2 transcripts are restricted to the spinal cord, brainstem and cerebellum.  The onset of both GLYT1 and GLYT2 expression in the brainstem occurred in late fetal life, and full expression of these proteins was observed before weaning.  There was a stepwise increase in the levels of mRNA and protein for these two transporters, reaching a maximum by the second postnatal week, followed by a slight decrease until adult values were reached by the fourth postnatal week.  These data reveal interesting parallelism between the distribution of different glycine transporters and glycine receptor subunits, and suggest discrete roles for distinct glycine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDFJVKKstoSBwLZxei1HN8fW6udTcc2eadeseyv69FNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FntlansQ%253D%253D&md5=92d70c6c51655791493852bda8b4e1ef</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.1995.tb01125.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.1995.tb01125.x%26sid%3Dliteratum%253Aachs%26aulast%3DZafra%26aufirst%3DF.%26aulast%3DGomeza%26aufirst%3DJ.%26aulast%3DOlivares%26aufirst%3DL.%26aulast%3DAragon%26aufirst%3DC.%26aulast%3DGimenez%26aufirst%3DC.%26atitle%3DRegional%2520distribution%2520and%2520developmental%2520variation%2520of%2520the%2520glycine%2520transporters%2520GLYT1%2520and%2520GLYT2%2520in%2520the%2520rat%2520CNS%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D1995%26volume%3D7%26spage%3D1342%26epage%3D1352%26doi%3D10.1111%2Fj.1460-9568.1995.tb01125.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Harvey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, B. K.</span><span> </span><span class="NLM_article-title">Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1038/nrd3893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd3893" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=866-885&author=R.+J.+Harveyauthor=B.+K.+Yee&title=Glycine+transporters+as+novel+therapeutic+targets+in+schizophrenia%2C+alcohol+dependence+and+pain&doi=10.1038%2Fnrd3893"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnrd3893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3893%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DR.%2BJ.%26aulast%3DYee%26aufirst%3DB.%2BK.%26atitle%3DGlycine%2520transporters%2520as%2520novel%2520therapeutic%2520targets%2520in%2520schizophrenia%252C%2520alcohol%2520dependence%2520and%2520pain%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D866%26epage%3D885%26doi%3D10.1038%2Fnrd3893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Blackaby, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Street, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guscott, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamill, T. G.</span><span> </span><span class="NLM_article-title">Identification of an orally bioavailable, potent, and selective inhibitor of GlyT1</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1021/ml1001085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1001085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=350-354&author=W.+P.+Blackabyauthor=R.+T.+Lewisauthor=J.+L.+Thomsonauthor=A.+S.+Jenningsauthor=S.+C.+Goodacreauthor=L.+J.+Streetauthor=A.+M.+MacLeodauthor=A.+Pikeauthor=S.+Woodauthor=S.+Thomasauthor=T.+A.+Brownauthor=A.+Smithauthor=G.+Pillaiauthor=S.+Almondauthor=M.+R.+Guscottauthor=H.+D.+Burnsauthor=W.+Engauthor=C.+Ryanauthor=J.+Cookauthor=T.+G.+Hamill&title=Identification+of+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+GlyT1&doi=10.1021%2Fml1001085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fml1001085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001085%26sid%3Dliteratum%253Aachs%26aulast%3DBlackaby%26aufirst%3DW.%2BP.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DThomson%26aufirst%3DJ.%2BL.%26aulast%3DJennings%26aufirst%3DA.%2BS.%26aulast%3DGoodacre%26aufirst%3DS.%2BC.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DPillai%26aufirst%3DG.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DGuscott%26aufirst%3DM.%2BR.%26aulast%3DBurns%26aufirst%3DH.%2BD.%26aulast%3DEng%26aufirst%3DW.%26aulast%3DRyan%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DHamill%26aufirst%3DT.%2BG.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520GlyT1%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D350%26epage%3D354%26doi%3D10.1021%2Fml1001085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Spooren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riemer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H.</span><span> </span><span class="NLM_article-title">Opinion: NK3 receptor antagonists: the next generation of antipsychotics?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">975</span><span class="refDoi"> DOI: 10.1038/nrd1905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd1905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=967-975&author=W.+Spoorenauthor=C.+Riemerauthor=H.+Meltzer&title=Opinion%3A+NK3+receptor+antagonists%3A+the+next+generation+of+antipsychotics%3F&doi=10.1038%2Fnrd1905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnrd1905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1905%26sid%3Dliteratum%253Aachs%26aulast%3DSpooren%26aufirst%3DW.%26aulast%3DRiemer%26aufirst%3DC.%26aulast%3DMeltzer%26aufirst%3DH.%26atitle%3DOpinion%253A%2520NK3%2520receptor%2520antagonists%253A%2520the%2520next%2520generation%2520of%2520antipsychotics%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D967%26epage%3D975%26doi%3D10.1038%2Fnrd1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legos, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitmore, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barone, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span> </span><span class="NLM_article-title">Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10992004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1yns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=373-381&author=H.+M.+Sarauauthor=D.+E.+Griswoldauthor=B.+Bushauthor=W.+Pottsauthor=P.+Sandhuauthor=D.+Lundbergauthor=J.+J.+Foleyauthor=D.+B.+Schmidtauthor=E.+F.+Webbauthor=L.+D.+Martinauthor=J.+J.+Legosauthor=R.+G.+Whitmoreauthor=F.+C.+Baroneauthor=A.+D.+Medhurstauthor=M.+A.+Luttmannauthor=G.+A.+Giardinaauthor=D.+W.+Hay&title=Nonpeptide+tachykinin+receptor+antagonists.+II.+Pharmacological+and+pharmacokinetic+profile+of+SB-222200%2C+a+central+nervous+system+penetrant%2C+potent+and+selective+NK-3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist</span></div><div class="casAuthors">Sarau, Henry M.; Griswold, Don E.; Bush, Brian; Potts, William; Sandhu, Punam; Lundberg, Dave; Foley, James J.; Schmidt, Dulcie B.; Webb, Edward F.; Martin, Lenox D.; Legos, Jeffrey J.; Whitmore, Robert G.; Barone, Frank C.; Medhurst, Andrew D.; Luttmann, Mark A.; Giardina, Giuseppe A. M.; Hay, Douglas W. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">373-381</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(α-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide], a human NK-3 receptor (hNK-3R) antagonist, was detd.  SB-222200 inhibited 125I-[MePhe7]neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a Ki = 4.4 nM and antagonized NKB-induced Ca2+ mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC50 = 18.4 nM.  SB-222200 was selective for hNK-3 receptors compared with hNK-1 (Ki > 100,000 nM) and hNK-2 receptors (Ki = 250 nM).  In HEK 293 cells transiently expressing murine NK-3 receptors (HEK 293-mNK-3R), SB-222200 inhibited binding of 125I-[MePhe7]NKB (Ki = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC50 = 265 nM).  In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED50 values of approx. 5 mg/kg.  SB-222200 effectively crossed the blood-brain barrier in the mouse and rat.  The inhibitory effect of SB-222200 against senktide-induced behavioral responses in the mouse correlated significantly with brain, but not plasma, concns. of the compd.  Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concns. (Cmax = about 400 ng/mL) and bioavailability of 46%.  The preclin. profile of SB-222200, demonstrating high affinity, selectivity, reversibility, oral activity, and central nervous system penetration, suggests that it will be a useful tool compd. to define the physiol. and pathophysiol. roles of NK-3 receptors, in particular in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4JZQOhE9yRbVg90H21EOLACvtfcHk0lgQwvBS84ZpcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1yns70%253D&md5=e6527a2b05e366ed5d82245451e316b0</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DBush%26aufirst%3DB.%26aulast%3DPotts%26aufirst%3DW.%26aulast%3DSandhu%26aufirst%3DP.%26aulast%3DLundberg%26aufirst%3DD.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DLegos%26aufirst%3DJ.%2BJ.%26aulast%3DWhitmore%26aufirst%3DR.%2BG.%26aulast%3DBarone%26aufirst%3DF.%2BC.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DHay%26aufirst%3DD.%2BW.%26atitle%3DNonpeptide%2520tachykinin%2520receptor%2520antagonists.%2520II.%2520Pharmacological%2520and%2520pharmacokinetic%2520profile%2520of%2520SB-222200%252C%2520a%2520central%2520nervous%2520system%2520penetrant%252C%2520potent%2520and%2520selective%2520NK-3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D373%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmead, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Flor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluderay, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murkitt, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. W.</span><span> </span><span class="NLM_article-title">In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">627</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2009.10.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.ejphar.2009.10.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19879867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=627&publication_year=2010&pages=106-114&author=L.+A.+Dawsonauthor=C.+J.+Langmeadauthor=A.+Dadaauthor=J.+M.+Watsonauthor=Z.+Wuauthor=R.+de+la+Florauthor=G.+A.+Jonesauthor=J.+E.+Cluderayauthor=E.+Southamauthor=G.+S.+Murkittauthor=M.+D.+Hillauthor=D.+N.+Jonesauthor=C.+H.+Daviesauthor=J.+J.+Haganauthor=P.+W.+Smith&title=In+vitro+and+in+vivo+comparison+of+two+non-peptide+tachykinin+NK3+receptor+antagonists%3A+improvements+in+efficacy+achieved+through+enhanced+brain+penetration+or+altered+pharmacological+characteristics&doi=10.1016%2Fj.ejphar.2009.10.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics</span></div><div class="casAuthors">Dawson, Lee A.; Langmead, Christopher J.; Dada, Adeshola; Watson, Jeannette M.; Wu, Zining; de la Flor, Raul; Jones, Gareth A.; Cluderay, Jane E.; Southam, Eric; Murkitt, Graham S.; Hill, Mark D.; Jones, Declan N. C.; Davies, Ceri H.; Hagan, Jim J.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">627</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">106-114</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Clin. evaluation of tachykinin NK3 receptor antagonists has provided support for the therapeutic utility of this target in schizophrenia.  However, these studies have not been entirely conclusive, possibly because of the pharmacokinetic limitations of these mols.  In the search for tachykinin NK3 receptor antagonists with improved properties, we have discovered GSK172981 and GSK256471.  Both compds. demonstrated high affinity for recombinant human (pKi values 7.7 and 8.9, resp.) and native guinea pig (pKi values 7.8 and 8.4, resp.) tachykinin NK3 receptors.  In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA2 = 7.2) at cloned human tachykinin NK3 receptor whereas GSK256471 diminished the neurokinin B-induced E max response, indicative of non-surmountable antagonist pharmacol. (pA2 = 9.2).  GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pKB = 8.1), while GSK256471 abolished the agonist-induced response.  Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK3 receptor occupancy in medial prefrontal cortex (ED50 values of 0.8 and 0.9 mg/kg, i.p., resp.) and the dose-dependent attenuation of agonist-induced "wet dog shake" behaviors in guinea pigs.  Finally, in vivo microdialysis studies demonstrated that acute GSK172981 (30 mg/kg, i.p.) and GSK256471 (1 mg/kg, i.p.) attenuated haloperidol-induced increases in extracellular dopamine in the guinea pig nucleus accumbens.  Taken together, these in vitro and in vivo characterisations of the tachykinin NK3 receptor antagonists GSK172981 and GSK256471 support their potential utility in the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_w2uZctUt4rVg90H21EOLACvtfcHk0lhzpYj4eox51w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVahtA%253D%253D&md5=02869117d79be9afe983ab3614423a7b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.10.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.10.054%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DDada%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3Dde%2Bla%2BFlor%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DG.%2BA.%26aulast%3DCluderay%26aufirst%3DJ.%2BE.%26aulast%3DSoutham%26aufirst%3DE.%26aulast%3DMurkitt%26aufirst%3DG.%2BS.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BN.%26aulast%3DDavies%26aufirst%3DC.%2BH.%26aulast%3DHagan%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520comparison%2520of%2520two%2520non-peptide%2520tachykinin%2520NK3%2520receptor%2520antagonists%253A%2520improvements%2520in%2520efficacy%2520achieved%2520through%2520enhanced%2520brain%2520penetration%2520or%2520altered%2520pharmacological%2520characteristics%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D627%26spage%3D106%26epage%3D114%26doi%3D10.1016%2Fj.ejphar.2009.10.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Yan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuck, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tory, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauley, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashler, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratman, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parodi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrikson, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span> </span><span class="NLM_article-title">Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">402</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1038/990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2F990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10591213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=1999&pages=533-537&author=R.+Yanauthor=M.+J.+Bienkowskiauthor=M.+E.+Shuckauthor=H.+Miaoauthor=M.+C.+Toryauthor=A.+M.+Pauleyauthor=J.+R.+Brashlerauthor=N.+C.+Stratmanauthor=W.+R.+Mathewsauthor=A.+E.+Buhlauthor=D.+B.+Carterauthor=A.+G.+Tomasselliauthor=L.+A.+Parodiauthor=R.+L.+Heinriksonauthor=M.+E.+Gurney&title=Membrane-anchored+aspartyl+protease+with+Alzheimer%E2%80%99s+disease+beta-secretase+activity&doi=10.1038%2F990107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity</span></div><div class="casAuthors">Yan, Riqiang; Bienkowski, Michael J.; Shuck, Mary E.; Miao, Huiyi; Tory, Monica C.; Pauley, Adele M.; Brashler, John R.; Stratman, Nancy C.; Mathews, W. Rodney; Buhl, Allen E.; Carter, Donald B.; Tomasselli, Alfredo G.; Parodi, Luis A.; Heinrikson, Robert L.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">6761</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Mutations in the gene encoding the amyloid protein precursor (APP) cause autosomal dominant Alzheimer's disease.  Cleavage of APP by unidentified proteases, referred to as β- and γ-secretases, generates the amyloid β-peptide, the main component of the amyloid plaques found in Alzheimer's disease patients.  The disease-causing mutations flank the protease cleavage sites in APP and facilitate its cleavage.  Here the authors identify a new membrane-bound aspartyl protease (Asp2) with β-secretase activity.  The Asp2 gene is expressed widely in brain and other tissues.  Decreasing the expression of Asp2 in cells reduces amyloid β-peptide prodn. and blocks the accumulation of the carboxy-terminal APP fragment that is created by β-secretase cleavage.  Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the β-secretase site, and the rate of cleavage is increased tenfold by a mutation assocd. with early-onset Alzheimer's disease in Sweden.  Thus, Asp2 is a new protein target for drugs that are designed to block the prodn. of amyloid β-peptide peptide and the consequent formation of amyloid plaque in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6iE74jtk5LVg90H21EOLACvtfcHk0lhzpYj4eox51w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D&md5=96af7cd9b7c3315de029937497f04616</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2F990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F990107%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DBienkowski%26aufirst%3DM.%2BJ.%26aulast%3DShuck%26aufirst%3DM.%2BE.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DTory%26aufirst%3DM.%2BC.%26aulast%3DPauley%26aufirst%3DA.%2BM.%26aulast%3DBrashler%26aufirst%3DJ.%2BR.%26aulast%3DStratman%26aufirst%3DN.%2BC.%26aulast%3DMathews%26aufirst%3DW.%2BR.%26aulast%3DBuhl%26aufirst%3DA.%2BE.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DParodi%26aufirst%3DL.%2BA.%26aulast%3DHeinrikson%26aufirst%3DR.%2BL.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DMembrane-anchored%2520aspartyl%2520protease%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%2520beta-secretase%2520activity%26jtitle%3DNature%26date%3D1999%26volume%3D402%26spage%3D533%26epage%3D537%26doi%3D10.1038%2F990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Cumming, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misiaszek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iserloh, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voigt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuvelkar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favreau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czarniecki, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKittrick, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span> </span><span class="NLM_article-title">Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2444</span><span class="NLM_x">–</span> <span class="NLM_lpage">2449</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2012.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22390835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2444-2449&author=J.+N.+Cummingauthor=E.+M.+Smithauthor=L.+Wangauthor=J.+Misiaszekauthor=J.+Durkinauthor=J.+Panauthor=U.+Iserlohauthor=Y.+Wuauthor=Z.+Zhuauthor=C.+Stricklandauthor=J.+Voigtauthor=X.+Chenauthor=M.+E.+Kennedyauthor=R.+Kuvelkarauthor=L.+A.+Hydeauthor=K.+Coxauthor=L.+Favreauauthor=M.+F.+Czarnieckiauthor=W.+J.+Greenleeauthor=B.+A.+McKittrickauthor=E.+M.+Parkerauthor=A.+W.+Stamford&title=Structure+based+design+of+iminohydantoin+BACE1+inhibitors%3A+identification+of+an+orally+available%2C+centrally+active+BACE1+inhibitor&doi=10.1016%2Fj.bmcl.2012.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor</span></div><div class="casAuthors">Cumming, Jared N.; Smith, Elizabeth M.; Wang, Lingyan; Misiaszek, Jeffrey; Durkin, James; Pan, Jianping; Iserloh, Ulrich; Wu, Yusheng; Zhu, Zhaoning; Strickland, Corey; Voigt, Johannes; Chen, Xia; Kennedy, Matthew E.; Kuvelkar, Reshma; Hyde, Lynn A.; Cox, Kathleen; Favreau, Leonard; Czarniecki, Michael F.; Greenlee, William J.; McKittrick, Brian A.; Parker, Eric M.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2444-2449</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">From an initial lead 2-imino-1-methyl-4,4-diphenyl-5-imidazolidinone, a structure-based design approach led to identification of the novel, high-affinity iminohydantoin BACE1 inhibitor I that lowers CNS-derived Aβ following oral administration to rats.  SAR development in the S3 and F' subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for I are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tWBE09QKNLVg90H21EOLACvtfcHk0ljbDYO5ekGm4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D&md5=783b6cb9a6d9608ff5e9dc4f5d634397</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DSmith%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DDurkin%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DCzarniecki%26aufirst%3DM.%2BF.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DStructure%2520based%2520design%2520of%2520iminohydantoin%2520BACE1%2520inhibitors%253A%2520identification%2520of%2520an%2520orally%2520available%252C%2520centrally%2520active%2520BACE1%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2444%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2012.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Garofalo, A. W.</span><span> </span><span class="NLM_article-title">Patents targeting gamma-secretase inhibition and modulation for the treatment of Alzheimer’s disease: 2004–2008</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span><span class="refDoi"> DOI: 10.1517/13543776.18.7.693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1517%2F13543776.18.7.693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlGgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=693-703&author=A.+W.+Garofalo&title=Patents+targeting+gamma-secretase+inhibition+and+modulation+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+2004%E2%80%932008&doi=10.1517%2F13543776.18.7.693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Patents targeting γ-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004 - 2008</span></div><div class="casAuthors">Garofalo, Albert W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">693-703</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Although Alzheimer's disease has been defined for over a century, at present there is no effective treatment.  Amyloid deposition and plaque formation are widely believed to contribute to the pathol. of the disease.  As the etiol. of plaque formation has become better understood, the search for therapies has bred small mols. capable of inhibiting or regulating the activity of γ-secretase.  This paper reviews patents from the past 4 years claiming modulators or inhibitors of γ-secretase as a treatment for Alzheimer's disease.  One or two compds. from each patent were selected to represent the claimed chem. space.  Compd. selection was influenced by literature accounts, which are also discussed.  Although an attempt has been made to include major contributions in the field, the list of patents reviewed should not be considered exhaustive.  This review seeks to expand upon a previous review covering patents from 2000-2004.  Since then there has been an increase in the no. of structural and mechanistic approaches being pursued and several compds. have entered the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptzyUbNbn4uLVg90H21EOLACvtfcHk0ljbDYO5ekGm4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlGgu78%253D&md5=a26891676fdd05b0b3c2501824ced28f</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.7.693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.7.693%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%2BW.%26atitle%3DPatents%2520targeting%2520gamma-secretase%2520inhibition%2520and%2520modulation%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%25202004%25E2%2580%25932008%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D693%26epage%3D703%26doi%3D10.1517%2F13543776.18.7.693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Josien, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clader, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favreau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6032</span><span class="NLM_x">–</span> <span class="NLM_lpage">6037</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2009.09.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6032-6037&author=H.+Josienauthor=T.+Baraauthor=M.+Rajagopalanauthor=J.+W.+Claderauthor=W.+J.+Greenleeauthor=L.+Favreauauthor=L.+A.+Hydeauthor=A.+A.+Nomeirauthor=E.+M.+Parkerauthor=L.+Songauthor=L.+Zhangauthor=Q.+Zhang&title=Novel+orally+active+morpholine+N-arylsulfonamides+gamma-secretase+inhibitors+with+low+CYP+3A4+liability&doi=10.1016%2Fj.bmcl.2009.09.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.055%26sid%3Dliteratum%253Aachs%26aulast%3DJosien%26aufirst%3DH.%26aulast%3DBara%26aufirst%3DT.%26aulast%3DRajagopalan%26aufirst%3DM.%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DNovel%2520orally%2520active%2520morpholine%2520N-arylsulfonamides%2520gamma-secretase%2520inhibitors%2520with%2520low%2520CYP%25203A4%2520liability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6032%26epage%3D6037%26doi%3D10.1016%2Fj.bmcl.2009.09.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Grosveld, G. C.</span><span> </span><span class="NLM_article-title">Gamma-secretase inhibitors: notch so bad</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1038/nm0109-20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnm0109-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19129776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1Oqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=20-21&author=G.+C.+Grosveld&title=Gamma-secretase+inhibitors%3A+notch+so+bad&doi=10.1038%2Fnm0109-20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">γ-secretase inhibitors: Notch so bad</span></div><div class="casAuthors">Grosveld, Gerard C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-21</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  γ-Secretase inhibitors inhibit Notch, a transmembrane receptor that drives many cases of T cell acute lymphoblastic leukemia - but there are safety concerns with such drugs.  Combining these inhibitors with glucocorticoids could provide a more effective and safer approach (pages 50-58).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLPK5315EjbVg90H21EOLACvtfcHk0ljbDYO5ekGm4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1Oqtg%253D%253D&md5=5c681c9ba6ce540e935386a264b1c785</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fnm0109-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0109-20%26sid%3Dliteratum%253Aachs%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26atitle%3DGamma-secretase%2520inhibitors%253A%2520notch%2520so%2520bad%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D20%26epage%3D21%26doi%3D10.1038%2Fnm0109-20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Taly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corringer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestage, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changeux, J. P.</span><span> </span><span class="NLM_article-title">Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1038/nrd2927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd2927" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=733-750&author=A.+Talyauthor=P.+J.+Corringerauthor=D.+Guedinauthor=P.+Lestageauthor=J.+P.+Changeux&title=Nicotinic+receptors%3A+allosteric+transitions+and+therapeutic+targets+in+the+nervous+system&doi=10.1038%2Fnrd2927"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1038%2Fnrd2927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2927%26sid%3Dliteratum%253Aachs%26aulast%3DTaly%26aufirst%3DA.%26aulast%3DCorringer%26aufirst%3DP.%2BJ.%26aulast%3DGuedin%26aufirst%3DD.%26aulast%3DLestage%26aufirst%3DP.%26aulast%3DChangeux%26aufirst%3DJ.%2BP.%26atitle%3DNicotinic%2520receptors%253A%2520allosteric%2520transitions%2520and%2520therapeutic%2520targets%2520in%2520the%2520nervous%2520system%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D733%26epage%3D750%26doi%3D10.1038%2Fnrd2927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Gotti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clementi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fornari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaimarri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiducci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfredi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrazzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoli, M.</span><span> </span><span class="NLM_article-title">Structural and functional diversity of native brain neuronal nicotinic receptors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">703</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.1016/j.bcp.2009.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bcp.2009.05.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=703-711&author=C.+Gottiauthor=F.+Clementiauthor=A.+Fornariauthor=A.+Gaimarriauthor=S.+Guiducciauthor=I.+Manfrediauthor=M.+Morettiauthor=P.+Pedrazziauthor=L.+Pucciauthor=M.+Zoli&title=Structural+and+functional+diversity+of+native+brain+neuronal+nicotinic+receptors&doi=10.1016%2Fj.bcp.2009.05.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2009.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2009.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DGotti%26aufirst%3DC.%26aulast%3DClementi%26aufirst%3DF.%26aulast%3DFornari%26aufirst%3DA.%26aulast%3DGaimarri%26aufirst%3DA.%26aulast%3DGuiducci%26aufirst%3DS.%26aulast%3DManfredi%26aufirst%3DI.%26aulast%3DMoretti%26aufirst%3DM.%26aulast%3DPedrazzi%26aufirst%3DP.%26aulast%3DPucci%26aufirst%3DL.%26aulast%3DZoli%26aufirst%3DM.%26atitle%3DStructural%2520and%2520functional%2520diversity%2520of%2520native%2520brain%2520neuronal%2520nicotinic%2520receptors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D78%26spage%3D703%26epage%3D711%26doi%3D10.1016%2Fj.bcp.2009.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuckmantel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajjuri, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedolak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghavami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Chemistry and behavioral studies identify chiral cyclopropanes as selective alpha4beta2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.1021/jm201157c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201157c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=717-724&author=H.+Zhangauthor=W.+Tuckmantelauthor=J.+B.+Eatonauthor=P.+W.+Yuenauthor=L.+F.+Yuauthor=K.+M.+Bajjuriauthor=A.+Fedolakauthor=D.+Wangauthor=A.+Ghavamiauthor=B.+Caldaroneauthor=N.+E.+Patersonauthor=D.+A.+Loweauthor=D.+Brunnerauthor=R.+J.+Lukasauthor=A.+P.+Kozikowski&title=Chemistry+and+behavioral+studies+identify+chiral+cyclopropanes+as+selective+alpha4beta2-nicotinic+acetylcholine+receptor+partial+agonists+exhibiting+an+antidepressant+profile&doi=10.1021%2Fjm201157c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm201157c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201157c%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DTuckmantel%26aufirst%3DW.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DBajjuri%26aufirst%3DK.%2BM.%26aulast%3DFedolak%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGhavami%26aufirst%3DA.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DPaterson%26aufirst%3DN.%2BE.%26aulast%3DLowe%26aufirst%3DD.%2BA.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DChemistry%2520and%2520behavioral%2520studies%2520identify%2520chiral%2520cyclopropanes%2520as%2520selective%2520alpha4beta2-nicotinic%2520acetylcholine%2520receptor%2520partial%2520agonists%2520exhibiting%2520an%2520antidepressant%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D717%26epage%3D724%26doi%3D10.1021%2Fjm201157c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajjuri, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chellappan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karadi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manzano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span> </span><span class="NLM_article-title">Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1279</span><span class="NLM_x">–</span> <span class="NLM_lpage">1291</span><span class="refDoi"> DOI: 10.1002/cmdc.200900079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fcmdc.200900079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1279-1291&author=A.+P.+Kozikowskiauthor=J.+B.+Eatonauthor=K.+M.+Bajjuriauthor=S.+K.+Chellappanauthor=Y.+Chenauthor=S.+Karadiauthor=R.+Heauthor=B.+Caldaroneauthor=M.+Manzanoauthor=P.+W.+Yuenauthor=R.+J.+Lukas&title=Chemistry+and+pharmacology+of+nicotinic+ligands+based+on+6-%5B5-%28azetidin-2-ylmethoxy%29pyridin-3-yl%5Dhex-5-yn-1-ol+%28AMOP-H-OH%29+for+possible+use+in+depression&doi=10.1002%2Fcmdc.200900079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900079%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DBajjuri%26aufirst%3DK.%2BM.%26aulast%3DChellappan%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKaradi%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DManzano%26aufirst%3DM.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26atitle%3DChemistry%2520and%2520pharmacology%2520of%2520nicotinic%2520ligands%2520based%2520on%25206-%255B5-%2528azetidin-2-ylmethoxy%2529pyridin-3-yl%255Dhex-5-yn-1-ol%2520%2528AMOP-H-OH%2529%2520for%2520possible%2520use%2520in%2520depression%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1279%26epage%3D1291%26doi%3D10.1002%2Fcmdc.200900079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Turner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellano, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blendy, J. A.</span><span> </span><span class="NLM_article-title">Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1124/jpet.110.166280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1124%2Fjpet.110.166280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20435920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=665-672&author=J.+R.+Turnerauthor=L.+M.+Castellanoauthor=J.+A.+Blendy&title=Nicotinic+partial+agonists+varenicline+and+sazetidine-A+have+differential+effects+on+affective+behavior&doi=10.1124%2Fjpet.110.166280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior</span></div><div class="casAuthors">Turner, Jill R.; Castellano, Laura M.; Blendy, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clin. and preclin. studies suggest that nicotinic acetylcholine receptors are involved in affective disorders; therefore, the potential therapeutic value of nicotinic partial agonists as treatments of these disorders is of growing interest.  This study evaluated the effects of acute and chronic administration of nicotine and the α4β2 nicotinic partial agonists varenicline and sazetidine-A in mouse models of anxiety and depression.  Acutely, only nicotine and varenicline had anxiolytic effects in the marble-burying test and in the novelty-induced hypophagia (NIH) test.  In contrast, in animal models of antidepressant efficacy, such as the forced swim and the tail suspension test, only acute sazetidine-A had significant antidepressant-like effects.  The NIH test provides an anxiety-related measure that is sensitive to the effects of chronic but not acute antidepressant treatment.  Chronic nicotine and chronic sazetidine-A treatment were effective in this paradigm, but varenicline was ineffective.  These results suggest that the partial agonists varenicline and sazetidine-A may have diverse therapeutic benefits in affective disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogo1Sj2UHr5bVg90H21EOLACvtfcHk0lgkytzGElCvCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kisb%252FE&md5=79c7a0573c7aea5e0bb72ab5d5a4e05d</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.166280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.166280%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DJ.%2BR.%26aulast%3DCastellano%26aufirst%3DL.%2BM.%26aulast%3DBlendy%26aufirst%3DJ.%2BA.%26atitle%3DNicotinic%2520partial%2520agonists%2520varenicline%2520and%2520sazetidine-A%2520have%2520differential%2520effects%2520on%2520affective%2520behavior%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D665%26epage%3D672%26doi%3D10.1124%2Fjpet.110.166280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Zhang, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nys, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzolari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Elk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanania, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabath, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedolak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Insights into the structural determinants required for high-affinity binding of chiral cyclopropane-containing ligands to alpha4beta2-nicotinic acetylcholine receptors: an integrated approach to behaviorally active nicotinic ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8028</span><span class="NLM_x">–</span> <span class="NLM_lpage">8037</span><span class="refDoi"> DOI: 10.1021/jm3008739</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008739" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yhsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8028-8037&author=H.+K.+Zhangauthor=J.+B.+Eatonauthor=L.+F.+Yuauthor=M.+Nysauthor=A.+Mazzolariauthor=R.+van+Elkauthor=A.+B.+Smitauthor=V.+Alexandrovauthor=T.+Hananiaauthor=E.+Sabathauthor=A.+Fedolakauthor=D.+Brunnerauthor=R.+J.+Lukasauthor=G.+Vistoliauthor=C.+Ulensauthor=A.+P.+Kozikowski&title=Insights+into+the+structural+determinants+required+for+high-affinity+binding+of+chiral+cyclopropane-containing+ligands+to+alpha4beta2-nicotinic+acetylcholine+receptors%3A+an+integrated+approach+to+behaviorally+active+nicotinic+ligands&doi=10.1021%2Fjm3008739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Structural Determinants Required for High-Affinity Binding of Chiral Cyclopropane-Containing Ligands to α4β2-Nicotinic Acetylcholine Receptors: An Integrated Approach to Behaviorally Active Nicotinic Ligands</span></div><div class="casAuthors">Zhang, Han-Kun; Eaton, J. Brek; Yu, Li-Fang; Nys, Mieke; Mazzolari, Angelica; van Elk, Rene; Smit, August B.; Alexandrov, Vadim; Hanania, Taleen; Sabath, Emily; Fedolak, Allison; Brunner, Daniela; Lukas, Ronald J.; Vistoli, Giulio; Ulens, Chris; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8028-8037</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design can potentially accelerate the development of new therapeutics.  In this study, a cocrystal structure of the acetylcholine binding protein (AChBP) from Capitella teleta (Ct) in complex with a cyclopropane-contg. selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonist (compd. 5) was acquired.  The structural determinants required for ligand binding obtained from this AChBP X-ray structure were used to refine a previous model of the human α4β2-nAChR, thus possibly providing a better understanding of the structure of the human receptor.  To validate the potential application of the structure of the Ct-AChBP in the engineering of new α4β2-nAChR ligands, homol. modeling methods, combined with in silico ADME calcns., were used to design analogs of compd. 5.  The most promising compd., 12, exhibited an improved metabolic stability in comparison to the parent compd. 5 while retaining favorable pharmacol. parameters together with appropriate behavioral end points in the rodent studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYwv3p-k-0s7Vg90H21EOLACvtfcHk0liPsmvCeRFfqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yhsLnL&md5=7dabc32c08ffc77bd322e55c6dbd585c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm3008739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008739%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DNys%26aufirst%3DM.%26aulast%3DMazzolari%26aufirst%3DA.%26aulast%3Dvan%2BElk%26aufirst%3DR.%26aulast%3DSmit%26aufirst%3DA.%2BB.%26aulast%3DAlexandrov%26aufirst%3DV.%26aulast%3DHanania%26aufirst%3DT.%26aulast%3DSabath%26aufirst%3DE.%26aulast%3DFedolak%26aufirst%3DA.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DUlens%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DInsights%2520into%2520the%2520structural%2520determinants%2520required%2520for%2520high-affinity%2520binding%2520of%2520chiral%2520cyclopropane-containing%2520ligands%2520to%2520alpha4beta2-nicotinic%2520acetylcholine%2520receptors%253A%2520an%2520integrated%2520approach%2520to%2520behaviorally%2520active%2520nicotinic%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8028%26epage%3D8037%26doi%3D10.1021%2Fjm3008739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Onajole, O. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiede, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Enantiopure cyclopropane-bearing pyridyldiazabicyclo[3.3.0]octanes as selective alpha4beta2-nAChR ligands</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span><span class="refDoi"> DOI: 10.1021/ml500129k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500129k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1196-1201&author=O.+K.+Onajoleauthor=J.+B.+Eatonauthor=R.+J.+Lukasauthor=D.+Brunnerauthor=L.+Thiedeauthor=B.+J.+Caldaroneauthor=A.+P.+Kozikowski&title=Enantiopure+cyclopropane-bearing+pyridyldiazabicyclo%5B3.3.0%5Doctanes+as+selective+alpha4beta2-nAChR+ligands&doi=10.1021%2Fml500129k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fml500129k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500129k%26sid%3Dliteratum%253Aachs%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DThiede%26aufirst%3DL.%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DEnantiopure%2520cyclopropane-bearing%2520pyridyldiazabicyclo%255B3.3.0%255Doctanes%2520as%2520selective%2520alpha4beta2-nAChR%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1196%26epage%3D1201%26doi%3D10.1021%2Fml500129k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Pesquero, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araujo, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heppenstall, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stucky, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, J. A.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesquero, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paiva, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calixto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, M.</span><span> </span><span class="NLM_article-title">Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">8140</span><span class="NLM_x">–</span> <span class="NLM_lpage">8145</span><span class="refDoi"> DOI: 10.1073/pnas.120035997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.120035997" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8140-8145&author=J.+B.+Pesqueroauthor=R.+C.+Araujoauthor=P.+A.+Heppenstallauthor=C.+L.+Stuckyauthor=J.+A.+Silvaauthor=T.+Waltherauthor=S.+M.+Oliveiraauthor=J.+L.+Pesqueroauthor=A.+C.+Paivaauthor=J.+B.+Calixtoauthor=G.+R.+Lewinauthor=M.+Bader&title=Hypoalgesia+and+altered+inflammatory+responses+in+mice+lacking+kinin+B1+receptors&doi=10.1073%2Fpnas.120035997"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1073%2Fpnas.120035997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.120035997%26sid%3Dliteratum%253Aachs%26aulast%3DPesquero%26aufirst%3DJ.%2BB.%26aulast%3DAraujo%26aufirst%3DR.%2BC.%26aulast%3DHeppenstall%26aufirst%3DP.%2BA.%26aulast%3DStucky%26aufirst%3DC.%2BL.%26aulast%3DSilva%26aufirst%3DJ.%2BA.%26aulast%3DWalther%26aufirst%3DT.%26aulast%3DOliveira%26aufirst%3DS.%2BM.%26aulast%3DPesquero%26aufirst%3DJ.%2BL.%26aulast%3DPaiva%26aufirst%3DA.%2BC.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26aulast%3DLewin%26aufirst%3DG.%2BR.%26aulast%3DBader%26aufirst%3DM.%26atitle%3DHypoalgesia%2520and%2520altered%2520inflammatory%2520responses%2520in%2520mice%2520lacking%2520kinin%2520B1%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D8140%26epage%3D8145%26doi%3D10.1073%2Fpnas.120035997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Ferreira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araujo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesquero, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calixto, J. B.</span><span> </span><span class="NLM_article-title">The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1188</span><span class="NLM_x">–</span> <span class="NLM_lpage">1197</span><span class="refDoi"> DOI: 10.1016/S0028-3908(02)00311-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0028-3908%2802%2900311-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1188-1197&author=J.+Ferreiraauthor=M.+M.+Camposauthor=R.+Araujoauthor=M.+Baderauthor=J.+B.+Pesqueroauthor=J.+B.+Calixto&title=The+use+of+kinin+B1+and+B2+receptor+knockout+mice+and+selective+antagonists+to+characterize+the+nociceptive+responses+caused+by+kinins+at+the+spinal+level&doi=10.1016%2FS0028-3908%2802%2900311-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2802%2900311-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252802%252900311-8%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DCampos%26aufirst%3DM.%2BM.%26aulast%3DAraujo%26aufirst%3DR.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DPesquero%26aufirst%3DJ.%2BB.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520use%2520of%2520kinin%2520B1%2520and%2520B2%2520receptor%2520knockout%2520mice%2520and%2520selective%2520antagonists%2520to%2520characterize%2520the%2520nociceptive%2520responses%2520caused%2520by%2520kinins%2520at%2520the%2520spinal%2520level%26jtitle%3DNeuropharmacology%26date%3D2002%26volume%3D43%26spage%3D1188%26epage%3D1197%26doi%3D10.1016%2FS0028-3908%2802%2900311-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homnick, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lis, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stump, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondiskey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Benzodiazepines as potent and selective bradykinin B1 antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span><span class="refDoi"> DOI: 10.1021/jm034020y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034020y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFCksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1803-1806&author=M.+R.+Woodauthor=J.+J.+Kimauthor=W.+Hanauthor=B.+D.+Dorseyauthor=C.+F.+Homnickauthor=R.+M.+DiPardoauthor=S.+D.+Kudukauthor=T.+MacNeilauthor=K.+L.+Murphyauthor=E.+V.+Lisauthor=R.+W.+Ransomauthor=G.+L.+Stumpauthor=J.+J.+Lynchauthor=S.+S.+O%E2%80%99Malleyauthor=P.+J.+Millerauthor=T.+B.+Chenauthor=C.+M.+Harrellauthor=R.+S.+Changauthor=P.+Sandhuauthor=J.+D.+Ellisauthor=P.+J.+Bondiskeyauthor=D.+J.+Pettiboneauthor=R.+M.+Freidingerauthor=M.+G.+Bock&title=Benzodiazepines+as+potent+and+selective+bradykinin+B1+antagonists&doi=10.1021%2Fjm034020y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepines as Potent and Selective Bradykinin B1 Antagonists</span></div><div class="casAuthors">Wood, Michael R.; Kim, June J.; Han, Wei; Dorsey, Bruce D.; Homnick, Carl F.; DiPardo, Robert M.; Kuduk, Scott D.; MacNeil, Tanya; Murphy, Kathy L.; Lis, Edward V.; Ransom, Richard W.; Stump, Gary L.; Lynch, Joseph J.; O'Malley, Stacey S.; Miller, Patricia J.; Chen, Tsing-Bau; Harrell, Charles M.; Chang, Raymond S. L.; Sandhu, Punam; Ellis, Joan D.; Bondiskey, Peter J.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1803-1806</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonism of the bradykinin B1 receptor was demonstrated to be a potential treatment for chronic pain and inflammation.  Novel benzodiazepines were designed that display subnanomolar affinity for the bradykinin B1 receptor (Ki = 0.59 nM) and high selectivity against the bradykinin B2 receptor (Ki > 10 μM).  In vivo efficacy, comparable to morphine, was demonstrated for lead compds. in a rodent hyperalgesia model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnWdPzXxm7TbVg90H21EOLACvtfcHk0lghNrzGLH4Lug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFCksrY%253D&md5=25321091d569d913a963ec4e33baa772</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm034020y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034020y%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DHomnick%26aufirst%3DC.%2BF.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DLis%26aufirst%3DE.%2BV.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DStump%26aufirst%3DG.%2BL.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DS.%2BS.%26aulast%3DMiller%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DSandhu%26aufirst%3DP.%26aulast%3DEllis%26aufirst%3DJ.%2BD.%26aulast%3DBondiskey%26aufirst%3DP.%2BJ.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DBenzodiazepines%2520as%2520potent%2520and%2520selective%2520bradykinin%2520B1%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1803%26epage%3D1806%26doi%3D10.1021%2Fjm034020y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Feng, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.02.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.02.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2385-2388&author=D.+M.+Fengauthor=J.+M.+Waiauthor=S.+D.+Kudukauthor=C.+Ngauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+Reissauthor=R.+S.+Changauthor=C.+M.+Harrellauthor=T.+MacNeilauthor=C.+Tangauthor=T.+Prueksaritanontauthor=R.+M.+Freidingerauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=2%2C3-Diaminopyridine+as+a+platform+for+designing+structurally+unique+nonpeptide+bradykinin+B1+receptor+antagonists&doi=10.1016%2Fj.bmcl.2005.02.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.02.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.02.077%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DD.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BM.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3D2%252C3-Diaminopyridine%2520as%2520a%2520platform%2520for%2520designing%2520structurally%2520unique%2520nonpeptide%2520bradykinin%2520B1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2385%26epage%3D2388%26doi%3D10.1016%2Fj.bmcl.2005.02.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krymgold, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span> </span><span class="NLM_article-title">Bioactivation of 2,3-diaminopyridine-containing bradykinin B1 receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">934</span><span class="NLM_x">–</span> <span class="NLM_lpage">945</span><span class="refDoi"> DOI: 10.1021/tx0500427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0500427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=934-945&author=C.+Tangauthor=R.+Subramanianauthor=Y.+Kuoauthor=S.+Krymgoldauthor=P.+Luauthor=S.+D.+Kudukauthor=C.+Ngauthor=D.+M.+Fengauthor=C.+Elmoreauthor=E.+Soliauthor=J.+Hoauthor=M.+G.+Bockauthor=T.+A.+Baillieauthor=T.+Prueksaritanont&title=Bioactivation+of+2%2C3-diaminopyridine-containing+bradykinin+B1+receptor+antagonists%3A+irreversible+binding+to+liver+microsomal+proteins+and+formation+of+glutathione+conjugates&doi=10.1021%2Ftx0500427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Ftx0500427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0500427%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DKrymgold%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DD.%2BM.%26aulast%3DElmore%26aufirst%3DC.%26aulast%3DSoli%26aufirst%3DE.%26aulast%3DHo%26aufirst%3DJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26atitle%3DBioactivation%2520of%25202%252C3-diaminopyridine-containing%2520bradykinin%2520B1%2520receptor%2520antagonists%253A%2520irreversible%2520binding%2520to%2520liver%2520microsomal%2520proteins%2520and%2520formation%2520of%2520glutathione%2520conjugates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D934%26epage%3D945%26doi%3D10.1021%2Ftx0500427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirripa, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detwiler, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hettrick, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1234</span><span class="refDoi"> DOI: 10.1021/jm0511280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0511280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1231-1234&author=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=B.+L.+Wanauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=R.+S.+Changauthor=C.+Tangauthor=T.+Prueksaritanontauthor=T.+J.+Detwilerauthor=L.+A.+Hettrickauthor=E.+R.+Landisauthor=Y.+M.+Leonardauthor=J.+A.+Kruegerauthor=S.+D.+Lewisauthor=D.+J.+Pettiboneauthor=R.+M.+Freidingerauthor=M.+G.+Bock&title=Cyclopropylamino+acid+amide+as+a+pharmacophoric+replacement+for+2%2C3-diaminopyridine.+Application+to+the+design+of+novel+bradykinin+B1+receptor+antagonists&doi=10.1021%2Fjm0511280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm0511280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0511280%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DDetwiler%26aufirst%3DT.%2BJ.%26aulast%3DHettrick%26aufirst%3DL.%2BA.%26aulast%3DLandis%26aufirst%3DE.%2BR.%26aulast%3DLeonard%26aufirst%3DY.%2BM.%26aulast%3DKrueger%26aufirst%3DJ.%2BA.%26aulast%3DLewis%26aufirst%3DS.%2BD.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DCyclopropylamino%2520acid%2520amide%2520as%2520a%2520pharmacophoric%2520replacement%2520for%25202%252C3-diaminopyridine.%2520Application%2520to%2520the%2520design%2520of%2520novel%2520bradykinin%2520B1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1231%26epage%3D1234%26doi%3D10.1021%2Fjm0511280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3608</span><span class="NLM_x">–</span> <span class="NLM_lpage">3612</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.04.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2007.04.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3608-3612&author=S.+D.+Kudukauthor=R.+M.+DiPardoauthor=R.+K.+Changauthor=C.+N.+Di+Marcoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+R.+Reissauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=Bradykinin+B1+antagonists%3A+biphenyl+SAR+studies+in+the+cyclopropanecarboxamide+series&doi=10.1016%2Fj.bmcl.2007.04.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.040%26sid%3Dliteratum%253Aachs%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DBradykinin%2520B1%2520antagonists%253A%2520biphenyl%2520SAR%2520studies%2520in%2520the%2520cyclopropanecarboxamide%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3608%26epage%3D3612%26doi%3D10.1016%2Fj.bmcl.2007.04.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirripa, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holahan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sain, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1021/jm061094b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061094b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=272-282&author=S.+D.+Kudukauthor=C.+N.+Di+Marcoauthor=R.+K.+Changauthor=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=J.+M.+Waiauthor=R.+M.+DiPardoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=C.+M.+Harrellauthor=D.+R.+Reissauthor=M.+A.+Holahanauthor=J.+Cookauthor=J.+F.+Hessauthor=N.+Sainauthor=M.+O.+Urbanauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=Development+of+orally+bioavailable+and+CNS+penetrant+biphenylaminocyclopropane+carboxamide+bradykinin+B1+receptor+antagonists&doi=10.1021%2Fjm061094b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B1 Receptor Antagonists</span></div><div class="casAuthors">Kuduk, Scott D.; Di Marco, Christina N.; Chang, Ronald K.; Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Wai, Jenny M. C.; DiPardo, Robert M.; Murphy, Kathy L.; Ransom, Richard W.; Harrell, C. Meacham; Reiss, Duane R.; Holahan, Marie A.; Cook, Jacquelynn; Hess, J. Fred; Sain, Nova; Urban, Mark O.; Tang, Cuyue; Prueksaritanont, Thomayant; Pettibone, Douglas J.; Bock, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">272-282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant.  Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential.  One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Ky-bZSOQr7Vg90H21EOLACvtfcHk0limdD51D5Hqlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgs7zL&md5=9fac6ea81be63ee5dfae76dd7d2c37b5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fjm061094b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061094b%26sid%3Dliteratum%253Aachs%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DWai%26aufirst%3DJ.%2BM.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DHolahan%26aufirst%3DM.%2BA.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DJ.%2BF.%26aulast%3DSain%26aufirst%3DN.%26aulast%3DUrban%26aufirst%3DM.%2BO.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DDevelopment%2520of%2520orally%2520bioavailable%2520and%2520CNS%2520penetrant%2520biphenylaminocyclopropane%2520carboxamide%2520bradykinin%2520B1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D272%26epage%3D282%26doi%3D10.1021%2Fjm061094b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Betschart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintermann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotesta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ofner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyer, D.</span><span> </span><span class="NLM_article-title">Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7590</span><span class="NLM_x">–</span> <span class="NLM_lpage">7607</span><span class="refDoi"> DOI: 10.1021/jm4007627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7590-7607&author=C.+Betschartauthor=S.+Hintermannauthor=D.+Behnkeauthor=S.+Cotestaauthor=M.+Fendtauthor=C.+E.+Geeauthor=L.+H.+Jacobsonauthor=G.+Laueauthor=S.+Ofnerauthor=V.+Chaudhariauthor=S.+Badigerauthor=C.+Panditauthor=J.+Wagnerauthor=D.+Hoyer&title=Identification+of+a+novel+series+of+orexin+receptor+antagonists+with+a+distinct+effect+on+sleep+architecture+for+the+treatment+of+insomnia&doi=10.1021%2Fjm4007627"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fjm4007627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007627%26sid%3Dliteratum%253Aachs%26aulast%3DBetschart%26aufirst%3DC.%26aulast%3DHintermann%26aufirst%3DS.%26aulast%3DBehnke%26aufirst%3DD.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DFendt%26aufirst%3DM.%26aulast%3DGee%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DLaue%26aufirst%3DG.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DV.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DPandit%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520a%2520novel%2520series%2520of%2520orexin%2520receptor%2520antagonists%2520with%2520a%2520distinct%2520effect%2520on%2520sleep%2520architecture%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7590%26epage%3D7607%26doi%3D10.1021%2Fjm4007627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGaughey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogusky, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span> </span><span class="NLM_article-title">Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H −1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5320</span><span class="NLM_x">–</span> <span class="NLM_lpage">5332</span><span class="refDoi"> DOI: 10.1021/jm100541c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100541c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5320-5332&author=C.+D.+Coxauthor=M.+J.+Breslinauthor=D.+B.+Whitmanauthor=J.+D.+Schreierauthor=G.+B.+McGaugheyauthor=M.+J.+Boguskyauthor=A.+J.+Roeckerauthor=S.+P.+Mercerauthor=R.+A.+Bednarauthor=W.+Lemaireauthor=J.+G.+Brunoauthor=D.+R.+Reissauthor=C.+M.+Harrellauthor=K.+L.+Murphyauthor=S.+L.+Garsonauthor=S.+M.+Doranauthor=T.+Prueksaritanontauthor=W.+B.+Andersonauthor=C.+Tangauthor=S.+Rollerauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=G.+D.+Hartmanauthor=S.+D.+Youngauthor=K.+S.+Koblanauthor=C.+J.+Winrowauthor=J.+J.+Rengerauthor=P.+J.+Coleman&title=Discovery+of+the+dual+orexin+receptor+antagonist+%5B%287R%29-4-%285-chloro-1%2C3-benzoxazol-2-yl%29-7-methyl-1%2C4-diazepan-1-yl%5D%5B5-methyl-2-%282H+%E2%88%921%2C2%2C3-triazol-2-yl%29phenyl%5Dmethanone+%28MK-4305%29+for+the+treatment+of+insomnia&doi=10.1021%2Fjm100541c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm100541c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100541c%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DWhitman%26aufirst%3DD.%2BB.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBogusky%26aufirst%3DM.%2BJ.%26aulast%3DRoecker%26aufirst%3DA.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DW.%2BB.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%2520the%2520dual%2520orexin%2520receptor%2520antagonist%2520%255B%25287R%2529-4-%25285-chloro-1%252C3-benzoxazol-2-yl%2529-7-methyl-1%252C4-diazepan-1-yl%255D%255B5-methyl-2-%25282H%2520%25E2%2588%25921%252C2%252C3-triazol-2-yl%2529phenyl%255Dmethanone%2520%2528MK-4305%2529%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5320%26epage%3D5332%26doi%3D10.1021%2Fjm100541c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobarec, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span> </span><span class="NLM_article-title">Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">519</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1038/nature14035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnature14035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=25533960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=519&publication_year=2015&pages=247-250&author=J.+Yinauthor=J.+C.+Mobarecauthor=P.+Kolbauthor=D.+M.+Rosenbaum&title=Crystal+structure+of+the+human+OX2+orexin+receptor+bound+to+the+insomnia+drug+suvorexant&doi=10.1038%2Fnature14035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant</span></div><div class="casAuthors">Yin, Jie; Mobarec, Juan Carlos; Kolb, Peter; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">519</span>
        (<span class="NLM_cas:issue">7542</span>),
    <span class="NLM_cas:pages">247-250</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The orexin (also known as hypocretin) G protein-coupled receptors (GPCRs) respond to orexin neuropeptides in the central nervous system to regulate sleep and other behavioral functions in humans.  Defects in orexin signalling are responsible for the human diseases of narcolepsy and cataplexy; inhibition of orexin receptors is an effective therapy for insomnia.  The human OX2 receptor (OX2R) belongs to the β branch of the rhodopsin family of GPCRs, and can bind to diverse compds. including the native agonist peptides orexin-A and orexin-B and the potent therapeutic inhibitor suvorexant.  Here, using lipid-mediated crystn. and protein engineering with a novel fusion chimaera, we solved the structure of the human OX2R bound to suvorexant at 2.5 Å resoln.  The structure reveals how suvorexant adopts a π-stacked horseshoe-like conformation and binds to the receptor deep in the orthosteric pocket, stabilizing a network of extracellular salt bridges and blocking transmembrane (TM) helix motions necessary for activation.  Computational docking suggests how other classes of synthetic antagonists may interact with the receptor at a similar position in an analogous π-stacked fashion.  Elucidation of the mol. architecture of the human OX2R expands our understanding of peptidergic GPCR ligand recognition and will aid further efforts to modulate orexin signaling for therapeutic ends.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWKzbWNxv4W7Vg90H21EOLACvtfcHk0lj0XusuF8fnKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntb0%253D&md5=461a6633274dbcfd9edce1a2e13b9c4f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1038%2Fnature14035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14035%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DMobarec%26aufirst%3DJ.%2BC.%26aulast%3DKolb%26aufirst%3DP.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520OX2%2520orexin%2520receptor%2520bound%2520to%2520the%2520insomnia%2520drug%2520suvorexant%26jtitle%3DNature%26date%3D2015%26volume%3D519%26spage%3D247%26epage%3D250%26doi%3D10.1038%2Fnature14035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span> </span><span class="NLM_article-title">The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span><span class="refDoi"> DOI: 10.1038/bjp.2008.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fbjp.2008.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18469850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1166-1181&author=T.+A.+Esbenshadeauthor=K.+E.+Browmanauthor=R.+S.+Bitnerauthor=M.+Strakhovaauthor=M.+D.+Cowartauthor=J.+D.+Brioni&title=The+histamine+H3+receptor%3A+an+attractive+target+for+the+treatment+of+cognitive+disorders&doi=10.1038%2Fbjp.2008.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</span></div><div class="casAuthors">Esbenshade, T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.; Brioni, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1166-1181</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous labs. as it represents an attractive drug target for a no. of indications including cognition.  The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclin. and clin. advancement.  Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in cognitive processes.  The cognitive-enhancing effects of H3 antagonists across multiple cognitive domains in a wide no. of preclin. cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia.  However, although a no. of clin. studies examg. the efficacy of H3 receptor antagonists for a variety of cognitive disorders are currently underway, no clin. proof of concept for an H3 receptor antagonist has been reported to date.  The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of cognitive disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.  British Journal of Pharmacol. (2008) 154, 1166-1181; doi:10.1038/bjp.2008.147; published online 12 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2N2Dg3cdZfrVg90H21EOLACvtfcHk0lj0XusuF8fnKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D&md5=05bcda7b1140e9d16b4ca4072902d925</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.147%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBitner%26aufirst%3DR.%2BS.%26aulast%3DStrakhova%26aufirst%3DM.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520histamine%2520H3%2520receptor%253A%2520an%2520attractive%2520target%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1166%26epage%3D1181%26doi%3D10.1038%2Fbjp.2008.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajpai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneville, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcallister, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mani, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndifor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sands, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snook, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span> </span><span class="NLM_article-title">Novel benzamide-based histamine h3 receptor antagonists: the identification of two candidates for clinical development</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">450</span><span class="NLM_x">–</span> <span class="NLM_lpage">454</span><span class="refDoi"> DOI: 10.1021/ml5005156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml5005156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=450-454&author=M.+A.+Letavicauthor=L.+Aluisioauthor=R.+Apodacaauthor=M.+Bajpaiauthor=A.+J.+Barbierauthor=A.+Bonnevilleauthor=P.+Bonaventureauthor=N.+I.+Carruthersauthor=C.+Dugovicauthor=I.+C.+Fraserauthor=M.+L.+Kramerauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=L.+Y.+Liauthor=K.+S.+Lyauthor=H.+Mcallisterauthor=N.+S.+Maniauthor=K.+L.+Mortonauthor=A.+Ndiforauthor=S.+D.+Nepomucenoauthor=C.+R.+Panditauthor=S.+B.+Sandsauthor=C.+R.+Shahauthor=J.+E.+Sheltonauthor=S.+S.+Snookauthor=D.+M.+Swansonauthor=W.+Xiao&title=Novel+benzamide-based+histamine+h3+receptor+antagonists%3A+the+identification+of+two+candidates+for+clinical+development&doi=10.1021%2Fml5005156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fml5005156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml5005156%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DBajpai%26aufirst%3DM.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DBonneville%26aufirst%3DA.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DKramer%26aufirst%3DM.%2BL.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DLy%26aufirst%3DK.%2BS.%26aulast%3DMcallister%26aufirst%3DH.%26aulast%3DMani%26aufirst%3DN.%2BS.%26aulast%3DMorton%26aufirst%3DK.%2BL.%26aulast%3DNdifor%26aufirst%3DA.%26aulast%3DNepomuceno%26aufirst%3DS.%2BD.%26aulast%3DPandit%26aufirst%3DC.%2BR.%26aulast%3DSands%26aufirst%3DS.%2BB.%26aulast%3DShah%26aufirst%3DC.%2BR.%26aulast%3DShelton%26aufirst%3DJ.%2BE.%26aulast%3DSnook%26aufirst%3DS.%2BS.%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DXiao%26aufirst%3DW.%26atitle%3DNovel%2520benzamide-based%2520histamine%2520h3%2520receptor%2520antagonists%253A%2520the%2520identification%2520of%2520two%2520candidates%2520for%2520clinical%2520development%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D450%26epage%3D454%26doi%3D10.1021%2Fml5005156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Pages, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavalda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehner, M. D.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2005 - 2009)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1519</span><span class="refDoi"> DOI: 10.1517/13543770903313753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1517%2F13543770903313753" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1501-1519&author=L.+Pagesauthor=A.+Gavaldaauthor=M.+D.+Lehner&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282005+-+2009%29&doi=10.1517%2F13543770903313753"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1517%2F13543770903313753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903313753%26sid%3Dliteratum%253Aachs%26aulast%3DPages%26aufirst%3DL.%26aulast%3DGavalda%26aufirst%3DA.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282005%2520-%25202009%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1501%26epage%3D1519%26doi%3D10.1517%2F13543770903313753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors as potential cognition enhancing agents</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.2174/156802610790411009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F156802610790411009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20166957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFajsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=222-230&author=C.+J.+Schmidt&title=Phosphodiesterase+inhibitors+as+potential+cognition+enhancing+agents&doi=10.2174%2F156802610790411009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors as potential cognition enhancing agents</span></div><div class="casAuthors">Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  As might be predicted for an organ designed for cell to cell communication, cyclic nucleotide signaling in the brain is highly organized and regulated.  Augmentation of cyclic nucleotide signaling by means of phosphodiesterase inhibition appears to be a viable and tractable means of enhancing neuronal communication.  Of the various CNS disorders that have been considered as target indications for phosphodiesterase inhibitors, no condition has received more attention than cognitive dysfunction.  This review provides a background for understanding the expanding literature in this field as well as a brief update on the rationale driving the search for selective inhibitors of targets such as PDE1B, PDE2, PDE5 and PDE9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBVYtnViej97Vg90H21EOLACvtfcHk0liwc5XOlzQwfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFajsrY%253D&md5=47e8397d9f69207c27940575411bbe12</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.2174%2F156802610790411009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790411009%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DPhosphodiesterase%2520inhibitors%2520as%2520potential%2520cognition%2520enhancing%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D222%26epage%3D230%26doi%3D10.2174%2F156802610790411009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Gallant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspiotis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesen, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styhler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, Y.</span><span> </span><span class="NLM_article-title">Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6387</span><span class="NLM_x">–</span> <span class="NLM_lpage">6393</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.09.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2010.09.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6387-6393&author=M.+Gallantauthor=R.+Aspiotisauthor=S.+Dayauthor=R.+Diasauthor=D.+Dubeauthor=L.+Dubeauthor=R.+W.+Friesenauthor=M.+Girardauthor=D.+Guayauthor=P.+Hamelauthor=Z.+Huangauthor=P.+Lacombeauthor=S.+Laliberteauthor=J.+F.+Levesqueauthor=S.+Liuauthor=D.+Macdonaldauthor=J.+Manciniauthor=D.+W.+Nicholsonauthor=A.+Styhlerauthor=K.+Townsonauthor=K.+Watersauthor=R.+N.+Youngauthor=Y.+Girard&title=Discovery+of+MK-0952%2C+a+selective+PDE4+inhibitor+for+the+treatment+of+long-term+memory+loss+and+mild+cognitive+impairment&doi=10.1016%2Fj.bmcl.2010.09.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.087%26sid%3Dliteratum%253Aachs%26aulast%3DGallant%26aufirst%3DM.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DDias%26aufirst%3DR.%26aulast%3DDube%26aufirst%3DD.%26aulast%3DDube%26aufirst%3DL.%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DHamel%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DLacombe%26aufirst%3DP.%26aulast%3DLaliberte%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DJ.%2BF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DMancini%26aufirst%3DJ.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DStyhler%26aufirst%3DA.%26aulast%3DTownson%26aufirst%3DK.%26aulast%3DWaters%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DGirard%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520MK-0952%252C%2520a%2520selective%2520PDE4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520long-term%2520memory%2520loss%2520and%2520mild%2520cognitive%2520impairment%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6387%26epage%3D6393%26doi%3D10.1016%2Fj.bmcl.2010.09.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Guay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesen, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muise, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styhler, A.</span><span> </span><span class="NLM_article-title">Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5554</span><span class="NLM_x">–</span> <span class="NLM_lpage">5558</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.09.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5554-5558&author=D.+Guayauthor=L.+Bouletauthor=R.+W.+Friesenauthor=M.+Girardauthor=P.+Hamelauthor=Z.+Huangauthor=F.+Laliberteauthor=S.+Laliberteauthor=J.+A.+Manciniauthor=E.+Muiseauthor=D.+Ponauthor=A.+Styhler&title=Optimization+and+structure-activity+relationship+of+a+series+of+1-phenyl-1%2C8-naphthyridin-4-one-3-carboxamides%3A+identification+of+MK-0873%2C+a+potent+and+effective+PDE4+inhibitor&doi=10.1016%2Fj.bmcl.2008.09.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DBoulet%26aufirst%3DL.%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DLaliberte%26aufirst%3DF.%26aulast%3DLaliberte%26aufirst%3DS.%26aulast%3DMancini%26aufirst%3DJ.%2BA.%26aulast%3DMuise%26aufirst%3DE.%26aulast%3DPon%26aufirst%3DD.%26aulast%3DStyhler%26aufirst%3DA.%26atitle%3DOptimization%2520and%2520structure-activity%2520relationship%2520of%2520a%2520series%2520of%25201-phenyl-1%252C8-naphthyridin-4-one-3-carboxamides%253A%2520identification%2520of%2520MK-0873%252C%2520a%2520potent%2520and%2520effective%2520PDE4%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5554%26epage%3D5558%26doi%3D10.1016%2Fj.bmcl.2008.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Marks, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patkar, A. A.</span><span> </span><span class="NLM_article-title">Triple reuptake inhibitors: the next generation of antidepressants</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span><span class="refDoi"> DOI: 10.2174/157015908787386078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F157015908787386078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19587855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=338-343&author=D.+M.+Marksauthor=C.+U.+Paeauthor=A.+A.+Patkar&title=Triple+reuptake+inhibitors%3A+the+next+generation+of+antidepressants&doi=10.2174%2F157015908787386078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors: the next generation of antidepressants</span></div><div class="casAuthors">Marks, David M.; Pae, Chi-Un; Patkar, Ashwin A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression has been assocd. with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacol. treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission.  Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action.  The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors.  The evidence for and against the claim that broader spectrum agents are more efficacious is discussed.  Examples of triple reuptake inhibitors in development are compared, and preclin. and clin. research with these agents to date is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8YVs9W5UsbVg90H21EOLACvtfcHk0lg-HgjemJLYnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D&md5=b8108bdcd4ddc03bc3e7c31b2ac0824f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.2174%2F157015908787386078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908787386078%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DD.%2BM.%26aulast%3DPae%26aufirst%3DC.%2BU.%26aulast%3DPatkar%26aufirst%3DA.%2BA.%26atitle%3DTriple%2520reuptake%2520inhibitors%253A%2520the%2520next%2520generation%2520of%2520antidepressants%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26spage%3D338%26epage%3D343%26doi%3D10.2174%2F157015908787386078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Micheli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreotti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arban, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettelini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonanomi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carletti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Checchia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazzolari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchioro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlo-Pich, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliosi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedesco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terreni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zonzini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fabio, R.</span><span> </span><span class="NLM_article-title">6-(3,4-Dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4989</span><span class="NLM_x">–</span> <span class="NLM_lpage">5001</span><span class="refDoi"> DOI: 10.1021/jm100481d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100481d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4989-5001&author=F.+Micheliauthor=P.+Cavanniauthor=D.+Andreottiauthor=R.+Arbanauthor=R.+Benedettiauthor=B.+Bertaniauthor=M.+Bettatiauthor=L.+Betteliniauthor=G.+Bonanomiauthor=S.+Braggioauthor=R.+Carlettiauthor=A.+Checchiaauthor=M.+Corsiauthor=E.+Fazzolariauthor=S.+Fontanaauthor=C.+Marchioroauthor=E.+Merlo-Pichauthor=M.+Negriauthor=B.+Oliosiauthor=E.+Rattiauthor=K.+D.+Readauthor=M.+Roscicauthor=I.+Sartoriauthor=S.+Spadaauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=F.+Visentiniauthor=A.+Zocchiauthor=L.+Zonziniauthor=R.+Di+Fabio&title=6-%283%2C4-Dichlorophenyl%29-1-%5B%28methyloxy%29methyl%5D-3-azabicyclo%5B4.1.0%5Dheptane%3A+a+new+potent+and+selective+triple+reuptake+inhibitor&doi=10.1021%2Fjm100481d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">6-(3,4-Dichlorophenyl)-1-[(Methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A New Potent and Selective Triple Reuptake Inhibitor</span></div><div class="casAuthors">Micheli, Fabrizio; Cavanni, Paolo; Andreotti, Daniele; Arban, Roberto; Benedetti, Roberto; Bertani, Barbara; Bettati, Michela; Bettelini, Letizia; Bonanomi, Giorgio; Braggio, Simone; Carletti, Renzo; Checchia, Anna; Corsi, Mauro; Fazzolari, Elettra; Fontana, Stefano; Marchioro, Carla; Merlo-Pich, Emilio; Negri, Michele; Oliosi, Beatrice; Ratti, Emiliangelo; Read, Kevin D.; Roscic, Maja; Sartori, Ilaria; Spada, Simone; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Visentini, Filippo; Zocchi, Alessandro; Zonzini, Laura; Di Fabio, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4989-5001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported.  Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics.  Excellent bioavailability and brain penetration are assocd. with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT.  In vivo microdialysis expts. in different animal models and receptor occupancy studies in rat confirmed that deriv. 17 (I) showed an appropriate profile to guarantee further progression of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NYLPRsborLVg90H21EOLACvtfcHk0lg-HgjemJLYnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D&md5=b250a9a4f7772f81ab2702180348b254</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm100481d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100481d%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DAndreotti%26aufirst%3DD.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBettelini%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCarletti%26aufirst%3DR.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DCorsi%26aufirst%3DM.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMerlo-Pich%26aufirst%3DE.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DRoscic%26aufirst%3DM.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DSpada%26aufirst%3DS.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26atitle%3D6-%25283%252C4-Dichlorophenyl%2529-1-%255B%2528methyloxy%2529methyl%255D-3-azabicyclo%255B4.1.0%255Dheptane%253A%2520a%2520new%2520potent%2520and%2520selective%2520triple%2520reuptake%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4989%26epage%3D5001%26doi%3D10.1021%2Fjm100481d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Manoury, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binet, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefevre-Borg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavero, I. G.</span><span> </span><span class="NLM_article-title">Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1003</span><span class="NLM_x">–</span> <span class="NLM_lpage">1011</span><span class="refDoi"> DOI: 10.1021/jm00389a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00389a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=1003-1011&author=P.+M.+Manouryauthor=J.+L.+Binetauthor=J.+Rousseauauthor=F.+Lefevre-Borgauthor=I.+G.+Cavero&title=Synthesis+of+a+series+of+compounds+related+to+betaxolol%2C+a+new+beta+1-adrenoceptor+antagonist+with+a+pharmacological+and+pharmacokinetic+profile+optimized+for+the+treatment+of+chronic+cardiovascular+diseases&doi=10.1021%2Fjm00389a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fjm00389a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00389a008%26sid%3Dliteratum%253Aachs%26aulast%3DManoury%26aufirst%3DP.%2BM.%26aulast%3DBinet%26aufirst%3DJ.%2BL.%26aulast%3DRousseau%26aufirst%3DJ.%26aulast%3DLefevre-Borg%26aufirst%3DF.%26aulast%3DCavero%26aufirst%3DI.%2BG.%26atitle%3DSynthesis%2520of%2520a%2520series%2520of%2520compounds%2520related%2520to%2520betaxolol%252C%2520a%2520new%2520beta%25201-adrenoceptor%2520antagonist%2520with%2520a%2520pharmacological%2520and%2520pharmacokinetic%2520profile%2520optimized%2520for%2520the%2520treatment%2520of%2520chronic%2520cardiovascular%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D1003%26epage%3D1011%26doi%3D10.1021%2Fjm00389a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Arfwidsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skanberg, I.</span><span> </span><span class="NLM_article-title">Metabolism of metoprolol in the rat in vitro and in vivo</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.3109/00498257609151681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.3109%2F00498257609151681" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1976&pages=691-711&author=A.+Arfwidssonauthor=K.+O.+Borgauthor=K.+J.+Hoffmannauthor=I.+Skanberg&title=Metabolism+of+metoprolol+in+the+rat+in+vitro+and+in+vivo&doi=10.3109%2F00498257609151681"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.3109%2F00498257609151681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498257609151681%26sid%3Dliteratum%253Aachs%26aulast%3DArfwidsson%26aufirst%3DA.%26aulast%3DBorg%26aufirst%3DK.%2BO.%26aulast%3DHoffmann%26aufirst%3DK.%2BJ.%26aulast%3DSkanberg%26aufirst%3DI.%26atitle%3DMetabolism%2520of%2520metoprolol%2520in%2520the%2520rat%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DXenobiotica%26date%3D1976%26volume%3D6%26spage%3D691%26epage%3D711%26doi%3D10.3109%2F00498257609151681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">VAN Giezen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berntsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissing, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordanetto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, P. J.</span><span> </span><span class="NLM_article-title">Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1556</span><span class="NLM_x">–</span> <span class="NLM_lpage">1565</span><span class="refDoi"> DOI: 10.1111/j.1538-7836.2009.03527.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1111%2Fj.1538-7836.2009.03527.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19552634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ehsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=1556-1565&author=J.+J.+VAN+Giezenauthor=L.+Nilssonauthor=P.+Berntssonauthor=B.+M.+Wissingauthor=F.+Giordanettoauthor=W.+Tomlinsonauthor=P.+J.+Greasley&title=Ticagrelor+binds+to+human+P2Y%2812%29+independently+from+ADP+but+antagonizes+ADP-induced+receptor+signaling+and+platelet+aggregation&doi=10.1111%2Fj.1538-7836.2009.03527.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation</span></div><div class="casAuthors">Van Giezen, J. J. J.; Nilsson, L.; Berntsson, P.; Wissing, B.-M.; Giordanetto, F.; Tomlinson, W.; Greasley, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1556-1565</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: P2Y12 plays an important role in regulating platelet aggregation and function.  This receptor is the primary target of thienopyridine antiplatelet agents, the active metabolites of which bind irreversibly to the receptor, and of newer agents that can directly and reversibly modulate receptor activity.  Objective: To characterize the receptor biol. of the first reversibly binding oral P2Y12 antagonist, ticagrelor (AZD6140), a member of the new cyclopentyltriazolopyrimidine (CPTP) class currently in phase III development.  Methods: Ticagrelor displayed apparent non-competitive or insurmountable antagonism of ADP-induced aggregation in human washed platelets.  This was investigated using competition binding against [3H]ADP, [33P]2MeS-ADP and the investigational CPTP compd. [125I]AZ11931285 at recombinant human P2Y12.  Functional receptor inhibition studies were performed using a GTPγS-binding assay, and further binding studies were performed using membranes prepd. from washed human platelets.  Results: Radioligand-binding studies demonstrated that ticagrelor binds potently and reversibly to human P2Y12 with Kon and Koff of (1.1 ± 0.2) × 10-4 nM-1 s-1 and (8.7 ± 1.4) × 10-4 s-1, resp.  Ticagrelor does not displace [3H]ADP from the receptor (Ki > 10 μM) but binds competitively with [33P]2MeS-ADP (Ki = 4.3 ± 1.3 nM) and [125I]AZ11931285 (Ki = 0.33 ± 0.04 nM), and shows apparent non-competitive inhibition of ADP-induced signaling but competitive inhibition of 2MeS-ADP-induced signaling.  Binding studies on membranes prepd. from human washed platelets demonstrated similar non-competitive binding for ADP and ticagrelor.  Conclusions: These data indicate that P2Y12 is targeted by ticagrelor via a mechanism that is non-competitive with ADP, suggesting the existence of an independent receptor-binding site for CPTPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCr1KnUks7MrVg90H21EOLACvtfcHk0lgj_UsVFhus8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ehsr%252FE&md5=a054b99f153bdab7acf6dea8a4b26d94</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2009.03527.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2009.03527.x%26sid%3Dliteratum%253Aachs%26aulast%3DVAN%2BGiezen%26aufirst%3DJ.%2BJ.%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3DBerntsson%26aufirst%3DP.%26aulast%3DWissing%26aufirst%3DB.%2BM.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DTomlinson%26aufirst%3DW.%26aulast%3DGreasley%26aufirst%3DP.%2BJ.%26atitle%3DTicagrelor%2520binds%2520to%2520human%2520P2Y%252812%2529%2520independently%2520from%2520ADP%2520but%2520antagonizes%2520ADP-induced%2520receptor%2520signaling%2520and%2520platelet%2520aggregation%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2009%26volume%3D7%26spage%3D1556%26epage%3D1565%26doi%3D10.1111%2Fj.1538-7836.2009.03527.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Capodanno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dharmashankar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolillo, D. J.</span><span> </span><span class="NLM_article-title">Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist</span> <span class="citation_source-journal">Expert Rev. Cardiovasc. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1586/erc.09.172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1586%2Ferc.09.172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20136601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1yltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=151-158&author=D.+Capodannoauthor=K.+Dharmashankarauthor=D.+J.+Angiolillo&title=Mechanism+of+action+and+clinical+development+of+ticagrelor%2C+a+novel+platelet+ADP+P2Y12+receptor+antagonist&doi=10.1586%2Ferc.09.172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist</span></div><div class="casAuthors">Capodanno, Davide; Dharmashankar, Kodlipet; Angiolillo, Dominick J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Cardiovascular Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">ERCTAS</span>;
        ISSN:<span class="NLM_cas:issn">1477-9072</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhibition of the platelet ADP P2Y12 receptor has shown to be assocd. with a marked risk redn. of atherothrombotic events in high-risk settings, including patients with acute coronary syndromes and those undergoing percutaneous coronary interventions.  Clin. and lab. experiences have led to a better comprehension of the drawbacks of currently available P2Y12 receptor antagonists, stimulating the development of novel agents.  Ticagrelor (AZD6140) is the first drug of a new chem. class called cyclopentyltriazolopyrimidine, which is administered orally and has a reversible P2Y12 receptor inhibitory effect.  Preclin. and early-phase clin. studies have shown ticagrelor to be characterized by a rapid, greater and consistent antiplatelet effect with a favorable safety profile.  Recent findings from large-scale Phase III trials showed ticagrelor to be more effective in preventing ischemic events in acute coronary syndrome patients without an increased risk of protocol-defined major bleeding, but with an increase in the rate of nonprocedure-related bleeding, compared with currently recommended treatment regimens.  This article provides an overview of the pharmacol. properties and clin. development of ticagrelor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGret9Jrzf-JM7Vg90H21EOLACvtfcHk0lgj_UsVFhus8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1yltrc%253D&md5=564687ac7accfd6a34fd682826d85bcd</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1586%2Ferc.09.172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Ferc.09.172%26sid%3Dliteratum%253Aachs%26aulast%3DCapodanno%26aufirst%3DD.%26aulast%3DDharmashankar%26aufirst%3DK.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DMechanism%2520of%2520action%2520and%2520clinical%2520development%2520of%2520ticagrelor%252C%2520a%2520novel%2520platelet%2520ADP%2520P2Y12%2520receptor%2520antagonist%26jtitle%3DExpert%2520Rev.%2520Cardiovasc.%2520Ther.%26date%3D2010%26volume%3D8%26spage%3D151%26epage%3D158%26doi%3D10.1586%2Ferc.09.172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Nilsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giezen, J. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, P. J.</span><span> </span><span class="NLM_article-title">Evidence for distinct ligand binding sites on recombinant P2Y<sub>12</sub> receptors</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl II</span><span class="NLM_x">) </span> <span class="NLM_fpage">II</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2006&pages=II-248&issue=Suppl+II&author=L.+Nilssonauthor=J.+J.+J.+van+Giezenauthor=P.+J.+Greasley&title=Evidence+for+distinct+ligand+binding+sites+on+recombinant+P2Y12+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DGreasley%26aufirst%3DP.%2BJ.%26atitle%3DEvidence%2520for%2520distinct%2520ligand%2520binding%2520sites%2520on%2520recombinant%2520P2Y12%2520receptors%26jtitle%3DCirculation%26date%3D2006%26volume%3D114%26issue%3DSuppl%2520II%26spage%3DII%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Springthorpe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birkinshaw, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guile, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ince, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimore, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigby, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teobald, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webborn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, P. A.</span><span> </span><span class="NLM_article-title">From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6013</span><span class="NLM_x">–</span> <span class="NLM_lpage">6018</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.07.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2007.07.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17827008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6013-6018&author=B.+Springthorpeauthor=A.+Baileyauthor=P.+Bartonauthor=T.+N.+Birkinshawauthor=R.+V.+Bonnertauthor=R.+C.+Brownauthor=D.+Chapmanauthor=J.+Dixonauthor=S.+D.+Guileauthor=R.+G.+Humphriesauthor=S.+F.+Huntauthor=F.+Inceauthor=A.+H.+Ingallauthor=I.+P.+Kirkauthor=P.+D.+Leesonauthor=P.+Leffauthor=R.+J.+Lewisauthor=B.+P.+Martinauthor=D.+F.+McGinnityauthor=M.+P.+Mortimoreauthor=S.+W.+Paineauthor=G.+Pairaudeauauthor=A.+Patelauthor=A.+J.+Rigbyauthor=R.+J.+Rileyauthor=B.+J.+Teobaldauthor=W.+Tomlinsonauthor=P.+J.+Webbornauthor=P.+A.+Willis&title=From+ATP+to+AZD6140%3A+the+discovery+of+an+orally+active+reversible+P2Y12+receptor+antagonist+for+the+prevention+of+thrombosis&doi=10.1016%2Fj.bmcl.2007.07.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis</span></div><div class="casAuthors">Springthorpe, Brian; Bailey, Andrew; Barton, Patrick; Birkinshaw, Timothy N.; Bonnert, Roger V.; Brown, Roger C.; Chapman, David; Dixon, John; Guile, Simon D.; Humphries, Robert G.; Hunt, Simon F.; Ince, Francis; Ingall, Anthony H.; Kirk, Ian P.; Leeson, Paul D.; Leff, Paul; Lewis, Richard J.; Martin, Barrie P.; McGinnity, Dermot F.; Mortimore, Michael P.; Paine, Stuart W.; Pairaudeau, Garry; Patel, Anil; Rigby, Aaron J.; Riley, Robert J.; Teobald, Barry J.; Tomlinson, Wendy; Webborn, Peter J. H.; Willis, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6013-6018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Starting from ATP, the identification of a novel series of P2Y12 receptor antagonists and exploitation of their SAR is described.  Modifications of the acidic side chain and the purine core and investigation of hydrophobic substituents led to a series of neutral mols.  The leading compd., (AZD6140, I), is currently in a large phase III clin. trial for the treatment of acute coronary syndromes and prevention of thromboembolic clin. sequelae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOx3G4xnQGbVg90H21EOLACvtfcHk0lhPAVqMPlaWWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSitLvN&md5=9342d8eeb232c86e3aa0ffb2a96af659</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.057%26sid%3Dliteratum%253Aachs%26aulast%3DSpringthorpe%26aufirst%3DB.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBirkinshaw%26aufirst%3DT.%2BN.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBrown%26aufirst%3DR.%2BC.%26aulast%3DChapman%26aufirst%3DD.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DGuile%26aufirst%3DS.%2BD.%26aulast%3DHumphries%26aufirst%3DR.%2BG.%26aulast%3DHunt%26aufirst%3DS.%2BF.%26aulast%3DInce%26aufirst%3DF.%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DKirk%26aufirst%3DI.%2BP.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DR.%2BJ.%26aulast%3DMartin%26aufirst%3DB.%2BP.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DMortimore%26aufirst%3DM.%2BP.%26aulast%3DPaine%26aufirst%3DS.%2BW.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DRigby%26aufirst%3DA.%2BJ.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DTeobald%26aufirst%3DB.%2BJ.%26aulast%3DTomlinson%26aufirst%3DW.%26aulast%3DWebborn%26aufirst%3DP.%2BJ.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26atitle%3DFrom%2520ATP%2520to%2520AZD6140%253A%2520the%2520discovery%2520of%2520an%2520orally%2520active%2520reversible%2520P2Y12%2520receptor%2520antagonist%2520for%2520the%2520prevention%2520of%2520thrombosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6013%26epage%3D6018%26doi%3D10.1016%2Fj.bmcl.2007.07.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Caplain, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaud, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Necciari, J.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of clopidogrel</span> <span class="citation_source-journal">Semin. Thromb. Hemost.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10440419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1MXltVKmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1999&pages=25-28&issue=Suppl+2&author=H.+Caplainauthor=F.+Donatauthor=C.+Gaudauthor=J.+Necciari&title=Pharmacokinetics+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of clopidogrel</span></div><div class="casAuthors">Caplain, Henri; Donat, Francois; Gaud, C.; Necciari, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">25-28</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">Single- and multiple-dose pharmacokinetics of SR26334, the inactive carboxylic acid metabolite of clopidogrel, were investigated following oral doses of clopidogrel to healthy men.  The mean max. plasma concns. (Cmax) of SR26334 following single doses of 50, 75, 100, and 150 mg clopidogrel were 1.6, 2.9, 3.1, and 4.9 mg/L, resp.  This demonstrated a dose-proportional increase of Cmax in this range of clopidogrel doses.  The urinary excretion of SR26334 was low (2.2-2.4% of the dose administered), and renal clearance remained virtually const. for 2-24 h after all 4 doses.  Median times required to reach Cmax (0.8-1.0 h) and mean plasma half-lives (7.2-7.6 h) were not significantly different among the doses.  Following repeated doses of 75 mg clopidogrel, mean plasma trough concns. of SR26334 at steady state ranged 0.11-0.80 mg/L.  These values are similar to those obsd. during the 12-wk administration of clopidogrel, indicating that steady-state values are reproducible and that the esterase biotransformation of clopidogrel into its carboxylic acid metabolite remains const. over a no. of months of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzkQR1dw1j2rVg90H21EOLACvtfcHk0lhPAVqMPlaWWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVKmurY%253D&md5=1d6ce13080c8e860e5bac57bc1b2b77f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaplain%26aufirst%3DH.%26aulast%3DDonat%26aufirst%3DF.%26aulast%3DGaud%26aufirst%3DC.%26aulast%3DNecciari%26aufirst%3DJ.%26atitle%3DPharmacokinetics%2520of%2520clopidogrel%26jtitle%3DSemin.%2520Thromb.%2520Hemost.%26date%3D1999%26volume%3D25%26issue%3DSuppl%25202%26spage%3D25%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garofolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shwajch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, H.</span><span> </span><span class="NLM_article-title">Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1002/rcm.2813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Frcm.2813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17154350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1OqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=169-179&author=N.+A.+Faridauthor=M.+McIntoshauthor=F.+Garofoloauthor=E.+Wongauthor=A.+Shwajchauthor=M.+Kennedyauthor=M.+Youngauthor=P.+Sarkarauthor=K.+Kawabataauthor=M.+Takahashiauthor=H.+Pang&title=Determination+of+the+active+and+inactive+metabolites+of+prasugrel+in+human+plasma+by+liquid+chromatography%2Ftandem+mass+spectrometry&doi=10.1002%2Frcm.2813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry</span></div><div class="casAuthors">Farid, Nagy A.; McIntosh, Mary; Garofolo, Fabio; Wong, Ernest; Shwajch, Amanda; Kennedy, Monika; Young, Michelle; Sarkar, Pratibha; Kawabata, Kiyoshi; Takahashi, Makoto; Pang, Henrianna</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Two fast and sensitive liq. chromatog./tandem mass spectrometry (LC/MS/MS)-based bioanal. assays were developed and validated to quantify the active and three inactive metabolites of prasugrel.  Prasugrel is a novel thienopyridine prodrug that is metabolized to the pharmacol. active metabolite in addn. to three inactive metabolites, which directly relate to the formation and elimination of the active metabolite.  After extn. and sepn., the analytes were detected and quantified using a triple quadrupole mass spectrometer using pos. electrospray ionization.  The validated concn. range for the inactive metabolites assay was from 1 to 500 ng/mL for each of the three analytes.  Addnl., a 5× diln. factor was validated.  The interday accuracy ranged from -10.5% to 12.5% and the precision ranged from 2.4% to 6.6% for all three analytes.  All results showed accuracy and precision within ±20% at the lower limit of quantification and ±15% at other levels.  The validated concn. range for the active metabolite assay was from 0.5 to 250 ng/mL.  Addnl., a 10× diln. factor was validated.  The interbatch accuracy ranged from -7.00% to 5.98%, while the precision ranged from 0.98% to 3.39%.  Derivatization of the active metabolite in blood with 2-bromo-3'-methoxyacetophenone immediately after collection was essential to ensure the stability of the metabolite during sample processing and storage.  These methods have been applied to det. the concns. of the active and inactive metabolites of prasugrel in human plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrcIZp5TlTbVg90H21EOLACvtfcHk0lhPAVqMPlaWWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1OqtA%253D%253D&md5=52a7520888b51d7e20a305466a18352f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1002%2Frcm.2813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.2813%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DMcIntosh%26aufirst%3DM.%26aulast%3DGarofolo%26aufirst%3DF.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DShwajch%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DSarkar%26aufirst%3DP.%26aulast%3DKawabata%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DH.%26atitle%3DDetermination%2520of%2520the%2520active%2520and%2520inactive%2520metabolites%2520of%2520prasugrel%2520in%2520human%2520plasma%2520by%2520liquid%2520chromatography%252Ftandem%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2007%26volume%3D21%26spage%3D169%26epage%3D179%26doi%3D10.1002%2Frcm.2813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Quan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallheer, J. M.</span><span> </span><span class="NLM_article-title">The race to an orally active Factor Xa inhibitor: recent advances</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15338955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvFOms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=460-469&author=M.+L.+Quanauthor=J.+M.+Smallheer&title=The+race+to+an+orally+active+Factor+Xa+inhibitor%3A+recent+advances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The race to an orally active factor Xa inhibitor: Recent advances</span></div><div class="casAuthors">Quan, Mimi L.; Smallheer, Joanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">460-469</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Factor Xa (fXa) is a key enzyme in the coagulation cascade and an essential component of the prothrombinase complex, which activates prothrombin to thrombin, leading to fibrin clot formation.  In the search for a more effective and safer orally active anticoagulant, fXa has emerged as a major target for potential therapeutic applications in the treatment and prevention of thrombosis.  This review focuses on recent advances in the chem. of drug design and lead optimization of orally bioavailable fXa inhibitors.  Many of these orally active fXa inhibitors are currently in clin. trials and are anticipated to change the landscape of thrombosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoypUcAjnM_r7Vg90H21EOLACvtfcHk0liiLxABqAGldQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvFOms7w%253D&md5=e39eb102ea35b44a97c5d18ca9d90304</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DSmallheer%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520race%2520to%2520an%2520orally%2520active%2520Factor%2520Xa%2520inhibitor%253A%2520recent%2520advances%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2004%26volume%3D7%26spage%3D460%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheney, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallwood, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rendina, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luettgen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knabb, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, P. Y.</span><span> </span><span class="NLM_article-title">Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4118</span><span class="NLM_x">–</span> <span class="NLM_lpage">4123</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.05.095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18550370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslequ7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4118-4123&author=J.+X.+Qiaoauthor=D.+L.+Cheneyauthor=R.+S.+Alexanderauthor=A.+M.+Smallwoodauthor=S.+R.+Kingauthor=K.+Heauthor=A.+R.+Rendinaauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=R.+R.+Wexlerauthor=P.+Y.+Lam&title=Achieving+structural+diversity+using+the+perpendicular+conformation+of+alpha-substituted+phenylcyclopropanes+to+mimic+the+bioactive+conformation+of+ortho-substituted+biphenyl+P4+moieties%3A+discovery+of+novel%2C+highly+potent+inhibitors+of+Factor+Xa&doi=10.1016%2Fj.bmcl.2008.05.095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa</span></div><div class="casAuthors">Qiao, Jennifer X.; Cheney, Daniel L.; Alexander, Richard S.; Smallwood, Angela M.; King, Sarah R.; He, Kan; Rendina, Alan R.; Luettgen, Joseph M.; Knabb, Robert M.; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4118-4123</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ortho-substituted biphenyl moieties are widely used in drug design.  We herein report a successful use of the perpendicular conformation of the alpha-substituted phenylcyclopropyl groups to mimic the aplanar, biol. active conformation of the ortho-substituted biphenyl moieties to achieve structural diversity.  This is exemplified by the design and synthesis of a series of highly potent pyrazole bicyclic-based Factor Xa (FXa) inhibitors bearing alpha-substituted phenylcyclopropyl P4 moieties.  The designed perpendicular conformation was confirmed by the X-ray structure of FXa-bound compd. I.  The potential structural basis for the high FXa potency in the phenylcyclopropyl P4 analogs and their improved FXa inhibitory activities compared with the biphenyl P4 counterparts are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK2wNc7asx8bVg90H21EOLACvtfcHk0liiLxABqAGldQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslequ7o%253D&md5=4c06af32c061accffbed26a39031108e</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.095%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DCheney%26aufirst%3DD.%2BL.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DSmallwood%26aufirst%3DA.%2BM.%26aulast%3DKing%26aufirst%3DS.%2BR.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%26atitle%3DAchieving%2520structural%2520diversity%2520using%2520the%2520perpendicular%2520conformation%2520of%2520alpha-substituted%2520phenylcyclopropanes%2520to%2520mimic%2520the%2520bioactive%2520conformation%2520of%2520ortho-substituted%2520biphenyl%2520P4%2520moieties%253A%2520discovery%2520of%2520novel%252C%2520highly%2520potent%2520inhibitors%2520of%2520Factor%2520Xa%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4118%26epage%3D4123%26doi%3D10.1016%2Fj.bmcl.2008.05.095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Pinto, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galemmo, R. A.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orwat, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallwood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luettgen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rendina, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knabb, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, P. Y.</span><span> </span><span class="NLM_article-title">Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5584</span><span class="NLM_x">–</span> <span class="NLM_lpage">5589</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2006.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16963264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSis7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5584-5589&author=D.+J.+Pintoauthor=R.+A.+Galemmoauthor=M.+L.+Quanauthor=M.+J.+Orwatauthor=C.+Clarkauthor=R.+Liauthor=B.+Wellsauthor=F.+Woernerauthor=R.+S.+Alexanderauthor=K.+A.+Rossiauthor=A.+Smallwoodauthor=P.+C.+Wongauthor=J.+M.+Luettgenauthor=A.+R.+Rendinaauthor=R.+M.+Knabbauthor=K.+Heauthor=R.+R.+Wexlerauthor=P.+Y.+Lam&title=Discovery+of+potent%2C+efficacious%2C+and+orally+bioavailable+inhibitors+of+blood+coagulation+factor+Xa+with+neutral+P1+moieties&doi=10.1016%2Fj.bmcl.2006.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties</span></div><div class="casAuthors">Pinto, Donald J. P.; Galemmo, Robert A.; Quan, Mimi L.; Orwat, Michael J.; Clark, Charles; Li, Renhua; Wells, Brian; Woerner, Francis; Alexander, Richard S.; Rossi, Karen A.; Smallwood, Angela; Wong, Pancras C.; Luettgen, Joseph M.; Rendina, Alan R.; Knabb, Robert M.; He, Kan; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5584-5589</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa.  The compd. 3-[6-(2'-dimethylaminomethylbiphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine-1-yl]-benzamide shows good factor Xa potency, selectivity, in vivo efficacy and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBUWs8zs_04LVg90H21EOLACvtfcHk0lgJrxOSe2LdZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSis7zF&md5=3b4511f8606ab5fa3a4ffeede492a55c</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DGalemmo%26aufirst%3DR.%2BA.%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DB.%26aulast%3DWoerner%26aufirst%3DF.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520potent%252C%2520efficacious%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520blood%2520coagulation%2520factor%2520Xa%2520with%2520neutral%2520P1%2520moieties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5584%26epage%3D5589%26doi%3D10.1016%2Fj.bmcl.2006.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kussmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochsenfeld, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slipchenko, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levchenko, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiStasio, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lochan, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besley, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassolov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maslen, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korambath, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dachsel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerksen, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreuw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunietz, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutoi, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furlani, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwaltney, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kedziora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalliulin, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klunzinger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proynov, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieniazek, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhee, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherrill, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmonett, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subotnik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodcock, H. L.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chipman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keil, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warshel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehre, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, H. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krylov, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head-Gordon, M.</span><span> </span><span class="NLM_article-title">Advances in methods and algorithms in a modern quantum chemistry program package</span> <span class="citation_source-journal">Phys. Chem. Chem. Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3172</span><span class="NLM_x">–</span> <span class="NLM_lpage">3191</span><span class="refDoi"> DOI: 10.1039/B517914A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1039%2FB517914A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16902710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsValsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=3172-3191&author=Y.+Shaoauthor=L.+F.+Molnarauthor=Y.+Jungauthor=J.+Kussmannauthor=C.+Ochsenfeldauthor=S.+T.+Brownauthor=A.+T.+Gilbertauthor=L.+V.+Slipchenkoauthor=S.+V.+Levchenkoauthor=D.+P.+O%E2%80%99Neillauthor=R.+A.+DiStasioauthor=R.+C.+Lochanauthor=T.+Wangauthor=G.+J.+Beranauthor=N.+A.+Besleyauthor=J.+M.+Herbertauthor=C.+Y.+Linauthor=T.+Van+Voorhisauthor=S.+H.+Chienauthor=A.+Sodtauthor=R.+P.+Steeleauthor=V.+A.+Rassolovauthor=P.+E.+Maslenauthor=P.+P.+Korambathauthor=R.+D.+Adamsonauthor=B.+Austinauthor=J.+Bakerauthor=E.+F.+Byrdauthor=H.+Dachselauthor=R.+J.+Doerksenauthor=A.+Dreuwauthor=B.+D.+Dunietzauthor=A.+D.+Dutoiauthor=T.+R.+Furlaniauthor=S.+R.+Gwaltneyauthor=A.+Heydenauthor=S.+Hirataauthor=C.+P.+Hsuauthor=G.+Kedzioraauthor=R.+Z.+Khalliulinauthor=P.+Klunzingerauthor=A.+M.+Leeauthor=M.+S.+Leeauthor=W.+Liangauthor=I.+Lotanauthor=N.+Nairauthor=B.+Petersauthor=E.+I.+Proynovauthor=P.+A.+Pieniazekauthor=Y.+M.+Rheeauthor=J.+Ritchieauthor=E.+Rostaauthor=C.+D.+Sherrillauthor=A.+C.+Simmonettauthor=J.+E.+Subotnikauthor=H.+L.+Woodcockauthor=W.+Zhangauthor=A.+T.+Bellauthor=A.+K.+Chakrabortyauthor=D.+M.+Chipmanauthor=F.+J.+Keilauthor=A.+Warshelauthor=W.+J.+Hehreauthor=H.+F.+Schaeferauthor=J.+Kongauthor=A.+I.+Krylovauthor=P.+M.+Gillauthor=M.+Head-Gordon&title=Advances+in+methods+and+algorithms+in+a+modern+quantum+chemistry+program+package&doi=10.1039%2FB517914A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in methods and algorithms in a modern quantum chemistry program package</span></div><div class="casAuthors">Shao, Yihan; Molnar, Laszlo Fusti; Jung, Yousung; Kussmann, Jorg; Ochsenfeld, Christian; Brown, Shawn T.; Gilbert, Andrew T. B.; Slipchenko, Lyudmila V.; Levchenko, Sergey V.; O'Neill, Darragh P.; DiStasio, Robert A., Jr.; Lochan, Rohini C.; Wang, Tao; Beran, Gregory J. O.; Besley, Nicholas A.; Herbert, John M.; Lin, Ching Yeh; Van Voorhis, Troy; Chien, Siu Hung; Sodt, Alex; Steele, Ryan P.; Rassolov, Vitaly A.; Maslen, Paul E.; Korambath, Prakashan P.; Adamson, Ross D.; Austin, Brian; Baker, Jon; Byrd, Edward F. C.; Dachsel, Holger; Doerksen, Robert J.; Dreuw, Andreas; Dunietz, Barry D.; Dutoi, Anthony D.; Furlani, Thomas R.; Gwaltney, Steven R.; Heyden, Andreas; Hirata, So; Hsu, Chao-Ping; Kedziora, Gary; Khalliulin, Rustam Z.; Klunzinger, Phil; Lee, Aaron M.; Lee, Michael S.; Liang, WanZhen; Lotan, Itay; Nair, Nikhil; Peters, Baron; Proynov, Emil I.; Pieniazek, Piotr A.; Rhee, Young Min; Ritchie, Jim; Rosta, Edina; Sherrill, C. David; Simmonett, Andrew C.; Subotnik, Joseph E.; Woodcock, H. Lee, III; Zhang, Weimin; Bell, Alexis T.; Chakraborty, Arup K.; Chipman, Daniel M.; Keil, Frerich J.; Warshel, Arieh; Hehre, Warren J.; Schaefer, Henry F., III; Kong, Jing; Krylov, Anna I.; Gill, Peter M. W.; Head-Gordon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3172-3191</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Advances in theory and algorithms for electronic structure calcns. must be incorporated into program packages to enable them to become routinely used by the broader chem. community.  This work reviews advances made over the past five years or so that constitute the major improvements contained in a new release of the Q-Chem quantum chem. package, together with illustrative timings and applications.  Specific developments discussed include fast methods for d. functional theory calcns., linear scaling evaluation of energies, NMR chem. shifts and elec. properties, fast auxiliary basis function methods for correlated energies and gradients, equation-of-motion coupled cluster methods for ground and excited states, geminal wavefunctions, embedding methods and techniques for exploring potential energy surfaces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNN2YG1uDDs7Vg90H21EOLACvtfcHk0lgJrxOSe2LdZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsValsbs%253D&md5=0ba1d2a350afc7922d2f9ca0c6e47d34</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1039%2FB517914A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB517914A%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DY.%26aulast%3DMolnar%26aufirst%3DL.%2BF.%26aulast%3DJung%26aufirst%3DY.%26aulast%3DKussmann%26aufirst%3DJ.%26aulast%3DOchsenfeld%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DS.%2BT.%26aulast%3DGilbert%26aufirst%3DA.%2BT.%26aulast%3DSlipchenko%26aufirst%3DL.%2BV.%26aulast%3DLevchenko%26aufirst%3DS.%2BV.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DD.%2BP.%26aulast%3DDiStasio%26aufirst%3DR.%2BA.%26aulast%3DLochan%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBeran%26aufirst%3DG.%2BJ.%26aulast%3DBesley%26aufirst%3DN.%2BA.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DVan%2BVoorhis%26aufirst%3DT.%26aulast%3DChien%26aufirst%3DS.%2BH.%26aulast%3DSodt%26aufirst%3DA.%26aulast%3DSteele%26aufirst%3DR.%2BP.%26aulast%3DRassolov%26aufirst%3DV.%2BA.%26aulast%3DMaslen%26aufirst%3DP.%2BE.%26aulast%3DKorambath%26aufirst%3DP.%2BP.%26aulast%3DAdamson%26aufirst%3DR.%2BD.%26aulast%3DAustin%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DByrd%26aufirst%3DE.%2BF.%26aulast%3DDachsel%26aufirst%3DH.%26aulast%3DDoerksen%26aufirst%3DR.%2BJ.%26aulast%3DDreuw%26aufirst%3DA.%26aulast%3DDunietz%26aufirst%3DB.%2BD.%26aulast%3DDutoi%26aufirst%3DA.%2BD.%26aulast%3DFurlani%26aufirst%3DT.%2BR.%26aulast%3DGwaltney%26aufirst%3DS.%2BR.%26aulast%3DHeyden%26aufirst%3DA.%26aulast%3DHirata%26aufirst%3DS.%26aulast%3DHsu%26aufirst%3DC.%2BP.%26aulast%3DKedziora%26aufirst%3DG.%26aulast%3DKhalliulin%26aufirst%3DR.%2BZ.%26aulast%3DKlunzinger%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DLotan%26aufirst%3DI.%26aulast%3DNair%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DB.%26aulast%3DProynov%26aufirst%3DE.%2BI.%26aulast%3DPieniazek%26aufirst%3DP.%2BA.%26aulast%3DRhee%26aufirst%3DY.%2BM.%26aulast%3DRitchie%26aufirst%3DJ.%26aulast%3DRosta%26aufirst%3DE.%26aulast%3DSherrill%26aufirst%3DC.%2BD.%26aulast%3DSimmonett%26aufirst%3DA.%2BC.%26aulast%3DSubotnik%26aufirst%3DJ.%2BE.%26aulast%3DWoodcock%26aufirst%3DH.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBell%26aufirst%3DA.%2BT.%26aulast%3DChakraborty%26aufirst%3DA.%2BK.%26aulast%3DChipman%26aufirst%3DD.%2BM.%26aulast%3DKeil%26aufirst%3DF.%2BJ.%26aulast%3DWarshel%26aufirst%3DA.%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26aulast%3DSchaefer%26aufirst%3DH.%2BF.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DKrylov%26aufirst%3DA.%2BI.%26aulast%3DGill%26aufirst%3DP.%2BM.%26aulast%3DHead-Gordon%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520methods%2520and%2520algorithms%2520in%2520a%2520modern%2520quantum%2520chemistry%2520program%2520package%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2006%26volume%3D8%26spage%3D3172%26epage%3D3191%26doi%3D10.1039%2FB517914A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Prins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoeven, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBoer, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C.</span><span> </span><span class="NLM_article-title">Conformational studies on acylcyclopropanes-I: the He-I photoelectron spectra of alpha-alkylphenylcyclopropanes</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1016/0040-4020(77)80443-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0040-4020%2877%2980443-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1977&pages=127-131&author=I.+Prinsauthor=J.+W.+Verhoevenauthor=T.+J.+deBoerauthor=C.+Worrell&title=Conformational+studies+on+acylcyclopropanes-I%3A+the+He-I+photoelectron+spectra+of+alpha-alkylphenylcyclopropanes&doi=10.1016%2F0040-4020%2877%2980443-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2877%2980443-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252877%252980443-2%26sid%3Dliteratum%253Aachs%26aulast%3DPrins%26aufirst%3DI.%26aulast%3DVerhoeven%26aufirst%3DJ.%2BW.%26aulast%3DdeBoer%26aufirst%3DT.%2BJ.%26aulast%3DWorrell%26aufirst%3DC.%26atitle%3DConformational%2520studies%2520on%2520acylcyclopropanes-I%253A%2520the%2520He-I%2520photoelectron%2520spectra%2520of%2520alpha-alkylphenylcyclopropanes%26jtitle%3DTetrahedron%26date%3D1977%26volume%3D33%26spage%3D127%26epage%3D131%26doi%3D10.1016%2F0040-4020%2877%2980443-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Williams, E. M. V.</span><span> </span><span class="NLM_article-title">A classification of antiarrhythmic actions reassessed after a decade of new drugs</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1002/j.1552-4604.1984.tb01822.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fj.1552-4604.1984.tb01822.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=6144698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVegs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1984&pages=129-147&author=E.+M.+V.+Williams&title=A+classification+of+antiarrhythmic+actions+reassessed+after+a+decade+of+new+drugs&doi=10.1002%2Fj.1552-4604.1984.tb01822.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">A classification of antiarrhythmic actions reassessed after a decade of new drugs</span></div><div class="casAuthors">Williams, E. M. Vaughan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">129-47</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">A review and discussion with 86 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7_u82uQNcrrVg90H21EOLACvtfcHk0lgd9VIV8Le3OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVegs74%253D&md5=660259418d1cd21fd1343118eae1c76a</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1984.tb01822.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1984.tb01822.x%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DE.%2BM.%2BV.%26atitle%3DA%2520classification%2520of%2520antiarrhythmic%2520actions%2520reassessed%2520after%2520a%2520decade%2520of%2520new%2520drugs%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D24%26spage%3D129%26epage%3D147%26doi%3D10.1002%2Fj.1552-4604.1984.tb01822.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claremon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkiewicz, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieckhaus, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, K.</span><span> </span><span class="NLM_article-title">Novel 5-cyclopropyl-1,4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span><span class="refDoi"> DOI: 10.1016/S0960-894X(03)00049-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0960-894X%2803%2900049-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=1165-1168&author=J.+W.+Butcherauthor=N.+J.+Livertonauthor=D.+A.+Claremonauthor=R.+M.+Freidingerauthor=N.+K.+Jurkiewiczauthor=J.+J.+Lynchauthor=J.+J.+Salataauthor=J.+Wangauthor=C.+M.+Dieckhausauthor=D.+E.+Slaughterauthor=K.+Vyas&title=Novel+5-cyclopropyl-1%2C4-benzodiazepin-2-ones+as+potent+and+selective+I%28Ks%29-blocking+class+III+antiarrhythmic+agents&doi=10.1016%2FS0960-894X%2803%2900049-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900049-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900049-0%26sid%3Dliteratum%253Aachs%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DClaremon%26aufirst%3DD.%2BA.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DJurkiewicz%26aufirst%3DN.%2BK.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDieckhaus%26aufirst%3DC.%2BM.%26aulast%3DSlaughter%26aufirst%3DD.%2BE.%26aulast%3DVyas%26aufirst%3DK.%26atitle%3DNovel%25205-cyclopropyl-1%252C4-benzodiazepin-2-ones%2520as%2520potent%2520and%2520selective%2520I%2528Ks%2529-blocking%2520class%2520III%2520antiarrhythmic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D1165%26epage%3D1168%26doi%3D10.1016%2FS0960-894X%2803%2900049-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Selnick, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claremon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libby, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pribush, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remy, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkiewicz, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, K.</span><span> </span><span class="NLM_article-title">Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">3865</span><span class="NLM_x">–</span> <span class="NLM_lpage">3868</span><span class="refDoi"> DOI: 10.1021/jm970517u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970517u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=3865-3868&author=H.+G.+Selnickauthor=N.+J.+Livertonauthor=J.+J.+Baldwinauthor=J.+W.+Butcherauthor=D.+A.+Claremonauthor=J.+M.+Elliottauthor=R.+M.+Freidingerauthor=S.+A.+Kingauthor=B.+E.+Libbyauthor=C.+J.+McIntyreauthor=D.+A.+Pribushauthor=D.+C.+Remyauthor=G.+R.+Smithauthor=A.+J.+Tebbenauthor=N.+K.+Jurkiewiczauthor=J.+J.+Lynchauthor=J.+J.+Salataauthor=M.+C.+Sanguinettiauthor=P.+K.+Sieglauthor=D.+E.+Slaughterauthor=K.+Vyas&title=Class+III+antiarrhythmic+activity+in+vivo+by+selective+blockade+of+the+slowly+activating+cardiac+delayed+rectifier+potassium+current+IKs+by+%28R%29-2-%282%2C4-trifluoromethyl%29-N-%5B2-oxo-5-phenyl-1-%282%2C2%2C2-trifluoroethyl%29-+2%2C+3-dihydro-1H-benzo%5Be%5D%5B1%2C4%5Ddiazepin-3-yl%5Dacetamide&doi=10.1021%2Fjm970517u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Fjm970517u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970517u%26sid%3Dliteratum%253Aachs%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DClaremon%26aufirst%3DD.%2BA.%26aulast%3DElliott%26aufirst%3DJ.%2BM.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DKing%26aufirst%3DS.%2BA.%26aulast%3DLibby%26aufirst%3DB.%2BE.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DPribush%26aufirst%3DD.%2BA.%26aulast%3DRemy%26aufirst%3DD.%2BC.%26aulast%3DSmith%26aufirst%3DG.%2BR.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DJurkiewicz%26aufirst%3DN.%2BK.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DSlaughter%26aufirst%3DD.%2BE.%26aulast%3DVyas%26aufirst%3DK.%26atitle%3DClass%2520III%2520antiarrhythmic%2520activity%2520in%2520vivo%2520by%2520selective%2520blockade%2520of%2520the%2520slowly%2520activating%2520cardiac%2520delayed%2520rectifier%2520potassium%2520current%2520IKs%2520by%2520%2528R%2529-2-%25282%252C4-trifluoromethyl%2529-N-%255B2-oxo-5-phenyl-1-%25282%252C2%252C2-trifluoroethyl%2529-%25202%252C%25203-dihydro-1H-benzo%255Be%255D%255B1%252C4%255Ddiazepin-3-yl%255Dacetamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D3865%26epage%3D3868%26doi%3D10.1021%2Fjm970517u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Revermann, M.</span><span> </span><span class="NLM_article-title">Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/j.coph.2009.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.coph.2009.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20079692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs12ntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=173-178&author=M.+Revermann&title=Pharmacological+inhibition+of+the+soluble+epoxide+hydrolase-from+mouse+to+man&doi=10.1016%2Fj.coph.2009.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man</span></div><div class="casAuthors">Revermann, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review Epoxyeicosatrienoic acids (EETs) build a family consisting of four arachidonic acid derived regioisomers that are generated by P 450 epoxygenases.  In the past years, growing interest in influencing EET level arose since EETs possess numerous beneficial effects in the cardiovascular system, for example, vasodilation, anti-inflammation and elicit renal and myocardial protection.  Because EETs are primarily metabolized by the sol. epoxide hydrolase (sEH) and potent inhibitors of this enzyme are currently available, pharmacol. sEH inhibition seems to be a feasible approach to elevate EET level in vivo.  Hence, first clin. trials on sEH inhibition in man have begun.  This review focuses on sEH inhibition as a novel pharmacol. cardiovascular protective strategy with special regard to in vivo investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJbmf7xKGAirVg90H21EOLACvtfcHk0ljSstJNOJ_7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs12ntbY%253D&md5=d339f41d4a8d604928684f67c2966cd8</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2009.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2009.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DRevermann%26aufirst%3DM.%26atitle%3DPharmacological%2520inhibition%2520of%2520the%2520soluble%2520epoxide%2520hydrolase-from%2520mouse%2520to%2520man%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2010%26volume%3D10%26spage%3D173%26epage%3D178%26doi%3D10.1016%2Fj.coph.2009.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Imig, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammock, B. D.</span><span> </span><span class="NLM_article-title">Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">794</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span><span class="refDoi"> DOI: 10.1038/nrd2875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd2875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19794443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=794-805&author=J.+D.+Imigauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+as+a+therapeutic+target+for+cardiovascular+diseases&doi=10.1038%2Fnrd2875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases</span></div><div class="casAuthors">Imig, John D.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">794-805</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions.  These endogenous lipid mediators are broken down into diols by sol. epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial cardiovascular properties of EETs.  SEH inhibitors (sEHIs) that are based on 1,3-disubstituted urea were rapidly developed, and were shown to be antihypertensive and anti-inflammatory, and to protect the brain, heart and kidney from damage.  Although challenges for the future exist - including improving the drug-like properties of sEHIs and finding better ways to target sEHIs to specific tissues - the recent initiation of the first clin. trials of sEHIs has highlighted the therapeutic potential of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopFEiIF428mLVg90H21EOLACvtfcHk0ljSstJNOJ_7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurnK&md5=fc2af5b4802701035998e0435c8d2699</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnrd2875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2875%26sid%3Dliteratum%253Aachs%26aulast%3DImig%26aufirst%3DJ.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520as%2520a%2520therapeutic%2520target%2520for%2520cardiovascular%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D794%26epage%3D805%26doi%3D10.1038%2Fnrd2875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Takai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiyo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nariai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakatani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, T.</span><span> </span><span class="NLM_article-title">Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1705</span><span class="NLM_x">–</span> <span class="NLM_lpage">1708</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2015.02.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1705-1708&author=K.+Takaiauthor=N.+Chiyoauthor=T.+Nakajimaauthor=T.+Nariaiauthor=C.+Ishikawaauthor=S.+Nakataniauthor=A.+Ikenoauthor=S.+Yamamotoauthor=T.+Sone&title=Three-dimensional+rational+approach+to+the+discovery+of+potent+substituted+cyclopropyl+urea+soluble+epoxide+hydrolase+inhibitors&doi=10.1016%2Fj.bmcl.2015.02.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.076%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DK.%26aulast%3DChiyo%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DNariai%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DC.%26aulast%3DNakatani%26aufirst%3DS.%26aulast%3DIkeno%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DSone%26aufirst%3DT.%26atitle%3DThree-dimensional%2520rational%2520approach%2520to%2520the%2520discovery%2520of%2520potent%2520substituted%2520cyclopropyl%2520urea%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1705%26epage%3D1708%26doi%3D10.1016%2Fj.bmcl.2015.02.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakashita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakoda, R.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2727</span><span class="NLM_x">–</span> <span class="NLM_lpage">2743</span><span class="refDoi"> DOI: 10.1016/S0968-0896(01)00198-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0968-0896%2801%2900198-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2001&pages=2727-2743&author=M.+Suzukiauthor=H.+Iwasakiauthor=Y.+Fujikawaauthor=M.+Kitaharaauthor=M.+Sakashitaauthor=R.+Sakoda&title=Synthesis+and+biological+evaluations+of+quinoline-based+HMG-CoA+reductase+inhibitors&doi=10.1016%2FS0968-0896%2801%2900198-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2801%2900198-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252801%252900198-5%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DFujikawa%26aufirst%3DY.%26aulast%3DKitahara%26aufirst%3DM.%26aulast%3DSakashita%26aufirst%3DM.%26aulast%3DSakoda%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%2520quinoline-based%2520HMG-CoA%2520reductase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2001%26volume%3D9%26spage%3D2727%26epage%3D2743%26doi%3D10.1016%2FS0968-0896%2801%2900198-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Augeri, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betebenner, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpkins, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abboa-Offei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cap, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozzo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzel, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biller, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5025</span><span class="NLM_x">–</span> <span class="NLM_lpage">5037</span><span class="refDoi"> DOI: 10.1021/jm050261p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050261p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5025-5037&author=D.+J.+Augeriauthor=J.+A.+Roblauthor=D.+A.+Betebennerauthor=D.+R.+Magninauthor=A.+Khannaauthor=J.+G.+Robertsonauthor=A.+Wangauthor=L.+M.+Simpkinsauthor=P.+Taunkauthor=Q.+Huangauthor=S.+P.+Hanauthor=B.+Abboa-Offeiauthor=M.+Capauthor=L.+Xinauthor=L.+Taoauthor=E.+Tozzoauthor=G.+E.+Welzelauthor=D.+M.+Eganauthor=J.+Marcinkevicieneauthor=S.+Y.+Changauthor=S.+A.+Billerauthor=M.+S.+Kirbyauthor=R.+A.+Parkerauthor=L.+G.+Hamann&title=Discovery+and+preclinical+profile+of+saxagliptin+%28BMS-477118%29%3A+a+highly+potent%2C+long-acting%2C+orally+active+dipeptidyl+peptidase+IV+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm050261p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Augeri, David J.; Robl, Jeffrey A.; Betebenner, David A.; Magnin, David R.; Khanna, Ashish; Robertson, James G.; Wang, Aiying; Simpkins, Ligaya M.; Taunk, Prakash; Huang, Qi; Han, Song-Ping; Abboa-Offei, Benoni; Cap, Michael; Xin, Li; Tao, Li; Tozzo, Effie; Welzel, Gustav E.; Egan, Donald M.; Marcinkeviciene, Jovita; Chang, Shu Y.; Biller, Scott A.; Kirby, Mark S.; Parker, Rex A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5025-5037</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efforts to further elucidate structure-activity relationships (SAR) within the authors previously disclosed series of β-quaternary amino acid linked L-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the investigation of vinyl substitution at the β-position of α-cycloalkyl-substituted glycines.  Despite poor systemic exposure, vinyl-substituted compds. showed extended duration of action in acute rat ex vivo plasma DPP-IV inhibition models.  Oxygenated putative metabolites were prepd. and were shown to exhibit the potency and extended duration of action of their precursors in efficacy models measuring glucose clearance in Zuckerfa/fa rats.  Extension of this approach to adamantylglycine-derived inhibitors led to the discovery of highly potent inhibitors, including hydroxyadamantyl compd. BMS-477118 (saxagliptin), a highly efficacious, stable, and long-acting DPP-IV inhibitor, which is currently undergoing clin. trials for treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrIJX7K8p67Vg90H21EOLACvtfcHk0lgoYl8TOa8F2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb0%253D&md5=878355880133bb0ddd6bd14ecbf1d070</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm050261p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050261p%26sid%3Dliteratum%253Aachs%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DMagnin%26aufirst%3DD.%2BR.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DJ.%2BG.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DSimpkins%26aufirst%3DL.%2BM.%26aulast%3DTaunk%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DS.%2BP.%26aulast%3DAbboa-Offei%26aufirst%3DB.%26aulast%3DCap%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DTozzo%26aufirst%3DE.%26aulast%3DWelzel%26aufirst%3DG.%2BE.%26aulast%3DEgan%26aufirst%3DD.%2BM.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DS.%2BY.%26aulast%3DBiller%26aufirst%3DS.%2BA.%26aulast%3DKirby%26aufirst%3DM.%2BS.%26aulast%3DParker%26aufirst%3DR.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DDiscovery%2520and%2520preclinical%2520profile%2520of%2520saxagliptin%2520%2528BMS-477118%2529%253A%2520a%2520highly%2520potent%252C%2520long-acting%252C%2520orally%2520active%2520dipeptidyl%2520peptidase%2520IV%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5025%26epage%3D5037%26doi%3D10.1021%2Fjm050261p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Ashworth, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szelke, M.</span><span> </span><span class="NLM_article-title">4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2745</span><span class="NLM_x">–</span> <span class="NLM_lpage">2748</span><span class="refDoi"> DOI: 10.1016/S0960-894X(96)00491-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0960-894X%2896%2900491-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=2745-2748&author=D.+M.+Ashworthauthor=B.+Atrashauthor=G.+R.+Bakerauthor=A.+J.+Baxterauthor=P.+D.+Jenkinsauthor=D.+M.+Jonesauthor=M.+Szelke&title=4-Cyanothiazolidides+as+very+potent%2C+stable+inhibitors+of+dipeptidyl+peptidase+IV&doi=10.1016%2FS0960-894X%2896%2900491-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2896%2900491-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252896%252900491-X%26sid%3Dliteratum%253Aachs%26aulast%3DAshworth%26aufirst%3DD.%2BM.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DG.%2BR.%26aulast%3DBaxter%26aufirst%3DA.%2BJ.%26aulast%3DJenkins%26aufirst%3DP.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DSzelke%26aufirst%3DM.%26atitle%3D4-Cyanothiazolidides%2520as%2520very%2520potent%252C%2520stable%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D2745%26epage%3D2748%26doi%3D10.1016%2FS0960-894X%2896%2900491-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Magnin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulsky, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augeri, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpkins, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunk, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betebenner, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abboa-Offei, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cap, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitkoff, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gougoutas, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2587</span><span class="NLM_x">–</span> <span class="NLM_lpage">2598</span><span class="refDoi"> DOI: 10.1021/jm049924d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049924d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2587-2598&author=D.+R.+Magninauthor=J.+A.+Roblauthor=R.+B.+Sulskyauthor=D.+J.+Augeriauthor=Y.+Huangauthor=L.+M.+Simpkinsauthor=P.+C.+Taunkauthor=D.+A.+Betebennerauthor=J.+G.+Robertsonauthor=B.+E.+Abboa-Offeiauthor=A.+Wangauthor=M.+Capauthor=L.+Xinauthor=L.+Taoauthor=D.+F.+Sitkoffauthor=M.+F.+Malleyauthor=J.+Z.+Gougoutasauthor=A.+Khannaauthor=Q.+Huangauthor=S.+P.+Hanauthor=R.+A.+Parkerauthor=L.+G.+Hamann&title=Synthesis+of+novel+potent+dipeptidyl+peptidase+IV+inhibitors+with+enhanced+chemical+stability%3A+interplay+between+the+N-terminal+amino+acid+alkyl+side+chain+and+the+cyclopropyl+group+of+alpha-aminoacyl-l-cis-4%2C5-methanoprolinenitrile-based+inhibitors&doi=10.1021%2Fjm049924d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fjm049924d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049924d%26sid%3Dliteratum%253Aachs%26aulast%3DMagnin%26aufirst%3DD.%2BR.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DSulsky%26aufirst%3DR.%2BB.%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DSimpkins%26aufirst%3DL.%2BM.%26aulast%3DTaunk%26aufirst%3DP.%2BC.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DRobertson%26aufirst%3DJ.%2BG.%26aulast%3DAbboa-Offei%26aufirst%3DB.%2BE.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DCap%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DSitkoff%26aufirst%3DD.%2BF.%26aulast%3DMalley%26aufirst%3DM.%2BF.%26aulast%3DGougoutas%26aufirst%3DJ.%2BZ.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DS.%2BP.%26aulast%3DParker%26aufirst%3DR.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DSynthesis%2520of%2520novel%2520potent%2520dipeptidyl%2520peptidase%2520IV%2520inhibitors%2520with%2520enhanced%2520chemical%2520stability%253A%2520interplay%2520between%2520the%2520N-terminal%2520amino%2520acid%2520alkyl%2520side%2520chain%2520and%2520the%2520cyclopropyl%2520group%2520of%2520alpha-aminoacyl-l-cis-4%252C5-methanoprolinenitrile-based%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2587%26epage%3D2598%26doi%3D10.1021%2Fjm049924d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Metzler, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanchunas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span> </span><span class="NLM_article-title">Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1110/ps.073253208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1110%2Fps.073253208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18227430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVOntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=240-250&author=W.+J.+Metzlerauthor=J.+Yanchunasauthor=C.+Weigeltauthor=K.+Kishauthor=H.+E.+Kleiauthor=D.+Xieauthor=Y.+Zhangauthor=M.+Corbettauthor=J.+K.+Tamuraauthor=B.+Heauthor=L.+G.+Hamannauthor=M.+S.+Kirbyauthor=J.+Marcinkeviciene&title=Involvement+of+DPP-IV+catalytic+residues+in+enzyme-saxagliptin+complex+formation&doi=10.1110%2Fps.073253208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation</span></div><div class="casAuthors">Metzler, William J.; Yanchunas, Joseph; Weigelt, Carolyn; Kish, Kevin; Klei, Herbert E.; Xie, Dianlin; Zhang, Yaqun; Corbett, Martin; Tamura, James K.; He, Bin; Hamann, Lawrence G.; Kirby, Mark S.; Marcinkeviciene, Jovita</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-250</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The inhibition of DPP-IV by saxagliptin has been proposed to occur through formation of a covalent but reversible complex.  To evaluate further the mechanism of inhibition, we detd. the x-ray crystal structure of the DPP-IV:saxagliptin complex.  This structure reveals covalent attachment between S630 and the inhibitor nitrile carbon (C-O distance <1.3 Å).  To investigate whether this serine addn. is assisted by the catalytic His-Asp dyad, we generated two mutants of DPP-IV, S630A and H740Q, and assayed them for ability to bind inhibitor.  DPP-IVH740Q bound saxagliptin with an ∼1000-fold redn. in affinity relative to DPP-IVWT, while DPP-IVS630A showed no evidence for binding inhibitor.  An analog of saxagliptin lacking the nitrile group showed unchanged binding properties to the both mutant proteins, highlighting the essential role S630 and H740 play in covalent bond formation between S630 and saxagliptin.  Further supporting mechanism-based inhibition by saxagliptin, NMR spectra of enzyme-saxagliptin complexes revealed the presence of three downfield resonances with low fractionation factors characteristic of short and strong hydrogen bonds (SSHB).  Comparison of the NMR spectra of various wild-type and mutant DPP-IV:ligand complexes enabled assignment of a resonance at ∼14 ppm to H740.  Two addnl. DPP-IV mutants, Y547F and Y547Q, generated to probe potential stabilization of the enzyme-inhibitor complex by this residue, did not show any differences in inhibitor binding either by ITC or NMR.  Together with the previously published enzymic data, the structural and binding data presented here strongly support a histidine-assisted covalent bond formation between S630 hydroxyl oxygen and the nitrile group of saxagliptin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9JzGRDJ1J7rVg90H21EOLACvtfcHk0lgoYl8TOa8F2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVOntLo%253D&md5=d76619e8d6843e595a5bc971191a4828</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1110%2Fps.073253208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.073253208%26sid%3Dliteratum%253Aachs%26aulast%3DMetzler%26aufirst%3DW.%2BJ.%26aulast%3DYanchunas%26aufirst%3DJ.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DTamura%26aufirst%3DJ.%2BK.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKirby%26aufirst%3DM.%2BS.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26atitle%3DInvolvement%2520of%2520DPP-IV%2520catalytic%2520residues%2520in%2520enzyme-saxagliptin%2520complex%2520formation%26jtitle%3DProtein%2520Sci.%26date%3D2008%26volume%3D17%26spage%3D240%26epage%3D250%26doi%3D10.1110%2Fps.073253208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopcho, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langish, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipkova, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, M. S.</span><span> </span><span class="NLM_article-title">Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor</span> <span class="citation_source-journal">BMC Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">2210–12–2</span><span class="refDoi"> DOI: 10.1186/1471-2210-12-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1186%2F1471-2210-12-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22475049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVajsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=2-2210%E2%80%9312%E2%80%932&author=A.+Wangauthor=C.+Dorsoauthor=L.+Kopchoauthor=G.+Lockeauthor=R.+Langishauthor=E.+Harstadauthor=P.+Shipkovaauthor=J.+Marcinkevicieneauthor=L.+Hamannauthor=M.+S.+Kirby&title=Potency%2C+selectivity+and+prolonged+binding+of+saxagliptin+to+DPP4%3A+maintenance+of+DPP4+inhibition+by+saxagliptin+in+vitro+and+ex+vivo+when+compared+to+a+rapidly-dissociating+DPP4+inhibitor&doi=10.1186%2F1471-2210-12-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor</span></div><div class="casAuthors">Wang, Aiying; Dorso, Charles; Kopcho, Lisa; Locke, Gregory; Langish, Robert; Harstad, Eric; Shipkova, Petia; Marcinkeviciene, Jovita; Hamann, Lawrence; Kirby, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>CODEN:
                <span class="NLM_cas:coden">BPMHBU</span>;
        ISSN:<span class="NLM_cas:issn">1471-2210</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Dipeptidylpeptidase 4 (DPP4) inhibitors have clin. benefit in patients with type 2 diabetes mellitus by increasing levels of glucose-lowering incretin hormones, such as glucagon-like peptide-1 (GLP-1), a peptide with a short half life that is secreted for approx. 1 h following a meal.  Since drugs with prolonged binding to their target have been shown to maximize pharmacodynamic effects while minimizing drug levels, we developed a time-dependent inhibitor that has a half-life for dissocn. from DPP4 close to the duration of the first phase of GLP-1 release.  Results: Saxagliptin and its active metabolite (5-hydroxysaxagliptin) are potent inhibitors of human DPP4 with prolonged dissocn. from its active site (Ki = 1.3 nM and 2.6 nM, t1/2 = 50 and 23 min resp. at 37°C).  In comparison, both vildagliptin (3.5 min) and sitagliptin (< 2 min) rapidly dissocd. from DPP4 at 37°C.  Saxagliptin and 5-hydroxysaxagliptin are selective for inhibition of DPP4 vs. other DPP family members and a large panel of other proteases, and have similar potency and efficacy across multiple species.  Inhibition of plasma DPP activity is used as a biomarker in animal models and clin. trials.  However, most DPP4 inhibitors are competitive with substrate and rapidly dissoc. from DPP4; therefore, the type of substrate, vol. of addn. and final concn. of substrate in these assays can change measured inhibition.  We show that unlike a rapidly dissocg. DPP4 inhibitor, inhibition of plasma DPP activity by saxagliptin and 5-hydroxysaxagliptin in an ex vivo assay was not dependent on substrate concn. when substrate was added rapidly because saxagliptin and 5-hydroxysaxagliptin dissoc. slowly from DPP4, once bound.  We also show that substrate concn. was important for rapidly dissocg. DPP4 inhibitors.  Conclusions: Saxagliptin and its active metabolite are potent, selective inhibitors of DPP4, with prolonged dissocn. from its active site.  They also demonstrate prolonged inhibition of plasma DPP4 ex vivo in animal models, which implies that saxagliptin and 5-hydroxysaxagliptin would continue to inhibit DPP4 during rapid increases in substrates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi2ZNdKARmHrVg90H21EOLACvtfcHk0lgIKA17M0Wb_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVajsr8%253D&md5=ec6bafcaf3438b60e5d70e22b8d16543</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1186%2F1471-2210-12-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2210-12-2%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DDorso%26aufirst%3DC.%26aulast%3DKopcho%26aufirst%3DL.%26aulast%3DLocke%26aufirst%3DG.%26aulast%3DLangish%26aufirst%3DR.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DShipkova%26aufirst%3DP.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DHamann%26aufirst%3DL.%26aulast%3DKirby%26aufirst%3DM.%2BS.%26atitle%3DPotency%252C%2520selectivity%2520and%2520prolonged%2520binding%2520of%2520saxagliptin%2520to%2520DPP4%253A%2520maintenance%2520of%2520DPP4%2520inhibition%2520by%2520saxagliptin%2520in%2520vitro%2520and%2520ex%2520vivo%2520when%2520compared%2520to%2520a%2520rapidly-dissociating%2520DPP4%2520inhibitor%26jtitle%3DBMC%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D2%26epage%3D2210%25E2%2580%259312%25E2%2580%25932%26doi%3D10.1186%2F1471-2210-12-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Li, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmarais, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, W. C.</span><span> </span><span class="NLM_article-title">Identification of a potent and selective non-basic cathepsin K inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1985</span><span class="NLM_x">–</span> <span class="NLM_lpage">1989</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.12.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.12.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16413777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVyqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1985-1989&author=C.+S.+Liauthor=D.+Deschenesauthor=S.+Desmaraisauthor=J.+P.+Falgueyretauthor=J.+Y.+Gauthierauthor=D.+B.+Kimmelauthor=S.+Legerauthor=F.+Masseauthor=M.+E.+McGrathauthor=D.+J.+McKayauthor=M.+D.+Percivalauthor=D.+Riendeauauthor=S.+B.+Rodanauthor=M.+Therienauthor=V.+L.+Truongauthor=G.+Wesolowskiauthor=R.+Zamboniauthor=W.+C.+Black&title=Identification+of+a+potent+and+selective+non-basic+cathepsin+K+inhibitor&doi=10.1016%2Fj.bmcl.2005.12.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent and selective non-basic cathepsin K inhibitor</span></div><div class="casAuthors">Li, Chun Sing; Deschenes, Denis; Desmarais, Sylvie; Falgueyret, Jean-Pierre; Gauthier, Jacques Yves; Kimmel, Donald. B.; Leger, Serge; Masse, Frederic; McGrath, Mary E.; McKay, Daniel J.; Percival, M. David; Riendeau, Denis; Rodan, Sevgi B.; Therien, Michel; Truong, Vouy-Linh; Wesolowski, Gregg; Zamboni, Robert; Black, W. Cameron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1985-1989</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on our previous study with trifluoroethylamine as a P2-P3 amide isostere of cathepsin K inhibitor, further optimization led to identification of L-873724 (I) as a potent and selective non-basic cathepsin K inhibitor.  This compd. showed excellent pharmacokinetics and efficacy in an ovariectomized (OVX) rhesus monkey model.  The vols. of distribution close to unity were consistent with this compd. not being lysosomotropic, which is a characteristic of basic cathepsin K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbVLlTt9kYhrVg90H21EOLACvtfcHk0lgIKA17M0Wb_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVyqs74%253D&md5=e63e471204893774e5a617993ed9be18</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.12.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.12.071%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDesmarais%26aufirst%3DS.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DKimmel%26aufirst%3DD.%2BB.%26aulast%3DLeger%26aufirst%3DS.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRodan%26aufirst%3DS.%2BB.%26aulast%3DTherien%26aufirst%3DM.%26aulast%3DTruong%26aufirst%3DV.%2BL.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DW.%2BC.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520selective%2520non-basic%2520cathepsin%2520K%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1985%26epage%3D1989%26doi%3D10.1016%2Fj.bmcl.2005.12.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Corvol, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freifeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahoudeau, J.</span><span> </span><span class="NLM_article-title">Antiandrogenic effect of spirolactones: mechanism of action</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1210/endo-97-1-52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1210%2Fendo-97-1-52" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1975&pages=52-58&author=P.+Corvolauthor=A.+Michaudauthor=J.+Menardauthor=M.+Freifeldauthor=J.+Mahoudeau&title=Antiandrogenic+effect+of+spirolactones%3A+mechanism+of+action&doi=10.1210%2Fendo-97-1-52"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1210%2Fendo-97-1-52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo-97-1-52%26sid%3Dliteratum%253Aachs%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DMenard%26aufirst%3DJ.%26aulast%3DFreifeld%26aufirst%3DM.%26aulast%3DMahoudeau%26aufirst%3DJ.%26atitle%3DAntiandrogenic%2520effect%2520of%2520spirolactones%253A%2520mechanism%2520of%2520action%26jtitle%3DEndocrinology%26date%3D1975%26volume%3D97%26spage%3D52%26epage%3D58%26doi%3D10.1210%2Fendo-97-1-52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Wiechert, R.</span> In  <span class="citation_source-book">Analogue-based drug discovery</span>. <span class="NLM_contrib-group">Fischer, J.; Ganellin, C. R.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2F3527608001.ch20" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=395-400&author=R.+Wiechertauthor=J.+Fischer&author=C.+R.+Ganellin&title=Analogue-based+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1002%2F3527608001.ch20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F3527608001.ch20%26sid%3Dliteratum%253Aachs%26aulast%3DWiechert%26aufirst%3DR.%26btitle%3DAnalogue-based%2520drug%2520discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%26date%3D2006%26spage%3D395%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">Oelkers, W.</span><span> </span><span class="NLM_article-title">Drospirenone, a progestogen with antimineralocorticoid properties: a short review</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">217</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.mce.2003.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.mce.2003.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15134826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVCjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2004&pages=255-261&author=W.+Oelkers&title=Drospirenone%2C+a+progestogen+with+antimineralocorticoid+properties%3A+a+short+review&doi=10.1016%2Fj.mce.2003.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Drospirenone, a progestogen with antimineralocorticoid properties: a short review</span></div><div class="casAuthors">Oelkers, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Progesterone (P) has high affinity to the mineralocorticoid receptor (MCR), and it is an MCR antagonist.  Almost all synthetic progestogens are devoid of this antimineralocorticoid (anti-MC) effect.  They are unable to antagonize the salt retaining effect of estrogens.  This could be one cause of wt. gain and an increase in blood pressure with the use of combined oral contraceptives (OC) and, in some susceptible women, with postmenopausal estrogen/(progestogen) treatment.  The purpose of this presentation is to review results of clin. studies with drospirenone (DRSP), a new progestogen developed by Schering A.G., with anti-MCR activity.  DRSP is a deriv. of 17-α-spirolactone.  In rats, rabbits and in man, it is a PR-agonist and an MCR- and androgen-R antagonist with no effect on the glucocorticoid-R and the estrogen-R.  In normally menstruating women, 2-3 mg DRSP per day, taken from day 5 to 25 of the cycle, inhibit ovulation, lead to a mild natriuresis, and a slight compensatory activation of the renin-aldosterone system.  Compared with an OC contg. 30 μg ethinylestradiol (EE) and 150 μg levonorgestrel, a combination of 3 mg DRSP with 30 μg EE given over 6 mo led to a slight decrease in body wt. and blood pressure.  The redn. in mean body wt. by a combination of DRSP with EE compared with a conventional OC could be confirmed in a study over 26 mo in 900 young women.  The OC contg. DRSP has favorable effects in patients suffering from the premenstrual syndrome (PMS), and, partly due to the antiandrogenic effect of DRSP, in those with acne vulgaris.  For postmenopausal women, a combination of DRSP with estradiol has been developed with the expectation that the slight blood pressure lowering and wt. reducing effects will minimize cardiovascular morbidity in patients needing hormone treatment because of hot flushes and other climacteric symptoms.  Conclusions: DRSP, by its anti-MCR effect and its potential to slightly decrease body wt. and blood pressure, shares many pharmacodynamic properties with progesterone, and it is a candidate for reducing cardiovascular morbidity in women using OCs or postmenopausal hormone treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWKtG2YQOR0rVg90H21EOLACvtfcHk0ljnJNYpzz0zpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVCjsr8%253D&md5=e97edb2c2ca7bef3ca756ec98c942499</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2003.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2003.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DOelkers%26aufirst%3DW.%26atitle%3DDrospirenone%252C%2520a%2520progestogen%2520with%2520antimineralocorticoid%2520properties%253A%2520a%2520short%2520review%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2004%26volume%3D217%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.mce.2003.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">Chinn, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salamon, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, B. N.</span><span> </span><span class="NLM_article-title">A structure-activity relationship study of spirolactones. Contribution of the cyclopropane ring to antimineralocorticoid activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span><span class="refDoi"> DOI: 10.1021/jm00141a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00141a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1103-1107&author=L.+J.+Chinnauthor=K.+W.+Salamonauthor=B.+N.+Desai&title=A+structure-activity+relationship+study+of+spirolactones.+Contribution+of+the+cyclopropane+ring+to+antimineralocorticoid+activity&doi=10.1021%2Fjm00141a020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm00141a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00141a020%26sid%3Dliteratum%253Aachs%26aulast%3DChinn%26aufirst%3DL.%2BJ.%26aulast%3DSalamon%26aufirst%3DK.%2BW.%26aulast%3DDesai%26aufirst%3DB.%2BN.%26atitle%3DA%2520structure-activity%2520relationship%2520study%2520of%2520spirolactones.%2520Contribution%2520of%2520the%2520cyclopropane%2520ring%2520to%2520antimineralocorticoid%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D1103%26epage%3D1107%26doi%3D10.1021%2Fjm00141a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Hoveyda, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benakli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaubien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saint-Louis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinault, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaseshan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foucher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchemin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bherer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, G. L.</span><span> </span><span class="NLM_article-title">Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): development of ulimorelin (TZP-101) from hit to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8305</span><span class="NLM_x">–</span> <span class="NLM_lpage">8320</span><span class="refDoi"> DOI: 10.1021/jm2007062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fms1antg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8305-8320&author=H.+R.+Hoveydaauthor=E.+Marsaultauthor=R.+Gagnonauthor=A.+P.+Mathieuauthor=M.+Vezinaauthor=A.+Landryauthor=Z.+Wangauthor=K.+Benakliauthor=S.+Beaubienauthor=C.+Saint-Louisauthor=M.+Brassardauthor=J.+F.+Pinaultauthor=L.+Ouelletauthor=S.+Bhatauthor=M.+Ramaseshanauthor=X.+Pengauthor=L.+Foucherauthor=S.+Beaucheminauthor=P.+Bhererauthor=D.+F.+Veberauthor=M.+L.+Petersonauthor=G.+L.+Fraser&title=Optimization+of+the+potency+and+pharmacokinetic+properties+of+a+macrocyclic+ghrelin+receptor+agonist+%28Part+I%29%3A+development+of+ulimorelin+%28TZP-101%29+from+hit+to+clinic&doi=10.1021%2Fjm2007062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic</span></div><div class="casAuthors">Hoveyda Hamid R; Marsault Eric; Gagnon Rene; Mathieu Axel P; Vezina Martin; Landry Annick; Wang Zhigang; Benakli Kamel; Beaubien Sylvie; Saint-Louis Carl; Brassard Martin; Pinault Jean-Francois; Ouellet Luc; Bhat Shridhar; Ramaseshan Mahesh; Peng Xiaowen; Foucher Laurence; Beauchemin Sophie; Bherer Patrick; Veber Daniel F; Peterson Mark L; Fraser Graeme L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8305-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel agonists against this G-protein coupled receptor.  Early hits such as 1 (Ki=86 nM, EC50=134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization.  While such macrocycles are not fully rule-of-five compliant, principally due to their molecular weight and clogP, optimization of their pharmacokinetic properties proved feasible largely through conformational rigidification.  Extensive SAR led to the identification of 2 (Ki=16 nM, EC50=29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus.  X-ray structure and detailed NMR studies indicated a rigid peptidomimetic portion in 2 that is best defined as a nonideal type-I' β-turn.  Compound 2 is 24% orally bioavailable in both rats and monkeys.  Despite its potency, in vitro and in gastric emptying studies, 2 did not induce growth hormone (GH) release in rats, thus demarcating the GH versus GI pharmacology of GRLN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREoes2wBiC73y-c-E1v-fmfW6udTcc2eb4GjbVjlB6HLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fms1antg%253D%253D&md5=bdc3b14ed821c61c4fecea50c60f0b07</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fjm2007062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007062%26sid%3Dliteratum%253Aachs%26aulast%3DHoveyda%26aufirst%3DH.%2BR.%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DGagnon%26aufirst%3DR.%26aulast%3DMathieu%26aufirst%3DA.%2BP.%26aulast%3DVezina%26aufirst%3DM.%26aulast%3DLandry%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBenakli%26aufirst%3DK.%26aulast%3DBeaubien%26aufirst%3DS.%26aulast%3DSaint-Louis%26aufirst%3DC.%26aulast%3DBrassard%26aufirst%3DM.%26aulast%3DPinault%26aufirst%3DJ.%2BF.%26aulast%3DOuellet%26aufirst%3DL.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DRamaseshan%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFoucher%26aufirst%3DL.%26aulast%3DBeauchemin%26aufirst%3DS.%26aulast%3DBherer%26aufirst%3DP.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26aulast%3DFraser%26aufirst%3DG.%2BL.%26atitle%3DOptimization%2520of%2520the%2520potency%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520macrocyclic%2520ghrelin%2520receptor%2520agonist%2520%2528Part%2520I%2529%253A%2520development%2520of%2520ulimorelin%2520%2528TZP-101%2529%2520from%2520hit%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8305%26epage%3D8320%26doi%3D10.1021%2Fjm2007062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">van De Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. K.</span><span> </span><span class="NLM_article-title">Property-based design: optimization of drug absorption and pharmacokinetics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1313</span><span class="NLM_x">–</span> <span class="NLM_lpage">1333</span><span class="refDoi"> DOI: 10.1021/jm000407e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000407e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1313-1333&author=H.+van+De+Waterbeemdauthor=D.+A.+Smithauthor=K.+Beaumontauthor=D.+K.+Walker&title=Property-based+design%3A+optimization+of+drug+absorption+and+pharmacokinetics&doi=10.1021%2Fjm000407e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Property-based design: optimization of drug absorption and pharmacokinetics</span></div><div class="casAuthors">van de Waterbeemd, Han; Smith, Dennis A.; Beaumont, Kevin; Walker, Don K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1313-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 223 refs.  The authors discuss some aspects of the properties of biol. barriers.  In different sections the estn. of drug absorption via important barriers including gastrointestinal tract, blood-brain barrier, and skin are reviewed.  Various approaches for the measurement and computation of physicochem. and mol. properties currently used in the optimization of absorption as well as the use of physicochem. properties in the design of optimal pharmacokinetic profiles are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQwsmoX0-mbVg90H21EOLACvtfcHk0lgzqz-mr35TwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D&md5=3183baedca70020f4ce27f306ba0997e</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Fjm000407e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000407e%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BDe%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DProperty-based%2520design%253A%2520optimization%2520of%2520drug%2520absorption%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1313%26epage%3D1333%26doi%3D10.1021%2Fjm000407e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Martin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matha, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulnik, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topol, I. A.</span><span> </span><span class="NLM_article-title">Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1581</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span><span class="refDoi"> DOI: 10.1021/jm980033d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980033d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1581-1597&author=S.+F.+Martinauthor=G.+O.+Dorseyauthor=T.+Ganeauthor=M.+C.+Hillierauthor=H.+Kesslerauthor=M.+Baurauthor=B.+Mathaauthor=J.+W.+Ericksonauthor=T.+N.+Bhatauthor=S.+Munshiauthor=S.+V.+Gulnikauthor=I.+A.+Topol&title=Cyclopropane-derived+peptidomimetics.+Design%2C+synthesis%2C+evaluation%2C+and+structure+of+novel+HIV-1+protease+inhibitors&doi=10.1021%2Fjm980033d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Fjm980033d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980033d%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DDorsey%26aufirst%3DG.%2BO.%26aulast%3DGane%26aufirst%3DT.%26aulast%3DHillier%26aufirst%3DM.%2BC.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DBaur%26aufirst%3DM.%26aulast%3DMatha%26aufirst%3DB.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DMunshi%26aufirst%3DS.%26aulast%3DGulnik%26aufirst%3DS.%2BV.%26aulast%3DTopol%26aufirst%3DI.%2BA.%26atitle%3DCyclopropane-derived%2520peptidomimetics.%2520Design%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structure%2520of%2520novel%2520HIV-1%2520protease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1581%26epage%3D1597%26doi%3D10.1021%2Fjm980033d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Davidson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waksman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Calorimetric and structural studies of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1021/ja011746f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja011746f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=205-215&author=J.+P.+Davidsonauthor=O.+Lubmanauthor=T.+Roseauthor=G.+Waksmanauthor=S.+F.+Martin&title=Calorimetric+and+structural+studies+of+1%2C2%2C3-trisubstituted+cyclopropanes+as+conformationally+constrained+peptide+inhibitors+of+Src+SH2+domain+binding&doi=10.1021%2Fja011746f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fja011746f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja011746f%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26aulast%3DLubman%26aufirst%3DO.%26aulast%3DRose%26aufirst%3DT.%26aulast%3DWaksman%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DCalorimetric%2520and%2520structural%2520studies%2520of%25201%252C2%252C3-trisubstituted%2520cyclopropanes%2520as%2520conformationally%2520constrained%2520peptide%2520inhibitors%2520of%2520Src%2520SH2%2520domain%2520binding%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D205%26epage%3D215%26doi%3D10.1021%2Fja011746f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazuta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5587</span><span class="NLM_x">–</span> <span class="NLM_lpage">5596</span><span class="refDoi"> DOI: 10.1021/jm0603318</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603318" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVCls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5587-5596&author=M.+Watanabeauthor=Y.+Kazutaauthor=H.+Hayashiauthor=S.+Yamadaauthor=A.+Matsudaauthor=S.+Shuto&title=Stereochemical+diversity-oriented+conformational+restriction+strategy.+Development+of+potent+histamine+H3+and%2For+H4+receptor+antagonists+with+an+imidazolylcyclopropane+structure&doi=10.1021%2Fjm0603318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemical Diversity-Oriented Conformational Restriction Strategy. Development of Potent Histamine H3 and/or H4 Receptor Antagonists with an Imidazolylcyclopropane Structure</span></div><div class="casAuthors">Watanabe, Mizuki; Kazuta, Yuji; Hayashi, Hideki; Yamada, Shizuo; Matsuda, Akira; Shuto, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5587-5596</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop potent H3 and H4 receptor antagonists, a series of conformationally restricted analogs of histamine with a chiral cis- or trans-cyclopropane structure were designed on the basis of stereochem. diversity-oriented conformational restriction strategy.  The target compds. I (n = 1, 2; R = cyclohexylmethyl, 4-ClC6H4CH2) were synthesized from the versatile chiral cyclopropane units, (1S,2R)- and (1R,2R)-2-(tert-butyldiphenylsilyloxy)methyl-1-formylcyclopropanes or their enantiomers.  Pharmacol. profiles of these conformationally restricted analogs were shown to be different depending on the cyclopropane backbones.  Among the analogs, (1R,2S)-I (n = 2; R = 4-ClC6H4CH2) with the (1R)-trans-cyclopropane structure has remarkable antagonistic activity to both the H3 (Ki = 8.4 nM) and H4 (Ki = 7.6 nM) receptors.  Its enantiomer with the (1S)-trans-cyclopropane structure turned out to be a highly potent and selective H3 receptor antagonist with a Ki of 3.6 nM.  Conversely, (1R,2R)-I (n = 1; R = 4-ClC6H4CH2) with the (1R)-trans structure was selective for the H4 receptor (Ki = 118 nM) compared to the H3 receptor (Ki > 103 nM).  These results show that when the structure of the target protein is unknown, the stereochem. diversity-oriented approach can be a powerful strategy in medicinal chem. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobv8NEj2pLVg90H21EOLACvtfcHk0lgzqz-mr35TwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVCls7Y%253D&md5=70552c118df50813b649b30cffec0e41</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fjm0603318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603318%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DKazuta%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DS.%26aulast%3DMatsuda%26aufirst%3DA.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DStereochemical%2520diversity-oriented%2520conformational%2520restriction%2520strategy.%2520Development%2520of%2520potent%2520histamine%2520H3%2520and%252For%2520H4%2520receptor%2520antagonists%2520with%2520an%2520imidazolylcyclopropane%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5587%26epage%3D5596%26doi%3D10.1021%2Fjm0603318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Shimamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohfune, Y.</span><span> </span><span class="NLM_article-title">Syntheses and conformational analyses of glutamate analogs: 2-(2-carboxy-3-substituted-cyclopropyl)glycines as useful probes for excitatory amino acid receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span><span class="refDoi"> DOI: 10.1021/jm9502908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9502908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=407-423&author=K.+Shimamotoauthor=Y.+Ohfune&title=Syntheses+and+conformational+analyses+of+glutamate+analogs%3A+2-%282-carboxy-3-substituted-cyclopropyl%29glycines+as+useful+probes+for+excitatory+amino+acid+receptors&doi=10.1021%2Fjm9502908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm9502908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9502908%26sid%3Dliteratum%253Aachs%26aulast%3DShimamoto%26aufirst%3DK.%26aulast%3DOhfune%26aufirst%3DY.%26atitle%3DSyntheses%2520and%2520conformational%2520analyses%2520of%2520glutamate%2520analogs%253A%25202-%25282-carboxy-3-substituted-cyclopropyl%2529glycines%2520as%2520useful%2520probes%2520for%2520excitatory%2520amino%2520acid%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D407%26epage%3D423%26doi%3D10.1021%2Fjm9502908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Cannon, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rege, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, J. P.</span><span> </span><span class="NLM_article-title">1,2-Disubstituted cyclopropane and cyclobutane derivatives related to acetylcholine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1021/jm00271a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00271a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1972&pages=71-75&author=J.+G.+Cannonauthor=A.+B.+Regeauthor=T.+L.+Gruenauthor=J.+P.+Long&title=1%2C2-Disubstituted+cyclopropane+and+cyclobutane+derivatives+related+to+acetylcholine&doi=10.1021%2Fjm00271a019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm00271a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00271a019%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DJ.%2BG.%26aulast%3DRege%26aufirst%3DA.%2BB.%26aulast%3DGruen%26aufirst%3DT.%2BL.%26aulast%3DLong%26aufirst%3DJ.%2BP.%26atitle%3D1%252C2-Disubstituted%2520cyclopropane%2520and%2520cyclobutane%2520derivatives%2520related%2520to%2520acetylcholine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1972%26volume%3D15%26spage%3D71%26epage%3D75%26doi%3D10.1021%2Fjm00271a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 297 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaoxu Wang, Jing Ke, Yiling Zhu, Arghya Deb, Yijie Xu, <span class="NLM_string-name hlFld-ContribAuthor">X. Peter Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Radical Process for General Synthesis of Chiral Heteroaryl Cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (29)
                                     , 11121-11129. <a href="https://doi.org/10.1021/jacs.1c04655" title="DOI URL">https://doi.org/10.1021/jacs.1c04655</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c04655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c04655%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAsymmetric%252BRadical%252BProcess%252Bfor%252BGeneral%252BSynthesis%252Bof%252BChiral%252BHeteroaryl%252BCyclopropanes%26aulast%3DWang%26aufirst%3DXiaoxu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04052021%26date%3D20072021%26volume%3D143%26issue%3D29%26spage%3D11121%26epage%3D11129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mauro Mato, Allegra Franchino, Cristina Garcı́a-Morales, <span class="NLM_string-name hlFld-ContribAuthor">Antonio M. Echavarren</span>. </span><span class="cited-content_cbyCitation_article-title">Gold-Catalyzed Synthesis of Small Rings. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (14)
                                     , 8613-8684. <a href="https://doi.org/10.1021/acs.chemrev.0c00697" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00697%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DGold-Catalyzed%252BSynthesis%252Bof%252BSmall%252BRings%26aulast%3DMato%26aufirst%3DMauro%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D03072020%26date%3D02112020%26volume%3D121%26issue%3D14%26spage%3D8613%26epage%3D8684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huarui Cui, Angela S. Carlson, Mary A. Schleiff, Anand Divakaran, Jorden A. Johnson, Caroline R. Buchholz, Huda Zahid, Nora R. Vail, Ke Shi, Hideki Aihara, Daniel A. Harki, Grover P. Miller, Joseph J. Topczewski, <span class="NLM_string-name hlFld-ContribAuthor">William C. K. Pomerantz</span>. </span><span class="cited-content_cbyCitation_article-title">4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 10497-10511. <a href="https://doi.org/10.1021/acs.jmedchem.1c00933" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00933</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00933%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Methyl-1%25252C2%25252C3-Triazoles%252Bas%252BN-Acetyl-Lysine%252BMimics%252BAfford%252BPotent%252BBET%252BBromodomain%252BInhibitors%252Bwith%252BImproved%252BSelectivity%26aulast%3DCui%26aufirst%3DHuarui%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D24052021%26date%3D08072021%26volume%3D64%26issue%3D14%26spage%3D10497%26epage%3D10511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mauro Mato, Marc Montesinos-Magraner, Arnau R. Sugranyes, <span class="NLM_string-name hlFld-ContribAuthor">Antonio M. Echavarren</span>. </span><span class="cited-content_cbyCitation_article-title">Rh(II)-Catalyzed Alkynylcyclopropanation of Alkenes by Decarbenation of Alkynylcycloheptatrienes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (28)
                                     , 10760-10769. <a href="https://doi.org/10.1021/jacs.1c05422" title="DOI URL">https://doi.org/10.1021/jacs.1c05422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c05422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c05422%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DRh%252528II%252529-Catalyzed%252BAlkynylcyclopropanation%252Bof%252BAlkenes%252Bby%252BDecarbenation%252Bof%252BAlkynylcycloheptatrienes%26aulast%3DMato%26aufirst%3DMauro%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D26052021%26date%3D08072021%26volume%3D143%26issue%3D28%26spage%3D10760%26epage%3D10769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gauthier Lefebvre, Olivier Charron, Janine Cossy, <span class="NLM_string-name hlFld-ContribAuthor">Christophe Meyer</span>. </span><span class="cited-content_cbyCitation_article-title">Radical Addition of SF5Cl to Cyclopropenes: Synthesis of (Pentafluorosulfanyl)cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (14)
                                     , 5491-5495. <a href="https://doi.org/10.1021/acs.orglett.1c01840" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c01840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c01840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c01840%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRadical%252BAddition%252Bof%252BSF5Cl%252Bto%252BCyclopropenes%25253A%252BSynthesis%252Bof%252B%252528Pentafluorosulfanyl%252529cyclopropanes%26aulast%3DLefebvre%26aufirst%3DGauthier%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D02062021%26date%3D25062021%26volume%3D23%26issue%3D14%26spage%3D5491%26epage%3D5495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kazuyuki Torii, Kazuki Tabaru, <span class="NLM_string-name hlFld-ContribAuthor">Yasushi Obora</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Three-Component Silylalkoxylation of 1,3-Diene with Alcohol and Disilane via Oxidative Coupling. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (12)
                                     , 4898-4902. <a href="https://doi.org/10.1021/acs.orglett.1c01648" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c01648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c01648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c01648%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPalladium-Catalyzed%252BThree-Component%252BSilylalkoxylation%252Bof%252B1%25252C3-Diene%252Bwith%252BAlcohol%252Band%252BDisilane%252Bvia%252BOxidative%252BCoupling%26aulast%3DTorii%26aufirst%3DKazuyuki%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D15052021%26date%3D26052021%26volume%3D23%26issue%3D12%26spage%3D4898%26epage%3D4902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Samo Guzelj, Sanja Nabergoj, Martina Gobec, Stane Pajk, Veronika Klančič, Bram Slütter, Ruža Frkanec, Adela Štimac, Primož Šket, Janez Plavec, Irena Mlinarič-Raščan, <span class="NLM_string-name hlFld-ContribAuthor">Žiga Jakopin</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7809-7838. <a href="https://doi.org/10.1021/acs.jmedchem.1c00644" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00644</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00644%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BFine-Tuning%252Bof%252BDesmuramylpeptide%252BNOD2%252BAgonists%252BDefines%252BTheir%252BIn%252BVivo%252BAdjuvant%252BActivity%26aulast%3DGuzelj%26aufirst%3DSamo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08042021%26date%3D27052021%26volume%3D64%26issue%3D11%26spage%3D7809%26epage%3D7838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Edward Sisco, <span class="NLM_string-name hlFld-ContribAuthor">Korry L. Barnes</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel 1,3-Oxazole Sulfonamides as Tubulin Polymerization Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 1030-1037. <a href="https://doi.org/10.1021/acsmedchemlett.1c00219" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00219%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252B1%25252C3-Oxazole%252BSulfonamides%252Bas%252BTubulin%252BPolymerization%252BInhibitors%26aulast%3DSisco%26aufirst%3DEdward%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D16042021%26date%3D19052021%26date%3D25052021%26volume%3D12%26issue%3D6%26spage%3D1030%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Naoki Teno, Yusuke Iguchi, Keisuke Oda, Yukiko Yamashita, Arisa Masuda, Ko Fujimori, Mizuho Une, <span class="NLM_string-name hlFld-ContribAuthor">Keigo Gohda</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 420-425. <a href="https://doi.org/10.1021/acsmedchemlett.0c00640" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00640%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BOrally%252BActive%252Band%252BNonsteroidal%252BFarnesoid%252BX%252BReceptor%252B%252528FXR%252529%252BAntagonist%252Bwith%252BPropensity%252Bfor%252BAccumulation%252Band%252BResponsiveness%252Bin%252BIleum%26aulast%3DTeno%26aufirst%3DNaoki%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D06122020%26date%3D16022021%26date%3D24022021%26volume%3D12%26issue%3D3%26spage%3D420%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arturs Sperga, Renate Melngaile, Armands Kazia, Sergey Belyakov, <span class="NLM_string-name hlFld-ContribAuthor">Janis Veliks</span>. </span><span class="cited-content_cbyCitation_article-title">Optimized Monofluoromethylsulfonium Reagents for Fluoromethylene-Transfer Chemistry. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (4)
                                     , 3196-3212. <a href="https://doi.org/10.1021/acs.joc.0c02561" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02561%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOptimized%252BMonofluoromethylsulfonium%252BReagents%252Bfor%252BFluoromethylene-Transfer%252BChemistry%26aulast%3DSperga%26aufirst%3DArturs%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28102020%26date%3D27012021%26volume%3D86%26issue%3D4%26spage%3D3196%26epage%3D3212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wen-Bo Shen, Xiang-Ting Tang, Ting-Ting Zhang, Dong-Can Lv, Dan Zhao, Tong-Fu Su, <span class="NLM_string-name hlFld-ContribAuthor">Lei Meng</span>. </span><span class="cited-content_cbyCitation_article-title">Copper(I)-Catalyzed Enyne Oxidation/Cyclopropanation: Divergent and Enantioselective Synthesis of Cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (4)
                                     , 1285-1290. <a href="https://doi.org/10.1021/acs.orglett.0c04268" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c04268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c04268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c04268%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCopper%252528I%252529-Catalyzed%252BEnyne%252BOxidation%25252FCyclopropanation%25253A%252BDivergent%252Band%252BEnantioselective%252BSynthesis%252Bof%252BCyclopropanes%26aulast%3DShen%26aufirst%3DWen-Bo%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D27122020%26date%3D02022021%26volume%3D23%26issue%3D4%26spage%3D1285%26epage%3D1290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Donggeon Nam, Viktoria Steck, Robert J. Potenzino, <span class="NLM_string-name hlFld-ContribAuthor">Rudi Fasan</span>. </span><span class="cited-content_cbyCitation_article-title">A Diverse Library of Chiral Cyclopropane Scaffolds via Chemoenzymatic Assembly and Diversification of Cyclopropyl Ketones. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (5)
                                     , 2221-2231. <a href="https://doi.org/10.1021/jacs.0c09504" title="DOI URL">https://doi.org/10.1021/jacs.0c09504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c09504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c09504%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DA%252BDiverse%252BLibrary%252Bof%252BChiral%252BCyclopropane%252BScaffolds%252Bvia%252BChemoenzymatic%252BAssembly%252Band%252BDiversification%252Bof%252BCyclopropyl%252BKetones%26aulast%3DNam%26aufirst%3DDonggeon%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D03092020%26date%3D26012021%26volume%3D143%26issue%3D5%26spage%3D2221%26epage%3D2231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elliot D. Mock, Ioli Kotsogianni, Wouter P. F. Driever, Carmen S. Fonseca, Jelle M. Vooijs, Hans den Dulk, Constant A. A. van Boeckel, <span class="NLM_string-name hlFld-ContribAuthor">Mario van der Stelt</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship Studies of Pyrimidine-4-Carboxamides as Inhibitors of N-Acylphosphatidylethanolamine Phospholipase D. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 481-515. <a href="https://doi.org/10.1021/acs.jmedchem.0c01441" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01441%26sid%3Dliteratum%253Aachs%26aulast%3DMock%26jtitle%3DNat%2520Chem.%2520Biol.%26date%3D2020%26volume%3D16%26spage%3D667%26epage%3D675%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%252Bof%252BPyrimidine-4-Carboxamides%252Bas%252BInhibitors%252Bof%252BN-Acylphosphatidylethanolamine%252BPhospholipase%252BD%26aulast%3DMock%26aufirst%3DElliot%2BD.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D19082020%26date%3D31122020%26volume%3D64%26issue%3D1%26spage%3D481%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yangyang Yang, Jet Tsien, Ayala Ben David, Jonathan M. E. Hughes, Rohan R. Merchant, <span class="NLM_string-name hlFld-ContribAuthor">Tian Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Practical and Modular Construction of C(sp3)-Rich Alkyl Boron Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (1)
                                     , 471-480. <a href="https://doi.org/10.1021/jacs.0c11964" title="DOI URL">https://doi.org/10.1021/jacs.0c11964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c11964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c11964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPractical%252Band%252BModular%252BConstruction%252Bof%252BC%252528sp3%252529-Rich%252BAlkyl%252BBoron%252BCompounds%26aulast%3DYang%26aufirst%3DYangyang%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D15112020%26date%3D21122020%26volume%3D143%26issue%3D1%26spage%3D471%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rui-Ying Zhang, Feng Jin, Xiao-Guang Bao, Hai-Yan Li, Xiao-Ping Xu, <span class="NLM_string-name hlFld-ContribAuthor">Shun-Jun Ji</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Spiro 3,3’-Cyclopropyl Oxindoles Via N-Bromosuccinimide-Mediated Ring-Closing and Contraction Cascade. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (1)
                                     , 1141-1151. <a href="https://doi.org/10.1021/acs.joc.0c02610" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02610%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BSpiro%252B3%25252C3%2525E2%252580%252599-Cyclopropyl%252BOxindoles%252BVia%252BN-Bromosuccinimide-Mediated%252BRing-Closing%252Band%252BContraction%252BCascade%26aulast%3DZhang%26aufirst%3DRui-Ying%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D03112020%26date%3D14122020%26volume%3D86%26issue%3D1%26spage%3D1141%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janis Veliks, Melita Videja, Artis Kinens, Raitis Bobrovs, Martins Priede, <span class="NLM_string-name hlFld-ContribAuthor">Janis Kuka</span>. </span><span class="cited-content_cbyCitation_article-title">trans-Fluorine Effect in Cyclopropane: Diastereoselective Synthesis of Fluorocyclopropyl Cabozantinib Analogs. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2146-2150. <a href="https://doi.org/10.1021/acsmedchemlett.0c00220" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00220%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3Dtrans-Fluorine%252BEffect%252Bin%252BCyclopropane%25253A%252BDiastereoselective%252BSynthesis%252Bof%252BFluorocyclopropyl%252BCabozantinib%252BAnalogs%26aulast%3DVeliks%26aufirst%3DJanis%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28042020%26date%3D11092020%26date%3D16092020%26date%3D11092020%26volume%3D11%26issue%3D11%26spage%3D2146%26epage%3D2150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Laura Goracci, Jenny Desantis, Aurora Valeri, Beatrice Castellani, Michela Eleuteri, <span class="NLM_string-name hlFld-ContribAuthor">Gabriele Cruciani</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11615-11638. <a href="https://doi.org/10.1021/acs.jmedchem.0c00793" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00793%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUnderstanding%252Bthe%252BMetabolism%252Bof%252BProteolysis%252BTargeting%252BChimeras%252B%252528PROTACs%252529%25253A%252BThe%252BNext%252BStep%252Btoward%252BPharmaceutical%252BApplications%26aulast%3DGoracci%26aufirst%3DLaura%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11052020%26date%3D07102020%26volume%3D63%26issue%3D20%26spage%3D11615%26epage%3D11638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Athri D. Rathnayake, Yunjeong Kim, Chamandi S. Dampalla, Harry Nhat Nguyen, Abdul-Rahman M. Jesri, Maithri M. Kashipathy, Gerald H. Lushington, Kevin P. Battaile, Scott Lovell, Kyeong-Ok Chang, <span class="NLM_string-name hlFld-ContribAuthor">William C. Groutas</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Optimization of Dipeptidyl Inhibitors of Norovirus 3CL Protease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11945-11963. <a href="https://doi.org/10.1021/acs.jmedchem.0c01252" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01252%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Guided%252BOptimization%252Bof%252BDipeptidyl%252BInhibitors%252Bof%252BNorovirus%252B3CL%252BProtease%26aulast%3DRathnayake%26aufirst%3DAthri%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17072020%26date%3D02102020%26date%3D18092020%26volume%3D63%26issue%3D20%26spage%3D11945%26epage%3D11963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anton V. Chernykh, Oleksandr S. Olifir, Yuliya O. Kuchkovska, Dmitriy M. Volochnyuk, Vladimir S. Yarmolchuk, <span class="NLM_string-name hlFld-ContribAuthor">Oleksandr O. Grygorenko</span>. </span><span class="cited-content_cbyCitation_article-title">Fluoroalkyl-Substituted Cyclopropane Derivatives: Synthesis and Physicochemical Properties. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (19)
                                     , 12692-12702. <a href="https://doi.org/10.1021/acs.joc.0c01848" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01848%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DFluoroalkyl-Substituted%252BCyclopropane%252BDerivatives%25253A%252BSynthesis%252Band%252BPhysicochemical%252BProperties%26aulast%3DChernykh%26aufirst%3DAnton%2BV.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31072020%26date%3D11092020%26date%3D01092020%26volume%3D85%26issue%3D19%26spage%3D12692%26epage%3D12702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joseph P. Mancinelli, <span class="NLM_string-name hlFld-ContribAuthor">Sidney M. Wilkerson-Hill</span>. </span><span class="cited-content_cbyCitation_article-title">Tris(pentafluorophenyl)borane-Catalyzed Cyclopropanation of Styrenes with Aryldiazoacetates. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (19)
                                     , 11171-11176. <a href="https://doi.org/10.1021/acscatal.0c03218" title="DOI URL">https://doi.org/10.1021/acscatal.0c03218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c03218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c03218%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DTris%252528pentafluorophenyl%252529borane-Catalyzed%252BCyclopropanation%252Bof%252BStyrenes%252Bwith%252BAryldiazoacetates%26aulast%3DMancinelli%26aufirst%3DJoseph%2BP.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23072020%26date%3D04092020%26date%3D16092020%26date%3D10092020%26volume%3D10%26issue%3D19%26spage%3D11171%26epage%3D11176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Antonin Clemenceau, Pierre Thesmar, Maxime Gicquel, Alexandre Le Flohic, <span class="NLM_string-name hlFld-ContribAuthor">Olivier Baudoin</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Synthesis of Cyclopropanes from gem-Dialkyl Groups through Double C–H Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (36)
                                     , 15355-15361. <a href="https://doi.org/10.1021/jacs.0c05887" title="DOI URL">https://doi.org/10.1021/jacs.0c05887</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c05887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c05887%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDirect%252BSynthesis%252Bof%252BCyclopropanes%252Bfrom%252Bgem-Dialkyl%252BGroups%252Bthrough%252BDouble%252BC%2525E2%252580%252593H%252BActivation%26aulast%3DClemenceau%26aufirst%3DAntonin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30052020%26date%3D26082020%26date%3D12082020%26volume%3D142%26issue%3D36%26spage%3D15355%26epage%3D15361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anandarao Munakala, Krishna Kumar Gollapelli, Jagadeesh Babu Nanubolu, <span class="NLM_string-name hlFld-ContribAuthor">Rambabu Chegondi</span>. </span><span class="cited-content_cbyCitation_article-title">Silver(I)-Catalyzed Oxidative Intramolecular Cyclopropanation: Access to Complex Tricyclo[3.3.1.0]nonanediones via Semipinacol-Type Rearrangement. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (17)
                                     , 7019-7024. <a href="https://doi.org/10.1021/acs.orglett.0c02555" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02555</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02555%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSilver%252528I%252529-Catalyzed%252BOxidative%252BIntramolecular%252BCyclopropanation%25253A%252BAccess%252Bto%252BComplex%252BTricyclo%25255B3.3.1.0%25255Dnonanediones%252Bvia%252BSemipinacol-Type%252BRearrangement%26aulast%3DMunakala%26aufirst%3DAnandarao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01082020%26date%3D26082020%26volume%3D22%26issue%3D17%26spage%3D7019%26epage%3D7024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liliya T. Sahharova, Evgeniy G. Gordeev, Dmitry B. Eremin, <span class="NLM_string-name hlFld-ContribAuthor">Valentine P. Ananikov</span>. </span><span class="cited-content_cbyCitation_article-title">Pd-Catalyzed Synthesis of Densely Functionalized Cyclopropyl Vinyl Sulfides Reveals the Origin of High Selectivity in a Fundamental Alkyne Insertion Step. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (17)
                                     , 9872-9888. <a href="https://doi.org/10.1021/acscatal.0c02053" title="DOI URL">https://doi.org/10.1021/acscatal.0c02053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c02053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c02053%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DPd-Catalyzed%252BSynthesis%252Bof%252BDensely%252BFunctionalized%252BCyclopropyl%252BVinyl%252BSulfides%252BReveals%252Bthe%252BOrigin%252Bof%252BHigh%252BSelectivity%252Bin%252Ba%252BFundamental%252BAlkyne%252BInsertion%252BStep%26aulast%3DSahharova%26aufirst%3DLiliya%2BT.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08052020%26date%3D31072020%26date%3D19082020%26volume%3D10%26issue%3D17%26spage%3D9872%26epage%3D9888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jeffery D. Zwicker, David Smith, Alfredo J. Guerra, Jacob R. Hitchens, Nicole Haug, Steve Vander Roest, Pil Lee, Bo Wen, Duxin Sun, Lu Wang, Richard F. Keep, Jianming Xiang, Vern B. Carruthers, <span class="NLM_string-name hlFld-ContribAuthor">Scott D. Larsen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (16)
                                     , 2450-2463. <a href="https://doi.org/10.1021/acschemneuro.9b00674" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00674%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BTriazine%252BNitrile%252BInhibitors%252Bof%252BToxoplasma%252Bgondii%252BCathepsin%252BL%252Bfor%252Bthe%252BPotential%252BTreatment%252Bof%252BChronic%252BToxoplasmosis%252Bin%252Bthe%252BCNS%26aulast%3DZwicker%26aufirst%3DJeffery%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D17122019%26date%3D06022020%26date%3D18022020%26date%3D06022020%26volume%3D11%26issue%3D16%26spage%3D2450%26epage%3D2463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fu-Peng Wu, Xiaoling Luo, Udo Radius, Todd B. Marder, <span class="NLM_string-name hlFld-ContribAuthor">Xiao-Feng Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed Synthesis of Stereodefined Cyclopropyl Bis(boronates) from Alkenes with CO as the C1 Source. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (33)
                                     , 14074-14079. <a href="https://doi.org/10.1021/jacs.0c06800" title="DOI URL">https://doi.org/10.1021/jacs.0c06800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c06800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c06800%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DCopper-Catalyzed%252BSynthesis%252Bof%252BStereodefined%252BCyclopropyl%252BBis%252528boronates%252529%252Bfrom%252BAlkenes%252Bwith%252BCO%252Bas%252Bthe%252BC1%252BSource%26aulast%3DWu%26aufirst%3DFu-Peng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24062020%26date%3D04082020%26date%3D29072020%26volume%3D142%26issue%3D33%26spage%3D14074%26epage%3D14079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Muhammad Murtaza Hassan, Johan Israelian, Nabanita Nawar, Giovanni Ganda, Pimyupa Manaswiyoungkul, Yasir S. Raouf, David Armstrong, Abootaleb Sedighi, Olasunkanmi O. Olaoye, Fettah Erdogan, Aaron D. Cabral, Fabrizio Angeles, Rabia Altintas, Elvin D. de Araujo, <span class="NLM_string-name hlFld-ContribAuthor">Patrick T. Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8634-8648. <a href="https://doi.org/10.1021/acs.jmedchem.0c01025" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01025%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCharacterization%252Bof%252BConformationally%252BConstrained%252BBenzanilide%252BScaffolds%252Bfor%252BPotent%252Band%252BSelective%252BHDAC8%252BTargeting%26aulast%3DHassan%26aufirst%3DMuhammad%2BMurtaza%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15062020%26date%3D31072020%26date%3D16072020%26volume%3D63%26issue%3D15%26spage%3D8634%26epage%3D8648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Karunakar Reddy Bonepally, Norihito Takahashi, Naoya Matsuoka, Hikari Koi, Haruki Mizoguchi, Takahisa Hiruma, Kyohei Ochiai, Shun Suzuki, Yutaka Yamagishi, Hideaki Oikawa, Aki Ishiyama, Rei Hokari, Masato Iwatsuki, Kazuhiko Otoguro, Satoshi O̅mura, Nobutaka Kato, <span class="NLM_string-name hlFld-ContribAuthor">Hiroki Oguri</span>. </span><span class="cited-content_cbyCitation_article-title">Rapid and Systematic Exploration of Chemical Space Relevant to Artemisinins: Anti-malarial Activities of Skeletally Diversified Tetracyclic Peroxides and 6-Aza-artemisinins. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (15)
                                     , 9694-9712. <a href="https://doi.org/10.1021/acs.joc.0c01017" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01017%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRapid%252Band%252BSystematic%252BExploration%252Bof%252BChemical%252BSpace%252BRelevant%252Bto%252BArtemisinins%25253A%252BAnti-malarial%252BActivities%252Bof%252BSkeletally%252BDiversified%252BTetracyclic%252BPeroxides%252Band%252B6-Aza-artemisinins%26aulast%3DBonepally%26aufirst%3DKarunakar%2BReddy%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D25042020%26date%3D13072020%26date%3D02072020%26volume%3D85%26issue%3D15%26spage%3D9694%26epage%3D9712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicole Erin Behnke, Juha H. Siitonen, Stephen A. Chamness, <span class="NLM_string-name hlFld-ContribAuthor">László Kürti</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Highly Substituted Cyclopropanes via the Quasi-Favorskii Rearrangement of α,α-Dichlorocyclobutanols. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (15)
                                     , 5715-5720. <a href="https://doi.org/10.1021/acs.orglett.0c01229" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01229%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BHighly%252BSubstituted%252BCyclopropanes%252Bvia%252Bthe%252BQuasi-Favorskii%252BRearrangement%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B1-Dichlorocyclobutanols%26aulast%3DBehnke%26aufirst%3DNicole%2BErin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06042020%26date%3D24042020%26volume%3D22%26issue%3D15%26spage%3D5715%26epage%3D5720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Antonis M. Messinis, Lars H. Finger, Lianrui Hu, <span class="NLM_string-name hlFld-ContribAuthor">Lutz Ackermann</span>. </span><span class="cited-content_cbyCitation_article-title">Allenes for Versatile Iron-Catalyzed C–H Activation by Weak O-Coordination: Mechanistic Insights by Kinetics, Intermediate Isolation, and Computation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (30)
                                     , 13102-13111. <a href="https://doi.org/10.1021/jacs.0c04837" title="DOI URL">https://doi.org/10.1021/jacs.0c04837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c04837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c04837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAllenes%252Bfor%252BVersatile%252BIron-Catalyzed%252BC%2525E2%252580%252593H%252BActivation%252Bby%252BWeak%252BO-Coordination%25253A%252BMechanistic%252BInsights%252Bby%252BKinetics%25252C%252BIntermediate%252BIsolation%25252C%252Band%252BComputation%26aulast%3DMessinis%26aufirst%3DAntonis%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D16072020%26date%3D13062020%26volume%3D142%26issue%3D30%26spage%3D13102%26epage%3D13111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">L. Reginald Mills, John J. Monteith, Gabriel dos Passos Gomes, Alán Aspuru-Guzik, <span class="NLM_string-name hlFld-ContribAuthor">Sophie A. L. Rousseaux</span>. </span><span class="cited-content_cbyCitation_article-title">The Cyclopropane Ring as a Reporter of Radical Leaving-Group Reactivity for Ni-Catalyzed C(sp3)–O Arylation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (30)
                                     , 13246-13254. <a href="https://doi.org/10.1021/jacs.0c06904" title="DOI URL">https://doi.org/10.1021/jacs.0c06904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c06904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c06904%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DThe%252BCyclopropane%252BRing%252Bas%252Ba%252BReporter%252Bof%252BRadical%252BLeaving-Group%252BReactivity%252Bfor%252BNi-Catalyzed%252BC%252528sp3%252529%2525E2%252580%252593O%252BArylation%26aulast%3DMills%26aufirst%3DL.%2BReginald%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26062020%26date%3D15072020%26date%3D01072020%26volume%3D142%26issue%3D30%26spage%3D13246%26epage%3D13254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amandine Guérinot, <span class="NLM_string-name hlFld-ContribAuthor">Janine Cossy</span>. </span><span class="cited-content_cbyCitation_article-title">Cobalt-Catalyzed Cross-Couplings between Alkyl Halides and Grignard Reagents. </span><span class="cited-content_cbyCitation_journal-name">Accounts of Chemical Research</span><span> <strong>2020,</strong> <em>53 </em>
                                    (7)
                                     , 1351-1363. <a href="https://doi.org/10.1021/acs.accounts.0c00238" title="DOI URL">https://doi.org/10.1021/acs.accounts.0c00238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.accounts.0c00238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.accounts.0c00238%26sid%3Dliteratum%253Aachs%26jtitle%3DAccounts%2520of%2520Chemical%2520Research%26atitle%3DCobalt-Catalyzed%252BCross-Couplings%252Bbetween%252BAlkyl%252BHalides%252Band%252BGrignard%252BReagents%26aulast%3DGu%25C3%25A9rinot%26aufirst%3DAmandine%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D25042020%26date%3D10072020%26volume%3D53%26issue%3D7%26spage%3D1351%26epage%3D1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lun An, Fei-Fei Tong, Shu Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xingang Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Functionalization of Racemic Cyclopropylzinc Reagents via Enantiodivergent Relay Coupling. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (27)
                                     , 11884-11892. <a href="https://doi.org/10.1021/jacs.0c04462" title="DOI URL">https://doi.org/10.1021/jacs.0c04462</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c04462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c04462%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DStereoselective%252BFunctionalization%252Bof%252BRacemic%252BCyclopropylzinc%252BReagents%252Bvia%252BEnantiodivergent%252BRelay%252BCoupling%26aulast%3DAn%26aufirst%3DLun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23042020%26date%3D26062020%26date%3D12062020%26volume%3D142%26issue%3D27%26spage%3D11884%26epage%3D11892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bruce J. Wittmann, Anders M. Knight, Julie L. Hofstra, Sarah E. Reisman, S. B. Jennifer Kan, <span class="NLM_string-name hlFld-ContribAuthor">Frances H. Arnold</span>. </span><span class="cited-content_cbyCitation_article-title">Diversity-Oriented Enzymatic Synthesis of Cyclopropane Building Blocks. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (13)
                                     , 7112-7116. <a href="https://doi.org/10.1021/acscatal.0c01888" title="DOI URL">https://doi.org/10.1021/acscatal.0c01888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c01888%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DDiversity-Oriented%252BEnzymatic%252BSynthesis%252Bof%252BCyclopropane%252BBuilding%252BBlocks%26aulast%3DWittmann%26aufirst%3DBruce%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28042020%26date%3D04062020%26date%3D17062020%26date%3D04062020%26volume%3D10%26issue%3D13%26spage%3D7112%26epage%3D7116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James P. Driscoll, Corinne M. Sadlowski, Nina R. Shah, <span class="NLM_string-name hlFld-ContribAuthor">Antonio Feula</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism and Bioactivation: It’s Time to Expect the Unexpected. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6303-6314. <a href="https://doi.org/10.1021/acs.jmedchem.0c00026" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMetabolism%252Band%252BBioactivation%25253A%252BIt%2525E2%252580%252599s%252BTime%252Bto%252BExpect%252Bthe%252BUnexpected%26aulast%3DDriscoll%26aufirst%3DJames%2BP.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07012020%26date%3D21042020%26date%3D08042020%26volume%3D63%26issue%3D12%26spage%3D6303%26epage%3D6314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Longyang Dian, <span class="NLM_string-name hlFld-ContribAuthor">Ilan Marek</span>. </span><span class="cited-content_cbyCitation_article-title">Cobalt-Catalyzed Diastereoselective and Enantioselective Hydrosilylation of Achiral Cyclopropenes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (12)
                                     , 4914-4918. <a href="https://doi.org/10.1021/acs.orglett.0c01833" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01833</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01833%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCobalt-Catalyzed%252BDiastereoselective%252Band%252BEnantioselective%252BHydrosilylation%252Bof%252BAchiral%252BCyclopropenes%26aulast%3DDian%26aufirst%3DLongyang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31052020%26date%3D08062020%26volume%3D22%26issue%3D12%26spage%3D4914%26epage%3D4918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rohan R. Merchant, Simon B. Lang, Tingting Yu, Shuilian Zhao, Zhiqi Qi, Takao Suzuki, <span class="NLM_string-name hlFld-ContribAuthor">Jianming Bao</span>. </span><span class="cited-content_cbyCitation_article-title">A General One-Pot Protocol for Hindered N-Alkyl Azaheterocycles from Tertiary Carboxylic Acids. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (11)
                                     , 4180-4184. <a href="https://doi.org/10.1021/acs.orglett.0c01254" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01254%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BGeneral%252BOne-Pot%252BProtocol%252Bfor%252BHindered%252BN-Alkyl%252BAzaheterocycles%252Bfrom%252BTertiary%252BCarboxylic%252BAcids%26aulast%3DMerchant%26aufirst%3DRohan%2BR.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08042020%26date%3D08052020%26volume%3D22%26issue%3D11%26spage%3D4180%26epage%3D4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Promita Biswas, Subhasis Mandal, <span class="NLM_string-name hlFld-ContribAuthor">Joyram Guin</span>. </span><span class="cited-content_cbyCitation_article-title">Aerobic Acylarylation of α,β-Unsaturated Amides with Aldehydes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (11)
                                     , 4294-4299. <a href="https://doi.org/10.1021/acs.orglett.0c01336" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01336</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01336%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAerobic%252BAcylarylation%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BAmides%252Bwith%252BAldehydes%26aulast%3DBiswas%26aufirst%3DPromita%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17042020%26date%3D26052020%26volume%3D22%26issue%3D11%26spage%3D4294%26epage%3D4299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guo-Shu Chen, Xiao-Xue Yan, Shu-Jie Chen, Xiang-Yu Mao, Zhao-Dong Li, <span class="NLM_string-name hlFld-ContribAuthor">Yun-Lin Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective Synthesis of 1,3-Diyne-Tethered Trifluoromethylcyclopropanes through a Sulfur Ylide Mediated Cyclopropanation/DBU-Mediated Epimerization Sequence. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (10)
                                     , 6252-6260. <a href="https://doi.org/10.1021/acs.joc.0c00162" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00162</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00162%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDiastereoselective%252BSynthesis%252Bof%252B1%25252C3-Diyne-Tethered%252BTrifluoromethylcyclopropanes%252Bthrough%252Ba%252BSulfur%252BYlide%252BMediated%252BCyclopropanation%25252FDBU-Mediated%252BEpimerization%252BSequence%26aulast%3DChen%26aufirst%3DGuo-Shu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21012020%26date%3D20042020%26date%3D16042020%26volume%3D85%26issue%3D10%26spage%3D6252%26epage%3D6260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pauline Chaumont-Olive, <span class="NLM_string-name hlFld-ContribAuthor">Janine Cossy</span>. </span><span class="cited-content_cbyCitation_article-title">A One-Pot Iodo-Cyclization/Transition Metal-Catalyzed Cross-Coupling Sequence: Synthesis of Substituted Oxazolidin-2-ones from N-Boc-allylamines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (10)
                                     , 3870-3874. <a href="https://doi.org/10.1021/acs.orglett.0c01114" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01114%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BOne-Pot%252BIodo-Cyclization%25252FTransition%252BMetal-Catalyzed%252BCross-Coupling%252BSequence%25253A%252BSynthesis%252Bof%252BSubstituted%252BOxazolidin-2-ones%252Bfrom%252BN-Boc-allylamines%26aulast%3DChaumont-Olive%26aufirst%3DPauline%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D28042020%26volume%3D22%26issue%3D10%26spage%3D3870%26epage%3D3874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Xu, Ludovic Troian-Gautier, Ryan Dykstra, Robert T. Martin, Osvaldo Gutierrez, <span class="NLM_string-name hlFld-ContribAuthor">Uttam K. Tambar</span>. </span><span class="cited-content_cbyCitation_article-title">Photocatalyzed Diastereoselective Isomerization of Cinnamyl Chlorides to Cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (13)
                                     , 6206-6215. <a href="https://doi.org/10.1021/jacs.0c00147" title="DOI URL">https://doi.org/10.1021/jacs.0c00147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c00147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c00147%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPhotocatalyzed%252BDiastereoselective%252BIsomerization%252Bof%252BCinnamyl%252BChlorides%252Bto%252BCyclopropanes%26aulast%3DXu%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06012020%26date%3D19032020%26date%3D04032020%26volume%3D142%26issue%3D13%26spage%3D6206%26epage%3D6215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rohan R. Merchant, <span class="NLM_string-name hlFld-ContribAuthor">Jovan A. Lopez</span>. </span><span class="cited-content_cbyCitation_article-title">A General C(sp3)–C(sp3) Cross-Coupling of Benzyl Sulfonylhydrazones with Alkyl Boronic Acids. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (6)
                                     , 2271-2275. <a href="https://doi.org/10.1021/acs.orglett.0c00471" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c00471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c00471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c00471%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BGeneral%252BC%252528sp3%252529%2525E2%252580%252593C%252528sp3%252529%252BCross-Coupling%252Bof%252BBenzyl%252BSulfonylhydrazones%252Bwith%252BAlkyl%252BBoronic%252BAcids%26aulast%3DMerchant%26aufirst%3DRohan%2BR.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06022020%26date%3D02032020%26volume%3D22%26issue%3D6%26spage%3D2271%26epage%3D2275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Baptiste Villemagne, Arnaud Machelart, Ngoc Chau Tran, Marion Flipo, Martin Moune, Florence Leroux, Catherine Piveteau, Alexandre Wohlkönig, René Wintjens, Xue Li, Ruxandra Gref, Priscille Brodin, Benoit Deprez, Alain R Baulard, <span class="NLM_string-name hlFld-ContribAuthor">Nicolas Willand</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (3)
                                     , 366-378. <a href="https://doi.org/10.1021/acsinfecdis.9b00277" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00277</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00277%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DFragment-Based%252BOptimized%252BEthR%252BInhibitors%252Bwith%252Bin%252BVivo%252BEthionamide%252BBoosting%252BActivity%26aulast%3DVillemagne%26aufirst%3DBaptiste%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D25072019%26date%3D02032020%26date%3D03022020%26volume%3D6%26issue%3D3%26spage%3D366%26epage%3D378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Volodymyr V. Semeno, Vadym O. Vasylchenko, Bohdan V. Vashchenko, Dmytro O. Lutsenko, Rustam T. Iminov, Olesia B. Volovenko, <span class="NLM_string-name hlFld-ContribAuthor">Oleksandr O. Grygorenko</span>. </span><span class="cited-content_cbyCitation_article-title">Building the Housane: Diastereoselective Synthesis and Characterization of Bicyclo[2.1.0]pentane Carboxylic Acids. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (4)
                                     , 2321-2337. <a href="https://doi.org/10.1021/acs.joc.9b03044" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03044%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DBuilding%252Bthe%252BHousane%25253A%252BDiastereoselective%252BSynthesis%252Band%252BCharacterization%252Bof%252BBicyclo%25255B2.1.0%25255Dpentane%252BCarboxylic%252BAcids%26aulast%3DSemeno%26aufirst%3DVolodymyr%2BV.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11112019%26date%3D06012020%26date%3D20122019%26volume%3D85%26issue%3D4%26spage%3D2321%26epage%3D2337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hayato Inoue, Nga Phan Thi Thanh, Ikuhide Fujisawa, <span class="NLM_string-name hlFld-ContribAuthor">Seiji Iwasa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Forms of a Chiral Ruthenium Complex Containing a Ru–Colefin(sp2) Bond and Their Application to Catalytic Asymmetric Cyclopropanation Reactions. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (4)
                                     , 1475-1479. <a href="https://doi.org/10.1021/acs.orglett.0c00050" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c00050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c00050%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BForms%252Bof%252Ba%252BChiral%252BRuthenium%252BComplex%252BContaining%252Ba%252BRu%2525E2%252580%252593Colefin%252528sp2%252529%252BBond%252Band%252BTheir%252BApplication%252Bto%252BCatalytic%252BAsymmetric%252BCyclopropanation%252BReactions%26aulast%3DInoue%26aufirst%3DHayato%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06012020%26date%3D28012020%26volume%3D22%26issue%3D4%26spage%3D1475%26epage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Min Wu, Shuang Lin, Guoxun Zhu, Ming Sun, Zhi Zhou, Hui Gao, <span class="NLM_string-name hlFld-ContribAuthor">Wei Yi</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic Dual Directing Groups-Enabled Diastereoselective C–H Cyclopropylation via Rh(III)-Catalyzed Couplings with Cyclopropenyl Alcohols. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (4)
                                     , 1295-1300. <a href="https://doi.org/10.1021/acs.orglett.9b04608" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b04608</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b04608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b04608%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynergistic%252BDual%252BDirecting%252BGroups-Enabled%252BDiastereoselective%252BC%2525E2%252580%252593H%252BCyclopropylation%252Bvia%252BRh%252528III%252529-Catalyzed%252BCouplings%252Bwith%252BCyclopropenyl%252BAlcohols%26aulast%3DWu%26aufirst%3DMin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D23122019%26date%3D04022020%26volume%3D22%26issue%3D4%26spage%3D1295%26epage%3D1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bo Wei, Jack C. Sharland, Patricia Lin, Sidney M. Wilkerson-Hill, Felicia A. Fullilove, Sam McKinnon, Donna G. Blackmond, <span class="NLM_string-name hlFld-ContribAuthor">Huw M. L. Davies</span>. </span><span class="cited-content_cbyCitation_article-title">In Situ Kinetic Studies of Rh(II)-Catalyzed Asymmetric Cyclopropanation with Low Catalyst Loadings. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (2)
                                     , 1161-1170. <a href="https://doi.org/10.1021/acscatal.9b04595" title="DOI URL">https://doi.org/10.1021/acscatal.9b04595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.9b04595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.9b04595%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DIn%252BSitu%252BKinetic%252BStudies%252Bof%252BRh%252528II%252529-Catalyzed%252BAsymmetric%252BCyclopropanation%252Bwith%252BLow%252BCatalyst%252BLoadings%26aulast%3DWei%26aufirst%3DBo%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24102019%26date%3D09122019%26date%3D30122019%26volume%3D10%26issue%3D2%26spage%3D1161%26epage%3D1170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen Ahenkorah, Dina Coertzen, Jie Xin Tong, Kevin Fridianto, Sergio Wittlin, Lyn-Marie Birkholtz, Kevin S. W. Tan, Yulin Lam, Mei-Lin Go, <span class="NLM_string-name hlFld-ContribAuthor">Richard K. Haynes</span>. </span><span class="cited-content_cbyCitation_article-title">Antimalarial N1,N3-Dialkyldioxonaphthoimidazoliums: Synthesis, Biological Activity, and Structure–activity Relationships. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 49-55. <a href="https://doi.org/10.1021/acsmedchemlett.9b00457" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00457%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAntimalarial%252BN1%25252CN3-Dialkyldioxonaphthoimidazoliums%25253A%252BSynthesis%25252C%252BBiological%252BActivity%25252C%252Band%252BStructure%2525E2%252580%252593activity%252BRelationships%26aulast%3DAhenkorah%26aufirst%3DStephen%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02102019%26date%3D11122019%26date%3D19122019%26date%3D11122019%26volume%3D11%26issue%3D1%26spage%3D49%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jose M. Medina, Taeho Kang, Tuğçe G. Erbay, Huiling Shao, Gary M. Gallego, Shouliang Yang, Michelle Tran-Dubé, Paul F. Richardson, Joseph Derosa, Ryan T. Helsel, Ryan L. Patman, Fen Wang, Christopher P. Ashcroft, John F. Braganza, Indrawan McAlpine, Peng Liu, <span class="NLM_string-name hlFld-ContribAuthor">Keary M. Engle</span>. </span><span class="cited-content_cbyCitation_article-title">Cu-Catalyzed Hydroboration of Benzylidenecyclopropanes: Reaction Optimization, (Hetero)Aryl Scope, and Origins of Pathway Selectivity. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2019,</strong> <em>9 </em>
                                    (12)
                                     , 11130-11136. <a href="https://doi.org/10.1021/acscatal.9b03557" title="DOI URL">https://doi.org/10.1021/acscatal.9b03557</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.9b03557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.9b03557%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DCu-Catalyzed%252BHydroboration%252Bof%252BBenzylidenecyclopropanes%25253A%252BReaction%252BOptimization%25252C%252B%252528Hetero%252529Aryl%252BScope%25252C%252Band%252BOrigins%252Bof%252BPathway%252BSelectivity%26aulast%3DMedina%26aufirst%3DJose%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20082019%26date%3D26102019%26date%3D08112019%26date%3D29102019%26volume%3D9%26issue%3D12%26spage%3D11130%26epage%3D11136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia D’Arienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8973-8995. <a href="https://doi.org/10.1021/acs.jmedchem.9b00444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%252BInhibition%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%25253A%252BDiscovery%252Bof%252Bthe%252BAllosteric%252BInhibitor%252BBMS-986165%26aulast%3DWrobleski%26aufirst%3DStephen%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D18072019%26volume%3D62%26issue%3D20%26spage%3D8973%26epage%3D8995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael
S. West, L. Reginald Mills, Tyler R. McDonald, Jessica B. Lee, Deeba Ensan, <span class="NLM_string-name hlFld-ContribAuthor">Sophie A. L. Rousseaux</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of trans-2-Substituted Cyclopropylamines from α-Chloroaldehydes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (20)
                                     , 8409-8413. <a href="https://doi.org/10.1021/acs.orglett.9b03172" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03172</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03172%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252Btrans-2-Substituted%252BCyclopropylamines%252Bfrom%252B%2525CE%2525B1-Chloroaldehydes%26aulast%3DWest%26aufirst%3DMichael%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06092019%26date%3D08102019%26volume%3D21%26issue%3D20%26spage%3D8409%26epage%3D8413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aika Takeshima, Taichi Kano, <span class="NLM_string-name hlFld-ContribAuthor">Keiji Maruoka</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Phenylcyclopropane-Based Secondary Amine Catalysts and Their Applications in Enamine Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (19)
                                     , 8071-8074. <a href="https://doi.org/10.1021/acs.orglett.9b03070" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03070%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BPhenylcyclopropane-Based%252BSecondary%252BAmine%252BCatalysts%252Band%252BTheir%252BApplications%252Bin%252BEnamine%252BCatalysis%26aulast%3DTakeshima%26aufirst%3DAika%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28082019%26date%3D12092019%26volume%3D21%26issue%3D19%26spage%3D8071%26epage%3D8074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniela
M. Carminati, <span class="NLM_string-name hlFld-ContribAuthor">Rudi Fasan</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Cyclopropanation of Electron-Deficient Olefins with a Cofactor Redesigned Carbene Transferase Featuring Radical Reactivity. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2019,</strong> <em>9 </em>
                                    (10)
                                     , 9683-9697. <a href="https://doi.org/10.1021/acscatal.9b02272" title="DOI URL">https://doi.org/10.1021/acscatal.9b02272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.9b02272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.9b02272%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DStereoselective%252BCyclopropanation%252Bof%252BElectron-Deficient%252BOlefins%252Bwith%252Ba%252BCofactor%252BRedesigned%252BCarbene%252BTransferase%252BFeaturing%252BRadical%252BReactivity%26aulast%3DCarminati%26aufirst%3DDaniela%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D31052019%26date%3D23082019%26date%3D27092019%26date%3D05092019%26volume%3D9%26issue%3D10%26spage%3D9683%26epage%3D9697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Francesca Turnu, Alberto Luridiana, Andrea Cocco, Stefania Porcu, Angelo Frongia, Giorgia Sarais, <span class="NLM_string-name hlFld-ContribAuthor">Francesco Secci</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Tandem Friedel–Crafts Alkylation/C4–C3 Ring-Contraction Reaction: An Efficient Route for the Synthesis of Indolyl Cyclopropanecarbaldehydes and Ketones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (18)
                                     , 7329-7332. <a href="https://doi.org/10.1021/acs.orglett.9b02617" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02617%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCatalytic%252BTandem%252BFriedel%2525E2%252580%252593Crafts%252BAlkylation%25252FC4%2525E2%252580%252593C3%252BRing-Contraction%252BReaction%25253A%252BAn%252BEfficient%252BRoute%252Bfor%252Bthe%252BSynthesis%252Bof%252BIndolyl%252BCyclopropanecarbaldehydes%252Band%252BKetones%26aulast%3DTurnu%26aufirst%3DFrancesca%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25072019%26date%3D06092019%26volume%3D21%26issue%3D18%26spage%3D7329%26epage%3D7332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christoph Köllmann, Svenja M. Wiechert, Peter G. Jones, Thomas Pietschmann, <span class="NLM_string-name hlFld-ContribAuthor">Daniel B. Werz</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4′/5′-Spirocyclopropanated Uridine and d-Xylouridine Derivatives and Their Activity against the Human Respiratory Syncytial Virus. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (17)
                                     , 6966-6971. <a href="https://doi.org/10.1021/acs.orglett.9b02555" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02555</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02555%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252B4%2525E2%252580%2525B2%25252F5%2525E2%252580%2525B2-Spirocyclopropanated%252BUridine%252Band%252Bd-Xylouridine%252BDerivatives%252Band%252BTheir%252BActivity%252Bagainst%252Bthe%252BHuman%252BRespiratory%252BSyncytial%252BVirus%26aulast%3DK%25C3%25B6llmann%26aufirst%3DChristoph%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22072019%26date%3D21082019%26volume%3D21%26issue%3D17%26spage%3D6966%26epage%3D6971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Renate Melngaile, Arturs Sperga, Kim K. Baldridge, <span class="NLM_string-name hlFld-ContribAuthor">Janis Veliks</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective Monofluorocyclopropanation Using Fluoromethylsulfonium Salts. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (17)
                                     , 7174-7178. <a href="https://doi.org/10.1021/acs.orglett.9b02867" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02867</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02867%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDiastereoselective%252BMonofluorocyclopropanation%252BUsing%252BFluoromethylsulfonium%252BSalts%26aulast%3DMelngaile%26aufirst%3DRenate%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D21082019%26volume%3D21%26issue%3D17%26spage%3D7174%26epage%3D7178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhunzhun Yu, <span class="NLM_string-name hlFld-ContribAuthor">Abraham Mendoza</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Assembly of Congested Cyclopropanes using Redox-Active Aryldiazoacetates. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2019,</strong> <em>9 </em>
                                    (9)
                                     , 7870-7875. <a href="https://doi.org/10.1021/acscatal.9b02615" title="DOI URL">https://doi.org/10.1021/acscatal.9b02615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.9b02615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.9b02615%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DEnantioselective%252BAssembly%252Bof%252BCongested%252BCyclopropanes%252Busing%252BRedox-Active%252BAryldiazoacetates%26aulast%3DYu%26aufirst%3DZhunzhun%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21062019%26date%3D25072019%26date%3D01082019%26date%3D26072019%26volume%3D9%26issue%3D9%26spage%3D7870%26epage%3D7875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhanyu Li, Mengru Zhang, Yu Zhang, Shuang Liu, Jinbo Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Qian Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Multicomponent Cyclopropane Synthesis Enabled by Cu-Catalyzed Cyclopropene Carbometalation with Organoboron Reagent: Enantioselective Modular Access to Polysubstituted 2-Arylcyclopropylamines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (14)
                                     , 5432-5437. <a href="https://doi.org/10.1021/acs.orglett.9b01650" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b01650</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b01650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b01650%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DMulticomponent%252BCyclopropane%252BSynthesis%252BEnabled%252Bby%252BCu-Catalyzed%252BCyclopropene%252BCarbometalation%252Bwith%252BOrganoboron%252BReagent%25253A%252BEnantioselective%252BModular%252BAccess%252Bto%252BPolysubstituted%252B2-Arylcyclopropylamines%26aulast%3DLi%26aufirst%3DZhanyu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D09052019%26date%3D28062019%26volume%3D21%26issue%3D14%26spage%3D5432%26epage%3D5437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Francisco
O. Battiti, Sophie L. Cemaj, Adrian M. Guerrero, Anver Basha Shaik, Jenny Lam, Rana Rais, Barbara S. Slusher, Jeffery R. Deschamps, Greg H. Imler, Amy Hauck Newman, <span class="NLM_string-name hlFld-ContribAuthor">Alessandro Bonifazi</span>. </span><span class="cited-content_cbyCitation_article-title">The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6287-6314. <a href="https://doi.org/10.1021/acs.jmedchem.9b00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BSignificance%252Bof%252BChirality%252Bin%252BDrug%252BDesign%252Band%252BSynthesis%252Bof%252BBitopic%252BLigands%252Bas%252BD3%252BReceptor%252B%252528D3R%252529%252BSelective%252BAgonists%26aulast%3DBattiti%26aufirst%3DFrancisco%2BO.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D29042019%26date%3D01072019%26date%3D19062019%26volume%3D62%26issue%3D13%26spage%3D6287%26epage%3D6314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongjia Shi, Qian Gao, <span class="NLM_string-name hlFld-ContribAuthor">Senmiao Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)–H Borylation of Cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (27)
                                     , 10599-10604. <a href="https://doi.org/10.1021/jacs.9b04549" title="DOI URL">https://doi.org/10.1021/jacs.9b04549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b04549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b04549%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DChiral%252BBidentate%252BBoryl%252BLigand%252BEnabled%252BIridium-Catalyzed%252BEnantioselective%252BC%252528sp3%252529%2525E2%252580%252593H%252BBorylation%252Bof%252BCyclopropanes%26aulast%3DShi%26aufirst%3DYongjia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28042019%26date%3D01072019%26date%3D25062019%26volume%3D141%26issue%3D27%26spage%3D10599%26epage%3D10604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qing-Feng Xu-Xu, Xiao Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Shu-Li You</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of 4-Aminotetrahydroquinolines via 1,2-Reductive Dearomatization of Quinolines and Copper(I) Hydride-Catalyzed Asymmetric Hydroamination. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (13)
                                     , 5357-5362. <a href="https://doi.org/10.1021/acs.orglett.9b02034" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02034%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DEnantioselective%252BSynthesis%252Bof%252B4-Aminotetrahydroquinolines%252Bvia%252B1%25252C2-Reductive%252BDearomatization%252Bof%252BQuinolines%252Band%252BCopper%252528I%252529%252BHydride-Catalyzed%252BAsymmetric%252BHydroamination%26aulast%3DXu-Xu%26aufirst%3DQing-Feng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13062019%26date%3D20062019%26volume%3D21%26issue%3D13%26spage%3D5357%26epage%3D5362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Uday Kiran Velagapudi, Marie-France Langelier, Cristina Delgado-Martin, Morgan E. Diolaiti, Sietske Bakker, Alan Ashworth, Bhargav A. Patel, Xuwei Shao, John M. Pascal, <span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (11)
                                     , 5330-5357. <a href="https://doi.org/10.1021/acs.jmedchem.8b01709" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01709</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01709%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase%252BInhibitors%25253A%252BImpact%252Bof%252BAdenosine%252BPocket-Binding%252BMotif%252BAppendage%252Bto%252Bthe%252B3-Oxo-2%25252C3-dihydrobenzofuran-7-carboxamide%252Bon%252BPotency%252Band%252BSelectivity%26aulast%3DVelagapudi%26aufirst%3DUday%2BKiran%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D01112018%26date%3D24052019%26date%3D01052019%26volume%3D62%26issue%3D11%26spage%3D5330%26epage%3D5357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ajay L. Chandgude, Xinkun Ren, <span class="NLM_string-name hlFld-ContribAuthor">Rudi Fasan</span>. </span><span class="cited-content_cbyCitation_article-title">Stereodivergent Intramolecular Cyclopropanation Enabled by Engineered Carbene Transferases. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (23)
                                     , 9145-9150. <a href="https://doi.org/10.1021/jacs.9b02700" title="DOI URL">https://doi.org/10.1021/jacs.9b02700</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b02700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b02700%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DStereodivergent%252BIntramolecular%252BCyclopropanation%252BEnabled%252Bby%252BEngineered%252BCarbene%252BTransferases%26aulast%3DChandgude%26aufirst%3DAjay%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11032019%26date%3D29052019%26date%3D17052019%26volume%3D141%26issue%3D23%26spage%3D9145%26epage%3D9150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dorus Heijnen, Hugo Helbert, Gert Luurtsema, Philip H. Elsinga, <span class="NLM_string-name hlFld-ContribAuthor">Ben L. Feringa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Substituted Benzaldehydes via a Two-Step, One-Pot Reduction/Cross-Coupling Procedure. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (11)
                                     , 4087-4091. <a href="https://doi.org/10.1021/acs.orglett.9b01274" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b01274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b01274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b01274%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BSubstituted%252BBenzaldehydes%252Bvia%252Ba%252BTwo-Step%25252C%252BOne-Pot%252BReduction%25252FCross-Coupling%252BProcedure%26aulast%3DHeijnen%26aufirst%3DDorus%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11042019%26date%3D14052019%26volume%3D21%26issue%3D11%26spage%3D4087%26epage%3D4091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arnab Dey, Neetipalli Thrimurtulu, <span class="NLM_string-name hlFld-ContribAuthor">Chandra M. R. Volla</span>. </span><span class="cited-content_cbyCitation_article-title">Cobalt-Catalyzed Annulation Reactions of Alkylidenecyclopropanes: Access to Spirocyclopropanes at Room Temperature. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (10)
                                     , 3871-3875. <a href="https://doi.org/10.1021/acs.orglett.9b01392" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b01392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b01392%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCobalt-Catalyzed%252BAnnulation%252BReactions%252Bof%252BAlkylidenecyclopropanes%25253A%252BAccess%252Bto%252BSpirocyclopropanes%252Bat%252BRoom%252BTemperature%26aulast%3DDey%26aufirst%3DArnab%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21042019%26date%3D02052019%26volume%3D21%26issue%3D10%26spage%3D3871%26epage%3D3875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, <span class="NLM_string-name hlFld-ContribAuthor">Jon T. Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">A Survey of the Structures of US FDA Approved Combination Drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4265-4311. <a href="https://doi.org/10.1021/acs.jmedchem.8b01610" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01610%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSurvey%252Bof%252Bthe%252BStructures%252Bof%252BUS%252BFDA%252BApproved%252BCombination%252BDrugs%26aulast%3DDas%26aufirst%3DPradipta%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D16102018%26date%3D30112018%26date%3D16112018%26volume%3D62%26issue%3D9%26spage%3D4265%26epage%3D4311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Erik J.
T. Phipps, <span class="NLM_string-name hlFld-ContribAuthor">Tomislav Rovis</span>. </span><span class="cited-content_cbyCitation_article-title">Rh(III)-Catalyzed C–H Activation-Initiated Directed Cyclopropanation of Allylic Alcohols. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (17)
                                     , 6807-6811. <a href="https://doi.org/10.1021/jacs.9b02156" title="DOI URL">https://doi.org/10.1021/jacs.9b02156</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b02156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b02156%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DRh%252528III%252529-Catalyzed%252BC%2525E2%252580%252593H%252BActivation-Initiated%252BDirected%252BCyclopropanation%252Bof%252BAllylic%252BAlcohols%26aulast%3DPhipps%26aufirst%3DErik%2BJ.%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25022019%26date%3D18042019%26volume%3D141%26issue%3D17%26spage%3D6807%26epage%3D6811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brandon
A. Wright, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Ardolino</span>. </span><span class="cited-content_cbyCitation_article-title">Surprising Reactivity in NiXantphos/Palladium-Catalyzed α-Arylation of Substituted Cyclopropyl Nitriles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (8)
                                     , 4670-4679. <a href="https://doi.org/10.1021/acs.joc.8b02238" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02238%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSurprising%252BReactivity%252Bin%252BNiXantphos%25252FPalladium-Catalyzed%252B%2525CE%2525B1-Arylation%252Bof%252BSubstituted%252BCyclopropyl%252BNitriles%26aulast%3DWright%26aufirst%3DBrandon%2BA.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D29082018%26date%3D19112018%26date%3D09112018%26volume%3D84%26issue%3D8%26spage%3D4670%26epage%3D4679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Camilla Mayer, Carolyn L. Ladd, <span class="NLM_string-name hlFld-ContribAuthor">André B. Charette</span>. </span><span class="cited-content_cbyCitation_article-title">Utilization of BozPhos as an Effective Ligand in Enantioselective C–H Functionalization of Cyclopropanes: Synthesis of Dihydroisoquinolones and Dihydroquinolones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (8)
                                     , 2639-2644. <a href="https://doi.org/10.1021/acs.orglett.9b00627" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00627</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00627%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DUtilization%252Bof%252BBozPhos%252Bas%252Ban%252BEffective%252BLigand%252Bin%252BEnantioselective%252BC%2525E2%252580%252593H%252BFunctionalization%252Bof%252BCyclopropanes%25253A%252BSynthesis%252Bof%252BDihydroisoquinolones%252Band%252BDihydroquinolones%26aulast%3DMayer%26aufirst%3DCamilla%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19022019%26date%3D29032019%26volume%3D21%26issue%3D8%26spage%3D2639%26epage%3D2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Masahito Murai, Ryuji Taniguchi, Chisato Mizuta, <span class="NLM_string-name hlFld-ContribAuthor">Kazuhiko Takai</span>. </span><span class="cited-content_cbyCitation_article-title">Chromium-Mediated Stannylcyclopropanation of Alkenes with (Diiodomethyl)stannanes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (8)
                                     , 2668-2672. <a href="https://doi.org/10.1021/acs.orglett.9b00658" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00658%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DChromium-Mediated%252BStannylcyclopropanation%252Bof%252BAlkenes%252Bwith%252B%252528Diiodomethyl%252529stannanes%26aulast%3DMurai%26aufirst%3DMasahito%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D04042019%26volume%3D21%26issue%3D8%26spage%3D2668%26epage%3D2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Patrick Cyr, Joël Flynn-Robitaille, Patrick Boissarie, <span class="NLM_string-name hlFld-ContribAuthor">Anne Marinier</span>. </span><span class="cited-content_cbyCitation_article-title">Mild and Diazo-Free Synthesis of Trifluoromethyl-Cyclopropanes Using Sulfonium Ylides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (7)
                                     , 2265-2268. <a href="https://doi.org/10.1021/acs.orglett.9b00557" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00557</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00557%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DMild%252Band%252BDiazo-Free%252BSynthesis%252Bof%252BTrifluoromethyl-Cyclopropanes%252BUsing%252BSulfonium%252BYlides%26aulast%3DCyr%26aufirst%3DPatrick%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12022019%26date%3D18032019%26volume%3D21%26issue%3D7%26spage%3D2265%26epage%3D2268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Claire Andersen, Vincent Ferey, Marc Daumas, Patrick Bernardelli, Amandine Guérinot, <span class="NLM_string-name hlFld-ContribAuthor">Janine Cossy</span>. </span><span class="cited-content_cbyCitation_article-title">Introduction of Cyclopropyl and Cyclobutyl Ring on Alkyl Iodides through Cobalt-Catalyzed Cross-Coupling. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (7)
                                     , 2285-2289. <a href="https://doi.org/10.1021/acs.orglett.9b00579" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b00579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b00579%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DIntroduction%252Bof%252BCyclopropyl%252Band%252BCyclobutyl%252BRing%252Bon%252BAlkyl%252BIodides%252Bthrough%252BCobalt-Catalyzed%252BCross-Coupling%26aulast%3DAndersen%26aufirst%3DClaire%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15022019%26date%3D21032019%26volume%3D21%26issue%3D7%26spage%3D2285%26epage%3D2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Deyu Kong, Tao Xue, Bin Guo, Jianjun Cheng, Shunyin Liu, Jianhai Wei, Zhengyu Lu, Haoran Liu, Guoqing Gong, Tian Lan, Wenhao Hu, <span class="NLM_string-name hlFld-ContribAuthor">Yushe Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 3088-3106. <a href="https://doi.org/10.1021/acs.jmedchem.8b01971" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01971</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01971%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252BP2Y12%252BAntagonist%252BEthyl%252B6-%2525284-%252528%252528Benzylsulfonyl%252529carbamoyl%252529piperidin-1-yl%252529-5-cyano-2-methylnicotinate%252B%252528AZD1283%252529%252BLed%252Bto%252Bthe%252BDiscovery%252Bof%252Ban%252BOral%252BAntiplatelet%252BAgent%252Bwith%252BImproved%252BDruglike%252BProperties%26aulast%3DKong%26aufirst%3DDeyu%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D17122018%26date%3D19032019%26date%3D07032019%26volume%3D62%26issue%3D6%26spage%3D3088%26epage%3D3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Soufyan Jerhaoui, Jean-Pierre Djukic, Joanna Wencel-Delord, <span class="NLM_string-name hlFld-ContribAuthor">Françoise Colobert</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric, Nearly Barrierless C(sp3)–H Activation Promoted by Easily-Accessible N-Protected Aminosulfoxides as New Chiral Ligands. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 2532-2542. <a href="https://doi.org/10.1021/acscatal.8b04946" title="DOI URL">https://doi.org/10.1021/acscatal.8b04946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.8b04946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.8b04946%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DAsymmetric%25252C%252BNearly%252BBarrierless%252BC%252528sp3%252529%2525E2%252580%252593H%252BActivation%252BPromoted%252Bby%252BEasily-Accessible%252BN-Protected%252BAminosulfoxides%252Bas%252BNew%252BChiral%252BLigands%26aulast%3DJerhaoui%26aufirst%3DSoufyan%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D2019%26date%3D11122018%26date%3D24012019%26date%3D18022019%26date%3D04022019%26volume%3D9%26issue%3D3%26spage%3D2532%26epage%3D2542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kevin M. Peese, Christopher W. Allard, Timothy Connolly, Barry L. Johnson, Chen Li, Manoj Patel, Margaret E. Sorensen, Michael A. Walker, Nicholas A. Meanwell, Brian McAuliffe, Beatrice Minassian, Mark Krystal, Dawn D. Parker, Hal A. Lewis, Kevin Kish, Ping Zhang, Robert T. Nolte, Jean Simmermacher, Susan Jenkins, Christopher Cianci, <span class="NLM_string-name hlFld-ContribAuthor">B. Narasimhulu Naidu</span>. </span><span class="cited-content_cbyCitation_article-title">5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1348-1361. <a href="https://doi.org/10.1021/acs.jmedchem.8b01473" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01473%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D5%25252C6%25252C7%25252C8-Tetrahydro-1%25252C6-naphthyridine%252BDerivatives%252Bas%252BPotent%252BHIV-1-Integrase-Allosteric-Site%252BInhibitors%26aulast%3DPeese%26aufirst%3DKevin%2BM.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21092018%26date%3D18012019%26date%3D04012019%26volume%3D62%26issue%3D3%26spage%3D1348%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alessandro Bonifazi, Hideaki Yano, Adrian M. Guerrero, Vivek Kumar, Alexander F. Hoffman, Carl R. Lupica, Lei Shi, <span class="NLM_string-name hlFld-ContribAuthor">Amy Hauck Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2019,</strong> <em>2 </em>
                                    (1)
                                     , 52-65. <a href="https://doi.org/10.1021/acsptsci.8b00060" title="DOI URL">https://doi.org/10.1021/acsptsci.8b00060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.8b00060%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DNovel%252Band%252BPotent%252BDopamine%252BD2%252BReceptor%252BGo-Protein%252BBiased%252BAgonists%26aulast%3DBonifazi%26aufirst%3DAlessandro%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21122018%26date%3D28012019%26date%3D14012019%26volume%3D2%26issue%3D1%26spage%3D52%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Antonio Tinoco, Yang Wei, John-Paul Bacik, Daniela M. Carminati, Eric J. Moore, Nozomi Ando, Yong Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Rudi Fasan</span>. </span><span class="cited-content_cbyCitation_article-title">Origin of High Stereocontrol in Olefin Cyclopropanation Catalyzed by an Engineered Carbene Transferase. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2019,</strong> <em>9 </em>
                                    (2)
                                     , 1514-1524. <a href="https://doi.org/10.1021/acscatal.8b04073" title="DOI URL">https://doi.org/10.1021/acscatal.8b04073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.8b04073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.8b04073%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DOrigin%252Bof%252BHigh%252BStereocontrol%252Bin%252BOlefin%252BCyclopropanation%252BCatalyzed%252Bby%252Ban%252BEngineered%252BCarbene%252BTransferase%26aulast%3DTinoco%26aufirst%3DAntonio%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09102018%26date%3D20122018%26date%3D23012019%26date%3D28122018%26volume%3D9%26issue%3D2%26spage%3D1514%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Uttam
K. Mishra, Kaushalendra Patel, <span class="NLM_string-name hlFld-ContribAuthor">S. S. V. Ramasastry</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Cyclopropanoids via Substrate-Based Cyclization Pathways. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (1)
                                     , 175-179. <a href="https://doi.org/10.1021/acs.orglett.8b03537" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03537</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03537%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BCyclopropanoids%252Bvia%252BSubstrate-Based%252BCyclization%252BPathways%26aulast%3DMishra%26aufirst%3DUttam%2BK.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D05112018%26date%3D13122018%26volume%3D21%26issue%3D1%26spage%3D175%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bohdan Waszkowycz, Kate M. Smith, Alison E. McGonagle, Allan M. Jordan, Ben Acton, Emma E. Fairweather, Louise A. Griffiths, Niall M. Hamilton, Nicola S. Hamilton, James R. Hitchin, Colin P. Hutton, Dominic I. James, Clifford D. Jones, Stuart Jones, Daniel P. Mould, Helen F. Small, Alexandra I. J. Stowell, Julie A. Tucker, Ian D. Waddell, <span class="NLM_string-name hlFld-ContribAuthor">Donald J. Ogilvie</span>. </span><span class="cited-content_cbyCitation_article-title">Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10767-10792. <a href="https://doi.org/10.1021/acs.jmedchem.8b01407" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01407%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCell-Active%252BSmall%252BMolecule%252BInhibitors%252Bof%252Bthe%252BDNA-Damage%252BRepair%252BEnzyme%252BPoly%252528ADP-ribose%252529%252BGlycohydrolase%252B%252528PARG%252529%25253A%252BDiscovery%252Band%252BOptimization%252Bof%252BOrally%252BBioavailable%252BQuinazolinedione%252BSulfonamides%26aulast%3DWaszkowycz%26aufirst%3DBohdan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11092018%26date%3D19112018%26date%3D07112018%26volume%3D61%26issue%3D23%26spage%3D10767%26epage%3D10792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhengren Xu, Guohui Pan, Hao Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Ben Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of 1-Aminocyclopropane-1-carboxylic Acid Synthase of Bacterial Origin. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (49)
                                     , 16957-16961. <a href="https://doi.org/10.1021/jacs.8b11463" title="DOI URL">https://doi.org/10.1021/jacs.8b11463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b11463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b11463%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252B1-Aminocyclopropane-1-carboxylic%252BAcid%252BSynthase%252Bof%252BBacterial%252BOrigin%26aulast%3DXu%26aufirst%3DZhengren%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24102018%26date%3D28112018%26date%3D25112018%26volume%3D140%26issue%3D49%26spage%3D16957%26epage%3D16961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Motohiro Yasui, Rina Ota, Chihiro Tsukano, <span class="NLM_string-name hlFld-ContribAuthor">Yoshiji Takemoto</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of cis-/All-cis-Substituted Cyclopropanes through Stereocontrolled Metalation and Pd-Catalyzed Negishi Coupling. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (23)
                                     , 7656-7660. <a href="https://doi.org/10.1021/acs.orglett.8b03390" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03390%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252Bcis-%25252FAll-cis-Substituted%252BCyclopropanes%252Bthrough%252BStereocontrolled%252BMetalation%252Band%252BPd-Catalyzed%252BNegishi%252BCoupling%26aulast%3DYasui%26aufirst%3DMotohiro%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D23102018%26date%3D21112018%26volume%3D20%26issue%3D23%26spage%3D7656%26epage%3D7660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Limeng Zheng, Bingwei Zhou, Hongwei Jin, Ting Li, <span class="NLM_string-name hlFld-ContribAuthor">Yunkui Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Radical-Triggered Tandem Cyclization of 1,6-Enynes with H2O: A Way to Access Strained 1H-Cyclopropa[b]naph thalene-2,7-diones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (22)
                                     , 7053-7056. <a href="https://doi.org/10.1021/acs.orglett.8b03007" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03007%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRadical-Triggered%252BTandem%252BCyclization%252Bof%252B1%25252C6-Enynes%252Bwith%252BH2O%25253A%252BA%252BWay%252Bto%252BAccess%252BStrained%252B1H-Cyclopropa%25255Bb%25255Dnaph%252Bthalene-2%25252C7-diones%26aulast%3DZheng%26aufirst%3DLimeng%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19092018%26date%3D25102018%26volume%3D20%26issue%3D22%26spage%3D7053%26epage%3D7056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sobi Asako, Takaaki Kobashi, <span class="NLM_string-name hlFld-ContribAuthor">Kazuhiko Takai</span>. </span><span class="cited-content_cbyCitation_article-title">Use of Cyclopropane as C1 Synthetic Unit by Directed Retro-Cyclopropanation with Ethylene Release. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (45)
                                     , 15425-15429. <a href="https://doi.org/10.1021/jacs.8b09297" title="DOI URL">https://doi.org/10.1021/jacs.8b09297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b09297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b09297%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DUse%252Bof%252BCyclopropane%252Bas%252BC1%252BSynthetic%252BUnit%252Bby%252BDirected%252BRetro-Cyclopropanation%252Bwith%252BEthylene%252BRelease%26aulast%3DAsako%26aufirst%3DSobi%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D29082018%26date%3D02112018%26date%3D22102018%26volume%3D140%26issue%3D45%26spage%3D15425%26epage%3D15429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">John A. Milligan, James P. Phelan, Viktor C. Polites, Christopher B. Kelly, <span class="NLM_string-name hlFld-ContribAuthor">Gary A. Molander</span>. </span><span class="cited-content_cbyCitation_article-title">Radical/Polar Annulation Reactions (RPARs) Enable the Modular Construction of Cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (21)
                                     , 6840-6844. <a href="https://doi.org/10.1021/acs.orglett.8b02968" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b02968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b02968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b02968%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRadical%25252FPolar%252BAnnulation%252BReactions%252B%252528RPARs%252529%252BEnable%252Bthe%252BModular%252BConstruction%252Bof%252BCyclopropanes%26aulast%3DMilligan%26aufirst%3DJohn%2BA.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17092018%26date%3D15102018%26volume%3D20%26issue%3D21%26spage%3D6840%26epage%3D6844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Longyang Dian, <span class="NLM_string-name hlFld-ContribAuthor">Ilan Marek</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Preparation of Polysubstituted Cyclopropanes Based on Direct Functionalization of Achiral Three-Membered Carbocycles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2018,</strong> <em>118 </em>
                                    (18)
                                     , 8415-8434. <a href="https://doi.org/10.1021/acs.chemrev.8b00304" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00304</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00304%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DAsymmetric%252BPreparation%252Bof%252BPolysubstituted%252BCyclopropanes%252BBased%252Bon%252BDirect%252BFunctionalization%252Bof%252BAchiral%252BThree-Membered%252BCarbocycles%26aulast%3DDian%26aufirst%3DLongyang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16052018%26date%3D29082018%26volume%3D118%26issue%3D18%26spage%3D8415%26epage%3D8434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kim N. Tu, Chao Gao, <span class="NLM_string-name hlFld-ContribAuthor">Suzanne A. Blum</span>. </span><span class="cited-content_cbyCitation_article-title">An Oxyboration Route to a Single Regioisomer of Borylated Dihydrofurans and Isochromenes. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (18)
                                     , 11204-11217. <a href="https://doi.org/10.1021/acs.joc.8b01790" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01790%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAn%252BOxyboration%252BRoute%252Bto%252Ba%252BSingle%252BRegioisomer%252Bof%252BBorylated%252BDihydrofurans%252Band%252BIsochromenes%26aulast%3DTu%26aufirst%3DKim%2BN.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D13072018%26date%3D06082018%26date%3D25072018%26volume%3D83%26issue%3D18%26spage%3D11204%26epage%3D11217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryutaro Kanada, Makoto Tanabe, Ryuta Muromoto, Yukina Sato, Tomoki Kuwahara, Hayato Fukuda, Mitsuhiro Arisawa, Tadashi Matsuda, Mizuki Watanabe, <span class="NLM_string-name hlFld-ContribAuthor">Satoshi Shuto</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Chiral cis-Cyclopropane Bearing Indole and Chromone as Potential TNFα Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (15)
                                     , 7672-7682. <a href="https://doi.org/10.1021/acs.joc.8b00466" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00466%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BChiral%252Bcis-Cyclopropane%252BBearing%252BIndole%252Band%252BChromone%252Bas%252BPotential%252BTNF%2525CE%2525B1%252BInhibitors%26aulast%3DKanada%26aufirst%3DRyutaro%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17022018%26date%3D24072018%26date%3D13072018%26volume%3D83%26issue%3D15%26spage%3D7672%26epage%3D7682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Saumen Hajra, Sayan Roy, <span class="NLM_string-name hlFld-ContribAuthor">SK Abu Saleh</span>. </span><span class="cited-content_cbyCitation_article-title">Domino Corey–Chaykovsky Reaction for One-Pot Access to Spirocyclopropyl Oxindoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (15)
                                     , 4540-4544. <a href="https://doi.org/10.1021/acs.orglett.8b01840" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b01840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b01840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b01840%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDomino%252BCorey%2525E2%252580%252593Chaykovsky%252BReaction%252Bfor%252BOne-Pot%252BAccess%252Bto%252BSpirocyclopropyl%252BOxindoles%26aulast%3DHajra%26aufirst%3DSaumen%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D13062018%26date%3D23072018%26volume%3D20%26issue%3D15%26spage%3D4540%26epage%3D4544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eric J. Moore, Viktoria Steck, Priyanka Bajaj, <span class="NLM_string-name hlFld-ContribAuthor">Rudi Fasan</span>. </span><span class="cited-content_cbyCitation_article-title">Chemoselective Cyclopropanation over Carbene Y–H Insertion Catalyzed by an Engineered Carbene Transferase. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (14)
                                     , 7480-7490. <a href="https://doi.org/10.1021/acs.joc.8b00946" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00946%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DChemoselective%252BCyclopropanation%252Bover%252BCarbene%252BY%2525E2%252580%252593H%252BInsertion%252BCatalyzed%252Bby%252Ban%252BEngineered%252BCarbene%252BTransferase%26aulast%3DMoore%26aufirst%3DEric%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20042018%26date%3D06072018%26date%3D15062018%26volume%3D83%26issue%3D14%26spage%3D7480%26epage%3D7490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James
P. Phelan, Simon B. Lang, Jordan S. Compton, Christopher B. Kelly, Ryan Dykstra, Osvaldo Gutierrez, <span class="NLM_string-name hlFld-ContribAuthor">Gary A. Molander</span>. </span><span class="cited-content_cbyCitation_article-title">Redox-Neutral Photocatalytic Cyclopropanation via Radical/Polar Crossover. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (25)
                                     , 8037-8047. <a href="https://doi.org/10.1021/jacs.8b05243" title="DOI URL">https://doi.org/10.1021/jacs.8b05243</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b05243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b05243%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DRedox-Neutral%252BPhotocatalytic%252BCyclopropanation%252Bvia%252BRadical%25252FPolar%252BCrossover%26aulast%3DPhelan%26aufirst%3DJames%2BP.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18052018%26date%3D19062018%26volume%3D140%26issue%3D25%26spage%3D8037%26epage%3D8047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peng-Xiang Shen, Liang Hu, Qian Shao, Kai Hong, <span class="NLM_string-name hlFld-ContribAuthor">Jin-Quan Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Pd(II)-Catalyzed Enantioselective C(sp3)–H Arylation of Free Carboxylic Acids. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (21)
                                     , 6545-6549. <a href="https://doi.org/10.1021/jacs.8b03509" title="DOI URL">https://doi.org/10.1021/jacs.8b03509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b03509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b03509%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPd%252528II%252529-Catalyzed%252BEnantioselective%252BC%252528sp3%252529%2525E2%252580%252593H%252BArylation%252Bof%252BFree%252BCarboxylic%252BAcids%26aulast%3DShen%26aufirst%3DPeng-Xiang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D30032018%26date%3D17052018%26date%3D09052018%26volume%3D140%26issue%3D21%26spage%3D6545%26epage%3D6549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhuqing Liu, Fei Huang, Ping Wu, Quannan Wang, <span class="NLM_string-name hlFld-ContribAuthor">Zhengkun Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Amide Bond Formation Assisted by Vicinal Alkylthio Migration in Enaminones: Metal- and CO-Free Synthesis of α,β-Unsaturated Amides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (10)
                                     , 5731-5750. <a href="https://doi.org/10.1021/acs.joc.8b00775" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00775%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAmide%252BBond%252BFormation%252BAssisted%252Bby%252BVicinal%252BAlkylthio%252BMigration%252Bin%252BEnaminones%25253A%252BMetal-%252Band%252BCO-Free%252BSynthesis%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BAmides%26aulast%3DLiu%26aufirst%3DZhuqing%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03042018%26date%3D30042018%26date%3D17042018%26volume%3D83%26issue%3D10%26spage%3D5731%26epage%3D5750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael R. Harris, Hanna M. Wisniewska, Wenhua Jiao, Xiaochun Wang, <span class="NLM_string-name hlFld-ContribAuthor">James N. Bradow</span>. </span><span class="cited-content_cbyCitation_article-title">A Modular Approach to the Synthesis of gem-Disubstituted Cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (10)
                                     , 2867-2871. <a href="https://doi.org/10.1021/acs.orglett.8b00899" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00899%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BModular%252BApproach%252Bto%252Bthe%252BSynthesis%252Bof%252Bgem-Disubstituted%252BCyclopropanes%26aulast%3DHarris%26aufirst%3DMichael%2BR.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D30042018%26volume%3D20%26issue%3D10%26spage%3D2867%26epage%3D2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Martina Gobec, Tihomir Tomašič, Adela Štimac, Ruža Frkanec, Jurij Trontelj, Marko Anderluh, Irena Mlinarič-Raščan, <span class="NLM_string-name hlFld-ContribAuthor">Žiga Jakopin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2707-2724. <a href="https://doi.org/10.1021/acs.jmedchem.7b01052" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01052%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNanomolar%252BDesmuramylpeptide%252BAgonists%252Bof%252Bthe%252BInnate%252BImmune%252BReceptor%252BNucleotide-Binding%252BOligomerization%252BDomain-Containing%252BProtein%252B2%252B%252528NOD2%252529%252BPossessing%252BImmunostimulatory%252BProperties%26aulast%3DGobec%26aufirst%3DMartina%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D04092017%26date%3D22032018%26date%3D15032018%26volume%3D61%26issue%3D7%26spage%3D2707%26epage%3D2724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zheyuan Xu, Yinuo Yang, Julong Jiang, <span class="NLM_string-name hlFld-ContribAuthor">Yao Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical Investigation on Ni-Catalyzed C(sp3)–F Activation and Ring Contraction of Tetrahydropyrans: Exploration of an SN2 Pathway. </span><span class="cited-content_cbyCitation_journal-name">Organometallics</span><span> <strong>2018,</strong> <em>37 </em>
                                    (7)
                                     , 1114-1122. <a href="https://doi.org/10.1021/acs.organomet.7b00894" title="DOI URL">https://doi.org/10.1021/acs.organomet.7b00894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.organomet.7b00894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.organomet.7b00894%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganometallics%26atitle%3DTheoretical%252BInvestigation%252Bon%252BNi-Catalyzed%252BC%252528sp3%252529%2525E2%252580%252593F%252BActivation%252Band%252BRing%252BContraction%252Bof%252BTetrahydropyrans%25253A%252BExploration%252Bof%252Ban%252BSN2%252BPathway%26aulast%3DXu%26aufirst%3DZheyuan%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D17122017%26date%3D19032018%26volume%3D37%26issue%3D7%26spage%3D1114%26epage%3D1122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joseph Derosa, Miriam L. O’Duill, Matthew Holcomb, Mark N. Boulous, Ryan L. Patman, Fen Wang, Michelle Tran-Dubé, Indrawan McAlpine, <span class="NLM_string-name hlFld-ContribAuthor">Keary M. Engle</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed Chan–Lam Cyclopropylation of Phenols and Azaheterocycles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (7)
                                     , 3417-3425. <a href="https://doi.org/10.1021/acs.joc.7b03100" title="DOI URL">https://doi.org/10.1021/acs.joc.7b03100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b03100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b03100%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCopper-Catalyzed%252BChan%2525E2%252580%252593Lam%252BCyclopropylation%252Bof%252BPhenols%252Band%252BAzaheterocycles%26aulast%3DDerosa%26aufirst%3DJoseph%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D07122017%26date%3D13032018%26date%3D02032018%26volume%3D83%26issue%3D7%26spage%3D3417%26epage%3D3425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Oliver
F. Brandenberg, Christopher K. Prier, Kai Chen, Anders M. Knight, Zachary Wu, <span class="NLM_string-name hlFld-ContribAuthor">Frances H. Arnold</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Enzymatic Synthesis of Heteroatom-Substituted Cyclopropanes. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2018,</strong> <em>8 </em>
                                    (4)
                                     , 2629-2634. <a href="https://doi.org/10.1021/acscatal.7b04423" title="DOI URL">https://doi.org/10.1021/acscatal.7b04423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.7b04423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.7b04423%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DStereoselective%252BEnzymatic%252BSynthesis%252Bof%252BHeteroatom-Substituted%252BCyclopropanes%26aulast%3DBrandenberg%26aufirst%3DOliver%2BF.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2018%26date%3D23122017%26date%3D07022018%26date%3D24022018%26volume%3D8%26issue%3D4%26spage%3D2629%26epage%3D2634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2166-2210. <a href="https://doi.org/10.1021/acs.jmedchem.7b00315" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00315%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNatural-Products-Inspired%252BUse%252Bof%252Bthe%252Bgem-Dimethyl%252BGroup%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D27022017%26date%3D08092017%26date%3D29082017%26volume%3D61%26issue%3D6%26spage%3D2166%26epage%3D2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuanyuan Zheng, Wenrui Zheng, Jiaoyang Wang, Huifang Chang, <span class="NLM_string-name hlFld-ContribAuthor">Danfeng Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Study on N–N Homolytic Bond Dissociation Enthalpies of Hydrazine Derivatives. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry A</span><span> <strong>2018,</strong> <em>122 </em>
                                    (10)
                                     , 2764-2780. <a href="https://doi.org/10.1021/acs.jpca.7b12094" title="DOI URL">https://doi.org/10.1021/acs.jpca.7b12094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpca.7b12094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpca.7b12094%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520A%26atitle%3DComputational%252BStudy%252Bon%252BN%2525E2%252580%252593N%252BHomolytic%252BBond%252BDissociation%252BEnthalpies%252Bof%252BHydrazine%252BDerivatives%26aulast%3DZheng%26aufirst%3DYuanyuan%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2018%26date%3D10122017%26date%3D19012018%26date%3D01032018%26date%3D22022018%26volume%3D122%26issue%3D10%26spage%3D2764%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yang Wei, Antonio Tinoco, Viktoria Steck, Rudi Fasan, <span class="NLM_string-name hlFld-ContribAuthor">Yong Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclopropanations via Heme Carbenes: Basic Mechanism and Effects of Carbene Substituent, Protein Axial Ligand, and Porphyrin Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (5)
                                     , 1649-1662. <a href="https://doi.org/10.1021/jacs.7b09171" title="DOI URL">https://doi.org/10.1021/jacs.7b09171</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b09171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b09171%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DCyclopropanations%252Bvia%252BHeme%252BCarbenes%25253A%252BBasic%252BMechanism%252Band%252BEffects%252Bof%252BCarbene%252BSubstituent%25252C%252BProtein%252BAxial%252BLigand%25252C%252Band%252BPorphyrin%252BSubstitution%26aulast%3DWei%26aufirst%3DYang%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D28082017%26date%3D24012018%26date%3D22122017%26volume%3D140%26issue%3D5%26spage%3D1649%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Pirovano</span>, <span class="hlFld-ContribAuthor ">Elisa  Brambilla</span>, and <span class="hlFld-ContribAuthor ">Giorgio  Tseberlidis</span>  . </span><span class="cited-content_cbyCitation_article-title">[Copper(I)(Pyridine-Containing Ligand)] Catalyzed Regio- and Steroselective Synthesis of 2-Vinylcyclopropa[b]indolines from 2-Vinylindoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (2)
                                     , 405-408. <a href="https://doi.org/10.1021/acs.orglett.7b03704" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b03704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b03704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b03704%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3D%25255BCopper%252528I%252529%252528Pyridine-Containing%252BLigand%252529%25255D%252BCatalyzed%252BRegio-%252Band%252BSteroselective%252BSynthesis%252Bof%252B2-Vinylcyclopropa%25255Bb%25255Dindolines%252Bfrom%252B2-Vinylindoles%26aulast%3DPirovano%26aufirst%3DValentina%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D29112017%26date%3D10012018%26date%3D19012018%26volume%3D20%26issue%3D2%26spage%3D405%26epage%3D408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Facs.jmedchem.6b00472&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00472&amp;citedByCount=297&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0075.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of compounds <b>1</b> (<i>trans</i>-chrysanthemic acid) and <b>2</b> (1-aminocyclopropane carboxylic acid).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures and in vitro potency of compounds <b>3</b> and <b>4</b> (trametinib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of compound <b>5</b> (lenvatinib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of compounds <b>6</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures, in vitro potency, and PK properties of Plk4 inhibitory compounds <b>8</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and in vitro potency of tyrosine kinase inhibitors <b>11</b>–<b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures, in vitro potency, and physicochemical properties of Aurora kinase inhibitors <b>16</b>–<b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures, in vitro potency, and PK properties of PARP inhibitors <b>19</b> and <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure and in vitro potency of LSD1 inhibitor <b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of P-gp inhibitors <b>22</b> and <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of HCV NS3/4A protease inhibitors <b>24</b> and <b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of HCV NS3/4A protease inhibitors <b>26</b>–<b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structure and in vitro potency of HCV NS3/4A protease inhibitor <b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures and in vitro potency of HCV NS3/4A protease inhibitors <b>31</b>–<b>33</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure, in vitro potency, and PK properties of HCV NS3/4A protease inhibitor <b>34</b>–<b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures, in vitro potency, and PK properties of HCV NS3/4A protease inhibitors <b>37</b> and <b>38</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures, in vitro potency, and PK properties of HCV NS5A inhibitors <b>39</b> and <b>40</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures, in vitro potency, and PK properties of HCV NS5B inhibitors <b>41</b> and <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures, in vitro potency, and physicochemical properties of RSV fusion inhibitors <b>43</b>–<b>45</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures of HIV-1 RT inhibitors <b>46</b> and <b>47</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structure of HIV-1 RT inhibitor <b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of HIV-1 RT inhibitors <b>49</b> and <b>50</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of quinolone antibacterial drugs <b>51</b>–<b>54</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures of compounds <b>55</b> and <b>56</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structure of phosphodiesterase 4 inhibitor <b>57</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures of LTD<sub>4</sub> antagonists <b>58</b> and <b>59</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures, in vitro potency, and PK properties of adenosine A2B antagonists <b>60</b>–<b>62</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures, in vitro potency, and PK properties of IKK inhibitors <b>63</b> and <b>64</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structures, in vitro potency, and PK properties of p38α MAP kinase inhibitors <b>65</b>–<b>67</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures, in vitro potency, and physicochemical properties of ITK inhibitors <b>68</b>–<b>70</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures, in vitro potency, and PK properties of histamine H<sub>4</sub> receptor antagonists <b>71</b> and <b>72</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures of lck inhibitors <b>73</b> and <b>74</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of BTK inhibitors <b>75</b>–<b>78</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structures of URAT1 inhibitors <b>79</b> and <b>80</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structures, in vitro potency, and PK properties of p38α MAP kinase inhibitors <b>81</b>–<b>84</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Structures, in vitro potency, and liver microsomal stability data of RORγ inhibitors <b>85</b>–<b>87</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0037.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Structures of serotonin and norepinephrine reuptake inhibitors <b>88</b> and <b>89</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0038.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures of opioid antagonists <b>90</b>–<b>92</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0039.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structure of opioid receptor partial agonist <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0040.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structure of opioid receptor antagonist <b>94</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0041.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure and mechanism of action of MAO inhibitor <b>95</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0042.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structures of melatonin receptor agonists <b>96</b> and <b>97</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0043.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Structures, in vitro potency, and liver microsomal stability data of GlyT1 inhibitors <b>98</b> and <b>99</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0044.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Structures, in vitro potency, and PK profile of NK-3 inhibitors <b>100</b>–<b>103</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0045.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structures, in vitro potency, and permeability data of BACE1 inhibitors <b>104</b> and <b>105</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0046.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Structures, in vitro potency, and PK properties of BACE1 inhibitors <b>106</b>–<b>109</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0047.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structures, in vitro potency, and PK properties of gamma secretase inhibitors <b>110</b> and <b>111</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0048.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Structures and in vitro potency of α4β2 nAChR partial agonists <b>112</b>–<b>116</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0049.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Structures, in vitro potency, and PK properties of bradykinin B1 receptor antagonist <b>117</b>–<b>120</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0050.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. 2D Structure (left panel) and 3D model (right panel) of orexin receptor antagonist <b>121</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0051.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. Structures, in vitro potency, and PK properties of histamine H<sub>3</sub> receptor antagonists <b>122</b> and <b>123</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0052.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. Structures, in vitro potency, and PK properties of PDE4 inhibitors <b>124</b>–<b>127</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0053.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. Structure of a triple reuptake inhibitor <b>128</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0054.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. Structures of β blockers <b>129</b> and <b>130</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0055.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Structures, in vitro potency, and PK properties of P2Y<sub>12</sub> receptor antagonists <b>131</b>–<b>133</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0056.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Structures and metabolism of P2Y<sub>12</sub> receptor antagonists <b>134</b> and <b>135</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0057.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Structures of FXa inhibitors <b>136</b> and <b>137</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0058.jpeg" id="rightTab-gr58" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Structures (left panel) and metabolism (right panel) of the Iks inhibitors <b>138</b>–<b>141</b>. Stereochemistry at the C3-chiral center in <b>139</b>–<b>141</b> is not determined.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0059.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. Structures of sEH inhibitors <b>142</b>–<b>144</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0060.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Structures of HMG-CoA inhibitors <b>145</b> and <b>146</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0061.jpeg" id="rightTab-gr61" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. Structure of DPP-IV inhibitor <b>147</b> (left panel) and mechanism of acid catalyzed inactivation of noncyclopropane analogues of compound <b>147</b> (right panel).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0062.jpeg" id="rightTab-gr62" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. Structures, in vitro potency, and microsomal stability data of DGAT2 inhibitors <b>148</b> and <b>149</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0063.jpeg" id="rightTab-gr63" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. Structures, in vitro potency, and PK properties of cathepsin K inhibitors <b>150</b> and <b>151</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig64" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Figure 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0064.jpeg" id="rightTab-gr64" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 64. Structures of steroids <b>152</b>–<b>154</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig64"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig65" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Figure 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0065.jpeg" id="rightTab-gr65" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 65. Structures, in vitro potency, and PK properties of ghrelin receptor agonists <b>155</b>–<b>157</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig65"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig66" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Figure 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0066.jpeg" id="rightTab-gr66" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 66. Structures and in vitro potency of peptidomimetic HIV protease inhibitors <b>158</b> and <b>159</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig66"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig67" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Figure 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0067.jpeg" id="rightTab-gr67" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 67. Structures, binding affinity, and thermodynamic properties of peptidomimetic Src SH2 domain inhibitors <b>160</b> and <b>161</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig67"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig68" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Figure 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/medium/jm-2016-004729_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0068.jpeg" id="rightTab-gr68" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 68. Structures and in vitro potency of H<sub>3</sub>/H<sub>4</sub> receptor antagonists <b>162</b> and <b>163</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00472/20161007/images/large/jm-2016-004729_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00472&amp;id=fig68"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i92">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 203 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Freund, A.</span><span> </span><span class="NLM_article-title">Ueber trimethylen</span> <span class="citation_source-journal">J. Prakt. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1882</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span><span class="refDoi"> DOI: 10.1002/prac.18820260125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fprac.18820260125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1882&pages=367-377&author=A.+Freund&title=Ueber+trimethylen&doi=10.1002%2Fprac.18820260125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fprac.18820260125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.18820260125%26sid%3Dliteratum%253Aachs%26aulast%3DFreund%26aufirst%3DA.%26atitle%3DUeber%2520trimethylen%26jtitle%3DJ.%2520Prakt.%2520Chem.%26date%3D1882%26volume%3D26%26spage%3D367%26epage%3D377%26doi%3D10.1002%2Fprac.18820260125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Henderson, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, G. H. W.</span><span> </span><span class="NLM_article-title">Cyclopropane: a new anesthetic</span> <span class="citation_source-journal">Anesth. Analg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1930</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1213/00000539-193001000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1213%2F00000539-193001000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaA3cXhtlWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1930&pages=1-6&author=V.+E.+Hendersonauthor=G.+H.+W.+Lucas&title=Cyclopropane%3A+a+new+anesthetic&doi=10.1213%2F00000539-193001000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropane: a new anesthetic</span></div><div class="casAuthors">Henderson, V. E.; Lucas, G. H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">1930</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    </div><div class="casAbstract">The gas was first prepd. by reducing an alc. soln. of trimethylene bromide, to which a few drops of water had been added, with Zn dust.  Anesthesia was maintained in the dog for 90 min. with a very slight fall in the blood pressure and good respiratory vol. over a wide range in gas %.  The gas has a sweetish odor much like that of a mixt. of ethylene and chloroform and is not unpleasant to breathe.  It is heavier than air and is explosive in 5% and upward in O; mixts. above 10% in air are not explosive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj8KUF51z7bVg90H21EOLACvtfcHk0lgVffd9WGDrvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA3cXhtlWmsg%253D%253D&md5=b76804bafa90a159c914c9f93e3c317a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1213%2F00000539-193001000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252F00000539-193001000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DV.%2BE.%26aulast%3DLucas%26aufirst%3DG.%2BH.%2BW.%26atitle%3DCyclopropane%253A%2520a%2520new%2520anesthetic%26jtitle%3DAnesth.%2520Analg.%26date%3D1930%26volume%3D9%26spage%3D1%26epage%3D6%26doi%3D10.1213%2F00000539-193001000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Staudinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzicka, L.</span><span> </span><span class="NLM_article-title">Insect poisons. I. Isolation and constitution of the active portion of dalmatian insect powder</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1924</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1002/hlca.19240070124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fhlca.19240070124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1924&pages=177-201&author=H.+Staudingerauthor=L.+Ruzicka&title=Insect+poisons.+I.+Isolation+and+constitution+of+the+active+portion+of+dalmatian+insect+powder&doi=10.1002%2Fhlca.19240070124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19240070124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19240070124%26sid%3Dliteratum%253Aachs%26aulast%3DStaudinger%26aufirst%3DH.%26aulast%3DRuzicka%26aufirst%3DL.%26atitle%3DInsect%2520poisons.%2520I.%2520Isolation%2520and%2520constitution%2520of%2520the%2520active%2520portion%2520of%2520dalmatian%2520insect%2520powder%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1924%26volume%3D7%26spage%3D177%26epage%3D201%26doi%3D10.1002%2Fhlca.19240070124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Yang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, N. E.</span><span> </span><span class="NLM_article-title">Ethylene biosynthesis and its regulation in higher plants</span> <span class="citation_source-journal">Annu. Rev. Plant Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1146/annurev.pp.35.060184.001103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1146%2Fannurev.pp.35.060184.001103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2cXkvVOnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1984&pages=155-189&author=S.+F.+Yangauthor=N.+E.+Hoffman&title=Ethylene+biosynthesis+and+its+regulation+in+higher+plants&doi=10.1146%2Fannurev.pp.35.060184.001103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Ethylene biosynthesis and its regulation in higher plants</span></div><div class="casAuthors">Yang, Shang Fa; Hoffman, Neil E.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Plant Physiology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-89</span>CODEN:
                <span class="NLM_cas:coden">ARPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0066-4294</span>.
    </div><div class="casAbstract">A review with 192 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuCcCtFPglebVg90H21EOLACvtfcHk0lgVffd9WGDrvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvVOnsrg%253D&md5=5d938a2255e8f4c9393ade15c81a3282</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pp.35.060184.001103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pp.35.060184.001103%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DHoffman%26aufirst%3DN.%2BE.%26atitle%3DEthylene%2520biosynthesis%2520and%2520its%2520regulation%2520in%2520higher%2520plants%26jtitle%3DAnnu.%2520Rev.%2520Plant%2520Physiol.%26date%3D1984%26volume%3D35%26spage%3D155%26epage%3D189%26doi%3D10.1146%2Fannurev.pp.35.060184.001103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Burger, A.</span><span> </span><span class="NLM_article-title">Cyclopropane compounds of biological interest</span> <span class="citation_source-journal">Prog. Drug Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1007/978-3-0348-7078-8_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2F978-3-0348-7078-8_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaE38XltV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1971&pages=227-270&author=A.+Burger&title=Cyclopropane+compounds+of+biological+interest&doi=10.1007%2F978-3-0348-7078-8_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropane compounds of biological interest</span></div><div class="casAuthors">Burger, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Drug Research</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-70</span>CODEN:
                <span class="NLM_cas:coden">FAZMAE</span>;
        ISSN:<span class="NLM_cas:issn">0071-786X</span>.
    </div><div class="casAbstract">An extensive discussion and review with 145 refs. of cyclopropane compds. possessing biol. activity, such as tranylcypromine [3721-28-6], 2-(4-imidazolyl)cyclopropylamine [24160-41-6], cyclazocine [3572-80-3], cyclorphan [4163-15-9], prazepam [2955-38-6], and cyprolidol [7433-09-2].  The biol. actions of cyclopropane contg. fatty acids, steroids, triterpenes, and amino acids are included as well as the structure-activity relations of arylcyclopropylamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquy4v0ynjnJbVg90H21EOLACvtfcHk0lhbJsfMrPpqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE38XltV2iu7Y%253D&md5=45aea895d4edba8fed5e9701b2df3e12</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2F978-3-0348-7078-8_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-0348-7078-8_7%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%26atitle%3DCyclopropane%2520compounds%2520of%2520biological%2520interest%26jtitle%3DProg.%2520Drug%2520Res.%26date%3D1971%26volume%3D15%26spage%3D227%26epage%3D270%26doi%3D10.1007%2F978-3-0348-7078-8_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Lebel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcoux, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinaro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charette, A. B.</span><span> </span><span class="NLM_article-title">Stereoselective cyclopropanation reactions</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">1050</span><span class="refDoi"> DOI: 10.1021/cr010007e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr010007e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXislSjt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2003&pages=977-1050&author=H.+Lebelauthor=J.+F.+Marcouxauthor=C.+Molinaroauthor=A.+B.+Charette&title=Stereoselective+cyclopropanation+reactions&doi=10.1021%2Fcr010007e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective Cyclopropanation Reactions</span></div><div class="casAuthors">Lebel, Helene; Marcoux, Jean-Francois; Molinaro, Carmela; Charette, Andre B.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">977-1050</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAxS9Vy1tYLVg90H21EOLACvtfcHk0lhbJsfMrPpqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXislSjt7o%253D&md5=ddd27c744fcd09d7991420025aa613d2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fcr010007e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr010007e%26sid%3Dliteratum%253Aachs%26aulast%3DLebel%26aufirst%3DH.%26aulast%3DMarcoux%26aufirst%3DJ.%2BF.%26aulast%3DMolinaro%26aufirst%3DC.%26aulast%3DCharette%26aufirst%3DA.%2BB.%26atitle%3DStereoselective%2520cyclopropanation%2520reactions%26jtitle%3DChem.%2520Rev.%26date%3D2003%26volume%3D103%26spage%3D977%26epage%3D1050%26doi%3D10.1021%2Fcr010007e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Bartoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencivenni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalpozzo, R.</span><span> </span><span class="NLM_article-title">Asymmetric cyclopropanation reactions</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">–</span> <span class="NLM_lpage">1029</span><span class="refDoi"> DOI: 10.1055/s-0033-1340838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1055%2Fs-0033-1340838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFeqsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=979-1029&author=G.+Bartoliauthor=G.+Bencivenniauthor=R.+Dalpozzo&title=Asymmetric+cyclopropanation+reactions&doi=10.1055%2Fs-0033-1340838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric cyclopropanation reactions</span></div><div class="casAuthors">Bartoli, Giuseppe; Bencivenni, Giorgio; Dalpozzo, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">979-1029, 51 pp.</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">A review.  Both phys. and org. chemists are interested in the cyclopropane ring, the former owing to the strain inherent to the small ring structure, the latter prompted by the importance of this ring in naturally occurring compds.  In recent years, the increasing interest in enantioselective org. synthesis has led to a large no. of papers on the prepn. of cyclopropane compds. in enantioenriched form.  The last review on asym. cyclopropanation reactions is dated 2008, thus an update is necessary with crit. comparison of prepns. using chiral auxiliaries, chiral metal complexes and organocatalysts.  The aim of this review is an overview of these topics from 2008 to mid-2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIuWaZ3RVc7bVg90H21EOLACvtfcHk0lhbJsfMrPpqoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFeqsb3K&md5=2fc8619f099d7d5fde1e175565b8f1fb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1055%2Fs-0033-1340838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0033-1340838%26sid%3Dliteratum%253Aachs%26aulast%3DBartoli%26aufirst%3DG.%26aulast%3DBencivenni%26aufirst%3DG.%26aulast%3DDalpozzo%26aufirst%3DR.%26atitle%3DAsymmetric%2520cyclopropanation%2520reactions%26jtitle%3DSynthesis%26date%3D2014%26volume%3D46%26spage%3D979%26epage%3D1029%26doi%3D10.1055%2Fs-0033-1340838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wiberg, K. B.</span><span> </span><span class="NLM_article-title">The concept of strain in organic chemistry</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1002/anie.198603121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fanie.198603121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1986&pages=312-322&author=K.+B.+Wiberg&title=The+concept+of+strain+in+organic+chemistry&doi=10.1002%2Fanie.198603121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.198603121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198603121%26sid%3Dliteratum%253Aachs%26aulast%3DWiberg%26aufirst%3DK.%2BB.%26atitle%3DThe%2520concept%2520of%2520strain%2520in%2520organic%2520chemistry%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1986%26volume%3D25%26spage%3D312%26epage%3D322%26doi%3D10.1002%2Fanie.198603121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gagnon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duplessis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fader, L.</span><span> </span><span class="NLM_article-title">Arylcyclopropanes: properties, synthesis and use in medicinal chemistry</span> <span class="citation_source-journal">Org. Prep. Proced. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1080/00304940903507788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1080%2F00304940903507788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFGis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=1-69&author=A.+Gagnonauthor=M.+Duplessisauthor=L.+Fader&title=Arylcyclopropanes%3A+properties%2C+synthesis+and+use+in+medicinal+chemistry&doi=10.1080%2F00304940903507788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Arylcyclopropanes: properties, synthesis and use in medicinal chemistry</span></div><div class="casAuthors">Gagnon, Alexandre; Duplessis, Martin; Fader, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Organic Preparations and Procedures International</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-69</span>CODEN:
                <span class="NLM_cas:coden">OPPIAK</span>;
        ISSN:<span class="NLM_cas:issn">0030-4948</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Topics thus discussed included conjugative, phys. and conformation properties, microsomal metab., (aryl)cyclopropanes in medicinal chem., cross-coupling reactions between (cyclopropyl)metal compds. and aryl halides and pseudohalides, Negishi cross-coupling reaction, Kumada-Corriu reaction, Suzuki reaction, Stille coupling reaction and reactions of other metals.  Other topics included cross-coupling reactions between (aryl)metals and halocyclopropanes, addn. to cyclopropene derivs., carbon-hydrogen bond activation, formal arom. nucleophilic substitution, migration reaction, rearrangement reaction, other methods, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1nOaFva4JrbVg90H21EOLACvtfcHk0lhBNo3_4zylSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFGis7g%253D&md5=663f28aec3b48d165e099062b75217f4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1080%2F00304940903507788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00304940903507788%26sid%3Dliteratum%253Aachs%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DFader%26aufirst%3DL.%26atitle%3DArylcyclopropanes%253A%2520properties%252C%2520synthesis%2520and%2520use%2520in%2520medicinal%2520chemistry%26jtitle%3DOrg.%2520Prep.%2520Proced.%2520Int.%26date%3D2010%26volume%3D42%26spage%3D1%26epage%3D69%26doi%3D10.1080%2F00304940903507788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">de Meijere, A.</span><span> </span><span class="NLM_article-title">Bonding properties of cyclopropane and their chemical consequences</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.1002/anie.197908093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fanie.197908093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1979&pages=809-826&author=A.+de+Meijere&title=Bonding+properties+of+cyclopropane+and+their+chemical+consequences&doi=10.1002%2Fanie.197908093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.197908093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.197908093%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMeijere%26aufirst%3DA.%26atitle%3DBonding%2520properties%2520of%2520cyclopropane%2520and%2520their%2520chemical%2520consequences%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1979%26volume%3D18%26spage%3D809%26epage%3D826%26doi%3D10.1002%2Fanie.197908093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Barnes-Seeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatsis, P.</span><span> </span><span class="NLM_article-title">Metabolically stable tert-butyl replacement</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1021/ml400045j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400045j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ymt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=514-516&author=D.+Barnes-Seemanauthor=M.+Jainauthor=L.+Bellauthor=S.+Ferreiraauthor=S.+Cohenauthor=X.+H.+Chenauthor=J.+Aminauthor=B.+Snodgrassauthor=P.+Hatsis&title=Metabolically+stable+tert-butyl+replacement&doi=10.1021%2Fml400045j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolically Stable tert-Butyl Replacement</span></div><div class="casAuthors">Barnes-Seeman, David; Jain, Monish; Bell, Leslie; Ferreira, Suzie; Cohen, Scott; Chen, Xiao-Hui; Amin, Jakal; Snodgrass, Brad; Hatsis, Panos</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">514-516</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Susceptibility to metab. is a common issue with the tert-Bu group on compds. of medicinal interest.  The authors demonstrate an approach of removing all the fully Sp3 C-Hs from a tert-Bu group: replacing some C-Hs with C-Fs and increasing the s-character of the remaining C-Hs.  This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability.  Trifluoromethylcyclopropyl-contg. analogs had consistently higher metabolic stability in vitro and in vivo compared to their tert-butyl-contg. counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrao2I5ukFsTrVg90H21EOLACvtfcHk0lhBNo3_4zylSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ymt78%253D&md5=156572485ea3a48f5e1b6ea7409f1f61</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml400045j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400045j%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes-Seeman%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DL.%26aulast%3DFerreira%26aufirst%3DS.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DAmin%26aufirst%3DJ.%26aulast%3DSnodgrass%26aufirst%3DB.%26aulast%3DHatsis%26aufirst%3DP.%26atitle%3DMetabolically%2520stable%2520tert-butyl%2520replacement%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D514%26epage%3D516%26doi%3D10.1021%2Fml400045j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Blanksby, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellison, G. B.</span><span> </span><span class="NLM_article-title">Bond dissociation energies of organic molecules</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1021/ar020230d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar020230d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=255-263&author=S.+J.+Blanksbyauthor=G.+B.+Ellison&title=Bond+dissociation+energies+of+organic+molecules&doi=10.1021%2Far020230d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Bond Dissociation Energies of Organic Molecules</span></div><div class="casAuthors">Blanksby, Stephen J.; Ellison, G. Barney</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this Account the authors have compiled a list of reliable bond energies that are based on a set of critically evaluated expts.  A brief description of the three most important exptl. techniques for measuring bond energies is provided.  The authors demonstrate how these exptl. data can be applied to yield the heats of formation of org. radicals and the bond enthalpies of more than 100 representative org. mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Gd4XRKVyrbVg90H21EOLACvtfcHk0lhBNo3_4zylSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D&md5=e313bd3c3a7809b70baa32c83e70d135</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Far020230d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far020230d%26sid%3Dliteratum%253Aachs%26aulast%3DBlanksby%26aufirst%3DS.%2BJ.%26aulast%3DEllison%26aufirst%3DG.%2BB.%26atitle%3DBond%2520dissociation%2520energies%2520of%2520organic%2520molecules%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D255%26epage%3D263%26doi%3D10.1021%2Far020230d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhNuYhJUCmgUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yu, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalterio, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadjura, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dando, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">901</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2006.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17169560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=895-901&author=K.+L.+Yuauthor=N.+Sinauthor=R.+L.+Civielloauthor=X.+A.+Wangauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=B.+L.+Venablesauthor=J.+J.+Wrightauthor=R.+A.+Dalterioauthor=L.+Zadjuraauthor=A.+Marinoauthor=S.+Dandoauthor=C.+D%E2%80%99Arienzoauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=Z.+Liauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=R.+J.+Colonnoauthor=Z.+Yangauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+4%3A+optimization+for+oral+bioavailability&doi=10.1016%2Fj.bmcl.2006.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span></div><div class="casAuthors">Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes.  1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (I, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTTCqYL_6iLVg90H21EOLACvtfcHk0lhNuYhJUCmgUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D&md5=1df6d784bda1cabee0b57b799f1f165e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DDalterio%26aufirst%3DR.%2BA.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DDando%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25204%253A%2520optimization%2520for%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D895%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2006.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Abe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakefuda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakegawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmartin, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span> </span><span class="NLM_article-title">Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">320</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1021/ml200004g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+G.+Laquerre&title=Discovery+of+a+highly+potent+and+selective+MEK+inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+solvate%29&doi=10.1021%2Fml200004g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span></div><div class="casAuthors">Abe, Hiroyuki; Kikuchi, Shinichi; Hayakawa, Kazuhide; Iida, Tetsuya; Nagahashi, Noboru; Maeda, Katsuya; Sakamoto, Johei; Matsumoto, Noriaki; Miura, Tomoya; Matsumura, Koji; Seki, Noriyoshi; Inaba, Takashi; Kawasaki, Hisashi; Yamaguchi, Takayuki; Kakefuda, Reina; Nanayama, Toyomichi; Kurachi, Hironori; Hori, Yoshikazu; Yoshida, Takayuki; Kakegawa, Junya; Watanabe, Yoshihiro; Gilmartin, Aidan G.; Richter, Mark C.; Moss, Katherine G.; Laquerre, Sylvie G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">320-324</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) represents a promising strategy for the discovery of a new generation of anticancer chemotherapeutics.  Our synthetic efforts, beginning from the lead compd. 2, were directed at improving antiproliferative activity against cancer cells as well as various drug properties.  These efforts led to the discovery of N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethylsulfoxide solvate (GSK1120212, JTP-74057 DMSO solvate; 1), a selective and highly potent MEK inhibitor with improved drug properties.  We further confirmed that the antiproliferative activity correlates with cellular MEK inhibition and obsd. significant antitumor activity with daily oral dosing of 1 in a tumor xenograft model.  These qualities led to the selection of 1 for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCuItdsb_1bVg90H21EOLACvtfcHk0lhNuYhJUCmgUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D&md5=0cb3bfa4e142b8d5ecc591e6792cd692</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%2520and%2520selective%2520MEK%2520inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D320%26epage%3D324%26doi%3D10.1021%2Fml200004g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4007</span><span class="NLM_x">–</span> <span class="NLM_lpage">4010</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.08.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.08.054" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4007-4010&author=J.+Wityakauthor=J.+Dasauthor=R.+V.+Moquinauthor=Z.+Shenauthor=J.+Linauthor=P.+Chenauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=G.+L.+Schievenauthor=S.+B.+Kannerauthor=J.+C.+Barrish&title=Discovery+and+initial+SAR+of+2-amino-5-carboxamidothiazoles+as+inhibitors+of+the+Src-family+kinase+p56%28Lck%29&doi=10.1016%2Fj.bmcl.2003.08.054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.08.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.08.054%26sid%3Dliteratum%253Aachs%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%25202-amino-5-carboxamidothiazoles%2520as%2520inhibitors%2520of%2520the%2520Src-family%2520kinase%2520p56%2528Lck%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4007%26epage%3D4010%26doi%3D10.1016%2Fj.bmcl.2003.08.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Smith, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafinowska, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coggon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murkitt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. A.</span><span> </span><span class="NLM_article-title">New quinoline NK3 receptor antagonists with CNS activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">837</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19117759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2itrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=837-840&author=P.+W.+Smithauthor=P.+A.+Wymanauthor=P.+Lovellauthor=C.+Goodacreauthor=H.+T.+Serafinowskaauthor=A.+Vongauthor=F.+Harringtonauthor=S.+Flynnauthor=D.+M.+Bradleyauthor=R.+Porterauthor=S.+Coggonauthor=G.+Murkittauthor=K.+Searleauthor=D.+R.+Thomasauthor=J.+M.+Watsonauthor=W.+Martinauthor=Z.+Wuauthor=L.+A.+Dawson&title=New+quinoline+NK3+receptor+antagonists+with+CNS+activity&doi=10.1016%2Fj.bmcl.2008.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">New quinoline NK3 receptor antagonists with CNS activity</span></div><div class="casAuthors">Smith, Paul W.; Wyman, Paul A.; Lovell, Peter; Goodacre, Caroline; Serafinowska, Halina T.; Vong, Antonio; Harrington, Frank; Flynn, Sean; Bradley, Daniel M.; Porter, Rod; Coggon, Sara; Murkitt, Graham; Searle, Kirsten; Thomas, David R.; Watson, Jeannette M.; Martin, William; Wu, Zining; Dawson, Lee A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">837-840</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lead optimization starting from the previously reported selective quinoline NK3 receptor antagonists talnetant (SB-223412) and (SB-222200) led to the identification of 3-aminoquinoline NK3 antagonist GSK172981 with excellent CNS penetration.  Investigation of a structurally related series of sulfonamides with reduced lipophilicity led to the discovery of GSK256471.  Both GSK172981 and GSK256471 are high affinity, potent NK3 receptor antagonists which despite having different degrees of CNS penetration produced excellent NK3 receptor occupancy in an ex vivo binding study in gerbil cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHKvtoPGv4rbVg90H21EOLACvtfcHk0lgm31nVXvvAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2itrg%253D&md5=58b576420e152c8a008fea4bae4009a5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BW.%26aulast%3DWyman%26aufirst%3DP.%2BA.%26aulast%3DLovell%26aufirst%3DP.%26aulast%3DGoodacre%26aufirst%3DC.%26aulast%3DSerafinowska%26aufirst%3DH.%2BT.%26aulast%3DVong%26aufirst%3DA.%26aulast%3DHarrington%26aufirst%3DF.%26aulast%3DFlynn%26aufirst%3DS.%26aulast%3DBradley%26aufirst%3DD.%2BM.%26aulast%3DPorter%26aufirst%3DR.%26aulast%3DCoggon%26aufirst%3DS.%26aulast%3DMurkitt%26aufirst%3DG.%26aulast%3DSearle%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DD.%2BR.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26atitle%3DNew%2520quinoline%2520NK3%2520receptor%2520antagonists%2520with%2520CNS%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D837%26epage%3D840%26doi%3D10.1016%2Fj.bmcl.2008.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span> </span><span class="NLM_article-title">Adams discovery of nevirapine: a NNI of HIV-1 RT</span>. In  <span class="citation_source-book">The Search for Antiviral Drugs: Case Histories from Concept to Clinic</span>; <span class="NLM_contrib-group">Adams, J.; Merluzzi, V.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1993</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2F978-1-4899-6718-3_3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=45-70&author=J.+Adams&author=V.+Merluzzi&title=The+Search+for+Antiviral+Drugs%3A+Case+Histories+from+Concept+to+Clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2F978-1-4899-6718-3_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4899-6718-3_3%26sid%3Dliteratum%253Aachs%26atitle%3DAdams%2520discovery%2520of%2520nevirapine%253A%2520a%2520NNI%2520of%2520HIV-1%2520RT%26btitle%3DThe%2520Search%2520for%2520Antiviral%2520Drugs%253A%2520Case%2520Histories%2520from%2520Concept%2520to%2520Clinic%26aulast%3DAdams%26aufirst%3DJ.%26pub%3DSpringer%26date%3D1993%26spage%3D45%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauret, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromlish, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmarais, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamontagne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRiche, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oballa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodan, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venuti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, W. C.</span><span> </span><span class="NLM_article-title">The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">928</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2007.12.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18226527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=923-928&author=J.+Y.+Gauthierauthor=N.+Chauretauthor=W.+Cromlishauthor=S.+Desmaraisauthor=L.+T.+Duongauthor=J.+P.+Falgueyretauthor=D.+B.+Kimmelauthor=S.+Lamontagneauthor=S.+Legerauthor=T.+LeRicheauthor=C.+S.+Liauthor=F.+Masseauthor=D.+J.+McKayauthor=D.+A.+Nicoll-Griffithauthor=R.+M.+Oballaauthor=J.+T.+Palmerauthor=M.+D.+Percivalauthor=D.+Riendeauauthor=J.+Robichaudauthor=G.+A.+Rodanauthor=S.+B.+Rodanauthor=C.+Setoauthor=M.+Therienauthor=V.+L.+Truongauthor=M.+C.+Venutiauthor=G.+Wesolowskiauthor=R.+N.+Youngauthor=R.+Zamboniauthor=W.+C.+Black&title=The+discovery+of+odanacatib+%28MK-0822%29%2C+a+selective+inhibitor+of+cathepsin+K&doi=10.1016%2Fj.bmcl.2007.12.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K</span></div><div class="casAuthors">Gauthier, Jacques Yves; Chauret, Nathalie; Cromlish, Wanda; Desmarais, Sylvie; Duong, Le T.; Falgueyret, Jean-Pierre; Kimmel, Donald B.; Lamontagne, Sonia; Leger, Serge; LeRiche, Tammy; Li, Chun Sing; Masse, Frederic; McKay, Daniel J.; Nicoll-Griffith, Deborah A.; Oballa, Renata M.; Palmer, James T.; Percival, M. David; Riendeau, Denis; Robichaud, Joel; Rodan, Gideon A.; Rodan, Sevgi B.; Seto, Carmai; Therien, Michel; Truong, Vouy-Linh; Venuti, Michael C.; Wesolowski, Gregg; Young, Robert N.; Zamboni, Robert; Black, W. Cameron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">923-928</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724.  Substituting P1 and modifying the P2 side chain led to a metabolically robust inhibitor with a long half-life in preclin. species.  Odanacatib was more selective in whole cell assays than the published Cat K inhibitors balicatib and relacatib.  Evaluation in dermal fibroblast culture showed minimal intracellular collagen accumulation relative to less selective Cat K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7ytNI-SBgarVg90H21EOLACvtfcHk0lgm31nVXvvAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWktro%253D&md5=e432a420a3ec99c784117750b9bbeda8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.047%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DDesmarais%26aufirst%3DS.%26aulast%3DDuong%26aufirst%3DL.%2BT.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DKimmel%26aufirst%3DD.%2BB.%26aulast%3DLamontagne%26aufirst%3DS.%26aulast%3DLeger%26aufirst%3DS.%26aulast%3DLeRiche%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRobichaud%26aufirst%3DJ.%26aulast%3DRodan%26aufirst%3DG.%2BA.%26aulast%3DRodan%26aufirst%3DS.%2BB.%26aulast%3DSeto%26aufirst%3DC.%26aulast%3DTherien%26aufirst%3DM.%26aulast%3DTruong%26aufirst%3DV.%2BL.%26aulast%3DVenuti%26aufirst%3DM.%2BC.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DW.%2BC.%26atitle%3DThe%2520discovery%2520of%2520odanacatib%2520%2528MK-0822%2529%252C%2520a%2520selective%2520inhibitor%2520of%2520cathepsin%2520K%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D923%26epage%3D928%26doi%3D10.1016%2Fj.bmcl.2007.12.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Futatsugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspnes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erion, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pabst, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goosen, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosset, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niosi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettersen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfefferkorn, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, B.</span><span> </span><span class="NLM_article-title">Discovery and optimization of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7173</span><span class="NLM_x">–</span> <span class="NLM_lpage">7185</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7173-7185&author=K.+Futatsugiauthor=D.+W.+Kungauthor=S.+T.+Orrauthor=S.+Cabralauthor=D.+Hepworthauthor=G.+Aspnesauthor=S.+Baderauthor=J.+Bianauthor=M.+Boehmauthor=P.+A.+Carpinoauthor=S.+B.+Coffeyauthor=M.+S.+Dowlingauthor=M.+Herrauthor=W.+Jiaoauthor=S.+Y.+Lavergneauthor=Q.+Liauthor=R.+W.+Clarkauthor=D.+M.+Erionauthor=K.+Kouauthor=K.+Leeauthor=B.+A.+Pabstauthor=S.+M.+Perezauthor=J.+Purkalauthor=C.+C.+Jorgensenauthor=T.+C.+Goosenauthor=J.+R.+Gossetauthor=M.+Niosiauthor=J.+C.+Pettersenauthor=J.+A.+Pfefferkornauthor=K.+Ahnauthor=B.+Goodwin&title=Discovery+and+optimization+of+imidazopyridine-based+inhibitors+of+diacylglycerol+acyltransferase+2+%28DGAT2%29&doi=10.1021%2Facs.jmedchem.5b01006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)</span></div><div class="casAuthors">Futatsugi, Kentaro; Kung, Daniel W.; Orr, Suvi T. M.; Cabral, Shawn; Hepworth, David; Aspnes, Gary; Bader, Scott; Bian, Jianwei; Boehm, Markus; Carpino, Philip A.; Coffey, Steven B.; Dowling, Matthew S.; Herr, Michael; Jiao, Wenhua; Lavergne, Sophie Y.; Li, Qifang; Clark, Ronald W.; Erion, Derek M.; Kou, Kou; Lee, Kyuha; Pabst, Brandon A.; Perez, Sylvie M.; Purkal, Julie; Jorgensen, Csilla C.; Goosen, Theunis C.; Gosset, James R.; Niosi, Mark; Pettersen, John C.; Pfefferkorn, Jeffrey A.; Ahn, Kay; Goodwin, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7173-7185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. and preclin. biol. of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2) is described.  A screening hit 1 with low lipophilic efficiency (LipE) was optimized through two key structural modifications: (1) identification of the pyrrolidine amide group for a significant LipE improvement, and (2) insertion of a sp3-hybridized carbon center in the core of the mol. for simultaneous improvement of N-glucuronidation metabolic liability and off-target pharmacol.  The preclin. candidate I (PF-06424439) demonstrated excellent ADMET properties and decreased circulating and hepatic lipids when orally administered to dyslipidemic rodent models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvVkKqv3LxSbVg90H21EOLACvtfcHk0ljWHECqjxefow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7jK&md5=272bf0a5d0251e3a3716f7b6c34b3eb4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01006%26sid%3Dliteratum%253Aachs%26aulast%3DFutatsugi%26aufirst%3DK.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DCabral%26aufirst%3DS.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DAspnes%26aufirst%3DG.%26aulast%3DBader%26aufirst%3DS.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DDowling%26aufirst%3DM.%2BS.%26aulast%3DHerr%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DLavergne%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DClark%26aufirst%3DR.%2BW.%26aulast%3DErion%26aufirst%3DD.%2BM.%26aulast%3DKou%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DPabst%26aufirst%3DB.%2BA.%26aulast%3DPerez%26aufirst%3DS.%2BM.%26aulast%3DPurkal%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DC.%2BC.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DNiosi%26aufirst%3DM.%26aulast%3DPettersen%26aufirst%3DJ.%2BC.%26aulast%3DPfefferkorn%26aufirst%3DJ.%2BA.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DGoodwin%26aufirst%3DB.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520imidazopyridine-based%2520inhibitors%2520of%2520diacylglycerol%2520acyltransferase%25202%2520%2528DGAT2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7173%26epage%3D7185%26doi%3D10.1021%2Facs.jmedchem.5b01006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Sampson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirgadze, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">The discovery of polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3′[3H]indol]-2′(1′H).ones as orally bioavailable antitumor agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1021/jm500537u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500537u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=130-146&author=P.+B.+Sampsonauthor=Y.+Liuauthor=N.+K.+Patelauthor=M.+Feherauthor=B.+Forrestauthor=S.+W.+Liauthor=L.+Edwardsauthor=R.+Lauferauthor=Y.+Langauthor=F.+Banauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=J.+M.+Masonauthor=X.+Weiauthor=R.+Kiarashauthor=E.+Greenauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+discovery+of+polo-like+kinase+4+inhibitors%3A+design+and+optimization+of+spiro%5Bcyclopropane-1%2C3%E2%80%B2%5B3H%5Dindol%5D-2%E2%80%B2%281%E2%80%B2H%29.ones+as+orally+bioavailable+antitumor+agents&doi=10.1021%2Fjm500537u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3'[3H]indol]-2'(1'H)-ones as Orally Bioavailable Antitumor Agents</span></div><div class="casAuthors">Sampson, Peter B.; Liu, Yong; Patel, Narendra Kumar; Feher, Miklos; Forrest, Bryan; Li, Sze-Wan; Edwards, Louise; Laufer, Radoslaw; Lang, Yunhui; Ban, Fuqiang; Awrey, Donald E.; Mao, Guodong; Plotnikova, Olga; Leung, Genie; Hodgson, Richard; Mason, Jacqueline; Wei, Xin; Kiarash, Reza; Green, Erin; Qiu, Wei; Chirgadze, Nickolay Y.; Mak, Tak W.; Pan, Guohua; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 4 (PLK4), a unique member of the polo-like kinase family of serine-threonine kinases, is a master regulator of centriole duplication that is important for maintaining genome integrity.  Overexpression of PLK4 is found in several human cancers and is linked with a predisposition to tumorigenesis.  Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones reported herein.  Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 x-ray structure and SAR attained from the analogous alkene-linked series.  The racemic cyclopropane-linked compds. showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved physicochem., ADME, and pharmacokinetic properties.  Pos. xenograft results from the MDA-MB-468 human breast cancer xenograft model for compd. I support the investigation of PLK4 inhibitors as anticancer therapeutics.  A PLK4 x-ray co-structure with compd. I revealed preferential binding of the 1R,2S enantiomer to the PLK4 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nQjbJy_sMLVg90H21EOLACvtfcHk0ljWHECqjxefow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D&md5=90d60867ee5d6c27f597ebe32db64278</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm500537u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500537u%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520polo-like%2520kinase%25204%2520inhibitors%253A%2520design%2520and%2520optimization%2520of%2520spiro%255Bcyclopropane-1%252C3%25E2%2580%25B2%255B3H%255Dindol%255D-2%25E2%2580%25B2%25281%25E2%2580%25B2H%2529.ones%2520as%2520orally%2520bioavailable%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D130%26epage%3D146%26doi%3D10.1021%2Fjm500537u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Vuligonda, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandraratna, R. A. S.</span><span> </span><span class="NLM_article-title">Synthesis of highly potent RXR-specific retinoids: the use of a cyclopropyl group as a double bond isostere</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00588-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0960-894X%2895%2900588-K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=213-218&author=V.+Vuligondaauthor=Y.+Linauthor=R.+A.+S.+Chandraratna&title=Synthesis+of+highly+potent+RXR-specific+retinoids%3A+the+use+of+a+cyclopropyl+group+as+a+double+bond+isostere&doi=10.1016%2F0960-894X%2895%2900588-K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900588-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900588-K%26sid%3Dliteratum%253Aachs%26aulast%3DVuligonda%26aufirst%3DV.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DChandraratna%26aufirst%3DR.%2BA.%2BS.%26atitle%3DSynthesis%2520of%2520highly%2520potent%2520RXR-specific%2520retinoids%253A%2520the%2520use%2520of%2520a%2520cyclopropyl%2520group%2520as%2520a%2520double%2520bond%2520isostere%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D213%26epage%3D218%26doi%3D10.1016%2F0960-894X%2895%2900588-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant-Young, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro-Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanumegowda, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.1021/jm4016894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.+S.+Yeungauthor=X.+Zhengauthor=S.+Chaoauthor=J.+H.+Sunauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.+H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.+K.+Wangauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+preclinical+characterization+of+the+cyclopropylindolobenzazepine+BMS-791325%2C+a+potent+allosteric+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase&doi=10.1021%2Fjm4016894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span></div><div class="casAuthors">Gentles, Robert G.; Ding, Min; Bender, John A.; Bergstrom, Carl P.; Grant-Young, Katharine; Hewawasam, Piyasena; Hudyma, Thomas; Martin, Scott; Nickel, Andrew; Regueiro-Ren, Alicia; Tu, Yong; Yang, Zhong; Yeung, Kap-Sun; Zheng, Xiaofan; Beno, Brett R.; Camac, Daniel M.; Chang, Chong-Hwan; Gao, Mian; Morin, Paul E.; Sheriff, Steven; Tredup, Jeff; Wan, John; Witmer, Mark R.; Xie, Dianlin; Hanumegowda, Umesh; Knipe, Jay; Mosure, Kathy; Santone, Kenneth S.; Parker, Dawn D.; Zhuo, Xiaoliang; Lemm, Julie; Liu, Mengping; Pelosi, Lenore; Rigat, Karen; Voss, Stacey; Wang, Yi; Wang, Ying-Kai; Colonno, Richard C.; Gao, Min; Roberts, Susan B.; Gao, Qi; Ng, Alicia; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1855-1879</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors.  Subsequent iterations of analog design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochem. properties of lead compds.  Those analogs exhibiting improved soly. and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.  Addnl., a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compd. BMS-791325 (I) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4YKQoSYkS7Vg90H21EOLACvtfcHk0lgTj7uqB7PL_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D&md5=f13f5d86a1c17737784e905c7843ff72</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520cyclopropylindolobenzazepine%2520BMS-791325%252C%2520a%2520potent%2520allosteric%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879%26doi%3D10.1021%2Fjm4016894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lerchner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machauer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betschart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veenstra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueeger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tintelnot-Blomley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaton, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desrayaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staufenbiel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paganetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondeau, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, U.</span><span> </span><span class="NLM_article-title">Macrocyclic BACE-1 inhibitors acutely reduce amyloid beta in brain after po application</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">607</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2009.11.092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=603-607&author=A.+Lerchnerauthor=R.+Machauerauthor=C.+Betschartauthor=S.+Veenstraauthor=H.+Rueegerauthor=C.+McCarthyauthor=M.+Tintelnot-Blomleyauthor=A.+L.+Jatonauthor=S.+Rabeauthor=S.+Desrayaudauthor=A.+Enzauthor=M.+Staufenbielauthor=P.+Paganettiauthor=J.+M.+Rondeauauthor=U.+Neumann&title=Macrocyclic+BACE-1+inhibitors+acutely+reduce+amyloid+beta+in+brain+after+po+application&doi=10.1016%2Fj.bmcl.2009.11.092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.092%26sid%3Dliteratum%253Aachs%26aulast%3DLerchner%26aufirst%3DA.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DBetschart%26aufirst%3DC.%26aulast%3DVeenstra%26aufirst%3DS.%26aulast%3DRueeger%26aufirst%3DH.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DJaton%26aufirst%3DA.%2BL.%26aulast%3DRabe%26aufirst%3DS.%26aulast%3DDesrayaud%26aufirst%3DS.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DPaganetti%26aufirst%3DP.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DNeumann%26aufirst%3DU.%26atitle%3DMacrocyclic%2520BACE-1%2520inhibitors%2520acutely%2520reduce%2520amyloid%2520beta%2520in%2520brain%2520after%2520po%2520application%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D603%26epage%3D607%26doi%3D10.1016%2Fj.bmcl.2009.11.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Yoshida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takemura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorimachi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonaga, M.</span><span> </span><span class="NLM_article-title">Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluor opyridin-2-yl)cyclopropanecarboxamide (E2006): a potent and efficacious oral orexin receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4648</span><span class="NLM_x">–</span> <span class="NLM_lpage">4664</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00217</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00217" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4648-4664&author=Y.+Yoshidaauthor=Y.+Naoeauthor=T.+Terauchiauthor=F.+Ozakiauthor=T.+Dokoauthor=A.+Takemuraauthor=T.+Tanakaauthor=K.+Sorimachiauthor=C.+T.+Beuckmannauthor=M.+Suzukiauthor=T.+Uenoauthor=S.+Ozakiauthor=M.+Yonaga&title=Discovery+of+%281R%2C2S%29-2-%7B%5B%282%2C4-Dimethylpyrimidin-5-yl%29oxy%5Dmethyl%7D-2-%283-fluorophenyl%29-N-%285-fluor+opyridin-2-yl%29cyclopropanecarboxamide+%28E2006%29%3A+a+potent+and+efficacious+oral+orexin+receptor+antagonist&doi=10.1021%2Facs.jmedchem.5b00217"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00217%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DNaoe%26aufirst%3DY.%26aulast%3DTerauchi%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DDoko%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSorimachi%26aufirst%3DK.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25281R%252C2S%2529-2-%257B%255B%25282%252C4-Dimethylpyrimidin-5-yl%2529oxy%255Dmethyl%257D-2-%25283-fluorophenyl%2529-N-%25285-fluor%2520opyridin-2-yl%2529cyclopropanecarboxamide%2520%2528E2006%2529%253A%2520a%2520potent%2520and%2520efficacious%2520oral%2520orexin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4648%26epage%3D4664%26doi%3D10.1021%2Facs.jmedchem.5b00217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Marson, C. M.</span><span> </span><span class="NLM_article-title">New and unusual scaffolds in medicinal chemistry</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">5514</span><span class="NLM_x">–</span> <span class="NLM_lpage">5533</span><span class="refDoi"> DOI: 10.1039/c1cs15119c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1039%2Fc1cs15119c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=21837344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaiu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=5514-5533&author=C.+M.+Marson&title=New+and+unusual+scaffolds+in+medicinal+chemistry&doi=10.1039%2Fc1cs15119c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">New and unusual scaffolds in medicinal chemistry</span></div><div class="casAuthors">Marson, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5514-5533</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Contemporary medicinal chem. faces diverse challenges from several directions, including the need for both potency and specificity of any therapeutic agent; the increasingly demanding requirements of low toxicity shown across all patients treated; and the need for novelty in intellectual property, given the extensive use of benzenoid and heteroarom. ring systems in numerous patents.  Increasingly, such challenges are being met by a shift to new and/or unusual ring systems (scaffolds) that lie outside the field of (hetero)arom. systems.  This crit. review surveys a necessarily limited selection of currently atypical scaffolds, chiefly drawn from the literature of the last three years, that have found application in medicinal chem., some being present in agents with therapeutic potential while others are found in agents already in clin. use (163 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkgg5kRzVt8rVg90H21EOLACvtfcHk0lh1AUCtrKTw3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaiu7fM&md5=9c2e6b865432fee1aaee7cc8dbb92213</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15119c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15119c%26sid%3Dliteratum%253Aachs%26aulast%3DMarson%26aufirst%3DC.%2BM.%26atitle%3DNew%2520and%2520unusual%2520scaffolds%2520in%2520medicinal%2520chemistry%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D5514%26epage%3D5533%26doi%3D10.1039%2Fc1cs15119c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Foote, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blades, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fillery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichard, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacq, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewsbury, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissink, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thommes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadhurst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, C.</span><span> </span><span class="NLM_article-title">Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2125</span><span class="NLM_x">–</span> <span class="NLM_lpage">2138</span><span class="refDoi"> DOI: 10.1021/jm301859s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301859s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2125-2138&author=K.+M.+Footeauthor=K.+Bladesauthor=A.+Croninauthor=S.+Filleryauthor=S.+S.+Guichardauthor=L.+Hassallauthor=I.+Hicksonauthor=X.+Jacqauthor=P.+J.+Jewsburyauthor=T.+M.+McGuireauthor=J.+W.+Nissinkauthor=R.+Odedraauthor=K.+Pageauthor=P.+Perkinsauthor=A.+Sulemanauthor=K.+Tamauthor=P.+Thommesauthor=R.+Broadhurstauthor=C.+Wood&title=Discovery+of+4-%7B4-%5B%283R%29-3-Methylmorpholin-4-yl%5D-6-%5B1-%28methylsulfonyl%29cyclopropyl%5Dpyrimidin-2-y+l%7D-1H-indole+%28AZ20%29%3A+a+potent+and+selective+inhibitor+of+ATR+protein+kinase+with+monotherapy+in+vivo+antitumor+activity&doi=10.1021%2Fjm301859s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm301859s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301859s%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DCronin%26aufirst%3DA.%26aulast%3DFillery%26aufirst%3DS.%26aulast%3DGuichard%26aufirst%3DS.%2BS.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DJacq%26aufirst%3DX.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DMcGuire%26aufirst%3DT.%2BM.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DSuleman%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DK.%26aulast%3DThommes%26aufirst%3DP.%26aulast%3DBroadhurst%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25204-%257B4-%255B%25283R%2529-3-Methylmorpholin-4-yl%255D-6-%255B1-%2528methylsulfonyl%2529cyclopropyl%255Dpyrimidin-2-y%2520l%257D-1H-indole%2520%2528AZ20%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520ATR%2520protein%2520kinase%2520with%2520monotherapy%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2125%26epage%3D2138%26doi%3D10.1021%2Fjm301859s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Hogberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahlberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelhardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noreen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kangasmetsa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahlberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovgren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridborg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backbro, K.</span><span> </span><span class="NLM_article-title">Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4150</span><span class="NLM_x">–</span> <span class="NLM_lpage">4160</span><span class="refDoi"> DOI: 10.1021/jm990095j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990095j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4150-4160&author=M.+Hogbergauthor=C.+Sahlbergauthor=P.+Engelhardtauthor=R.+Noreenauthor=J.+Kangasmetsaauthor=N.+G.+Johanssonauthor=B.+Obergauthor=L.+Vrangauthor=H.+Zhangauthor=B.+L.+Sahlbergauthor=T.+Ungeauthor=S.+Lovgrenauthor=K.+Fridborgauthor=K.+Backbro&title=Urea-PETT+compounds+as+a+new+class+of+HIV-1+reverse+transcriptase+inhibitors.+3.+Synthesis+and+further+structure-activity+relationship+studies+of+PETT+analogues&doi=10.1021%2Fjm990095j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm990095j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990095j%26sid%3Dliteratum%253Aachs%26aulast%3DHogberg%26aufirst%3DM.%26aulast%3DSahlberg%26aufirst%3DC.%26aulast%3DEngelhardt%26aufirst%3DP.%26aulast%3DNoreen%26aufirst%3DR.%26aulast%3DKangasmetsa%26aufirst%3DJ.%26aulast%3DJohansson%26aufirst%3DN.%2BG.%26aulast%3DOberg%26aufirst%3DB.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSahlberg%26aufirst%3DB.%2BL.%26aulast%3DUnge%26aufirst%3DT.%26aulast%3DLovgren%26aufirst%3DS.%26aulast%3DFridborg%26aufirst%3DK.%26aulast%3DBackbro%26aufirst%3DK.%26atitle%3DUrea-PETT%2520compounds%2520as%2520a%2520new%2520class%2520of%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors.%25203.%2520Synthesis%2520and%2520further%2520structure-activity%2520relationship%2520studies%2520of%2520PETT%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4150%26epage%3D4160%26doi%3D10.1021%2Fjm990095j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><a href="http://www.pharmacytimes.com" class="extLink">http://www.pharmacytimes.com</a> (accessed March 9, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.pharmacytimes.com+%28accessed+March+9%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Taylor, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacCoss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, A. D.</span><span> </span><span class="NLM_article-title">Rings in drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5845</span><span class="NLM_x">–</span> <span class="NLM_lpage">5859</span><span class="refDoi"> DOI: 10.1021/jm4017625</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5845-5859&author=R.+D.+Taylorauthor=M.+MacCossauthor=A.+D.+Lawson&title=Rings+in+drugs&doi=10.1021%2Fjm4017625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Rings in Drugs</span></div><div class="casAuthors">Taylor, Richard D.; MacCoss, Malcolm; Lawson, Alastair D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5845-5859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We have analyzed the rings, ring systems, and frameworks in drugs listed in the FDA Orange Book to understand the frequency, time-lines, mol. property space, and the application of these rings in different therapeutic areas and target classes.  This anal. shows that there are only 351 ring systems and 1197 frameworks in drugs that came onto the market before 2013.  Furthermore, on av. six new ring systems enter drug space each year and approx. 28% of new drugs contain a new ring system.  Moreover, it is very unusual for a drug to contain more than one new ring system and the majority of the most frequently used ring systems (83%) were first used in drugs developed prior to 1983.  These observations give insight into the chem. novelty of drugs and potentially efficient ways to assess compd. libraries and develop compds. from hit identification to lead optimization and beyond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_e_L4z4XCrVg90H21EOLACvtfcHk0lg8mWVB6tV0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D&md5=c84ce84b8698eb6fad38fa82b0ab4912</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm4017625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017625%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%2BD.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DLawson%26aufirst%3DA.%2BD.%26atitle%3DRings%2520in%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5845%26epage%3D5859%26doi%3D10.1021%2Fjm4017625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Wishart, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrivastava, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stothard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolsey, J.</span><span> </span><span class="NLM_article-title">DrugBank: a comprehensive resource for in silico drug discovery and exploration</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">D668</span><span class="NLM_x">–</span> <span class="NLM_lpage">D672</span><span class="refDoi"> DOI: 10.1093/nar/gkj067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1093%2Fnar%2Fgkj067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16381955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFOrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=D668-D672&author=D.+S.+Wishartauthor=C.+Knoxauthor=A.+C.+Guoauthor=S.+Shrivastavaauthor=M.+Hassanaliauthor=P.+Stothardauthor=Z.+Changauthor=J.+Woolsey&title=DrugBank%3A+a+comprehensive+resource+for+in+silico+drug+discovery+and+exploration&doi=10.1093%2Fnar%2Fgkj067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">DrugBank: a comprehensive resource for in silico drug discovery and exploration</span></div><div class="casAuthors">Wishart, David S.; Knox, Craig; Guo, An Chi; Shrivastava, Savita; Hassanali, Murtaza; Stothard, Paul; Chang, Zhan; Woolsey, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Database</span>),
    <span class="NLM_cas:pages">D668-D672</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">DrugBank is a unique bioinformatics/cheminformatics resource that combines detailed drug (i.e. chem.) data with comprehensive drug target (i.e. protein) information.  The database contains >4100 drug entries including >800 FDA approved small mol. and biotech drugs as well as >3200 exptl. drugs.  Addnl., >14 000 protein or drug target sequences are linked to these drug entries.  Each DrugCard entry contains >80 data fields with half of the information being devoted to drug/chem. data and the other half devoted to drug target or protein data.  Many data fields are hyperlinked to other databases (KEGG, PubChem, ChEBI, PDB, Swiss-Prot and GenBank) and a variety of structure viewing applets.  The database is fully searchable supporting extensive text, sequence, chem. structure and relational query searches.  Potential applications of DrugBank include in silico drug target discovery, drug design, drug docking or screening, drug metab. prediction, drug interaction prediction and general pharmaceutical education.  DrugBank is available at http://redpoll.pharmacy.ualberta.ca/drugbank/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaNy9WiVtlu7Vg90H21EOLACvtfcHk0lg8mWVB6tV0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFOrsw%253D%253D&md5=c3f4ad2fc489440be5b16f91bc9cf7db</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkj067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkj067%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DD.%2BS.%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DShrivastava%26aufirst%3DS.%26aulast%3DHassanali%26aufirst%3DM.%26aulast%3DStothard%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DZ.%26aulast%3DWoolsey%26aufirst%3DJ.%26atitle%3DDrugBank%253A%2520a%2520comprehensive%2520resource%2520for%2520in%2520silico%2520drug%2520discovery%2520and%2520exploration%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2006%26volume%3D34%26spage%3DD668%26epage%3DD672%26doi%3D10.1093%2Fnar%2Fgkj067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">McCubrey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tafuri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martelli, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steelman, L. S.</span><span> </span><span class="NLM_article-title">Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=614-630&author=J.+A.+McCubreyauthor=M.+Milellaauthor=A.+Tafuriauthor=A.+M.+Martelliauthor=P.+Lunghiauthor=A.+Bonatiauthor=M.+Cervelloauthor=J.+T.+Leeauthor=L.+S.+Steelman&title=Targeting+the+Raf%2FMEK%2FERK+pathway+with+small-molecule+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DMilella%26aufirst%3DM.%26aulast%3DTafuri%26aufirst%3DA.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DLunghi%26aufirst%3DP.%26aulast%3DBonati%26aufirst%3DA.%26aulast%3DCervello%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26atitle%3DTargeting%2520the%2520Raf%252FMEK%252FERK%2520pathway%2520with%2520small-molecule%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D614%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">McDermott, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, C.</span><span> </span><span class="NLM_article-title">Allosteric MEK1/2 inhibitors for the treatment of cancer: an overview</span> <span class="citation_source-journal">J. Drug. Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="refDoi"> DOI: 10.16966/2470-1009.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.16966%2F2470-1009.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=101&author=L.+McDermottauthor=C.+Qin&title=Allosteric+MEK1%2F2+inhibitors+for+the+treatment+of+cancer%3A+an+overview&doi=10.16966%2F2470-1009.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.16966%2F2470-1009.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.16966%252F2470-1009.101%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DC.%26atitle%3DAllosteric%2520MEK1%252F2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520an%2520overview%26jtitle%3DJ.%2520Drug.%2520Res.%2520Dev.%26date%3D2015%26volume%3D1%26spage%3D101%26doi%3D10.16966%2F2470-1009.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugi, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span> </span><span class="NLM_article-title">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1016/j.canlet.2013.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.canlet.2013.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=23856031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=97-103&author=K.+Okamotoauthor=K.+Kodamaauthor=K.+Takaseauthor=N.+H.+Sugiauthor=Y.+Yamamotoauthor=M.+Iwataauthor=A.+Tsuruoka&title=Antitumor+activities+of+the+targeted+multi-tyrosine+kinase+inhibitor+lenvatinib+%28E7080%29+against+RET+gene+fusion-driven+tumor+models&doi=10.1016%2Fj.canlet.2013.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models</span></div><div class="casAuthors">Okamoto, Kiyoshi; Kodama, Kotaro; Takase, Kazuma; Sugi, Naoko Hata; Yamamoto, Yuji; Iwata, Masao; Tsuruoka, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-103</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas.  Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clin. trials.  Here we evaluated lenvatinib in RET gene fusion-driven preclin. models.  In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET.  Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells.  These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr151nVk6WXn7Vg90H21EOLACvtfcHk0lg8mWVB6tV0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygtb7M&md5=e2399184aae74ae2c4b18997a6b7273b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKodama%26aufirst%3DK.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DSugi%26aufirst%3DN.%2BH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DTsuruoka%26aufirst%3DA.%26atitle%3DAntitumor%2520activities%2520of%2520the%2520targeted%2520multi-tyrosine%2520kinase%2520inhibitor%2520lenvatinib%2520%2528E7080%2529%2520against%2520RET%2520gene%2520fusion-driven%2520tumor%2520models%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D97%26epage%3D103%26doi%3D10.1016%2Fj.canlet.2013.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Okamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikemori-Kawada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jestel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Konig, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, J.</span><span> </span><span class="NLM_article-title">Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1021/ml500394m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500394m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=89-94&author=K.+Okamotoauthor=M.+Ikemori-Kawadaauthor=A.+Jestelauthor=K.+von+Konigauthor=Y.+Funahashiauthor=T.+Matsushimaauthor=A.+Tsuruokaauthor=A.+Inoueauthor=J.+Matsui&title=Distinct+binding+mode+of+multikinase+inhibitor+lenvatinib+revealed+by+biochemical+characterization&doi=10.1021%2Fml500394m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization</span></div><div class="casAuthors">Okamoto, Kiyoshi; Ikemori-Kawada, Megumi; Jestel, Anja; von Konig, Konstanze; Funahashi, Yasuhiro; Matsushima, Tomohiro; Tsuruoka, Akihiko; Inoue, Atsushi; Matsui, Junji</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-94</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases.  To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction anal. of lenvatinib with VEGFR2 and x-ray anal. of the crystal structure of VEGFR2-lenvatinib complexes.  Kinetic anal. revealed that lenvatinib had a rapid assocn. rate const. and a relatively slow dissocn. rate const. in complex with VEGFR2.  Co-crystal structure anal. demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation.  These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUysiHRGw3P7Vg90H21EOLACvtfcHk0ljMjG6psPJdyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqtb7E&md5=5461832fad0577f2ea93b47521b4bbdc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fml500394m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500394m%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DIkemori-Kawada%26aufirst%3DM.%26aulast%3DJestel%26aufirst%3DA.%26aulast%3Dvon%2BKonig%26aufirst%3DK.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DMatsui%26aufirst%3DJ.%26atitle%3DDistinct%2520binding%2520mode%2520of%2520multikinase%2520inhibitor%2520lenvatinib%2520revealed%2520by%2520biochemical%2520characterization%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D89%26epage%3D94%26doi%3D10.1021%2Fml500394m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Strebhardt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Targeting polo-like kinase 1 for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1038/nrc1841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrc1841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16557283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=321-330&author=K.+Strebhardtauthor=A.+Ullrich&title=Targeting+polo-like+kinase+1+for+cancer+therapy&doi=10.1038%2Fnrc1841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting polo-like kinase 1 for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">321-330</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Human polo-like kinase 1 (PLK1) is essential during mitosis and in the maintenance of genomic stability.  PLK1 is overexpressed in human tumors and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target.  The use of different PLK1 inhibitors has increased our knowledge of mitotic regulation and allowed us to assess their ability to suppress tumor growth in vivo.  We address the structural features of the kinase domain and the unique polo-box domain of PLK1 that are most suited for drug development and discuss our current understanding of the therapeutic potential of PLK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdeCr1fiAaaLVg90H21EOLACvtfcHk0ljMjG6psPJdyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVyqtrk%253D&md5=b43638c4eb123292a507734fb87e89ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnrc1841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1841%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DTargeting%2520polo-like%2520kinase%25201%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D321%26epage%3D330%26doi%3D10.1038%2Fnrc1841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Rudolph, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haslinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3094</span><span class="NLM_x">–</span> <span class="NLM_lpage">3102</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F1078-0432.CCR-08-2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19383823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3094-3102&author=D.+Rudolphauthor=M.+Steegmaierauthor=M.+Hoffmannauthor=M.+Grauertauthor=A.+Baumauthor=J.+Quantauthor=C.+Haslingerauthor=P.+Garin-Chesaauthor=G.+R.+Adolf&title=BI+6727%2C+a+polo-like+kinase+inhibitor+with+improved+pharmacokinetic+profile+and+broad+antitumor+activity&doi=10.1158%2F1078-0432.CCR-08-2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span></div><div class="casAuthors">Rudolph, Dorothea; Steegmaier, Martin; Hoffmann, Matthias; Grauert, Matthias; Baum, Anke; Quant, Jens; Haslinger, Christian; Garin-Chesa, Pilar; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3094-3102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers.  To identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.  The first compd. in this series, suitable for i.v. administration, has entered clin. development.  To fully explore the potential of Polo-like kinase 1 inhibition in oncol., we have profiled addnl. compds. and now describe a novel clin. candidate.  BI 6727 is a highly potent (enzyme IC50 = 0.87 nmol/L, EC50 = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties.  First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high vol. of distribution and a long terminal half-life in mice (Vss = 7.6 L/kg, t1/2 = 46 h) and rats (Vss = 22 L/kg, t1/2 = 54 h).  Second, BI 6727 has physicochem. and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules.  Finally, BI 6727 shows marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.  With oral and i.v. routes of administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated dosing schedules.  These findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clin. studies have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YEX91EOHHLVg90H21EOLACvtfcHk0ljMjG6psPJdyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D&md5=daed550be9d9b99ac6797c359039d295</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2445%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DBI%25206727%252C%2520a%2520polo-like%2520kinase%2520inhibitor%2520with%2520improved%2520pharmacokinetic%2520profile%2520and%2520broad%2520antitumor%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3094%26epage%3D3102%26doi%3D10.1158%2F1078-0432.CCR-08-2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Steegmaier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenart, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronczki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurtler, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+Lenartauthor=M.+Petronczkiauthor=M.+Krssakauthor=U.+Gurtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.+M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+potent+and+selective+inhibitor+of+polo-like+kinase+1%2C+inhibits+tumor+growth+in+vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0ljCedFonL4fSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DLenart%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DGurtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520polo-like%2520kinase%25201%252C%2520inhibits%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Bettencourt-Dias, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues-Martins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riparbelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatt, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balloux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glover, D. M.</span><span> </span><span class="NLM_article-title">SAK/PLK4 is required for centriole duplication and flagella development</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2199</span><span class="NLM_x">–</span> <span class="NLM_lpage">2207</span><span class="refDoi"> DOI: 10.1016/j.cub.2005.11.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.cub.2005.11.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16326102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlahu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2199-2207&author=M.+Bettencourt-Diasauthor=A.+Rodrigues-Martinsauthor=L.+Carpenterauthor=M.+Riparbelliauthor=L.+Lehmannauthor=M.+K.+Gattauthor=N.+Carmoauthor=F.+Ballouxauthor=G.+Callainiauthor=D.+M.+Glover&title=SAK%2FPLK4+is+required+for+centriole+duplication+and+flagella+development&doi=10.1016%2Fj.cub.2005.11.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">SAK/PLK4 Is Required for Centriole Duplication and Flagella Development</span></div><div class="casAuthors">Bettencourt-Dias, M.; Rodrigues-Martins, A.; Carpenter, L.; Riparbelli, M.; Lehmann, L.; Gatt, M. K.; Carmo, N.; Balloux, F.; Callaini, G.; Glover, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2199-2207</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SAK/PLK4 is a distinct member of the polo-like kinase family.  SAK-/- mice die during embryogenesis, whereas SAK+/- mice develop liver and lung tumors and SAK+/- MEFs show mitotic abnormalities.  However, the mechanism underlying these phenotypes is still not known.  Here, the authors show that downregulation of SAK in Drosophila cells, by mutation or RNAi, leads to loss of centrioles, the core structures of centrosomes.  Such cells are able to undergo repeated rounds of cell division, but display broad disorganized mitotic spindle poles.  The authors also show that SAK mutants lose their centrioles during the mitotic divisions preceding male meiosis but still produce cysts of 16 primary spermatocytes as in the wild-type.  Math. modeling of the stereotyped cell divisions of spermatogenesis can account for such loss by defective centriole duplication.  The majority of spermatids in SAK mutants lack centrioles and so are unable to make sperm axonemes.  Finally, the authors show that depletion of SAK in human cells also prevents centriole duplication and gives rise to mitotic abnormalities.  SAK/PLK4 is necessary for centriole duplication both in Drosophila and human cells.  Drosophila cells tolerate the lack of centrioles and undertake mitosis but cannot form basal bodies and hence flagella.  Human cells depleted of SAK show error-prone mitosis, likely to underlie its tumor-suppressor role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFoGUh8x0B_7Vg90H21EOLACvtfcHk0ljCedFonL4fSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlahu7fP&md5=31069d55e1b8e6ecdaaababd791b72a7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2005.11.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2005.11.042%26sid%3Dliteratum%253Aachs%26aulast%3DBettencourt-Dias%26aufirst%3DM.%26aulast%3DRodrigues-Martins%26aufirst%3DA.%26aulast%3DCarpenter%26aufirst%3DL.%26aulast%3DRiparbelli%26aufirst%3DM.%26aulast%3DLehmann%26aufirst%3DL.%26aulast%3DGatt%26aufirst%3DM.%2BK.%26aulast%3DCarmo%26aufirst%3DN.%26aulast%3DBalloux%26aufirst%3DF.%26aulast%3DCallaini%26aufirst%3DG.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26atitle%3DSAK%252FPLK4%2520is%2520required%2520for%2520centriole%2520duplication%2520and%2520flagella%2520development%26jtitle%3DCurr.%2520Biol.%26date%3D2005%26volume%3D15%26spage%3D2199%26epage%3D2207%26doi%3D10.1016%2Fj.cub.2005.11.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awrey, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plotnikova, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletskaya, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ban, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiarash, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, H. W.</span><span> </span><span class="NLM_article-title">The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6069</span><span class="NLM_x">–</span> <span class="NLM_lpage">6087</span><span class="refDoi"> DOI: 10.1021/jm400380m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400380m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6069-6087&author=R.+Lauferauthor=B.+Forrestauthor=S.+W.+Liauthor=Y.+Liuauthor=P.+Sampsonauthor=L.+Edwardsauthor=Y.+Langauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=I.+Beletskayaauthor=J.+M.+Masonauthor=X.+Luoauthor=X.+Weiauthor=Y.+Yaoauthor=M.+Feherauthor=F.+Banauthor=R.+Kiarashauthor=E.+Greenauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+discovery+of+PLK4+inhibitors%3A+%28E%29-3-%28%281H-Indazol-6-yl%29methylene%29indolin-2-ones+as+novel+antiproliferative+agents&doi=10.1021%2Fjm400380m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm400380m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400380m%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSampson%26aufirst%3DP.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520PLK4%2520inhibitors%253A%2520%2528E%2529-3-%2528%25281H-Indazol-6-yl%2529methylene%2529indolin-2-ones%2520as%2520novel%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6069%26epage%3D6087%26doi%3D10.1021%2Fjm400380m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span><span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+Mullerauthor=P.+Schoffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0lhNyuUdvDKMHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DMuller%26aufirst%3DS.%2BP.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases&doi=10.1158%2F0008-5472.CAN-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0lhNyuUdvDKMHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensinger, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkoski, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samarakoon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telikepalli, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogeti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. L.</span><span> </span><span class="NLM_article-title">Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2023</span><span class="NLM_x">–</span> <span class="NLM_lpage">2034</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F1535-7163.MCT-14-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26285778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2023-2034&author=B.+D.+Smithauthor=M.+D.+Kaufmanauthor=C.+B.+Learyauthor=B.+A.+Turnerauthor=S.+C.+Wiseauthor=Y.+M.+Ahnauthor=R.+J.+Boothauthor=T.+M.+Caldwellauthor=C.+L.+Ensingerauthor=M.+M.+Hoodauthor=W.+P.+Luauthor=T.+W.+Pattauthor=W.+C.+Pattauthor=T.+J.+Rutkoskiauthor=T.+Samarakoonauthor=H.+Telikepalliauthor=L.+Vogetiauthor=S.+Vogetiauthor=K.+M.+Yatesauthor=L.+Chunauthor=L.+J.+Stewartauthor=M.+Clareauthor=D.+L.+Flynn&title=Altiratinib+inhibits+tumor+growth%2C+invasion%2C+angiogenesis%2C+and+microenvironment-mediated+drug+resistance+via+balanced+inhibition+of+MET%2C+TIE2%2C+and+VEGFR2&doi=10.1158%2F1535-7163.MCT-14-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2</span></div><div class="casAuthors">Smith, Bryan D.; Kaufman, Michael D.; Leary, Cynthia B.; Turner, Benjamin A.; Wise, Scott C.; Ahn, Yu Mi; Booth, R. John; Caldwell, Timothy M.; Ensinger, Carol L.; Hood, Molly M.; Lu, Wei-Ping; Patt, Tristan W.; Patt, William C.; Rutkoski, Thomas J.; Samarakoon, Thiwanka; Telikepalli, Hanumaiah; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen M.; Chun, Lawrence; Stewart, Lance J.; Clare, Michael; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2023-2034</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1).  Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment through balanced inhibition of MET, TIE2 (TEK), and VEGFR2 (KDR) kinases.  This profile was achieved by optimizing binding into the switch control pocket of all three kinases, inducing type II inactive conformations.  Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo.  Through its balanced inhibitory potency vs. MET, TIE2, and VEGFR2, altiratinib provides an agent that inhibits three major evasive (re)vascularization and resistance pathways (HGF, ANG, and VEGF) and blocks tumor invasion and metastasis.  Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9E33eWjRqBrVg90H21EOLACvtfcHk0ljqM1BNvMEz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVegs7vE&md5=34170ba7d22a7fbcea68715fd6a2179b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1105%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLeary%26aufirst%3DC.%2BB.%26aulast%3DTurner%26aufirst%3DB.%2BA.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DEnsinger%26aufirst%3DC.%2BL.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DLu%26aufirst%3DW.%2BP.%26aulast%3DPatt%26aufirst%3DT.%2BW.%26aulast%3DPatt%26aufirst%3DW.%2BC.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSamarakoon%26aufirst%3DT.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DYates%26aufirst%3DK.%2BM.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DClare%26aufirst%3DM.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DAltiratinib%2520inhibits%2520tumor%2520growth%252C%2520invasion%252C%2520angiogenesis%252C%2520and%2520microenvironment-mediated%2520drug%2520resistance%2520via%2520balanced%2520inhibition%2520of%2520MET%252C%2520TIE2%252C%2520and%2520VEGFR2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2023%26epage%3D2034%26doi%3D10.1158%2F1535-7163.MCT-14-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Nakagawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tohyama, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funasaka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirotori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obaishi, H.</span><span> </span><span class="NLM_article-title">E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2009.01343.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1111%2Fj.1349-7006.2009.01343.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19832844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2010&pages=210-215&author=T.+Nakagawaauthor=O.+Tohyamaauthor=A.+Yamaguchiauthor=T.+Matsushimaauthor=K.+Takahashiauthor=S.+Funasakaauthor=S.+Shirotoriauthor=M.+Asadaauthor=H.+Obaishi&title=E7050%3A+a+dual+c-Met+and+VEGFR-2+tyrosine+kinase+inhibitor+promotes+tumor+regression+and+prolongs+survival+in+mouse+xenograft+models&doi=10.1111%2Fj.1349-7006.2009.01343.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models</span></div><div class="casAuthors">Nakagawa, Takayuki; Tohyama, Osamu; Yamaguchi, Atsumi; Matsushima, Tomohiro; Takahashi, Keiko; Funasaka, Setsuo; Shirotori, Shuji; Asada, Makoto; Obaishi, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">C-Met is the cellular receptor for hepatocyte growth factor (HGF) and is known to be dysregulated in various types of human cancers.  Activation of the HGF/c-Met pathway causes tumor progression, invasion, and metastasis.  Vascular endothelial growth factor (VEGF) is also known as a key mol. in tumor progression through the induction of tumor angiogenesis.  Because of their key roles in tumor progression, these pathways provide attractive targets for therapeutic intervention.  We have generated a novel, orally active, small mol. compd., E7050, which inhibits both c-Met and vascular endothelial growth factor receptor (VEGFR)-2.  In vitro studies indicate that E7050 potently inhibits phosphorylation of both c-Met and VEGFR-2.  E7050 also potently represses the growth of both c-met amplified tumor cells and endothelial cells stimulated with either HGF or VEGF.  In vivo studies using E7050 showed inhibition of the phosphorylation of c-Met and VEGFR-2 in tumors, and strong inhibition of tumor growth and tumor angiogenesis in xenograft models.  Treatment of some tumor lines contg. c-met amplifications with high doses of E7050 (50-200 mg/kg) induced tumor regression and disappearance.  In a peritoneal dissemination model, E7050 showed an antitumor effect against peritoneal tumors as well as a significant prolongation of lifespan in treated mice.  Our results indicate that E7050 is a potent inhibitor of c-Met and VEGFR-2 and has therapeutic potential for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd7smhBTumtLVg90H21EOLACvtfcHk0ljqM1BNvMEz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOisA%253D%253D&md5=e8ce73fa1262f767cea173f0561d8e35</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2009.01343.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2009.01343.x%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DTohyama%26aufirst%3DO.%26aulast%3DYamaguchi%26aufirst%3DA.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DFunasaka%26aufirst%3DS.%26aulast%3DShirotori%26aufirst%3DS.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DObaishi%26aufirst%3DH.%26atitle%3DE7050%253A%2520a%2520dual%2520c-Met%2520and%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitor%2520promotes%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DCancer%2520Sci.%26date%3D2010%26volume%3D101%26spage%3D210%26epage%3D215%26doi%3D10.1111%2Fj.1349-7006.2009.01343.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Howard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span><span class="refDoi"> DOI: 10.1021/jm800984v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800984v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Wn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=379-388&author=S.+Howardauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=J.+Curryauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=L.+Fazalauthor=A.+L.+Gillauthor=M.+Heathcoteauthor=S.+Mamanauthor=J.+E.+Matthewsauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=M.+Reuleauthor=D.+Tisiauthor=G.+Williamsauthor=M.+Vinkovicauthor=P.+G.+Wyatt&title=Fragment-based+discovery+of+the+pyrazol-4-yl+urea+%28AT9283%29%2C+a+multitargeted+kinase+inhibitor+with+potent+aurora+kinase+activity&doi=10.1021%2Fjm800984v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity</span></div><div class="casAuthors">Howard, Steven; Berdini, Valerio; Boulstridge, John A.; Carr, Maria G.; Cross, David M.; Curry, Jayne; Devine, Lindsay A.; Early, Theresa R.; Fazal, Lynsey; Gill, Adrian L.; Heathcote, Michelle; Maman, Sarita; Matthews, Julia E.; McMenamin, Rachel L.; Navarro, Eva F.; O'Brien, Michael A.; O'Reilly, Marc; Rees, David C.; Reule, Matthias; Tisi, Dominic; Williams, Glyn; Vinkovic, Mladen; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we describe the identification of a clin. candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment.  Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment of cancer.  X-ray crystallog. structures were generated using a novel soakable form of Aurora A and were used to drive the optimization toward potent (IC50 ≈ 3 nM) dual Aurora A/Aurora B inhibitors.  These compds. inhibited growth and survival of HCT116 cells and produced the polyploid cellular phenotype typically assocd. with Aurora B kinase inhibition.  Optimization of cellular activity and physicochem. properties ultimately led to the identification of compd. 16 (AT9283, I).  In addn. to Aurora A and Aurora B, compd. 16 was also found to inhibit a no. of other kinases including JAK2 and Abl (T315I).  This compd. demonstrated in vivo efficacy in mouse xenograft models and is currently under evaluation in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVEuaBVqyIq7Vg90H21EOLACvtfcHk0ljqM1BNvMEz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Wn&md5=c24b9958c590e28210085df291c2207f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm800984v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800984v%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DHeathcote%26aufirst%3DM.%26aulast%3DMaman%26aufirst%3DS.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520the%2520pyrazol-4-yl%2520urea%2520%2528AT9283%2529%252C%2520a%2520multitargeted%2520kinase%2520inhibitor%2520with%2520potent%2520aurora%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D379%26epage%3D388%26doi%3D10.1021%2Fjm800984v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-+1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0liTbgRzQ-b5eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-%25201-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Kim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKee, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tzou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricks, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladouceur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfuma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venugopal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4257</span><span class="NLM_x">–</span> <span class="NLM_lpage">4261</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1158%2F1078-0432.CCR-15-0887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26187614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1antL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4257-4261&author=G.+Kimauthor=G.+Isonauthor=A.+E.+McKeeauthor=H.+Zhangauthor=S.+Tangauthor=T.+Gwiseauthor=R.+Sridharaauthor=E.+Leeauthor=A.+Tzouauthor=R.+Philipauthor=H.+J.+Chiuauthor=T.+K.+Ricksauthor=T.+Palmbyauthor=A.+M.+Russellauthor=G.+Ladouceurauthor=E.+Pfumaauthor=H.+Liauthor=L.+Zhaoauthor=Q.+Liuauthor=R.+Venugopalauthor=A.+Ibrahimauthor=R.+Pazdur&title=FDA+approval+summary%3A+olaparib+monotherapy+in+patients+with+deleterious+germline+BRCA-mutated+advanced+ovarian+cancer+treated+with+three+or+more+lines+of+chemotherapy&doi=10.1158%2F1078-0432.CCR-15-0887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy</span></div><div class="casAuthors">Kim, Geoffrey; Ison, Gwynn; McKee, Amy E.; Zhang, Hui; Tang, Shenghui; Gwise, Thomas; Sridhara, Rajeshwari; Lee, Eunice; Tzou, Abraham; Philip, Reena; Chiu, Haw-Jyh; Ricks, Tiffany K.; Palmby, Todd; Russell, Anne Marie; Ladouceur, Gaetan; Pfuma, Elimika; Li, Hongshan; Zhao, Liang; Liu, Qi; Venugopal, Rajesh; Ibrahim, Amna; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4257-4261</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Dec. 19, 2014, the FDA approved olaparib capsules (Lynparza; AstraZeneca) for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.  The BRACAnal. CDx (Myriad Genetic Labs., Inc.) was approved concurrently.  An international multicenter, single-arm trial enrolled 137 patients with measurable gBRCAm-assocd. ovarian cancer treated with three or more prior lines of chemotherapy.  Patients received olaparib at a dose of 400 mg by mouth twice daily until disease progression or unacceptable toxicity.  The objective response rate (ORR) was 34% with median response duration of 7.9 mo in this cohort.  The most common adverse reactions (≥20%) in patients treated with olaparib were anemia, nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngitis/upper respiratory infection, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash, and abdominal pain/discomfort.  Myelodysplatic syndrome and/or acute myeloid leukemia occurred in 2% of the patients enrolled on this trial.  Clin Cancer Res; 21(19); 4257-61. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUGE-lJX1VTrVg90H21EOLACvtfcHk0liTbgRzQ-b5eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1antL3P&md5=ae7b27e347759be47e84ee8d555ff094</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0887%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%26aulast%3DIson%26aufirst%3DG.%26aulast%3DMcKee%26aufirst%3DA.%2BE.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DGwise%26aufirst%3DT.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DTzou%26aufirst%3DA.%26aulast%3DPhilip%26aufirst%3DR.%26aulast%3DChiu%26aufirst%3DH.%2BJ.%26aulast%3DRicks%26aufirst%3DT.%2BK.%26aulast%3DPalmby%26aufirst%3DT.%26aulast%3DRussell%26aufirst%3DA.%2BM.%26aulast%3DLadouceur%26aufirst%3DG.%26aulast%3DPfuma%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DVenugopal%26aufirst%3DR.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520olaparib%2520monotherapy%2520in%2520patients%2520with%2520deleterious%2520germline%2520BRCA-mutated%2520advanced%2520ovarian%2520cancer%2520treated%2520with%2520three%2520or%2520more%2520lines%2520of%2520chemotherapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4257%26epage%3D4261%26doi%3D10.1158%2F1078-0432.CCR-15-0887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Mohammad, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federowicz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aller, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneck, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butticello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnette, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappalardi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasparec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crouthamel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hann, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, R. G.</span><span> </span><span class="NLM_article-title">A DNA Hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.ccell.2015.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26175415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Grt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=57-69&author=H.+P.+Mohammadauthor=K.+N.+Smithemanauthor=C.+D.+Kamatauthor=D.+Soongauthor=K.+E.+Federowiczauthor=G.+S.+Van+Allerauthor=J.+L.+Schneckauthor=J.+D.+Carsonauthor=Y.+Liuauthor=M.+Butticelloauthor=W.+G.+Bonnetteauthor=S.+A.+Gormanauthor=Y.+Degenhardtauthor=Y.+Baiauthor=M.+T.+McCabeauthor=M.+B.+Pappalardiauthor=J.+Kasparecauthor=X.+Tianauthor=K.+C.+McNultyauthor=M.+Rouseauthor=P.+McDevittauthor=T.+Hoauthor=M.+Crouthamelauthor=T.+K.+Hartauthor=N.+O.+Conchaauthor=C.+F.+McHughauthor=W.+H.+Millerauthor=D.+Dhanakauthor=P.+J.+Tumminoauthor=C.+L.+Carpenterauthor=N.+W.+Johnsonauthor=C.+L.+Hannauthor=R.+G.+Kruger&title=A+DNA+Hypomethylation+signature+predicts+antitumor+activity+of+LSD1+inhibitors+in+SCLC&doi=10.1016%2Fj.ccell.2015.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC</span></div><div class="casAuthors">Mohammad, Helai P.; Smitheman, Kimberly N.; Kamat, Chandrashekhar D.; Soong, David; Federowicz, Kelly E.; Van Aller, Glenn S.; Schneck, Jess L.; Carson, Jeffrey D.; Liu, Yan; Butticello, Michael; Bonnette, William G.; Gorman, Shelby A.; Degenhardt, Yan; Bai, Yuchen; McCabe, Michael T.; Pappalardi, Melissa B.; Kasparec, Jiri; Tian, Xinrong; McNulty, Kenneth C.; Rouse, Meagan; McDevitt, Patrick; Ho, Thau; Crouthamel, Michelle; Hart, Timothy K.; Concha, Nestor O.; McHugh, Charles F.; Miller, William H.; Dhanak, Dashyant; Tummino, Peter J.; Carpenter, Christopher L.; Johnson, Neil W.; Hann, Christine L.; Kruger, Ryan G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-69</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Epigenetic dysregulation has emerged as an important mechanism in cancer.  Alterations in epigenetic machinery have become a major focus for targeted therapies.  The current report describes the discovery and biol. activity of a cyclopropylamine contg. inhibitor of Lysine Demethylase 1 (LSD1), GSK2879552.  This small mol. is a potent, selective, orally bioavailable, mechanism-based irreversible inactivator of LSD1.  A proliferation screen of cell lines representing a no. of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 inhibition.  The subset of SCLC lines and primary samples that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes, suggesting this may be used as a predictive biomarker of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppluiM41UspbVg90H21EOLACvtfcHk0liTxyZgD_VJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Grt7fJ&md5=863924e99fa3576dc1c67824b45462f8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DH.%2BP.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKamat%26aufirst%3DC.%2BD.%26aulast%3DSoong%26aufirst%3DD.%26aulast%3DFederowicz%26aufirst%3DK.%2BE.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DSchneck%26aufirst%3DJ.%2BL.%26aulast%3DCarson%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DButticello%26aufirst%3DM.%26aulast%3DBonnette%26aufirst%3DW.%2BG.%26aulast%3DGorman%26aufirst%3DS.%2BA.%26aulast%3DDegenhardt%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DMcCabe%26aufirst%3DM.%2BT.%26aulast%3DPappalardi%26aufirst%3DM.%2BB.%26aulast%3DKasparec%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DMcNulty%26aufirst%3DK.%2BC.%26aulast%3DRouse%26aufirst%3DM.%26aulast%3DMcDevitt%26aufirst%3DP.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DCrouthamel%26aufirst%3DM.%26aulast%3DHart%26aufirst%3DT.%2BK.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DMcHugh%26aufirst%3DC.%2BF.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCarpenter%26aufirst%3DC.%2BL.%26aulast%3DJohnson%26aufirst%3DN.%2BW.%26aulast%3DHann%26aufirst%3DC.%2BL.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26atitle%3DA%2520DNA%2520Hypomethylation%2520signature%2520predicts%2520antitumor%2520activity%2520of%2520LSD1%2520inhibitors%2520in%2520SCLC%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D57%26epage%3D69%26doi%3D10.1016%2Fj.ccell.2015.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Johnson, N. W.; Kasparec, J.; Miller, W. H.; Rouse, M. B.; Suarez, D.; Tian, X.</span><span> </span><span class="NLM_article-title">Preparation of cyclopropylamines as LSD1 inhibitors in the treatment of cancer</span>. WO2012135113A2,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=N.+W.+Johnson&author=J.+Kasparec&author=W.+H.+Miller&author=M.+B.+Rouse&author=D.+Suarez&author=X.+Tian&title=Preparation+of+cyclopropylamines+as+LSD1+inhibitors+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DN.%2BW.%26atitle%3DPreparation%2520of%2520cyclopropylamines%2520as%2520LSD1%2520inhibitors%2520in%2520the%2520treatment%2520of%2520cancer%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Lu, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokharel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebawy, M.</span><span> </span><span class="NLM_article-title">MRP1 and its role in anticancer drug resistance</span> <span class="citation_source-journal">Drug Metab. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.3109/03602532.2015.1105253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.3109%2F03602532.2015.1105253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=26541366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2mtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2015&pages=406-419&author=J.+F.+Luauthor=D.+Pokharelauthor=M.+Bebawy&title=MRP1+and+its+role+in+anticancer+drug+resistance&doi=10.3109%2F03602532.2015.1105253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">MRP1 and its role in anticancer drug resistance</span></div><div class="casAuthors">Lu, Jamie F.; Pokharel, Deep; Bebawy, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">406-419</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The phenomenon of multidrug resistance (MDR) in cancer is assocd. with the overexpression of the ATP-binding cassette (ABC) transporter proteins, including multidrug resistance-assocd. protein 1 (MRP1) and P-glycoprotein.  MRP1 plays an active role in protecting cells by its ability to efflux a vast array of drugs to sub-lethal levels.  There has been much effort in elucidating the mechanisms of action, structure and substrates and substrate binding sites of MRP1 in the last decade.  In this review, we detail our current understanding of MRP1, its clin. relevance and highlight the current environment in the search for MRP1 inhibitors.  We also look at the capacity for the rapid intercellular transfer of MRP1 phenotype from spontaneously shed membrane vesicles known as microparticles and discuss the clin. and therapeutic significance of this in the context of cancer MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO5yPSgh6OvbVg90H21EOLACvtfcHk0liTxyZgD_VJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2mtr3I&md5=deed6bc06e93cc0667efdb58d53116c7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3109%2F03602532.2015.1105253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2015.1105253%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%2BF.%26aulast%3DPokharel%26aufirst%3DD.%26aulast%3DBebawy%26aufirst%3DM.%26atitle%3DMRP1%2520and%2520its%2520role%2520in%2520anticancer%2520drug%2520resistance%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2015%26volume%3D47%26spage%3D406%26epage%3D419%26doi%3D10.3109%2F03602532.2015.1105253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Sato, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukazawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruo, T.</span><span> </span><span class="NLM_article-title">Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2420</span><span class="NLM_x">–</span> <span class="NLM_lpage">2424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=2420-2424&author=W.+Satoauthor=N.+Fukazawaauthor=T.+Suzukiauthor=K.+Yusaauthor=T.+Tsuruo&title=Circumvention+of+multidrug+resistance+by+a+newly+synthesized+quinoline+derivative%2C+MS-073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DW.%26aulast%3DFukazawa%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DYusa%26aufirst%3DK.%26aulast%3DTsuruo%26aufirst%3DT.%26atitle%3DCircumvention%2520of%2520multidrug%2520resistance%2520by%2520a%2520newly%2520synthesized%2520quinoline%2520derivative%252C%2520MS-073%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D2420%26epage%3D2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Pfister, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makra, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muehldorf, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zutshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slate, D. L.</span><span> </span><span class="NLM_article-title">Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2473</span><span class="NLM_x">–</span> <span class="NLM_lpage">2476</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00426-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0960-894X%2895%2900426-T" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=2473-2476&author=J.+R.+Pfisterauthor=F.+Makraauthor=A.+V.+Muehldorfauthor=H.+Wuauthor=J.+T.+Nelsonauthor=P.+Cheungauthor=N.+A.+Brunoauthor=S.+M.+Caseyauthor=N.+Zutshiauthor=D.+L.+Slate&title=Methanodibenzosuberylpiperazines+as+potent+multidrug+resistance+reversal+agents&doi=10.1016%2F0960-894X%2895%2900426-T"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900426-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900426-T%26sid%3Dliteratum%253Aachs%26aulast%3DPfister%26aufirst%3DJ.%2BR.%26aulast%3DMakra%26aufirst%3DF.%26aulast%3DMuehldorf%26aufirst%3DA.%2BV.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DJ.%2BT.%26aulast%3DCheung%26aufirst%3DP.%26aulast%3DBruno%26aufirst%3DN.%2BA.%26aulast%3DCasey%26aufirst%3DS.%2BM.%26aulast%3DZutshi%26aufirst%3DN.%26aulast%3DSlate%26aufirst%3DD.%2BL.%26atitle%3DMethanodibenzosuberylpiperazines%2520as%2520potent%2520multidrug%2520resistance%2520reversal%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D2473%26epage%3D2476%26doi%3D10.1016%2F0960-894X%2895%2900426-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arasappan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhanam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broske, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfmacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogdanowich-Knipp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6074</span><span class="NLM_x">–</span> <span class="NLM_lpage">6086</span><span class="refDoi"> DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.+T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.+C.+Chengauthor=Y.+Hsiehauthor=J.+M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-amino-1-%28cyclobutylmethyl%29-2%2C3-dioxopropyl%5D-+3-%5B2%28S%29-%5B%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5Damino%5D-3%2C3-dimethyl-1-oxobutyl%5D-+6%2C6-dimethyl-3-azabicyclo%5B3.1.0%5Dhexan-2%28S%29-carboxamide+%28SCH+503034%29%2C+a+selective%2C+potent%2C+orally+bioavailable+hepatitis+C+virus+NS3+protease+inhibitor%3A+a+potential+therapeutic+agent+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0ljt8wHa2OgF-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.%2BM.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-amino-1-%2528cyclobutylmethyl%2529-2%252C3-dioxopropyl%255D-%25203-%255B2%2528S%2529-%255B%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255Damino%255D-3%252C3-dimethyl-1-oxobutyl%255D-%25206%252C6-dimethyl-3-azabicyclo%255B3.1.0%255Dhexan-2%2528S%2529-carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520selective%252C%2520potent%252C%2520orally%2520bioavailable%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%253A%2520a%2520potential%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britt, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landro, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schairer, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Drie, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4059</span><span class="NLM_x">–</span> <span class="NLM_lpage">4063</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.08.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.08.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4059-4063&author=R.+B.+Perniauthor=S.+D.+Brittauthor=J.+C.+Courtauthor=L.+F.+Courtneyauthor=D.+D.+Deiningerauthor=L.+J.+Farmerauthor=C.+A.+Gatesauthor=S.+L.+Harbesonauthor=J.+L.+Kimauthor=J.+A.+Landroauthor=R.+B.+Levinauthor=Y.+P.+Luongauthor=E.+T.+O%E2%80%99Malleyauthor=J.+Pitlikauthor=B.+G.+Raoauthor=W.+C.+Schairerauthor=J.+A.+Thomsonauthor=R.+D.+Tungauthor=J.+H.+Van+Drieauthor=Y.+Wei&title=Inhibitors+of+hepatitis+C+virus+NS3.4A+protease+1.+Non-charged+tetrapeptide+variants&doi=10.1016%2Fj.bmcl.2003.08.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.08.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.08.050%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DBritt%26aufirst%3DS.%2BD.%26aulast%3DCourt%26aufirst%3DJ.%2BC.%26aulast%3DCourtney%26aufirst%3DL.%2BF.%26aulast%3DDeininger%26aufirst%3DD.%2BD.%26aulast%3DFarmer%26aufirst%3DL.%2BJ.%26aulast%3DGates%26aufirst%3DC.%2BA.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DLevin%26aufirst%3DR.%2BB.%26aulast%3DLuong%26aufirst%3DY.%2BP.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DPitlik%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DSchairer%26aufirst%3DW.%2BC.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DInhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS3.4A%2520protease%25201.%2520Non-charged%2520tetrapeptide%2520variants%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4059%26epage%3D4063%26doi%3D10.1016%2Fj.bmcl.2003.08.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britt, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Drie, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1446</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.01.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2004.01.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1441-1446&author=R.+B.+Perniauthor=J.+Pitlikauthor=S.+D.+Brittauthor=J.+J.+Courtauthor=L.+F.+Courtneyauthor=D.+D.+Deiningerauthor=L.+J.+Farmerauthor=C.+A.+Gatesauthor=S.+L.+Harbesonauthor=R.+B.+Levinauthor=C.+Linauthor=K.+Linauthor=Y.+C.+Moonauthor=Y.+P.+Luongauthor=E.+T.+O%E2%80%99Malleyauthor=B.+G.+Raoauthor=J.+A.+Thomsonauthor=R.+D.+Tungauthor=J.+H.+Van+Drieauthor=Y.+Wei&title=Inhibitors+of+hepatitis+C+virus+NS3.4A+protease+2.+Warhead+SAR+and+optimization&doi=10.1016%2Fj.bmcl.2004.01.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DPitlik%26aufirst%3DJ.%26aulast%3DBritt%26aufirst%3DS.%2BD.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DCourtney%26aufirst%3DL.%2BF.%26aulast%3DDeininger%26aufirst%3DD.%2BD.%26aulast%3DFarmer%26aufirst%3DL.%2BJ.%26aulast%3DGates%26aufirst%3DC.%2BA.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DLevin%26aufirst%3DR.%2BB.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DMoon%26aufirst%3DY.%2BC.%26aulast%3DLuong%26aufirst%3DY.%2BP.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DInhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS3.4A%2520protease%25202.%2520Warhead%2520SAR%2520and%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1441%26epage%3D1446%26doi%3D10.1016%2Fj.bmcl.2004.01.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Yip, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barket, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venable, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakulchik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villarreal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colacino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yumibe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebbe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munroe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. H.</span><span> </span><span class="NLM_article-title">Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.09.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=251-256&author=Y.+Yipauthor=F.+Victorauthor=J.+Lamarauthor=R.+Johnsonauthor=Q.+M.+Wangauthor=D.+Barketauthor=J.+Glassauthor=L.+Jinauthor=L.+Liuauthor=D.+Venableauthor=M.+Wakulchikauthor=C.+Xieauthor=B.+Heinzauthor=E.+Villarrealauthor=J.+Colacinoauthor=N.+Yumibeauthor=M.+Tebbeauthor=J.+Munroeauthor=S.+H.+Chen&title=Discovery+of+a+novel+bicycloproline+P2+bearing+peptidyl+alpha-ketoamide+LY514962+as+HCV+protease+inhibitor&doi=10.1016%2Fj.bmcl.2003.09.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DYip%26aufirst%3DY.%26aulast%3DVictor%26aufirst%3DF.%26aulast%3DLamar%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DBarket%26aufirst%3DD.%26aulast%3DGlass%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DVenable%26aufirst%3DD.%26aulast%3DWakulchik%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DHeinz%26aufirst%3DB.%26aulast%3DVillarreal%26aufirst%3DE.%26aulast%3DColacino%26aufirst%3DJ.%26aulast%3DYumibe%26aufirst%3DN.%26aulast%3DTebbe%26aufirst%3DM.%26aulast%3DMunroe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520bicycloproline%2520P2%2520bearing%2520peptidyl%2520alpha-ketoamide%2520LY514962%2520as%2520HCV%2520protease%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D251%26epage%3D256%26doi%3D10.1016%2Fj.bmcl.2003.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Victor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yumibe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. H.</span><span> </span><span class="NLM_article-title">P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.09.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2003.09.075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=257-261&author=F.+Victorauthor=J.+Lamarauthor=N.+Snyderauthor=Y.+Yipauthor=D.+Guoauthor=N.+Yumibeauthor=R.+B.+Johnsonauthor=Q.+M.+Wangauthor=J.+I.+Glassauthor=S.+H.+Chen&title=P1+and+P3+optimization+of+novel+bicycloproline+P2+bearing+tetrapeptidyl+alpha-ketoamide+based+HCV+protease+inhibitors&doi=10.1016%2Fj.bmcl.2003.09.075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.09.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.09.075%26sid%3Dliteratum%253Aachs%26aulast%3DVictor%26aufirst%3DF.%26aulast%3DLamar%26aufirst%3DJ.%26aulast%3DSnyder%26aufirst%3DN.%26aulast%3DYip%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DYumibe%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DR.%2BB.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DGlass%26aufirst%3DJ.%2BI.%26aulast%3DChen%26aufirst%3DS.%2BH.%26atitle%3DP1%2520and%2520P3%2520optimization%2520of%2520novel%2520bicycloproline%2520P2%2520bearing%2520tetrapeptidyl%2520alpha-ketoamide%2520based%2520HCV%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D257%26epage%3D261%26doi%3D10.1016%2Fj.bmcl.2003.09.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span><span class="refDoi"> DOI: 10.1021/jm9015526</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.+L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.+S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fjm9015526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0lg3cDMNnIjDmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.%2BS.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463%26doi%3D10.1021%2Fjm9015526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiFilippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crescenzi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianetti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0ljSGyKxFrsa4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Unravelling hepatitis C virus replication from genome to function</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">436</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span><span class="refDoi"> DOI: 10.1038/nature04077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnature04077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16107832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXotFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=436&publication_year=2005&pages=933-938&author=B.+D.+Lindenbachauthor=C.+M.+Rice&title=Unravelling+hepatitis+C+virus+replication+from+genome+to+function&doi=10.1038%2Fnature04077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Unravelling hepatitis C virus replication from genome to function</span></div><div class="casAuthors">Lindenbach, Brett D.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">436</span>
        (<span class="NLM_cas:issue">7053</span>),
    <span class="NLM_cas:pages">933-938</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the discovery of the hepatitis C virus over 15 years ago, scientists have raced to develop diagnostics, study the virus and find new therapies.  Yet virtually every attempt to dissect this pathogen has met with roadblocks that impeded progress.  Its replication was restricted to humans or exptl. infected chimpanzees, and efficient growth of the virus in cell culture failed until very recently.  Nevertheless hard-fought progress has been made and the first wave of antiviral drugs is entering clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI6vc6EOs8vLVg90H21EOLACvtfcHk0ljSGyKxFrsa4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXotFent7o%253D&md5=553517cac32b797ef7a2d07f496a7b5c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnature04077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04077%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DUnravelling%2520hepatitis%2520C%2520virus%2520replication%2520from%2520genome%2520to%2520function%26jtitle%3DNature%26date%3D2005%26volume%3D436%26spage%3D933%26epage%3D938%26doi%3D10.1038%2Fnature04077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1708</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span><span class="refDoi"> DOI: 10.1021/jm401840s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401840s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1708-1729&author=P.+M.+Scolaauthor=A.+X.+Wangauthor=A.+C.+Goodauthor=L.+Q.+Sunauthor=K.+D.+Combrinkauthor=J.+A.+Campbellauthor=J.+Chenauthor=Y.+Tuauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.+Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=M.+Dingauthor=J.+Thuringauthor=J.+Liauthor=D.+Hernandezauthor=F.+Yuauthor=P.+Falkauthor=G.+Zhaiauthor=A.+K.+Sheafferauthor=C.+Chenauthor=M.+S.+Leeauthor=D.+Barryauthor=J.+O.+Knipeauthor=W.+Liauthor=Y.+H.+Hanauthor=S.+Jenkinsauthor=C.+Gesenbergauthor=Q.+Gaoauthor=M.+W.+Sinzauthor=K.+S.+Santoneauthor=T.+Zvyagaauthor=R.+Rajamaniauthor=H.+E.+Kleiauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=E.+Hughesauthor=C.+Chienauthor=S.+Adamsauthor=P.+C.+Levesqueauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=Discovery+and+early+clinical+evaluation+of+BMS-605339%2C+a+potent+and+orally+efficacious+tripeptidic+acylsulfonamide+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401840s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Wang, Alan Xiangdong; Good, Andrew C.; Sun, Li-Qiang; Combrink, Keith D.; Campbell, Jeffrey A.; Chen, Jie; Tu, Yong; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley; Zheng, Barbara; Hewawasam, Piyasena; Ding, Min; Thuring, Jan; Li, Jianqing; Hernandez, Dennis; Yu, Fei; Falk, Paul; Zhai, Guangzhi; Sheaffer, Amy K.; Chen, Chaoqun; Lee, Min S.; Barry, Diana; Knipe, Jay O.; Li, Wenying; Han, Yong-Hae; Jenkins, Susan; Gesenberg, Christoph; Gao, Qi; Sinz, Michael W.; Santone, Kenneth S.; Zvyaga, Tatyana; Rajamani, Ramkumar; Klei, Herbert E.; Colonno, Richard J.; Grasela, Dennis M.; Hughes, Eric; Chien, Caly; Adams, Stephen; Levesque, Paul C.; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1708-1729</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of BMS-605339 (35), a tripeptidic inhibitor of the NS3/4A enzyme, is described.  This compd. incorporates a cyclopropylacylsulfonamide moiety that was designed to improve the potency of carboxylic acid prototypes through the introduction of favorable nonbonding interactions within the S1' site of the protease.  The identification of 35 was enabled through the optimization and balance of crit. properties including potency and pharmacokinetics (PK).  This was achieved through modulation of the P2* subsite of the inhibitor which identified the isoquinoline ring system as a key template for improving PK properties with further optimization achieved through functionalization.  A methoxy moiety at the C6 position of this isoquinoline ring system proved to be optimal with respect to potency and PK, thus providing the clin. compd. 35 which demonstrated antiviral activity in HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJmlq7vS_NcLVg90H21EOLACvtfcHk0lik_7huGOYd-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D&md5=cac18d2020ecf9d3ac1a8e1237e0ea7c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm401840s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401840s%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DSun%26aufirst%3DL.%2BQ.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DThuring%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520evaluation%2520of%2520BMS-605339%252C%2520a%2520potent%2520and%2520orally%2520efficacious%2520tripeptidic%2520acylsulfonamide%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1708%26epage%3D1729%26doi%3D10.1021%2Fjm401840s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalmeijer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Rosa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span> </span><span class="NLM_article-title">Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">–</span> <span class="NLM_lpage">1693</span><span class="refDoi"> DOI: 10.1021/jm401507s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401507s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1673-1693&author=A.+Rosenquistauthor=B.+Samuelssonauthor=P.+O.+Johanssonauthor=M.+D.+Cummingsauthor=O.+Lenzauthor=P.+Raboissonauthor=K.+Simmenauthor=S.+Vendevilleauthor=H.+de+Kockauthor=M.+Nilssonauthor=A.+Horvathauthor=R.+Kalmeijerauthor=G.+de+la+Rosaauthor=M.+Beumont-Mauviel&title=Discovery+and+development+of+simeprevir+%28TMC435%29%2C+a+HCV+NS3%2F4A+protease+inhibitor&doi=10.1021%2Fjm401507s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor</span></div><div class="casAuthors">Rosenquist, Aasa; Samuelsson, Bertil; Johansson, Per-Ola; Cummings, Maxwell D.; Lenz, Oliver; Raboisson, Pierre; Simmen, Kenny; Vendeville, Sandrine; de Kock, Herman; Nilsson, Magnus; Horvath, Andras; Kalmeijer, Ronald; de la Rosa, Guy; Beumont-Mauviel, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1673-1693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus is a blood-borne infection and the leading cause of chronic liver disease (including cirrhosis and cancer) and liver transplantation.  Since the identification of HCV in 1989, there has been an extensive effort to identify and improve treatment options.  An important milestone was reached in 2011 with the approval of the first-generation HCV NS3/4A protease inhibitors.  However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tolerability.  Here we summarize the extensive medicinal chem. effort to develop novel P2 cyclopentane macrocyclic inhibitors guided by HCV NS3 protease assays, the cellular replicon system, structure-based design, and a panel of DMPK assays.  The selection of compd. 29 (simeprevir, TMC435) as clin. candidate was based on its excellent biol., PK, and safety pharmacol. profile.  Compd. 29 has recently been approved for treatment of chronic HCV infection in combination with pegylated interferon-α and ribavirin in Japan, Canada, and USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryCRg3NRRjzrVg90H21EOLACvtfcHk0lik_7huGOYd-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslekuw%253D%253D&md5=fd9c1df095e47a111d9680af4c40ccc6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm401507s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401507s%26sid%3Dliteratum%253Aachs%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DJohansson%26aufirst%3DP.%2BO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DHorvath%26aufirst%3DA.%26aulast%3DKalmeijer%26aufirst%3DR.%26aulast%3Dde%2Bla%2BRosa%26aufirst%3DG.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520simeprevir%2520%2528TMC435%2529%252C%2520a%2520HCV%2520NS3%252F4A%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1673%26epage%3D1693%26doi%3D10.1021%2Fjm401507s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Link, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mogalian, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondou, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornpropst, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, M. C.</span><span> </span><span class="NLM_article-title">Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2046</span><span class="refDoi"> DOI: 10.1021/jm401499g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401499g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2033-2046&author=J.+O.+Linkauthor=J.+G.+Taylorauthor=L.+Xuauthor=M.+Mitchellauthor=H.+Guoauthor=H.+Liuauthor=D.+Katoauthor=T.+Kirschbergauthor=J.+Sunauthor=N.+Squiresauthor=J.+Parrishauthor=T.+Kellerauthor=Z.+Y.+Yangauthor=C.+Yangauthor=M.+Matlesauthor=Y.+Wangauthor=K.+Wangauthor=G.+Chengauthor=Y.+Tianauthor=E.+Mogalianauthor=E.+Mondouauthor=M.+Cornpropstauthor=J.+Perryauthor=M.+C.+Desai&title=Discovery+of+ledipasvir+%28GS-5885%29%3A+a+potent%2C+once-daily+oral+NS5A+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401499g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Link, John O.; Taylor, James G.; Xu, Lianhong; Mitchell, Michael; Guo, Hongyan; Liu, Hongtao; Kato, Darryl; Kirschberg, Thorsten; Sun, Jianyu; Squires, Neil; Parrish, Jay; Kellar, Terry; Yang, Zheng-Yu; Yang, Chris; Matles, Mike; Wang, Yujin; Wang, Kelly; Cheng, Guofeng; Tian, Yang; Mogalian, Erik; Mondou, Elsa; Cornpropst, Melanie; Perry, Jason; Desai, Manoj C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2033-2046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of highly potent NS5A inhibitors with an unsym. benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]-azabicyclic ring system was discovered.  Optimization of antiviral potency and pharmacokinetics led to the identification of ledipasvir (GS-5885).  Ledipasvir (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load redn. in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. ledipasvir has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLazFwyH5rrVg90H21EOLACvtfcHk0lik_7huGOYd-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltb3I&md5=30cec1d10b7b7dd02faae4fba4b88bd8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm401499g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401499g%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DJ.%2BO.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DKirschberg%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DSquires%26aufirst%3DN.%26aulast%3DParrish%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%2BY.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DMatles%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DMogalian%26aufirst%3DE.%26aulast%3DMondou%26aufirst%3DE.%26aulast%3DCornpropst%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DDesai%26aufirst%3DM.%2BC.%26atitle%3DDiscovery%2520of%2520ledipasvir%2520%2528GS-5885%2529%253A%2520a%2520potent%252C%2520once-daily%2520oral%2520NS5A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2033%26epage%3D2046%26doi%3D10.1021%2Fjm401499g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Patil, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samanta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masand, N.</span><span> </span><span class="NLM_article-title">Current perspective of HCV NS5B inhibitors: a review</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5564</span><span class="NLM_x">–</span> <span class="NLM_lpage">5597</span><span class="refDoi"> DOI: 10.2174/092986711798347234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F092986711798347234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22172066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=5564-5597&author=V.+M.+Patilauthor=S.+P.+Guptaauthor=S.+Samantaauthor=N.+Masand&title=Current+perspective+of+HCV+NS5B+inhibitors%3A+a+review&doi=10.2174%2F092986711798347234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Current perspective of HCV NS5B inhibitors: a review</span></div><div class="casAuthors">Patil, V. M.; Gupta, S. P.; Samanta, S.; Masand, N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5564-5597</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection has emerged as one of the most significant disease to affect humans.  Despite its large medical and economical impact, there are no vaccines or efficient therapies without major side effects.  The HCV non-structural protein 5B (NS5B) is the RNA-dependent RNA polymerase responsible for the complete copy of the RNA viral genome and is a target of choice for the development of anti-HCV drugs.  Although many small mols. have been identified as allosteric inhibitors of NS5B, very few are active in clin. applications.  Developments in the field have prompted us to review the research work on HCV NS5B polymerase inhibitors, esp. their structure activity relationships and mol. modeling studies.  This review will focus on the journey of drug discovery of HCV NS5B inhibitors covering both nucleoside and non-nucleosides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7q2y0ZJu6vLVg90H21EOLACvtfcHk0liB4aAQNj-HMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbF&md5=06e6f5def2c5dd67974c057ead364322</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2174%2F092986711798347234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711798347234%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DV.%2BM.%26aulast%3DGupta%26aufirst%3DS.%2BP.%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DMasand%26aufirst%3DN.%26atitle%3DCurrent%2520perspective%2520of%2520HCV%2520NS5B%2520inhibitors%253A%2520a%2520review%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D5564%26epage%3D5597%26doi%3D10.2174%2F092986711798347234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2925</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2011.03.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2925-2929&author=X.+Zhengauthor=T.+W.+Hudymaauthor=S.+W.+Martinauthor=C.+Bergstromauthor=M.+Dingauthor=F.+Heauthor=J.+Romineauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=C.+H.+Changauthor=J.+Wanauthor=M.+R.+Witmerauthor=P.+Morinauthor=D.+M.+Camacauthor=S.+Sheriffauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+Fridellauthor=J.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Syntheses+and+initial+evaluation+of+a+series+of+indolo-fused+heterocyclic+inhibitors+of+the+polymerase+enzyme+%28NS5B%29+of+the+hepatitis+C+virus&doi=10.1016%2Fj.bmcl.2011.03.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DBergstrom%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DRomine%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSyntheses%2520and%2520initial%2520evaluation%2520of%2520a%2520series%2520of%2520indolo-fused%2520heterocyclic%2520inhibitors%2520of%2520the%2520polymerase%2520enzyme%2520%2528NS5B%2529%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2925%26epage%3D2929%26doi%3D10.1016%2Fj.bmcl.2011.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Yu, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civiello, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehan, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianci, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovesi, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyde, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 3: water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">–</span> <span class="NLM_lpage">1122</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.11.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.11.109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1115-1122&author=K.+L.+Yuauthor=X.+A.+Wangauthor=R.+L.+Civielloauthor=A.+K.+Trehanauthor=B.+C.+Pearceauthor=Z.+Yinauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=Y.+Zhangauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=P.+R.+Wydeauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+3%3A+water-soluble+benzimidazol-2-one+derivatives+with+antiviral+activity+in+vivo&doi=10.1016%2Fj.bmcl.2005.11.109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.11.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.11.109%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DTrehan%26aufirst%3DA.%2BK.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DWyde%26aufirst%3DP.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25203%253A%2520water-soluble%2520benzimidazol-2-one%2520derivatives%2520with%2520antiviral%2520activity%2520in%2520vivo%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1115%26epage%3D1122%26doi%3D10.1016%2Fj.bmcl.2005.11.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Hansch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S. M.</span><span> </span><span class="NLM_article-title">The structure-activity relationship in barbiturates and its similarity to that in other narcotics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1021/jm00317a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00317a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=745-753&author=C.+Hanschauthor=S.+M.+Anderson&title=The+structure-activity+relationship+in+barbiturates+and+its+similarity+to+that+in+other+narcotics&doi=10.1021%2Fjm00317a001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm00317a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00317a001%26sid%3Dliteratum%253Aachs%26aulast%3DHansch%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DS.%2BM.%26atitle%3DThe%2520structure-activity%2520relationship%2520in%2520barbiturates%2520and%2520its%2520similarity%2520to%2520that%2520in%2520other%2520narcotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26spage%3D745%26epage%3D753%26doi%3D10.1021%2Fjm00317a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Hansch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikaitani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, E. J.</span><span> </span><span class="NLM_article-title">″Aromatic″ substituent constants for structure-activity correlations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1207</span><span class="NLM_x">–</span> <span class="NLM_lpage">1216</span><span class="refDoi"> DOI: 10.1021/jm00269a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00269a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaE3sXlt1Wkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1973&pages=1207-1216&author=C.+Hanschauthor=A.+Leoauthor=S.+H.+Ungerauthor=K.+H.+Kimauthor=D.+Nikaitaniauthor=E.+J.+Lien&title=%E2%80%B3Aromatic%E2%80%B3+substituent+constants+for+structure-activity+correlations&doi=10.1021%2Fjm00269a003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatic substituent constants for structure-activity correlations</span></div><div class="casAuthors">Hansch, Corwin; Leo, Albert; Unger, Stefan H.; Kim, Ki Hwai; Nikaitani, Donald; Lien, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1207-16</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The arom. substituent consts. π (lipophilic), σm and σp (electronic), and molar refractivity (steric) were collected from the literature for 236 substituents, including 128 π values and 191 values for which both σm and σp were found.  The field and resonance electronic properties of C. G. Swain and E. C. Lupton (1968) were calcd. for these 191 substituents by a corrected procedure and were essentially orthogonal.  The mutual correlation of σm and σp was high.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLTaEbCgQaX7Vg90H21EOLACvtfcHk0lgu-uG80KTYcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXlt1Wkt7o%253D&md5=e0ee110086f19b9853838f47ba1c1d4d</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm00269a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00269a003%26sid%3Dliteratum%253Aachs%26aulast%3DHansch%26aufirst%3DC.%26aulast%3DLeo%26aufirst%3DA.%26aulast%3DUnger%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DNikaitani%26aufirst%3DD.%26aulast%3DLien%26aufirst%3DE.%2BJ.%26atitle%3D%25E2%2580%25B3Aromatic%25E2%2580%25B3%2520substituent%2520constants%2520for%2520structure-activity%2520correlations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1973%26volume%3D16%26spage%3D1207%26epage%3D1216%26doi%3D10.1021%2Fjm00269a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Patel, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benfield, P.</span><span> </span><span class="NLM_article-title">New drug profile: nevirapine</span> <span class="citation_source-journal">Clin. Immunother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1007/BF03259093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2FBF03259093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=307-317&author=S.+S.+Patelauthor=P.+Benfield&title=New+drug+profile%3A+nevirapine&doi=10.1007%2FBF03259093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2FBF03259093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03259093%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%2BS.%26aulast%3DBenfield%26aufirst%3DP.%26atitle%3DNew%2520drug%2520profile%253A%2520nevirapine%26jtitle%3DClin.%2520Immunother.%26date%3D1996%26volume%3D6%26spage%3D307%26epage%3D317%26doi%3D10.1007%2FBF03259093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Ren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, D. K.</span><span> </span><span class="NLM_article-title">Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1094</span><span class="refDoi"> DOI: 10.1016/S0969-2126(00)00513-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0969-2126%2800%2900513-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=11080630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVOiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=1089-1094&author=J.+Renauthor=J.+Miltonauthor=K.+L.+Weaverauthor=S.+A.+Shortauthor=D.+I.+Stuartauthor=D.+K.+Stammers&title=Structural+basis+for+the+resilience+of+efavirenz+%28DMP-266%29+to+drug+resistance+mutations+in+HIV-1+reverse+transcriptase&doi=10.1016%2FS0969-2126%2800%2900513-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Resilience of Efavirenz (DMP-266) to Drug Resistance Mutations in HIV-1 Reverse Transcriptase</span></div><div class="casAuthors">Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1089-1094</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Background: Efavirenz is a second-generation non-nucleoside inhibitor of HIV-1 reverse transcriptase (RT) that has recently been approved for use against HIV-1 infection.  Compared with first-generation drugs such as nevirapine, efavirenz shows greater resilience to drug resistance mutations within HIV-1 RT.  In order to understand the basis for this resilience at the mol. level and to help the design of further-improved anti-AIDS drugs, the authors have detd. crystal structures of efavirenz and nevirapine with wild-type RT and the clin. important K103N mutant.  Results: The relatively compact efavirenz mol. binds, as expected, within the non-nucleoside inhibitor binding pocket of RT.  There are significant rearrangements of the drug binding site within the mutant RT compared with the wild-type enzyme.  These changes, which lead to the repositioning of the inhibitor, are not seen in the interaction with the first-generation drug nevirapine.  Conclusions: The repositioning of efavirenz within the drug binding pocket of the mutant RT, together with conformational rearrangements in the protein, could represent a general mechanism whereby certain second-generation non-nucleoside inhibitors are able to reduce the effect of drug-resistance mutations on binding potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW53vhU1qR4rVg90H21EOLACvtfcHk0lgu-uG80KTYcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVOiur0%253D&md5=a3349e79d1037c74527b4ced74d33b5c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2800%2900513-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252800%252900513-X%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520resilience%2520of%2520efavirenz%2520%2528DMP-266%2529%2520to%2520drug%2520resistance%2520mutations%2520in%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DStructure%26date%3D2000%26volume%3D8%26spage%3D1089%26epage%3D1094%26doi%3D10.1016%2FS0969-2126%2800%2900513-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Rizzo, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span> </span><span class="NLM_article-title">Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">12898</span><span class="NLM_x">–</span> <span class="NLM_lpage">12900</span><span class="refDoi"> DOI: 10.1021/ja003113r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja003113r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=12898-12900&author=R.+C.+Rizzoauthor=D.+P.+Wangauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Validation+of+a+model+for+the+complex+of+HIV-1+reverse+transcriptase+with+sustiva+through+computation+of+resistance+profiles&doi=10.1021%2Fja003113r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fja003113r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja003113r%26sid%3Dliteratum%253Aachs%26aulast%3DRizzo%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DD.%2BP.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DValidation%2520of%2520a%2520model%2520for%2520the%2520complex%2520of%2520HIV-1%2520reverse%2520transcriptase%2520with%2520sustiva%2520through%2520computation%2520of%2520resistance%2520profiles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D12898%26epage%3D12900%26doi%3D10.1021%2Fja003113r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Daluge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faletto, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Clair, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boone, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisdale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dornsife, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averett, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krenitsky, T. A.</span><span> </span><span class="NLM_article-title">1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1093</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1082-1093&author=S.+M.+Dalugeauthor=S.+S.+Goodauthor=M.+B.+Falettoauthor=W.+H.+Millerauthor=M.+H.+St.+Clairauthor=L.+R.+Booneauthor=M.+Tisdaleauthor=N.+R.+Parryauthor=J.+E.+Reardonauthor=R.+E.+Dornsifeauthor=D.+R.+Averettauthor=T.+A.+Krenitsky&title=1592U89%2C+a+novel+carbocyclic+nucleoside+analog+with+potent%2C+selective+anti-human+immunodeficiency+virus+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaluge%26aufirst%3DS.%2BM.%26aulast%3DGood%26aufirst%3DS.%2BS.%26aulast%3DFaletto%26aufirst%3DM.%2BB.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DSt.%2BClair%26aufirst%3DM.%2BH.%26aulast%3DBoone%26aufirst%3DL.%2BR.%26aulast%3DTisdale%26aufirst%3DM.%26aulast%3DParry%26aufirst%3DN.%2BR.%26aulast%3DReardon%26aufirst%3DJ.%2BE.%26aulast%3DDornsife%26aufirst%3DR.%2BE.%26aulast%3DAverett%26aufirst%3DD.%2BR.%26aulast%3DKrenitsky%26aufirst%3DT.%2BA.%26atitle%3D1592U89%252C%2520a%2520novel%2520carbocyclic%2520nucleoside%2520analog%2520with%2520potent%252C%2520selective%2520anti-human%2520immunodeficiency%2520virus%2520activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26spage%3D1082%26epage%3D1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Lesher, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froelich, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brundage, R. P.</span><span> </span><span class="NLM_article-title">1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents</span> <span class="citation_source-journal">J. Med. Pharm. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1962</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1063</span><span class="NLM_x">–</span> <span class="NLM_lpage">1065</span><span class="refDoi"> DOI: 10.1021/jm01240a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm01240a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaF3sXhs1Ohsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1962&pages=1063-1065&author=G.+Y.+Lesherauthor=E.+J.+Froelichauthor=M.+D.+Gruettauthor=J.+H.+Baileyauthor=R.+P.+Brundage&title=1%2C8-Naphthyridine+derivatives.+A+new+class+of+chemotherapeutic+agents&doi=10.1021%2Fjm01240a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents</span></div><div class="casAuthors">Lesher, George Y.; Froelich, Ernest J.; Gruett, Monte D.; Bailey, John H.; Brundage, R. Pauline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1063-5</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">Six 1-alkyl-1,8-naphthyridines were prepd. from the appropriate 6-substituted-2-aminopyridine for testing against 10 microorganisms.  The most active compd. was3-carboxy-l-ethyl-7-methyl-1,8-naphthyridin-4-one.  The in vivo activity of the compd. was most pronounced against gram-neg. bacteria.  Chemotherapeutic studies in mice showed maximal activity against systemic infections caused by Escherichia coli, Aerobacter aerogenes, Proteus mirabilis, Shigella flexneri, Pasteurella multocida, and Salmonella typhimurium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1T0jx8kJWeLVg90H21EOLACvtfcHk0liw6-aUaKPOHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXhs1Ohsg%253D%253D&md5=4436d03992230c76d547e2d002b54956</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm01240a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm01240a021%26sid%3Dliteratum%253Aachs%26aulast%3DLesher%26aufirst%3DG.%2BY.%26aulast%3DFroelich%26aufirst%3DE.%2BJ.%26aulast%3DGruett%26aufirst%3DM.%2BD.%26aulast%3DBailey%26aufirst%3DJ.%2BH.%26aulast%3DBrundage%26aufirst%3DR.%2BP.%26atitle%3D1%252C8-Naphthyridine%2520derivatives.%2520A%2520new%2520class%2520of%2520chemotherapeutic%2520agents%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1962%26volume%3D5%26spage%3D1063%26epage%3D1065%26doi%3D10.1021%2Fjm01240a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Cornett, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wentland, M. P.</span><span> </span><span class="NLM_article-title">Quinolone antibacterial agents</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">139</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/S0065-7743(08)61124-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0065-7743%2808%2961124-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1986&pages=139-148&author=J.+B.+Cornettauthor=M.+P.+Wentland&title=Quinolone+antibacterial+agents&doi=10.1016%2FS0065-7743%2808%2961124-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2961124-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252961124-0%26sid%3Dliteratum%253Aachs%26aulast%3DCornett%26aufirst%3DJ.%2BB.%26aulast%3DWentland%26aufirst%3DM.%2BP.%26atitle%3DQuinolone%2520antibacterial%2520agents%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D1986%26volume%3D21%26spage%3D139%26epage%3D148%26doi%3D10.1016%2FS0065-7743%2808%2961124-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Wise, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, L. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1128/AAC.23.4.559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1128%2FAAC.23.4.559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=559-564&author=R.+Wiseauthor=J.+M.+Andrewsauthor=L.+J.+Edwards&title=In+vitro+activity+of+Bay+09867%2C+a+new+quinoline+derivative%2C+compared+with+those+of+other+antimicrobial+agents&doi=10.1128%2FAAC.23.4.559"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.23.4.559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.23.4.559%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DJ.%2BM.%26aulast%3DEdwards%26aufirst%3DL.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bay%252009867%252C%2520a%2520new%2520quinoline%2520derivative%252C%2520compared%2520with%2520those%2520of%2520other%2520antimicrobial%2520agents%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1983%26volume%3D23%26spage%3D559%26epage%3D564%26doi%3D10.1128%2FAAC.23.4.559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Sanchez, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domagala, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heifetz, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutt, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trehan, A. K.</span><span> </span><span class="NLM_article-title">Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">991</span><span class="refDoi"> DOI: 10.1021/jm00400a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00400a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1988&pages=983-991&author=J.+P.+Sanchezauthor=J.+M.+Domagalaauthor=S.+E.+Hagenauthor=C.+L.+Heifetzauthor=M.+P.+Huttauthor=J.+B.+Nicholsauthor=A.+K.+Trehan&title=Quinolone+antibacterial+agents.+Synthesis+and+structure-activity+relationships+of+8-substituted+quinoline-3-carboxylic+acids+and+1%2C8-naphthyridine-3-carboxylic+acids&doi=10.1021%2Fjm00400a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm00400a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00400a016%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DJ.%2BP.%26aulast%3DDomagala%26aufirst%3DJ.%2BM.%26aulast%3DHagen%26aufirst%3DS.%2BE.%26aulast%3DHeifetz%26aufirst%3DC.%2BL.%26aulast%3DHutt%26aufirst%3DM.%2BP.%26aulast%3DNichols%26aufirst%3DJ.%2BB.%26aulast%3DTrehan%26aufirst%3DA.%2BK.%26atitle%3DQuinolone%2520antibacterial%2520agents.%2520Synthesis%2520and%2520structure-activity%2520relationships%2520of%25208-substituted%2520quinoline-3-carboxylic%2520acids%2520and%25201%252C8-naphthyridine-3-carboxylic%2520acids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1988%26volume%3D31%26spage%3D983%26epage%3D991%26doi%3D10.1021%2Fjm00400a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Birnbaum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, J. S.</span><span> </span><span class="NLM_article-title">Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/0002-9343(85)90097-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0002-9343%2885%2990097-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=3859213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2MXlvVyrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1985&pages=3-21&author=J.+Birnbaumauthor=F.+M.+Kahanauthor=H.+Kroppauthor=J.+S.+MacDonald&title=Carbapenems%2C+a+new+class+of+beta-lactam+antibiotics.+Discovery+and+development+of+imipenem%2Fcilastatin&doi=10.1016%2F0002-9343%2885%2990097-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Carbapenems, a new class of beta-lactam antibiotics.  Discovery and development of imipenem/cilastatin</span></div><div class="casAuthors">Birnbaum, Jerome; Kahan, Frederick M.; Kropp, Helmut; Macdonald, James S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6A</span>),
    <span class="NLM_cas:pages">3-21</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">A review with 48 refs.  Cilastatin  [82009-34-5], coadministered with imipenem  [64221-86-9] in a 1:1 ratio, provided prolonged, reversible blockade of imipenem metab. and improved urinary recoveries to therapeutically significant levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCNK07atRIa7Vg90H21EOLACvtfcHk0lhEVE6AwvEAvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvVyrtb8%253D&md5=592664766841f1479bae6f0d68b46a50</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2885%2990097-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252885%252990097-X%26sid%3Dliteratum%253Aachs%26aulast%3DBirnbaum%26aufirst%3DJ.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DMacDonald%26aufirst%3DJ.%2BS.%26atitle%3DCarbapenems%252C%2520a%2520new%2520class%2520of%2520beta-lactam%2520antibiotics.%2520Discovery%2520and%2520development%2520of%2520imipenem%252Fcilastatin%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1985%26volume%3D78%26spage%3D3%26epage%3D21%26doi%3D10.1016%2F0002-9343%2885%2990097-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundelof, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, F. M.</span><span> </span><span class="NLM_article-title">Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1128/AAC.22.1.62</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1128%2FAAC.22.1.62" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1982&pages=62-70&author=H.+Kroppauthor=J.+G.+Sundelofauthor=R.+Hajduauthor=F.+M.+Kahan&title=Metabolism+of+thienamycin+and+related+carbapenem+antibiotics+by+the+renal+dipeptidase%2C+dehydropeptidase&doi=10.1128%2FAAC.22.1.62"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FAAC.22.1.62&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.22.1.62%26sid%3Dliteratum%253Aachs%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DSundelof%26aufirst%3DJ.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26atitle%3DMetabolism%2520of%2520thienamycin%2520and%2520related%2520carbapenem%2520antibiotics%2520by%2520the%2520renal%2520dipeptidase%252C%2520dehydropeptidase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1982%26volume%3D22%26spage%3D62%26epage%3D70%26doi%3D10.1128%2FAAC.22.1.62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundelof, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahan, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, J.</span><span> </span><span class="NLM_article-title">MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span><span class="refDoi"> DOI: 10.1128/AAC.17.6.993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1128%2FAAC.17.6.993" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1980&pages=993-1000&author=H.+Kroppauthor=J.+G.+Sundelofauthor=J.+S.+Kahanauthor=F.+M.+Kahanauthor=J.+Birnbaum&title=MK0787+%28N-formimidoyl+thienamycin%29%3A+evaluation+of+in+vitro+and+in+vivo+activities&doi=10.1128%2FAAC.17.6.993"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1128%2FAAC.17.6.993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.17.6.993%26sid%3Dliteratum%253Aachs%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DSundelof%26aufirst%3DJ.%2BG.%26aulast%3DKahan%26aufirst%3DJ.%2BS.%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DBirnbaum%26aufirst%3DJ.%26atitle%3DMK0787%2520%2528N-formimidoyl%2520thienamycin%2529%253A%2520evaluation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520activities%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1980%26volume%3D17%26spage%3D993%26epage%3D1000%26doi%3D10.1128%2FAAC.17.6.993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Kahan, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundelof, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, J.</span><span> </span><span class="NLM_article-title">Thienamycin: development of imipenen-cilastatin</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl D</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1093/jac/12.suppl_D.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1093%2Fjac%2F12.suppl_D.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=6365872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2cXhtlWrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1983&pages=1-35&issue=Suppl+D&author=F.+M.+Kahanauthor=H.+Kroppauthor=J.+G.+Sundelofauthor=J.+Birnbaum&title=Thienamycin%3A+development+of+imipenen-cilastatin&doi=10.1093%2Fjac%2F12.suppl_D.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Thienamycin:  development of imipenem-cilastatin</span></div><div class="casAuthors">Kahan, Frederick M.; Kropp, Helmut; Sundelof, Jon G.; Birnbaum, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">Suppl. D</span>),
    <span class="NLM_cas:pages">1-35, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    </div><div class="casAbstract">A review with 100 refs. on a new antimicrobial combination imipenem (I)  [64221-86-9]-cilastatin (II)  [81129-83-1].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL61M0vyPeObVg90H21EOLACvtfcHk0lhEVE6AwvEAvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhtlWrtL4%253D&md5=d3fe2b99658740ff431bf483206dd554</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F12.suppl_D.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F12.suppl_D.1%26sid%3Dliteratum%253Aachs%26aulast%3DKahan%26aufirst%3DF.%2BM.%26aulast%3DKropp%26aufirst%3DH.%26aulast%3DSundelof%26aufirst%3DJ.%2BG.%26aulast%3DBirnbaum%26aufirst%3DJ.%26atitle%3DThienamycin%253A%2520development%2520of%2520imipenen-cilastatin%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1983%26volume%3D12%26issue%3DSuppl%2520D%26spage%3D1%26epage%3D35%26doi%3D10.1093%2Fjac%2F12.suppl_D.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Liao, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R. Z.</span><span> </span><span class="NLM_article-title">Dipeptide hydrolysis by the dinuclear zinc enzyme human renal dipeptidase: mechanistic insights from DFT calculations</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2009.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.jinorgbio.2009.09.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=37-46&author=R.+Z.+Liaoauthor=F.+Himoauthor=J.+G.+Yuauthor=R.+Z.+Liu&title=Dipeptide+hydrolysis+by+the+dinuclear+zinc+enzyme+human+renal+dipeptidase%3A+mechanistic+insights+from+DFT+calculations&doi=10.1016%2Fj.jinorgbio.2009.09.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2009.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2009.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DR.%2BZ.%26aulast%3DHimo%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DJ.%2BG.%26aulast%3DLiu%26aufirst%3DR.%2BZ.%26atitle%3DDipeptide%2520hydrolysis%2520by%2520the%2520dinuclear%2520zinc%2520enzyme%2520human%2520renal%2520dipeptidase%253A%2520mechanistic%2520insights%2520from%2520DFT%2520calculations%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2010%26volume%3D104%26spage%3D37%26epage%3D46%26doi%3D10.1016%2Fj.jinorgbio.2009.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Nitanai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satow, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujimoto, M.</span><span> </span><span class="NLM_article-title">Crystal structure of human renal dipeptidase involved in beta-lactam hydrolysis</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1016/S0022-2836(02)00632-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0022-2836%2802%2900632-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2002&pages=177-184&author=Y.+Nitanaiauthor=Y.+Satowauthor=H.+Adachiauthor=M.+Tsujimoto&title=Crystal+structure+of+human+renal+dipeptidase+involved+in+beta-lactam+hydrolysis&doi=10.1016%2FS0022-2836%2802%2900632-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2802%2900632-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252802%252900632-0%26sid%3Dliteratum%253Aachs%26aulast%3DNitanai%26aufirst%3DY.%26aulast%3DSatow%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DH.%26aulast%3DTsujimoto%26aufirst%3DM.%26atitle%3DCrystal%2520structure%2520of%2520human%2520renal%2520dipeptidase%2520involved%2520in%2520beta-lactam%2520hydrolysis%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2002%26volume%3D321%26spage%3D177%26epage%3D184%26doi%3D10.1016%2FS0022-2836%2802%2900632-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Smyth, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitanai, Y.</span><span> </span><span class="NLM_article-title">A substrate variant as a high-affinity, reversible inhibitor: insight from the x-ray structure of cilastatin bound to membrane dipeptidase</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">998</span><span class="refDoi"> DOI: 10.1016/S0968-0896(02)00519-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0968-0896%2802%2900519-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=991-998&author=T.+P.+Smythauthor=J.+G.+Wallauthor=Y.+Nitanai&title=A+substrate+variant+as+a+high-affinity%2C+reversible+inhibitor%3A+insight+from+the+x-ray+structure+of+cilastatin+bound+to+membrane+dipeptidase&doi=10.1016%2FS0968-0896%2802%2900519-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900519-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900519-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DT.%2BP.%26aulast%3DWall%26aufirst%3DJ.%2BG.%26aulast%3DNitanai%26aufirst%3DY.%26atitle%3DA%2520substrate%2520variant%2520as%2520a%2520high-affinity%252C%2520reversible%2520inhibitor%253A%2520insight%2520from%2520the%2520x-ray%2520structure%2520of%2520cilastatin%2520bound%2520to%2520membrane%2520dipeptidase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D991%26epage%3D998%26doi%3D10.1016%2FS0968-0896%2802%2900519-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizizad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2233</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0lgwnkoFC99INg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Hohlfeld, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfeld, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavae-Mokhtari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredenbroeker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krug, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, R.</span><span> </span><span class="NLM_article-title">Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">623</span><span class="refDoi"> DOI: 10.1016/j.pupt.2008.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.pupt.2008.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18374614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslWntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=616-623&author=J.+M.+Hohlfeldauthor=K.+Schoenfeldauthor=M.+Lavae-Mokhtariauthor=F.+Schaumannauthor=M.+Muellerauthor=D.+Bredenbroekerauthor=N.+Krugauthor=R.+Hermann&title=Roflumilast+attenuates+pulmonary+inflammation+upon+segmental+endotoxin+challenge+in+healthy+subjects%3A+a+randomized+placebo-controlled+trial&doi=10.1016%2Fj.pupt.2008.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial</span></div><div class="casAuthors">Hohlfeld, Jens M.; Schoenfeld, Kerstin; Lavae-Mokhtari, Mehyar; Schaumann, Frank; Mueller, Meike; Bredenbroeker, Dirk; Krug, Norbert; Hermann, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">616-623</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Roflumilast, an investigational, targeted phosphodiesterase 4 inhibitor, reduces the in vitro and in vivo inflammatory activity of cells such as neutrophils, eosinophils, macrophages, and monocytes.  The aim of this study was to explore the anti-inflammatory properties of roflumilast in a human model of segmental bronchial endotoxin challenge.  In a randomized, placebo-controlled, double-blind, single-center parallel-group study, 37 healthy subjects of either sex were treated for 28 days with either oral roflumilast 500 μg once daily or placebo.  At day 29, a baseline bronchoalveolar lavage was performed, followed by segmental endotoxin challenge (4 ng/kg) and saline control challenge.  After 24 h, bronchoalveolar lavage fluid was sampled from the challenged segments and cells were counted and differentiated.  After endotoxin challenge, influx of total cells (difference from baseline) in bronchoalveolar lavage of roflumilast-treated subjects was 36% lower than with placebo (p=0.02).  Correspondingly, the influx of neutrophils and eosinophils of roflumilast-treated subjects was 39% (p=0.02) and 74% (p=0.01) lower than with placebo, resp.  In contrast, endotoxin-induced influx of monocytes was not different between roflumilast- and placebo-treated subjects.  No significant differences existed between the groups pertaining to endotoxin-induced influx of macrophages and lymphocytes.  Roflumilast was well tolerated.  No unexpected or serious treatment-emergent signs and symptoms were obsd.  Roflumilast attenuated the endotoxin-induced influx of neutrophils and eosinophils into the airways.  This study demonstrates the anti-inflammatory properties of roflumilast on bronchoalveolar granulocytes in endotoxin-induced airway inflammation in healthy subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6bLT7qqY5KbVg90H21EOLACvtfcHk0lgwnkoFC99INg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslWntbg%253D&md5=fdeef042b32e68e44cbed0b1d2b411bc</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2008.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2008.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DHohlfeld%26aufirst%3DJ.%2BM.%26aulast%3DSchoenfeld%26aufirst%3DK.%26aulast%3DLavae-Mokhtari%26aufirst%3DM.%26aulast%3DSchaumann%26aufirst%3DF.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DBredenbroeker%26aufirst%3DD.%26aulast%3DKrug%26aufirst%3DN.%26aulast%3DHermann%26aufirst%3DR.%26atitle%3DRoflumilast%2520attenuates%2520pulmonary%2520inflammation%2520upon%2520segmental%2520endotoxin%2520challenge%2520in%2520healthy%2520subjects%253A%2520a%2520randomized%2520placebo-controlled%2520trial%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D21%26spage%3D616%26epage%3D623%26doi%3D10.1016%2Fj.pupt.2008.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Labelle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gareau, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarlane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metters, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouimet, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piechuta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochette, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford-Hutchinson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span> </span><span class="NLM_article-title">Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonists devoid of peroxisomal enzyme induction</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00023-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0960-894X%2895%2900023-M" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=283-288&author=M.+Labelleauthor=M.+Belleyauthor=Y.+Gareauauthor=J.+Y.+Gauthierauthor=D.+Guayauthor=R.+Gordonauthor=S.+G.+Grossmanauthor=T.+R.+Jonesauthor=Y.+Leblancauthor=M.+McAuliffeauthor=C.+McFarlaneauthor=P.+Massonauthor=K.+M.+Mettersauthor=N.+Ouimetauthor=D.+H.+Patrickauthor=H.+Piechutaauthor=C.+Rochetteauthor=N.+Sawyerauthor=Y.+B.+Xiangauthor=C.+B.+Pickettauthor=A.+W.+Ford-Hutchinsonauthor=R.+J.+Zamboniauthor=R.+N.+Young&title=Discovery+of+MK-0476%2C+a+potent+and+orally+active+leukotriene+D4+receptor+antagonists+devoid+of+peroxisomal+enzyme+induction&doi=10.1016%2F0960-894X%2895%2900023-M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900023-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900023-M%26sid%3Dliteratum%253Aachs%26aulast%3DLabelle%26aufirst%3DM.%26aulast%3DBelley%26aufirst%3DM.%26aulast%3DGareau%26aufirst%3DY.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGrossman%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DT.%2BR.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DMcAuliffe%26aufirst%3DM.%26aulast%3DMcFarlane%26aufirst%3DC.%26aulast%3DMasson%26aufirst%3DP.%26aulast%3DMetters%26aufirst%3DK.%2BM.%26aulast%3DOuimet%26aufirst%3DN.%26aulast%3DPatrick%26aufirst%3DD.%2BH.%26aulast%3DPiechuta%26aufirst%3DH.%26aulast%3DRochette%26aufirst%3DC.%26aulast%3DSawyer%26aufirst%3DN.%26aulast%3DXiang%26aufirst%3DY.%2BB.%26aulast%3DPickett%26aufirst%3DC.%2BB.%26aulast%3DFord-Hutchinson%26aufirst%3DA.%2BW.%26aulast%3DZamboni%26aufirst%3DR.%2BJ.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26atitle%3DDiscovery%2520of%2520MK-0476%252C%2520a%2520potent%2520and%2520orally%2520active%2520leukotriene%2520D4%2520receptor%2520antagonists%2520devoid%2520of%2520peroxisomal%2520enzyme%2520induction%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D283%26epage%3D288%26doi%3D10.1016%2F0960-894X%2895%2900023-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Holgate, S. T.</span><span> </span><span class="NLM_article-title">The quintiles prize lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1015</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0706272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fsj.bjp.0706272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15980878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2005&pages=1009-1015&author=S.+T.+Holgate&title=The+quintiles+prize+lecture+2004.+The+identification+of+the+adenosine+A2B+receptor+as+a+novel+therapeutic+target+in+asthma&doi=10.1038%2Fsj.bjp.0706272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">The Quintiles Prize Lecture 2004: The identification of the adenosine A2B receptor as a novel therapeutic target in asthma</span></div><div class="casAuthors">Holgate, Stephen T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1009-1015</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine is a powerful bronchoconstrictor of asthmatic, but not normal, airways.  In vitro studies on isolated human mast cells and basophils revealed that adenosine and selective analogs augmented inflammatory mediator release from mast cells by stimulating A2 receptors.  Pharmacol. blockade of mast cell mediator release in vivo also attenuated adenosine-induced bronchoconstriction, as did theophylline, by adenosine A2 receptor antagonism.  Further in vitro studies revealed that the asthmatic response to adenosine is likely to be mediated via the A2B subtype which is selectively antagonized by enprofylline.  Studies in animal models, esp. mice, have shown a close synergistic interaction between adenosine, Th2 and airway remodelling responses.  The recent description of A2B receptors on human airway smooth muscle cells that mediate cytokine and chemokine release and induce differentiation of fibroblasts into myofibroblasts strengthens the view that adenosine maybe more than an inflammatory mediator in asthma but also participates in airway wall remodelling in this disease.  These data have provided a firm basis for developing adenosine A2B receptor antagonists as a new therapeutic approach to this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGLJSncqFzDrVg90H21EOLACvtfcHk0liKgUVmWU5sFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Wrsbo%253D&md5=864c391c58206f15fe4f818d600385b7</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706272%26sid%3Dliteratum%253Aachs%26aulast%3DHolgate%26aufirst%3DS.%2BT.%26atitle%3DThe%2520quintiles%2520prize%2520lecture%25202004.%2520The%2520identification%2520of%2520the%2520adenosine%2520A2B%2520receptor%2520as%2520a%2520novel%2520therapeutic%2520target%2520in%2520asthma%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D145%26spage%3D1009%26epage%3D1015%26doi%3D10.1038%2Fsj.bjp.0706272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Eastwood, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteve, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonquerna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiguade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carranco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domenech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordoba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godessart, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loza, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadavid, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nueda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, B.</span><span> </span><span class="NLM_article-title">Discovery of LAS101057: a potent, selective, and orally efficacious A2B adenosine receptor antagonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1021/ml100249e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100249e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=213-218&author=P.+Eastwoodauthor=C.+Esteveauthor=J.+Gonzalezauthor=S.+Fonquernaauthor=J.+Aiguadeauthor=I.+Carrancoauthor=T.+Domenechauthor=M.+Apariciauthor=M.+Miralpeixauthor=J.+Albertiauthor=M.+Cordobaauthor=R.+Fernandezauthor=M.+Pontauthor=N.+Godessartauthor=N.+Pratsauthor=M.+I.+Lozaauthor=M.+I.+Cadavidauthor=A.+Nuedaauthor=B.+Vidal&title=Discovery+of+LAS101057%3A+a+potent%2C+selective%2C+and+orally+efficacious+A2B+adenosine+receptor+antagonist&doi=10.1021%2Fml100249e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fml100249e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100249e%26sid%3Dliteratum%253Aachs%26aulast%3DEastwood%26aufirst%3DP.%26aulast%3DEsteve%26aufirst%3DC.%26aulast%3DGonzalez%26aufirst%3DJ.%26aulast%3DFonquerna%26aufirst%3DS.%26aulast%3DAiguade%26aufirst%3DJ.%26aulast%3DCarranco%26aufirst%3DI.%26aulast%3DDomenech%26aufirst%3DT.%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DAlberti%26aufirst%3DJ.%26aulast%3DCordoba%26aufirst%3DM.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DPont%26aufirst%3DM.%26aulast%3DGodessart%26aufirst%3DN.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DCadavid%26aufirst%3DM.%2BI.%26aulast%3DNueda%26aufirst%3DA.%26aulast%3DVidal%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520LAS101057%253A%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520A2B%2520adenosine%2520receptor%2520antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D213%26epage%3D218%26doi%3D10.1021%2Fml100249e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0liKgUVmWU5sFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaynor, R. B.</span><span> </span><span class="NLM_article-title">IkappaB kinases: key regulators of the NF-kappaB pathway</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.tibs.2003.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.tibs.2003.12.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=72-79&author=Y.+Yamamotoauthor=R.+B.+Gaynor&title=IkappaB+kinases%3A+key+regulators+of+the+NF-kappaB+pathway&doi=10.1016%2Fj.tibs.2003.12.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2003.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2003.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DGaynor%26aufirst%3DR.%2BB.%26atitle%3DIkappaB%2520kinases%253A%2520key%2520regulators%2520of%2520the%2520NF-kappaB%2520pathway%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2004%26volume%3D29%26spage%3D72%26epage%3D79%26doi%3D10.1016%2Fj.tibs.2003.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baud, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhase, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deerinck, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellisman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span> </span><span class="NLM_article-title">Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.1126/science.284.5412.316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1126%2Fscience.284.5412.316" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1999&pages=316-320&author=Y.+Huauthor=V.+Baudauthor=M.+Delhaseauthor=P.+Zhangauthor=T.+Deerinckauthor=M.+Ellismanauthor=R.+Johnsonauthor=M.+Karin&title=Abnormal+morphogenesis+but+intact+IKK+activation+in+mice+lacking+the+IKKalpha+subunit+of+IkappaB+kinase&doi=10.1126%2Fscience.284.5412.316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscience.284.5412.316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.284.5412.316%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DBaud%26aufirst%3DV.%26aulast%3DDelhase%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DDeerinck%26aufirst%3DT.%26aulast%3DEllisman%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DR.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DAbnormal%2520morphogenesis%2520but%2520intact%2520IKK%2520activation%2520in%2520mice%2520lacking%2520the%2520IKKalpha%2520subunit%2520of%2520IkappaB%2520kinase%26jtitle%3DScience%26date%3D1999%26volume%3D284%26spage%3D316%26epage%3D320%26doi%3D10.1126%2Fscience.284.5412.316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Strnad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span> </span><span class="NLM_article-title">IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.tips.2007.01.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=142-148&author=J.+Strnadauthor=J.+R.+Burke&title=IkappaB+kinase+inhibitors+for+treating+autoimmune+and+inflammatory+disorders%3A+potential+and+challenges&doi=10.1016%2Fj.tips.2007.01.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DIkappaB%2520kinase%2520inhibitors%2520for%2520treating%2520autoimmune%2520and%2520inflammatory%2520disorders%253A%2520potential%2520and%2520challenges%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D142%26epage%3D148%26doi%3D10.1016%2Fj.tips.2007.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Liddle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousins, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez-Molina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumsey, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tape, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicentini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitworth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, R. A.</span><span> </span><span class="NLM_article-title">4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5222</span><span class="NLM_x">–</span> <span class="NLM_lpage">5226</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2012.06.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22801646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCjsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=5222-5226&author=J.+Liddleauthor=P.+Bamboroughauthor=M.+D.+Barkerauthor=S.+Camposauthor=C.+W.+Chungauthor=R.+P.+Cousinsauthor=P.+Faulderauthor=M.+L.+Heathcoteauthor=H.+Hobbsauthor=D.+S.+Holmesauthor=C.+Ioannouauthor=C.+Ramirez-Molinaauthor=M.+A.+Morseauthor=R.+Osbornauthor=J.+J.+Payneauthor=J.+M.+Pritchardauthor=W.+L.+Rumseyauthor=D.+T.+Tapeauthor=G.+Vicentiniauthor=C.+Whitworthauthor=R.+A.+Williamson&title=4-Phenyl-7-azaindoles+as+potent%2C+selective+and+bioavailable+IKK2+inhibitors+demonstrating+good+in+vivo+efficacy&doi=10.1016%2Fj.bmcl.2012.06.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy</span></div><div class="casAuthors">Liddle, John; Bamborough, Paul; Barker, Michael D.; Campos, Sebastien; Chung, Chun-Wa; Cousins, Rick P. C.; Faulder, Paul; Heathcote, Michelle L.; Hobbs, Heather; Holmes, Duncan S.; Ioannou, Chris; Ramirez-Molina, Cesar; Morse, Mary A.; Osborn, Ruth; Payne, Jeremy J.; Pritchard, John M.; Rumsey, William L.; Tape, Daniel T.; Vicentini, Giorgia; Whitworth, Caroline; Williamson, Rick A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5222-5226</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The lead optimization of a series of potent azaindole IKK2 inhibitors is described.  Optimization of the human whole blood activity and selectivity over IKK1 in parallel led to the discovery of 16, a potent and selective IKK2 inhibitor showing good efficacy in a rat model of neutrophil activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDgiw_Aw0Bc7Vg90H21EOLACvtfcHk0ljD8wAu6wOseA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCjsbvE&md5=0cf65e328cf53e8ba1f72b1f08ad22bf</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.065%26sid%3Dliteratum%253Aachs%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBarker%26aufirst%3DM.%2BD.%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DCousins%26aufirst%3DR.%2BP.%26aulast%3DFaulder%26aufirst%3DP.%26aulast%3DHeathcote%26aufirst%3DM.%2BL.%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DIoannou%26aufirst%3DC.%26aulast%3DRamirez-Molina%26aufirst%3DC.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26aulast%3DOsborn%26aufirst%3DR.%26aulast%3DPayne%26aufirst%3DJ.%2BJ.%26aulast%3DPritchard%26aufirst%3DJ.%2BM.%26aulast%3DRumsey%26aufirst%3DW.%2BL.%26aulast%3DTape%26aufirst%3DD.%2BT.%26aulast%3DVicentini%26aufirst%3DG.%26aulast%3DWhitworth%26aufirst%3DC.%26aulast%3DWilliamson%26aufirst%3DR.%2BA.%26atitle%3D4-Phenyl-7-azaindoles%2520as%2520potent%252C%2520selective%2520and%2520bioavailable%2520IKK2%2520inhibitors%2520demonstrating%2520good%2520in%2520vivo%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D5222%26epage%3D5226%26doi%3D10.1016%2Fj.bmcl.2012.06.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Herlaar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, Z.</span><span> </span><span class="NLM_article-title">P38 MAPK signalling cascades in inflammatory disease</span> <span class="citation_source-journal">Mol. Med. Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1016/S1357-4310(99)01544-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS1357-4310%2899%2901544-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10498912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=439-447&author=E.+Herlaarauthor=Z.+Brown&title=P38+MAPK+signalling+cascades+in+inflammatory+disease&doi=10.1016%2FS1357-4310%2899%2901544-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAPK signalling cascades in inflammatory disease</span></div><div class="casAuthors">Herlaar, E.; Brown, Z.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Today</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">439-447</span>CODEN:
                <span class="NLM_cas:coden">MMTOFK</span>;
        ISSN:<span class="NLM_cas:issn">1357-4310</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 44 refs.  Inflammatory mediators released during acute and chronic diseases activate multiple intracellular signaling cascades including the mitogen-activated protein kinase (MAPK) signal transduction pathway, which plays a significant role in the recruitment of leukocytes to sites of inflammation.  Stimulation of leukocytes by pro-inflammatory cytokines is known to result in the activation of the MAPK isoform p38.  However, the functional consequences of p38 MAPK activation during leukocyte recruitment, including adhesion, migration and effector functions such as oxidative burst and degranulation, are only just beginning to be elucidated.  Specific p38 inhibitors aimed at reducing the prodn. of inflammatory mediators are now being developed, and might in the future provide more effective treatment for inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIhoJ67g0sRrVg90H21EOLACvtfcHk0ljD8wAu6wOseA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWiu7g%253D&md5=3bf8c8ba39b01b5a3188d75b06107709</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS1357-4310%2899%2901544-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-4310%252899%252901544-0%26sid%3Dliteratum%253Aachs%26aulast%3DHerlaar%26aufirst%3DE.%26aulast%3DBrown%26aufirst%3DZ.%26atitle%3DP38%2520MAPK%2520signalling%2520cascades%2520in%2520inflammatory%2520disease%26jtitle%3DMol.%2520Med.%2520Today%26date%3D1999%26volume%3D5%26spage%3D439%26epage%3D447%26doi%3D10.1016%2FS1357-4310%2899%2901544-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Angell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBoeck, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laine, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span> </span><span class="NLM_article-title">Biphenyl amide p38 kinase inhibitors 3: improvement of cellular and in vivo activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4432</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.06.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.06.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18614366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVequ7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4428-4432&author=R.+Angellauthor=N.+M.+Astonauthor=P.+Bamboroughauthor=J.+B.+Bucktonauthor=S.+Cockerillauthor=S.+J.+deBoeckauthor=C.+D.+Edwardsauthor=D.+S.+Holmesauthor=K.+L.+Jonesauthor=D.+I.+Laineauthor=S.+Patelauthor=P.+A.+Smeeauthor=K.+J.+Smithauthor=D.+O.+Somersauthor=A.+L.+Walker&title=Biphenyl+amide+p38+kinase+inhibitors+3%3A+improvement+of+cellular+and+in+vivo+activity&doi=10.1016%2Fj.bmcl.2008.06.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity</span></div><div class="casAuthors">Angell, Richard; Aston, Nicola M.; Bamborough, Paul; Buckton, Jacky B.; Cockerill, Stuart; de Boeck, Suzanne J.; Edwards, Chris D.; Holmes, Duncan S.; Jones, Katherine L.; Laine, Dramane I.; Patel, Shila; Smee, Penny A.; Smith, Kathryn J.; Somers, Don O.; Walker, Ann L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4428-4432</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The biphenyl amides (BPAs) are a novel series of p38α MAP kinase inhibitor.  The optimization of the series to give compds. that are potent in an in vivo disease model is discussed.  SAR is presented and rationalised with ref. to the crystallog. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXT0cyGCATNLVg90H21EOLACvtfcHk0liTzf5HFX_i6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVequ7c%253D&md5=89ae52223f0cffd31df2b0d830d40ec5</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.048%26sid%3Dliteratum%253Aachs%26aulast%3DAngell%26aufirst%3DR.%26aulast%3DAston%26aufirst%3DN.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBuckton%26aufirst%3DJ.%2BB.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DdeBoeck%26aufirst%3DS.%2BJ.%26aulast%3DEdwards%26aufirst%3DC.%2BD.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DLaine%26aufirst%3DD.%2BI.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSmee%26aufirst%3DP.%2BA.%26aulast%3DSmith%26aufirst%3DK.%2BJ.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26atitle%3DBiphenyl%2520amide%2520p38%2520kinase%2520inhibitors%25203%253A%2520improvement%2520of%2520cellular%2520and%2520in%2520vivo%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4428%26epage%3D4432%26doi%3D10.1016%2Fj.bmcl.2008.06.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Aston, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamborough, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somers, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitulli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span> </span><span class="NLM_article-title">P38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6257</span><span class="NLM_x">–</span> <span class="NLM_lpage">6269</span><span class="refDoi"> DOI: 10.1021/jm9004779</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004779" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6257-6269&author=N.+M.+Astonauthor=P.+Bamboroughauthor=J.+B.+Bucktonauthor=C.+D.+Edwardsauthor=D.+S.+Holmesauthor=K.+L.+Jonesauthor=V.+K.+Patelauthor=P.+A.+Smeeauthor=D.+O.+Somersauthor=G.+Vitulliauthor=A.+L.+Walker&title=P38alpha+mitogen-activated+protein+kinase+inhibitors%3A+optimization+of+a+series+of+biphenylamides+to+give+a+molecule+suitable+for+clinical+progression&doi=10.1021%2Fjm9004779"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm9004779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004779%26sid%3Dliteratum%253Aachs%26aulast%3DAston%26aufirst%3DN.%2BM.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DBuckton%26aufirst%3DJ.%2BB.%26aulast%3DEdwards%26aufirst%3DC.%2BD.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DPatel%26aufirst%3DV.%2BK.%26aulast%3DSmee%26aufirst%3DP.%2BA.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26atitle%3DP38alpha%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%253A%2520optimization%2520of%2520a%2520series%2520of%2520biphenylamides%2520to%2520give%2520a%2520molecule%2520suitable%2520for%2520clinical%2520progression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6257%26epage%3D6269%26doi%3D10.1021%2Fjm9004779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Felices, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, L. J.</span><span> </span><span class="NLM_article-title">Tec kinases in T cell and mast cell signaling</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1016/S0065-2776(06)93004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0065-2776%2806%2993004-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=145-184&author=M.+Felicesauthor=M.+Falkauthor=Y.+Kosakaauthor=L.+J.+Berg&title=Tec+kinases+in+T+cell+and+mast+cell+signaling&doi=10.1016%2FS0065-2776%2806%2993004-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2806%2993004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252806%252993004-1%26sid%3Dliteratum%253Aachs%26aulast%3DFelices%26aufirst%3DM.%26aulast%3DFalk%26aufirst%3DM.%26aulast%3DKosaka%26aufirst%3DY.%26aulast%3DBerg%26aufirst%3DL.%2BJ.%26atitle%3DTec%2520kinases%2520in%2520T%2520cell%2520and%2520mast%2520cell%2520signaling%26jtitle%3DAdv.%2520Immunol.%26date%3D2007%26volume%3D93%26spage%3D145%26epage%3D184%26doi%3D10.1016%2FS0065-2776%2806%2993004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Sahu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">August, A.</span><span> </span><span class="NLM_article-title">Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine-mediated migration</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">3833</span><span class="NLM_x">–</span> <span class="NLM_lpage">3838</span><span class="refDoi"> DOI: 10.4049/jimmunol.180.6.3833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.4049%2Fjimmunol.180.6.3833" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=3833-3838&author=N.+Sahuauthor=C.+Muellerauthor=A.+Fischerauthor=A.+August&title=Differential+sensitivity+to+Itk+kinase+signals+for+T+helper+2+cytokine+production+and+chemokine-mediated+migration&doi=10.4049%2Fjimmunol.180.6.3833"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.180.6.3833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.180.6.3833%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DN.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DA.%26aulast%3DAugust%26aufirst%3DA.%26atitle%3DDifferential%2520sensitivity%2520to%2520Itk%2520kinase%2520signals%2520for%2520T%2520helper%25202%2520cytokine%2520production%2520and%2520chemokine-mediated%2520migration%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D3833%26epage%3D3838%26doi%3D10.4049%2Fjimmunol.180.6.3833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Burch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brookfield, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellebrandt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismaili, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kordt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwan, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span> </span><span class="NLM_article-title">Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5714</span><span class="NLM_x">–</span> <span class="NLM_lpage">5727</span><span class="refDoi"> DOI: 10.1021/jm500550e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500550e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Srtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5714-5727&author=J.+D.+Burchauthor=K.+Lauauthor=J.+J.+Barkerauthor=F.+Brookfieldauthor=Y.+Chenauthor=Y.+Chenauthor=C.+Eigenbrotauthor=C.+Ellebrandtauthor=M.+H.+Ismailiauthor=A.+Johnsonauthor=D.+Kordtauthor=C.+H.+MacKinnonauthor=P.+A.+McEwanauthor=D.+F.+Ortwineauthor=D.+B.+Steinauthor=X.+Wangauthor=D.+Winklerauthor=P.+W.+Yuenauthor=Y.+Zhangauthor=A.+A.+Zarrinauthor=Z.+Pei&title=Property-+and+structure-guided+discovery+of+a+tetrahydroindazole+series+of+interleukin-2+inducible+T-cell+kinase+inhibitors&doi=10.1021%2Fjm500550e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors</span></div><div class="casAuthors">Burch, Jason D.; Lau, Kevin; Barker, John J.; Brookfield, Fred; Chen, Yong; Chen, Yuan; Eigenbrot, Charles; Ellebrandt, Claire; Ismaili, M. Hicham A.; Johnson, Adam; Kordt, Daniel; MacKinnon, Colin H.; McEwan, Paul A.; Ortwine, Daniel F.; Stein, Daniel B.; Wang, Xiaolu; Winkler, Dirk; Yuen, Po-Wai; Zhang, Yamin; Zarrin, Ali A.; Pei, Zhonghua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5714-5727</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interleukin-2 inducible T-cell kinase (ITK), a member of the Tec family of tyrosine kinases, plays a major role in T-cell signaling downstream of the T-cell receptor (TCR), and considerable efforts have been directed toward discovery of ITK-selective inhibitors as potential treatments of inflammatory disorders such as asthma.  Using a previously disclosed indazole series of inhibitors as a starting point, and using x-ray crystallog. and soly. forecast index (SFI) as guides, we evolved a series of tetrahydroindazole inhibitors with improved potency, selectivity, and pharmaceutical properties.  Highlights include identification of a selectivity pocket above the ligand plane, and identification of appropriate lipophilic substituents to occupy this space.  This effort culminated in identification of a potent and selective ITK inhibitor (GNE-9822) with good ADME properties in preclin. species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdD-rop1z7rVg90H21EOLACvtfcHk0liTzf5HFX_i6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Srtrs%253D&md5=636420d73f6ad55bf5391b6c6aeb3dbd</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm500550e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500550e%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DBarker%26aufirst%3DJ.%2BJ.%26aulast%3DBrookfield%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllebrandt%26aufirst%3DC.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKordt%26aufirst%3DD.%26aulast%3DMacKinnon%26aufirst%3DC.%2BH.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DStein%26aufirst%3DD.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWinkler%26aufirst%3DD.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DProperty-%2520and%2520structure-guided%2520discovery%2520of%2520a%2520tetrahydroindazole%2520series%2520of%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5714%26epage%3D5727%26doi%3D10.1021%2Fjm500550e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Burch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismaili, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwan, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellebrandt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kordt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span> </span><span class="NLM_article-title">Tetrahydroindazoles as interleukin-2 inducible T-cell kinase inhibitors. Part II. Second-generation analogues with enhanced potency, selectivity, and pharmacodynamic modulation in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3806</span><span class="NLM_x">–</span> <span class="NLM_lpage">3816</span><span class="refDoi"> DOI: 10.1021/jm501998m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501998m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3806-3816&author=J.+D.+Burchauthor=K.+Barrettauthor=Y.+Chenauthor=J.+DeVossauthor=C.+Eigenbrotauthor=R.+Goldsmithauthor=M.+H.+Ismailiauthor=K.+Lauauthor=Z.+Linauthor=D.+F.+Ortwineauthor=A.+A.+Zarrinauthor=P.+A.+McEwanauthor=J.+J.+Barkerauthor=C.+Ellebrandtauthor=D.+Kordtauthor=D.+B.+Steinauthor=X.+Wangauthor=Y.+Chenauthor=B.+Huauthor=X.+Xuauthor=P.+W.+Yuenauthor=Y.+Zhangauthor=Z.+Pei&title=Tetrahydroindazoles+as+interleukin-2+inducible+T-cell+kinase+inhibitors.+Part+II.+Second-generation+analogues+with+enhanced+potency%2C+selectivity%2C+and+pharmacodynamic+modulation+in+vivo&doi=10.1021%2Fjm501998m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo</span></div><div class="casAuthors">Burch, Jason D.; Barrett, Kathy; Chen, Yuan; DeVoss, Jason; Eigenbrot, Charles; Goldsmith, Richard; Ismaili, M. Hicham A.; Lau, Kevin; Lin, Zhonghua; Ortwine, Daniel F.; Zarrin, Ali A.; McEwan, Paul A.; Barker, John J.; Ellebrandt, Claire; Kordt, Daniel; Stein, Daniel B.; Wang, Xiaolu; Chen, Yong; Hu, Baihua; Xu, Xiaofeng; Yuen, Po-Wai; Zhang, Yamin; Pei, Zhonghua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3806-3816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.  The authors have previously disclosed a structure- and property-guided lead optimization effort which resulted in the discovery of a new series of tetrahydroindazole-contg. selective ITK inhibitors.  Herein the authors disclose further optimization of this series that resulted in further potency improvements, reduced off-target receptor binding liabilities, and reduced cytotoxicity.  Specifically, the authors have identified a correlation between the basicity of solubilizing elements in the ITK inhibitors and off-target antiproliferative effects, which was exploited to reduce cytotoxicity while maintaining kinase selectivity.  Optimized analogs, e.g. I, were shown to reduce IL-2 and IL-13 prodn. in vivo following oral or i.p. dosing in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9z-34VWYnsbVg90H21EOLACvtfcHk0li2Om4h10bzPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVaktbo%253D&md5=59a2cd1c2c9d368f9b49344af9b75545</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm501998m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501998m%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DIsmaili%26aufirst%3DM.%2BH.%26aulast%3DLau%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DZarrin%26aufirst%3DA.%2BA.%26aulast%3DMcEwan%26aufirst%3DP.%2BA.%26aulast%3DBarker%26aufirst%3DJ.%2BJ.%26aulast%3DEllebrandt%26aufirst%3DC.%26aulast%3DKordt%26aufirst%3DD.%26aulast%3DStein%26aufirst%3DD.%2BB.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DZ.%26atitle%3DTetrahydroindazoles%2520as%2520interleukin-2%2520inducible%2520T-cell%2520kinase%2520inhibitors.%2520Part%2520II.%2520Second-generation%2520analogues%2520with%2520enhanced%2520potency%252C%2520selectivity%252C%2520and%2520pharmacodynamic%2520modulation%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3806%26epage%3D3816%26doi%3D10.1021%2Fjm501998m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Engelhardt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Esch, I. J.</span><span> </span><span class="NLM_article-title">A new generation of anti-histamines: histamine H4 receptor antagonists on their way to the clinic</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Devel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=628-643&author=H.+Engelhardtauthor=R.+A.+Smitsauthor=R.+Leursauthor=E.+Haaksmaauthor=I.+J.+de+Esch&title=A+new+generation+of+anti-histamines%3A+histamine+H4+receptor+antagonists+on+their+way+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DSmits%26aufirst%3DR.%2BA.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%26atitle%3DA%2520new%2520generation%2520of%2520anti-histamines%253A%2520histamine%2520H4%2520receptor%2520antagonists%2520on%2520their%2520way%2520to%2520the%2520clinic%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2009%26volume%3D12%26spage%3D628%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Mowbray, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paradowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenck, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span> </span><span class="NLM_article-title">Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6596</span><span class="NLM_x">–</span> <span class="NLM_lpage">6602</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2011.07.125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6596-6602&author=C.+E.+Mowbrayauthor=A.+S.+Bellauthor=N.+P.+Clarkeauthor=M.+Collinsauthor=R.+M.+Jonesauthor=C.+A.+Laneauthor=W.+L.+Liuauthor=S.+D.+Newmanauthor=M.+Paradowskiauthor=E.+J.+Schenckauthor=M.+D.+Selbyauthor=N.+A.+Swainauthor=D.+H.+Williams&title=Challenges+of+drug+discovery+in+novel+target+space.+The+discovery+and+evaluation+of+PF-3893787%3A+a+novel+histamine+H4+receptor+antagonist&doi=10.1016%2Fj.bmcl.2011.07.125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.125%26sid%3Dliteratum%253Aachs%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DW.%2BL.%26aulast%3DNewman%26aufirst%3DS.%2BD.%26aulast%3DParadowski%26aufirst%3DM.%26aulast%3DSchenck%26aufirst%3DE.%2BJ.%26aulast%3DSelby%26aufirst%3DM.%2BD.%26aulast%3DSwain%26aufirst%3DN.%2BA.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26atitle%3DChallenges%2520of%2520drug%2520discovery%2520in%2520novel%2520target%2520space.%2520The%2520discovery%2520and%2520evaluation%2520of%2520PF-3893787%253A%2520a%2520novel%2520histamine%2520H4%2520receptor%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6596%26epage%3D6602%26doi%3D10.1016%2Fj.bmcl.2011.07.125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Veillette, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolen, J. B.</span><span> </span><span class="NLM_article-title">Post-translational alterations of the tyrosine kinase p56lck in response to activators of protein kinase C</span> <span class="citation_source-journal">Oncogene Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=3041347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A280%3ADyaL1c3ovFSgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1988&pages=385-401&author=A.+Veilletteauthor=I.+D.+Horakauthor=J.+B.+Bolen&title=Post-translational+alterations+of+the+tyrosine+kinase+p56lck+in+response+to+activators+of+protein+kinase+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Post-translational alterations of the tyrosine kinase p56lck in response to activators of protein kinase C</span></div><div class="casAuthors">Veillette A; Horak I D; Bolen J B</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene research</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-401</span>
        ISSN:<span class="NLM_cas:issn">0890-6467</span>.
    </div><div class="casAbstract">We have found in different human cells of lymphoid and non-lymphoid origin that the 56 kilodalton (kDa) lck protein is rapidly converted to a product migrating at approximately 60 kDa (designated p60lck) in response to the phorbol ester 4 alpha-phorbol 12 beta-myristate (PMA) as well as the diacylglycerol analogue 1,2-dioctanoyl-sn-glycerol (diC8).  This conversion is associated with an increase in serine phosphorylation within the amino-terminal 18 kDa portion of the lck protein.  The serine phosphorylation modification and diminished electrophoretic mobility of the lck protein appear to be completely reversible within 60 min following treatment with diC8.  The changes in p56lck phosphorylation and gel mobility in response to activators of protein kinase C are also associated with a small but reproducible decrease in the ability of the lck protein to be phosphorylated in immune complex kinase assays.  While these alterations of the lck gene product may play an important role in antigen-mediated activation of T-lymphocytes, we demonstrated that they can also be induced independently of T-cell activation suggesting that they are not necessarily implicative of this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBSGHrthZSxJWtyewyzkyLfW6udTcc2eYx8O0vc7G9cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3ovFSgsg%253D%253D&md5=f9954131de26f8296bbbc1eddb508a82</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVeillette%26aufirst%3DA.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26atitle%3DPost-translational%2520alterations%2520of%2520the%2520tyrosine%2520kinase%2520p56lck%2520in%2520response%2520to%2520activators%2520of%2520protein%2520kinase%2520C%26jtitle%3DOncogene%2520Res.%26date%3D1988%26volume%3D2%26spage%3D385%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Anderson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlmutter, R. M.</span><span> </span><span class="NLM_article-title">Involvement of the protein tyrosine kinase p56lck in T cell signaling and thymocyte development</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/S0065-2776(08)60451-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0065-2776%2808%2960451-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1994&pages=151-178&author=S.+J.+Andersonauthor=S.+D.+Levinauthor=R.+M.+Perlmutter&title=Involvement+of+the+protein+tyrosine+kinase+p56lck+in+T+cell+signaling+and+thymocyte+development&doi=10.1016%2FS0065-2776%2808%2960451-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2FS0065-2776%2808%2960451-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2776%252808%252960451-4%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DS.%2BJ.%26aulast%3DLevin%26aufirst%3DS.%2BD.%26aulast%3DPerlmutter%26aufirst%3DR.%2BM.%26atitle%3DInvolvement%2520of%2520the%2520protein%2520tyrosine%2520kinase%2520p56lck%2520in%2520T%2520cell%2520signaling%2520and%2520thymocyte%2520development%26jtitle%3DAdv.%2520Immunol.%26date%3D1994%26volume%3D56%26spage%3D151%26epage%3D178%26doi%3D10.1016%2FS0065-2776%2808%2960451-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Kamens, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratnofsky, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirst, G. C.</span><span> </span><span class="NLM_article-title">Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1213</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=1213-1219&author=J.+S.+Kamensauthor=S.+E.+Ratnofskyauthor=G.+C.+Hirst&title=Lck+inhibitors+as+a+therapeutic+approach+to+autoimmune+disease+and+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamens%26aufirst%3DJ.%2BS.%26aulast%3DRatnofsky%26aufirst%3DS.%2BE.%26aulast%3DHirst%26aufirst%3DG.%2BC.%26atitle%3DLck%2520inhibitors%2520as%2520a%2520therapeutic%2520approach%2520to%2520autoimmune%2520disease%2520and%2520transplant%2520rejection%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2001%26volume%3D2%26spage%3D1213%26epage%3D1219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span><span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lhofW6l6VK5YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frauchiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewdney, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecic, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taygerly, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0lgxWVEikRrDrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polvent, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hingorani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quart, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manhard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, S.</span><span> </span><span class="NLM_article-title">RDEA594–111 study group pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia</span> <span class="citation_source-journal">Rheumatology (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2174</span><span class="refDoi"> DOI: 10.1093/rheumatology/ket487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1093%2Frheumatology%2Fket487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=24509406" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=2167-2174&author=R.+Fleischmannauthor=B.+Kerrauthor=L.+T.+Yehauthor=M.+Susterauthor=Z.+Shenauthor=E.+Polventauthor=V.+Hingoraniauthor=B.+Quartauthor=K.+Manhardauthor=J.+N.+Minerauthor=S.+Baumgartner&title=RDEA594%E2%80%93111+study+group+pharmacodynamic%2C+pharmacokinetic+and+tolerability+evaluation+of+concomitant+administration+of+lesinurad+and+febuxostat+in+gout+patients+with+hyperuricaemia&doi=10.1093%2Frheumatology%2Fket487"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fket487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fket487%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DKerr%26aufirst%3DB.%26aulast%3DYeh%26aufirst%3DL.%2BT.%26aulast%3DSuster%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DPolvent%26aufirst%3DE.%26aulast%3DHingorani%26aufirst%3DV.%26aulast%3DQuart%26aufirst%3DB.%26aulast%3DManhard%26aufirst%3DK.%26aulast%3DMiner%26aufirst%3DJ.%2BN.%26aulast%3DBaumgartner%26aufirst%3DS.%26atitle%3DRDEA594%25E2%2580%2593111%2520study%2520group%2520pharmacodynamic%252C%2520pharmacokinetic%2520and%2520tolerability%2520evaluation%2520of%2520concomitant%2520administration%2520of%2520lesinurad%2520and%2520febuxostat%2520in%2520gout%2520patients%2520with%2520hyperuricaemia%26jtitle%3DRheumatology%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2014%26volume%3D53%26spage%3D2167%26epage%3D2174%26doi%3D10.1093%2Frheumatology%2Fket487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Kotz, J.</span><span> </span><span class="NLM_article-title">The gout pipeline crystallizes</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1038/nrd3748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd3748" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=425-426&author=J.+Kotz&title=The+gout+pipeline+crystallizes&doi=10.1038%2Fnrd3748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnrd3748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3748%26sid%3Dliteratum%253Aachs%26aulast%3DKotz%26aufirst%3DJ.%26atitle%3DThe%2520gout%2520pipeline%2520crystallizes%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D425%26epage%3D426%26doi%3D10.1038%2Fnrd3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][ 1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6639</span><span class="refDoi"> DOI: 10.1021/jm100540x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100540x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6629-6639&author=C.+Liuauthor=J.+Linauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=J.+Hynesauthor=H.+Wuauthor=A.+J.+Dyckmanauthor=T.+Liauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=D.+J.+Shusterauthor=H.+Zhangauthor=P.+H.+Maratheauthor=A.+M.+Doweykoauthor=J.+S.+Sackauthor=S.+E.+Kieferauthor=K.+F.+Kishauthor=J.+A.+Newittauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Discovery+of+4-%285-%28cyclopropylcarbamoyl%29-2-methylphenylamino%29-5-methyl-N-propylpyrrolo%5B1%2C2-f%5D%5B+1%2C2%2C4%5Dtriazine-6-carboxamide+%28BMS-582949%29%2C+a+clinical+p38alpha+MAP+kinase+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Fjm100540x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm100540x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100540x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204-%25285-%2528cyclopropylcarbamoyl%2529-2-methylphenylamino%2529-5-methyl-N-propylpyrrolo%255B1%252C2-f%255D%255B%25201%252C2%252C4%255Dtriazine-6-carboxamide%2520%2528BMS-582949%2529%252C%2520a%2520clinical%2520p38alpha%2520MAP%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6629%26epage%3D6639%26doi%3D10.1021%2Fjm100540x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Schiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peura, D.</span><span> </span><span class="NLM_article-title">HZT-501 (DUEXIS((R)); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis</span> <span class="citation_source-journal">Expert Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1586/egh.11.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1586%2Fegh.11.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22149579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SgsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=25-35&author=M.+Schiffauthor=D.+Peura&title=HZT-501+%28DUEXIS%28%28R%29%29%3B+ibuprofen+800+mg%2Ffamotidine+26.6+mg%29+gastrointestinal+protection+in+the+treatment+of+the+signs+and+symptoms+of+rheumatoid+arthritis+and+osteoarthritis&doi=10.1586%2Fegh.11.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">HZT-501 (DUEXIS; ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis</span></div><div class="casAuthors">Schiff, Michael; Peura, David</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Arthritis affects nearly 50 million people in the USA and, with the aging of the population, the prevalence is expected to rise.  While NSAIDs are very effective in relieving pain assocd. with osteoarthritis (OA) and rheumatoid arthritis (RA), they are assocd. with side effects, including gastrointestinal (GI) toxicity, which may manifest as dyspepsia, ulcers and/or bleeding.  A no. of approaches have been employed in an effort to either completely avoid or reduce the risk of GI toxicities assocd. with NSAID use.  Two new products combining an NSAID with a gastroprotective agent have recently been approved and other agents are in the pipeline.  Patient adherence to prescribed gastroprotective therapy is known to be poor, often resulting in an increased risk of GI events in patients taking NSAIDs.  These newer combination products may fulfill an important need for many patients who need to receive NSAIDs for the pain of OA and RA, but who are also at risk of upper GI events.  This article reviews preclin. and clin. results for a new fixed-dose combination of ibuprofen and famotidine, DUEXIS (HZT-501), which has recently been approved in the USA for the relief of signs and symptoms of RA and OA and to decrease the risk of developing upper GI ulcers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9fBCfYQlWLVg90H21EOLACvtfcHk0lha7w65bdQR8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SgsLfO&md5=7e50e6619ae281cfba3dbcb9e669185d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1586%2Fegh.11.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fegh.11.88%26sid%3Dliteratum%253Aachs%26aulast%3DSchiff%26aufirst%3DM.%26aulast%3DPeura%26aufirst%3DD.%26atitle%3DHZT-501%2520%2528DUEXIS%2528%2528R%2529%2529%253B%2520ibuprofen%2520800%2520mg%252Ffamotidine%252026.6%2520mg%2529%2520gastrointestinal%2520protection%2520in%2520the%2520treatment%2520of%2520the%2520signs%2520and%2520symptoms%2520of%2520rheumatoid%2520arthritis%2520and%2520osteoarthritis%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2012%26volume%3D6%26spage%3D25%26epage%3D35%26doi%3D10.1586%2Fegh.11.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everlof, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galella, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3033</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2013.03.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3028-3033&author=C.+Liuauthor=J.+Linauthor=G.+Everlofauthor=C.+Gesenbergauthor=H.+Zhangauthor=P.+H.+Maratheauthor=M.+Malleyauthor=M.+A.+Galellaauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Synthesis+and+evaluation+of+carbamoylmethylene+linked+prodrugs+of+BMS-582949%2C+a+clinical+p38alpha+inhibitor&doi=10.1016%2Fj.bmcl.2013.03.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DEverlof%26aufirst%3DG.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DMalley%26aufirst%3DM.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520carbamoylmethylene%2520linked%2520prodrugs%2520of%2520BMS-582949%252C%2520a%2520clinical%2520p38alpha%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3028%26epage%3D3033%26doi%3D10.1016%2Fj.bmcl.2013.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Ivanov, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenzie, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadokoro, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepelley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafaille, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cua, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, D. R.</span><span> </span><span class="NLM_article-title">The orphan nuclear receptor RORgamma directs the differentiation program of proinflammatory IL-17+ T helper cells</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1133</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.07.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.cell.2006.07.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=1121-1133&author=I.+I.+Ivanovauthor=B.+S.+McKenzieauthor=L.+Zhouauthor=C.+E.+Tadokoroauthor=A.+Lepelleyauthor=J.+J.+Lafailleauthor=D.+J.+Cuaauthor=D.+R.+Littman&title=The+orphan+nuclear+receptor+RORgamma+directs+the+differentiation+program+of+proinflammatory+IL-17%2B+T+helper+cells&doi=10.1016%2Fj.cell.2006.07.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DIvanov%26aufirst%3DI.%2BI.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DTadokoro%26aufirst%3DC.%2BE.%26aulast%3DLepelley%26aufirst%3DA.%26aulast%3DLafaille%26aufirst%3DJ.%2BJ.%26aulast%3DCua%26aufirst%3DD.%2BJ.%26aulast%3DLittman%26aufirst%3DD.%2BR.%26atitle%3DThe%2520orphan%2520nuclear%2520receptor%2520RORgamma%2520directs%2520the%2520differentiation%2520program%2520of%2520proinflammatory%2520IL-17%252B%2520T%2520helper%2520cells%26jtitle%3DCell%26date%3D2006%26volume%3D126%26spage%3D1121%26epage%3D1133%26doi%3D10.1016%2Fj.cell.2006.07.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Hirata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotoku, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obika, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aratsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thacher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiozaki, M.</span><span> </span><span class="NLM_article-title">SAR exploration guided by LE and Fsp(3): discovery of a selective and orally efficacious RORgamma inhibitor</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00253</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00253" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=23-27&author=K.+Hirataauthor=M.+Kotokuauthor=N.+Sekiauthor=T.+Maebaauthor=K.+Maedaauthor=S.+Hirashimaauthor=T.+Sakaiauthor=S.+Obikaauthor=A.+Horiauthor=Y.+Haseauthor=T.+Yamaguchiauthor=Y.+Katsudaauthor=T.+Hataauthor=N.+Miyagawaauthor=K.+Aritaauthor=Y.+Nomuraauthor=K.+Asahinaauthor=Y.+Aratsuauthor=M.+Kamadaauthor=T.+Adachiauthor=M.+Noguchiauthor=S.+Doiauthor=P.+Croweauthor=E.+Bradleyauthor=R.+Steensmaauthor=H.+Taoauthor=M.+Fennauthor=R.+Babineauthor=X.+Liauthor=S.+Thacherauthor=H.+Hashimotoauthor=M.+Shiozaki&title=SAR+exploration+guided+by+LE+and+Fsp%283%29%3A+discovery+of+a+selective+and+orally+efficacious+RORgamma+inhibitor&doi=10.1021%2Facsmedchemlett.5b00253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00253%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DKotoku%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DMaeba%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DHirashima%26aufirst%3DS.%26aulast%3DSakai%26aufirst%3DT.%26aulast%3DObika%26aufirst%3DS.%26aulast%3DHori%26aufirst%3DA.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKatsuda%26aufirst%3DY.%26aulast%3DHata%26aufirst%3DT.%26aulast%3DMiyagawa%26aufirst%3DN.%26aulast%3DArita%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DY.%26aulast%3DAsahina%26aufirst%3DK.%26aulast%3DAratsu%26aufirst%3DY.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DDoi%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DP.%26aulast%3DBradley%26aufirst%3DE.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DFenn%26aufirst%3DM.%26aulast%3DBabine%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DThacher%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DShiozaki%26aufirst%3DM.%26atitle%3DSAR%2520exploration%2520guided%2520by%2520LE%2520and%2520Fsp%25283%2529%253A%2520discovery%2520of%2520a%2520selective%2520and%2520orally%2520efficacious%2520RORgamma%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D23%26epage%3D27%26doi%3D10.1021%2Facsmedchemlett.5b00253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Bonnaud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousse, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouzin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauran, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couzinier, J. P.</span><span> </span><span class="NLM_article-title">1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1021/jm00385a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00385a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=318-325&author=B.+Bonnaudauthor=H.+Cousseauthor=G.+Mouzinauthor=M.+Brileyauthor=A.+Stengerauthor=F.+Fauranauthor=J.+P.+Couzinier&title=1-Aryl-2-%28aminomethyl%29cyclopropanecarboxylic+acid+derivatives.+A+new+series+of+potential+antidepressants&doi=10.1021%2Fjm00385a013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm00385a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00385a013%26sid%3Dliteratum%253Aachs%26aulast%3DBonnaud%26aufirst%3DB.%26aulast%3DCousse%26aufirst%3DH.%26aulast%3DMouzin%26aufirst%3DG.%26aulast%3DBriley%26aufirst%3DM.%26aulast%3DStenger%26aufirst%3DA.%26aulast%3DFauran%26aufirst%3DF.%26aulast%3DCouzinier%26aufirst%3DJ.%2BP.%26atitle%3D1-Aryl-2-%2528aminomethyl%2529cyclopropanecarboxylic%2520acid%2520derivatives.%2520A%2520new%2520series%2520of%2520potential%2520antidepressants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D318%26epage%3D325%26doi%3D10.1021%2Fjm00385a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Auclair, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assie, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heusler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cussac, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman-Tancredi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depoortere, R.</span><span> </span><span class="NLM_article-title">Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.neuropharm.2013.02.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2013&pages=338-347&author=A.+L.+Auclairauthor=J.+C.+Martelauthor=M.+B.+Assieauthor=L.+Bardinauthor=P.+Heuslerauthor=D.+Cussacauthor=M.+Marienauthor=A.+Newman-Tancrediauthor=J.+A.+O%E2%80%99Connorauthor=R.+Depoortere&title=Levomilnacipran+%28F2695%29%2C+a+norepinephrine-preferring+SNRI%3A+profile+in+vitro+and+in+models+of+depression+and+anxiety&doi=10.1016%2Fj.neuropharm.2013.02.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DAuclair%26aufirst%3DA.%2BL.%26aulast%3DMartel%26aufirst%3DJ.%2BC.%26aulast%3DAssie%26aufirst%3DM.%2BB.%26aulast%3DBardin%26aufirst%3DL.%26aulast%3DHeusler%26aufirst%3DP.%26aulast%3DCussac%26aufirst%3DD.%26aulast%3DMarien%26aufirst%3DM.%26aulast%3DNewman-Tancredi%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DJ.%2BA.%26aulast%3DDepoortere%26aufirst%3DR.%26atitle%3DLevomilnacipran%2520%2528F2695%2529%252C%2520a%2520norepinephrine-preferring%2520SNRI%253A%2520profile%2520in%2520vitro%2520and%2520in%2520models%2520of%2520depression%2520and%2520anxiety%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D70%26spage%3D338%26epage%3D347%26doi%3D10.1016%2Fj.neuropharm.2013.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Wentland, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bidlack, J. M.</span><span> </span><span class="NLM_article-title">Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2107</span><span class="NLM_x">–</span> <span class="NLM_lpage">2110</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.02.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2107-2110&author=M.+P.+Wentlandauthor=Q.+Luauthor=R.+Louauthor=Y.+Buauthor=B.+I.+Knappauthor=J.+M.+Bidlack&title=Synthesis+and+opioid+receptor+binding+properties+of+a+highly+potent+4-hydroxy+analogue+of+naltrexone&doi=10.1016%2Fj.bmcl.2005.02.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DWentland%26aufirst%3DM.%2BP.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DLou%26aufirst%3DR.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DB.%2BI.%26aulast%3DBidlack%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%2520and%2520opioid%2520receptor%2520binding%2520properties%2520of%2520a%2520highly%2520potent%25204-hydroxy%2520analogue%2520of%2520naltrexone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2107%26epage%3D2110%26doi%3D10.1016%2Fj.bmcl.2005.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Bart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schluger, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bidlack, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreek, M. J.</span><span> </span><span class="NLM_article-title">Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2254</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span><span class="refDoi"> DOI: 10.1038/sj.npp.1300811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fsj.npp.1300811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15988468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2005&pages=2254-2262&author=G.+Bartauthor=J.+H.+Schlugerauthor=L.+Borgauthor=A.+Hoauthor=J.+M.+Bidlackauthor=M.+J.+Kreek&title=Nalmefene+induced+elevation+in+serum+prolactin+in+normal+human+volunteers%3A+partial+kappa+opioid+agonist+activity%3F&doi=10.1038%2Fsj.npp.1300811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?</span></div><div class="casAuthors">Bart, Gavin; Schluger, James H.; Borg, Lisa; Ho, Ann; Bidlack, Jean M.; Kreek, Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2254-2262</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In humans, mu- and kappa-opioid receptor agonists lower tuberoinfundibular dopamine, which tonically inhibits prolactin release.  Serum prolactin is, therefore, a useful biomarker for tuberoinfundibular dopamine.  The current study evaluated the unexpected finding that the relative mu- and kappa-opioid receptor selective antagonist nalmefene increases serum prolactin, indicating possible kappa-opioid receptor agonist activity.  In all, 33 healthy human volunteers (14 female) with no history of psychiatric or substance use disorders received placebo, nalmefene 3 mg, and nalmefene 10 mg in a double-blind manner.  Drugs were administered between 0900 and 1000 on sep. days via 2-min i.v. infusion.  Serial blood specimens were analyzed for serum levels of prolactin.  Addnl. in vitro studies of nalmefene binding to cloned human kappa-opioid receptors transfected into Chinese hamster ovary cells were performed.  Compared to placebo, both doses of nalmefene caused significant elevations in serum prolactin (p<0.002 for nalmefene 3 mg and p<0.0005 for nalmefene 10 mg).  There was no difference in prolactin response between the 3 and 10 mg doses.  Binding assays confirmed nalmefene's affinity at kappa-opioid receptors and antagonism of mu-opioid receptors. [35S]GTPγS binding studies demonstrated that nalmefene is a full antagonist at mu-opioid receptors and has partial agonist properties at kappa-opioid receptors.  Elevations in serum prolactin following nalmefene are consistent with this partial agonist effect at kappa-opioid receptors.  As kappa-opioid receptor activation can lower dopamine in brain regions important to the persistence of alc. and cocaine dependence, the partial kappa agonist effect of nalmefene may enhance its therapeutic efficacy in selected addictive diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNyaQ97u9HsbVg90H21EOLACvtfcHk0lh1NvJ2_L38Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqurvN&md5=791e1e9c10f9c18157662e02d0d0ce2c</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300811%26sid%3Dliteratum%253Aachs%26aulast%3DBart%26aufirst%3DG.%26aulast%3DSchluger%26aufirst%3DJ.%2BH.%26aulast%3DBorg%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DBidlack%26aufirst%3DJ.%2BM.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DNalmefene%2520induced%2520elevation%2520in%2520serum%2520prolactin%2520in%2520normal%2520human%2520volunteers%253A%2520partial%2520kappa%2520opioid%2520agonist%2520activity%253F%26jtitle%3DNeuropsychopharmacology%26date%3D2005%26volume%3D30%26spage%3D2254%26epage%3D2262%26doi%3D10.1038%2Fsj.npp.1300811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Pogozheva, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lomize, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosberg, H. I.</span><span> </span><span class="NLM_article-title">Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints</span> <span class="citation_source-journal">Biophys. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">634</span><span class="refDoi"> DOI: 10.1016/S0006-3495(98)77552-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0006-3495%2898%2977552-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=9675164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1cXltFyitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1998&pages=612-634&author=I.+D.+Pogozhevaauthor=A.+L.+Lomizeauthor=H.+I.+Mosberg&title=Opioid+receptor+three-dimensional+structures+from+distance+geometry+calculations+with+hydrogen+bonding+constraints&doi=10.1016%2FS0006-3495%2898%2977552-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints</span></div><div class="casAuthors">Pogozheva, Irina D.; Lomize, Andrei L.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">612-634</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Biophysical Society</span>)
        </div><div class="casAbstract">Three-dimensional structures of the transmembrane, seven α-helical domains and extracellular loops of δ, μ, and κ opioid receptors, were calcd. using the distance geometry algorithm, with hydrogen bonding constraints based on the previously developed general model of the transmembrane α-bundle for rhodopsin-like G-protein coupled receptors (Biophys. J. 1997. 70:1963).  Each calcd. opioid receptor structure has an extensive network of interhelical hydrogen bonds and a ligand-binding crevice that is partially covered by a β-hairpin formed by the second extracellular loop.  The binding cavities consist of an inner "conserved region" composed of 18 residues that are identical in δ, μ, and κ opioid receptors, and a peripheral "variable region," composed of 19 residues that are different in δ, μ, and κ subtypes and are responsible for the subtype specificity of various ligands.  Sixteen δ-, μ-, or κ-selective, conformationally constrained peptide and nonpeptide opioid agonists and antagonists and affinity labels were fit into the binding pockets of the opioid receptors.  All ligands considered have a similar spatial arrangement in the receptors, with the tyramine moiety of alkaloids or Tyr1 of opioid peptides interacting with conserved residues in the bottom of the pocket and the tyramine N+ and OH groups forming ionic interactions or H-bonds with a conserved aspartate from helix III and a conserved histidine from helix VI, resp.  The central, conformationally constrained fragments of the opioids (the disulfide-bridged cycles of the peptides and various ring structures in the nonpeptide ligands) are oriented approx. perpendicular to the tyramine and directed toward the extracellular surface.  The results obtained are qual. consistent with ligand affinities, crosslinking studies, and mutagenesis data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomsqriUZlUkLVg90H21EOLACvtfcHk0lh1NvJ2_L38Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFyitr4%253D&md5=d676d455db7c5e99247284e4315c2a04</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0006-3495%2898%2977552-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3495%252898%252977552-6%26sid%3Dliteratum%253Aachs%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DLomize%26aufirst%3DA.%2BL.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DOpioid%2520receptor%2520three-dimensional%2520structures%2520from%2520distance%2520geometry%2520calculations%2520with%2520hydrogen%2520bonding%2520constraints%26jtitle%3DBiophys.%2520J.%26date%3D1998%26volume%3D75%26spage%3D612%26epage%3D634%26doi%3D10.1016%2FS0006-3495%2898%2977552-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Feinberg, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creese, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. H.</span><span> </span><span class="NLM_article-title">The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">4215</span><span class="NLM_x">–</span> <span class="NLM_lpage">4219</span><span class="refDoi"> DOI: 10.1073/pnas.73.11.4215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.73.11.4215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=186791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4215-4219&author=A.+P.+Feinbergauthor=I.+Creeseauthor=S.+H.+Snyder&title=The+opiate+receptor%3A+a+model+explaining+structure-activity+relationships+of+opiate+agonists+and+antagonists&doi=10.1073%2Fpnas.73.11.4215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The opiate receptor:  A model explaining structure-activity relations of opiate agonists and antagonists</span></div><div class="casAuthors">Feinberg, Andrew P.; Creese, Ian; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4215-19</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A model of the opiate receptor is proposed which explains structure-activity relationships of opiate drugs, including the unique potency of certain opiates such as etonitazene, fentanyl, phenazocine, and oripavines; the role of N-allyl substituents in conferring antagonist properties; and chem. features that afford pure antagonists.  The model indicates mol. mechanisms for interconversion of the opiate receptor between respective states that bind agonists or antagonists with high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcp-YfSxhKX7Vg90H21EOLACvtfcHk0ljjAalO9UwldQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXltVOqtg%253D%253D&md5=13320bdc14257c1f4c0fe84ad05e1421</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.4215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.4215%26sid%3Dliteratum%253Aachs%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26aulast%3DCreese%26aufirst%3DI.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DThe%2520opiate%2520receptor%253A%2520a%2520model%2520explaining%2520structure-activity%2520relationships%2520of%2520opiate%2520agonists%2520and%2520antagonists%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1976%26volume%3D73%26spage%3D4215%26epage%3D4219%26doi%3D10.1073%2Fpnas.73.11.4215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Lutfy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, A.</span><span> </span><span class="NLM_article-title">Buprenorphine: a unique drug with complex pharmacology</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span><span class="refDoi"> DOI: 10.2174/1570159043359477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F1570159043359477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18997874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFejtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=395-402&author=K.+Lutfyauthor=A.+Cowan&title=Buprenorphine%3A+a+unique+drug+with+complex+pharmacology&doi=10.2174%2F1570159043359477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Buprenorphine: A unique drug with complex pharmacology</span></div><div class="casAuthors">Lutfy, Kabirullah; Cowan, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-402</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1570-159X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Buprenorphine, an opioid with mixed agonist-antagonist activity at classical opioid receptors, has been approved recently for the treatment of opioid dependency.  Buprenorphine is also used as an analgesic.  The buprenorphine dose-response curve is sometimes submaximal, or even bell-shaped, in nociceptive assays, depending upon the nature and intensity of the noxious stimulus.  Moreover, buprenorphine, when administered with full agonists, such as morphine, antagonizes the action of these drugs.  Partial agonism at the mu opioid receptor and, in some cases, antagonism at the kappa or delta opioid receptor have been considered as possible underlying mechanisms for the ceiling effect and bell-shaped dose-response curve of buprenorphine.  While ceiling effects can be explained by the partial agonist activity of buprenorphine, the bell-shaped dose-response curve cannot be a consequence of this property of the drug.  Recently, buprenorphine has been shown to activate the opioid receptor-like (ORL-1; also known as NOP) receptor.  Supraspinal activation of the ORL-1 receptor counteracts the antinociceptive and rewarding actions of morphine, raising the possibility that these actions of buprenorphine can also be altered by its ability to concomitantly activate the ORL-1 receptor.  The use of mol. biol. techniques has advanced the knowledge regarding the role of opioid receptors in modulation of pain and reward.  In particular, generation of opioid receptor knockout mice has proven useful in this regard.  Indeed, using knockout mice, the authors have recently shown that the antinociceptive effect of buprenorphine mediated primarily by the mu opioid receptor is attenuated by the ability of the drug to activate the ORL-1 receptor.  Thus, the goal of this review is to provide evidence demonstrating that the ORL-1 receptor plays a functional role not only in the antinociceptive effect of buprenorphine but also in other actions of the drug as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6_wNsmaXoM7Vg90H21EOLACvtfcHk0ljjAalO9UwldQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFejtbg%253D&md5=1771d5a23a42e2ff5347fb7270a2853e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.2174%2F1570159043359477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159043359477%26sid%3Dliteratum%253Aachs%26aulast%3DLutfy%26aufirst%3DK.%26aulast%3DCowan%26aufirst%3DA.%26atitle%3DBuprenorphine%253A%2520a%2520unique%2520drug%2520with%2520complex%2520pharmacology%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2004%26volume%3D2%26spage%3D395%26epage%3D402%26doi%3D10.2174%2F1570159043359477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Harrison, C.</span><span> </span><span class="NLM_article-title">Trial watch: opioid receptor blocker shows promise in phase II depression trial</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="refDoi"> DOI: 10.1038/nrd4028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd4028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=415&author=C.+Harrison&title=Trial+watch%3A+opioid+receptor+blocker+shows+promise+in+phase+II+depression+trial&doi=10.1038%2Fnrd4028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1038%2Fnrd4028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4028%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26atitle%3DTrial%2520watch%253A%2520opioid%2520receptor%2520blocker%2520shows%2520promise%2520in%2520phase%2520II%2520depression%2520trial%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D415%26doi%3D10.1038%2Fnrd4028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Burger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, W. L.</span><span> </span><span class="NLM_article-title">Arylcycloalkylamines. I. 2-Phneylcyclopropylamine</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1948</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2198</span><span class="NLM_x">–</span> <span class="NLM_lpage">2201</span><span class="refDoi"> DOI: 10.1021/ja01186a062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01186a062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1948&pages=2198-2201&author=A.+Burgerauthor=W.+L.+Yost&title=Arylcycloalkylamines.+I.+2-Phneylcyclopropylamine&doi=10.1021%2Fja01186a062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fja01186a062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01186a062%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%26aulast%3DYost%26aufirst%3DW.%2BL.%26atitle%3DArylcycloalkylamines.%2520I.%25202-Phneylcyclopropylamine%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1948%26volume%3D70%26spage%3D2198%26epage%3D2201%26doi%3D10.1021%2Fja01186a062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Tedeschi, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedeschi, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fellows, E. J.</span><span> </span><span class="NLM_article-title">Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span><span class="refDoi"> DOI: 10.3181/00379727-102-25256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.3181%2F00379727-102-25256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaF3cXhvVCksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1959&pages=380-381&author=R.+E.+Tedeschiauthor=D.+H.+Tedeschiauthor=P.+L.+Amesauthor=L.+Cookauthor=P.+A.+Mattisauthor=E.+J.+Fellows&title=Some+pharmacological+observations+on+tranylcypromine+%28SKF+trans-385%29%2C+a+potent+inhibitor+of+monoamine+oxidase&doi=10.3181%2F00379727-102-25256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase</span></div><div class="casAuthors">Tedeschi, Ralph E.; Tedeschi, David H.; Ames, Peter L.; Cook, Leonard; Mattis, Paul A.; Fellows, Edwin J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Society for Experimental Biology and Medicine</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">380-1</span>CODEN:
                <span class="NLM_cas:coden">PSEBAA</span>;
        ISSN:<span class="NLM_cas:issn">0037-9727</span>.
    </div><div class="casAbstract">Treatment of rabbits with tranylcypromine (2-phenylcyclopropylamine-HCl) (I) followed by injection of reserpine produces central nervous system stimulation and a marked rise in rectal temp.  The effects of I are assumed to reflect its activity as an inhibitor of monoamine oxidase.  The activity of I is compared with that of iproniazid and d-amphetamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphjbU0S_o0VLVg90H21EOLACvtfcHk0ljjAalO9UwldQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXhvVCksA%253D%253D&md5=cbe7ce410fd2ab862333341c0ed8e161</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3181%2F00379727-102-25256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3181%252F00379727-102-25256%26sid%3Dliteratum%253Aachs%26aulast%3DTedeschi%26aufirst%3DR.%2BE.%26aulast%3DTedeschi%26aufirst%3DD.%2BH.%26aulast%3DAmes%26aufirst%3DP.%2BL.%26aulast%3DCook%26aufirst%3DL.%26aulast%3DMattis%26aufirst%3DP.%2BA.%26aulast%3DFellows%26aufirst%3DE.%2BJ.%26atitle%3DSome%2520pharmacological%2520observations%2520on%2520tranylcypromine%2520%2528SKF%2520trans-385%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520monoamine%2520oxidase%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D1959%26volume%3D102%26spage%3D380%26epage%3D381%26doi%3D10.3181%2F00379727-102-25256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Binda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubalek, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Restelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattevi, A.</span><span> </span><span class="NLM_article-title">Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">9750</span><span class="NLM_x">–</span> <span class="NLM_lpage">9755</span><span class="refDoi"> DOI: 10.1073/pnas.1633804100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.1633804100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=12913124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVejt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=9750-9755&author=C.+Bindaauthor=M.+Liauthor=F.+Hubalekauthor=N.+Restelliauthor=D.+E.+Edmondsonauthor=A.+Mattevi&title=Insights+into+the+mode+of+inhibition+of+human+mitochondrial+monoamine+oxidase+B+from+high-resolution+crystal+structures&doi=10.1073%2Fpnas.1633804100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures</span></div><div class="casAuthors">Binda, Claudia; Li, Min; Hubalek, Frantisek; Restelli, Nadia; Edmondson, Dale E.; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9750-9755</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO-B) is an outer mitochondrial membrane-bound enzyme that catalyzes the oxidative deamination of arylalkylamine neurotransmitters and has been a target for a no. of clin. used drug inhibitors.  The 1.7-Å structure of the reversible isatin-MAO-B complex has been detd.; it forms a basis for the interpretation of the enzyme's structure when bound to either reversible or irreversible inhibitors.  1,4-Diphenyl-2-butene is found to be a reversible MAO-B inhibitor, which occupies both the entrance and substrate cavity space in the enzyme.  Comparison of these two structures identifies Ile-199 as a "gate" between the two cavities.  Rotation of the side chain allows for either sepn. or fusion of the two cavities.  Inhibition of the enzyme with N-(2-aminoethyl)-p-chlorobenzamide results in the formation of a covalent N(5) flavin adduct with the Ph ring of the inhibitor occupying a position in the catalytic site overlapping that of isatin.  Inhibition of MAO-B with the clin. used trans-2-phenylcyclopropylamine results in the formation of a covalent C(4a) flavin adduct with an opened cyclopropyl ring and the Ph ring in a parallel orientation to the flavin.  The peptide bond between the flavin-substituted Cys-397 and Tyr-398 is in a cis conformation, which allows the proper orientation of the phenolic ring of Tyr-398 in the active site.  The flavin ring exists in a twisted nonplanar conformation, which is obsd. in the oxidized form as well as in both the N(5) and the C(4a) adducts.  An immobile water mol. is H-bonded to Lys-296 and to the N(5) of the flavin as obsd. in other flavin-dependent amine oxidases.  The active site cavities are highly apolar; however, hydrophilic areas exist near the flavin and direct the amine moiety of the substrate for binding and catalysis.  Small conformational changes are obsd. on comparison of the different inhibitor-enzyme complexes.  Future MAO-B drug design will need to consider "induced fit" contributions as an element in ligand-enzyme interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0K1SiYQtmN7Vg90H21EOLACvtfcHk0liKIwCVpECMVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVejt7c%253D&md5=41ecf51fec3d1c4c811dc716c43beda5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1633804100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1633804100%26sid%3Dliteratum%253Aachs%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHubalek%26aufirst%3DF.%26aulast%3DRestelli%26aufirst%3DN.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520mode%2520of%2520inhibition%2520of%2520human%2520mitochondrial%2520monoamine%2520oxidase%2520B%2520from%2520high-resolution%2520crystal%2520structures%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D9750%26epage%3D9755%26doi%3D10.1073%2Fpnas.1633804100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Wafford, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B.</span><span> </span><span class="NLM_article-title">Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span><span class="refDoi"> DOI: 10.1038/nrd2464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd2464" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=530-540&author=K.+A.+Waffordauthor=B.+Ebert&title=Emerging+anti-insomnia+drugs%3A+tackling+sleeplessness+and+the+quality+of+wake+time&doi=10.1038%2Fnrd2464"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1038%2Fnrd2464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2464%26sid%3Dliteratum%253Aachs%26aulast%3DWafford%26aufirst%3DK.%2BA.%26aulast%3DEbert%26aufirst%3DB.%26atitle%3DEmerging%2520anti-insomnia%2520drugs%253A%2520tackling%2520sleeplessness%2520and%2520the%2520quality%2520of%2520wake%2520time%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D530%26epage%3D540%26doi%3D10.1038%2Fnrd2464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Lavedan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentile, A. J.</span><span> </span><span class="NLM_article-title">Tasimelteon: a selective and unique receptor binding profile</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2014.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.neuropharm.2014.12.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2015&pages=142-147&author=C.+Lavedanauthor=M.+Forsbergauthor=A.+J.+Gentile&title=Tasimelteon%3A+a+selective+and+unique+receptor+binding+profile&doi=10.1016%2Fj.neuropharm.2014.12.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2014.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2014.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DLavedan%26aufirst%3DC.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DGentile%26aufirst%3DA.%2BJ.%26atitle%3DTasimelteon%253A%2520a%2520selective%2520and%2520unique%2520receptor%2520binding%2520profile%26jtitle%3DNeuropharmacology%26date%3D2015%26volume%3D91%26spage%3D142%26epage%3D147%26doi%3D10.1016%2Fj.neuropharm.2014.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamantini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Giacomo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamba, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannacci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spadoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span> </span><span class="NLM_article-title">Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3383</span><span class="NLM_x">–</span> <span class="NLM_lpage">3391</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.12.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmc.2005.12.053" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3383-3391&author=S.+Rivaraauthor=G.+Diamantiniauthor=B.+Di+Giacomoauthor=D.+Lambaauthor=G.+Gattiauthor=V.+Luciniauthor=M.+Pannacciauthor=M.+Morauthor=G.+Spadoniauthor=G.+Tarzia&title=Reassessing+the+melatonin+pharmacophore%2D%2Denantiomeric+resolution%2C+pharmacological+activity%2C+structure+analysis%2C+and+molecular+modeling+of+a+constrained+chiral+melatonin+analogue&doi=10.1016%2Fj.bmc.2005.12.053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.12.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.12.053%26sid%3Dliteratum%253Aachs%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DDiamantini%26aufirst%3DG.%26aulast%3DDi%2BGiacomo%26aufirst%3DB.%26aulast%3DLamba%26aufirst%3DD.%26aulast%3DGatti%26aufirst%3DG.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DPannacci%26aufirst%3DM.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DSpadoni%26aufirst%3DG.%26aulast%3DTarzia%26aufirst%3DG.%26atitle%3DReassessing%2520the%2520melatonin%2520pharmacophore--enantiomeric%2520resolution%252C%2520pharmacological%2520activity%252C%2520structure%2520analysis%252C%2520and%2520molecular%2520modeling%2520of%2520a%2520constrained%2520chiral%2520melatonin%2520analogue%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3383%26epage%3D3391%26doi%3D10.1016%2Fj.bmc.2005.12.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title">N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span> <span class="citation_source-journal">Psychopharmacology (Berl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span><span class="refDoi"> DOI: 10.1007/s00213-005-2199-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1007%2Fs00213-005-2199-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15761697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2005&pages=30-53&author=M.+J.+Millan&title=N-Methyl-D-aspartate+receptors+as+a+target+for+improved+antipsychotic+agents%3A+novel+insights+and+clinical+perspectives&doi=10.1007%2Fs00213-005-2199-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-53</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Activation of "co-agonist" N-methyl-d-aspartate (NMDA) and GlycineB sites is mandatory for the operation of NMDA receptors, which play an important role in the control of mood, cognition, and motor function.  This article outlines the complex regulation of activity at GlycineB/NMDA receptors by multiple classes of endogenous ligand.  It also summarizes the evidence that a hypoactivity of GlycineB/NMDA receptors contributes to the pathogenesis of psychotic states, and that drugs which enhance activity at these sites may possess antipsychotic properties.  Polymorphisms in several genes known to interact with NMDA receptors are related to an altered risk for schizophrenia, and psychotic patients display changes in levels of mRNA encoding NMDA receptors, including the NR1 subunit on which GlycineB sites are located.  Schizophrenia is also assocd. with an overall decrease in activity of endogenous agonists at GlycineB/NMDA sites, whereas levels of endogenous antagonists are elevated.  NMDA receptor "open channel blockers," such as phencyclidine, are psychotomimetic in man and in rodents, and antipsychotic agents attenuate certain of their effects.  Moreover, mice with genetically invalidated GlycineB/NMDA receptors reveal similar changes in behavior.  Finally, in initial clin. studies, GlycineB agonists and inhibitors of Gly reuptake were found to potentiate the ability of "conventional" antipsychotics to improve neg. and, albeit modestly, cognitive and pos. symptoms.  In contrast, therapeutic effects of clozapine are not reinforced, likely since clozapine itself enhances activity at NMDA receptors.  Reduced activity at NMDA receptors is implicated in the etiol. of schizophrenia.  Correspondingly, drugs that (directly or indirectly) increase activity at GlycineB sites may be of use as adjuncts to other classes of antipsychotic agent.  However, there is an urgent need for broader clin. evaluation of this possibility, and, to date, there is no evidence that stimulation of GlycineB sites alone improves psychotic states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrik4YrYY-zS7Vg90H21EOLACvtfcHk0liKIwCVpECMVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtV2iur0%253D&md5=08bfcddb54b062d8ec9c0f1294984608</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs00213-005-2199-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-005-2199-1%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DN-Methyl-D-aspartate%2520receptors%2520as%2520a%2520target%2520for%2520improved%2520antipsychotic%2520agents%253A%2520novel%2520insights%2520and%2520clinical%2520perspectives%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2005%26volume%3D179%26spage%3D30%26epage%3D53%26doi%3D10.1007%2Fs00213-005-2199-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Zafra, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomeza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aragon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimenez, C.</span><span> </span><span class="NLM_article-title">Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1342</span><span class="NLM_x">–</span> <span class="NLM_lpage">1352</span><span class="refDoi"> DOI: 10.1111/j.1460-9568.1995.tb01125.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1111%2Fj.1460-9568.1995.tb01125.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=7582108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A280%3ADyaK28%252FntlansQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1995&pages=1342-1352&author=F.+Zafraauthor=J.+Gomezaauthor=L.+Olivaresauthor=C.+Aragonauthor=C.+Gimenez&title=Regional+distribution+and+developmental+variation+of+the+glycine+transporters+GLYT1+and+GLYT2+in+the+rat+CNS&doi=10.1111%2Fj.1460-9568.1995.tb01125.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS</span></div><div class="casAuthors">Zafra F; Gomeza J; Olivares L; Aragon C; Gimenez C</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1342-52</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">The high-affinity glycine transporter in neurons and glial cells is the primary means of inactivating synaptic glycine.  Previous molecular cloning studies have indicated heterogeneity of glycine transporters in the CNS.  Here the distribution of glycine transporter GLYT1 and GLYT2 transcripts and proteins in different regions and developmental stages of the rat brain were analysed by Northern, Western and in situ hybridization techniques.  Sequence-specific riboprobes and two specific antibodies raised against fusion proteins were used, containing either 76 or 193 amino acids of the C or N terminus of the GLYT1 and GLYT2 transporters respectively.  High levels of GLYT1 transcripts were found in the spinal cord, brainstem and cerebellum, and moderate levels in forebrain regions such as the cortex or hippocampus.  GLYT2 transcripts are restricted to the spinal cord, brainstem and cerebellum.  The onset of both GLYT1 and GLYT2 expression in the brainstem occurred in late fetal life, and full expression of these proteins was observed before weaning.  There was a stepwise increase in the levels of mRNA and protein for these two transporters, reaching a maximum by the second postnatal week, followed by a slight decrease until adult values were reached by the fourth postnatal week.  These data reveal interesting parallelism between the distribution of different glycine transporters and glycine receptor subunits, and suggest discrete roles for distinct glycine transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDFJVKKstoSBwLZxei1HN8fW6udTcc2eZTEgTYuMsydbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FntlansQ%253D%253D&md5=92d70c6c51655791493852bda8b4e1ef</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.1995.tb01125.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.1995.tb01125.x%26sid%3Dliteratum%253Aachs%26aulast%3DZafra%26aufirst%3DF.%26aulast%3DGomeza%26aufirst%3DJ.%26aulast%3DOlivares%26aufirst%3DL.%26aulast%3DAragon%26aufirst%3DC.%26aulast%3DGimenez%26aufirst%3DC.%26atitle%3DRegional%2520distribution%2520and%2520developmental%2520variation%2520of%2520the%2520glycine%2520transporters%2520GLYT1%2520and%2520GLYT2%2520in%2520the%2520rat%2520CNS%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D1995%26volume%3D7%26spage%3D1342%26epage%3D1352%26doi%3D10.1111%2Fj.1460-9568.1995.tb01125.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Harvey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, B. K.</span><span> </span><span class="NLM_article-title">Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">866</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1038/nrd3893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd3893" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=866-885&author=R.+J.+Harveyauthor=B.+K.+Yee&title=Glycine+transporters+as+novel+therapeutic+targets+in+schizophrenia%2C+alcohol+dependence+and+pain&doi=10.1038%2Fnrd3893"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnrd3893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3893%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DR.%2BJ.%26aulast%3DYee%26aufirst%3DB.%2BK.%26atitle%3DGlycine%2520transporters%2520as%2520novel%2520therapeutic%2520targets%2520in%2520schizophrenia%252C%2520alcohol%2520dependence%2520and%2520pain%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D866%26epage%3D885%26doi%3D10.1038%2Fnrd3893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Blackaby, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Street, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guscott, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamill, T. G.</span><span> </span><span class="NLM_article-title">Identification of an orally bioavailable, potent, and selective inhibitor of GlyT1</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1021/ml1001085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1001085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=350-354&author=W.+P.+Blackabyauthor=R.+T.+Lewisauthor=J.+L.+Thomsonauthor=A.+S.+Jenningsauthor=S.+C.+Goodacreauthor=L.+J.+Streetauthor=A.+M.+MacLeodauthor=A.+Pikeauthor=S.+Woodauthor=S.+Thomasauthor=T.+A.+Brownauthor=A.+Smithauthor=G.+Pillaiauthor=S.+Almondauthor=M.+R.+Guscottauthor=H.+D.+Burnsauthor=W.+Engauthor=C.+Ryanauthor=J.+Cookauthor=T.+G.+Hamill&title=Identification+of+an+orally+bioavailable%2C+potent%2C+and+selective+inhibitor+of+GlyT1&doi=10.1021%2Fml1001085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fml1001085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001085%26sid%3Dliteratum%253Aachs%26aulast%3DBlackaby%26aufirst%3DW.%2BP.%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DThomson%26aufirst%3DJ.%2BL.%26aulast%3DJennings%26aufirst%3DA.%2BS.%26aulast%3DGoodacre%26aufirst%3DS.%2BC.%26aulast%3DStreet%26aufirst%3DL.%2BJ.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DPillai%26aufirst%3DG.%26aulast%3DAlmond%26aufirst%3DS.%26aulast%3DGuscott%26aufirst%3DM.%2BR.%26aulast%3DBurns%26aufirst%3DH.%2BD.%26aulast%3DEng%26aufirst%3DW.%26aulast%3DRyan%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DHamill%26aufirst%3DT.%2BG.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520GlyT1%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D350%26epage%3D354%26doi%3D10.1021%2Fml1001085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Spooren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riemer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H.</span><span> </span><span class="NLM_article-title">Opinion: NK3 receptor antagonists: the next generation of antipsychotics?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">975</span><span class="refDoi"> DOI: 10.1038/nrd1905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd1905" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=967-975&author=W.+Spoorenauthor=C.+Riemerauthor=H.+Meltzer&title=Opinion%3A+NK3+receptor+antagonists%3A+the+next+generation+of+antipsychotics%3F&doi=10.1038%2Fnrd1905"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnrd1905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1905%26sid%3Dliteratum%253Aachs%26aulast%3DSpooren%26aufirst%3DW.%26aulast%3DRiemer%26aufirst%3DC.%26aulast%3DMeltzer%26aufirst%3DH.%26atitle%3DOpinion%253A%2520NK3%2520receptor%2520antagonists%253A%2520the%2520next%2520generation%2520of%2520antipsychotics%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D967%26epage%3D975%26doi%3D10.1038%2Fnrd1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legos, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitmore, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barone, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhurst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span> </span><span class="NLM_article-title">Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10992004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1yns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=373-381&author=H.+M.+Sarauauthor=D.+E.+Griswoldauthor=B.+Bushauthor=W.+Pottsauthor=P.+Sandhuauthor=D.+Lundbergauthor=J.+J.+Foleyauthor=D.+B.+Schmidtauthor=E.+F.+Webbauthor=L.+D.+Martinauthor=J.+J.+Legosauthor=R.+G.+Whitmoreauthor=F.+C.+Baroneauthor=A.+D.+Medhurstauthor=M.+A.+Luttmannauthor=G.+A.+Giardinaauthor=D.+W.+Hay&title=Nonpeptide+tachykinin+receptor+antagonists.+II.+Pharmacological+and+pharmacokinetic+profile+of+SB-222200%2C+a+central+nervous+system+penetrant%2C+potent+and+selective+NK-3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist</span></div><div class="casAuthors">Sarau, Henry M.; Griswold, Don E.; Bush, Brian; Potts, William; Sandhu, Punam; Lundberg, Dave; Foley, James J.; Schmidt, Dulcie B.; Webb, Edward F.; Martin, Lenox D.; Legos, Jeffrey J.; Whitmore, Robert G.; Barone, Frank C.; Medhurst, Andrew D.; Luttmann, Mark A.; Giardina, Giuseppe A. M.; Hay, Douglas W. P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">373-381</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacol. and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(α-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide], a human NK-3 receptor (hNK-3R) antagonist, was detd.  SB-222200 inhibited 125I-[MePhe7]neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a Ki = 4.4 nM and antagonized NKB-induced Ca2+ mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC50 = 18.4 nM.  SB-222200 was selective for hNK-3 receptors compared with hNK-1 (Ki > 100,000 nM) and hNK-2 receptors (Ki = 250 nM).  In HEK 293 cells transiently expressing murine NK-3 receptors (HEK 293-mNK-3R), SB-222200 inhibited binding of 125I-[MePhe7]NKB (Ki = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC50 = 265 nM).  In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED50 values of approx. 5 mg/kg.  SB-222200 effectively crossed the blood-brain barrier in the mouse and rat.  The inhibitory effect of SB-222200 against senktide-induced behavioral responses in the mouse correlated significantly with brain, but not plasma, concns. of the compd.  Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concns. (Cmax = about 400 ng/mL) and bioavailability of 46%.  The preclin. profile of SB-222200, demonstrating high affinity, selectivity, reversibility, oral activity, and central nervous system penetration, suggests that it will be a useful tool compd. to define the physiol. and pathophysiol. roles of NK-3 receptors, in particular in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4JZQOhE9yRbVg90H21EOLACvtfcHk0lgP0btu-o6k3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1yns70%253D&md5=e6527a2b05e366ed5d82245451e316b0</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DBush%26aufirst%3DB.%26aulast%3DPotts%26aufirst%3DW.%26aulast%3DSandhu%26aufirst%3DP.%26aulast%3DLundberg%26aufirst%3DD.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DLegos%26aufirst%3DJ.%2BJ.%26aulast%3DWhitmore%26aufirst%3DR.%2BG.%26aulast%3DBarone%26aufirst%3DF.%2BC.%26aulast%3DMedhurst%26aufirst%3DA.%2BD.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DHay%26aufirst%3DD.%2BW.%26atitle%3DNonpeptide%2520tachykinin%2520receptor%2520antagonists.%2520II.%2520Pharmacological%2520and%2520pharmacokinetic%2520profile%2520of%2520SB-222200%252C%2520a%2520central%2520nervous%2520system%2520penetrant%252C%2520potent%2520and%2520selective%2520NK-3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26spage%3D373%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmead, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Flor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluderay, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murkitt, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. W.</span><span> </span><span class="NLM_article-title">In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">627</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2009.10.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.ejphar.2009.10.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19879867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=627&publication_year=2010&pages=106-114&author=L.+A.+Dawsonauthor=C.+J.+Langmeadauthor=A.+Dadaauthor=J.+M.+Watsonauthor=Z.+Wuauthor=R.+de+la+Florauthor=G.+A.+Jonesauthor=J.+E.+Cluderayauthor=E.+Southamauthor=G.+S.+Murkittauthor=M.+D.+Hillauthor=D.+N.+Jonesauthor=C.+H.+Daviesauthor=J.+J.+Haganauthor=P.+W.+Smith&title=In+vitro+and+in+vivo+comparison+of+two+non-peptide+tachykinin+NK3+receptor+antagonists%3A+improvements+in+efficacy+achieved+through+enhanced+brain+penetration+or+altered+pharmacological+characteristics&doi=10.1016%2Fj.ejphar.2009.10.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics</span></div><div class="casAuthors">Dawson, Lee A.; Langmead, Christopher J.; Dada, Adeshola; Watson, Jeannette M.; Wu, Zining; de la Flor, Raul; Jones, Gareth A.; Cluderay, Jane E.; Southam, Eric; Murkitt, Graham S.; Hill, Mark D.; Jones, Declan N. C.; Davies, Ceri H.; Hagan, Jim J.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">627</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">106-114</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Clin. evaluation of tachykinin NK3 receptor antagonists has provided support for the therapeutic utility of this target in schizophrenia.  However, these studies have not been entirely conclusive, possibly because of the pharmacokinetic limitations of these mols.  In the search for tachykinin NK3 receptor antagonists with improved properties, we have discovered GSK172981 and GSK256471.  Both compds. demonstrated high affinity for recombinant human (pKi values 7.7 and 8.9, resp.) and native guinea pig (pKi values 7.8 and 8.4, resp.) tachykinin NK3 receptors.  In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA2 = 7.2) at cloned human tachykinin NK3 receptor whereas GSK256471 diminished the neurokinin B-induced E max response, indicative of non-surmountable antagonist pharmacol. (pA2 = 9.2).  GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pKB = 8.1), while GSK256471 abolished the agonist-induced response.  Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK3 receptor occupancy in medial prefrontal cortex (ED50 values of 0.8 and 0.9 mg/kg, i.p., resp.) and the dose-dependent attenuation of agonist-induced "wet dog shake" behaviors in guinea pigs.  Finally, in vivo microdialysis studies demonstrated that acute GSK172981 (30 mg/kg, i.p.) and GSK256471 (1 mg/kg, i.p.) attenuated haloperidol-induced increases in extracellular dopamine in the guinea pig nucleus accumbens.  Taken together, these in vitro and in vivo characterisations of the tachykinin NK3 receptor antagonists GSK172981 and GSK256471 support their potential utility in the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_w2uZctUt4rVg90H21EOLACvtfcHk0lhjDEKvEMqZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVahtA%253D%253D&md5=02869117d79be9afe983ab3614423a7b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.10.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.10.054%26sid%3Dliteratum%253Aachs%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26aulast%3DDada%26aufirst%3DA.%26aulast%3DWatson%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3Dde%2Bla%2BFlor%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DG.%2BA.%26aulast%3DCluderay%26aufirst%3DJ.%2BE.%26aulast%3DSoutham%26aufirst%3DE.%26aulast%3DMurkitt%26aufirst%3DG.%2BS.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BN.%26aulast%3DDavies%26aufirst%3DC.%2BH.%26aulast%3DHagan%26aufirst%3DJ.%2BJ.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520comparison%2520of%2520two%2520non-peptide%2520tachykinin%2520NK3%2520receptor%2520antagonists%253A%2520improvements%2520in%2520efficacy%2520achieved%2520through%2520enhanced%2520brain%2520penetration%2520or%2520altered%2520pharmacological%2520characteristics%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D627%26spage%3D106%26epage%3D114%26doi%3D10.1016%2Fj.ejphar.2009.10.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Yan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienkowski, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuck, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tory, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauley, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashler, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratman, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parodi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrikson, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurney, M. E.</span><span> </span><span class="NLM_article-title">Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">402</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1038/990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2F990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10591213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=402&publication_year=1999&pages=533-537&author=R.+Yanauthor=M.+J.+Bienkowskiauthor=M.+E.+Shuckauthor=H.+Miaoauthor=M.+C.+Toryauthor=A.+M.+Pauleyauthor=J.+R.+Brashlerauthor=N.+C.+Stratmanauthor=W.+R.+Mathewsauthor=A.+E.+Buhlauthor=D.+B.+Carterauthor=A.+G.+Tomasselliauthor=L.+A.+Parodiauthor=R.+L.+Heinriksonauthor=M.+E.+Gurney&title=Membrane-anchored+aspartyl+protease+with+Alzheimer%E2%80%99s+disease+beta-secretase+activity&doi=10.1038%2F990107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity</span></div><div class="casAuthors">Yan, Riqiang; Bienkowski, Michael J.; Shuck, Mary E.; Miao, Huiyi; Tory, Monica C.; Pauley, Adele M.; Brashler, John R.; Stratman, Nancy C.; Mathews, W. Rodney; Buhl, Allen E.; Carter, Donald B.; Tomasselli, Alfredo G.; Parodi, Luis A.; Heinrikson, Robert L.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">402</span>
        (<span class="NLM_cas:issue">6761</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Mutations in the gene encoding the amyloid protein precursor (APP) cause autosomal dominant Alzheimer's disease.  Cleavage of APP by unidentified proteases, referred to as β- and γ-secretases, generates the amyloid β-peptide, the main component of the amyloid plaques found in Alzheimer's disease patients.  The disease-causing mutations flank the protease cleavage sites in APP and facilitate its cleavage.  Here the authors identify a new membrane-bound aspartyl protease (Asp2) with β-secretase activity.  The Asp2 gene is expressed widely in brain and other tissues.  Decreasing the expression of Asp2 in cells reduces amyloid β-peptide prodn. and blocks the accumulation of the carboxy-terminal APP fragment that is created by β-secretase cleavage.  Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the β-secretase site, and the rate of cleavage is increased tenfold by a mutation assocd. with early-onset Alzheimer's disease in Sweden.  Thus, Asp2 is a new protein target for drugs that are designed to block the prodn. of amyloid β-peptide peptide and the consequent formation of amyloid plaque in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6iE74jtk5LVg90H21EOLACvtfcHk0lhjDEKvEMqZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFKmu7k%253D&md5=96af7cd9b7c3315de029937497f04616</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1038%2F990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F990107%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DBienkowski%26aufirst%3DM.%2BJ.%26aulast%3DShuck%26aufirst%3DM.%2BE.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DTory%26aufirst%3DM.%2BC.%26aulast%3DPauley%26aufirst%3DA.%2BM.%26aulast%3DBrashler%26aufirst%3DJ.%2BR.%26aulast%3DStratman%26aufirst%3DN.%2BC.%26aulast%3DMathews%26aufirst%3DW.%2BR.%26aulast%3DBuhl%26aufirst%3DA.%2BE.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DParodi%26aufirst%3DL.%2BA.%26aulast%3DHeinrikson%26aufirst%3DR.%2BL.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DMembrane-anchored%2520aspartyl%2520protease%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%2520beta-secretase%2520activity%26jtitle%3DNature%26date%3D1999%26volume%3D402%26spage%3D533%26epage%3D537%26doi%3D10.1038%2F990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Cumming, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misiaszek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iserloh, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voigt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuvelkar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favreau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czarniecki, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKittrick, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span> </span><span class="NLM_article-title">Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2444</span><span class="NLM_x">–</span> <span class="NLM_lpage">2449</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2012.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22390835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2444-2449&author=J.+N.+Cummingauthor=E.+M.+Smithauthor=L.+Wangauthor=J.+Misiaszekauthor=J.+Durkinauthor=J.+Panauthor=U.+Iserlohauthor=Y.+Wuauthor=Z.+Zhuauthor=C.+Stricklandauthor=J.+Voigtauthor=X.+Chenauthor=M.+E.+Kennedyauthor=R.+Kuvelkarauthor=L.+A.+Hydeauthor=K.+Coxauthor=L.+Favreauauthor=M.+F.+Czarnieckiauthor=W.+J.+Greenleeauthor=B.+A.+McKittrickauthor=E.+M.+Parkerauthor=A.+W.+Stamford&title=Structure+based+design+of+iminohydantoin+BACE1+inhibitors%3A+identification+of+an+orally+available%2C+centrally+active+BACE1+inhibitor&doi=10.1016%2Fj.bmcl.2012.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor</span></div><div class="casAuthors">Cumming, Jared N.; Smith, Elizabeth M.; Wang, Lingyan; Misiaszek, Jeffrey; Durkin, James; Pan, Jianping; Iserloh, Ulrich; Wu, Yusheng; Zhu, Zhaoning; Strickland, Corey; Voigt, Johannes; Chen, Xia; Kennedy, Matthew E.; Kuvelkar, Reshma; Hyde, Lynn A.; Cox, Kathleen; Favreau, Leonard; Czarniecki, Michael F.; Greenlee, William J.; McKittrick, Brian A.; Parker, Eric M.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2444-2449</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">From an initial lead 2-imino-1-methyl-4,4-diphenyl-5-imidazolidinone, a structure-based design approach led to identification of the novel, high-affinity iminohydantoin BACE1 inhibitor I that lowers CNS-derived Aβ following oral administration to rats.  SAR development in the S3 and F' subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for I are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tWBE09QKNLVg90H21EOLACvtfcHk0lhjDEKvEMqZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D&md5=783b6cb9a6d9608ff5e9dc4f5d634397</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DSmith%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DDurkin%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DCzarniecki%26aufirst%3DM.%2BF.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DStructure%2520based%2520design%2520of%2520iminohydantoin%2520BACE1%2520inhibitors%253A%2520identification%2520of%2520an%2520orally%2520available%252C%2520centrally%2520active%2520BACE1%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2444%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2012.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Garofalo, A. W.</span><span> </span><span class="NLM_article-title">Patents targeting gamma-secretase inhibition and modulation for the treatment of Alzheimer’s disease: 2004–2008</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span><span class="refDoi"> DOI: 10.1517/13543776.18.7.693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1517%2F13543776.18.7.693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlGgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=693-703&author=A.+W.+Garofalo&title=Patents+targeting+gamma-secretase+inhibition+and+modulation+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+2004%E2%80%932008&doi=10.1517%2F13543776.18.7.693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Patents targeting γ-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004 - 2008</span></div><div class="casAuthors">Garofalo, Albert W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">693-703</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Although Alzheimer's disease has been defined for over a century, at present there is no effective treatment.  Amyloid deposition and plaque formation are widely believed to contribute to the pathol. of the disease.  As the etiol. of plaque formation has become better understood, the search for therapies has bred small mols. capable of inhibiting or regulating the activity of γ-secretase.  This paper reviews patents from the past 4 years claiming modulators or inhibitors of γ-secretase as a treatment for Alzheimer's disease.  One or two compds. from each patent were selected to represent the claimed chem. space.  Compd. selection was influenced by literature accounts, which are also discussed.  Although an attempt has been made to include major contributions in the field, the list of patents reviewed should not be considered exhaustive.  This review seeks to expand upon a previous review covering patents from 2000-2004.  Since then there has been an increase in the no. of structural and mechanistic approaches being pursued and several compds. have entered the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptzyUbNbn4uLVg90H21EOLACvtfcHk0ljgML8skEcUfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlGgu78%253D&md5=a26891676fdd05b0b3c2501824ced28f</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.7.693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.7.693%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%2BW.%26atitle%3DPatents%2520targeting%2520gamma-secretase%2520inhibition%2520and%2520modulation%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%25202004%25E2%2580%25932008%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D693%26epage%3D703%26doi%3D10.1517%2F13543776.18.7.693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Josien, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajagopalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clader, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favreau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span> </span><span class="NLM_article-title">Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6032</span><span class="NLM_x">–</span> <span class="NLM_lpage">6037</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2009.09.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6032-6037&author=H.+Josienauthor=T.+Baraauthor=M.+Rajagopalanauthor=J.+W.+Claderauthor=W.+J.+Greenleeauthor=L.+Favreauauthor=L.+A.+Hydeauthor=A.+A.+Nomeirauthor=E.+M.+Parkerauthor=L.+Songauthor=L.+Zhangauthor=Q.+Zhang&title=Novel+orally+active+morpholine+N-arylsulfonamides+gamma-secretase+inhibitors+with+low+CYP+3A4+liability&doi=10.1016%2Fj.bmcl.2009.09.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.055%26sid%3Dliteratum%253Aachs%26aulast%3DJosien%26aufirst%3DH.%26aulast%3DBara%26aufirst%3DT.%26aulast%3DRajagopalan%26aufirst%3DM.%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DNovel%2520orally%2520active%2520morpholine%2520N-arylsulfonamides%2520gamma-secretase%2520inhibitors%2520with%2520low%2520CYP%25203A4%2520liability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6032%26epage%3D6037%26doi%3D10.1016%2Fj.bmcl.2009.09.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Grosveld, G. C.</span><span> </span><span class="NLM_article-title">Gamma-secretase inhibitors: notch so bad</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1038/nm0109-20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnm0109-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19129776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1Oqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=20-21&author=G.+C.+Grosveld&title=Gamma-secretase+inhibitors%3A+notch+so+bad&doi=10.1038%2Fnm0109-20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">γ-secretase inhibitors: Notch so bad</span></div><div class="casAuthors">Grosveld, Gerard C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-21</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  γ-Secretase inhibitors inhibit Notch, a transmembrane receptor that drives many cases of T cell acute lymphoblastic leukemia - but there are safety concerns with such drugs.  Combining these inhibitors with glucocorticoids could provide a more effective and safer approach (pages 50-58).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLPK5315EjbVg90H21EOLACvtfcHk0ljgML8skEcUfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1Oqtg%253D%253D&md5=5c681c9ba6ce540e935386a264b1c785</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fnm0109-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0109-20%26sid%3Dliteratum%253Aachs%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26atitle%3DGamma-secretase%2520inhibitors%253A%2520notch%2520so%2520bad%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D20%26epage%3D21%26doi%3D10.1038%2Fnm0109-20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Taly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corringer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestage, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changeux, J. P.</span><span> </span><span class="NLM_article-title">Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1038/nrd2927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd2927" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=733-750&author=A.+Talyauthor=P.+J.+Corringerauthor=D.+Guedinauthor=P.+Lestageauthor=J.+P.+Changeux&title=Nicotinic+receptors%3A+allosteric+transitions+and+therapeutic+targets+in+the+nervous+system&doi=10.1038%2Fnrd2927"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1038%2Fnrd2927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2927%26sid%3Dliteratum%253Aachs%26aulast%3DTaly%26aufirst%3DA.%26aulast%3DCorringer%26aufirst%3DP.%2BJ.%26aulast%3DGuedin%26aufirst%3DD.%26aulast%3DLestage%26aufirst%3DP.%26aulast%3DChangeux%26aufirst%3DJ.%2BP.%26atitle%3DNicotinic%2520receptors%253A%2520allosteric%2520transitions%2520and%2520therapeutic%2520targets%2520in%2520the%2520nervous%2520system%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D733%26epage%3D750%26doi%3D10.1038%2Fnrd2927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Gotti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clementi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fornari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaimarri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiducci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfredi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrazzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoli, M.</span><span> </span><span class="NLM_article-title">Structural and functional diversity of native brain neuronal nicotinic receptors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">703</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.1016/j.bcp.2009.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bcp.2009.05.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2009&pages=703-711&author=C.+Gottiauthor=F.+Clementiauthor=A.+Fornariauthor=A.+Gaimarriauthor=S.+Guiducciauthor=I.+Manfrediauthor=M.+Morettiauthor=P.+Pedrazziauthor=L.+Pucciauthor=M.+Zoli&title=Structural+and+functional+diversity+of+native+brain+neuronal+nicotinic+receptors&doi=10.1016%2Fj.bcp.2009.05.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2009.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2009.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DGotti%26aufirst%3DC.%26aulast%3DClementi%26aufirst%3DF.%26aulast%3DFornari%26aufirst%3DA.%26aulast%3DGaimarri%26aufirst%3DA.%26aulast%3DGuiducci%26aufirst%3DS.%26aulast%3DManfredi%26aufirst%3DI.%26aulast%3DMoretti%26aufirst%3DM.%26aulast%3DPedrazzi%26aufirst%3DP.%26aulast%3DPucci%26aufirst%3DL.%26aulast%3DZoli%26aufirst%3DM.%26atitle%3DStructural%2520and%2520functional%2520diversity%2520of%2520native%2520brain%2520neuronal%2520nicotinic%2520receptors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D78%26spage%3D703%26epage%3D711%26doi%3D10.1016%2Fj.bcp.2009.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuckmantel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajjuri, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedolak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghavami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Chemistry and behavioral studies identify chiral cyclopropanes as selective alpha4beta2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">724</span><span class="refDoi"> DOI: 10.1021/jm201157c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201157c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=717-724&author=H.+Zhangauthor=W.+Tuckmantelauthor=J.+B.+Eatonauthor=P.+W.+Yuenauthor=L.+F.+Yuauthor=K.+M.+Bajjuriauthor=A.+Fedolakauthor=D.+Wangauthor=A.+Ghavamiauthor=B.+Caldaroneauthor=N.+E.+Patersonauthor=D.+A.+Loweauthor=D.+Brunnerauthor=R.+J.+Lukasauthor=A.+P.+Kozikowski&title=Chemistry+and+behavioral+studies+identify+chiral+cyclopropanes+as+selective+alpha4beta2-nicotinic+acetylcholine+receptor+partial+agonists+exhibiting+an+antidepressant+profile&doi=10.1021%2Fjm201157c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm201157c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201157c%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DTuckmantel%26aufirst%3DW.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DBajjuri%26aufirst%3DK.%2BM.%26aulast%3DFedolak%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGhavami%26aufirst%3DA.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DPaterson%26aufirst%3DN.%2BE.%26aulast%3DLowe%26aufirst%3DD.%2BA.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DChemistry%2520and%2520behavioral%2520studies%2520identify%2520chiral%2520cyclopropanes%2520as%2520selective%2520alpha4beta2-nicotinic%2520acetylcholine%2520receptor%2520partial%2520agonists%2520exhibiting%2520an%2520antidepressant%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D717%26epage%3D724%26doi%3D10.1021%2Fjm201157c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajjuri, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chellappan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karadi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manzano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span> </span><span class="NLM_article-title">Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1279</span><span class="NLM_x">–</span> <span class="NLM_lpage">1291</span><span class="refDoi"> DOI: 10.1002/cmdc.200900079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fcmdc.200900079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1279-1291&author=A.+P.+Kozikowskiauthor=J.+B.+Eatonauthor=K.+M.+Bajjuriauthor=S.+K.+Chellappanauthor=Y.+Chenauthor=S.+Karadiauthor=R.+Heauthor=B.+Caldaroneauthor=M.+Manzanoauthor=P.+W.+Yuenauthor=R.+J.+Lukas&title=Chemistry+and+pharmacology+of+nicotinic+ligands+based+on+6-%5B5-%28azetidin-2-ylmethoxy%29pyridin-3-yl%5Dhex-5-yn-1-ol+%28AMOP-H-OH%29+for+possible+use+in+depression&doi=10.1002%2Fcmdc.200900079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900079%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DBajjuri%26aufirst%3DK.%2BM.%26aulast%3DChellappan%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKaradi%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DManzano%26aufirst%3DM.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26atitle%3DChemistry%2520and%2520pharmacology%2520of%2520nicotinic%2520ligands%2520based%2520on%25206-%255B5-%2528azetidin-2-ylmethoxy%2529pyridin-3-yl%255Dhex-5-yn-1-ol%2520%2528AMOP-H-OH%2529%2520for%2520possible%2520use%2520in%2520depression%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1279%26epage%3D1291%26doi%3D10.1002%2Fcmdc.200900079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Turner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellano, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blendy, J. A.</span><span> </span><span class="NLM_article-title">Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1124/jpet.110.166280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1124%2Fjpet.110.166280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20435920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kisb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=665-672&author=J.+R.+Turnerauthor=L.+M.+Castellanoauthor=J.+A.+Blendy&title=Nicotinic+partial+agonists+varenicline+and+sazetidine-A+have+differential+effects+on+affective+behavior&doi=10.1124%2Fjpet.110.166280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior</span></div><div class="casAuthors">Turner, Jill R.; Castellano, Laura M.; Blendy, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clin. and preclin. studies suggest that nicotinic acetylcholine receptors are involved in affective disorders; therefore, the potential therapeutic value of nicotinic partial agonists as treatments of these disorders is of growing interest.  This study evaluated the effects of acute and chronic administration of nicotine and the α4β2 nicotinic partial agonists varenicline and sazetidine-A in mouse models of anxiety and depression.  Acutely, only nicotine and varenicline had anxiolytic effects in the marble-burying test and in the novelty-induced hypophagia (NIH) test.  In contrast, in animal models of antidepressant efficacy, such as the forced swim and the tail suspension test, only acute sazetidine-A had significant antidepressant-like effects.  The NIH test provides an anxiety-related measure that is sensitive to the effects of chronic but not acute antidepressant treatment.  Chronic nicotine and chronic sazetidine-A treatment were effective in this paradigm, but varenicline was ineffective.  These results suggest that the partial agonists varenicline and sazetidine-A may have diverse therapeutic benefits in affective disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogo1Sj2UHr5bVg90H21EOLACvtfcHk0lhZnmBaUgkZyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kisb%252FE&md5=79c7a0573c7aea5e0bb72ab5d5a4e05d</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.166280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.166280%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DJ.%2BR.%26aulast%3DCastellano%26aufirst%3DL.%2BM.%26aulast%3DBlendy%26aufirst%3DJ.%2BA.%26atitle%3DNicotinic%2520partial%2520agonists%2520varenicline%2520and%2520sazetidine-A%2520have%2520differential%2520effects%2520on%2520affective%2520behavior%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D665%26epage%3D672%26doi%3D10.1124%2Fjpet.110.166280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Zhang, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nys, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzolari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Elk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanania, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabath, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedolak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Insights into the structural determinants required for high-affinity binding of chiral cyclopropane-containing ligands to alpha4beta2-nicotinic acetylcholine receptors: an integrated approach to behaviorally active nicotinic ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8028</span><span class="NLM_x">–</span> <span class="NLM_lpage">8037</span><span class="refDoi"> DOI: 10.1021/jm3008739</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008739" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yhsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8028-8037&author=H.+K.+Zhangauthor=J.+B.+Eatonauthor=L.+F.+Yuauthor=M.+Nysauthor=A.+Mazzolariauthor=R.+van+Elkauthor=A.+B.+Smitauthor=V.+Alexandrovauthor=T.+Hananiaauthor=E.+Sabathauthor=A.+Fedolakauthor=D.+Brunnerauthor=R.+J.+Lukasauthor=G.+Vistoliauthor=C.+Ulensauthor=A.+P.+Kozikowski&title=Insights+into+the+structural+determinants+required+for+high-affinity+binding+of+chiral+cyclopropane-containing+ligands+to+alpha4beta2-nicotinic+acetylcholine+receptors%3A+an+integrated+approach+to+behaviorally+active+nicotinic+ligands&doi=10.1021%2Fjm3008739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Structural Determinants Required for High-Affinity Binding of Chiral Cyclopropane-Containing Ligands to α4β2-Nicotinic Acetylcholine Receptors: An Integrated Approach to Behaviorally Active Nicotinic Ligands</span></div><div class="casAuthors">Zhang, Han-Kun; Eaton, J. Brek; Yu, Li-Fang; Nys, Mieke; Mazzolari, Angelica; van Elk, Rene; Smit, August B.; Alexandrov, Vadim; Hanania, Taleen; Sabath, Emily; Fedolak, Allison; Brunner, Daniela; Lukas, Ronald J.; Vistoli, Giulio; Ulens, Chris; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8028-8037</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design can potentially accelerate the development of new therapeutics.  In this study, a cocrystal structure of the acetylcholine binding protein (AChBP) from Capitella teleta (Ct) in complex with a cyclopropane-contg. selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonist (compd. 5) was acquired.  The structural determinants required for ligand binding obtained from this AChBP X-ray structure were used to refine a previous model of the human α4β2-nAChR, thus possibly providing a better understanding of the structure of the human receptor.  To validate the potential application of the structure of the Ct-AChBP in the engineering of new α4β2-nAChR ligands, homol. modeling methods, combined with in silico ADME calcns., were used to design analogs of compd. 5.  The most promising compd., 12, exhibited an improved metabolic stability in comparison to the parent compd. 5 while retaining favorable pharmacol. parameters together with appropriate behavioral end points in the rodent studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYwv3p-k-0s7Vg90H21EOLACvtfcHk0lh9LMJiWq9pQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yhsLnL&md5=7dabc32c08ffc77bd322e55c6dbd585c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm3008739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008739%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DNys%26aufirst%3DM.%26aulast%3DMazzolari%26aufirst%3DA.%26aulast%3Dvan%2BElk%26aufirst%3DR.%26aulast%3DSmit%26aufirst%3DA.%2BB.%26aulast%3DAlexandrov%26aufirst%3DV.%26aulast%3DHanania%26aufirst%3DT.%26aulast%3DSabath%26aufirst%3DE.%26aulast%3DFedolak%26aufirst%3DA.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DUlens%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DInsights%2520into%2520the%2520structural%2520determinants%2520required%2520for%2520high-affinity%2520binding%2520of%2520chiral%2520cyclopropane-containing%2520ligands%2520to%2520alpha4beta2-nicotinic%2520acetylcholine%2520receptors%253A%2520an%2520integrated%2520approach%2520to%2520behaviorally%2520active%2520nicotinic%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8028%26epage%3D8037%26doi%3D10.1021%2Fjm3008739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Onajole, O. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiede, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Enantiopure cyclopropane-bearing pyridyldiazabicyclo[3.3.0]octanes as selective alpha4beta2-nAChR ligands</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1196</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span><span class="refDoi"> DOI: 10.1021/ml500129k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500129k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1196-1201&author=O.+K.+Onajoleauthor=J.+B.+Eatonauthor=R.+J.+Lukasauthor=D.+Brunnerauthor=L.+Thiedeauthor=B.+J.+Caldaroneauthor=A.+P.+Kozikowski&title=Enantiopure+cyclopropane-bearing+pyridyldiazabicyclo%5B3.3.0%5Doctanes+as+selective+alpha4beta2-nAChR+ligands&doi=10.1021%2Fml500129k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fml500129k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500129k%26sid%3Dliteratum%253Aachs%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DEaton%26aufirst%3DJ.%2BB.%26aulast%3DLukas%26aufirst%3DR.%2BJ.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DThiede%26aufirst%3DL.%26aulast%3DCaldarone%26aufirst%3DB.%2BJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DEnantiopure%2520cyclopropane-bearing%2520pyridyldiazabicyclo%255B3.3.0%255Doctanes%2520as%2520selective%2520alpha4beta2-nAChR%2520ligands%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1196%26epage%3D1201%26doi%3D10.1021%2Fml500129k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Pesquero, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araujo, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heppenstall, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stucky, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, J. A.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesquero, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paiva, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calixto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, M.</span><span> </span><span class="NLM_article-title">Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">8140</span><span class="NLM_x">–</span> <span class="NLM_lpage">8145</span><span class="refDoi"> DOI: 10.1073/pnas.120035997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1073%2Fpnas.120035997" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8140-8145&author=J.+B.+Pesqueroauthor=R.+C.+Araujoauthor=P.+A.+Heppenstallauthor=C.+L.+Stuckyauthor=J.+A.+Silvaauthor=T.+Waltherauthor=S.+M.+Oliveiraauthor=J.+L.+Pesqueroauthor=A.+C.+Paivaauthor=J.+B.+Calixtoauthor=G.+R.+Lewinauthor=M.+Bader&title=Hypoalgesia+and+altered+inflammatory+responses+in+mice+lacking+kinin+B1+receptors&doi=10.1073%2Fpnas.120035997"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1073%2Fpnas.120035997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.120035997%26sid%3Dliteratum%253Aachs%26aulast%3DPesquero%26aufirst%3DJ.%2BB.%26aulast%3DAraujo%26aufirst%3DR.%2BC.%26aulast%3DHeppenstall%26aufirst%3DP.%2BA.%26aulast%3DStucky%26aufirst%3DC.%2BL.%26aulast%3DSilva%26aufirst%3DJ.%2BA.%26aulast%3DWalther%26aufirst%3DT.%26aulast%3DOliveira%26aufirst%3DS.%2BM.%26aulast%3DPesquero%26aufirst%3DJ.%2BL.%26aulast%3DPaiva%26aufirst%3DA.%2BC.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26aulast%3DLewin%26aufirst%3DG.%2BR.%26aulast%3DBader%26aufirst%3DM.%26atitle%3DHypoalgesia%2520and%2520altered%2520inflammatory%2520responses%2520in%2520mice%2520lacking%2520kinin%2520B1%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D8140%26epage%3D8145%26doi%3D10.1073%2Fpnas.120035997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Ferreira, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araujo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesquero, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calixto, J. B.</span><span> </span><span class="NLM_article-title">The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1188</span><span class="NLM_x">–</span> <span class="NLM_lpage">1197</span><span class="refDoi"> DOI: 10.1016/S0028-3908(02)00311-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0028-3908%2802%2900311-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1188-1197&author=J.+Ferreiraauthor=M.+M.+Camposauthor=R.+Araujoauthor=M.+Baderauthor=J.+B.+Pesqueroauthor=J.+B.+Calixto&title=The+use+of+kinin+B1+and+B2+receptor+knockout+mice+and+selective+antagonists+to+characterize+the+nociceptive+responses+caused+by+kinins+at+the+spinal+level&doi=10.1016%2FS0028-3908%2802%2900311-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2802%2900311-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252802%252900311-8%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DCampos%26aufirst%3DM.%2BM.%26aulast%3DAraujo%26aufirst%3DR.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DPesquero%26aufirst%3DJ.%2BB.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520use%2520of%2520kinin%2520B1%2520and%2520B2%2520receptor%2520knockout%2520mice%2520and%2520selective%2520antagonists%2520to%2520characterize%2520the%2520nociceptive%2520responses%2520caused%2520by%2520kinins%2520at%2520the%2520spinal%2520level%26jtitle%3DNeuropharmacology%26date%3D2002%26volume%3D43%26spage%3D1188%26epage%3D1197%26doi%3D10.1016%2FS0028-3908%2802%2900311-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homnick, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lis, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stump, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondiskey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Benzodiazepines as potent and selective bradykinin B1 antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span><span class="refDoi"> DOI: 10.1021/jm034020y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034020y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFCksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1803-1806&author=M.+R.+Woodauthor=J.+J.+Kimauthor=W.+Hanauthor=B.+D.+Dorseyauthor=C.+F.+Homnickauthor=R.+M.+DiPardoauthor=S.+D.+Kudukauthor=T.+MacNeilauthor=K.+L.+Murphyauthor=E.+V.+Lisauthor=R.+W.+Ransomauthor=G.+L.+Stumpauthor=J.+J.+Lynchauthor=S.+S.+O%E2%80%99Malleyauthor=P.+J.+Millerauthor=T.+B.+Chenauthor=C.+M.+Harrellauthor=R.+S.+Changauthor=P.+Sandhuauthor=J.+D.+Ellisauthor=P.+J.+Bondiskeyauthor=D.+J.+Pettiboneauthor=R.+M.+Freidingerauthor=M.+G.+Bock&title=Benzodiazepines+as+potent+and+selective+bradykinin+B1+antagonists&doi=10.1021%2Fjm034020y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Benzodiazepines as Potent and Selective Bradykinin B1 Antagonists</span></div><div class="casAuthors">Wood, Michael R.; Kim, June J.; Han, Wei; Dorsey, Bruce D.; Homnick, Carl F.; DiPardo, Robert M.; Kuduk, Scott D.; MacNeil, Tanya; Murphy, Kathy L.; Lis, Edward V.; Ransom, Richard W.; Stump, Gary L.; Lynch, Joseph J.; O'Malley, Stacey S.; Miller, Patricia J.; Chen, Tsing-Bau; Harrell, Charles M.; Chang, Raymond S. L.; Sandhu, Punam; Ellis, Joan D.; Bondiskey, Peter J.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1803-1806</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonism of the bradykinin B1 receptor was demonstrated to be a potential treatment for chronic pain and inflammation.  Novel benzodiazepines were designed that display subnanomolar affinity for the bradykinin B1 receptor (Ki = 0.59 nM) and high selectivity against the bradykinin B2 receptor (Ki > 10 μM).  In vivo efficacy, comparable to morphine, was demonstrated for lead compds. in a rodent hyperalgesia model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnWdPzXxm7TbVg90H21EOLACvtfcHk0lg-gSXTLorHSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFCksrY%253D&md5=25321091d569d913a963ec4e33baa772</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm034020y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034020y%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DHomnick%26aufirst%3DC.%2BF.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DLis%26aufirst%3DE.%2BV.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DStump%26aufirst%3DG.%2BL.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DS.%2BS.%26aulast%3DMiller%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DT.%2BB.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DSandhu%26aufirst%3DP.%26aulast%3DEllis%26aufirst%3DJ.%2BD.%26aulast%3DBondiskey%26aufirst%3DP.%2BJ.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DBenzodiazepines%2520as%2520potent%2520and%2520selective%2520bradykinin%2520B1%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1803%26epage%3D1806%26doi%3D10.1021%2Fjm034020y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Feng, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.02.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.02.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2385-2388&author=D.+M.+Fengauthor=J.+M.+Waiauthor=S.+D.+Kudukauthor=C.+Ngauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+Reissauthor=R.+S.+Changauthor=C.+M.+Harrellauthor=T.+MacNeilauthor=C.+Tangauthor=T.+Prueksaritanontauthor=R.+M.+Freidingerauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=2%2C3-Diaminopyridine+as+a+platform+for+designing+structurally+unique+nonpeptide+bradykinin+B1+receptor+antagonists&doi=10.1016%2Fj.bmcl.2005.02.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.02.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.02.077%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DD.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BM.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3D2%252C3-Diaminopyridine%2520as%2520a%2520platform%2520for%2520designing%2520structurally%2520unique%2520nonpeptide%2520bradykinin%2520B1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2385%26epage%3D2388%26doi%3D10.1016%2Fj.bmcl.2005.02.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krymgold, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span> </span><span class="NLM_article-title">Bioactivation of 2,3-diaminopyridine-containing bradykinin B1 receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">934</span><span class="NLM_x">–</span> <span class="NLM_lpage">945</span><span class="refDoi"> DOI: 10.1021/tx0500427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0500427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=934-945&author=C.+Tangauthor=R.+Subramanianauthor=Y.+Kuoauthor=S.+Krymgoldauthor=P.+Luauthor=S.+D.+Kudukauthor=C.+Ngauthor=D.+M.+Fengauthor=C.+Elmoreauthor=E.+Soliauthor=J.+Hoauthor=M.+G.+Bockauthor=T.+A.+Baillieauthor=T.+Prueksaritanont&title=Bioactivation+of+2%2C3-diaminopyridine-containing+bradykinin+B1+receptor+antagonists%3A+irreversible+binding+to+liver+microsomal+proteins+and+formation+of+glutathione+conjugates&doi=10.1021%2Ftx0500427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Ftx0500427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0500427%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DKrymgold%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DD.%2BM.%26aulast%3DElmore%26aufirst%3DC.%26aulast%3DSoli%26aufirst%3DE.%26aulast%3DHo%26aufirst%3DJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26atitle%3DBioactivation%2520of%25202%252C3-diaminopyridine-containing%2520bradykinin%2520B1%2520receptor%2520antagonists%253A%2520irreversible%2520binding%2520to%2520liver%2520microsomal%2520proteins%2520and%2520formation%2520of%2520glutathione%2520conjugates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D934%26epage%3D945%26doi%3D10.1021%2Ftx0500427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirripa, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detwiler, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hettrick, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1234</span><span class="refDoi"> DOI: 10.1021/jm0511280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0511280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1231-1234&author=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=B.+L.+Wanauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=R.+S.+Changauthor=C.+Tangauthor=T.+Prueksaritanontauthor=T.+J.+Detwilerauthor=L.+A.+Hettrickauthor=E.+R.+Landisauthor=Y.+M.+Leonardauthor=J.+A.+Kruegerauthor=S.+D.+Lewisauthor=D.+J.+Pettiboneauthor=R.+M.+Freidingerauthor=M.+G.+Bock&title=Cyclopropylamino+acid+amide+as+a+pharmacophoric+replacement+for+2%2C3-diaminopyridine.+Application+to+the+design+of+novel+bradykinin+B1+receptor+antagonists&doi=10.1021%2Fjm0511280"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm0511280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0511280%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DChang%26aufirst%3DR.%2BS.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DDetwiler%26aufirst%3DT.%2BJ.%26aulast%3DHettrick%26aufirst%3DL.%2BA.%26aulast%3DLandis%26aufirst%3DE.%2BR.%26aulast%3DLeonard%26aufirst%3DY.%2BM.%26aulast%3DKrueger%26aufirst%3DJ.%2BA.%26aulast%3DLewis%26aufirst%3DS.%2BD.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DCyclopropylamino%2520acid%2520amide%2520as%2520a%2520pharmacophoric%2520replacement%2520for%25202%252C3-diaminopyridine.%2520Application%2520to%2520the%2520design%2520of%2520novel%2520bradykinin%2520B1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1231%26epage%3D1234%26doi%3D10.1021%2Fjm0511280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Bradykinin B1 antagonists: biphenyl SAR studies in the cyclopropanecarboxamide series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3608</span><span class="NLM_x">–</span> <span class="NLM_lpage">3612</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.04.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2007.04.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3608-3612&author=S.+D.+Kudukauthor=R.+M.+DiPardoauthor=R.+K.+Changauthor=C.+N.+Di+Marcoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+R.+Reissauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=Bradykinin+B1+antagonists%3A+biphenyl+SAR+studies+in+the+cyclopropanecarboxamide+series&doi=10.1016%2Fj.bmcl.2007.04.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.040%26sid%3Dliteratum%253Aachs%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DBradykinin%2520B1%2520antagonists%253A%2520biphenyl%2520SAR%2520studies%2520in%2520the%2520cyclopropanecarboxamide%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3608%26epage%3D3612%26doi%3D10.1016%2Fj.bmcl.2007.04.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirripa, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holahan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sain, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span><span class="refDoi"> DOI: 10.1021/jm061094b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061094b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=272-282&author=S.+D.+Kudukauthor=C.+N.+Di+Marcoauthor=R.+K.+Changauthor=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=J.+M.+Waiauthor=R.+M.+DiPardoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=C.+M.+Harrellauthor=D.+R.+Reissauthor=M.+A.+Holahanauthor=J.+Cookauthor=J.+F.+Hessauthor=N.+Sainauthor=M.+O.+Urbanauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=Development+of+orally+bioavailable+and+CNS+penetrant+biphenylaminocyclopropane+carboxamide+bradykinin+B1+receptor+antagonists&doi=10.1021%2Fjm061094b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B1 Receptor Antagonists</span></div><div class="casAuthors">Kuduk, Scott D.; Di Marco, Christina N.; Chang, Ronald K.; Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Wai, Jenny M. C.; DiPardo, Robert M.; Murphy, Kathy L.; Ransom, Richard W.; Harrell, C. Meacham; Reiss, Duane R.; Holahan, Marie A.; Cook, Jacquelynn; Hess, J. Fred; Sain, Nova; Urban, Mark O.; Tang, Cuyue; Prueksaritanont, Thomayant; Pettibone, Douglas J.; Bock, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">272-282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant.  Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential.  One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Ky-bZSOQr7Vg90H21EOLACvtfcHk0lhLb7z3ip_tsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgs7zL&md5=9fac6ea81be63ee5dfae76dd7d2c37b5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fjm061094b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061094b%26sid%3Dliteratum%253Aachs%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DWai%26aufirst%3DJ.%2BM.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DHolahan%26aufirst%3DM.%2BA.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DJ.%2BF.%26aulast%3DSain%26aufirst%3DN.%26aulast%3DUrban%26aufirst%3DM.%2BO.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DDevelopment%2520of%2520orally%2520bioavailable%2520and%2520CNS%2520penetrant%2520biphenylaminocyclopropane%2520carboxamide%2520bradykinin%2520B1%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D272%26epage%3D282%26doi%3D10.1021%2Fjm061094b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Betschart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintermann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotesta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ofner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyer, D.</span><span> </span><span class="NLM_article-title">Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7590</span><span class="NLM_x">–</span> <span class="NLM_lpage">7607</span><span class="refDoi"> DOI: 10.1021/jm4007627</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7590-7607&author=C.+Betschartauthor=S.+Hintermannauthor=D.+Behnkeauthor=S.+Cotestaauthor=M.+Fendtauthor=C.+E.+Geeauthor=L.+H.+Jacobsonauthor=G.+Laueauthor=S.+Ofnerauthor=V.+Chaudhariauthor=S.+Badigerauthor=C.+Panditauthor=J.+Wagnerauthor=D.+Hoyer&title=Identification+of+a+novel+series+of+orexin+receptor+antagonists+with+a+distinct+effect+on+sleep+architecture+for+the+treatment+of+insomnia&doi=10.1021%2Fjm4007627"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fjm4007627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007627%26sid%3Dliteratum%253Aachs%26aulast%3DBetschart%26aufirst%3DC.%26aulast%3DHintermann%26aufirst%3DS.%26aulast%3DBehnke%26aufirst%3DD.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DFendt%26aufirst%3DM.%26aulast%3DGee%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DLaue%26aufirst%3DG.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DV.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DPandit%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520a%2520novel%2520series%2520of%2520orexin%2520receptor%2520antagonists%2520with%2520a%2520distinct%2520effect%2520on%2520sleep%2520architecture%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7590%26epage%3D7607%26doi%3D10.1021%2Fjm4007627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGaughey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogusky, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span> </span><span class="NLM_article-title">Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H −1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5320</span><span class="NLM_x">–</span> <span class="NLM_lpage">5332</span><span class="refDoi"> DOI: 10.1021/jm100541c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100541c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5320-5332&author=C.+D.+Coxauthor=M.+J.+Breslinauthor=D.+B.+Whitmanauthor=J.+D.+Schreierauthor=G.+B.+McGaugheyauthor=M.+J.+Boguskyauthor=A.+J.+Roeckerauthor=S.+P.+Mercerauthor=R.+A.+Bednarauthor=W.+Lemaireauthor=J.+G.+Brunoauthor=D.+R.+Reissauthor=C.+M.+Harrellauthor=K.+L.+Murphyauthor=S.+L.+Garsonauthor=S.+M.+Doranauthor=T.+Prueksaritanontauthor=W.+B.+Andersonauthor=C.+Tangauthor=S.+Rollerauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=G.+D.+Hartmanauthor=S.+D.+Youngauthor=K.+S.+Koblanauthor=C.+J.+Winrowauthor=J.+J.+Rengerauthor=P.+J.+Coleman&title=Discovery+of+the+dual+orexin+receptor+antagonist+%5B%287R%29-4-%285-chloro-1%2C3-benzoxazol-2-yl%29-7-methyl-1%2C4-diazepan-1-yl%5D%5B5-methyl-2-%282H+%E2%88%921%2C2%2C3-triazol-2-yl%29phenyl%5Dmethanone+%28MK-4305%29+for+the+treatment+of+insomnia&doi=10.1021%2Fjm100541c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm100541c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100541c%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DWhitman%26aufirst%3DD.%2BB.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBogusky%26aufirst%3DM.%2BJ.%26aulast%3DRoecker%26aufirst%3DA.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DW.%2BB.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%2520the%2520dual%2520orexin%2520receptor%2520antagonist%2520%255B%25287R%2529-4-%25285-chloro-1%252C3-benzoxazol-2-yl%2529-7-methyl-1%252C4-diazepan-1-yl%255D%255B5-methyl-2-%25282H%2520%25E2%2588%25921%252C2%252C3-triazol-2-yl%2529phenyl%255Dmethanone%2520%2528MK-4305%2529%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5320%26epage%3D5332%26doi%3D10.1021%2Fjm100541c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobarec, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span> </span><span class="NLM_article-title">Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">519</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1038/nature14035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnature14035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=25533960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=519&publication_year=2015&pages=247-250&author=J.+Yinauthor=J.+C.+Mobarecauthor=P.+Kolbauthor=D.+M.+Rosenbaum&title=Crystal+structure+of+the+human+OX2+orexin+receptor+bound+to+the+insomnia+drug+suvorexant&doi=10.1038%2Fnature14035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant</span></div><div class="casAuthors">Yin, Jie; Mobarec, Juan Carlos; Kolb, Peter; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">519</span>
        (<span class="NLM_cas:issue">7542</span>),
    <span class="NLM_cas:pages">247-250</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The orexin (also known as hypocretin) G protein-coupled receptors (GPCRs) respond to orexin neuropeptides in the central nervous system to regulate sleep and other behavioral functions in humans.  Defects in orexin signalling are responsible for the human diseases of narcolepsy and cataplexy; inhibition of orexin receptors is an effective therapy for insomnia.  The human OX2 receptor (OX2R) belongs to the β branch of the rhodopsin family of GPCRs, and can bind to diverse compds. including the native agonist peptides orexin-A and orexin-B and the potent therapeutic inhibitor suvorexant.  Here, using lipid-mediated crystn. and protein engineering with a novel fusion chimaera, we solved the structure of the human OX2R bound to suvorexant at 2.5 Å resoln.  The structure reveals how suvorexant adopts a π-stacked horseshoe-like conformation and binds to the receptor deep in the orthosteric pocket, stabilizing a network of extracellular salt bridges and blocking transmembrane (TM) helix motions necessary for activation.  Computational docking suggests how other classes of synthetic antagonists may interact with the receptor at a similar position in an analogous π-stacked fashion.  Elucidation of the mol. architecture of the human OX2R expands our understanding of peptidergic GPCR ligand recognition and will aid further efforts to modulate orexin signaling for therapeutic ends.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWKzbWNxv4W7Vg90H21EOLACvtfcHk0lhipFOlAQwVMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Sntb0%253D&md5=461a6633274dbcfd9edce1a2e13b9c4f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1038%2Fnature14035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14035%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DMobarec%26aufirst%3DJ.%2BC.%26aulast%3DKolb%26aufirst%3DP.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520OX2%2520orexin%2520receptor%2520bound%2520to%2520the%2520insomnia%2520drug%2520suvorexant%26jtitle%3DNature%26date%3D2015%26volume%3D519%26spage%3D247%26epage%3D250%26doi%3D10.1038%2Fnature14035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Esbenshade, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowart, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brioni, J. D.</span><span> </span><span class="NLM_article-title">The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span><span class="refDoi"> DOI: 10.1038/bjp.2008.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fbjp.2008.147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18469850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1166-1181&author=T.+A.+Esbenshadeauthor=K.+E.+Browmanauthor=R.+S.+Bitnerauthor=M.+Strakhovaauthor=M.+D.+Cowartauthor=J.+D.+Brioni&title=The+histamine+H3+receptor%3A+an+attractive+target+for+the+treatment+of+cognitive+disorders&doi=10.1038%2Fbjp.2008.147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: an attractive target for the treatment of cognitive disorders</span></div><div class="casAuthors">Esbenshade, T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.; Brioni, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1166-1181</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The histamine H3 receptor, first described in 1983 as a histamine autoreceptor and later shown to also function as a heteroreceptor that regulates the release of other neurotransmitters, has been the focus of research by numerous labs. as it represents an attractive drug target for a no. of indications including cognition.  The purpose of this review is to acquaint the reader with the current understanding of H3 receptor localization and function as a modulator of neurotransmitter release and its effects on cognitive processes, as well as to provide an update on selected H3 antagonists in various states of preclin. and clin. advancement.  Blockade of centrally localized H3 receptors by selective H3 receptor antagonists has been shown to enhance the release of neurotransmitters such as histamine, ACh, dopamine and norepinephrine, among others, which play important roles in cognitive processes.  The cognitive-enhancing effects of H3 antagonists across multiple cognitive domains in a wide no. of preclin. cognition models also bolster confidence in this therapeutic approach for the treatment of attention deficit hyperactivity disorder, Alzheimer's disease and schizophrenia.  However, although a no. of clin. studies examg. the efficacy of H3 receptor antagonists for a variety of cognitive disorders are currently underway, no clin. proof of concept for an H3 receptor antagonist has been reported to date.  The discovery of effective H3 antagonists as therapeutic agents for the novel treatment of cognitive disorders will only be accomplished through continued research efforts that further our insights into the functions of the H3 receptor.  British Journal of Pharmacol. (2008) 154, 1166-1181; doi:10.1038/bjp.2008.147; published online 12 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2N2Dg3cdZfrVg90H21EOLACvtfcHk0lhipFOlAQwVMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCjtL4%253D&md5=05bcda7b1140e9d16b4ca4072902d925</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.147%26sid%3Dliteratum%253Aachs%26aulast%3DEsbenshade%26aufirst%3DT.%2BA.%26aulast%3DBrowman%26aufirst%3DK.%2BE.%26aulast%3DBitner%26aufirst%3DR.%2BS.%26aulast%3DStrakhova%26aufirst%3DM.%26aulast%3DCowart%26aufirst%3DM.%2BD.%26aulast%3DBrioni%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520histamine%2520H3%2520receptor%253A%2520an%2520attractive%2520target%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1166%26epage%3D1181%26doi%3D10.1038%2Fbjp.2008.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apodaca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajpai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbier, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneville, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcallister, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mani, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ndifor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sands, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snook, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span> </span><span class="NLM_article-title">Novel benzamide-based histamine h3 receptor antagonists: the identification of two candidates for clinical development</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">450</span><span class="NLM_x">–</span> <span class="NLM_lpage">454</span><span class="refDoi"> DOI: 10.1021/ml5005156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml5005156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=450-454&author=M.+A.+Letavicauthor=L.+Aluisioauthor=R.+Apodacaauthor=M.+Bajpaiauthor=A.+J.+Barbierauthor=A.+Bonnevilleauthor=P.+Bonaventureauthor=N.+I.+Carruthersauthor=C.+Dugovicauthor=I.+C.+Fraserauthor=M.+L.+Kramerauthor=B.+Lordauthor=T.+W.+Lovenbergauthor=L.+Y.+Liauthor=K.+S.+Lyauthor=H.+Mcallisterauthor=N.+S.+Maniauthor=K.+L.+Mortonauthor=A.+Ndiforauthor=S.+D.+Nepomucenoauthor=C.+R.+Panditauthor=S.+B.+Sandsauthor=C.+R.+Shahauthor=J.+E.+Sheltonauthor=S.+S.+Snookauthor=D.+M.+Swansonauthor=W.+Xiao&title=Novel+benzamide-based+histamine+h3+receptor+antagonists%3A+the+identification+of+two+candidates+for+clinical+development&doi=10.1021%2Fml5005156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fml5005156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml5005156%26sid%3Dliteratum%253Aachs%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DAluisio%26aufirst%3DL.%26aulast%3DApodaca%26aufirst%3DR.%26aulast%3DBajpai%26aufirst%3DM.%26aulast%3DBarbier%26aufirst%3DA.%2BJ.%26aulast%3DBonneville%26aufirst%3DA.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DKramer%26aufirst%3DM.%2BL.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DLy%26aufirst%3DK.%2BS.%26aulast%3DMcallister%26aufirst%3DH.%26aulast%3DMani%26aufirst%3DN.%2BS.%26aulast%3DMorton%26aufirst%3DK.%2BL.%26aulast%3DNdifor%26aufirst%3DA.%26aulast%3DNepomuceno%26aufirst%3DS.%2BD.%26aulast%3DPandit%26aufirst%3DC.%2BR.%26aulast%3DSands%26aufirst%3DS.%2BB.%26aulast%3DShah%26aufirst%3DC.%2BR.%26aulast%3DShelton%26aufirst%3DJ.%2BE.%26aulast%3DSnook%26aufirst%3DS.%2BS.%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DXiao%26aufirst%3DW.%26atitle%3DNovel%2520benzamide-based%2520histamine%2520h3%2520receptor%2520antagonists%253A%2520the%2520identification%2520of%2520two%2520candidates%2520for%2520clinical%2520development%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D450%26epage%3D454%26doi%3D10.1021%2Fml5005156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Pages, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavalda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehner, M. D.</span><span> </span><span class="NLM_article-title">PDE4 inhibitors: a review of current developments (2005 - 2009)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1519</span><span class="refDoi"> DOI: 10.1517/13543770903313753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1517%2F13543770903313753" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1501-1519&author=L.+Pagesauthor=A.+Gavaldaauthor=M.+D.+Lehner&title=PDE4+inhibitors%3A+a+review+of+current+developments+%282005+-+2009%29&doi=10.1517%2F13543770903313753"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1517%2F13543770903313753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903313753%26sid%3Dliteratum%253Aachs%26aulast%3DPages%26aufirst%3DL.%26aulast%3DGavalda%26aufirst%3DA.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DPDE4%2520inhibitors%253A%2520a%2520review%2520of%2520current%2520developments%2520%25282005%2520-%25202009%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1501%26epage%3D1519%26doi%3D10.1517%2F13543770903313753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Schmidt, C. J.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors as potential cognition enhancing agents</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span><span class="refDoi"> DOI: 10.2174/156802610790411009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F156802610790411009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20166957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFajsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=222-230&author=C.+J.+Schmidt&title=Phosphodiesterase+inhibitors+as+potential+cognition+enhancing+agents&doi=10.2174%2F156802610790411009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors as potential cognition enhancing agents</span></div><div class="casAuthors">Schmidt, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-230</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  As might be predicted for an organ designed for cell to cell communication, cyclic nucleotide signaling in the brain is highly organized and regulated.  Augmentation of cyclic nucleotide signaling by means of phosphodiesterase inhibition appears to be a viable and tractable means of enhancing neuronal communication.  Of the various CNS disorders that have been considered as target indications for phosphodiesterase inhibitors, no condition has received more attention than cognitive dysfunction.  This review provides a background for understanding the expanding literature in this field as well as a brief update on the rationale driving the search for selective inhibitors of targets such as PDE1B, PDE2, PDE5 and PDE9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBVYtnViej97Vg90H21EOLACvtfcHk0liK2KsFTS0FaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFajsrY%253D&md5=47e8397d9f69207c27940575411bbe12</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.2174%2F156802610790411009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790411009%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26atitle%3DPhosphodiesterase%2520inhibitors%2520as%2520potential%2520cognition%2520enhancing%2520agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D222%26epage%3D230%26doi%3D10.2174%2F156802610790411009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Gallant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aspiotis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesen, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styhler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, Y.</span><span> </span><span class="NLM_article-title">Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6387</span><span class="NLM_x">–</span> <span class="NLM_lpage">6393</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.09.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2010.09.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6387-6393&author=M.+Gallantauthor=R.+Aspiotisauthor=S.+Dayauthor=R.+Diasauthor=D.+Dubeauthor=L.+Dubeauthor=R.+W.+Friesenauthor=M.+Girardauthor=D.+Guayauthor=P.+Hamelauthor=Z.+Huangauthor=P.+Lacombeauthor=S.+Laliberteauthor=J.+F.+Levesqueauthor=S.+Liuauthor=D.+Macdonaldauthor=J.+Manciniauthor=D.+W.+Nicholsonauthor=A.+Styhlerauthor=K.+Townsonauthor=K.+Watersauthor=R.+N.+Youngauthor=Y.+Girard&title=Discovery+of+MK-0952%2C+a+selective+PDE4+inhibitor+for+the+treatment+of+long-term+memory+loss+and+mild+cognitive+impairment&doi=10.1016%2Fj.bmcl.2010.09.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.087%26sid%3Dliteratum%253Aachs%26aulast%3DGallant%26aufirst%3DM.%26aulast%3DAspiotis%26aufirst%3DR.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DDias%26aufirst%3DR.%26aulast%3DDube%26aufirst%3DD.%26aulast%3DDube%26aufirst%3DL.%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DHamel%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DLacombe%26aufirst%3DP.%26aulast%3DLaliberte%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DJ.%2BF.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMacdonald%26aufirst%3DD.%26aulast%3DMancini%26aufirst%3DJ.%26aulast%3DNicholson%26aufirst%3DD.%2BW.%26aulast%3DStyhler%26aufirst%3DA.%26aulast%3DTownson%26aufirst%3DK.%26aulast%3DWaters%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DGirard%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520MK-0952%252C%2520a%2520selective%2520PDE4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520long-term%2520memory%2520loss%2520and%2520mild%2520cognitive%2520impairment%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6387%26epage%3D6393%26doi%3D10.1016%2Fj.bmcl.2010.09.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Guay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesen, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muise, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styhler, A.</span><span> </span><span class="NLM_article-title">Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5554</span><span class="NLM_x">–</span> <span class="NLM_lpage">5558</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.09.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5554-5558&author=D.+Guayauthor=L.+Bouletauthor=R.+W.+Friesenauthor=M.+Girardauthor=P.+Hamelauthor=Z.+Huangauthor=F.+Laliberteauthor=S.+Laliberteauthor=J.+A.+Manciniauthor=E.+Muiseauthor=D.+Ponauthor=A.+Styhler&title=Optimization+and+structure-activity+relationship+of+a+series+of+1-phenyl-1%2C8-naphthyridin-4-one-3-carboxamides%3A+identification+of+MK-0873%2C+a+potent+and+effective+PDE4+inhibitor&doi=10.1016%2Fj.bmcl.2008.09.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DBoulet%26aufirst%3DL.%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DLaliberte%26aufirst%3DF.%26aulast%3DLaliberte%26aufirst%3DS.%26aulast%3DMancini%26aufirst%3DJ.%2BA.%26aulast%3DMuise%26aufirst%3DE.%26aulast%3DPon%26aufirst%3DD.%26aulast%3DStyhler%26aufirst%3DA.%26atitle%3DOptimization%2520and%2520structure-activity%2520relationship%2520of%2520a%2520series%2520of%25201-phenyl-1%252C8-naphthyridin-4-one-3-carboxamides%253A%2520identification%2520of%2520MK-0873%252C%2520a%2520potent%2520and%2520effective%2520PDE4%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5554%26epage%3D5558%26doi%3D10.1016%2Fj.bmcl.2008.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Marks, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pae, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patkar, A. A.</span><span> </span><span class="NLM_article-title">Triple reuptake inhibitors: the next generation of antidepressants</span> <span class="citation_source-journal">Curr. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">338</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span><span class="refDoi"> DOI: 10.2174/157015908787386078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.2174%2F157015908787386078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19587855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=338-343&author=D.+M.+Marksauthor=C.+U.+Paeauthor=A.+A.+Patkar&title=Triple+reuptake+inhibitors%3A+the+next+generation+of+antidepressants&doi=10.2174%2F157015908787386078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors: the next generation of antidepressants</span></div><div class="casAuthors">Marks, David M.; Pae, Chi-Un; Patkar, Ashwin A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">338-343</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression has been assocd. with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacol. treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission.  Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action.  The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors.  The evidence for and against the claim that broader spectrum agents are more efficacious is discussed.  Examples of triple reuptake inhibitors in development are compared, and preclin. and clin. research with these agents to date is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8YVs9W5UsbVg90H21EOLACvtfcHk0lhwwda1VyC1HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSqu78%253D&md5=b8108bdcd4ddc03bc3e7c31b2ac0824f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.2174%2F157015908787386078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015908787386078%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DD.%2BM.%26aulast%3DPae%26aufirst%3DC.%2BU.%26aulast%3DPatkar%26aufirst%3DA.%2BA.%26atitle%3DTriple%2520reuptake%2520inhibitors%253A%2520the%2520next%2520generation%2520of%2520antidepressants%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2008%26volume%3D6%26spage%3D338%26epage%3D343%26doi%3D10.2174%2F157015908787386078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Micheli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreotti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arban, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettelini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonanomi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braggio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carletti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Checchia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazzolari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchioro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlo-Pich, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliosi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedesco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terreni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zonzini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fabio, R.</span><span> </span><span class="NLM_article-title">6-(3,4-Dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4989</span><span class="NLM_x">–</span> <span class="NLM_lpage">5001</span><span class="refDoi"> DOI: 10.1021/jm100481d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100481d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4989-5001&author=F.+Micheliauthor=P.+Cavanniauthor=D.+Andreottiauthor=R.+Arbanauthor=R.+Benedettiauthor=B.+Bertaniauthor=M.+Bettatiauthor=L.+Betteliniauthor=G.+Bonanomiauthor=S.+Braggioauthor=R.+Carlettiauthor=A.+Checchiaauthor=M.+Corsiauthor=E.+Fazzolariauthor=S.+Fontanaauthor=C.+Marchioroauthor=E.+Merlo-Pichauthor=M.+Negriauthor=B.+Oliosiauthor=E.+Rattiauthor=K.+D.+Readauthor=M.+Roscicauthor=I.+Sartoriauthor=S.+Spadaauthor=G.+Tedescoauthor=L.+Tarsiauthor=S.+Terreniauthor=F.+Visentiniauthor=A.+Zocchiauthor=L.+Zonziniauthor=R.+Di+Fabio&title=6-%283%2C4-Dichlorophenyl%29-1-%5B%28methyloxy%29methyl%5D-3-azabicyclo%5B4.1.0%5Dheptane%3A+a+new+potent+and+selective+triple+reuptake+inhibitor&doi=10.1021%2Fjm100481d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">6-(3,4-Dichlorophenyl)-1-[(Methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A New Potent and Selective Triple Reuptake Inhibitor</span></div><div class="casAuthors">Micheli, Fabrizio; Cavanni, Paolo; Andreotti, Daniele; Arban, Roberto; Benedetti, Roberto; Bertani, Barbara; Bettati, Michela; Bettelini, Letizia; Bonanomi, Giorgio; Braggio, Simone; Carletti, Renzo; Checchia, Anna; Corsi, Mauro; Fazzolari, Elettra; Fontana, Stefano; Marchioro, Carla; Merlo-Pich, Emilio; Negri, Michele; Oliosi, Beatrice; Ratti, Emiliangelo; Read, Kevin D.; Roscic, Maja; Sartori, Ilaria; Spada, Simone; Tedesco, Giovanna; Tarsi, Luca; Terreni, Silvia; Visentini, Filippo; Zocchi, Alessandro; Zonzini, Laura; Di Fabio, Romano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4989-5001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported.  Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics.  Excellent bioavailability and brain penetration are assocd. with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT.  In vivo microdialysis expts. in different animal models and receptor occupancy studies in rat confirmed that deriv. 17 (I) showed an appropriate profile to guarantee further progression of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NYLPRsborLVg90H21EOLACvtfcHk0lhwwda1VyC1HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntF2jtbo%253D&md5=b250a9a4f7772f81ab2702180348b254</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm100481d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100481d%26sid%3Dliteratum%253Aachs%26aulast%3DMicheli%26aufirst%3DF.%26aulast%3DCavanni%26aufirst%3DP.%26aulast%3DAndreotti%26aufirst%3DD.%26aulast%3DArban%26aufirst%3DR.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DBertani%26aufirst%3DB.%26aulast%3DBettati%26aufirst%3DM.%26aulast%3DBettelini%26aufirst%3DL.%26aulast%3DBonanomi%26aufirst%3DG.%26aulast%3DBraggio%26aufirst%3DS.%26aulast%3DCarletti%26aufirst%3DR.%26aulast%3DChecchia%26aufirst%3DA.%26aulast%3DCorsi%26aufirst%3DM.%26aulast%3DFazzolari%26aufirst%3DE.%26aulast%3DFontana%26aufirst%3DS.%26aulast%3DMarchioro%26aufirst%3DC.%26aulast%3DMerlo-Pich%26aufirst%3DE.%26aulast%3DNegri%26aufirst%3DM.%26aulast%3DOliosi%26aufirst%3DB.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DRoscic%26aufirst%3DM.%26aulast%3DSartori%26aufirst%3DI.%26aulast%3DSpada%26aufirst%3DS.%26aulast%3DTedesco%26aufirst%3DG.%26aulast%3DTarsi%26aufirst%3DL.%26aulast%3DTerreni%26aufirst%3DS.%26aulast%3DVisentini%26aufirst%3DF.%26aulast%3DZocchi%26aufirst%3DA.%26aulast%3DZonzini%26aufirst%3DL.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26atitle%3D6-%25283%252C4-Dichlorophenyl%2529-1-%255B%2528methyloxy%2529methyl%255D-3-azabicyclo%255B4.1.0%255Dheptane%253A%2520a%2520new%2520potent%2520and%2520selective%2520triple%2520reuptake%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4989%26epage%3D5001%26doi%3D10.1021%2Fjm100481d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Manoury, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binet, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefevre-Borg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavero, I. G.</span><span> </span><span class="NLM_article-title">Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1003</span><span class="NLM_x">–</span> <span class="NLM_lpage">1011</span><span class="refDoi"> DOI: 10.1021/jm00389a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00389a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=1003-1011&author=P.+M.+Manouryauthor=J.+L.+Binetauthor=J.+Rousseauauthor=F.+Lefevre-Borgauthor=I.+G.+Cavero&title=Synthesis+of+a+series+of+compounds+related+to+betaxolol%2C+a+new+beta+1-adrenoceptor+antagonist+with+a+pharmacological+and+pharmacokinetic+profile+optimized+for+the+treatment+of+chronic+cardiovascular+diseases&doi=10.1021%2Fjm00389a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fjm00389a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00389a008%26sid%3Dliteratum%253Aachs%26aulast%3DManoury%26aufirst%3DP.%2BM.%26aulast%3DBinet%26aufirst%3DJ.%2BL.%26aulast%3DRousseau%26aufirst%3DJ.%26aulast%3DLefevre-Borg%26aufirst%3DF.%26aulast%3DCavero%26aufirst%3DI.%2BG.%26atitle%3DSynthesis%2520of%2520a%2520series%2520of%2520compounds%2520related%2520to%2520betaxolol%252C%2520a%2520new%2520beta%25201-adrenoceptor%2520antagonist%2520with%2520a%2520pharmacological%2520and%2520pharmacokinetic%2520profile%2520optimized%2520for%2520the%2520treatment%2520of%2520chronic%2520cardiovascular%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D1003%26epage%3D1011%26doi%3D10.1021%2Fjm00389a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Arfwidsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borg, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skanberg, I.</span><span> </span><span class="NLM_article-title">Metabolism of metoprolol in the rat in vitro and in vivo</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.3109/00498257609151681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.3109%2F00498257609151681" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1976&pages=691-711&author=A.+Arfwidssonauthor=K.+O.+Borgauthor=K.+J.+Hoffmannauthor=I.+Skanberg&title=Metabolism+of+metoprolol+in+the+rat+in+vitro+and+in+vivo&doi=10.3109%2F00498257609151681"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.3109%2F00498257609151681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498257609151681%26sid%3Dliteratum%253Aachs%26aulast%3DArfwidsson%26aufirst%3DA.%26aulast%3DBorg%26aufirst%3DK.%2BO.%26aulast%3DHoffmann%26aufirst%3DK.%2BJ.%26aulast%3DSkanberg%26aufirst%3DI.%26atitle%3DMetabolism%2520of%2520metoprolol%2520in%2520the%2520rat%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DXenobiotica%26date%3D1976%26volume%3D6%26spage%3D691%26epage%3D711%26doi%3D10.3109%2F00498257609151681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">VAN Giezen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berntsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissing, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordanetto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, P. J.</span><span> </span><span class="NLM_article-title">Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation</span> <span class="citation_source-journal">J. Thromb. Haemostasis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1556</span><span class="NLM_x">–</span> <span class="NLM_lpage">1565</span><span class="refDoi"> DOI: 10.1111/j.1538-7836.2009.03527.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1111%2Fj.1538-7836.2009.03527.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19552634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ehsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=1556-1565&author=J.+J.+VAN+Giezenauthor=L.+Nilssonauthor=P.+Berntssonauthor=B.+M.+Wissingauthor=F.+Giordanettoauthor=W.+Tomlinsonauthor=P.+J.+Greasley&title=Ticagrelor+binds+to+human+P2Y%2812%29+independently+from+ADP+but+antagonizes+ADP-induced+receptor+signaling+and+platelet+aggregation&doi=10.1111%2Fj.1538-7836.2009.03527.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation</span></div><div class="casAuthors">Van Giezen, J. J. J.; Nilsson, L.; Berntsson, P.; Wissing, B.-M.; Giordanetto, F.; Tomlinson, W.; Greasley, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1556-1565</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: P2Y12 plays an important role in regulating platelet aggregation and function.  This receptor is the primary target of thienopyridine antiplatelet agents, the active metabolites of which bind irreversibly to the receptor, and of newer agents that can directly and reversibly modulate receptor activity.  Objective: To characterize the receptor biol. of the first reversibly binding oral P2Y12 antagonist, ticagrelor (AZD6140), a member of the new cyclopentyltriazolopyrimidine (CPTP) class currently in phase III development.  Methods: Ticagrelor displayed apparent non-competitive or insurmountable antagonism of ADP-induced aggregation in human washed platelets.  This was investigated using competition binding against [3H]ADP, [33P]2MeS-ADP and the investigational CPTP compd. [125I]AZ11931285 at recombinant human P2Y12.  Functional receptor inhibition studies were performed using a GTPγS-binding assay, and further binding studies were performed using membranes prepd. from washed human platelets.  Results: Radioligand-binding studies demonstrated that ticagrelor binds potently and reversibly to human P2Y12 with Kon and Koff of (1.1 ± 0.2) × 10-4 nM-1 s-1 and (8.7 ± 1.4) × 10-4 s-1, resp.  Ticagrelor does not displace [3H]ADP from the receptor (Ki > 10 μM) but binds competitively with [33P]2MeS-ADP (Ki = 4.3 ± 1.3 nM) and [125I]AZ11931285 (Ki = 0.33 ± 0.04 nM), and shows apparent non-competitive inhibition of ADP-induced signaling but competitive inhibition of 2MeS-ADP-induced signaling.  Binding studies on membranes prepd. from human washed platelets demonstrated similar non-competitive binding for ADP and ticagrelor.  Conclusions: These data indicate that P2Y12 is targeted by ticagrelor via a mechanism that is non-competitive with ADP, suggesting the existence of an independent receptor-binding site for CPTPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCr1KnUks7MrVg90H21EOLACvtfcHk0lhRvirya16hFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ehsr%252FE&md5=a054b99f153bdab7acf6dea8a4b26d94</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2009.03527.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2009.03527.x%26sid%3Dliteratum%253Aachs%26aulast%3DVAN%2BGiezen%26aufirst%3DJ.%2BJ.%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3DBerntsson%26aufirst%3DP.%26aulast%3DWissing%26aufirst%3DB.%2BM.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DTomlinson%26aufirst%3DW.%26aulast%3DGreasley%26aufirst%3DP.%2BJ.%26atitle%3DTicagrelor%2520binds%2520to%2520human%2520P2Y%252812%2529%2520independently%2520from%2520ADP%2520but%2520antagonizes%2520ADP-induced%2520receptor%2520signaling%2520and%2520platelet%2520aggregation%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2009%26volume%3D7%26spage%3D1556%26epage%3D1565%26doi%3D10.1111%2Fj.1538-7836.2009.03527.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Capodanno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dharmashankar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolillo, D. J.</span><span> </span><span class="NLM_article-title">Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist</span> <span class="citation_source-journal">Expert Rev. Cardiovasc. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1586/erc.09.172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1586%2Ferc.09.172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20136601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1yltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=151-158&author=D.+Capodannoauthor=K.+Dharmashankarauthor=D.+J.+Angiolillo&title=Mechanism+of+action+and+clinical+development+of+ticagrelor%2C+a+novel+platelet+ADP+P2Y12+receptor+antagonist&doi=10.1586%2Ferc.09.172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist</span></div><div class="casAuthors">Capodanno, Davide; Dharmashankar, Kodlipet; Angiolillo, Dominick J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Cardiovascular Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">ERCTAS</span>;
        ISSN:<span class="NLM_cas:issn">1477-9072</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhibition of the platelet ADP P2Y12 receptor has shown to be assocd. with a marked risk redn. of atherothrombotic events in high-risk settings, including patients with acute coronary syndromes and those undergoing percutaneous coronary interventions.  Clin. and lab. experiences have led to a better comprehension of the drawbacks of currently available P2Y12 receptor antagonists, stimulating the development of novel agents.  Ticagrelor (AZD6140) is the first drug of a new chem. class called cyclopentyltriazolopyrimidine, which is administered orally and has a reversible P2Y12 receptor inhibitory effect.  Preclin. and early-phase clin. studies have shown ticagrelor to be characterized by a rapid, greater and consistent antiplatelet effect with a favorable safety profile.  Recent findings from large-scale Phase III trials showed ticagrelor to be more effective in preventing ischemic events in acute coronary syndrome patients without an increased risk of protocol-defined major bleeding, but with an increase in the rate of nonprocedure-related bleeding, compared with currently recommended treatment regimens.  This article provides an overview of the pharmacol. properties and clin. development of ticagrelor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGret9Jrzf-JM7Vg90H21EOLACvtfcHk0lhRvirya16hFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1yltrc%253D&md5=564687ac7accfd6a34fd682826d85bcd</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1586%2Ferc.09.172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Ferc.09.172%26sid%3Dliteratum%253Aachs%26aulast%3DCapodanno%26aufirst%3DD.%26aulast%3DDharmashankar%26aufirst%3DK.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DMechanism%2520of%2520action%2520and%2520clinical%2520development%2520of%2520ticagrelor%252C%2520a%2520novel%2520platelet%2520ADP%2520P2Y12%2520receptor%2520antagonist%26jtitle%3DExpert%2520Rev.%2520Cardiovasc.%2520Ther.%26date%3D2010%26volume%3D8%26spage%3D151%26epage%3D158%26doi%3D10.1586%2Ferc.09.172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Nilsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giezen, J. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, P. J.</span><span> </span><span class="NLM_article-title">Evidence for distinct ligand binding sites on recombinant P2Y<sub>12</sub> receptors</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl II</span><span class="NLM_x">) </span> <span class="NLM_fpage">II</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2006&pages=II-248&issue=Suppl+II&author=L.+Nilssonauthor=J.+J.+J.+van+Giezenauthor=P.+J.+Greasley&title=Evidence+for+distinct+ligand+binding+sites+on+recombinant+P2Y12+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DGreasley%26aufirst%3DP.%2BJ.%26atitle%3DEvidence%2520for%2520distinct%2520ligand%2520binding%2520sites%2520on%2520recombinant%2520P2Y12%2520receptors%26jtitle%3DCirculation%26date%3D2006%26volume%3D114%26issue%3DSuppl%2520II%26spage%3DII%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Springthorpe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birkinshaw, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guile, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ince, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, I. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimore, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigby, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teobald, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webborn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, P. A.</span><span> </span><span class="NLM_article-title">From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6013</span><span class="NLM_x">–</span> <span class="NLM_lpage">6018</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.07.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2007.07.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17827008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSitLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6013-6018&author=B.+Springthorpeauthor=A.+Baileyauthor=P.+Bartonauthor=T.+N.+Birkinshawauthor=R.+V.+Bonnertauthor=R.+C.+Brownauthor=D.+Chapmanauthor=J.+Dixonauthor=S.+D.+Guileauthor=R.+G.+Humphriesauthor=S.+F.+Huntauthor=F.+Inceauthor=A.+H.+Ingallauthor=I.+P.+Kirkauthor=P.+D.+Leesonauthor=P.+Leffauthor=R.+J.+Lewisauthor=B.+P.+Martinauthor=D.+F.+McGinnityauthor=M.+P.+Mortimoreauthor=S.+W.+Paineauthor=G.+Pairaudeauauthor=A.+Patelauthor=A.+J.+Rigbyauthor=R.+J.+Rileyauthor=B.+J.+Teobaldauthor=W.+Tomlinsonauthor=P.+J.+Webbornauthor=P.+A.+Willis&title=From+ATP+to+AZD6140%3A+the+discovery+of+an+orally+active+reversible+P2Y12+receptor+antagonist+for+the+prevention+of+thrombosis&doi=10.1016%2Fj.bmcl.2007.07.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis</span></div><div class="casAuthors">Springthorpe, Brian; Bailey, Andrew; Barton, Patrick; Birkinshaw, Timothy N.; Bonnert, Roger V.; Brown, Roger C.; Chapman, David; Dixon, John; Guile, Simon D.; Humphries, Robert G.; Hunt, Simon F.; Ince, Francis; Ingall, Anthony H.; Kirk, Ian P.; Leeson, Paul D.; Leff, Paul; Lewis, Richard J.; Martin, Barrie P.; McGinnity, Dermot F.; Mortimore, Michael P.; Paine, Stuart W.; Pairaudeau, Garry; Patel, Anil; Rigby, Aaron J.; Riley, Robert J.; Teobald, Barry J.; Tomlinson, Wendy; Webborn, Peter J. H.; Willis, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6013-6018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Starting from ATP, the identification of a novel series of P2Y12 receptor antagonists and exploitation of their SAR is described.  Modifications of the acidic side chain and the purine core and investigation of hydrophobic substituents led to a series of neutral mols.  The leading compd., (AZD6140, I), is currently in a large phase III clin. trial for the treatment of acute coronary syndromes and prevention of thromboembolic clin. sequelae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOx3G4xnQGbVg90H21EOLACvtfcHk0libJzAAEfZ8IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSitLvN&md5=9342d8eeb232c86e3aa0ffb2a96af659</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.057%26sid%3Dliteratum%253Aachs%26aulast%3DSpringthorpe%26aufirst%3DB.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBirkinshaw%26aufirst%3DT.%2BN.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBrown%26aufirst%3DR.%2BC.%26aulast%3DChapman%26aufirst%3DD.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DGuile%26aufirst%3DS.%2BD.%26aulast%3DHumphries%26aufirst%3DR.%2BG.%26aulast%3DHunt%26aufirst%3DS.%2BF.%26aulast%3DInce%26aufirst%3DF.%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DKirk%26aufirst%3DI.%2BP.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DR.%2BJ.%26aulast%3DMartin%26aufirst%3DB.%2BP.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DMortimore%26aufirst%3DM.%2BP.%26aulast%3DPaine%26aufirst%3DS.%2BW.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DRigby%26aufirst%3DA.%2BJ.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DTeobald%26aufirst%3DB.%2BJ.%26aulast%3DTomlinson%26aufirst%3DW.%26aulast%3DWebborn%26aufirst%3DP.%2BJ.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26atitle%3DFrom%2520ATP%2520to%2520AZD6140%253A%2520the%2520discovery%2520of%2520an%2520orally%2520active%2520reversible%2520P2Y12%2520receptor%2520antagonist%2520for%2520the%2520prevention%2520of%2520thrombosis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6013%26epage%3D6018%26doi%3D10.1016%2Fj.bmcl.2007.07.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Caplain, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaud, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Necciari, J.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of clopidogrel</span> <span class="citation_source-journal">Semin. Thromb. Hemost.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10440419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaK1MXltVKmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1999&pages=25-28&issue=Suppl+2&author=H.+Caplainauthor=F.+Donatauthor=C.+Gaudauthor=J.+Necciari&title=Pharmacokinetics+of+clopidogrel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of clopidogrel</span></div><div class="casAuthors">Caplain, Henri; Donat, Francois; Gaud, C.; Necciari, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">25-28</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">Single- and multiple-dose pharmacokinetics of SR26334, the inactive carboxylic acid metabolite of clopidogrel, were investigated following oral doses of clopidogrel to healthy men.  The mean max. plasma concns. (Cmax) of SR26334 following single doses of 50, 75, 100, and 150 mg clopidogrel were 1.6, 2.9, 3.1, and 4.9 mg/L, resp.  This demonstrated a dose-proportional increase of Cmax in this range of clopidogrel doses.  The urinary excretion of SR26334 was low (2.2-2.4% of the dose administered), and renal clearance remained virtually const. for 2-24 h after all 4 doses.  Median times required to reach Cmax (0.8-1.0 h) and mean plasma half-lives (7.2-7.6 h) were not significantly different among the doses.  Following repeated doses of 75 mg clopidogrel, mean plasma trough concns. of SR26334 at steady state ranged 0.11-0.80 mg/L.  These values are similar to those obsd. during the 12-wk administration of clopidogrel, indicating that steady-state values are reproducible and that the esterase biotransformation of clopidogrel into its carboxylic acid metabolite remains const. over a no. of months of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzkQR1dw1j2rVg90H21EOLACvtfcHk0libJzAAEfZ8IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVKmurY%253D&md5=1d6ce13080c8e860e5bac57bc1b2b77f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaplain%26aufirst%3DH.%26aulast%3DDonat%26aufirst%3DF.%26aulast%3DGaud%26aufirst%3DC.%26aulast%3DNecciari%26aufirst%3DJ.%26atitle%3DPharmacokinetics%2520of%2520clopidogrel%26jtitle%3DSemin.%2520Thromb.%2520Hemost.%26date%3D1999%26volume%3D25%26issue%3DSuppl%25202%26spage%3D25%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Farid, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garofolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shwajch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, H.</span><span> </span><span class="NLM_article-title">Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1002/rcm.2813</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Frcm.2813" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=17154350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpt1OqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=169-179&author=N.+A.+Faridauthor=M.+McIntoshauthor=F.+Garofoloauthor=E.+Wongauthor=A.+Shwajchauthor=M.+Kennedyauthor=M.+Youngauthor=P.+Sarkarauthor=K.+Kawabataauthor=M.+Takahashiauthor=H.+Pang&title=Determination+of+the+active+and+inactive+metabolites+of+prasugrel+in+human+plasma+by+liquid+chromatography%2Ftandem+mass+spectrometry&doi=10.1002%2Frcm.2813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry</span></div><div class="casAuthors">Farid, Nagy A.; McIntosh, Mary; Garofolo, Fabio; Wong, Ernest; Shwajch, Amanda; Kennedy, Monika; Young, Michelle; Sarkar, Pratibha; Kawabata, Kiyoshi; Takahashi, Makoto; Pang, Henrianna</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-179</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Two fast and sensitive liq. chromatog./tandem mass spectrometry (LC/MS/MS)-based bioanal. assays were developed and validated to quantify the active and three inactive metabolites of prasugrel.  Prasugrel is a novel thienopyridine prodrug that is metabolized to the pharmacol. active metabolite in addn. to three inactive metabolites, which directly relate to the formation and elimination of the active metabolite.  After extn. and sepn., the analytes were detected and quantified using a triple quadrupole mass spectrometer using pos. electrospray ionization.  The validated concn. range for the inactive metabolites assay was from 1 to 500 ng/mL for each of the three analytes.  Addnl., a 5× diln. factor was validated.  The interday accuracy ranged from -10.5% to 12.5% and the precision ranged from 2.4% to 6.6% for all three analytes.  All results showed accuracy and precision within ±20% at the lower limit of quantification and ±15% at other levels.  The validated concn. range for the active metabolite assay was from 0.5 to 250 ng/mL.  Addnl., a 10× diln. factor was validated.  The interbatch accuracy ranged from -7.00% to 5.98%, while the precision ranged from 0.98% to 3.39%.  Derivatization of the active metabolite in blood with 2-bromo-3'-methoxyacetophenone immediately after collection was essential to ensure the stability of the metabolite during sample processing and storage.  These methods have been applied to det. the concns. of the active and inactive metabolites of prasugrel in human plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrcIZp5TlTbVg90H21EOLACvtfcHk0lioCQoIunI6Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpt1OqtA%253D%253D&md5=52a7520888b51d7e20a305466a18352f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1002%2Frcm.2813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.2813%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DMcIntosh%26aufirst%3DM.%26aulast%3DGarofolo%26aufirst%3DF.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DShwajch%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DSarkar%26aufirst%3DP.%26aulast%3DKawabata%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DH.%26atitle%3DDetermination%2520of%2520the%2520active%2520and%2520inactive%2520metabolites%2520of%2520prasugrel%2520in%2520human%2520plasma%2520by%2520liquid%2520chromatography%252Ftandem%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2007%26volume%3D21%26spage%3D169%26epage%3D179%26doi%3D10.1002%2Frcm.2813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Quan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallheer, J. M.</span><span> </span><span class="NLM_article-title">The race to an orally active Factor Xa inhibitor: recent advances</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15338955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvFOms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=460-469&author=M.+L.+Quanauthor=J.+M.+Smallheer&title=The+race+to+an+orally+active+Factor+Xa+inhibitor%3A+recent+advances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The race to an orally active factor Xa inhibitor: Recent advances</span></div><div class="casAuthors">Quan, Mimi L.; Smallheer, Joanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">460-469</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Factor Xa (fXa) is a key enzyme in the coagulation cascade and an essential component of the prothrombinase complex, which activates prothrombin to thrombin, leading to fibrin clot formation.  In the search for a more effective and safer orally active anticoagulant, fXa has emerged as a major target for potential therapeutic applications in the treatment and prevention of thrombosis.  This review focuses on recent advances in the chem. of drug design and lead optimization of orally bioavailable fXa inhibitors.  Many of these orally active fXa inhibitors are currently in clin. trials and are anticipated to change the landscape of thrombosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoypUcAjnM_r7Vg90H21EOLACvtfcHk0lioCQoIunI6Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvFOms7w%253D&md5=e39eb102ea35b44a97c5d18ca9d90304</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DSmallheer%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520race%2520to%2520an%2520orally%2520active%2520Factor%2520Xa%2520inhibitor%253A%2520recent%2520advances%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2004%26volume%3D7%26spage%3D460%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Qiao, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheney, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallwood, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rendina, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luettgen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knabb, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, P. Y.</span><span> </span><span class="NLM_article-title">Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4118</span><span class="NLM_x">–</span> <span class="NLM_lpage">4123</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2008.05.095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18550370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslequ7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4118-4123&author=J.+X.+Qiaoauthor=D.+L.+Cheneyauthor=R.+S.+Alexanderauthor=A.+M.+Smallwoodauthor=S.+R.+Kingauthor=K.+Heauthor=A.+R.+Rendinaauthor=J.+M.+Luettgenauthor=R.+M.+Knabbauthor=R.+R.+Wexlerauthor=P.+Y.+Lam&title=Achieving+structural+diversity+using+the+perpendicular+conformation+of+alpha-substituted+phenylcyclopropanes+to+mimic+the+bioactive+conformation+of+ortho-substituted+biphenyl+P4+moieties%3A+discovery+of+novel%2C+highly+potent+inhibitors+of+Factor+Xa&doi=10.1016%2Fj.bmcl.2008.05.095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa</span></div><div class="casAuthors">Qiao, Jennifer X.; Cheney, Daniel L.; Alexander, Richard S.; Smallwood, Angela M.; King, Sarah R.; He, Kan; Rendina, Alan R.; Luettgen, Joseph M.; Knabb, Robert M.; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4118-4123</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ortho-substituted biphenyl moieties are widely used in drug design.  We herein report a successful use of the perpendicular conformation of the alpha-substituted phenylcyclopropyl groups to mimic the aplanar, biol. active conformation of the ortho-substituted biphenyl moieties to achieve structural diversity.  This is exemplified by the design and synthesis of a series of highly potent pyrazole bicyclic-based Factor Xa (FXa) inhibitors bearing alpha-substituted phenylcyclopropyl P4 moieties.  The designed perpendicular conformation was confirmed by the X-ray structure of FXa-bound compd. I.  The potential structural basis for the high FXa potency in the phenylcyclopropyl P4 analogs and their improved FXa inhibitory activities compared with the biphenyl P4 counterparts are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK2wNc7asx8bVg90H21EOLACvtfcHk0lioCQoIunI6Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslequ7o%253D&md5=4c06af32c061accffbed26a39031108e</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.095%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DCheney%26aufirst%3DD.%2BL.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DSmallwood%26aufirst%3DA.%2BM.%26aulast%3DKing%26aufirst%3DS.%2BR.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%26atitle%3DAchieving%2520structural%2520diversity%2520using%2520the%2520perpendicular%2520conformation%2520of%2520alpha-substituted%2520phenylcyclopropanes%2520to%2520mimic%2520the%2520bioactive%2520conformation%2520of%2520ortho-substituted%2520biphenyl%2520P4%2520moieties%253A%2520discovery%2520of%2520novel%252C%2520highly%2520potent%2520inhibitors%2520of%2520Factor%2520Xa%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4118%26epage%3D4123%26doi%3D10.1016%2Fj.bmcl.2008.05.095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Pinto, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galemmo, R. A.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quan, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orwat, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallwood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luettgen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rendina, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knabb, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexler, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, P. Y.</span><span> </span><span class="NLM_article-title">Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5584</span><span class="NLM_x">–</span> <span class="NLM_lpage">5589</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2006.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16963264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSis7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5584-5589&author=D.+J.+Pintoauthor=R.+A.+Galemmoauthor=M.+L.+Quanauthor=M.+J.+Orwatauthor=C.+Clarkauthor=R.+Liauthor=B.+Wellsauthor=F.+Woernerauthor=R.+S.+Alexanderauthor=K.+A.+Rossiauthor=A.+Smallwoodauthor=P.+C.+Wongauthor=J.+M.+Luettgenauthor=A.+R.+Rendinaauthor=R.+M.+Knabbauthor=K.+Heauthor=R.+R.+Wexlerauthor=P.+Y.+Lam&title=Discovery+of+potent%2C+efficacious%2C+and+orally+bioavailable+inhibitors+of+blood+coagulation+factor+Xa+with+neutral+P1+moieties&doi=10.1016%2Fj.bmcl.2006.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties</span></div><div class="casAuthors">Pinto, Donald J. P.; Galemmo, Robert A.; Quan, Mimi L.; Orwat, Michael J.; Clark, Charles; Li, Renhua; Wells, Brian; Woerner, Francis; Alexander, Richard S.; Rossi, Karen A.; Smallwood, Angela; Wong, Pancras C.; Luettgen, Joseph M.; Rendina, Alan R.; Knabb, Robert M.; He, Kan; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5584-5589</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa.  The compd. 3-[6-(2'-dimethylaminomethylbiphenyl-4-yl)-7-oxo-3-trifluoromethyl-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine-1-yl]-benzamide shows good factor Xa potency, selectivity, in vivo efficacy and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBUWs8zs_04LVg90H21EOLACvtfcHk0ljGCWUsW1luBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSis7zF&md5=3b4511f8606ab5fa3a4ffeede492a55c</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DGalemmo%26aufirst%3DR.%2BA.%26aulast%3DQuan%26aufirst%3DM.%2BL.%26aulast%3DOrwat%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DB.%26aulast%3DWoerner%26aufirst%3DF.%26aulast%3DAlexander%26aufirst%3DR.%2BS.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DSmallwood%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DRendina%26aufirst%3DA.%2BR.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%26atitle%3DDiscovery%2520of%2520potent%252C%2520efficacious%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520blood%2520coagulation%2520factor%2520Xa%2520with%2520neutral%2520P1%2520moieties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5584%26epage%3D5589%26doi%3D10.1016%2Fj.bmcl.2006.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kussmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochsenfeld, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slipchenko, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levchenko, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiStasio, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lochan, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besley, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassolov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maslen, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korambath, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dachsel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerksen, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreuw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunietz, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutoi, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furlani, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwaltney, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kedziora, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khalliulin, R. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klunzinger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proynov, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieniazek, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhee, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherrill, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmonett, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subotnik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodcock, H. L.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chipman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keil, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warshel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehre, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, H. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krylov, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head-Gordon, M.</span><span> </span><span class="NLM_article-title">Advances in methods and algorithms in a modern quantum chemistry program package</span> <span class="citation_source-journal">Phys. Chem. Chem. Phys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3172</span><span class="NLM_x">–</span> <span class="NLM_lpage">3191</span><span class="refDoi"> DOI: 10.1039/B517914A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1039%2FB517914A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16902710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsValsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=3172-3191&author=Y.+Shaoauthor=L.+F.+Molnarauthor=Y.+Jungauthor=J.+Kussmannauthor=C.+Ochsenfeldauthor=S.+T.+Brownauthor=A.+T.+Gilbertauthor=L.+V.+Slipchenkoauthor=S.+V.+Levchenkoauthor=D.+P.+O%E2%80%99Neillauthor=R.+A.+DiStasioauthor=R.+C.+Lochanauthor=T.+Wangauthor=G.+J.+Beranauthor=N.+A.+Besleyauthor=J.+M.+Herbertauthor=C.+Y.+Linauthor=T.+Van+Voorhisauthor=S.+H.+Chienauthor=A.+Sodtauthor=R.+P.+Steeleauthor=V.+A.+Rassolovauthor=P.+E.+Maslenauthor=P.+P.+Korambathauthor=R.+D.+Adamsonauthor=B.+Austinauthor=J.+Bakerauthor=E.+F.+Byrdauthor=H.+Dachselauthor=R.+J.+Doerksenauthor=A.+Dreuwauthor=B.+D.+Dunietzauthor=A.+D.+Dutoiauthor=T.+R.+Furlaniauthor=S.+R.+Gwaltneyauthor=A.+Heydenauthor=S.+Hirataauthor=C.+P.+Hsuauthor=G.+Kedzioraauthor=R.+Z.+Khalliulinauthor=P.+Klunzingerauthor=A.+M.+Leeauthor=M.+S.+Leeauthor=W.+Liangauthor=I.+Lotanauthor=N.+Nairauthor=B.+Petersauthor=E.+I.+Proynovauthor=P.+A.+Pieniazekauthor=Y.+M.+Rheeauthor=J.+Ritchieauthor=E.+Rostaauthor=C.+D.+Sherrillauthor=A.+C.+Simmonettauthor=J.+E.+Subotnikauthor=H.+L.+Woodcockauthor=W.+Zhangauthor=A.+T.+Bellauthor=A.+K.+Chakrabortyauthor=D.+M.+Chipmanauthor=F.+J.+Keilauthor=A.+Warshelauthor=W.+J.+Hehreauthor=H.+F.+Schaeferauthor=J.+Kongauthor=A.+I.+Krylovauthor=P.+M.+Gillauthor=M.+Head-Gordon&title=Advances+in+methods+and+algorithms+in+a+modern+quantum+chemistry+program+package&doi=10.1039%2FB517914A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in methods and algorithms in a modern quantum chemistry program package</span></div><div class="casAuthors">Shao, Yihan; Molnar, Laszlo Fusti; Jung, Yousung; Kussmann, Jorg; Ochsenfeld, Christian; Brown, Shawn T.; Gilbert, Andrew T. B.; Slipchenko, Lyudmila V.; Levchenko, Sergey V.; O'Neill, Darragh P.; DiStasio, Robert A., Jr.; Lochan, Rohini C.; Wang, Tao; Beran, Gregory J. O.; Besley, Nicholas A.; Herbert, John M.; Lin, Ching Yeh; Van Voorhis, Troy; Chien, Siu Hung; Sodt, Alex; Steele, Ryan P.; Rassolov, Vitaly A.; Maslen, Paul E.; Korambath, Prakashan P.; Adamson, Ross D.; Austin, Brian; Baker, Jon; Byrd, Edward F. C.; Dachsel, Holger; Doerksen, Robert J.; Dreuw, Andreas; Dunietz, Barry D.; Dutoi, Anthony D.; Furlani, Thomas R.; Gwaltney, Steven R.; Heyden, Andreas; Hirata, So; Hsu, Chao-Ping; Kedziora, Gary; Khalliulin, Rustam Z.; Klunzinger, Phil; Lee, Aaron M.; Lee, Michael S.; Liang, WanZhen; Lotan, Itay; Nair, Nikhil; Peters, Baron; Proynov, Emil I.; Pieniazek, Piotr A.; Rhee, Young Min; Ritchie, Jim; Rosta, Edina; Sherrill, C. David; Simmonett, Andrew C.; Subotnik, Joseph E.; Woodcock, H. Lee, III; Zhang, Weimin; Bell, Alexis T.; Chakraborty, Arup K.; Chipman, Daniel M.; Keil, Frerich J.; Warshel, Arieh; Hehre, Warren J.; Schaefer, Henry F., III; Kong, Jing; Krylov, Anna I.; Gill, Peter M. W.; Head-Gordon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3172-3191</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Advances in theory and algorithms for electronic structure calcns. must be incorporated into program packages to enable them to become routinely used by the broader chem. community.  This work reviews advances made over the past five years or so that constitute the major improvements contained in a new release of the Q-Chem quantum chem. package, together with illustrative timings and applications.  Specific developments discussed include fast methods for d. functional theory calcns., linear scaling evaluation of energies, NMR chem. shifts and elec. properties, fast auxiliary basis function methods for correlated energies and gradients, equation-of-motion coupled cluster methods for ground and excited states, geminal wavefunctions, embedding methods and techniques for exploring potential energy surfaces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNN2YG1uDDs7Vg90H21EOLACvtfcHk0ljGCWUsW1luBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsValsbs%253D&md5=0ba1d2a350afc7922d2f9ca0c6e47d34</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1039%2FB517914A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB517914A%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DY.%26aulast%3DMolnar%26aufirst%3DL.%2BF.%26aulast%3DJung%26aufirst%3DY.%26aulast%3DKussmann%26aufirst%3DJ.%26aulast%3DOchsenfeld%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DS.%2BT.%26aulast%3DGilbert%26aufirst%3DA.%2BT.%26aulast%3DSlipchenko%26aufirst%3DL.%2BV.%26aulast%3DLevchenko%26aufirst%3DS.%2BV.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DD.%2BP.%26aulast%3DDiStasio%26aufirst%3DR.%2BA.%26aulast%3DLochan%26aufirst%3DR.%2BC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBeran%26aufirst%3DG.%2BJ.%26aulast%3DBesley%26aufirst%3DN.%2BA.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DVan%2BVoorhis%26aufirst%3DT.%26aulast%3DChien%26aufirst%3DS.%2BH.%26aulast%3DSodt%26aufirst%3DA.%26aulast%3DSteele%26aufirst%3DR.%2BP.%26aulast%3DRassolov%26aufirst%3DV.%2BA.%26aulast%3DMaslen%26aufirst%3DP.%2BE.%26aulast%3DKorambath%26aufirst%3DP.%2BP.%26aulast%3DAdamson%26aufirst%3DR.%2BD.%26aulast%3DAustin%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DByrd%26aufirst%3DE.%2BF.%26aulast%3DDachsel%26aufirst%3DH.%26aulast%3DDoerksen%26aufirst%3DR.%2BJ.%26aulast%3DDreuw%26aufirst%3DA.%26aulast%3DDunietz%26aufirst%3DB.%2BD.%26aulast%3DDutoi%26aufirst%3DA.%2BD.%26aulast%3DFurlani%26aufirst%3DT.%2BR.%26aulast%3DGwaltney%26aufirst%3DS.%2BR.%26aulast%3DHeyden%26aufirst%3DA.%26aulast%3DHirata%26aufirst%3DS.%26aulast%3DHsu%26aufirst%3DC.%2BP.%26aulast%3DKedziora%26aufirst%3DG.%26aulast%3DKhalliulin%26aufirst%3DR.%2BZ.%26aulast%3DKlunzinger%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DLotan%26aufirst%3DI.%26aulast%3DNair%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DB.%26aulast%3DProynov%26aufirst%3DE.%2BI.%26aulast%3DPieniazek%26aufirst%3DP.%2BA.%26aulast%3DRhee%26aufirst%3DY.%2BM.%26aulast%3DRitchie%26aufirst%3DJ.%26aulast%3DRosta%26aufirst%3DE.%26aulast%3DSherrill%26aufirst%3DC.%2BD.%26aulast%3DSimmonett%26aufirst%3DA.%2BC.%26aulast%3DSubotnik%26aufirst%3DJ.%2BE.%26aulast%3DWoodcock%26aufirst%3DH.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBell%26aufirst%3DA.%2BT.%26aulast%3DChakraborty%26aufirst%3DA.%2BK.%26aulast%3DChipman%26aufirst%3DD.%2BM.%26aulast%3DKeil%26aufirst%3DF.%2BJ.%26aulast%3DWarshel%26aufirst%3DA.%26aulast%3DHehre%26aufirst%3DW.%2BJ.%26aulast%3DSchaefer%26aufirst%3DH.%2BF.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DKrylov%26aufirst%3DA.%2BI.%26aulast%3DGill%26aufirst%3DP.%2BM.%26aulast%3DHead-Gordon%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520methods%2520and%2520algorithms%2520in%2520a%2520modern%2520quantum%2520chemistry%2520program%2520package%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2006%26volume%3D8%26spage%3D3172%26epage%3D3191%26doi%3D10.1039%2FB517914A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Prins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoeven, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBoer, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worrell, C.</span><span> </span><span class="NLM_article-title">Conformational studies on acylcyclopropanes-I: the He-I photoelectron spectra of alpha-alkylphenylcyclopropanes</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span><span class="refDoi"> DOI: 10.1016/0040-4020(77)80443-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2F0040-4020%2877%2980443-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1977&pages=127-131&author=I.+Prinsauthor=J.+W.+Verhoevenauthor=T.+J.+deBoerauthor=C.+Worrell&title=Conformational+studies+on+acylcyclopropanes-I%3A+the+He-I+photoelectron+spectra+of+alpha-alkylphenylcyclopropanes&doi=10.1016%2F0040-4020%2877%2980443-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2877%2980443-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252877%252980443-2%26sid%3Dliteratum%253Aachs%26aulast%3DPrins%26aufirst%3DI.%26aulast%3DVerhoeven%26aufirst%3DJ.%2BW.%26aulast%3DdeBoer%26aufirst%3DT.%2BJ.%26aulast%3DWorrell%26aufirst%3DC.%26atitle%3DConformational%2520studies%2520on%2520acylcyclopropanes-I%253A%2520the%2520He-I%2520photoelectron%2520spectra%2520of%2520alpha-alkylphenylcyclopropanes%26jtitle%3DTetrahedron%26date%3D1977%26volume%3D33%26spage%3D127%26epage%3D131%26doi%3D10.1016%2F0040-4020%2877%2980443-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Williams, E. M. V.</span><span> </span><span class="NLM_article-title">A classification of antiarrhythmic actions reassessed after a decade of new drugs</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1002/j.1552-4604.1984.tb01822.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2Fj.1552-4604.1984.tb01822.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=6144698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVegs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1984&pages=129-147&author=E.+M.+V.+Williams&title=A+classification+of+antiarrhythmic+actions+reassessed+after+a+decade+of+new+drugs&doi=10.1002%2Fj.1552-4604.1984.tb01822.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">A classification of antiarrhythmic actions reassessed after a decade of new drugs</span></div><div class="casAuthors">Williams, E. M. Vaughan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">129-47</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    </div><div class="casAbstract">A review and discussion with 86 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7_u82uQNcrrVg90H21EOLACvtfcHk0li-CJk_4FRIDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVegs74%253D&md5=660259418d1cd21fd1343118eae1c76a</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1984.tb01822.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1984.tb01822.x%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DE.%2BM.%2BV.%26atitle%3DA%2520classification%2520of%2520antiarrhythmic%2520actions%2520reassessed%2520after%2520a%2520decade%2520of%2520new%2520drugs%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1984%26volume%3D24%26spage%3D129%26epage%3D147%26doi%3D10.1002%2Fj.1552-4604.1984.tb01822.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claremon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkiewicz, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieckhaus, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, K.</span><span> </span><span class="NLM_article-title">Novel 5-cyclopropyl-1,4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1168</span><span class="refDoi"> DOI: 10.1016/S0960-894X(03)00049-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0960-894X%2803%2900049-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=1165-1168&author=J.+W.+Butcherauthor=N.+J.+Livertonauthor=D.+A.+Claremonauthor=R.+M.+Freidingerauthor=N.+K.+Jurkiewiczauthor=J.+J.+Lynchauthor=J.+J.+Salataauthor=J.+Wangauthor=C.+M.+Dieckhausauthor=D.+E.+Slaughterauthor=K.+Vyas&title=Novel+5-cyclopropyl-1%2C4-benzodiazepin-2-ones+as+potent+and+selective+I%28Ks%29-blocking+class+III+antiarrhythmic+agents&doi=10.1016%2FS0960-894X%2803%2900049-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900049-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900049-0%26sid%3Dliteratum%253Aachs%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DClaremon%26aufirst%3DD.%2BA.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DJurkiewicz%26aufirst%3DN.%2BK.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDieckhaus%26aufirst%3DC.%2BM.%26aulast%3DSlaughter%26aufirst%3DD.%2BE.%26aulast%3DVyas%26aufirst%3DK.%26atitle%3DNovel%25205-cyclopropyl-1%252C4-benzodiazepin-2-ones%2520as%2520potent%2520and%2520selective%2520I%2528Ks%2529-blocking%2520class%2520III%2520antiarrhythmic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D1165%26epage%3D1168%26doi%3D10.1016%2FS0960-894X%2803%2900049-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Selnick, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claremon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freidinger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libby, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pribush, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remy, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkiewicz, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, K.</span><span> </span><span class="NLM_article-title">Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">3865</span><span class="NLM_x">–</span> <span class="NLM_lpage">3868</span><span class="refDoi"> DOI: 10.1021/jm970517u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970517u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=3865-3868&author=H.+G.+Selnickauthor=N.+J.+Livertonauthor=J.+J.+Baldwinauthor=J.+W.+Butcherauthor=D.+A.+Claremonauthor=J.+M.+Elliottauthor=R.+M.+Freidingerauthor=S.+A.+Kingauthor=B.+E.+Libbyauthor=C.+J.+McIntyreauthor=D.+A.+Pribushauthor=D.+C.+Remyauthor=G.+R.+Smithauthor=A.+J.+Tebbenauthor=N.+K.+Jurkiewiczauthor=J.+J.+Lynchauthor=J.+J.+Salataauthor=M.+C.+Sanguinettiauthor=P.+K.+Sieglauthor=D.+E.+Slaughterauthor=K.+Vyas&title=Class+III+antiarrhythmic+activity+in+vivo+by+selective+blockade+of+the+slowly+activating+cardiac+delayed+rectifier+potassium+current+IKs+by+%28R%29-2-%282%2C4-trifluoromethyl%29-N-%5B2-oxo-5-phenyl-1-%282%2C2%2C2-trifluoroethyl%29-+2%2C+3-dihydro-1H-benzo%5Be%5D%5B1%2C4%5Ddiazepin-3-yl%5Dacetamide&doi=10.1021%2Fjm970517u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Fjm970517u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970517u%26sid%3Dliteratum%253Aachs%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DClaremon%26aufirst%3DD.%2BA.%26aulast%3DElliott%26aufirst%3DJ.%2BM.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DKing%26aufirst%3DS.%2BA.%26aulast%3DLibby%26aufirst%3DB.%2BE.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DPribush%26aufirst%3DD.%2BA.%26aulast%3DRemy%26aufirst%3DD.%2BC.%26aulast%3DSmith%26aufirst%3DG.%2BR.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DJurkiewicz%26aufirst%3DN.%2BK.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DSlaughter%26aufirst%3DD.%2BE.%26aulast%3DVyas%26aufirst%3DK.%26atitle%3DClass%2520III%2520antiarrhythmic%2520activity%2520in%2520vivo%2520by%2520selective%2520blockade%2520of%2520the%2520slowly%2520activating%2520cardiac%2520delayed%2520rectifier%2520potassium%2520current%2520IKs%2520by%2520%2528R%2529-2-%25282%252C4-trifluoromethyl%2529-N-%255B2-oxo-5-phenyl-1-%25282%252C2%252C2-trifluoroethyl%2529-%25202%252C%25203-dihydro-1H-benzo%255Be%255D%255B1%252C4%255Ddiazepin-3-yl%255Dacetamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D3865%26epage%3D3868%26doi%3D10.1021%2Fjm970517u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Revermann, M.</span><span> </span><span class="NLM_article-title">Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/j.coph.2009.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.coph.2009.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=20079692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs12ntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=173-178&author=M.+Revermann&title=Pharmacological+inhibition+of+the+soluble+epoxide+hydrolase-from+mouse+to+man&doi=10.1016%2Fj.coph.2009.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man</span></div><div class="casAuthors">Revermann, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review Epoxyeicosatrienoic acids (EETs) build a family consisting of four arachidonic acid derived regioisomers that are generated by P 450 epoxygenases.  In the past years, growing interest in influencing EET level arose since EETs possess numerous beneficial effects in the cardiovascular system, for example, vasodilation, anti-inflammation and elicit renal and myocardial protection.  Because EETs are primarily metabolized by the sol. epoxide hydrolase (sEH) and potent inhibitors of this enzyme are currently available, pharmacol. sEH inhibition seems to be a feasible approach to elevate EET level in vivo.  Hence, first clin. trials on sEH inhibition in man have begun.  This review focuses on sEH inhibition as a novel pharmacol. cardiovascular protective strategy with special regard to in vivo investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJbmf7xKGAirVg90H21EOLACvtfcHk0ljcBLYbpqThJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs12ntbY%253D&md5=d339f41d4a8d604928684f67c2966cd8</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2009.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2009.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DRevermann%26aufirst%3DM.%26atitle%3DPharmacological%2520inhibition%2520of%2520the%2520soluble%2520epoxide%2520hydrolase-from%2520mouse%2520to%2520man%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2010%26volume%3D10%26spage%3D173%26epage%3D178%26doi%3D10.1016%2Fj.coph.2009.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Imig, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammock, B. D.</span><span> </span><span class="NLM_article-title">Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">794</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span><span class="refDoi"> DOI: 10.1038/nrd2875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1038%2Fnrd2875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=19794443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=794-805&author=J.+D.+Imigauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+as+a+therapeutic+target+for+cardiovascular+diseases&doi=10.1038%2Fnrd2875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases</span></div><div class="casAuthors">Imig, John D.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">794-805</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions.  These endogenous lipid mediators are broken down into diols by sol. epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial cardiovascular properties of EETs.  SEH inhibitors (sEHIs) that are based on 1,3-disubstituted urea were rapidly developed, and were shown to be antihypertensive and anti-inflammatory, and to protect the brain, heart and kidney from damage.  Although challenges for the future exist - including improving the drug-like properties of sEHIs and finding better ways to target sEHIs to specific tissues - the recent initiation of the first clin. trials of sEHIs has highlighted the therapeutic potential of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopFEiIF428mLVg90H21EOLACvtfcHk0ljcBLYbpqThJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurnK&md5=fc2af5b4802701035998e0435c8d2699</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnrd2875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2875%26sid%3Dliteratum%253Aachs%26aulast%3DImig%26aufirst%3DJ.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520as%2520a%2520therapeutic%2520target%2520for%2520cardiovascular%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D794%26epage%3D805%26doi%3D10.1038%2Fnrd2875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Takai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiyo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nariai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakatani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sone, T.</span><span> </span><span class="NLM_article-title">Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1705</span><span class="NLM_x">–</span> <span class="NLM_lpage">1708</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2015.02.076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1705-1708&author=K.+Takaiauthor=N.+Chiyoauthor=T.+Nakajimaauthor=T.+Nariaiauthor=C.+Ishikawaauthor=S.+Nakataniauthor=A.+Ikenoauthor=S.+Yamamotoauthor=T.+Sone&title=Three-dimensional+rational+approach+to+the+discovery+of+potent+substituted+cyclopropyl+urea+soluble+epoxide+hydrolase+inhibitors&doi=10.1016%2Fj.bmcl.2015.02.076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.076%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DK.%26aulast%3DChiyo%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DNariai%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DC.%26aulast%3DNakatani%26aufirst%3DS.%26aulast%3DIkeno%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DSone%26aufirst%3DT.%26atitle%3DThree-dimensional%2520rational%2520approach%2520to%2520the%2520discovery%2520of%2520potent%2520substituted%2520cyclopropyl%2520urea%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1705%26epage%3D1708%26doi%3D10.1016%2Fj.bmcl.2015.02.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakashita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakoda, R.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2727</span><span class="NLM_x">–</span> <span class="NLM_lpage">2743</span><span class="refDoi"> DOI: 10.1016/S0968-0896(01)00198-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0968-0896%2801%2900198-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2001&pages=2727-2743&author=M.+Suzukiauthor=H.+Iwasakiauthor=Y.+Fujikawaauthor=M.+Kitaharaauthor=M.+Sakashitaauthor=R.+Sakoda&title=Synthesis+and+biological+evaluations+of+quinoline-based+HMG-CoA+reductase+inhibitors&doi=10.1016%2FS0968-0896%2801%2900198-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2801%2900198-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252801%252900198-5%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DFujikawa%26aufirst%3DY.%26aulast%3DKitahara%26aufirst%3DM.%26aulast%3DSakashita%26aufirst%3DM.%26aulast%3DSakoda%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%2520quinoline-based%2520HMG-CoA%2520reductase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2001%26volume%3D9%26spage%3D2727%26epage%3D2743%26doi%3D10.1016%2FS0968-0896%2801%2900198-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Augeri, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betebenner, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpkins, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abboa-Offei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cap, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozzo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzel, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biller, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5025</span><span class="NLM_x">–</span> <span class="NLM_lpage">5037</span><span class="refDoi"> DOI: 10.1021/jm050261p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050261p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5025-5037&author=D.+J.+Augeriauthor=J.+A.+Roblauthor=D.+A.+Betebennerauthor=D.+R.+Magninauthor=A.+Khannaauthor=J.+G.+Robertsonauthor=A.+Wangauthor=L.+M.+Simpkinsauthor=P.+Taunkauthor=Q.+Huangauthor=S.+P.+Hanauthor=B.+Abboa-Offeiauthor=M.+Capauthor=L.+Xinauthor=L.+Taoauthor=E.+Tozzoauthor=G.+E.+Welzelauthor=D.+M.+Eganauthor=J.+Marcinkevicieneauthor=S.+Y.+Changauthor=S.+A.+Billerauthor=M.+S.+Kirbyauthor=R.+A.+Parkerauthor=L.+G.+Hamann&title=Discovery+and+preclinical+profile+of+saxagliptin+%28BMS-477118%29%3A+a+highly+potent%2C+long-acting%2C+orally+active+dipeptidyl+peptidase+IV+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm050261p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Augeri, David J.; Robl, Jeffrey A.; Betebenner, David A.; Magnin, David R.; Khanna, Ashish; Robertson, James G.; Wang, Aiying; Simpkins, Ligaya M.; Taunk, Prakash; Huang, Qi; Han, Song-Ping; Abboa-Offei, Benoni; Cap, Michael; Xin, Li; Tao, Li; Tozzo, Effie; Welzel, Gustav E.; Egan, Donald M.; Marcinkeviciene, Jovita; Chang, Shu Y.; Biller, Scott A.; Kirby, Mark S.; Parker, Rex A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5025-5037</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Efforts to further elucidate structure-activity relationships (SAR) within the authors previously disclosed series of β-quaternary amino acid linked L-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the investigation of vinyl substitution at the β-position of α-cycloalkyl-substituted glycines.  Despite poor systemic exposure, vinyl-substituted compds. showed extended duration of action in acute rat ex vivo plasma DPP-IV inhibition models.  Oxygenated putative metabolites were prepd. and were shown to exhibit the potency and extended duration of action of their precursors in efficacy models measuring glucose clearance in Zuckerfa/fa rats.  Extension of this approach to adamantylglycine-derived inhibitors led to the discovery of highly potent inhibitors, including hydroxyadamantyl compd. BMS-477118 (saxagliptin), a highly efficacious, stable, and long-acting DPP-IV inhibitor, which is currently undergoing clin. trials for treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrIJX7K8p67Vg90H21EOLACvtfcHk0livj2b4005CBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsVeltb0%253D&md5=878355880133bb0ddd6bd14ecbf1d070</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm050261p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050261p%26sid%3Dliteratum%253Aachs%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DMagnin%26aufirst%3DD.%2BR.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DJ.%2BG.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DSimpkins%26aufirst%3DL.%2BM.%26aulast%3DTaunk%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DS.%2BP.%26aulast%3DAbboa-Offei%26aufirst%3DB.%26aulast%3DCap%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DTozzo%26aufirst%3DE.%26aulast%3DWelzel%26aufirst%3DG.%2BE.%26aulast%3DEgan%26aufirst%3DD.%2BM.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DS.%2BY.%26aulast%3DBiller%26aufirst%3DS.%2BA.%26aulast%3DKirby%26aufirst%3DM.%2BS.%26aulast%3DParker%26aufirst%3DR.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DDiscovery%2520and%2520preclinical%2520profile%2520of%2520saxagliptin%2520%2528BMS-477118%2529%253A%2520a%2520highly%2520potent%252C%2520long-acting%252C%2520orally%2520active%2520dipeptidyl%2520peptidase%2520IV%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5025%26epage%3D5037%26doi%3D10.1021%2Fjm050261p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Ashworth, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szelke, M.</span><span> </span><span class="NLM_article-title">4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2745</span><span class="NLM_x">–</span> <span class="NLM_lpage">2748</span><span class="refDoi"> DOI: 10.1016/S0960-894X(96)00491-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2FS0960-894X%2896%2900491-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=2745-2748&author=D.+M.+Ashworthauthor=B.+Atrashauthor=G.+R.+Bakerauthor=A.+J.+Baxterauthor=P.+D.+Jenkinsauthor=D.+M.+Jonesauthor=M.+Szelke&title=4-Cyanothiazolidides+as+very+potent%2C+stable+inhibitors+of+dipeptidyl+peptidase+IV&doi=10.1016%2FS0960-894X%2896%2900491-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2896%2900491-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252896%252900491-X%26sid%3Dliteratum%253Aachs%26aulast%3DAshworth%26aufirst%3DD.%2BM.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DBaker%26aufirst%3DG.%2BR.%26aulast%3DBaxter%26aufirst%3DA.%2BJ.%26aulast%3DJenkins%26aufirst%3DP.%2BD.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DSzelke%26aufirst%3DM.%26atitle%3D4-Cyanothiazolidides%2520as%2520very%2520potent%252C%2520stable%2520inhibitors%2520of%2520dipeptidyl%2520peptidase%2520IV%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D2745%26epage%3D2748%26doi%3D10.1016%2FS0960-894X%2896%2900491-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Magnin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulsky, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augeri, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpkins, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunk, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betebenner, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abboa-Offei, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cap, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitkoff, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gougoutas, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2587</span><span class="NLM_x">–</span> <span class="NLM_lpage">2598</span><span class="refDoi"> DOI: 10.1021/jm049924d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049924d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2587-2598&author=D.+R.+Magninauthor=J.+A.+Roblauthor=R.+B.+Sulskyauthor=D.+J.+Augeriauthor=Y.+Huangauthor=L.+M.+Simpkinsauthor=P.+C.+Taunkauthor=D.+A.+Betebennerauthor=J.+G.+Robertsonauthor=B.+E.+Abboa-Offeiauthor=A.+Wangauthor=M.+Capauthor=L.+Xinauthor=L.+Taoauthor=D.+F.+Sitkoffauthor=M.+F.+Malleyauthor=J.+Z.+Gougoutasauthor=A.+Khannaauthor=Q.+Huangauthor=S.+P.+Hanauthor=R.+A.+Parkerauthor=L.+G.+Hamann&title=Synthesis+of+novel+potent+dipeptidyl+peptidase+IV+inhibitors+with+enhanced+chemical+stability%3A+interplay+between+the+N-terminal+amino+acid+alkyl+side+chain+and+the+cyclopropyl+group+of+alpha-aminoacyl-l-cis-4%2C5-methanoprolinenitrile-based+inhibitors&doi=10.1021%2Fjm049924d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fjm049924d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049924d%26sid%3Dliteratum%253Aachs%26aulast%3DMagnin%26aufirst%3DD.%2BR.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DSulsky%26aufirst%3DR.%2BB.%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DSimpkins%26aufirst%3DL.%2BM.%26aulast%3DTaunk%26aufirst%3DP.%2BC.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DRobertson%26aufirst%3DJ.%2BG.%26aulast%3DAbboa-Offei%26aufirst%3DB.%2BE.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DCap%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DL.%26aulast%3DSitkoff%26aufirst%3DD.%2BF.%26aulast%3DMalley%26aufirst%3DM.%2BF.%26aulast%3DGougoutas%26aufirst%3DJ.%2BZ.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DS.%2BP.%26aulast%3DParker%26aufirst%3DR.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DSynthesis%2520of%2520novel%2520potent%2520dipeptidyl%2520peptidase%2520IV%2520inhibitors%2520with%2520enhanced%2520chemical%2520stability%253A%2520interplay%2520between%2520the%2520N-terminal%2520amino%2520acid%2520alkyl%2520side%2520chain%2520and%2520the%2520cyclopropyl%2520group%2520of%2520alpha-aminoacyl-l-cis-4%252C5-methanoprolinenitrile-based%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2587%26epage%3D2598%26doi%3D10.1021%2Fjm049924d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Metzler, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanchunas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span> </span><span class="NLM_article-title">Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1110/ps.073253208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1110%2Fps.073253208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=18227430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVOntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=240-250&author=W.+J.+Metzlerauthor=J.+Yanchunasauthor=C.+Weigeltauthor=K.+Kishauthor=H.+E.+Kleiauthor=D.+Xieauthor=Y.+Zhangauthor=M.+Corbettauthor=J.+K.+Tamuraauthor=B.+Heauthor=L.+G.+Hamannauthor=M.+S.+Kirbyauthor=J.+Marcinkeviciene&title=Involvement+of+DPP-IV+catalytic+residues+in+enzyme-saxagliptin+complex+formation&doi=10.1110%2Fps.073253208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation</span></div><div class="casAuthors">Metzler, William J.; Yanchunas, Joseph; Weigelt, Carolyn; Kish, Kevin; Klei, Herbert E.; Xie, Dianlin; Zhang, Yaqun; Corbett, Martin; Tamura, James K.; He, Bin; Hamann, Lawrence G.; Kirby, Mark S.; Marcinkeviciene, Jovita</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-250</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The inhibition of DPP-IV by saxagliptin has been proposed to occur through formation of a covalent but reversible complex.  To evaluate further the mechanism of inhibition, we detd. the x-ray crystal structure of the DPP-IV:saxagliptin complex.  This structure reveals covalent attachment between S630 and the inhibitor nitrile carbon (C-O distance <1.3 Å).  To investigate whether this serine addn. is assisted by the catalytic His-Asp dyad, we generated two mutants of DPP-IV, S630A and H740Q, and assayed them for ability to bind inhibitor.  DPP-IVH740Q bound saxagliptin with an ∼1000-fold redn. in affinity relative to DPP-IVWT, while DPP-IVS630A showed no evidence for binding inhibitor.  An analog of saxagliptin lacking the nitrile group showed unchanged binding properties to the both mutant proteins, highlighting the essential role S630 and H740 play in covalent bond formation between S630 and saxagliptin.  Further supporting mechanism-based inhibition by saxagliptin, NMR spectra of enzyme-saxagliptin complexes revealed the presence of three downfield resonances with low fractionation factors characteristic of short and strong hydrogen bonds (SSHB).  Comparison of the NMR spectra of various wild-type and mutant DPP-IV:ligand complexes enabled assignment of a resonance at ∼14 ppm to H740.  Two addnl. DPP-IV mutants, Y547F and Y547Q, generated to probe potential stabilization of the enzyme-inhibitor complex by this residue, did not show any differences in inhibitor binding either by ITC or NMR.  Together with the previously published enzymic data, the structural and binding data presented here strongly support a histidine-assisted covalent bond formation between S630 hydroxyl oxygen and the nitrile group of saxagliptin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9JzGRDJ1J7rVg90H21EOLACvtfcHk0livj2b4005CBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVOntLo%253D&md5=d76619e8d6843e595a5bc971191a4828</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1110%2Fps.073253208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.073253208%26sid%3Dliteratum%253Aachs%26aulast%3DMetzler%26aufirst%3DW.%2BJ.%26aulast%3DYanchunas%26aufirst%3DJ.%26aulast%3DWeigelt%26aufirst%3DC.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DTamura%26aufirst%3DJ.%2BK.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKirby%26aufirst%3DM.%2BS.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26atitle%3DInvolvement%2520of%2520DPP-IV%2520catalytic%2520residues%2520in%2520enzyme-saxagliptin%2520complex%2520formation%26jtitle%3DProtein%2520Sci.%26date%3D2008%26volume%3D17%26spage%3D240%26epage%3D250%26doi%3D10.1110%2Fps.073253208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopcho, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langish, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipkova, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, M. S.</span><span> </span><span class="NLM_article-title">Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor</span> <span class="citation_source-journal">BMC Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">2210–12–2</span><span class="refDoi"> DOI: 10.1186/1471-2210-12-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1186%2F1471-2210-12-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=22475049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVajsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=2-2210%E2%80%9312%E2%80%932&author=A.+Wangauthor=C.+Dorsoauthor=L.+Kopchoauthor=G.+Lockeauthor=R.+Langishauthor=E.+Harstadauthor=P.+Shipkovaauthor=J.+Marcinkevicieneauthor=L.+Hamannauthor=M.+S.+Kirby&title=Potency%2C+selectivity+and+prolonged+binding+of+saxagliptin+to+DPP4%3A+maintenance+of+DPP4+inhibition+by+saxagliptin+in+vitro+and+ex+vivo+when+compared+to+a+rapidly-dissociating+DPP4+inhibitor&doi=10.1186%2F1471-2210-12-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor</span></div><div class="casAuthors">Wang, Aiying; Dorso, Charles; Kopcho, Lisa; Locke, Gregory; Langish, Robert; Harstad, Eric; Shipkova, Petia; Marcinkeviciene, Jovita; Hamann, Lawrence; Kirby, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>CODEN:
                <span class="NLM_cas:coden">BPMHBU</span>;
        ISSN:<span class="NLM_cas:issn">1471-2210</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Dipeptidylpeptidase 4 (DPP4) inhibitors have clin. benefit in patients with type 2 diabetes mellitus by increasing levels of glucose-lowering incretin hormones, such as glucagon-like peptide-1 (GLP-1), a peptide with a short half life that is secreted for approx. 1 h following a meal.  Since drugs with prolonged binding to their target have been shown to maximize pharmacodynamic effects while minimizing drug levels, we developed a time-dependent inhibitor that has a half-life for dissocn. from DPP4 close to the duration of the first phase of GLP-1 release.  Results: Saxagliptin and its active metabolite (5-hydroxysaxagliptin) are potent inhibitors of human DPP4 with prolonged dissocn. from its active site (Ki = 1.3 nM and 2.6 nM, t1/2 = 50 and 23 min resp. at 37°C).  In comparison, both vildagliptin (3.5 min) and sitagliptin (< 2 min) rapidly dissocd. from DPP4 at 37°C.  Saxagliptin and 5-hydroxysaxagliptin are selective for inhibition of DPP4 vs. other DPP family members and a large panel of other proteases, and have similar potency and efficacy across multiple species.  Inhibition of plasma DPP activity is used as a biomarker in animal models and clin. trials.  However, most DPP4 inhibitors are competitive with substrate and rapidly dissoc. from DPP4; therefore, the type of substrate, vol. of addn. and final concn. of substrate in these assays can change measured inhibition.  We show that unlike a rapidly dissocg. DPP4 inhibitor, inhibition of plasma DPP activity by saxagliptin and 5-hydroxysaxagliptin in an ex vivo assay was not dependent on substrate concn. when substrate was added rapidly because saxagliptin and 5-hydroxysaxagliptin dissoc. slowly from DPP4, once bound.  We also show that substrate concn. was important for rapidly dissocg. DPP4 inhibitors.  Conclusions: Saxagliptin and its active metabolite are potent, selective inhibitors of DPP4, with prolonged dissocn. from its active site.  They also demonstrate prolonged inhibition of plasma DPP4 ex vivo in animal models, which implies that saxagliptin and 5-hydroxysaxagliptin would continue to inhibit DPP4 during rapid increases in substrates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi2ZNdKARmHrVg90H21EOLACvtfcHk0lj9MaHuJqAqmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVajsr8%253D&md5=ec6bafcaf3438b60e5d70e22b8d16543</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1186%2F1471-2210-12-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2210-12-2%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DDorso%26aufirst%3DC.%26aulast%3DKopcho%26aufirst%3DL.%26aulast%3DLocke%26aufirst%3DG.%26aulast%3DLangish%26aufirst%3DR.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DShipkova%26aufirst%3DP.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DHamann%26aufirst%3DL.%26aulast%3DKirby%26aufirst%3DM.%2BS.%26atitle%3DPotency%252C%2520selectivity%2520and%2520prolonged%2520binding%2520of%2520saxagliptin%2520to%2520DPP4%253A%2520maintenance%2520of%2520DPP4%2520inhibition%2520by%2520saxagliptin%2520in%2520vitro%2520and%2520ex%2520vivo%2520when%2520compared%2520to%2520a%2520rapidly-dissociating%2520DPP4%2520inhibitor%26jtitle%3DBMC%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D2%26epage%3D2210%25E2%2580%259312%25E2%2580%25932%26doi%3D10.1186%2F1471-2210-12-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Li, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmarais, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masse, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, W. C.</span><span> </span><span class="NLM_article-title">Identification of a potent and selective non-basic cathepsin K inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1985</span><span class="NLM_x">–</span> <span class="NLM_lpage">1989</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2005.12.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.bmcl.2005.12.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=16413777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVyqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1985-1989&author=C.+S.+Liauthor=D.+Deschenesauthor=S.+Desmaraisauthor=J.+P.+Falgueyretauthor=J.+Y.+Gauthierauthor=D.+B.+Kimmelauthor=S.+Legerauthor=F.+Masseauthor=M.+E.+McGrathauthor=D.+J.+McKayauthor=M.+D.+Percivalauthor=D.+Riendeauauthor=S.+B.+Rodanauthor=M.+Therienauthor=V.+L.+Truongauthor=G.+Wesolowskiauthor=R.+Zamboniauthor=W.+C.+Black&title=Identification+of+a+potent+and+selective+non-basic+cathepsin+K+inhibitor&doi=10.1016%2Fj.bmcl.2005.12.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent and selective non-basic cathepsin K inhibitor</span></div><div class="casAuthors">Li, Chun Sing; Deschenes, Denis; Desmarais, Sylvie; Falgueyret, Jean-Pierre; Gauthier, Jacques Yves; Kimmel, Donald. B.; Leger, Serge; Masse, Frederic; McGrath, Mary E.; McKay, Daniel J.; Percival, M. David; Riendeau, Denis; Rodan, Sevgi B.; Therien, Michel; Truong, Vouy-Linh; Wesolowski, Gregg; Zamboni, Robert; Black, W. Cameron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1985-1989</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on our previous study with trifluoroethylamine as a P2-P3 amide isostere of cathepsin K inhibitor, further optimization led to identification of L-873724 (I) as a potent and selective non-basic cathepsin K inhibitor.  This compd. showed excellent pharmacokinetics and efficacy in an ovariectomized (OVX) rhesus monkey model.  The vols. of distribution close to unity were consistent with this compd. not being lysosomotropic, which is a characteristic of basic cathepsin K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbVLlTt9kYhrVg90H21EOLACvtfcHk0lj9MaHuJqAqmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVyqs74%253D&md5=e63e471204893774e5a617993ed9be18</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.12.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.12.071%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDesmarais%26aufirst%3DS.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DKimmel%26aufirst%3DD.%2BB.%26aulast%3DLeger%26aufirst%3DS.%26aulast%3DMasse%26aufirst%3DF.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRodan%26aufirst%3DS.%2BB.%26aulast%3DTherien%26aufirst%3DM.%26aulast%3DTruong%26aufirst%3DV.%2BL.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DW.%2BC.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520selective%2520non-basic%2520cathepsin%2520K%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1985%26epage%3D1989%26doi%3D10.1016%2Fj.bmcl.2005.12.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Corvol, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freifeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahoudeau, J.</span><span> </span><span class="NLM_article-title">Antiandrogenic effect of spirolactones: mechanism of action</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1210/endo-97-1-52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1210%2Fendo-97-1-52" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1975&pages=52-58&author=P.+Corvolauthor=A.+Michaudauthor=J.+Menardauthor=M.+Freifeldauthor=J.+Mahoudeau&title=Antiandrogenic+effect+of+spirolactones%3A+mechanism+of+action&doi=10.1210%2Fendo-97-1-52"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1210%2Fendo-97-1-52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo-97-1-52%26sid%3Dliteratum%253Aachs%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DMenard%26aufirst%3DJ.%26aulast%3DFreifeld%26aufirst%3DM.%26aulast%3DMahoudeau%26aufirst%3DJ.%26atitle%3DAntiandrogenic%2520effect%2520of%2520spirolactones%253A%2520mechanism%2520of%2520action%26jtitle%3DEndocrinology%26date%3D1975%26volume%3D97%26spage%3D52%26epage%3D58%26doi%3D10.1210%2Fendo-97-1-52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Wiechert, R.</span> In  <span class="citation_source-book">Analogue-based drug discovery</span>. <span class="NLM_contrib-group">Fischer, J.; Ganellin, C. R.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH</span>: <span class="NLM_publisher-loc">Weinheim</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1002%2F3527608001.ch20" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=395-400&author=R.+Wiechertauthor=J.+Fischer&author=C.+R.+Ganellin&title=Analogue-based+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1002%2F3527608001.ch20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F3527608001.ch20%26sid%3Dliteratum%253Aachs%26aulast%3DWiechert%26aufirst%3DR.%26btitle%3DAnalogue-based%2520drug%2520discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%26date%3D2006%26spage%3D395%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">Oelkers, W.</span><span> </span><span class="NLM_article-title">Drospirenone, a progestogen with antimineralocorticoid properties: a short review</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">217</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.mce.2003.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=10.1016%2Fj.mce.2003.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=15134826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVCjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2004&pages=255-261&author=W.+Oelkers&title=Drospirenone%2C+a+progestogen+with+antimineralocorticoid+properties%3A+a+short+review&doi=10.1016%2Fj.mce.2003.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Drospirenone, a progestogen with antimineralocorticoid properties: a short review</span></div><div class="casAuthors">Oelkers, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Progesterone (P) has high affinity to the mineralocorticoid receptor (MCR), and it is an MCR antagonist.  Almost all synthetic progestogens are devoid of this antimineralocorticoid (anti-MC) effect.  They are unable to antagonize the salt retaining effect of estrogens.  This could be one cause of wt. gain and an increase in blood pressure with the use of combined oral contraceptives (OC) and, in some susceptible women, with postmenopausal estrogen/(progestogen) treatment.  The purpose of this presentation is to review results of clin. studies with drospirenone (DRSP), a new progestogen developed by Schering A.G., with anti-MCR activity.  DRSP is a deriv. of 17-α-spirolactone.  In rats, rabbits and in man, it is a PR-agonist and an MCR- and androgen-R antagonist with no effect on the glucocorticoid-R and the estrogen-R.  In normally menstruating women, 2-3 mg DRSP per day, taken from day 5 to 25 of the cycle, inhibit ovulation, lead to a mild natriuresis, and a slight compensatory activation of the renin-aldosterone system.  Compared with an OC contg. 30 μg ethinylestradiol (EE) and 150 μg levonorgestrel, a combination of 3 mg DRSP with 30 μg EE given over 6 mo led to a slight decrease in body wt. and blood pressure.  The redn. in mean body wt. by a combination of DRSP with EE compared with a conventional OC could be confirmed in a study over 26 mo in 900 young women.  The OC contg. DRSP has favorable effects in patients suffering from the premenstrual syndrome (PMS), and, partly due to the antiandrogenic effect of DRSP, in those with acne vulgaris.  For postmenopausal women, a combination of DRSP with estradiol has been developed with the expectation that the slight blood pressure lowering and wt. reducing effects will minimize cardiovascular morbidity in patients needing hormone treatment because of hot flushes and other climacteric symptoms.  Conclusions: DRSP, by its anti-MCR effect and its potential to slightly decrease body wt. and blood pressure, shares many pharmacodynamic properties with progesterone, and it is a candidate for reducing cardiovascular morbidity in women using OCs or postmenopausal hormone treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWKtG2YQOR0rVg90H21EOLACvtfcHk0lhf6g1F1Gy3_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVCjsr8%253D&md5=e97edb2c2ca7bef3ca756ec98c942499</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2003.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2003.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DOelkers%26aufirst%3DW.%26atitle%3DDrospirenone%252C%2520a%2520progestogen%2520with%2520antimineralocorticoid%2520properties%253A%2520a%2520short%2520review%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2004%26volume%3D217%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.mce.2003.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">Chinn, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salamon, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, B. N.</span><span> </span><span class="NLM_article-title">A structure-activity relationship study of spirolactones. Contribution of the cyclopropane ring to antimineralocorticoid activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1107</span><span class="refDoi"> DOI: 10.1021/jm00141a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00141a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1103-1107&author=L.+J.+Chinnauthor=K.+W.+Salamonauthor=B.+N.+Desai&title=A+structure-activity+relationship+study+of+spirolactones.+Contribution+of+the+cyclopropane+ring+to+antimineralocorticoid+activity&doi=10.1021%2Fjm00141a020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm00141a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00141a020%26sid%3Dliteratum%253Aachs%26aulast%3DChinn%26aufirst%3DL.%2BJ.%26aulast%3DSalamon%26aufirst%3DK.%2BW.%26aulast%3DDesai%26aufirst%3DB.%2BN.%26atitle%3DA%2520structure-activity%2520relationship%2520study%2520of%2520spirolactones.%2520Contribution%2520of%2520the%2520cyclopropane%2520ring%2520to%2520antimineralocorticoid%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D1103%26epage%3D1107%26doi%3D10.1021%2Fjm00141a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Hoveyda, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benakli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaubien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saint-Louis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinault, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaseshan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foucher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchemin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bherer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, G. L.</span><span> </span><span class="NLM_article-title">Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): development of ulimorelin (TZP-101) from hit to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8305</span><span class="NLM_x">–</span> <span class="NLM_lpage">8320</span><span class="refDoi"> DOI: 10.1021/jm2007062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A280%3ADC%252BC38%252Fms1antg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8305-8320&author=H.+R.+Hoveydaauthor=E.+Marsaultauthor=R.+Gagnonauthor=A.+P.+Mathieuauthor=M.+Vezinaauthor=A.+Landryauthor=Z.+Wangauthor=K.+Benakliauthor=S.+Beaubienauthor=C.+Saint-Louisauthor=M.+Brassardauthor=J.+F.+Pinaultauthor=L.+Ouelletauthor=S.+Bhatauthor=M.+Ramaseshanauthor=X.+Pengauthor=L.+Foucherauthor=S.+Beaucheminauthor=P.+Bhererauthor=D.+F.+Veberauthor=M.+L.+Petersonauthor=G.+L.+Fraser&title=Optimization+of+the+potency+and+pharmacokinetic+properties+of+a+macrocyclic+ghrelin+receptor+agonist+%28Part+I%29%3A+development+of+ulimorelin+%28TZP-101%29+from+hit+to+clinic&doi=10.1021%2Fjm2007062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic</span></div><div class="casAuthors">Hoveyda Hamid R; Marsault Eric; Gagnon Rene; Mathieu Axel P; Vezina Martin; Landry Annick; Wang Zhigang; Benakli Kamel; Beaubien Sylvie; Saint-Louis Carl; Brassard Martin; Pinault Jean-Francois; Ouellet Luc; Bhat Shridhar; Ramaseshan Mahesh; Peng Xiaowen; Foucher Laurence; Beauchemin Sophie; Bherer Patrick; Veber Daniel F; Peterson Mark L; Fraser Graeme L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8305-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel agonists against this G-protein coupled receptor.  Early hits such as 1 (Ki=86 nM, EC50=134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization.  While such macrocycles are not fully rule-of-five compliant, principally due to their molecular weight and clogP, optimization of their pharmacokinetic properties proved feasible largely through conformational rigidification.  Extensive SAR led to the identification of 2 (Ki=16 nM, EC50=29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus.  X-ray structure and detailed NMR studies indicated a rigid peptidomimetic portion in 2 that is best defined as a nonideal type-I' β-turn.  Compound 2 is 24% orally bioavailable in both rats and monkeys.  Despite its potency, in vitro and in gastric emptying studies, 2 did not induce growth hormone (GH) release in rats, thus demarcating the GH versus GI pharmacology of GRLN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREoes2wBiC73y-c-E1v-fmfW6udTcc2eb2t0gfZmOKlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252Fms1antg%253D%253D&md5=bdc3b14ed821c61c4fecea50c60f0b07</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fjm2007062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007062%26sid%3Dliteratum%253Aachs%26aulast%3DHoveyda%26aufirst%3DH.%2BR.%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DGagnon%26aufirst%3DR.%26aulast%3DMathieu%26aufirst%3DA.%2BP.%26aulast%3DVezina%26aufirst%3DM.%26aulast%3DLandry%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBenakli%26aufirst%3DK.%26aulast%3DBeaubien%26aufirst%3DS.%26aulast%3DSaint-Louis%26aufirst%3DC.%26aulast%3DBrassard%26aufirst%3DM.%26aulast%3DPinault%26aufirst%3DJ.%2BF.%26aulast%3DOuellet%26aufirst%3DL.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DRamaseshan%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFoucher%26aufirst%3DL.%26aulast%3DBeauchemin%26aufirst%3DS.%26aulast%3DBherer%26aufirst%3DP.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26aulast%3DFraser%26aufirst%3DG.%2BL.%26atitle%3DOptimization%2520of%2520the%2520potency%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520macrocyclic%2520ghrelin%2520receptor%2520agonist%2520%2528Part%2520I%2529%253A%2520development%2520of%2520ulimorelin%2520%2528TZP-101%2529%2520from%2520hit%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8305%26epage%3D8320%26doi%3D10.1021%2Fjm2007062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">van De Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. K.</span><span> </span><span class="NLM_article-title">Property-based design: optimization of drug absorption and pharmacokinetics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1313</span><span class="NLM_x">–</span> <span class="NLM_lpage">1333</span><span class="refDoi"> DOI: 10.1021/jm000407e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000407e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1313-1333&author=H.+van+De+Waterbeemdauthor=D.+A.+Smithauthor=K.+Beaumontauthor=D.+K.+Walker&title=Property-based+design%3A+optimization+of+drug+absorption+and+pharmacokinetics&doi=10.1021%2Fjm000407e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Property-based design: optimization of drug absorption and pharmacokinetics</span></div><div class="casAuthors">van de Waterbeemd, Han; Smith, Dennis A.; Beaumont, Kevin; Walker, Don K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1313-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 223 refs.  The authors discuss some aspects of the properties of biol. barriers.  In different sections the estn. of drug absorption via important barriers including gastrointestinal tract, blood-brain barrier, and skin are reviewed.  Various approaches for the measurement and computation of physicochem. and mol. properties currently used in the optimization of absorption as well as the use of physicochem. properties in the design of optimal pharmacokinetic profiles are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQwsmoX0-mbVg90H21EOLACvtfcHk0liYkFLdWOzTLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D&md5=3183baedca70020f4ce27f306ba0997e</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Fjm000407e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000407e%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BDe%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DProperty-based%2520design%253A%2520optimization%2520of%2520drug%2520absorption%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1313%26epage%3D1333%26doi%3D10.1021%2Fjm000407e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Martin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matha, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulnik, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topol, I. A.</span><span> </span><span class="NLM_article-title">Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1581</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span><span class="refDoi"> DOI: 10.1021/jm980033d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980033d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1581-1597&author=S.+F.+Martinauthor=G.+O.+Dorseyauthor=T.+Ganeauthor=M.+C.+Hillierauthor=H.+Kesslerauthor=M.+Baurauthor=B.+Mathaauthor=J.+W.+Ericksonauthor=T.+N.+Bhatauthor=S.+Munshiauthor=S.+V.+Gulnikauthor=I.+A.+Topol&title=Cyclopropane-derived+peptidomimetics.+Design%2C+synthesis%2C+evaluation%2C+and+structure+of+novel+HIV-1+protease+inhibitors&doi=10.1021%2Fjm980033d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Fjm980033d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980033d%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DDorsey%26aufirst%3DG.%2BO.%26aulast%3DGane%26aufirst%3DT.%26aulast%3DHillier%26aufirst%3DM.%2BC.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DBaur%26aufirst%3DM.%26aulast%3DMatha%26aufirst%3DB.%26aulast%3DErickson%26aufirst%3DJ.%2BW.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DMunshi%26aufirst%3DS.%26aulast%3DGulnik%26aufirst%3DS.%2BV.%26aulast%3DTopol%26aufirst%3DI.%2BA.%26atitle%3DCyclopropane-derived%2520peptidomimetics.%2520Design%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structure%2520of%2520novel%2520HIV-1%2520protease%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1581%26epage%3D1597%26doi%3D10.1021%2Fjm980033d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Davidson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waksman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Calorimetric and structural studies of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1021/ja011746f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja011746f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=205-215&author=J.+P.+Davidsonauthor=O.+Lubmanauthor=T.+Roseauthor=G.+Waksmanauthor=S.+F.+Martin&title=Calorimetric+and+structural+studies+of+1%2C2%2C3-trisubstituted+cyclopropanes+as+conformationally+constrained+peptide+inhibitors+of+Src+SH2+domain+binding&doi=10.1021%2Fja011746f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fja011746f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja011746f%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26aulast%3DLubman%26aufirst%3DO.%26aulast%3DRose%26aufirst%3DT.%26aulast%3DWaksman%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DCalorimetric%2520and%2520structural%2520studies%2520of%25201%252C2%252C3-trisubstituted%2520cyclopropanes%2520as%2520conformationally%2520constrained%2520peptide%2520inhibitors%2520of%2520Src%2520SH2%2520domain%2520binding%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D205%26epage%3D215%26doi%3D10.1021%2Fja011746f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazuta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5587</span><span class="NLM_x">–</span> <span class="NLM_lpage">5596</span><span class="refDoi"> DOI: 10.1021/jm0603318</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603318" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVCls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5587-5596&author=M.+Watanabeauthor=Y.+Kazutaauthor=H.+Hayashiauthor=S.+Yamadaauthor=A.+Matsudaauthor=S.+Shuto&title=Stereochemical+diversity-oriented+conformational+restriction+strategy.+Development+of+potent+histamine+H3+and%2For+H4+receptor+antagonists+with+an+imidazolylcyclopropane+structure&doi=10.1021%2Fjm0603318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Stereochemical Diversity-Oriented Conformational Restriction Strategy. Development of Potent Histamine H3 and/or H4 Receptor Antagonists with an Imidazolylcyclopropane Structure</span></div><div class="casAuthors">Watanabe, Mizuki; Kazuta, Yuji; Hayashi, Hideki; Yamada, Shizuo; Matsuda, Akira; Shuto, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5587-5596</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop potent H3 and H4 receptor antagonists, a series of conformationally restricted analogs of histamine with a chiral cis- or trans-cyclopropane structure were designed on the basis of stereochem. diversity-oriented conformational restriction strategy.  The target compds. I (n = 1, 2; R = cyclohexylmethyl, 4-ClC6H4CH2) were synthesized from the versatile chiral cyclopropane units, (1S,2R)- and (1R,2R)-2-(tert-butyldiphenylsilyloxy)methyl-1-formylcyclopropanes or their enantiomers.  Pharmacol. profiles of these conformationally restricted analogs were shown to be different depending on the cyclopropane backbones.  Among the analogs, (1R,2S)-I (n = 2; R = 4-ClC6H4CH2) with the (1R)-trans-cyclopropane structure has remarkable antagonistic activity to both the H3 (Ki = 8.4 nM) and H4 (Ki = 7.6 nM) receptors.  Its enantiomer with the (1S)-trans-cyclopropane structure turned out to be a highly potent and selective H3 receptor antagonist with a Ki of 3.6 nM.  Conversely, (1R,2R)-I (n = 1; R = 4-ClC6H4CH2) with the (1R)-trans structure was selective for the H4 receptor (Ki = 118 nM) compared to the H3 receptor (Ki > 103 nM).  These results show that when the structure of the target protein is unknown, the stereochem. diversity-oriented approach can be a powerful strategy in medicinal chem. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobv8NEj2pLVg90H21EOLACvtfcHk0liYkFLdWOzTLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVCls7Y%253D&md5=70552c118df50813b649b30cffec0e41</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fjm0603318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603318%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DKazuta%26aufirst%3DY.%26aulast%3DHayashi%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DS.%26aulast%3DMatsuda%26aufirst%3DA.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DStereochemical%2520diversity-oriented%2520conformational%2520restriction%2520strategy.%2520Development%2520of%2520potent%2520histamine%2520H3%2520and%252For%2520H4%2520receptor%2520antagonists%2520with%2520an%2520imidazolylcyclopropane%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5587%26epage%3D5596%26doi%3D10.1021%2Fjm0603318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Shimamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohfune, Y.</span><span> </span><span class="NLM_article-title">Syntheses and conformational analyses of glutamate analogs: 2-(2-carboxy-3-substituted-cyclopropyl)glycines as useful probes for excitatory amino acid receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span><span class="refDoi"> DOI: 10.1021/jm9502908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9502908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=407-423&author=K.+Shimamotoauthor=Y.+Ohfune&title=Syntheses+and+conformational+analyses+of+glutamate+analogs%3A+2-%282-carboxy-3-substituted-cyclopropyl%29glycines+as+useful+probes+for+excitatory+amino+acid+receptors&doi=10.1021%2Fjm9502908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm9502908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9502908%26sid%3Dliteratum%253Aachs%26aulast%3DShimamoto%26aufirst%3DK.%26aulast%3DOhfune%26aufirst%3DY.%26atitle%3DSyntheses%2520and%2520conformational%2520analyses%2520of%2520glutamate%2520analogs%253A%25202-%25282-carboxy-3-substituted-cyclopropyl%2529glycines%2520as%2520useful%2520probes%2520for%2520excitatory%2520amino%2520acid%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D407%26epage%3D423%26doi%3D10.1021%2Fjm9502908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Cannon, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rege, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, J. P.</span><span> </span><span class="NLM_article-title">1,2-Disubstituted cyclopropane and cyclobutane derivatives related to acetylcholine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">75</span><span class="refDoi"> DOI: 10.1021/jm00271a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00271a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1972&pages=71-75&author=J.+G.+Cannonauthor=A.+B.+Regeauthor=T.+L.+Gruenauthor=J.+P.+Long&title=1%2C2-Disubstituted+cyclopropane+and+cyclobutane+derivatives+related+to+acetylcholine&doi=10.1021%2Fjm00271a019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm00271a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00271a019%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DJ.%2BG.%26aulast%3DRege%26aufirst%3DA.%2BB.%26aulast%3DGruen%26aufirst%3DT.%2BL.%26aulast%3DLong%26aufirst%3DJ.%2BP.%26atitle%3D1%252C2-Disubstituted%2520cyclopropane%2520and%2520cyclobutane%2520derivatives%2520related%2520to%2520acetylcholine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1972%26volume%3D15%26spage%3D71%26epage%3D75%26doi%3D10.1021%2Fjm00271a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2w1g" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2w1g','PDB','2w1g'); return false;">PDB: 2w1g</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LOX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LOX','PDB','3LOX'); return false;">PDB: 3LOX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NWK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NWK','PDB','4NWK'); return false;">PDB: 4NWK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NLD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NLD','PDB','4NLD'); return false;">PDB: 4NLD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU','PDB','1XMU'); return false;">PDB: 1XMU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IPH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IPH','PDB','3IPH'); return false;">PDB: 3IPH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4rfm" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4rfm','PDB','4rfm'); return false;">PDB: 4rfm</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X6Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X6Y','PDB','4X6Y'); return false;">PDB: 4X6Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X6X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X6X','PDB','4X6X'); return false;">PDB: 4X6X</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i87"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00472">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_17150"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00472">10.1021/acs.jmedchem.6b00472</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional examples of clinically relevant cyclopropane-containing compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00472/suppl_file/jm6b00472_si_001.pdf">jm6b00472_si_001.pdf (664.67 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00472" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00472" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995f9c9c063c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
